"term" "context"
"25-30% DUCTAL COMPONENT" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0091;SAMPLE_TYPE:Primary;OS_MONTHS:52.92;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:52.92;TISSUE_SOURCE_SITE:YL;ICD_O_3_SITE:C61.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C61;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/13/14;PATH_T_STAGE:T3b;HISTOLOGICAL_DIAGNOSIS:Prostate Adenocarcinoma, Other Subtype;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1653;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-YL-A8HJ.A4B8AFC5-774E-4FB2-8191-735949EC3E42.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:370;SITE_OF_TUMOR_TISSUE:Prostate;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:25-30% ductal component;LYMPH_NODES_EXAMINED:NO;LATERALITY:Bilateral;PRIMARY_SITE_PATIENT:Overlapping / Multiple Zones;TARGETED_MOLECULAR_THERAPY:YES;CLIN_M_STAGE:M0;GLEASON_SCORE:9;BONE_SCAN_RESULT:Normal (no evidence of prostate cancer) [cM0];BIOCHEMICAL_RECURRENCE_INDICATOR:NO;CT_SCAN_AB_PELVIS_INDICATOR:YES;CT_SCAN_AB_PELVIS_RESULTS:No Evidence of Extraprostatic Extension;DAYS_TO_BONE_SCAN_PERFORMED:54;DAYS_TO_CT_SCAN_AB_PELVIS:-34;DAYS_TO_PSA:1589;DIAGNOSTIC_MRI_RESULT:NO;GLEASON_PATTERN_PRIMARY:4;GLEASON_PATTERN_SECONDARY:5;GLEASON_PATTERN_TERTIARY:3;INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD:Core needle biopsy;PSA_MOST_RECENT_RESULTS:0.03;TUMOR_LEVEL:Apex|Middle|Base"
"82463 NEUROENDOCRINE CARCINOMA NOS" "CANCER_TYPE_DETAILED:Pancreatic Neuroendocrine Tumor;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PANET;SOMATIC_STATUS:Matched;SEX:Male;AGE:67;FRACTION_GENOME_ALTERED:0.6846;SAMPLE_TYPE:Primary;OS_MONTHS:32.79;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:32.79;TISSUE_SOURCE_SITE:3A;ICD_O_3_SITE:C25.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C25.1;ICD_O_3_HISTOLOGY:8246/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/24/14;GRADE:G1;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IB;HISTOLOGICAL_DIAGNOSIS:Pancreas-Adenocarcinoma-Other Subtype;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1141;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3A-A9IS.BC3170CA-A046-4D78-9CC6-36C5B70A9C4C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:80;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:82463 NEUROENDOCRINE CARCINOMA NOS;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tissue Biopsy;PRIMARY_SITE_PATIENT:Body of Pancreas;TARGETED_MOLECULAR_THERAPY:NO;ALCOHOL_HISTORY_DOCUMENTED:NO;FAMILY_HISTORY_OF_CANCER:NO;DIABETES_DIAGNOSIS_INDICATOR:NO;TUMOR_RESECTED_MAX_DIMENSION:8;GRADE_TIER_SYSTEM:Four Tier;HISTORY_CHRONIC_PANCREATITIS:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"AB" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ACANTHOLYTIC" "CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:41.6333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:65;SAMPLE_TYPE:Metastasis;OS_MONTHS:56.0;OS_STATUS:0:LIVING;PRIMARY_SITE:Uknown;AJCC_STAGING_EDITION:4.0;HISTOLOGICAL_SUBTYPE:Acantholytic;M_STAGE:1;PURITY:30%;TUMOR_SIZE:N.d.;T_STAGE:Tx;N_STAGE:0;PRIOR_TREATMENT:Surgery +Xrt;DIFFERENTIATION:Moderate;PURITY_ABSOLUTE:20.00%;TOTAL_MUTATIONS:1885;TREATMENT_TYPE:Surgery;DISEASE_STATUS:Recurrent;DISTANT_METS:Yes;IMMUNOSUPPRESSION:No;A_C:0.0203;A_G:0.039;A_T:0.0203;ABSOLUTE_CANCER_DNA_FRACTION:0.31;C_A:0.0369;C_G:0.0535;C_T:0.7652;DETAILED_METASTATIC_SITE:Parotid;EFS_MONTHS:55.5;EFS_STATUS:0:Censored;HAS_OTHER_CANCER:No;INVASION_DEPTH:N.d.;PNI:No;CC_TT:0.0572;DISEASE_RECURRENCE_OR_PERSISTENCE:No;DISTANT_RECURRENCE_NUM:1;EVENT_DETAILS:Censored;INTERVAL_FROM_INDEX_LESION_TO_PRESENT_LESION:32.15342466;INTERVAL_FROM_LAST_LESION_TO_STUDY:33;INVADE_BONE:Yes;INVADE_LARGER_THAN_SUBCUTANEOUS_TISSUE:No;INVADE_SKULL_BASE:No;LOCAL_RECURRENCE_NUM:0;MULTIPLE_HN_CSCC:No;OTHER_DNP:0.0075;OTHER_SKIN_TUMORS:No;PERSISTANT_DISEASE_TUMOR_STUDIED:No;RECURRENT_DISEASE_TUMOR_STUDIED:No;RECURRENT_FREE_INTERVAL_MONTHS:55.53"
"ACC" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ACINAR ADENOCARCINOMA 85513" NA
"ACINAR CELL CARCINOMA" "CANCER_TYPE_DETAILED:Acinar Cell Carcinoma, NOS;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:ACN;TMB_NONSYNONYMOUS:0.033333333;SEX:Female;AGE:68.35044861;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;EQD_TERTILES:3rd tertile;TIME_FROM_DX_TO_SEQ:2286;XRT_TX:Yes"
"ACINAR CELL CARCINOMA OF THE PANCREAS" "CANCER_TYPE_DETAILED:Acinar Cell Carcinoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAC;TMB_NONSYNONYMOUS:4.101736183;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.7571;SAMPLE_TYPE:Metastasis;OS_MONTHS:28.274;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Pancreas;GENE_PANEL:IMPACT505;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Abdomen;TUMOR_PURITY:70;MSI_SCORE:4.44;MSI_TYPE:Indeterminate;SAMPLE_COVERAGE:729;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:60;MSI_COMMENT:MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:59;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"ACINAR CELL CARCINOMA, NOS" "CANCER_TYPE_DETAILED:Acinar Cell Carcinoma, NOS;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:ACN;TMB_NONSYNONYMOUS:0.033333333;SEX:Female;AGE:68.35044861;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;EQD_TERTILES:3rd tertile;TIME_FROM_DX_TO_SEQ:2286;XRT_TX:Yes"
"ACINIC CELL CARCINOMA" "CANCER_TYPE_DETAILED:Acinic Cell Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:ACCC;TMB_NONSYNONYMOUS:0.978719697615;SOMATIC_STATUS:Matched;SEX:Male;AGE:46.0;FRACTION_GENOME_ALTERED:0.0148;SAMPLE_TYPE:Primary;OS_MONTHS:168.2;OS_STATUS:0:LIVING;RACE:Asian Indian Pakistani;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:64.8;PRIMARY_SITE:Major Salivary Gland;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:80;SAMPLE_COVERAGE:152;VITAL_STATUS:AWD;SMOKING_HISTORY:Former;PARTC_CONSENTED_12_245:NO;ALCOHOL_CONSUMPTION_FREQUENCY:Occasional;ALCOHOL_HISTORY_DOCUMENTED:Former;SITE_OF_RECURRENCE:Distant (Iliac bone and Spine);AGENT:Vinorelbine;DISEASE_EXTENT:Distant;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:Yes;DISTANT_METS:Yes;TNM:T3N0MX;CLINICAL_TRIAL:None;DETAILED_PRIMARY_SITE:Parotid Gland;INITIAL_TREATMENT:Surgery + Radiation;SITE_SEQUENCED:Index primary;PRIOR_TX_TO_IMPACT_SAMPLE:None;TOBACCO_TYPE:Cigarettes;VAR_12_245:12-245"
"ACRAL" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:1.266666667;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Metastasis;SMOKING_HISTORY:Former Smoker;SPECIMEN_COLLECTION_PRE_OR_POST_CHEMO:post-chemotherapy;AGE_AT_LAST_FOLLOWUP:71;BODY_SITE:Presacral mass;CHEMOTHERAPY_PRIOR_SAMPLE_ACQUIRED:MVAC, Docetaxel;HIGHEST_RECORDED_CLINICAL_TNM_STAGE:IV;HISTOPATOLOGY_PRIMARY_TUMOR:UC"
"ACRAL LENTIGINOUS" "CANCER_TYPE_DETAILED:Acral Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:ACRM;TMB_NONSYNONYMOUS:7.1;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0;OS_MONTHS:40.82;OS_STATUS:0:LIVING;PFS_MONTHS:15.43;SUBTYPE:acral lentiginous;TUMOR_TYPE:Melanoma;HISTOLOGY:cutaneous;RECIST_RESPONSE:stable disease;CENSORED:LIVING;DRUG_TYPE:anti-CTLA-4;RECIST:SD;OTHER_CONCURRENT_THERAPY:no;ROH_RESPONSE:clinical benefit;VA_RESPONSE:clinical benefit"
"ACRAL MELANOMA" "CANCER_TYPE_DETAILED:Acral Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:ACRM;TMB_NONSYNONYMOUS:4.2;SOMATIC_STATUS:Matched;SEX:Female;SAMPLE_TYPE:Metastasis;OS_MONTHS:28.0;OS_STATUS:1:DECEASED;RACE:Caucasian;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:21.0;PRIMARY_SITE:Plantar Foot;RADIATION_TREATMENT_ADJUVANT:No;AGE_AT_DIAGNOSIS:77;TREATMENT:No;FOLLOW_UP_TIME_MONTHS:28.0;METASTASIS:No;PRIMARY_MELANOMA_TUMOR_ULCERATION:No;STAGE_AT_PRESENTATION:IIIB;TIME_TO_RECURRENCE_MONTHS:21.0;IN_TRANSIT:No;OR_TIME:21.0;PRIMARY_DEPTH:0.5;PRIMARY_MITOSES:<1;SITE_FIRST_RECURRENCE:Inguinal LN;SUB_SITE:Inguninal( LN Regional)"
"ACTIVATED B-CELL TYPE" "CANCER_TYPE_DETAILED:Activated B-cell Type;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:ABC;TMB_NONSYNONYMOUS:2.86666666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:12.7;OS_STATUS:1:DECEASED;AGE_AT_DIAGNOSIS:68.0;COHORT:Mayo/Iowa;MEAN_TARGET_COVERAGE_TUMOR:106.9;PURITY_ABSOLUTE:0.87;SAMPLE_COLLECTION_SOURCE:Frozen;IPI:4.0;NUM_NONSILENT_MUTATION:86;TESTICULAR_INVOLVEMENT:No;DRIVER_MUTATIONS:8;IPI_AGE:1.0;IPI_ECOG:0.0;IPI_LDH:1.0;NONSILENT_MUTATION_DENSITY:2.555325;NUM_SILENT_MUTATION:26;TOTAL_CNA:83;ANY_COO:ABC;CCC:BCR;CLUSTER:2;CNS_INVOLVEMENT:No;COO_GEP:ABC;DBSNP_MUTATION_DENSITY:0.386;DRIVER_MUTATION_DENSITY:0.238;IPI_EXBM:1.0;IPI_STAGE:1.0;MUTATION_DENSITY:3.327865;NUM_DBSNP_MUTATIONS:13;NUM_DRIVER_SCNA:15;NUM_DRIVER_SV:0;R_CHOP_LIKE_CHEMO:Yes;SILENT_MUTATION_DENSITY:0.773;TOTAL_REARRANGEMENT:5;TUMOR_IN_NORMAL_ESTIMATE:0"
"ACUTE BIPHENOTYPIC LEUKEMIA" "CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:7.33333333333;SUBTYPE:Acute Biphenotypic Leukemia;LINEAGE:blood;LINEAGE_SUBTYPE:acute_biphenotypic_leukemia"
"ACUTE ERYTHROID LEUKAEMIA" "CANCER_TYPE_DETAILED:Pure Erythroid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:PERL;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:24.77;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:67.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:67;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:3;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:20;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine | Consolidation | Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute erythroid leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute erythroid leukaemia;SURFACE_ANTIGENS:Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45.;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ACUTE ERYTHROID LEUKEMIA" "CANCER_TYPE_DETAILED:Pure Erythroid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:PERL;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Matched;STUDY:BeatAML;SEQUENCING_TYPE:Whole-exome;DETAILED_CANCER_TYPE:Acute erythroid leukemia"
"ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE" "CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, T/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALTNOS;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:13.29;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:52.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;WBC:14;AGE_AT_PROCUREMENT:53;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:11.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.68;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Post-Transplant|Post-Chemotherapy|Residual Disease;KARYOTYPE:45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3];PB_BLAST_PERCENTAGE:59;WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Decitabine;LDH_LEVEL:167;MOST_RECENT_TREATMENT_DURATION:80;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Deleted 5q;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:34;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:32;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:29;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Mixed phenotype acute leukaemia, T/myeloid, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mixed phenotype acute leukaemia, T/myeloid, NOS;TOTAL_PROTEIN_LEVEL:6.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE" "CANCER_TYPE_DETAILED:Acute Leukemias of Ambiguous Lineage;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;TMB_NONSYNONYMOUS:4.4;SEX:Female;AGE:12.92;FRACTION_GENOME_ALTERED:0.0004;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:t(11;19), MLL-MLLT1;CANCER_SUBTYPE_CURATED:MLL-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow;TX_17-DMAG:2;TX_19D12:1;TX_ABRAXANE:0;TX_ABT-199:0;TX_ABT-263:5;TX_ACTINOMYCIN D:0;TX_AZD-2171:1;TX_AZD-6244:2;TX_AZD1480:0;TX_AZD8055:0;TX_BAL101553:0;TX_BI6727 (VOLASERTIB):0;TX_BMN-673:0;TX_BMS-354825:3;TX_BMS-754807:1;TX_BORTEZOMIB:2;TX_CABOZANTINIB (XL-148):0;TX_CBL0137:0;TX_CDX-011 (GLEMBATUMUMAB):0;TX_CGC(PG)-11047:2;TX_CISPLATIN:2;TX_CLORETAZINE:0;TX_CPX351:0;TX_CX-5461 (POL1):0;TX_CYTARABINE:0;TX_E7438/EPZ6438:0;TX_EC1456:0;TX_ERIBULIN:0;TX_GENZ-644282:0;TX_GS-9820:0;TX_GSK690693:1;TX_GSK923295A:0;TX_HGS-ETR1:1;TX_IMC-A12:0;TX_INK128-1110-028:0;TX_JNJ26481585:3;TX_JNJ26854165:4;TX_KPT-330:0;TX_LAPATINIB:1;TX_LY 2606368:0;TX_MK-2206:0;TX_MK-8242:0;TX_MLN4924:3;TX_MLN8237:5;TX_MM-141:0;TX_NSC060043:0;TX_NSC750854:0;TX_PCI-32765:1;TX_PF-03084014:0;TX_PIXANTRONE:0;TX_PR-104:6;TX_RAPAMYCIN:2;TX_RG7112:0;TX_RO4929097:1;TX_RUXOLITINIB:0;TX_SAHA:1;TX_SAR3419:2;TX_SB-715992:4;TX_SCH 727965:0;TX_SGI-1776:1;TX_SGN-CD19A:0;TX_SORAFENIB:1;TX_STA9090 (GANETESPIB):0;TX_STF-118804:0;TX_SU11248:2;TX_SVV-001:0;TX_TAK-701:0;TX_TB-403:0;TX_TL32711:0;TX_TOPOTECAN:5;TX_TRISENOX(ATO):0;TX_VINCRISTINE:6;TX_VS-4718:0;TX_XL147:0;TX_XL765:0"
"ACUTE LYMPHOBLASTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Acute Lymphoblastic Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALL;TMB_NONSYNONYMOUS:0.0;SOMATIC_STATUS:Matched;SEX:Male;AGE:0.75;GENE_PANEL:Targeted_Seq;COHORT:INF_NON_MLLr_Validation;MLL_STATUS:INF_NON_MLLr;LEUKEMIA_TYPE:ALL"
"ACUTE LYMPHOBLASTIC LEUKEMIA ALL, B-CELL" NA
"ACUTE LYMPHOBLASTIC LEUKEMIA ALL, T-CELL" NA
"ACUTE LYMPHOID LEUKEMIA" "CANCER_TYPE_DETAILED:B-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:BALL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.17;GENE_PANEL:WGS;COHORT:INF_MLLr_Discovery;MUTATION_RATE:3.97E-08;MLL_STATUS:INF_MLLr;LEUKEMIA_TYPE:Pre-B"
"ACUTE MEGAKARYOBLASTIC LEUKAEMIA" "CANCER_TYPE_DETAILED:Acute Megakaryoblastic Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMKL;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:6.71;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:60.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:3.1;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:60;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:5;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY,del(13)(q12q14)[3]/46,XY[17];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:13;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:Yes;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-6;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute megakaryoblastic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute megakaryoblastic leukaemia;SURFACE_ANTIGENS:CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature c"
"ACUTE MEGAKARYOBLASTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Acute Megakaryoblastic Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMKL;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:6.71;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:60.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:3.1;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:60;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:5;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY,del(13)(q12q14)[3]/46,XY[17];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:13;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:Yes;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-6;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute megakaryoblastic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute megakaryoblastic leukaemia;SURFACE_ANTIGENS:CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature c"
"ACUTE MONOBLASTIC AND MONOCYTIC LEUKAEMIA" "CANCER_TYPE_DETAILED:Acute Monoblastic/Monocytic Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMOL;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:13.06;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:14.9;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;BRAF_MUTATION:G596R;FAB:M5;HEMOGLOBIN_LEVEL:7.6;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.85;CURRENT_STAGE:Allogeneic - Sibling;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:68;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation);CUMULATIVE_TREATMENT_STAGES:Allogeneic - Sibling | Consolidation | Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation);LDH_LEVEL:313;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:21.9;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.9;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3;PB_ALT_LEVEL:14;PB_AST_LEVEL:18;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:30;PB_MONOCYTES_PERCENTAGE:49;PB_NEUTROPHILS_PERCENTAGE:3;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute monoblastic and monocytic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute monoblastic and monocytic leukaemia;SURFACE_ANTIGENS:Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR;TOTAL_PROTEIN_LEVEL:5.5;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ACUTE MONOBLASTIC/MONOCYTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Acute Monoblastic/Monocytic Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMOL;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:13.06;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:14.9;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;BRAF_MUTATION:G596R;FAB:M5;HEMOGLOBIN_LEVEL:7.6;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.85;CURRENT_STAGE:Allogeneic - Sibling;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:68;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation);CUMULATIVE_TREATMENT_STAGES:Allogeneic - Sibling | Consolidation | Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation);LDH_LEVEL:313;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:21.9;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.9;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3;PB_ALT_LEVEL:14;PB_AST_LEVEL:18;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:30;PB_MONOCYTES_PERCENTAGE:49;PB_NEUTROPHILS_PERCENTAGE:3;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute monoblastic and monocytic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute monoblastic and monocytic leukaemia;SURFACE_ANTIGENS:Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR;TOTAL_PROTEIN_LEVEL:5.5;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ACUTE MYELOBLASTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0.166666666667;SOMATIC_STATUS:Matched;STUDY:LAML-KR;SEQUENCING_TYPE:Whole-exome;DETAILED_CANCER_TYPE:Acute myeloblastic leukemia"
"ACUTE MYELOBLASTIC LEUKEMIA, IN RELAPSE" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;STUDY:LAML-KR;SEQUENCING_TYPE:Whole-exome;DETAILED_CANCER_TYPE:Acute myeloblastic leukemia, in relapse"
"ACUTE MYELOGENOUS LEUKEMIA AML" NA
"ACUTE MYELOGENOUS LEUKEMIA AML, M2 MYELOBLASTIC" NA
"ACUTE MYELOGENOUS LEUKEMIA AML, M3 PROMYELOCYTIC" NA
"ACUTE MYELOGENOUS LEUKEMIA AML, M4 MYELOMONOCYTIC" NA
"ACUTE MYELOGENOUS LEUKEMIA AML, M5 EOSINOPHILIC/MONOCYTIC" NA
"ACUTE MYELOGENOUS LEUKEMIA AML, M5 MONOCYTIC" NA
"ACUTE MYELOGENOUS LEUKEMIA AML, M6 ERYTHROLEUKEMIA" NA
"ACUTE MYELOGENOUS LEUKEMIA AML, M7 MEGAKARYOBLASTIC" NA
"ACUTE MYELOGENOUS LEUKEMIA M5A" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:4.63333333333;SEX:Male;FRACTION_GENOME_ALTERED:0.0320;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Acute Myelogenous Leukemia (AML), M5 (Eosinophilic/Monocytic);TUMOR_TYPE:B-cell_ALL;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:83.25472569;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:acute myelogenous leukemia M5a;HIST_SUBTYPE1:acute_lymphoblastic_B_cell_leukaemia;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:blood;LINEAGE_SUB_SUBTYPE:M5;LINEAGE_SUBTYPE:AML;NAME:BDCM;PATHOLOGIST_ANNOTATION:Leukemia:ALL;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:B-cell_ALL"
"ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS" NA
"ACUTE MYELOID LEUKAEMIA AML AND RELATED PRECURSOR NEOPLASMS" NA
"ACUTE MYELOID LEUKAEMIA, NOS" "CANCER_TYPE_DETAILED:AML, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNOS;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:10.16;OS_STATUS:1:DECEASED;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:179.1;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s);FAB:NOS;HEMOGLOBIN_LEVEL:8.7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.93;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:60;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:81;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Hydroxyurea;LDH_LEVEL:673;MOST_RECENT_TREATMENT_DURATION:9;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Intermediate-I;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:1;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.3;PB_ALT_LEVEL:42;PB_AST_LEVEL:45;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:5;PB_MONOCYTES_PERCENTAGE:24;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myeloid leukaemia, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute myeloid leukaemia, NOS;SURFACE_ANTIGENS:CD13, CD34, CD38, CD117, CD123, HLA-DR;TOTAL_PROTEIN_LEVEL:6.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ACUTE MYELOID LEUKEMIA" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:11.83;GENE_PANEL:WES;COHORT:NON_INF_MLLr;MUTATION_RATE:1.99E-07;MLL_STATUS:NON_INF_MLLr;LEUKEMIA_TYPE:AML M0"
"ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA" "CANCER_TYPE_DETAILED:AML with Myelodysplasia-Related Changes;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLMRC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;STUDY:LAML-KR;SEQUENCING_TYPE:Whole-exome;DETAILED_CANCER_TYPE:Acute myeloid leukemia with multilineage dysplasia"
"ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA, NOT HAVING ACHIEVED REMISSION" "CANCER_TYPE_DETAILED:AML with Myelodysplasia-Related Changes;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLMRC;TMB_NONSYNONYMOUS:0.633333333333;SOMATIC_STATUS:Matched;STUDY:LAML-KR;SEQUENCING_TYPE:Whole-exome;DETAILED_CANCER_TYPE:Acute myeloid leukemia with multilineage dysplasia, not having achieved remission"
"ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA RELATED CHANGES" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:77;TUMOR_TISSUE_SITE:Bone marrow;WHO_CLASS:Acute Myeloid Leukemia With Myelodysplasia Related Changes;CYTOGENETICS:46,XY;GERMLINE_CONTROL:CD3+ T cell"
"ACUTE MYELOID LEUKEMIAS" "CANCER_TYPE_DETAILED:Acute myeloid leukemias;CANCER_TYPE:Leukemia;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:17.08;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:AML;SUBTYPE_DETAILS:M1Auer;TUMOR_DETAILS:Acute myeloid leukemias"
"ACUTE MYELOMONOCYTIC LEUKAEMIA" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.78;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:69.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:282.1;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:69;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M4;HEMOGLOBIN_LEVEL:7.7;SAMPLE_SITE:Leukapheresis;CREATININE_LEVEL_PRERESECTION:1.68;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:47,XY,+8[cp9]/46,XY[11];PB_BLAST_PERCENTAGE:19;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:80;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Hydroxyurea;LDH_LEVEL:4559;MOST_RECENT_TREATMENT_DURATION:3;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Signal copy for CEP 8 and ETO;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:4;ELN_2008:Intermediate-II;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:56;PB_AST_LEVEL:56;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:5;PB_MONOCYTES_PERCENTAGE:3;PB_NEUTROPHILS_PERCENTAGE:11;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myelomonocytic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute myelomonocytic leukaemia;SURFACE_ANTIGENS:dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive;TOTAL_PROTEIN_LEVEL:5.4;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ACUTE MYELOMONOCYTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Myeloid Neoplasm;CANCER_TYPE:Blood Cancer, NOS;ONCOTREE_CODE:MNM;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:10.26666667;OS_STATUS:1:DECEASED;GENE_PANEL:Enhanced exome;AGE_AT_DIAGNOSIS:88.5;SOURCE:WashU_on_study;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:40;DISEASE:AML;PERFORMANCE_STATUS:1;PERIPHERAL_BLASTS_PERCENTAGE:17.0;AML_FAB:Acute myelomonocytic leukemia (AMML - M4);CLINICAL_ONSET_AML:De novo;CYCLES_COMPLETED:7.0;CYTOGENETIC_RISK:Int;KYRYOTYPE:trisomy 8 85%;MORPHOLOGIC_RESPONSE:PR;PERIPHERAL_BLOOD_WBC:4.8;TRANSPLANT:No"
"ACUTE PROMYELOCYTIC LEUKAEMIA WITH T(15;17)(Q22;Q12); PML-RARA" NA
"ACUTE PROMYELOCYTIC LEUKAEMIA WITH T15;17Q22;Q12;  PML-RARA" NA
"ACUTE PROMYELOCYTIC LEUKAEMIA WITH T15;17Q22;Q12; PML-RARA" NA
"ACUTE UNDIFFERENTIATED LEUKAEMIA" "CANCER_TYPE_DETAILED:Acute Undifferentiated Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AUL;TMB_NONSYNONYMOUS:1.233333333;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:12.66;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:68.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;KRAS_MUTATION:Negative;WBC:2.22;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:68;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Intrathecal;HEMOGLOBIN_LEVEL:11.2;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.27;CURRENT_STAGE:Allogeneic - Matched Unrelated Donor;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:43.8;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:42;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:HyperCVAD Course B (Cytarabine, Methotrexate)|EWALL Protocol|Bu/Cy/TBI|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Intrathecal;CURRENT_REGIMEN:Bu/Cy/TBI;LDH_LEVEL:170;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:c/w karyotype;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:3;ELN_2008:Intermediate-I;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:32.5;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:100.9;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:p.G12S; MAF: 15%;PB_ALBUMIN_LEVEL:3.5;PB_ALT_LEVEL:23;PB_AST_LEVEL:20;PB_BASOPHILS_PERCENTAGE:1;PB_EOSINOPHILS_PERCENTAGE:0.9;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:26.7;PB_MONOCYTES_PERCENTAGE:5.7;PB_NEUTROPHILS_PERCENTAGE:20.9;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute undifferentiated leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute undifferentiated leukaemia;SURFACE_ANTIGENS:partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive;TOTAL_PROTEIN_LEVEL:6.3;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ACUTE UNDIFFERENTIATED LEUKEMIA" "CANCER_TYPE_DETAILED:Acute Undifferentiated Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AUL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:15.75;GENE_PANEL:WES;COHORT:NON_INF_MLLr;MUTATION_RATE:7.63E-07;MLL_STATUS:NON_INF_MLLr;LEUKEMIA_TYPE:AUL"
"ACUTE_BIPHENOTYPIC_LEUKEMIA" "CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:7.33333333333;SUBTYPE:Acute Biphenotypic Leukemia;LINEAGE:blood;LINEAGE_SUBTYPE:acute_biphenotypic_leukemia"
"ACUTE_LYMPHOBLASTIC_B_CELL_LEUKAEMIA" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:2.87341935688;SEX:Male;FRACTION_GENOME_ALTERED:0.0313;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:B-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_B_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"ACUTE_LYMPHOBLASTIC_LEUKAEMIA" "CANCER_TYPE_DETAILED:Acute Undifferentiated Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;TMB_NONSYNONYMOUS:1.98929032399;SEX:Male;FRACTION_GENOME_ALTERED:0.1062;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Leukemia_Other;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"ACUTE_LYMPHOBLASTIC_T_CELL_LEUKAEMIA" "CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:24.8661290499;SEX:Male;FRACTION_GENOME_ALTERED:0.1179;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:T-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_T_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"ACUTE_MONOCYTIC_LEUKEMIA" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:7.96666666667;SEX:Male;AGE:1;FRACTION_GENOME_ALTERED:0.2877;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Acute Myelogenous Leukemia (AML), M5 (Eosinophilic/Monocytic);TUMOR_TYPE:AML;HISTOLOGY:Haematopoietic_Neoplasm;PURITY:1;MUTATION_RATE:149.7150398;GENOME_DOUBLINGS:0;DOUBLING_TIME:101.8;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:acute_monocytic_leukemia;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640 + 10% FBS;HIST_SUBTYPE1:acute_myeloid_leukaemia;HIST_SUBTYPE2:M5;HIST_SUBTYPE3:NS;LIFE_STAGE:pediatric;LINEAGE:blood;LINEAGE_SUB_SUBTYPE:M5;LINEAGE_SUBTYPE:AML;NAME:THP-1;PATHOLOGIST_ANNOTATION:Leukemia:AML;PROTEOMICS_TMT_LABEL:130c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.05 mM 2-mercaptoethanol;TYPE_REFINED:AML"
"ACUTE_MYELOID_LEUKAEMIA" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:3.42600000243;SEX:Female;FRACTION_GENOME_ALTERED:0.2495;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Aml;HISTOLOGICAL_SUBTYPE:Acute_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"ACYC" "CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:ACYC;SOMATIC_STATUS:Matched;SEX:Male;AGE:39;SAMPLE_TYPE:Primary;PRIMARY_SITE:Salivary gland;TUMOR_TISSUE_SITE:Salivary gland;PLATFORM:Targeted Sequencing;TUMOR_STAGE:III;STUDY:ACyC (FMI 2014);FUSION_STATUS:NO;GENOMIC_ALTERATIONS:0;METASTATIC_TUMOR_INDICATOR:No;PATIENT_GRADE:Intermediate;ACTIONABLE_ALTERATIONS:0"
"ADAMANTINOMA" "CANCER_TYPE_DETAILED:Craniopharyngioma, Adamantinomatous Type;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:ACPG;SEX:Female;AGE:3;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;TUMOR_TISSUE_SITE:Suprasellar/Hypothalamic/Pituitary;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:No;SURGERY:Yes;SAMPLE_ORIGIN:Repeat resection;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1344;AGE_CLASS:[0,5);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1344;AGE_AT_SPECIMEN_DIAGNOSIS:1344;CANCER_PREDISPOSITIONS:None documented;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 Mutant;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;H3F3A_CTNNB1_STATUS:CTNNB1 Mutant;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Craniopharyngioma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:No;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:No;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Suprasellar/Hypothalamic/Pituitary;UPDATED_GRADE:I"
"ADCA ACINAR WITH MUCIN PRODUCTION" NA
"ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.266666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:5.2;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:65.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:161.89;AGE_AT_PROCUREMENT:65;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy|Other;HEMOGLOBIN_LEVEL:6.7;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.65;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis|Post-Chemotherapy;KARYOTYPE:46,XY,i(17)(q10)[20];PB_BLAST_PERCENTAGE:12;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:18;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Other;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:3923;MOST_RECENT_TREATMENT_DURATION:9;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metapha;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Intermediate-II;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:20.1;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:81;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:p.G12D; MAF 46%;PB_ALBUMIN_LEVEL:2.9;PB_ALT_LEVEL:44;PB_AST_LEVEL:165;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0.9;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:32;PB_LYMPHOCYTES_PERCENTAGE:7.4;PB_MONOCYTES_PERCENTAGE:35.2;PB_NEUTROPHILS_PERCENTAGE:18.5;PB_NUCLEATED_RBC_PERCENTAGE:4.8;PRIOR_CANCER:Pancreatic adenocarcinoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD13, CD33, CD34, CD117, and HLA-DR positive;TOTAL_PROTEIN_LEVEL:5.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ADENOCARCINOMA OF GALLBLADDER" "CANCER_TYPE_DETAILED:Adenocarcinoma of Gallbladder;CANCER_TYPE:Adenocarcinoma of Gallbladder;TMB_NONSYNONYMOUS:3.32746590179;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0857;SAMPLE_TYPE:Primary;ETHNICITY:Black/AA;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT341;TUMOR_PURITY:40;MSI_SCORE:0.19;MSI_TYPE:Stable;SAMPLE_COVERAGE:430;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:50;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:BAPTIST;AGE_CURRENT:48;ARCHER:NO;T_STAGE:1/2;N_STAGE:0;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:3.3;PARTA_CONSENTED_12_245:YES;TUMOR_GRADE:Moderate/Well;DATE_ADDED:4/7/15;MONTH_ADDED:2015/04;WEEK_ADDED:2015, Wk. 15;CRDB_CONSENT_DATE_DAYS:17734;CRDB_OFF_STUDY_DAYS:17853;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:17853;CVR_TMB_COHORT_PERCENTILE:44.1;CVR_TMB_TT_COHORT_PERCENTILE:59.4;CRDB_ADJ_TXT:YES;CRDB_BRAINMET:NO;CRDB_ECOG:1;CRDB_NOSYSTXT:1;CRDB_PRIOR_RX:NO;CBIOPORTAL_SAMPLE_CLASS:Tumor;CHOLELITHIASIS:0;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:7.457905544;OVERALL_SURVIVAL_MONTHS:7.457905544;TUMOR_STAGE_COLLECTION:4"
"ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION" "CANCER_TYPE_DETAILED:Adenocarcinoma of the Gastroesophageal Junction;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:GEJ;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.4074;SAMPLE_TYPE:Primary;OS_MONTHS:52;OS_STATUS:1:DECEASED;TUMOR_PURITY:30;MSI_SCORE:2.22;COHORT:Palliative;TUMOR_GRADE:2;WGD:1;FGA:0.651671059;SAMPLE_TYPE_DETAIL:Primary Esophagus;CSTAGE_CATEGORY:IV;PSTAGE_CATEGORY:IV;AGE_AT_SAMPLING:78"
"ADENOCARCINOMA PROSTATE WITH PROMINENT DUCTAL DIFFERENTIATION IDENTIFIED" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Male;AGE:71;FRACTION_GENOME_ALTERED:0.2006;SAMPLE_TYPE:Primary;OS_MONTHS:21.94;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:21.94;TISSUE_SOURCE_SITE:EJ;ICD_O_3_SITE:C61.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C61;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/24/13;PATH_T_STAGE:T3a;HISTOLOGICAL_DIAGNOSIS:Prostate Adenocarcinoma, Other Subtype;HISTORY_OTHER_MALIGNANCY:Yes, History of Prior Malignancy;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:219;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-EJ-A46G.ACBA1CE1-E248-47D3-B03D-BE0C1B4A6F21.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:430;SITE_OF_TUMOR_TISSUE:Prostate;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Adenocarcinoma prostate with prominent ductal differentiation identified;LYMPH_NODES_EXAMINED:YES;LATERALITY:Bilateral;TARGETED_MOLECULAR_THERAPY:NO;CLIN_M_STAGE:M0;CLIN_T_STAGE:T3a;GLEASON_SCORE:8;BONE_SCAN_RESULT:Normal (no evidence of prostate cancer) [cM0];BIOCHEMICAL_RECURRENCE_INDICATOR:NO;DAYS_TO_BONE_SCAN_PERFORMED:28;DAYS_TO_PSA:93;GLEASON_PATTERN_PRIMARY:4;GLEASON_PATTERN_SECONDARY:4;GLEASON_PATTERN_TERTIARY:5;INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD:Core needle biopsy;PSA_MOST_RECENT_RESULTS:0.1"
"ADENOCARCINOMA WITH FOCAL MUCINOUS FEATURES" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:2.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:67;FRACTION_GENOME_ALTERED:0.3677;SAMPLE_TYPE:Primary;OS_MONTHS:4.86;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:4.86;TISSUE_SOURCE_SITE:YJ;ICD_O_3_SITE:C61.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C61.9;ICD_O_3_HISTOLOGY:8480/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/13/14;PATH_T_STAGE:T3b;HISTOLOGICAL_DIAGNOSIS:Prostate Adenocarcinoma, Other Subtype;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2008;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2051;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-YJ-A8SW.33D6587B-0289-49B5-9D16-497B6C17EFD9.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:1000;SITE_OF_TUMOR_TISSUE:Prostate;HISTOLOGICAL_SUBTYPE:adenocarcinoma with focal mucinous features;LYMPH_NODES_EXAMINED:YES;LATERALITY:Right;CLIN_T_STAGE:T1c;GLEASON_SCORE:9;BIOCHEMICAL_RECURRENCE_INDICATOR:YES;DAYS_TO_BIOCHEMICAL_RECURRENCE_FIRST:148;DAYS_TO_PSA:148;GLEASON_PATTERN_PRIMARY:5;GLEASON_PATTERN_SECONDARY:4;INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD:Core needle biopsy;PSA_MOST_RECENT_RESULTS:0.38"
"ADENOCARCINOMA WITH NE FEATURES" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.6;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2390;TISSUE_SOURCE_SITE:Michigan;AGE_AT_DIAGNOSIS:69.5;TISSUE_SITE:Liver;GLEASON_SCORE:9;PSA:8.14;AGE_AT_PROCUREMENT:73;ABI_ENZA_EXPOSURE_STATUS:Naive;AR_SCORE:0.034240574;CHEMO_REGIMEN_CATEGORY:Other:  Carboplatin+Etopside;ETS_FUSION_SEQ:Positive;PATHOLOGY_CLASSIFICATION:Adenocarcinoma with NE features;AR_CAPTURE_SCORE:0.010512826;AR_POLYA_SCORE:0.034240574;CAPTURE_ARV7_SRPM:0;ETS_FUSION_DETAILS:TMPRSS2-ERG;NEPC_CAPTURE_SCORE:0.712959776;NEPC_POLYA_SCORE:0.768063486;NEPC_SCORE:0.768063486;NEUROENDOCRINE_FEATURES:Yes;POLYA_ARV7_SRPM:0;TAXANE_EXPOSURE_STATUS:Exposed;UNIQUE_PAPER_SAMPLES:YES"
"ADENOCARCINOMA, ENDOMETRIOID" "CANCER_TYPE_DETAILED:Endometrioid Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:EOV;TMB_NONSYNONYMOUS:61.4333333333;SEX:Female;FRACTION_GENOME_ALTERED:0.1109;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, endometrioid;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:0.97;MUTATION_RATE:545.552709;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:Riken;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:MEM+10% FBS;HIST_SUBTYPE1:endometrioid_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:endometrioid;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OVK18;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"ADENOCARCINOMA, LOW GRADE SEROUS" "CANCER_TYPE_DETAILED:Low-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:LGSOC;TMB_NONSYNONYMOUS:8.86666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.4479;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, low grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:111.0355795;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Ovarian Cancer;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:low_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:Hey-A8;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:127c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"ADENOCARCINOMA, MIXED" "CANCER_TYPE_DETAILED:Mixed Ovarian Carcinoma;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:MXOV;TMB_NONSYNONYMOUS:5.96666666667;SEX:Female;AGE:78;FRACTION_GENOME_ALTERED:0.1723;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, mixed;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:154.7010879;GENOME_DOUBLINGS:0;DOUBLING_TIME:58.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM:F12 (1:1)+5%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mixed_serous_clear_cell;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OV7;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM L-glutamine, 0.5ug/ml hydrocortisone, 10ug/ml insulin;TYPE_REFINED:ovary"
"ADENOCARCINOMA, MIXED SUBTYPES" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:4.56666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:77;FRACTION_GENOME_ALTERED:0.3249;OS_MONTHS:110.56666670000001;OS_STATUS:0:LIVING;ETHNICITY:Chinese;SAMPLE_CLASS:Tumor;SMOKING_PACK_YEARS:0.5;STAGE:I;COHORT:GSK;PURITY:0.25;SMOKING_STATUS:Yes;CHEMOTHERAPY:No;SEQUENCING_TYPE:WES + RNA-Seq;RNA_SEQ_ANALYSIS:Tumor;ADENOCARCINOMA_SUBTYPE_WHO2015:Adenocarcinoma, mixed subtypes;EXOME_SEQ:Paired;HISTOLOGICAL_GRADE:Moderately differentiated;IMSIG_B_CELLS:0.048237;IMSIG_INTERFERON:0.108619;IMSIG_MACROPHAGES:0.09546;IMSIG_MONOCYTES:0.093995;IMSIG_NEUTROPHILS:0.090214;IMSIG_NK_CELLS:0.040727;IMSIG_PLASMA_CELLS:0.077264;IMSIG_PROLIFERATION:0.07764;IMSIG_T_CELLS:0.078632;IMSIG_TRANSLATION:0.134912;TKI_TREATMENT:No"
"ADENOCARCINOMA, MUCINOUS" "CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:8.03333333333;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.9354;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Cystadenocarcinoma, mucinous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:178.9165928;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:RMUG-S;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"ADENOCARCINOMA, NOS" "CANCER_TYPE_DETAILED:Gallbladder Adenocarcinoma, NOS;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBAD;TMB_NONSYNONYMOUS:7.5;FRACTION_GENOME_ALTERED:0.6468;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Biliary_Tract;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:bile_duct;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:115.4161995;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:48 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bile_duct;LINEAGE_SUBTYPE:gallbladder_adenocarcinoma;NAME:SNU-308;PATHOLOGIST_ANNOTATION:Biliary_Tract:Carcinoma;SITE_SUBTYPE1:bile_duct;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:bile_duct"
"ADENOCARCINOMA, NOS 81403" NA
"ADENOCARCINOMA, SEROUS" "CANCER_TYPE_DETAILED:Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SOC;TMB_NONSYNONYMOUS:5.86666666667;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.2443;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:85.71718592;GENOME_DOUBLINGS:0;DOUBLING_TIME:148.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM:HAM's F12  1:1  +5% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OV56;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:128n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.5 ug/ml hydrocortisone + 10ug/ml insulin;TYPE_REFINED:ovary"
"ADENOCARCINOMA, SIGNET RING CELL" "CANCER_TYPE_DETAILED:Signet Ring Cell Carcinoma of the Stomach;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:SSRCC;TMB_NONSYNONYMOUS:11.9333333333;SEX:Male;AGE:34;FRACTION_GENOME_ALTERED:0.3853;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma, signet ring cell;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:198.6286534;GENOME_DOUBLINGS:0;GEOGRAPHIC_DISTRIBUTION:korea;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUB_SUBTYPE:signet_ring_cell;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:SNU-601;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:stomach"
"ADENOCARCINOMA, TUBULAR" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:7.36666666667;SEX:Male;AGE:55;FRACTION_GENOME_ALTERED:0.7421;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma, tubular;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:146.9369947;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUB_SUBTYPE:tubular;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:HuG1-N;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;PROTEOMICS_TMT_LABEL:127n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"ADENOCARCINOMA- MAMMARY GLAND" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:15.73333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:69;FRACTION_GENOME_ALTERED:0.4732;HISTOLOGICAL_SUBTYPE:Adenocarcinoma- mammary gland; breast; metastatic site: pleural effusion;;DOUBLING_TIME:25.4;P53:WT;CATEGORY_SAMPLE:Pleural effusion;EPITHELIAL:Yes;MDR:14"
"ADENOCARCINOMA- NOS" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:2.96666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:73;FRACTION_GENOME_ALTERED:0.0790;SAMPLE_TYPE:Primary;OS_MONTHS:14.13;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5.45;TISSUE_SOURCE_SITE:US;ICD_O_3_SITE:C25.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C25.0;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:12/17/13;GRADE:G3;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Pancreas-Adenocarcinoma-Other Subtype;HISTORY_OTHER_MALIGNANCY:Yes, History of Prior Malignancy;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:468;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-US-A77E.28115619-9EDD-41D9-A912-25D3BCB83DC4.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:200;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Adenocarcinoma- NOS;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:3;PRIMARY_SITE_PATIENT:Head of Pancreas;SMOKING_YEAR_STOPPED:1987;TARGETED_MOLECULAR_THERAPY:NO;PATIENT_DEATH_REASON:Pancreatic Cancer;CAUSE_OF_DEATH_SOURCE:Medical Record;FAMILY_HISTORY_CANCER_TYPE:Other;ALCOHOL_CONSUMPTION_FREQUENCY:7;ALCOHOL_HISTORY_DOCUMENTED:YES;DAILY_ALCOHOL:1;FAMILY_HISTORY_OF_CANCER:YES;DIABETES_DIAGNOSIS_INDICATOR:NO;TUMOR_RESECTED_MAX_DIMENSION:3.5;ALCOHOL_EXPOSURE_INTENSITY:Daily Drinker;GRADE_TIER_SYSTEM:Four Tier;HISTORY_CHRONIC_PANCREATITIS:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"ADENOCARCINOMA- PROSTATE" "CANCER_TYPE_DETAILED:Prostate;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PROSTATE;TMB_NONSYNONYMOUS:5.133333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:62;FRACTION_GENOME_ALTERED:0.2716;HISTOLOGICAL_SUBTYPE:Adenocarcinoma- prostate; metastatic site: bone;;DOUBLING_TIME:27.1;P53:MT;EPITHELIAL:Yes;MDR:11"
"ADENOCARCINOMA-MAMMARY GLAND" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:8.6;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.3208;HISTOLOGICAL_SUBTYPE:Adenocarcinoma-mammary gland; breast; epithelial; metastatic site: pleural effusion;;DOUBLING_TIME:41.9;P53:MT;CATEGORY_SAMPLE:Pleural effusion;EPITHELIAL:Yes;MDR:29"
"ADENOCARINOMA" "CANCER_TYPE_DETAILED:Ovary/Fallopian Tube;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVARY;TMB_NONSYNONYMOUS:7.9;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.3612;HISTOLOGICAL_SUBTYPE:Adenocarinoma;DOUBLING_TIME:34;P53:MT;EPITHELIAL:Yes;MDR:352"
"ADENOID CYSTIC BREAST CANCER" "CANCER_TYPE_DETAILED:Adenoid Cystic Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ACBC;TMB_NONSYNONYMOUS:0.366666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;SAMPLE_TYPE:Primary;PRIMARY_SITE:Breast;RADIATION_THERAPY:Not performed;VITAL_STATUS:Alive;PLATFORM:WES;TUMOR_STAGE:II;TUMOR_SIZE:40;STUDY:ACbC (MSKCC/Breast 2015);FUSION_STATUS:YES;GENOMIC_ALTERATIONS:15;IHC_HER2:Negative;OVERALL_PATIENT_HISTOLOGY:Cribriform/Tubular;METASTATIC_TUMOR_INDICATOR:No;MYB_MYBL1_FUSION:MYB-NFIB Fusion;ADJUVANT_CHEMO:Not performed;ADJUVANT_TX:Not performed;MYB_NFIB_FISH:Negative;TYPE_OF_SURGERY:Breast Conservation/Mastectomy;ER_STATUS_BY_IHC:Negative;NEOADJUVANT_CHEMO:Not performed;PR_STATUS_BY_IHC:Negative;LOCAL_REGIONAL_RECURRENCE:Positive;MYB_NFIB_REARRANGEMENT:MYB Exon 14-NFIB Exon 9;FOLLOWUP_YEARS:8;MYB_NFIB_CNA:9q13-q34.2 loss"
"ADENOID CYSTIC CARCINOMA" "CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:ACYC;SOMATIC_STATUS:Matched;SEX:Male;AGE:39;SAMPLE_TYPE:Primary;PRIMARY_SITE:Salivary gland;TUMOR_TISSUE_SITE:Salivary gland;PLATFORM:Targeted Sequencing;TUMOR_STAGE:III;STUDY:ACyC (FMI 2014);FUSION_STATUS:NO;GENOMIC_ALTERATIONS:0;METASTATIC_TUMOR_INDICATOR:No;PATIENT_GRADE:Intermediate;ACTIONABLE_ALTERATIONS:0"
"ADENOID CYSTIC CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUACC;TMB_NONSYNONYMOUS:3.374809745;SOMATIC_STATUS:Unmatched;SEX:Male;STUDY:ACyC, ACbC, LUACC Subtypes (MSK/FMI 2017);DATA_SOURCE:Foundation Medicine"
"ADENOSARCOMA" "CANCER_TYPE_DETAILED:Adenosarcoma;CANCER_TYPE:Adenosarcoma;ONCOTREE_CODE:LIAD;TMB_NONSYNONYMOUS:1.56666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.4201;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Pelvis;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:19"
"ADENOSQUAMOUS" "CANCER_TYPE_DETAILED:Cervical Adenosquamous Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEAS;TMB_NONSYNONYMOUS:1.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:25;FRACTION_GENOME_ALTERED:0.3921;SAMPLE_TYPE:Primary;OS_MONTHS:1.12;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:1.12;TISSUE_SOURCE_SITE:DG;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/11/13;GRADE:GX;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Adenosquamous;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DG-A2KH.E92814BB-F3A7-45E6-9F18-B775CD53693F.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:120;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b1;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:4;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);CLINICAL_STAGE:Stage IB1;PERFORMANCE_STATUS_TIMING:Pre-Adjuvant Therapy;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);CORPUS_INVOLVEMENT:ABSENT;HYSTERECTOMY_TYPE:Radical Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:ABSENT;PELVIC_EXTENSION_COMMENT:The pelvic nodules show circumscribed area of adipose tissue with local fat necrosis. No evidence of malignancy within this pelvic nodule.;PREGNANT_AT_DIAGNOSIS:NO"
"ADENOSQUAMOUS CARCINOMA" "CANCER_TYPE_DETAILED:Cervical Adenosquamous Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEAS;TMB_NONSYNONYMOUS:1.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:25;FRACTION_GENOME_ALTERED:0.3921;SAMPLE_TYPE:Primary;OS_MONTHS:1.12;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:1.12;TISSUE_SOURCE_SITE:DG;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/11/13;GRADE:GX;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Adenosquamous;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DG-A2KH.E92814BB-F3A7-45E6-9F18-B775CD53693F.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:120;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b1;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:4;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);CLINICAL_STAGE:Stage IB1;PERFORMANCE_STATUS_TIMING:Pre-Adjuvant Therapy;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);CORPUS_INVOLVEMENT:ABSENT;HYSTERECTOMY_TYPE:Radical Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:ABSENT;PELVIC_EXTENSION_COMMENT:The pelvic nodules show circumscribed area of adipose tissue with local fat necrosis. No evidence of malignancy within this pelvic nodule.;PREGNANT_AT_DIAGNOSIS:NO"
"ADENOSQUAMOUS CARCINOMA OF GALLBLADDER" "CANCER_TYPE_DETAILED:Adenosquamous Carcinoma of Gallbladder;CANCER_TYPE:Carcinoma with Squamous Differentiation;TMB_NONSYNONYMOUS:1.95743939523;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1797;SAMPLE_TYPE:Primary;ETHNICITY:White;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT410;TUMOR_PURITY:60;MSI_SCORE:0.92;MSI_TYPE:Stable;SAMPLE_COVERAGE:469;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:52;RELIGION:NONE;AGE_CURRENT:51;ARCHER:NO;T_STAGE:3/4;N_STAGE:1;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:2;PARTA_CONSENTED_12_245:YES;TUMOR_GRADE:Poor;DATE_ADDED:4/7/15;MONTH_ADDED:2015/04;WEEK_ADDED:2015, Wk. 15;CRDB_CONSENT_DATE_DAYS:18655;CRDB_OFF_STUDY_DAYS:18901;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:18901;CVR_TMB_COHORT_PERCENTILE:25.2;CVR_TMB_TT_COHORT_PERCENTILE:27.9;CBIOPORTAL_SAMPLE_CLASS:Tumor;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:9.133470226;OVERALL_SURVIVAL_MONTHS:9.133470226;TUMOR_STAGE_COLLECTION:4"
"ADENOSQUAMOUS CARCINOMA OF THE GALLBLADDER" "CANCER_TYPE_DETAILED:Adenosquamous Carcinoma of the Gallbladder;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBASC;TMB_NONSYNONYMOUS:2.594094285;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2446;SAMPLE_TYPE:Metastasis;OS_MONTHS:11.573;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Bile Duct;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Pelvis;TUMOR_PURITY:30;MSI_SCORE:0.46;MSI_TYPE:Stable;SAMPLE_COVERAGE:160;AGE_AT_SEQ_REPORTED_YEARS:55;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:55;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"ADENOSQUAMOUS CARCINOMA OF THE PANCREAS" "CANCER_TYPE_DETAILED:Adenosquamous Carcinoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;TMB_NONSYNONYMOUS:0.233333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:II;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1217;DIAGNOSIS AGE:54;GDNA(NG):2082;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"ADENOSQUAMOUS CARCINOMA OF THE STOMACH" "CANCER_TYPE_DETAILED:Adenosquamous Carcinoma of the Stomach;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAS;TMB_NONSYNONYMOUS:11.5333333333;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.4280;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:148.071063;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:epithelial-like;GROWTH_MEDIUM:RPMI 1640 medium with 10% fetal calf serum.;HIST_SUBTYPE1:mixed_adenosquamous_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:MKN1;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;PROTEOMICS_TMT_LABEL:130n;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"ADRENAL TUMOR" "CANCER_TYPE_DETAILED:Neuroblastoma;CANCER_TYPE:Peripheral Nervous System;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;AGE:3;OS_MONTHS:12.0;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic or Latino;GRADE:Unknown;ANALYSIS_COHORT:DISCOVERY;DIAGNOSIS:Unknown;PROTOCOL:3891, B003;OS_DAYS:365.0;TUMOR_SAMPLE_HISTOLOGY:Unknown;YEAR_OF_DIAGNOSIS:1993;AGE_IN_DAYS:936;RISK_GROUP:High Risk;FIRST_EVENT:Event;INSS_STAGE:Stage 4;MKI:Unknown;MYCN:Not Amplified;EFS_TIME:219.0;EFSCENS:1.0;ICDO:Unknown;ICDO_SNOMED_DESCRIPTION:Right sided abdominal adrenal tumor crossing midline - no intrapsinal extn. Size: 13cm x 6cm x 9.5cm, BM,;LAST_FOLLOWUP_YEAR:1994.0;SCENS:1.0;SNOMED:999;STIME:359.0"
"ADRENOCORTICAL ADENOMA" "CANCER_TYPE_DETAILED:Adrenocortical Adenoma;CANCER_TYPE:Adrenocortical Adenoma;ONCOTREE_CODE:ACA;TMB_NONSYNONYMOUS:13.70207577;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.6307;SAMPLE_TYPE:Metastasis;OS_MONTHS:16.67;OS_STATUS:0:LIVING;PRIMARY_SITE:Adrenal Gland;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lung;TUMOR_PURITY:60;SAMPLE_COVERAGE:1023;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:DNA;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"ADRENOCORTICAL CARCINOMA" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ADRENOCORTICAL CARCINOMA- MYXOID TYPE" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.86666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:26;FRACTION_GENOME_ALTERED:0.9014;SAMPLE_TYPE:Primary;OS_MONTHS:36.24;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:36.24;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/18/13;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical Carcinoma- Myxoid Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;DAYS_LAST_FOLLOWUP:674;INITIAL_PATHOLOGIC_DX_YEAR:2006;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2520;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5JQ.3AE0E638-5907-4B56-9C55-E58D97B27AFF.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:NO;LATERALITY:Right;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:YES;CLINICAL_STATUS_WITHIN_3_MTHS_SURGERY:No imaging evidence of disease;MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:None;MITOSES_PER_50_HPF:3;NECROSIS:Necrosis Absent;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Present;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:4;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ADRENOCORTICAL CARCINOMA- ONCOCYTIC TYPE" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.93333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:99.8;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:99.80;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/17/13;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical Carcinoma- Oncocytic Type;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;DAYS_LAST_FOLLOWUP:2782;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2571;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5JD.AA05D1FB-38B5-4D96-B9EE-07523C95C481.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;LATERALITY:Left;CLIN_M_STAGE:M0;MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:None;MITOSES_PER_50_HPF:4;NECROSIS:Necrosis Absent;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Present;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ADRENOCORTICAL CARCINOMA- USUAL TYPE" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ADULT T-CELL LEUKEMIA/LYMPHOMA" "CANCER_TYPE_DETAILED:Adult T-Cell Leukemia/Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:ATLL;TMB_NONSYNONYMOUS:7.43333333333;SEX:Male;AGE:61;FRACTION_GENOME_ALTERED:0.2069;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:T-cell_ALL;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:79.63113609;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:cutaneous T cell lymphoma;HIST_SUBTYPE1:adult_T_cell_lymphoma-leukaemia;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HH;PATHOLOGIST_ANNOTATION:Leukemia:ALL;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_ALL"
"ADULT_T_CELL_LYMPHOMA-LEUKAEMIA" "CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:2.76290322777;SEX:Male;FRACTION_GENOME_ALTERED:0.2060;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:T-Cell_All;HISTOLOGICAL_SUBTYPE:Adult_T_Cell_Lymphoma-Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"AGGRESSIVE DIGITAL PAPILLARY ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Aggressive Digital Papillary Adenocarcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:ADPA;SEX:Male;AGE:72.36139679;RACE:Other;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;EQD_TERTILES:2nd tertile;TIME_FROM_DX_TO_SEQ:0;XRT_TX:Yes"
"ALL" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ALVEOLAR RHABDOMYOSARCOMA" "CANCER_TYPE_DETAILED:Alveolar Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ARMS;TMB_NONSYNONYMOUS:14.8333333333;SEX:Male;AGE:17;FRACTION_GENOME_ALTERED:0.4922;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Rhabdomyosarcoma, alveolar;TUMOR_TYPE:soft_tissue;HISTOLOGY:Rhabdomyosarcoma;PURITY:0.98;MUTATION_RATE:195.104647;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:adherent epithelial-like cells growing as monolayer;DOUBLING_TIME_FROM_VENDOR:~  35 hrs;GROWTH_MEDIUM:90-95% RPMI 1640 +5-10 h.i. FBS;HIST_SUBTYPE1:alveolar;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUB_SUBTYPE:alveolar;LINEAGE_SUBTYPE:rhabdomyosarcoma;NAME:RH-30;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Rhabdoid;PROTEOMICS_TMT_LABEL:128c;SITE_OF_FINDING:bone_marrow;SITE_SUBTYPE1:striated_muscle;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"ALVEOLAR SOFT PART SARCOMA" "CANCER_TYPE_DETAILED:Alveolar Soft Part Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ASPS;TMB_NONSYNONYMOUS:2.4;SEX:Female;OS_MONTHS:154;OS_STATUS:0:LIVING;PRIMARY_SITE:Lung;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:17;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Lung;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:26.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:145;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"AMELANOTIC" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:12.43333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.1862;HISTOLOGICAL_SUBTYPE:Malignant amelanotic melanoma;PRIOR_TREATMENT:None;DOUBLING_TIME:20.5;P53:WT;EPITHELIAL:No;MDR:12"
"AMELANOTIC NODULAR" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0047;OS_MONTHS:31.94;OS_STATUS:0:LIVING;PFS_MONTHS:21.64;PFS_STATUS:1:Progressed;SUBTYPE:amelanotic nodular;TUMOR_TYPE:Melanoma;HISTOLOGY:cutaneous;RECIST_RESPONSE:clinical benefit;CENSORED:LIVING;DRUG_TYPE:anti-CTLA-4;RECIST:PR;AGE_START_IO:74.0;OTHER_CONCURRENT_THERAPY:no;ROH_RESPONSE:clinical benefit;VA_RESPONSE:clinical benefit"
"AML" "CANCER_TYPE_DETAILED:Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:LEUK;TMB_NONSYNONYMOUS:3.35249282986;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.27;GENE_PANEL:Targeted_Seq;COHORT:INF_NON_MLLr_Validation;MLL_STATUS:INF_NON_MLLr;LEUKEMIA_TYPE:AML/ALL"
"AML WITH BIALLELIC MUTATIONS OF CEBPA" "CANCER_TYPE_DETAILED:AML with Biallelic Mutations of CEBPA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLCEBPA;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:8.78;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:8.5;AGE_AT_PROCUREMENT:79;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:10.6;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.75;CURRENT_STAGE:Induction;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:45,X,-Y[19]/46,XY[1];PB_BLAST_PERCENTAGE:72;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:87;CEBPA_MUTATION:1031?1032 ins AAC; MAF 50%;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:460;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:32.3;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:103.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.4;PB_ALT_LEVEL:19;PB_AST_LEVEL:41;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:17;PB_MONOCYTES_PERCENTAGE:4;PB_NEUTROPHILS_PERCENTAGE:1;PRIOR_CANCER:Bladder Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated CEBPA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated CEBPA;SURFACE_ANTIGENS:CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +;TOTAL_PROTEIN_LEVEL:6.2;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH INV(16)(P13.1Q22) OR T(16;16)(P13.1;Q22); CBFB-MYH11" NA
"AML WITH INV(3)(Q21Q26.2) OR T(3;3)(Q21;Q26.2); RPN1-EVI1" NA
"AML WITH INV16P13.1;Q22 OR T16:16P13.1:Q22;  CBFB-MYH11" NA
"AML WITH INV16P13.1Q22 OR T16;16P13.1;Q22; CBFB-MYH11" NA
"AML WITH INV16P13.1Q22 OR T16;16P13.1;Q22;CBFB-MYH11" NA
"AML WITH INV3Q21.3;Q26.2 OR T3;3Q21.3;Q26.2; GATA2, MECOM" NA
"AML WITH INV3Q21.3Q26.2 OR T3;3Q21.3;Q26.2; GATA2, MECOM" NA
"AML WITH INV3Q21;Q26.2 OR T3;3Q21;Q26.2; RPN1-EVI1" NA
"AML WITH INV3Q21Q26.2 OR T3;3Q21;Q26.2; RPN1-EVI1" NA
"AML WITH MATURATION" "CANCER_TYPE_DETAILED:AML with Maturation;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AM;SOMATIC_STATUS:Matched;SEX:Male;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:61.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:16.5;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:61;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;FAB:M2;HEMOGLOBIN_LEVEL:8.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.05;CURRENT_STAGE:Induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:66;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:46;CUMULATIVE_TREATMENT_REGIMENS:3+7 (Cytarabine, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:3+7 (Cytarabine, Daunorubicin);LDH_LEVEL:551;MOST_RECENT_TREATMENT_DURATION:7;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.4;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:89.1;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:18;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:24;PB_MONOCYTES_PERCENTAGE:5;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with maturation;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with maturation;SURFACE_ANTIGENS:CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+);TOTAL_PROTEIN_LEVEL:7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH MINIMAL DIFFERENTIATION" "CANCER_TYPE_DETAILED:AML with Minimal Differentiation;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLMD;TMB_NONSYNONYMOUS:0.266666667;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.16;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:70.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:2.5;AGE_AT_PROCUREMENT:70;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M0;HEMOGLOBIN_LEVEL:9.1;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.9;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Residual Disease;KARYOTYPE:46,XY[18];PB_BLAST_PERCENTAGE:30;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:75;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Quizartinib;LDH_LEVEL:137;MOST_RECENT_TREATMENT_DURATION:155;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:25.8;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:89.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:16;PB_AST_LEVEL:22;PB_BASOPHILS_PERCENTAGE:1;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:64;PB_MONOCYTES_PERCENTAGE:0;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with minimal differentiation;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with minimal differentiation;SURFACE_ANTIGENS:partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive;TOTAL_PROTEIN_LEVEL:6.3;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH MUTATED CEBPA" "CANCER_TYPE_DETAILED:AML with Biallelic Mutations of CEBPA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLCEBPA;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:8.78;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:8.5;AGE_AT_PROCUREMENT:79;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:10.6;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.75;CURRENT_STAGE:Induction;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:45,X,-Y[19]/46,XY[1];PB_BLAST_PERCENTAGE:72;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:87;CEBPA_MUTATION:1031?1032 ins AAC; MAF 50%;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:460;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:32.3;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:103.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.4;PB_ALT_LEVEL:19;PB_AST_LEVEL:41;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:17;PB_MONOCYTES_PERCENTAGE:4;PB_NEUTROPHILS_PERCENTAGE:1;PRIOR_CANCER:Bladder Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated CEBPA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated CEBPA;SURFACE_ANTIGENS:CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +;TOTAL_PROTEIN_LEVEL:6.2;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH MUTATED NPM1" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.98;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:73.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:94;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:73;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M1;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.79;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:97;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:94;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:AC220 (Ambit);LDH_LEVEL:441;MOST_RECENT_TREATMENT_DURATION:30;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Intermediate-I;ELN_2017:Favorable or Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:19.3;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:100.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:4.1;PB_ALT_LEVEL:19;PB_AST_LEVEL:28;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:2;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;SURFACE_ANTIGENS:CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative;TOTAL_PROTEIN_LEVEL:7.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH MUTATED RUNX1" "CANCER_TYPE_DETAILED:AML with Mutated RUNX1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLRUNX1;TMB_NONSYNONYMOUS:3.7300941196;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:AML with mutated RUNX1"
"AML WITH MYELODYSPLASIA-RELATED CHANGES" "CANCER_TYPE_DETAILED:AML with Myelodysplasia-Related Changes;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLMRC;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:0.1;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:72.0;CHEMOTHERAPY:No;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:97;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:72;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:1;FAB:M4;HEMOGLOBIN_LEVEL:5.6;SAMPLE_SITE:Leukapheresis;CREATININE_LEVEL_PRERESECTION:0.96;CURRENT_STAGE:NONE;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:96;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:95;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:697;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Intermediate-I;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:16.5;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:114;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:2.7;PB_ALT_LEVEL:47;PB_AST_LEVEL:58;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:3;PB_MONOCYTES_PERCENTAGE:0;PB_NEUTROPHILS_PERCENTAGE:1;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with myelodysplasia-related changes;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with myelodysplasia-related changes;SURFACE_ANTIGENS:Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive;TOTAL_PROTEIN_LEVEL:4.9"
"AML WITH RECURRENT GENETIC ABNORMALITIES" "CANCER_TYPE_DETAILED:AML with Recurrent Genetic Abnormalities;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLRGA;TMB_NONSYNONYMOUS:0.066666667;SOMATIC_STATUS:Unmatched;SEX:Female;OS_MONTHS:15.99;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:40.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:9.1;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:40;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;HEMOGLOBIN_LEVEL:12;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.65;CURRENT_STAGE:Consolidation;FUSION:MLLT3-KMT2A;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX,t(9;11)(p22;q23)[20];PB_BLAST_PERCENTAGE:29;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:84;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Allogeneic - Sibling | Consolidation | Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:HiDAC;LDH_LEVEL:613;MOST_RECENT_TREATMENT_DURATION:5;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200];DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:35;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-1;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:21;PB_AST_LEVEL:23;PB_LYMPHOCYTES_PERCENTAGE:63;PB_MONOCYTES_PERCENTAGE:3;PB_NEUTROPHILS_PERCENTAGE:5;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with t(9;11)(p22;q23); MLLT3-MLL;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with t(9;11)(p22;q23); MLLT3-MLL;SURFACE_ANTIGENS:brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR;TOTAL_PROTEIN_LEVEL:6.5;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH T(6;9)(P23;Q34); DEK-NUP214" NA
"AML WITH T(8;21)(Q22;Q22); RUNX1-RUNX1T1" NA
"AML WITH T(9;11)(P22;Q23); MLLT3-MLL" NA
"AML WITH T6:9P23:Q34.1; DEK-NUP214" NA
"AML WITH T6;9P23;Q34.1;DEK-NUP214" NA
"AML WITH T6;9P23;Q34; DEK-NUP214" NA
"AML WITH T8;21Q22;Q22.1; RUNX1-RUNX1T1" NA
"AML WITH T8;21Q22;Q22.1;RUNX1-RUNX1T1" NA
"AML WITH T8;21Q22;Q22; RUNX1-RUNX1T1" NA
"AML WITH T9;11P22;Q23;  MLLT3-MLL" NA
"AML WITH T9;11P22;Q23; MLLT3-MLL" NA
"AML WITHOUT MATURATION" "CANCER_TYPE_DETAILED:AML without Maturation;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AWM;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:1.15;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:60.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:1;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:60;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:4;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;BRAF_MUTATION:Negative;FAB:M1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[21];PB_BLAST_PERCENTAGE:1;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:56;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:SWOG S1203 (7+3 +/- Vorinostat);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:SWOG S1203 (7+3 +/- Vorinostat);MOST_RECENT_TREATMENT_DURATION:7;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_MONOCYTES_PERCENTAGE:1.4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML without maturation;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML without maturation;SURFACE_ANTIGENS:CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML, NOS" "CANCER_TYPE_DETAILED:AML, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNOS;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:10.16;OS_STATUS:1:DECEASED;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:179.1;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s);FAB:NOS;HEMOGLOBIN_LEVEL:8.7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.93;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:60;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:81;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Hydroxyurea;LDH_LEVEL:673;MOST_RECENT_TREATMENT_DURATION:9;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Intermediate-I;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:1;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.3;PB_ALT_LEVEL:42;PB_AST_LEVEL:45;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:5;PB_MONOCYTES_PERCENTAGE:24;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myeloid leukaemia, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute myeloid leukaemia, NOS;SURFACE_ANTIGENS:CD13, CD34, CD38, CD117, CD123, HLA-DR;TOTAL_PROTEIN_LEVEL:6.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AMLM" "CANCER_TYPE_DETAILED:AML with Minimal Differentiation;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLMD;TMB_NONSYNONYMOUS:0.266666667;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.16;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:70.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:2.5;AGE_AT_PROCUREMENT:70;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M0;HEMOGLOBIN_LEVEL:9.1;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.9;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Residual Disease;KARYOTYPE:46,XY[18];PB_BLAST_PERCENTAGE:30;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:75;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Quizartinib;LDH_LEVEL:137;MOST_RECENT_TREATMENT_DURATION:155;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:25.8;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:89.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:16;PB_AST_LEVEL:22;PB_BASOPHILS_PERCENTAGE:1;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:64;PB_MONOCYTES_PERCENTAGE:0;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with minimal differentiation;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with minimal differentiation;SURFACE_ANTIGENS:partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive;TOTAL_PROTEIN_LEVEL:6.3;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AMPULLARY CANCER" "CANCER_TYPE_DETAILED:Ampullary Carcinoma;CANCER_TYPE:Ampullary Cancer;ONCOTREE_CODE:AMPCA;TMB_NONSYNONYMOUS:0.466666667;SOMATIC_STATUS:Matched;OS_MONTHS:112.2;OS_STATUS:0:LIVING;PRIMARY_SITE:AMP;GRADE:Poor Diff;VITAL_STATUS:NED;TNMSTAGE:IIA;DAYS_TO_LAST_FOLLOWUP:3411;DATA_SOURCE:Baylor College of Medicine Elkins Pancreatic Center;PB_BLAST_PERCENTAGE:0.0;ALLELE_FREQUENCY_CELLULARITY:14;IHC_SUBTYPE:Intestinal;MORPHOLOGY_SUBTYPE:Intestinal;ASSOCIATED_ADENOMA:Absent;INTESTINAL_PERCENTAGE:100"
"AMPULLARY CARCINOMA" "CANCER_TYPE_DETAILED:Ampullary Carcinoma;CANCER_TYPE:Ampullary Cancer;ONCOTREE_CODE:AMPCA;TMB_NONSYNONYMOUS:0.466666667;SOMATIC_STATUS:Matched;OS_MONTHS:112.2;OS_STATUS:0:LIVING;PRIMARY_SITE:AMP;GRADE:Poor Diff;VITAL_STATUS:NED;TNMSTAGE:IIA;DAYS_TO_LAST_FOLLOWUP:3411;DATA_SOURCE:Baylor College of Medicine Elkins Pancreatic Center;PB_BLAST_PERCENTAGE:0.0;ALLELE_FREQUENCY_CELLULARITY:14;IHC_SUBTYPE:Intestinal;MORPHOLOGY_SUBTYPE:Intestinal;ASSOCIATED_ADENOMA:Absent;INTESTINAL_PERCENTAGE:100"
"ANAL CANCER" "CANCER_TYPE_DETAILED:Anal Squamous Cell Carcinoma;CANCER_TYPE:Anal Cancer;ONCOTREE_CODE:ANSC;TMB_NONSYNONYMOUS:7.96666666667;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0;OS_MONTHS:27.01;OS_STATUS:0:LIVING;PFS_MONTHS:27.01;PFS_STATUS:1:Progressed;TUMOR_TYPE:Anal;RECIST_RESPONSE:clinical benefit;CENSORED:LIVING;DRUG_TYPE:anti-PD-1/anti-PD-L1;RECIST:CR;OTHER_CONCURRENT_THERAPY:no;ROH_RESPONSE:clinical benefit;VA_RESPONSE:clinical benefit"
"ANAL GLAND ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Anal Gland Adenocarcinoma;CANCER_TYPE:Anal Cancer;ONCOTREE_CODE:AGA;SEX:Male;AGE:59.69335938;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:432"
"ANAL SQUAMOUS CELL" "CANCER_TYPE_DETAILED:Anal Squamous Cell Carcinoma;CANCER_TYPE:Anal Cancer;ONCOTREE_CODE:ANSC;TMB_NONSYNONYMOUS:7.96666666667;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0;OS_MONTHS:27.01;OS_STATUS:0:LIVING;PFS_MONTHS:27.01;PFS_STATUS:1:Progressed;TUMOR_TYPE:Anal;RECIST_RESPONSE:clinical benefit;CENSORED:LIVING;DRUG_TYPE:anti-PD-1/anti-PD-L1;RECIST:CR;OTHER_CONCURRENT_THERAPY:no;ROH_RESPONSE:clinical benefit;VA_RESPONSE:clinical benefit"
"ANAL SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Anal Squamous Cell Carcinoma;CANCER_TYPE:Anal Cancer;ONCOTREE_CODE:ANSC;TMB_NONSYNONYMOUS:7.96666666667;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0;OS_MONTHS:27.01;OS_STATUS:0:LIVING;PFS_MONTHS:27.01;PFS_STATUS:1:Progressed;TUMOR_TYPE:Anal;RECIST_RESPONSE:clinical benefit;CENSORED:LIVING;DRUG_TYPE:anti-PD-1/anti-PD-L1;RECIST:CR;OTHER_CONCURRENT_THERAPY:no;ROH_RESPONSE:clinical benefit;VA_RESPONSE:clinical benefit"
"ANAPLASTIC ASTROCYTOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:1.266666667;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:20.95;OS_STATUS:1:DECEASED;ETHNICITY:Asian;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:46.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:42.57;AGE_AT_PROCUREMENT:46;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;HEMOGLOBIN_LEVEL:9.5;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.64;CURRENT_STAGE:Double Umbilical Cord Blood Transplant (DUCBT);FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18];PB_BLAST_PERCENTAGE:26.7;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:25;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT);CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Fludarabine, Melphalan, ATG;LDH_LEVEL:440;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:p.I824V; VAF 50%;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:1;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:32;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:80.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:p.G13R; MAF 50%;PB_ALBUMIN_LEVEL:3.1;PB_ALT_LEVEL:14;PB_AST_LEVEL:15;PB_BASOPHILS_PERCENTAGE:0.9;PB_EOSINOPHILS_PERCENTAGE:1.7;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:4.3;PB_LYMPHOCYTES_PERCENTAGE:6.1;PB_MONOCYTES_PERCENTAGE:32.2;PB_NEUTROPHILS_PERCENTAGE:48.7;PB_NUCLEATED_RBC_PERCENTAGE:0.2;PRIOR_CANCER:Anaplastic Astrocytoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a;TOTAL_PROTEIN_LEVEL:6.8;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ANAPLASTIC ASTROCYTOMA, IDH-MUTANT" "CANCER_TYPE_DETAILED:Anaplastic Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:AASTR;TMB_NONSYNONYMOUS:77.4;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1654;SAMPLE_TYPE:First Recurrence;OS_MONTHS:88;OS_STATUS:1:DECEASED;GENE_PANEL:WXS;SAMPLE_CLASS:Tumor;GRADE:III;HISTOLOGY:Astrocytoma;TUMOR_LOCATION:Corpus callosum;TYPE_OF_SURGERY:Craniotomy;COMMENTS:other notes;AGE_AT_DX:33;EXTENT_OF_RESECTION:Subtotal;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-JX-0006-R1-01D-WXS-F732CR;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;HYPERMUTATION_STATUS:Yes;INITIAL_GRADE:II;INITIAL_HISTOLOGY:Astrocytoma;POST_RECURRENCE_SURVIVAL_MONTHS:20;RADIATION_DOSE:100;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:50;SURGERY NUMBER:2;TIME_TO_FIRST_RECURRENCE:68;TISSUE_SOURCE:Jackson Laboratory;TMZ_CYCLES:11;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Anaplastic Astrocytoma, IDH-mutant;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:No"
"ANAPLASTIC ASTROCYTOMA, IDH-WILDTYPE" "CANCER_TYPE_DETAILED:Anaplastic Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:AASTR;TMB_NONSYNONYMOUS:1.36666666667;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1242;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:40;OS_STATUS:1:DECEASED;GENE_PANEL:WGS;SAMPLE_CLASS:Tumor;GRADE:III;HISTOLOGY:Astrocytoma;TUMOR_LOCATION:Temporal lobe;AGE_AT_DX:24;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-HK-0004-TP-01D-WGS-SJJS0H;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;HYPERMUTATION_STATUS:No;INITIAL_GRADE:III;INITIAL_HISTOLOGY:Astrocytoma;MGMT_METHYLATION:Methylated;POST_RECURRENCE_SURVIVAL_MONTHS:3;RADIATION_DOSE:60;RADIOTHERAPY:Yes;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:37;TISSUE_SOURCE:Chinese University of Hong Kong;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Anaplastic Astrocytoma, IDH-wildtype;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:Yes"
"ANAPLASTIC EPENDYMOMA" "CANCER_TYPE_DETAILED:Anaplastic ependymoma;CANCER_TYPE:Ependymomal Tumor;ONCOTREE_CODE:APE;TMB_NONSYNONYMOUS:1.53333333333;SEX:Male;OS_MONTHS:27;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade III;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:2;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:2.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:18;SAMPLE_TESTED_CATEGORY:Primary disease"
"ANAPLASTIC GANGLIOGLIOMA" "CANCER_TYPE_DETAILED:Anaplastic Ganglioglioma;CANCER_TYPE:Glioma;ONCOTREE_CODE:AGNG;TMB_NONSYNONYMOUS:0.978719698;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2347;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:166;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"ANAPLASTIC LARGE CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Anaplastic Large Cell Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:ALCL;TMB_NONSYNONYMOUS:20.3;SEX:Male;AGE:15;FRACTION_GENOME_ALTERED:0.4817;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Anaplastic Large Cell (ALCL);TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:208.2736925;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:lymphoblast-like;GROWTH_MEDIUM:RPMI 1640 medium with 10% fetal calf serum.;HIST_SUBTYPE1:anaplastic_large_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_ALCL;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:Ki-JK;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"ANAPLASTIC LARGE-CELL LYMPHOMA ALK NEGATIVE" "CANCER_TYPE_DETAILED:Anaplastic Large-Cell Lymphoma ALK Negative;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:ALCLALKN;SOMATIC_STATUS:No;SEX:Male;STAGE:IV;AGE_AT_DIAGNOSIS:46;PATIENT_DISPLAY_NAME:ALK_NEG_ALCL_1;SAMPLE_DISPLAY_NAME:ALK_NEG_ALCL_1;BIOPSY_SITE:Skin;LDH_ELEVATED:Yes;BONE_MARROW_POS:No;ECOG_GT_2:No;EXTRANODAL_DISEASE:Yes;FIRST_LINE_TREATMENT:BV-CHP;MSK_IMPACT_BEYOND_FIRST_RELAPSE_BIOPSY:Yes;MSK_IMPACT_ON_DIAGNOSTIC_BIOPSY:No;MSK_IMPACT_ON_FIRST_RELAPSE_BIOPSY:No;MSK_IMPACT_PANEL:IMPACT410;PFS_EVENT:Yes"
"ANAPLASTIC LARGE-CELL LYMPHOMA ALK POSITIVE" "CANCER_TYPE_DETAILED:Anaplastic Large-Cell Lymphoma ALK Positive;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:ALCLALKP;SOMATIC_STATUS:Yes;SEX:Female;STAGE:II (unconfirmed; missing BMB);AGE_AT_DIAGNOSIS:54;PATIENT_DISPLAY_NAME:ALK_POS_ALCL_1;SAMPLE_DISPLAY_NAME:ALK_POS_ALCL_1;BIOPSY_SITE:LN;LDH_ELEVATED:Unknown;ECOG_GT_2:No;EXTRANODAL_DISEASE:No;FIRST_LINE_TREATMENT:BV-CHP;MISSING_FROM_BASELINE_CLINICAL:BMB and LDH;MSK_IMPACT_ON_DIAGNOSTIC_BIOPSY:Yes;MSK_IMPACT_PANEL:IMPACT-HEME-400;PFS_EVENT:Yes"
"ANAPLASTIC MEDULLOBLASTOMA" "CANCER_TYPE_DETAILED:Large Cell/Anaplastic Medulloblastoma;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:AMBL;TMB_NONSYNONYMOUS:1.56666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:2.0;OS_MONTHS:33.0;OS_STATUS:0:LIVING;M_STAGE:M3;NOTE:WGS for germline, primary and recurrence 1;OVERALL_PATIENT_HISTOLOGY:LCA;RNASEQ_DATA:No;SUBGROUP:SHH;GERMLINE_CONTROL:Yes;SOURCE_OF_RECURRENCE_TISSUE:Biopsy"
"ANAPLASTIC MENINGIOMA" "CANCER_TYPE_DETAILED:Anaplastic Meningioma;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:ANM;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Unmatched;SEX:Male;FRACTION_GENOME_ALTERED:0.1104;SAMPLE_TYPE:Primary;OS_MONTHS:25.15;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:50;SAMPLE_COVERAGE:805;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Unmatched;DNA_INPUT:250"
"ANAPLASTIC OLIGOASTROCYTOMA" "CANCER_TYPE_DETAILED:Anaplastic Oligoastrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:AOAST;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:66;FRACTION_GENOME_ALTERED:0.1634;SAMPLE_TYPE:Primary;OS_MONTHS:52.07;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:DU;ICD_O_3_SITE:C71.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C71.0;ICD_O_3_HISTOLOGY:9451/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/21/11;GRADE:G3;HISTOLOGICAL_DIAGNOSIS:Oligodendroglioma;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1993;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-DU-6393.13d53e5b-0ff2-4903-91a4-b183b2a4fd62.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Central nervous system;TUMOR_SITE:Supratentorial, Occipital Lobe;SPECIMEN_SECOND_LONGEST_DIMENSION:0.7;LATERALITY:Left;LONGEST_DIMENSION:0.7;SHORTEST_DIMENSION:0.5;HISTORY_IONIZING_RT_TO_HEAD:NO;SUPRATENTORIAL_LOCALIZATION:White Matter"
"ANAPLASTIC OLIGODENDROGLIOMA" "CANCER_TYPE_DETAILED:Anaplastic Oligodendroglioma;CANCER_TYPE:Glioma;ONCOTREE_CODE:AODG;TMB_NONSYNONYMOUS:2.63333333333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2492;SAMPLE_TYPE:First Recurrence;OS_MONTHS:257;OS_STATUS:1:DECEASED;GENE_PANEL:WGS;SAMPLE_CLASS:Tumor;GRADE:III;HISTOLOGY:Oligodendroglioma;TUMOR_LOCATION:Occipital lobe;TYPE_OF_SURGERY:Craniotomy;AGE_AT_DX:45;EXTENT_OF_RESECTION:Total;TUMOR_LATERALITY:Right;1P19Q_STATUS:codel;ALIQUOT_BARCODE:GLSS-MD-0001-R1-01D-WGS-82NVSS;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;CHEMO_OTHER:Yes;HYPERMUTATION_STATUS:No;INITIAL_GRADE:II;INITIAL_HISTOLOGY:Oligodendroglioma;POST_RECURRENCE_SURVIVAL_MONTHS:18;RADIATION_DOSE:47.5;RADIATION_OTHER:IMRT;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:25;SURGERY NUMBER:2;SURGERY_INDICATION:Relapse;TIME_TO_FIRST_RECURRENCE:239;TISSUE_SOURCE:MD Anderson Cancer Center;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted;WHOLE_EXOME_SEQUENCED:No;WHOLE_GENOME_SEQUENCED:Yes"
"ANAPLASTIC OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q CO-DELETED" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;SAMPLE_TYPE:Recurrence;OS_MONTHS:18;OS_STATUS:0:LIVING;GRADE:III;TUMOR_LOCATION:Left temporal;WHO_CLASS:Anaplastic oligodendroglioma, IDH-mutant and 1p/19q co-deleted;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2017;MORPHOLOGY:Oligodendroglioma;TREATMENT_DETAIL_BEFORE_PDX:None"
"ANAPLASTIC OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED" "CANCER_TYPE_DETAILED:Anaplastic Oligodendroglioma;CANCER_TYPE:Glioma;ONCOTREE_CODE:AODG;TMB_NONSYNONYMOUS:2.63333333333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2492;SAMPLE_TYPE:First Recurrence;OS_MONTHS:257;OS_STATUS:1:DECEASED;GENE_PANEL:WGS;SAMPLE_CLASS:Tumor;GRADE:III;HISTOLOGY:Oligodendroglioma;TUMOR_LOCATION:Occipital lobe;TYPE_OF_SURGERY:Craniotomy;AGE_AT_DX:45;EXTENT_OF_RESECTION:Total;TUMOR_LATERALITY:Right;1P19Q_STATUS:codel;ALIQUOT_BARCODE:GLSS-MD-0001-R1-01D-WGS-82NVSS;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;CHEMO_OTHER:Yes;HYPERMUTATION_STATUS:No;INITIAL_GRADE:II;INITIAL_HISTOLOGY:Oligodendroglioma;POST_RECURRENCE_SURVIVAL_MONTHS:18;RADIATION_DOSE:47.5;RADIATION_OTHER:IMRT;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:25;SURGERY NUMBER:2;SURGERY_INDICATION:Relapse;TIME_TO_FIRST_RECURRENCE:239;TISSUE_SOURCE:MD Anderson Cancer Center;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted;WHOLE_EXOME_SEQUENCED:No;WHOLE_GENOME_SEQUENCED:Yes"
"ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA" "CANCER_TYPE_DETAILED:Anaplastic pleomorphic xanthoastrocytoma;CANCER_TYPE:Encapsulated Glioma;ONCOTREE_CODE:APXA;TMB_NONSYNONYMOUS:2.13333333333;SEX:Female;OS_MONTHS:34;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade III;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:10;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Brain- mesial left temporal brain tumor;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:24;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"ANAPLASTIC THYROID CANCER" "CANCER_TYPE_DETAILED:Anaplastic Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THAP;TMB_NONSYNONYMOUS:5.46666666667;SEX:Male;AGE:59;FRACTION_GENOME_ALTERED:0.3780;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:90.3074789;GENOME_DOUBLINGS:1;DOUBLING_TIME:45;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;DISEASE_ONTOLOGY:thyroid_squamous_cell_carcinoma;HIST_SUBTYPE1:anaplastic_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUBTYPE:thyroid_squamous;NAME:SW579;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"ANAPLASTIC THYROID CARCINOMA" "CANCER_TYPE_DETAILED:Anaplastic Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THAP;TMB_NONSYNONYMOUS:0.166666666667;SOMATIC_STATUS:Matched;AGE:77;FRACTION_GENOME_ALTERED:0.1114;SAMPLE_TYPE:Primary;OS_MONTHS:4.64;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;TUMOR_PURITY:0.33;PATH_T_STAGE:T3/T4;PATH_N_STAGE:N1a/N1b;SPECIMEN_PRESERVATION_TYPE:Frozen;M_STAGE:Mx;CYTOLOGICAL_PHENOTYPE:tall cell variant"
"ANAPLASTIC_LARGE_CELL_LYMPHOMA" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:2.87341935688;SEX:Male;FRACTION_GENOME_ALTERED:0.1341;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:Anaplastic_Large_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"ANGIOCENTRIC GLIOMA" "CANCER_TYPE_DETAILED:Angiocentric Glioma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:ANGL;TMB_NONSYNONYMOUS:0;SEX:Female;AGE:62.13004684;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:1256"
"ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Angioimmunoblastic T-Cell Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:AITL;TMB_NONSYNONYMOUS:3.91487879;SOMATIC_STATUS:Unmatched;SEX:Female;FRACTION_GENOME_ALTERED:0.0013;SAMPLE_TYPE:Primary;OS_MONTHS:12.03;OS_STATUS:1:DECEASED;PRIMARY_SITE:Lymph node;SAMPLE_CLASS:Tumor;TUMOR_PURITY:50;SAMPLE_COVERAGE:1033;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Unmatched;DNA_INPUT:250"
"ANGIOSARCOMA" "CANCER_TYPE_DETAILED:Angiosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ANGS;TMB_NONSYNONYMOUS:3.0;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1245;RACE:NOT REPORTED;PRIMARY_SITE_PATIENT:BREAST;SAMPLE_TIMEPOINT:ASCProject_EAuOu4uD_T1;TMB:2.850485825;BX_LOCATION:BREAST;BX_TIME_DAYS:13;BX_TYPE:RESECTION;AGE_AT_DIAGNOSIS_GROUP:36-40;PRD_HISPANIC:NOT REPORTED;PRD_OTHER_CANCER:YES;PRD_TREATED_AT_ENROLLMENT:NOT REPORTED;BX_NUCLEAR_GRADE:LOW;BX_SPINDLE_CELL:NO;BX_VASOFORMATIVE:YES;DX_BIOPSY_LOCATION:BREAST;PRD_DIAGNOSIS_LOC:NOT REPORTED;PRD_EVER_LOCATION:NOT REPORTED;PRD_LOCATION_AT_ENROLLMENT:NOT REPORTED;PRD_OTHER_CANCER_LIST:COLORECTAL;PRD_OTHER_CANCER_RADIATION:YES;PRD_RADIATION:YES;PRD_RADIATION_SURGERY:AFTER;PRD_SURGERY:YES;PRD_SURGERY_CLEAN_MARGINS:YES"
"ANSC" "CANCER_TYPE_DETAILED:Primary Myelofibrosis;CANCER_TYPE:Myeloproliferative Neoplasms;ONCOTREE_CODE:PMF;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:6.22;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:66.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Myelodysplastic Syndromes;WBC:239;AGE_AT_PROCUREMENT:67;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:6;TREATMENT_TYPE:Standard Chemotherapy;BRAF_MUTATION:p.G469A, MAF 7%;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Unknown;FUSION:None;GROUP:Residual Disease;KARYOTYPE:46,XY[17];PB_BLAST_PERCENTAGE:5;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:5;CUMULATIVE_TREATMENT_REGIMENS:Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Unknown;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Hydroxyurea;MOST_RECENT_TREATMENT_DURATION:263;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Not Enough Information;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:p.G12S, MAF 18%;PB_MONOCYTES_PERCENTAGE:1;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Primary myelofibrosis;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Primary myelofibrosis;SURFACE_ANTIGENS:Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. No BCR-ABL1 transcripts are detected. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alterations are detected in the ASXL1, BRAF, EZ"
"APAD" "CANCER_TYPE_DETAILED:Appendiceal Adenocarcinoma;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:APAD;SEX:Female;AGE:64.16700745;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:Yes;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:Yes;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:3rd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:3rd tertile;TERT_PLATINUM_TX:3rd tertile;TERT_TARGETED_TX:3rd tertile;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:3rd tertile;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:2440;TIME_TO_BLOOD_DRAW_FROM_TX:2388;TOPO_I_TX:Yes;TOPO_II_TX:No;XRT_TX:No"
"APL WITH PML-RARA" "CANCER_TYPE_DETAILED:APL with PML-RARA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:APLPMLRARA;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:0.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:65.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:9.8;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:65;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;FAB:M3;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.6;CURRENT_STAGE:Induction;FUSION:PML-RARA;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3];PB_BLAST_PERCENTAGE:57;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:72;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:3+7 (Cytarabine, Daunorubicin);LDH_LEVEL:398;MOST_RECENT_TREATMENT_DURATION:3;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Unusual t(15;17), with the fusion signal on the derivative chromosome 15;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Adverse;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:20.7;INDUCTION_RESPONSE:Unknown;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.2;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:2.9;PB_ALT_LEVEL:24;PB_AST_LEVEL:33;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:36;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:8;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SURFACE_ANTIGENS:partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive;TOTAL_PROTEIN_LEVEL:5.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"APPENDICEAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Mucinous Adenocarcinoma of the Appendix;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:MAAP;TMB_NONSYNONYMOUS:0.1;SEX:Male;AGE:73;FRACTION_GENOME_ALTERED:0.1090;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Stage IV;RFS_STATUS:Unknown/NA;SURGERY:Yes;DEATH:Yes;LOCALIZED_VS_METS_AT_DX:Metastatic;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Appendiceal Adenocarcinoma;DOB_LASTFU_TIME_YRS:75;DOB_PROG_START_TIME_YRS:73;DOB_PROG_TIME_YRS:75;DOB_REPORT_TIME_YRS:74;DOB_TISSUE_TIME_YRS:73;LINE_OBR_CHEMO:SD;LINE_OBR_CHEMO_G:No-Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:SD;LINE_OBR_NOTRK_G:No-Response;LINE_OBR_NTRK:SD;LINE_OBR_NTRK_G:No-Response;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:SD;LINE1_BR_NOTRK_G:No-Response;NUM_LINES:5;NUM_LINES_CHEMO:3;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:2;NUM_LINES_TARGETED:0;POS_ARCHER:Negative;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:IMPACT Only;PROG_DEATH:Yes;PROG_DEATH_TIME_YRS:2;PROG_EVAL_C:Yes;RECUR_EVAL_C:No;TISSUE_REPORT_TIME_YRS:1"
"APPENDICEAL CANCER" "CANCER_TYPE_DETAILED:Mucinous Adenocarcinoma of the Appendix;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:MAAP;TMB_NONSYNONYMOUS:0.1;SEX:Male;AGE:73;FRACTION_GENOME_ALTERED:0.1090;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Stage IV;RFS_STATUS:Unknown/NA;SURGERY:Yes;DEATH:Yes;LOCALIZED_VS_METS_AT_DX:Metastatic;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Appendiceal Adenocarcinoma;DOB_LASTFU_TIME_YRS:75;DOB_PROG_START_TIME_YRS:73;DOB_PROG_TIME_YRS:75;DOB_REPORT_TIME_YRS:74;DOB_TISSUE_TIME_YRS:73;LINE_OBR_CHEMO:SD;LINE_OBR_CHEMO_G:No-Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:SD;LINE_OBR_NOTRK_G:No-Response;LINE_OBR_NTRK:SD;LINE_OBR_NTRK_G:No-Response;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:SD;LINE1_BR_NOTRK_G:No-Response;NUM_LINES:5;NUM_LINES_CHEMO:3;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:2;NUM_LINES_TARGETED:0;POS_ARCHER:Negative;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:IMPACT Only;PROG_DEATH:Yes;PROG_DEATH_TIME_YRS:2;PROG_EVAL_C:Yes;RECUR_EVAL_C:No;TISSUE_REPORT_TIME_YRS:1"
"ASPS" "CANCER_TYPE_DETAILED:Alveolar Soft Part Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ASPS;TMB_NONSYNONYMOUS:2.4;SEX:Female;OS_MONTHS:154;OS_STATUS:0:LIVING;PRIMARY_SITE:Lung;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:17;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Lung;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:26.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:145;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"ASTROBLASTOMA" "CANCER_TYPE_DETAILED:Astroblastoma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:ASTB;TMB_NONSYNONYMOUS:3.91487879;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0789;SAMPLE_TYPE:Primary;OS_MONTHS:12.69;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:50;SAMPLE_COVERAGE:716;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"ASTROCYTOMA" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.066666667;SOMATIC_STATUS:Unmatched;SEX:Female;OS_MONTHS:48.13;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:27.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:58.8;AGE_AT_PROCUREMENT:27;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:6.3;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.69;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];WHOLE_EXOME_SEQUENCING:Yes;CEBPA_MUTATION:No Mutation info: RAF: 10-20%;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Sorafenib;LDH_LEVEL:426;MOST_RECENT_TREATMENT_DURATION:105;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:2;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;HEMATOCRIT_LEVEL:17.7;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:3;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:101.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:2.3;PB_ALT_LEVEL:8;PB_AST_LEVEL:15;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:7;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:2;PRIOR_CANCER:Juvenile pilocytic astrocytoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;TOTAL_PROTEIN_LEVEL:5.4;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ASTROCYTOMA, ANAPLASTIC" "CANCER_TYPE_DETAILED:Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:ASTR;TMB_NONSYNONYMOUS:6.23333333333;SUBTYPE:Astrocytoma, anaplastic;LINEAGE:central_nervous_system;LINEAGE_SUB_SUBTYPE:astrocytoma;LINEAGE_SUBTYPE:glioma;TYPE_REFINED:glioma"
"ASTROCYTOMA, SUBTYPE INDETERMINATE" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:17.5333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:31;SAMPLE_TYPE:Recurrence;OS_MONTHS:263.51;OS_STATUS:1:DECEASED;GRADE:III;TUMOR_LOCATION:Right parietal;WHO_CLASS:Glioblastoma, IDH-wildtype;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2016;IMPLANT_GRADE:IV;INITIAL_DIAGNOSIS_OF_RECURRENT_TUMORS:Astrocytoma, subtype indeterminate;INITIAL_DIAGNOSIS_YEAR:1995;MORPHOLOGY:NOS;ORIGINAL_DIAGNOSIS_AT_IMPLANT:Glioblastoma;TREATMENT_DETAIL_BEFORE_PDX:RT, Procarbazine, Lomustine, Vincristine"
"ASTROCYTOMA_GRADE_III" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:7.51509677953;SEX:Male;FRACTION_GENOME_ALTERED:0.3915;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Astrocytoma_Grade_Iii;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"ASTROCYTOMA_GRADE_III-IV" "CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;SEX:Female;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Astrocytoma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;MUTATION_RATE:115.8864018;ANNOTATION_SOURCE:ACHILLES;HIST_SUBTYPE1:astrocytoma_Grade_III-IV;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUB_SUBTYPE:astrocytoma;LINEAGE_SUBTYPE:glioma;NAME:SF767;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:cervix"
"ASTROCYTOMA_GRADE_IV" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:1.98929032399;SEX:Male;FRACTION_GENOME_ALTERED:0.6582;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Astrocytoma_Grade_Iv;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"ATL" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:7.16666666667;SEX:Female;AGE:59;FRACTION_GENOME_ALTERED:0.2996;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:134.9948889;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:korea;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:scatlered floating; suspention;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:SNU-620;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:stomach"
"ATRT" "CANCER_TYPE_DETAILED:Atypical Teratoid/Rhabdoid Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ATRT;SEX:Male;AGE:2;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6;TUMOR_TISSUE_SITE:Frontal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1038;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_STOP:1163;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1471;AGE_AT_RADIATION_START:1183;AGE_AT_RADIATION_STOP:1225;AGE_AT_SPECIMEN_DIAGNOSIS:1038;CANCER_PREDISPOSITIONS:None documented;CHEMOTHERAPY_AGENTS:Not Reported;CHEMOTHERAPY_TYPE:Treatment follows a protocol and subject is enrolled on a protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:5400 cGy;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;FORMULATION:Not Reported;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Atypical Teratoid Rhabdoid Tumor (ATRT);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:SJYC07;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Supratentorial;UPDATED_GRADE:IV"
"ATYPICAL CHOROID PLEXUS PAPILLOMA" "CANCER_TYPE_DETAILED:Atypical Choroid Plexus Papilloma;CANCER_TYPE:Choroid Plexus Tumor;ONCOTREE_CODE:ACPP;SEX:Male;AGE:54.37371826;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:2887"
"ATYPICAL CHRONIC MYELOID LEUKAEMIA, BCR-ABL1 NEGATIVE" "CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1-" "CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"ATYPICAL LUNG CARCINOID" "CANCER_TYPE_DETAILED:Atypical Lung Carcinoid;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:ALUCA;TMB_NONSYNONYMOUS:1.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:63;FRACTION_GENOME_ALTERED:0.1959;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Lung;ANALYSIS_COHORT:LUNG;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:12"
"ATYPICAL MENINGIOMA" "CANCER_TYPE_DETAILED:Atypical Meningioma;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:ATM;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:41;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Metastasis;RACE:East Asian;PRIMARY_SITE:Skull Base;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Brain;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:58"
"ATYPICAL NEVUS" "CANCER_TYPE_DETAILED:Atypical Nevus;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:AN;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;SAMPLE_TYPE:Metastasis;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;MSI_SCORE:-1;SAMPLE_COVERAGE:1199;INSTITUTE:MSKCC;RELIGION:UNKNOWN;AGE_CURRENT:77;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:YES"
"ATYPICAL TERATOID RHABDOID TUMOR ATRT" NA
"ATYPICAL TERATOID/RHABDOID TUMOR" "CANCER_TYPE_DETAILED:Atypical Teratoid/Rhabdoid Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ATRT;SEX:Male;AGE:2;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6;TUMOR_TISSUE_SITE:Frontal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1038;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_STOP:1163;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1471;AGE_AT_RADIATION_START:1183;AGE_AT_RADIATION_STOP:1225;AGE_AT_SPECIMEN_DIAGNOSIS:1038;CANCER_PREDISPOSITIONS:None documented;CHEMOTHERAPY_AGENTS:Not Reported;CHEMOTHERAPY_TYPE:Treatment follows a protocol and subject is enrolled on a protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:5400 cGy;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;FORMULATION:Not Reported;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Atypical Teratoid Rhabdoid Tumor (ATRT);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:SJYC07;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Supratentorial;UPDATED_GRADE:IV"
"B-CELL ACUTE LYMPHOID LEUKEMIA" "CANCER_TYPE_DETAILED:B-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:BALL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.17;GENE_PANEL:WGS;COHORT:INF_MLLr_Discovery;MUTATION_RATE:3.97E-08;MLL_STATUS:INF_MLLr;LEUKEMIA_TYPE:Pre-B"
"B-CELL NON-HODGKIN LYMPHOMA" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:16.7333333333;SEX:Male;AGE:43;FRACTION_GENOME_ALTERED:0.2067;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Diffuse Large B-cell Lymphoma (DLBCL);TUMOR_TYPE:lymphoma_DLBCL;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:128.1284701;GENOME_DOUBLINGS:0;DOUBLING_TIME:48;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:SUSPENSION;DISEASE_ONTOLOGY:B-cell non-Hodgkin lymphoma;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+ 20% FBS;HIST_SUBTYPE1:diffuse_large_B_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:DLBCL;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:SU-DHL-6;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:peritoneum;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_DLBCL"
"B-CELL, HODGKINS" "CANCER_TYPE_DETAILED:Hodgkin Lymphoma;CANCER_TYPE:Hodgkin Lymphoma;ONCOTREE_CODE:HL;TMB_NONSYNONYMOUS:3.26666666667;SEX:Female;AGE:48;FRACTION_GENOME_ALTERED:0.1059;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Hodgkins;TUMOR_TYPE:lymphoma_Hodgkin;HISTOLOGY:Lymphoid_Neoplasm;MUTATION_RATE:73.30584648;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:Hodgkin_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUBTYPE:hodgkin_lymphoma;NAME:Hs 611.T;PATHOLOGIST_ANNOTATION:Lymphoma:Hodgkin;SITE_SUBTYPE1:spleen;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_Hodgkin"
"B-CELL, NON-HODGKINS" "CANCER_TYPE_DETAILED:Burkitt Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:BL;TMB_NONSYNONYMOUS:11.4;SEX:Male;AGE:7;FRACTION_GENOME_ALTERED:0.0851;SAMPLE_TYPE:Metastasis;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins, Burkitts;TUMOR_TYPE:lymphoma_Burkitt;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:166.4564059;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Burkitts lymphoma;HIST_SUBTYPE1:Burkitt_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_burkitt;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:P3HR-1;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_Burkitt"
"B-CELL_ALL" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:2.87341935688;SEX:Male;FRACTION_GENOME_ALTERED:0.0313;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:B-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_B_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"B-CELL_LYMPHOMA_OTHER" "CANCER_TYPE_DETAILED:Mature B-Cell Neoplasms;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:MBN;TMB_NONSYNONYMOUS:10.0333333333;SEX:Male;FRACTION_GENOME_ALTERED:0.2323;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:0.99;MUTATION_RATE:132.9188091;GENOME_DOUBLINGS:0;DOUBLING_TIME:44.4;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:SUSPENSION LYMPHOBLASTS;DISEASE_ONTOLOGY:undifferentiated B lymphoma;DOUBLING_TIME_FROM_VENDOR:26-28 hrs;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+20%FBS;HIST_SUBTYPE1:B_cell_lymphoma_unspecified;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:MC116;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:B-cell_lymphoma_other"
"B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:7.5;GENE_PANEL:WXS;PROTOCOL:9900;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:90;SNAPSHOT_MUTATIONS:IKZF1,ETV6;DNA_INDEX:0.52;KNOWN_MOLECULAR_CLASSIFIER:Near haploid"
"B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA WITH T9;22Q34.1;Q11.2" NA
"B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA WITH T9;22Q34.1;Q11.2;BCR-ABL1" NA
"B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA, BCR-ABL1 LIKE" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLLBCRABL1L;TMB_NONSYNONYMOUS:3.43333333333;SEX:Male;AGE:4;FRACTION_GENOME_ALTERED:0.0017;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:Ph-likeALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow"
"B-PROLYMPHOCYTIC_LEUKEMIA" "CANCER_TYPE_DETAILED:Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:CLLSLL;TMB_NONSYNONYMOUS:5.73333333333;SEX:Female;AGE:63;FRACTION_GENOME_ALTERED:0.0708;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins, Mantle Cell;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:0.98;MUTATION_RATE:84.15284963;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:lymphoblastoid, round to polygonal cells growing in clusters in suspention;DISEASE_ONTOLOGY:B-prolymphocytic_leukemia;DOUBLING_TIME_FROM_VENDOR:~  50-70 hrs;GROWTH_MEDIUM:90% RPMI 1640 +10% h.i. FBS;HIST_SUBTYPE1:chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_mantle_cell;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:JVM-2;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:B-cell_lymphoma_other"
"B1" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:2.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:37;FRACTION_GENOME_ALTERED:0.6536;SAMPLE_TYPE:Primary;OS_MONTHS:57.49;OS_STATUS:1:DECEASED;RACE:WHITE;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/17/13;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2001;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4331;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5JC.328B8F7A-8CEC-4670-A83F-B16AF53E74CE.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:30;SITE_OF_TUMOR_TISSUE:Adrenal;LYMPH_NODES_EXAMINED:NO;LATERALITY:Left;MITOTIC_RATE:Mitotic Rate > 5/50 HPF Present;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Present;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Estrogen;HISTORY_BASIS_ADRENAL_HORMONE_DX:Biochemical Assessment;MITOSES_PER_50_HPF:24;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Present;WEISS_SCORE_OVERALL:8;WEISS_VENOUS_INVASION:Venous Invasion Present"
"B2" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:3.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:17;FRACTION_GENOME_ALTERED:0.4910;SAMPLE_TYPE:Primary;OS_MONTHS:69.15;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:15.67;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/17/13;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;PATH_T_STAGE:T1;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2703;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5JE.80EDB29A-262A-486D-B31A-EA015FA8A362.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:50;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:YES;LATERALITY:Left;CLIN_M_STAGE:M0;MITOTIC_RATE:Mitotic Rate > 5/50 HPF Present;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Present;CAPSULAR_INVASION:Invasion of Tumor Capsule Present;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Cortisol;HISTORY_BASIS_ADRENAL_HORMONE_DX:Biochemical Assessment;MITOSES_PER_50_HPF:60;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Present;PHARM_TX_MITOTANE_ADJUVANT:YES;PHARM_TX_MITOTANE_INDICATOR:YES;WEISS_SCORE_OVERALL:8;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"B3" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"BARRETT_ASSOCIATED_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:3.06666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.5497;PRIMARY_SITE:Oesophagus;SUBTYPE:Adenocarcinoma;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:80.64616702;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:ACHILLES;HIST_SUBTYPE1:barrett_associated_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:esophagus;LINEAGE_SUBTYPE:esophagus_adenocarcinoma;NAME:JH-EsoAd1;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:esophagus"
"BASAL CELL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Basal Cell Adenocarcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:BCAC;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0005;SAMPLE_TYPE:Primary;OS_MONTHS:17.03;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Salivary Gland;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:621;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:6;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:18;ARCHER:NO;PED_IND:Yes;PARTC_CONSENTED_12_245:YES;CVR_TMB_SCORE:0.9;PARTA_CONSENTED_12_245:YES;CVR_TMB_COHORT_PERCENTILE:14.3;CVR_TMB_TT_COHORT_PERCENTILE:33.4"
"BASAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Female;OS_MONTHS:4.24;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:29.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:2.42;AGE_AT_PROCUREMENT:29;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care;HEMOGLOBIN_LEVEL:9.4;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.69;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8];PB_BLAST_PERCENTAGE:3.1;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:98;CUMULATIVE_TREATMENT_REGIMENS:FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib;CUMULATIVE_TREATMENT_STAGES:Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care;CURRENT_REGIMEN:Hydroxyurea;MOST_RECENT_TREATMENT_DURATION:2;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:27.2;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-1;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:105.4;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:2.5;PB_ALT_LEVEL:393;PB_AST_LEVEL:350;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:2;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:60;PB_MONOCYTES_PERCENTAGE:13;PB_NEUTROPHILS_PERCENTAGE:24;PB_NUCLEATED_RBC_PERCENTAGE:1.7;PRIOR_CANCER:Basal Cell Carcinoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;SURFACE_ANTIGENS:CD11b, CD13, CD14, CD33, CD56 and bright CD64+;TOTAL_PROTEIN_LEVEL:5.4;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"BASAL-LIKE" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:0.766666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:66.0;FRACTION_GENOME_ALTERED:0.9463;SAMPLE_TYPE:Primary;OS_MONTHS:7.89;OS_STATUS:1:DECEASED;TUMOR_STAGE:T3;ER_STATUS:Negative;HER2_STATUS:Negative;METHYLATION_CLUSTER:5;PR_STATUS:Negative;METASTASIS:M1;RPPA_CLUSTER:Basal;MIRNA_CLUSTER:3;PAM50_SUBTYPE:Basal-like;CN_CLUSTER:3;CONVERTED_STAGE:No_Conversion;INTEGRATED_CLUSTERS_NO_EXP:2;INTEGRATED_CLUSTERS_UNSUP_EXP:2;INTEGRATED_CLUSTERS_WITH_PAM50:2;METASTASIS_CODED:Positive;NODE_CODED:Positive;NODES:N3;SIGCLUST_INTRINSIC_MRNA:-13;SIGCLUST_UNSUPERVISED_MRNA:0;SURVIVAL_DATA_FORM:followup;TUMOR_T1_CODED:T_Other"
"BASALOID LARGE CELL CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Basaloid Large Cell Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:BLCLC;TMB_NONSYNONYMOUS:9.787196976;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1401;SAMPLE_TYPE:Primary;OS_MONTHS:6.71;OS_STATUS:0:LIVING;PRIMARY_SITE:Lung;SAMPLE_CLASS:Tumor;TUMOR_PURITY:25;SAMPLE_COVERAGE:851;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"BASALOID PENILE SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Basaloid Penile Squamous Cell Carcinoma;CANCER_TYPE:Penile Cancer;ONCOTREE_CODE:BPSCC;SEX:Male;AGE:51.53456497;RACE:White;SMOKING_STATUS:Current Smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:196;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"BCP-ALL" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:5.66666666667;SEX:Female;AGE:5.42;FRACTION_GENOME_ALTERED:0.0132;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:BCP-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:Mixed_or_Unknown;PHASE:Relapse;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow;TX_17-DMAG:3;TX_19D12:1;TX_ABRAXANE:0;TX_ABT-199:1;TX_ABT-263:1;TX_ACTINOMYCIN D:0;TX_AZD-2171:1;TX_AZD-6244:1;TX_AZD1480:0;TX_AZD8055:1;TX_BAL101553:2;TX_BI6727 (VOLASERTIB):1;TX_BMN-673:1;TX_BMS-354825:1;TX_BMS-754807:1;TX_BORTEZOMIB:2;TX_CABOZANTINIB (XL-148):0;TX_CBL0137:4;TX_CDX-011 (GLEMBATUMUMAB):0;TX_CGC(PG)-11047:1;TX_CISPLATIN:1;TX_CLORETAZINE:0;TX_CPX351:5;TX_CX-5461 (POL1):1;TX_CYTARABINE:0;TX_E7438/EPZ6438:0;TX_EC1456:0;TX_ERIBULIN:6;TX_GENZ-644282:0;TX_GS-9820:1;TX_GSK690693:2;TX_GSK923295A:0;TX_HGS-ETR1:1;TX_IMC-A12:0;TX_INK128-1110-028:0;TX_JNJ26481585:2;TX_JNJ26854165:2;TX_KPT-330:2;TX_LAPATINIB:0;TX_LY 2606368:0;TX_MK-2206:2;TX_MK-8242:2;TX_MLN4924:2;TX_MLN8237:5;TX_MM-141:0;TX_NSC060043:0;TX_NSC750854:5;TX_PCI-32765:1;TX_PF-03084014:1;TX_PIXANTRONE:0;TX_PR-104:6;TX_RAPAMYCIN:2;TX_RG7112:0;TX_RO4929097:1;TX_RUXOLITINIB:0;TX_SAHA:0;TX_SAR3419:4;TX_SB-715992:5;TX_SCH 727965:2;TX_SGI-1776:1;TX_SGN-CD19A:0;TX_SORAFENIB:2;TX_STA9090 (GANETESPIB):0;TX_STF-118804:0;TX_SU11248:4;TX_SVV-001:0;TX_TAK-701:0;TX_TB-403:0;TX_TL32711:6;TX_TOPOTECAN:6;TX_TRISENOX(ATO):0;TX_VINCRISTINE:6;TX_VS-4718:1;TX_XL147:0;TX_XL765:0"
"BCR-ABL1" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;SOMATIC_STATUS:Matched;SEX:Male;AGE:8.0;OS_MONTHS:18.0;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic or Latino;MOLECULAR_SUBTYPE:BCR-ABL1;ANALYSIS_COHORT:DISCOVERY;PROTOCOL:AALL0232;WBC:144.0;DAYS_TO_DEATH:526.0;OS_DAYS:526.0;AGE_IN_DAYS:2823.0;DAYS_TO_EVENT:526.0;FIRST_EVENT:Death;CNS_SITE_OF_RELAPSE:No;CNS_STATUS:CNS 1;KARYOTYPE:46,X,der(Y)dup(Y)(q11.2q12)t(Y;8)(q12;q13),der(9)t(9;22)(q34;q11.2)add(9)(p11),der(22)t(9;22)[12]/46,XY,der(9)t(9;22)(q34;q11.2)add(9)(p11),del(9)(q13q34),der(22)t(9;22)[3]/46,XY[5];TESTICULAR_INVOLVEMENT:No;BONE_MARROW_SITE_OF_RELAPSE:No;DNA_INDEX:1;MLL_STATUS:Negative;OTHER_SITE_OF_RELAPSE:No;BCR_ABL1_STATUS:Positive;BM_DAY_15:0.0;BM_DAY_29:1.0;BM_DAY_8:72.0;CELL_OF_ORIGIN:B-Precursor;CONGENITAL_ABNORMALITY:No;ETV6_RUNX1_FUSION_STATUS:Negative;MRD_PERCENT_DAY_29:2.1;MRD_PERCENT_DAY_29_SENSITIVITY:0.01;TCF3_PBX1_STATUS:Negative;TESTES_SITE_OF_RELAPSE:No;TRISOMY_4_10:Negative"
"BENIGN PHYLLODES TUMOR OF THE BREAST" "CANCER_TYPE_DETAILED:Benign Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BPT;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:55;ETHNICITY:Chinese;HISTOLOGICAL_DIAGNOSIS:Benign PT;TUMOR_SIZE:180;SURGERY:Excision;MEAN_COVERAGE:50;NUM_SOMATIC_MUTATION:16"
"BENIGN PT" "CANCER_TYPE_DETAILED:Benign Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BPT;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:55;ETHNICITY:Chinese;HISTOLOGICAL_DIAGNOSIS:Benign PT;TUMOR_SIZE:180;SURGERY:Excision;MEAN_COVERAGE:50;NUM_SOMATIC_MUTATION:16"
"BENIGN_NEOPLASIA" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:3.26666666667;SEX:Male;AGE:7;SAMPLE_TYPE:Benign_Neoplasia;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Upper aerodigestive;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Other;PURITY:0.97;MUTATION_RATE:99.73208336;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;HIST_SUBTYPE1:papilloma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_upper_aerodigestive;NAME:Hs 840.T;SITE_SUBTYPE1:pharynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:fibroblast_like"
"BILIARY TRACT CANCER" "CANCER_TYPE_DETAILED:Gallbladder Cancer;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBC;TMB_NONSYNONYMOUS:0.0333333333333;SEX:Female;AGE:43;FRACTION_GENOME_ALTERED:0.0060;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Stage I;RFS_STATUS:Yes;SURGERY:Yes;DEATH:Yes;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:Yes;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Biliary Tract Cancer;DOB_LASTFU_TIME_YRS:50;DOB_PROG_START_TIME_YRS:46;DOB_PROG_TIME_YRS:47;DOB_RECUR_START_TIME_YRS:43;DOB_RECUR_TIME_YRS:46;DOB_REPORT_TIME_YRS:46;DOB_TISSUE_TIME_YRS:46;LINE_OBR_CHEMO:PR;LINE_OBR_CHEMO_G:Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:PR;LINE_OBR_NOTRK_G:Response;LINE_OBR_NTRK:PR;LINE_OBR_NTRK_G:Response;LINE_OBR_TARGETED:PR;LINE_OBR_TARGETED_G:Response;LINE1_BR_NOTRK:PR;LINE1_BR_NOTRK_G:Response;NUM_LINES:8;NUM_LINES_CHEMO:4;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:3;NUM_LINES_TARGETED:2;POS_ARCHER:Negative;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:IMPACT Only;PROG_DEATH:Yes;PROG_DEATH_TIME_YRS:4;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:0"
"BILIARY TRACT CANCER, NOS" "CANCER_TYPE_DETAILED:Biliary Tract;CANCER_TYPE:Biliary Tract Cancer, NOS;ONCOTREE_CODE:BILIARY_TRACT;SEX:Female;AGE:58.10540771;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:Yes;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:1st tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:2nd tertile;TERT_PLATINUM_TX:2nd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:114;TIME_TO_BLOOD_DRAW_FROM_TX:56;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"BIPHASIC MESOTHELIOMA" "CANCER_TYPE_DETAILED:Pleural Mesothelioma, Biphasic Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLBMESO;TMB_NONSYNONYMOUS:2.1;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.2014;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:LK;ICD_O_3_SITE:C38.4;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C45.0;ICD_O_3_HISTOLOGY:9053/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/6/13;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Biphasic mesothelioma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1111;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-LK-A4NY.841AD538-D6BE-4560-BA50-D33557B130CB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:630;SITE_OF_TUMOR_TISSUE:Pleura;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;LATERALITY:Right"
"BLADDER ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Gallbladder Adenocarcinoma, NOS;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBAD;TMB_NONSYNONYMOUS:7.5;FRACTION_GENOME_ALTERED:0.6468;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Biliary_Tract;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:bile_duct;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:115.4161995;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:48 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bile_duct;LINEAGE_SUBTYPE:gallbladder_adenocarcinoma;NAME:SNU-308;PATHOLOGIST_ANNOTATION:Biliary_Tract:Carcinoma;SITE_SUBTYPE1:bile_duct;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:bile_duct"
"BLADDER CANCER" "CANCER_TYPE_DETAILED:AML with Biallelic Mutations of CEBPA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLCEBPA;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:8.78;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:8.5;AGE_AT_PROCUREMENT:79;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:10.6;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.75;CURRENT_STAGE:Induction;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:45,X,-Y[19]/46,XY[1];PB_BLAST_PERCENTAGE:72;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:87;CEBPA_MUTATION:1031?1032 ins AAC; MAF 50%;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:460;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:32.3;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:103.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.4;PB_ALT_LEVEL:19;PB_AST_LEVEL:41;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:17;PB_MONOCYTES_PERCENTAGE:4;PB_NEUTROPHILS_PERCENTAGE:1;PRIOR_CANCER:Bladder Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated CEBPA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated CEBPA;SURFACE_ANTIGENS:CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +;TOTAL_PROTEIN_LEVEL:6.2;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"BLADDER SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Bladder Squamous Cell Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLSC;TMB_NONSYNONYMOUS:13.7333333333;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.5781;SAMPLE_TYPE:Primary;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Urinary_Tract;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:urinary_tract;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:173.1708489;GENOME_DOUBLINGS:1;DOUBLING_TIME:52.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:EMEM +10%FBS;HIST_SUBTYPE1:transitional_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:urinary_tract;LINEAGE_SUB_SUBTYPE:bladder_squamous;LINEAGE_SUBTYPE:bladder_carcinoma;NAME:SCaBER;PATHOLOGIST_ANNOTATION:Bladder:Carcinoma;SITE_SUBTYPE1:bladder;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2 mM L-Glutamine ; 1.5 g/L sodium bicarbonate; 0.1 mM NEAA; 1.0 mM sodium pyruvate;TYPE_REFINED:urinary_tract"
"BLADDER UROTHELIAL" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:3.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.0033;SAMPLE_TYPE:Primary;OS_MONTHS:7.33;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:BL;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/28/11;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:127;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BL-A13I.976FBDBF-55C5-4957-986B-D2DE85FF7540.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:410;SMOKING_PACK_YEARS:15;WEIGHT:51;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Non-Papillary;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;SMOKING_YEAR_STARTED:27;PROJECT_CODE:TCGA;DISEASE_CODE:FPPP;OCCUPATION_CURRENT:Dental Assistant"
"BLADDER UROTHELIAL CARCINOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:3.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.0033;SAMPLE_TYPE:Primary;OS_MONTHS:7.33;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:BL;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/28/11;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:127;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BL-A13I.976FBDBF-55C5-4957-986B-D2DE85FF7540.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:410;SMOKING_PACK_YEARS:15;WEIGHT:51;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Non-Papillary;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;SMOKING_YEAR_STARTED:27;PROJECT_CODE:TCGA;DISEASE_CODE:FPPP;OCCUPATION_CURRENT:Dental Assistant"
"BLADDER/URINARY TRACT CANCER" "CANCER_TYPE_DETAILED:Bladder/Urinary Tract;CANCER_TYPE:Bladder/Urinary Tract Cancer, NOS;ONCOTREE_CODE:BLADDER;TMB_NONSYNONYMOUS:18.59567425;SOMATIC_STATUS:Matched;PFS_MONTHS:1.2;COHORT:Bladder;PURITY:0.73;MSI_STATUS:MSS;MUTATION_BURDEN:19.60784314;AMPLIFICATION_STATUS:no;CLONALITY:clonal;BEST_ORR:PD;BUBBLE_GROUP:S310 Hotspot;CENTRAL:CONCORDANT;COVERAGE:1217;CRITERIA:RECIST;DATA:IMPACT;DOMAIN:Furin-like _ECD;DURATION_OF_THERAPY_DAYS:28;GENE:ERBB2;IMPACT:410;LOCAL_TEST:AMPLICON - VHIO;MULTI_ERBB2:no;ONCOPRINT:YES;ONGOING_TREATMENT:NO;QUALIFYING_MUT:S310Y;TUMOR_CHANGE:33.33333333;WATERFALL_GROUP:S310 Hotspot"
"BLADDER/URINARY TRACT CANCER, NOS" "CANCER_TYPE_DETAILED:Bladder/Urinary Tract;CANCER_TYPE:Bladder/Urinary Tract Cancer, NOS;ONCOTREE_CODE:BLADDER;TMB_NONSYNONYMOUS:18.59567425;SOMATIC_STATUS:Matched;PFS_MONTHS:1.2;COHORT:Bladder;PURITY:0.73;MSI_STATUS:MSS;MUTATION_BURDEN:19.60784314;AMPLIFICATION_STATUS:no;CLONALITY:clonal;BEST_ORR:PD;BUBBLE_GROUP:S310 Hotspot;CENTRAL:CONCORDANT;COVERAGE:1217;CRITERIA:RECIST;DATA:IMPACT;DOMAIN:Furin-like _ECD;DURATION_OF_THERAPY_DAYS:28;GENE:ERBB2;IMPACT:410;LOCAL_TEST:AMPLICON - VHIO;MULTI_ERBB2:no;ONCOPRINT:YES;ONGOING_TREATMENT:NO;QUALIFYING_MUT:S310Y;TUMOR_CHANGE:33.33333333;WATERFALL_GROUP:S310 Hotspot"
"BLADDER_CANCER" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:11.5;SEX:Male;FRACTION_GENOME_ALTERED:0.4444;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Urinary_Tract;SUBTYPE:Transitional Cell Carcinoma;TUMOR_TYPE:urinary_tract;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:124.7079624;GENOME_DOUBLINGS:2;DOUBLING_TIME:386.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial;DISEASE_ONTOLOGY:bladder_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:EMEM +10%FBS;HIST_SUBTYPE1:transitional_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:urinary_tract;LINEAGE_SUB_SUBTYPE:bladder_transitional_cell;LINEAGE_SUBTYPE:bladder_carcinoma;NAME:UM-UC-3;PATHOLOGIST_ANNOTATION:Bladder:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_SUBTYPE1:bladder;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:urinary_tract"
"BLADDER_CARCINOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:11.5;SEX:Male;FRACTION_GENOME_ALTERED:0.4444;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Urinary_Tract;SUBTYPE:Transitional Cell Carcinoma;TUMOR_TYPE:urinary_tract;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:124.7079624;GENOME_DOUBLINGS:2;DOUBLING_TIME:386.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial;DISEASE_ONTOLOGY:bladder_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:EMEM +10%FBS;HIST_SUBTYPE1:transitional_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:urinary_tract;LINEAGE_SUB_SUBTYPE:bladder_transitional_cell;LINEAGE_SUBTYPE:bladder_carcinoma;NAME:UM-UC-3;PATHOLOGIST_ANNOTATION:Bladder:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_SUBTYPE1:bladder;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:urinary_tract"
"BLADDER_SQUAMOUS" "CANCER_TYPE_DETAILED:Bladder Squamous Cell Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLSC;TMB_NONSYNONYMOUS:13.7333333333;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.5781;SAMPLE_TYPE:Primary;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Urinary_Tract;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:urinary_tract;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:173.1708489;GENOME_DOUBLINGS:1;DOUBLING_TIME:52.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:EMEM +10%FBS;HIST_SUBTYPE1:transitional_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:urinary_tract;LINEAGE_SUB_SUBTYPE:bladder_squamous;LINEAGE_SUBTYPE:bladder_carcinoma;NAME:SCaBER;PATHOLOGIST_ANNOTATION:Bladder:Carcinoma;SITE_SUBTYPE1:bladder;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2 mM L-Glutamine ; 1.5 g/L sodium bicarbonate; 0.1 mM NEAA; 1.0 mM sodium pyruvate;TYPE_REFINED:urinary_tract"
"BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM" "CANCER_TYPE_DETAILED:Blastic Plasmacytoid Dendritic Cell Neoplasm;CANCER_TYPE:Blastic Plasmacytoid Dendritic Cell Neoplasm;ONCOTREE_CODE:BPDCN;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Unmatched;SEX:Male;ETHNICITY:White;PLATFORM:WES;CHEMOTHERAPY:No;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;SAMPLE_TIMEPOINT:Denovo;CENTER:7;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:NONE;FUSION:Unknown;GROUP:Initial Acute Leukemia Diagnosis;WHOLE_EXOME_SEQUENCING:Yes;CURRENT_REGIMEN:NONE;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Blastic plasmacytoid dendritic cell neoplasm;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Blastic plasmacytoid dendritic cell neoplasm"
"BLAST_PHASE_CHRONIC_MYELOID_LEUKAEMIA" "CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"BLCA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:3.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.0033;SAMPLE_TYPE:Primary;OS_MONTHS:7.33;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:BL;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/28/11;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:127;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BL-A13I.976FBDBF-55C5-4957-986B-D2DE85FF7540.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:410;SMOKING_PACK_YEARS:15;WEIGHT:51;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Non-Papillary;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;SMOKING_YEAR_STARTED:27;PROJECT_CODE:TCGA;DISEASE_CODE:FPPP;OCCUPATION_CURRENT:Dental Assistant"
"BLL" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:7.5;GENE_PANEL:WXS;PROTOCOL:9900;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:90;SNAPSHOT_MUTATIONS:IKZF1,ETV6;DNA_INDEX:0.52;KNOWN_MOLECULAR_CLASSIFIER:Near haploid"
"BLOOD CANCER" "CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"BLOOD CANCER, NOS" "CANCER_TYPE_DETAILED:Myeloid Neoplasm;CANCER_TYPE:Blood Cancer, NOS;ONCOTREE_CODE:MNM;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:1.6;OS_STATUS:1:DECEASED;GENE_PANEL:Enhanced exome;AGE_AT_DIAGNOSIS:83.5;PRIOR_TREATMENT:Azacitidine x 1 cycle;SOURCE:WashU_on_study;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:16;DISEASE:MDS;PERFORMANCE_STATUS:1;PERIPHERAL_BLASTS_PERCENTAGE:0.0;AML_FAB:refractory anemia with excess blasts-2;CYCLES_COMPLETED:1.0;CYTOGENETIC_RISK:Int;IPSS_MDS:2.0;KYRYOTYPE:normal;MORPHOLOGIC_RESPONSE:PD;PERIPHERAL_BLOOD_WBC:1.2;TRANSPLANT:No"
"BLUE NEVUS" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:1.9;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0000;OS_MONTHS:33.78;OS_STATUS:0:LIVING;PFS_MONTHS:3.52;PFS_STATUS:0:Not Progressed;SUBTYPE:blue nevus;TUMOR_TYPE:Melanoma;HISTOLOGY:cutaneous;RECIST_RESPONSE:no clinical benefit;CENSORED:LIVING;DRUG_TYPE:anti-CTLA-4;RECIST:PD;AGE_START_IO:22.0;OTHER_CONCURRENT_THERAPY:no;ROH_RESPONSE:no clinical benefit;VA_RESPONSE:long-term survival"
"BONE CANCER" "CANCER_TYPE_DETAILED:Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:OS;TMB_NONSYNONYMOUS:0.0;SEX:Female;FRACTION_GENOME_ALTERED:0.5005;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Osteosarcoma;HISTOLOGICAL_TYPE:Osteosarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"BONE SARCOMA" "CANCER_TYPE_DETAILED:Chondroblastic Osteosarcoma;CANCER_TYPE:Bone Sarcoma;TMB_NONSYNONYMOUS:0.166666666667;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1188;DIAGNOSIS AGE:66;GDNA(NG):2472;SMOKE STATUS:Unknown;TUMOR_PURTITY:35"
"BONE SARCOMA OTHER" "CANCER_TYPE_DETAILED:Bone Sarcoma Other;CANCER_TYPE:Bone Sarcoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:II;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1039;DIAGNOSIS AGE:54;GDNA(NG):6360;SMOKE STATUS:Unknown;TUMOR_PURTITY:95"
"BONE_CANCER" "CANCER_TYPE_DETAILED:Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:OS;TMB_NONSYNONYMOUS:9.63333333333;SEX:Female;AGE:15;FRACTION_GENOME_ALTERED:0.5104;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Bone;SUBTYPE:Osteosarcoma;TUMOR_TYPE:osteosarcoma;HISTOLOGY:Osteosarcoma;PURITY:0.98;MUTATION_RATE:103.6905353;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:bone_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:McCoy's 5A +10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bone;LINEAGE_SUBTYPE:osteosarcoma;NAME:U-2 OS;PATHOLOGIST_ANNOTATION:Bone:Sarcoma_Osteo;PROTEOMICS_TMT_LABEL:129c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:osteosarcoma"
"BORDERLINE PHYLLODES TUMOR OF THE BREAST" "CANCER_TYPE_DETAILED:Borderline Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BLPT;TMB_NONSYNONYMOUS:2.26666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:38;ETHNICITY:Chinese;HISTOLOGICAL_DIAGNOSIS:Borderline PT;TUMOR_SIZE:95;SURGERY:Excision;MEAN_COVERAGE:79;NUM_SOMATIC_MUTATION:68"
"BORDERLINE PT" "CANCER_TYPE_DETAILED:Borderline Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BLPT;TMB_NONSYNONYMOUS:2.26666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:38;ETHNICITY:Chinese;HISTOLOGICAL_DIAGNOSIS:Borderline PT;TUMOR_SIZE:95;SURGERY:Excision;MEAN_COVERAGE:79;NUM_SOMATIC_MUTATION:68"
"BOTRYOID" "CANCER_TYPE_DETAILED:Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:RMS;TMB_NONSYNONYMOUS:0.0666666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:2;HISTOLOGICAL_SUBTYPE:Botryoid;TUMOR_SAMPLE_HISTOLOGY:Embryonal;RISK_GROUP:Intermediate;PRIMARY_TUMOR_LOCATION:Nasopharynx"
"BOWEL CANCER, NOS" "CANCER_TYPE_DETAILED:Bowel;CANCER_TYPE:Bowel Cancer, NOS;ONCOTREE_CODE:BOWEL;TMB_NONSYNONYMOUS:0.866666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:52;FRACTION_GENOME_ALTERED:0.0074;SAMPLE_TYPE:Metastasis;RACE:Caucasian;BIOPSY_SITE:Retroperitoneum;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:53"
"BRAIN CANCER" "CANCER_TYPE_DETAILED:Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:ASTR;TMB_NONSYNONYMOUS:5.0;SEX:Male;AGE:55;FRACTION_GENOME_ALTERED:0.3949;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Glioblastoma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;PURITY:1;MUTATION_RATE:91.51669099;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;DISEASE_ONTOLOGY:Brain Cancer;HIST_SUBTYPE1:astrocytoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUB_SUBTYPE:glioblastoma;LINEAGE_SUBTYPE:glioma;NAME:GOS-3;PATHOLOGIST_ANNOTATION:CNS:Glioma;SITE_SUBTYPE1:brain;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:glioma"
"BRAIN_CANCER" "CANCER_TYPE_DETAILED:Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:ASTR;TMB_NONSYNONYMOUS:0.666666666667;AGE:50;FRACTION_GENOME_ALTERED:0.5765;SAMPLE_TYPE:Primary;RACE:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Glioma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;PURITY:1;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;DISEASE_ONTOLOGY:brain_cancer;HIST_SUBTYPE1:astrocytoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUBTYPE:glioma;NAME:U-138 MG;SITE_SUBTYPE1:brain;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:glioma"
"BRCA" "CANCER_TYPE_DETAILED:Invasive Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:3.93333333333;SOMATIC_STATUS:Unmatched;SAMPLE_CLASS:Tumor;SEQUENCING_TYPE:Targeted"
"BRCA_HER2" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:15.26666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;FRACTION_GENOME_ALTERED:0.7164;SAMPLE_TYPE:Primary;OS_MONTHS:131.6697899;OS_STATUS:0:LIVING;RACE:Black or African American;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:131.6697899;TISSUE_SOURCE_SITE:Columbia University;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/28/14;PFS_MONTHS:131.6697899;AJCC_STAGING_EDITION:6TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Breast;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIB;SUBTYPE:BRCA_Her2;TUMOR_TYPE:Infiltrating Ductal Carcinoma;PATH_T_STAGE:T2;RADIATION_THERAPY:Yes;DAYS_LAST_FOLLOWUP:4005;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-18538;MSI_SENSOR_SCORE:0.74;CANCER_TYPE_ACRONYM:BRCA;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3449;PATH_N_STAGE:N1A;TISSUE_SOURCE_SITE_CODE:3C;DSS_MONTHS:131.6697899;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:5;RAGNUM_HYPOXIA_SCORE:18;WINTER_HYPOXIA_SCORE:20;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"BRCA_LUMA" "CANCER_TYPE_DETAILED:Breast Invasive Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ILC;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:55;FRACTION_GENOME_ALTERED:0.7787;SAMPLE_TYPE:Primary;OS_MONTHS:133.0505967;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:59.44044449;TISSUE_SOURCE_SITE:Columbia University;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8520/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:1/13/14;PFS_MONTHS:59.44044449;AJCC_STAGING_EDITION:6TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Breast;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE X;SUBTYPE:BRCA_LumA;TUMOR_TYPE:Infiltrating Lobular Carcinoma;PATH_T_STAGE:TX;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:4047;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-20211;MSI_SENSOR_SCORE:0.55;CANCER_TYPE_ACRONYM:BRCA;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3319;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:3C;DSS_MONTHS:133.0505967;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:MX;BUFFA_HYPOXIA_SCORE:-21;RAGNUM_HYPOXIA_SCORE:0;WINTER_HYPOXIA_SCORE:-28;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"BRCA_LUMB" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0.933333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.5340;SAMPLE_TYPE:Primary;OS_MONTHS:48.45974291;OS_STATUS:0:LIVING;RACE:Black or African American;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:48.45974291;TISSUE_SOURCE_SITE:Columbia University;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/28/14;PFS_MONTHS:48.45974291;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Breast;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIB;SUBTYPE:BRCA_LumB;TUMOR_TYPE:Infiltrating Ductal Carcinoma;PATH_T_STAGE:T2;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:1474;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-22848;MSI_SENSOR_SCORE:0.31;CANCER_TYPE_ACRONYM:BRCA;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3266;PATH_N_STAGE:N1A;TISSUE_SOURCE_SITE_CODE:3C;DSS_MONTHS:48.45974291;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:-5;RAGNUM_HYPOXIA_SCORE:12;WINTER_HYPOXIA_SCORE:-10;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"BRCA_NORMAL" "CANCER_TYPE_DETAILED:Breast Invasive Carcinoma (NOS);CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCNOS;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.0008;SAMPLE_TYPE:Primary;OS_MONTHS:8.514975178;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:8.514975178;TISSUE_SOURCE_SITE:UCSF;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8200/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:6/30/11;PFS_MONTHS:8.514975178;AJCC_STAGING_EDITION:6TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Breast;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:BRCA_Normal;TUMOR_TYPE:Other;PATH_T_STAGE:T1C;DAYS_LAST_FOLLOWUP:259;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-25833;MSI_SENSOR_SCORE:0.2;CANCER_TYPE_ACRONYM:BRCA;IN_PANCANPATHWAYS_FREEZE:Yes;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:A1;DSS_MONTHS:8.514975178;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:-35;RAGNUM_HYPOXIA_SCORE:-16;WINTER_HYPOXIA_SCORE:-40;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"BREAST ANGIOSARCOMA" "CANCER_TYPE_DETAILED:Breast Angiosarcoma;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BA;TMB_NONSYNONYMOUS:0;SEX:Female;AGE:62;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Unknown;RFS_STATUS:Yes;SURGERY:Yes;DEATH:Yes;LOCALIZED_VS_METS_AT_DX:Unknown;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Sarcoma NOS;DOB_LASTFU_TIME_YRS:72;DOB_PROG_START_TIME_YRS:66;DOB_PROG_TIME_YRS:70;DOB_RECUR_START_TIME_YRS:62;DOB_RECUR_TIME_YRS:64;DOB_REPORT_TIME_YRS:66;LINE_OBR_CHEMO:CR;LINE_OBR_CHEMO_G:Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:CR;LINE_OBR_NOTRK_G:Response;LINE_OBR_NTRK:SD;LINE_OBR_NTRK_G:No-Response;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:4;NUM_LINES_CHEMO:2;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:2;NUM_LINES_TARGETED:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:Archer;PROG_DEATH:Yes;PROG_DEATH_TIME_YRS:5;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes"
"BREAST CANCER" "CANCER_TYPE_DETAILED:Adenoid Cystic Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ACBC;TMB_NONSYNONYMOUS:0.366666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;SAMPLE_TYPE:Primary;PRIMARY_SITE:Breast;RADIATION_THERAPY:Not performed;VITAL_STATUS:Alive;PLATFORM:WES;TUMOR_STAGE:II;TUMOR_SIZE:40;STUDY:ACbC (MSKCC/Breast 2015);FUSION_STATUS:YES;GENOMIC_ALTERATIONS:15;IHC_HER2:Negative;OVERALL_PATIENT_HISTOLOGY:Cribriform/Tubular;METASTATIC_TUMOR_INDICATOR:No;MYB_MYBL1_FUSION:MYB-NFIB Fusion;ADJUVANT_CHEMO:Not performed;ADJUVANT_TX:Not performed;MYB_NFIB_FISH:Negative;TYPE_OF_SURGERY:Breast Conservation/Mastectomy;ER_STATUS_BY_IHC:Negative;NEOADJUVANT_CHEMO:Not performed;PR_STATUS_BY_IHC:Negative;LOCAL_REGIONAL_RECURRENCE:Positive;MYB_NFIB_REARRANGEMENT:MYB Exon 14-NFIB Exon 9;FOLLOWUP_YEARS:8;MYB_NFIB_CNA:9q13-q34.2 loss"
"BREAST CANCER, NOS" "CANCER_TYPE_DETAILED:Breast;CANCER_TYPE:Breast Cancer, NOS;ONCOTREE_CODE:BREAST;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:35;FRACTION_GENOME_ALTERED:0.5056;SAMPLE_TYPE:Metastasis;OS_MONTHS:113.73;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/6/11;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Infiltrating Ductal Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1999;RETROSPECTIVE_COLLECTION:YES;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1a;AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;PRIMARY_SITE_PATIENT:Right Upper Inner Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);METASTATIC_TUMOR_INDICATOR:NO;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;FIRST_SURGICAL_PROCEDURE_OTHER:total mastectomy with rigth axillary lymph node and sentinel lymph node dissection;SURGICAL_PROCEDURE_FIRST:Other"
"BREAST CARCINOMA" "CANCER_TYPE_DETAILED:Adenoid Cystic Breast Cancer;CANCER_TYPE:Invasive Breast Carcinoma;ONCOTREE_CODE:ACBC;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:67;SAMPLE_TYPE:Primary;PRIMARY_SITE:Breast;RADIATION_THERAPY:Performed;VITAL_STATUS:Alive;PLATFORM:WES;TUMOR_STAGE:I;TUMOR_SIZE:35;STUDY:ACbC (MSKCC/Breast 2015);FUSION_STATUS:YES;GENOMIC_ALTERATIONS:31;IHC_HER2:Negative;OVERALL_PATIENT_HISTOLOGY:Cribriform/Tubular;METASTATIC_TUMOR_INDICATOR:No;MYB_MYBL1_FUSION:MYB-NFIB Fusion;ADJUVANT_CHEMO:Not performed;ADJUVANT_TX:Chemotherapy/Radiation Therapy;MYB_NFIB_FISH:Positive;TYPE_OF_SURGERY:Mastectomy;ER_STATUS_BY_IHC:Negative;NEOADJUVANT_CHEMO:Adriamycine, Endoxan, Taxotere;PR_STATUS_BY_IHC:Negative;LOCAL_REGIONAL_RECURRENCE:Negative;MYB_NFIB_REARRANGEMENT:MYB Exon 14-NFIB Exon 9;FOLLOWUP_YEARS:8;MYB_NFIB_CNA:17q21-q25.1 gain; 17p13.3-p11.2 loss"
"BREAST CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Breast Carcinoma Other;CANCER_TYPE:Breast Carcinoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Chemotherapy;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1508;DIAGNOSIS AGE:47;GDNA(NG):1848;SMOKE STATUS:Unknown;TUMOR_PURTITY:20"
"BREAST DUCTAL CARCINOMA" "CANCER_TYPE_DETAILED:Breast Ductal Carcinoma In Situ;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:DCIS;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0049;SAMPLE_TIMEPOINT:MBCProject_lGCMIGT0_T1A;BX_LOCATION:BREAST;BX_TYPE:LUMPECTOMY;AGE_AT_DIAGNOSIS_GROUP:66-70;CALC_TREATMENT_NAIVE:N/A;METS_SITES_AT_METS_ABST_BONE:N/A;METS_SITES_AT_METS_ABST_LIVER:N/A;METS_SITES_AT_METS_ABST_LUNG:N/A;METS_SITES_AT_METS_DX_BONE:N/A;METS_SITES_AT_METS_DX_LIVER:N/A;METS_SITES_AT_METS_DX_LUNG:N/A;BX_DCIS:YES;BX_ER:UNKNOWN;BX_GRADE:N/A;BX_HER2FISH:UNKNOWN;BX_HER2IHC:UNKNOWN;BX_HER2OVERALL:UNKNOWN;BX_HISTOLOGY:DCIS;BX_KI67:UNKNOWN;BX_LCIS:NO;BX_PERCENT_ER:UNKNOWN;BX_PERCENT_PR:UNKNOWN;BX_PR:UNKNOWN;BXCEP17_COPY:UNKNOWN;BXHER2_COPY:UNKNOWN;BXHER2_RATIO:UNKNOWN;CALC_MET_SETTING:N/A;DX_ER:POSITIVE;DX_GRADE:II INTERMEDIATE GRADE (MODERATELY DIFFERENTIATED);DX_HER2_RATIO:1;DX_HER2FISH:NEGATIVE;DX_HER2IHC:N/A;DX_HER2OVERALL:NEGATIVE;DX_HISTOLOGY:IDC;DX_LOCATION:BREAST;DX_PERCENT_ER:95%;DX_PERCENT_PR:90%;DX_PR:POSITIVE;DX_STAGE:2A;DX_TYPE:CORE;EVER_METS_SITES:N/A;GERMLINE_MUTKNOWN_BRCA1:UNKNOWN;GERMLINE_MUTKNOWN_BRCA2:UNKNOWN;GERMLINE_MUTKNOWN_PALB2:UNKNOWN;HISPANIC:NO;METS_SITES_AT_METS_ABST_ADRENAL_GLAND:N/A;METS_SITES_AT_METS_ABST_ASCITES:N/A;METS_SITES_AT_METS_ABST_BRAIN_CNS:N/A;METS_SITES_AT_METS_ABST_CHEST_WALL:N/A;METS_SITES_AT_METS_ABST_DIST_LYMPH:N/A;METS_SITES_AT_METS_ABST_INTRA_ABDOMINAL:N/A;METS_SITES_AT_METS_ABST_OVARY:N/A;METS_SITES_AT_METS_ABST_PLEURAL_EFFUSION:N/A;METS_SITES_AT_METS_ABST_SKIN:N/A;METS_SITES_AT_METS_ABST_SOFT_TISSUE:N/A;METS_SITES_AT_METS_DX_ADRENAL_GLAND:N/A;METS_SITES_AT_METS_DX_ASCITES:N/A;METS_SITES_AT_METS_DX_BRAIN_CNS:N/A;METS_SITES_AT_METS_DX_CHEST_WALL:N/A;METS_SITES_AT_METS_DX_DIST_LYMPH:N/A;METS_SITES_AT_METS_DX_INTRA_ABDOMINAL:N/A;METS_SITES_AT_METS_DX_OVARY:N/A;METS_SITES_AT_METS_DX_PLEURAL_EFFUSION:N/A;METS_SITES_AT_METS_DX_SKIN:N/A;METS_SITES_AT_METS_DX_SOFT_TISSUE:N/A;SURGERY_AT_DX:LUMPECTOMY;ADJ_XRT:YES;ANY_THERAPY_2YRS:NO;DX_CEP17_COPY:3.6;DX_HER2_COPY:3.8;HER2_STATUS_REPORTED:DON'T KNOW;HORMONE_RECEPTOR_STATUS:YES;INFLAMMATORY_STATUS:NO;METS_SITES_AT_DX:N/A;METS_SITES_AT_METS_ABST_REG_LYMPH:N/A;METS_SITES_AT_METS_ABST_UNKNOWN:N/A;METS_SITES_AT_METS_DX_REG_LYMPH:N/A;METS_SITES_AT_METS_DX_UNKNOWN:N/A;N_STAGE_REPORTED:1A;RACE_CATEGORIZED:WHITE;T_STAGE_REPORTED:1C;TRIPLE_NEG_STATUS:DON'T KNOW;X2YR_AIS:FALSE;X2YR_ALKYLATING_AGENT:FALSE;X2YR_ANTHRACYCLINE:FALSE;X2YR_ANTIHER2:FALSE;X2YR_CAPECITABINE:FALSE;X2YR_CDK46:FALSE;X2YR_FULVESTRANT:FALSE;X2YR_TAMOXIFEN:FALSE;X2YR_TAXANE:FALSE;X2YR_VEGF_INHIBITOR:FALSE"
"BREAST DUCTAL CARCINOMA IN SITU" "CANCER_TYPE_DETAILED:Breast Ductal Carcinoma In Situ;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:DCIS;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0049;SAMPLE_TIMEPOINT:MBCProject_lGCMIGT0_T1A;BX_LOCATION:BREAST;BX_TYPE:LUMPECTOMY;AGE_AT_DIAGNOSIS_GROUP:66-70;CALC_TREATMENT_NAIVE:N/A;METS_SITES_AT_METS_ABST_BONE:N/A;METS_SITES_AT_METS_ABST_LIVER:N/A;METS_SITES_AT_METS_ABST_LUNG:N/A;METS_SITES_AT_METS_DX_BONE:N/A;METS_SITES_AT_METS_DX_LIVER:N/A;METS_SITES_AT_METS_DX_LUNG:N/A;BX_DCIS:YES;BX_ER:UNKNOWN;BX_GRADE:N/A;BX_HER2FISH:UNKNOWN;BX_HER2IHC:UNKNOWN;BX_HER2OVERALL:UNKNOWN;BX_HISTOLOGY:DCIS;BX_KI67:UNKNOWN;BX_LCIS:NO;BX_PERCENT_ER:UNKNOWN;BX_PERCENT_PR:UNKNOWN;BX_PR:UNKNOWN;BXCEP17_COPY:UNKNOWN;BXHER2_COPY:UNKNOWN;BXHER2_RATIO:UNKNOWN;CALC_MET_SETTING:N/A;DX_ER:POSITIVE;DX_GRADE:II INTERMEDIATE GRADE (MODERATELY DIFFERENTIATED);DX_HER2_RATIO:1;DX_HER2FISH:NEGATIVE;DX_HER2IHC:N/A;DX_HER2OVERALL:NEGATIVE;DX_HISTOLOGY:IDC;DX_LOCATION:BREAST;DX_PERCENT_ER:95%;DX_PERCENT_PR:90%;DX_PR:POSITIVE;DX_STAGE:2A;DX_TYPE:CORE;EVER_METS_SITES:N/A;GERMLINE_MUTKNOWN_BRCA1:UNKNOWN;GERMLINE_MUTKNOWN_BRCA2:UNKNOWN;GERMLINE_MUTKNOWN_PALB2:UNKNOWN;HISPANIC:NO;METS_SITES_AT_METS_ABST_ADRENAL_GLAND:N/A;METS_SITES_AT_METS_ABST_ASCITES:N/A;METS_SITES_AT_METS_ABST_BRAIN_CNS:N/A;METS_SITES_AT_METS_ABST_CHEST_WALL:N/A;METS_SITES_AT_METS_ABST_DIST_LYMPH:N/A;METS_SITES_AT_METS_ABST_INTRA_ABDOMINAL:N/A;METS_SITES_AT_METS_ABST_OVARY:N/A;METS_SITES_AT_METS_ABST_PLEURAL_EFFUSION:N/A;METS_SITES_AT_METS_ABST_SKIN:N/A;METS_SITES_AT_METS_ABST_SOFT_TISSUE:N/A;METS_SITES_AT_METS_DX_ADRENAL_GLAND:N/A;METS_SITES_AT_METS_DX_ASCITES:N/A;METS_SITES_AT_METS_DX_BRAIN_CNS:N/A;METS_SITES_AT_METS_DX_CHEST_WALL:N/A;METS_SITES_AT_METS_DX_DIST_LYMPH:N/A;METS_SITES_AT_METS_DX_INTRA_ABDOMINAL:N/A;METS_SITES_AT_METS_DX_OVARY:N/A;METS_SITES_AT_METS_DX_PLEURAL_EFFUSION:N/A;METS_SITES_AT_METS_DX_SKIN:N/A;METS_SITES_AT_METS_DX_SOFT_TISSUE:N/A;SURGERY_AT_DX:LUMPECTOMY;ADJ_XRT:YES;ANY_THERAPY_2YRS:NO;DX_CEP17_COPY:3.6;DX_HER2_COPY:3.8;HER2_STATUS_REPORTED:DON'T KNOW;HORMONE_RECEPTOR_STATUS:YES;INFLAMMATORY_STATUS:NO;METS_SITES_AT_DX:N/A;METS_SITES_AT_METS_ABST_REG_LYMPH:N/A;METS_SITES_AT_METS_ABST_UNKNOWN:N/A;METS_SITES_AT_METS_DX_REG_LYMPH:N/A;METS_SITES_AT_METS_DX_UNKNOWN:N/A;N_STAGE_REPORTED:1A;RACE_CATEGORIZED:WHITE;T_STAGE_REPORTED:1C;TRIPLE_NEG_STATUS:DON'T KNOW;X2YR_AIS:FALSE;X2YR_ALKYLATING_AGENT:FALSE;X2YR_ANTHRACYCLINE:FALSE;X2YR_ANTIHER2:FALSE;X2YR_CAPECITABINE:FALSE;X2YR_CDK46:FALSE;X2YR_FULVESTRANT:FALSE;X2YR_TAMOXIFEN:FALSE;X2YR_TAXANE:FALSE;X2YR_VEGF_INHIBITOR:FALSE"
"BREAST INVASIVE CANCER, NOS" "CANCER_TYPE_DETAILED:Breast Invasive Cancer, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCANOS;TMB_NONSYNONYMOUS:2.03333333333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2270;SAMPLE_TIMEPOINT:MBCProject_GvHkH2Hk_T1;BX_LOCATION:BONE;BX_TIME_DAYS:0;BX_TYPE:FNA;AGE_AT_DIAGNOSIS_GROUP:41-45;CALC_TIME_TO_METS_DX_DAYS:17;CALC_TIME_TO_METS_DX_MONTHS:0;CALC_TREATMENT_NAIVE:YES;METS_SITES_AT_METS_ABST_BONE:YES;METS_SITES_AT_METS_ABST_LIVER:NO;METS_SITES_AT_METS_ABST_LUNG:NO;METS_SITES_AT_METS_DX_BONE:YES;METS_SITES_AT_METS_DX_LIVER:NO;METS_SITES_AT_METS_DX_LUNG:NO;BX_DCIS:N/A;BX_ER:POSITIVE;BX_GRADE:UNKNOWN;BX_HER2FISH:UNKNOWN;BX_HER2IHC:UNKNOWN;BX_HER2OVERALL:UNKNOWN;BX_HISTOLOGY:ADENOCARCINOMA;BX_KI67:UNKNOWN;BX_LCIS:N/A;BX_PERCENT_ER:UNKNOWN;BX_PERCENT_PR:UNKNOWN;BX_PR:POSITIVE;BXCEP17_COPY:UNKNOWN;BXHER2_COPY:UNKNOWN;BXHER2_RATIO:UNKNOWN;CALC_MET_SETTING:METASTATIC DISEASE PRESENT;DX_ER:POSITIVE;DX_GRADE:II INTERMEDIATE GRADE (MODERATELY DIFFERENTIATED);DX_HER2_RATIO:UNKNOWN;DX_HER2FISH:NOT DONE;DX_HER2IHC:1+;DX_HER2OVERALL:NEGATIVE;DX_HISTOLOGY:IDC;DX_LOCATION:BREAST;DX_PERCENT_ER:UNKNOWN;DX_PERCENT_PR:UNKNOWN;DX_PR:POSITIVE;DX_STAGE:4;DX_TYPE:CORE;EVER_METS_SITES:BONE;GERMLINE_MUTKNOWN_BRCA1:NO;GERMLINE_MUTKNOWN_BRCA2:NO;GERMLINE_MUTKNOWN_PALB2:UNKNOWN;HISPANIC:NO;METS_SITES_AT_METS_ABST_ADRENAL_GLAND:NO;METS_SITES_AT_METS_ABST_ASCITES:NO;METS_SITES_AT_METS_ABST_BRAIN_CNS:NO;METS_SITES_AT_METS_ABST_CHEST_WALL:NO;METS_SITES_AT_METS_ABST_DIST_LYMPH:NO;METS_SITES_AT_METS_ABST_INTRA_ABDOMINAL:NO;METS_SITES_AT_METS_ABST_OVARY:NO;METS_SITES_AT_METS_ABST_PLEURAL_EFFUSION:NO;METS_SITES_AT_METS_ABST_SKIN:NO;METS_SITES_AT_METS_ABST_SOFT_TISSUE:NO;METS_SITES_AT_METS_DX_ADRENAL_GLAND:NO;METS_SITES_AT_METS_DX_ASCITES:NO;METS_SITES_AT_METS_DX_BRAIN_CNS:NO;METS_SITES_AT_METS_DX_CHEST_WALL:NO;METS_SITES_AT_METS_DX_DIST_LYMPH:NO;METS_SITES_AT_METS_DX_INTRA_ABDOMINAL:NO;METS_SITES_AT_METS_DX_OVARY:NO;METS_SITES_AT_METS_DX_PLEURAL_EFFUSION:NO;METS_SITES_AT_METS_DX_SKIN:NO;METS_SITES_AT_METS_DX_SOFT_TISSUE:NO;SURGERY_AT_DX:NO;ADJ_XRT:NO;ANY_THERAPY_2YRS:NO;DX_CEP17_COPY:UNKNOWN;DX_HER2_COPY:UNKNOWN;HER2_STATUS_REPORTED:NO;HORMONE_RECEPTOR_STATUS:YES;INFLAMMATORY_STATUS:NO;METS_SITES_AT_DX:BONE;METS_SITES_AT_METS_ABST_REG_LYMPH:NO;METS_SITES_AT_METS_ABST_UNKNOWN:NO;METS_SITES_AT_METS_DX_REG_LYMPH:NO;METS_SITES_AT_METS_DX_UNKNOWN:NO;N_STAGE_REPORTED:UNKNOWN;RACE_CATEGORIZED:UNKNOWN;T_STAGE_REPORTED:UNKNOWN;TRIPLE_NEG_STATUS:NO;X2YR_AIS:FALSE;X2YR_ALKYLATING_AGENT:FALSE;X2YR_ANTHRACYCLINE:FALSE;X2YR_ANTIHER2:FALSE;X2YR_CAPECITABINE:FALSE;X2YR_CDK46:FALSE;X2YR_FULVESTRANT:FALSE;X2YR_TAMOXIFEN:FALSE;X2YR_TAXANE:FALSE;X2YR_VEGF_INHIBITOR:FALSE"
"BREAST INVASIVE CARCINOMA" "CANCER_TYPE_DETAILED:Breast Invasive Carcinoma, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCNOS;TMB_NONSYNONYMOUS:4.666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.5955;SAMPLE_TYPE:Primary;OS_MONTHS:12.09;OS_STATUS:0:LIVING;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.09;TISSUE_SOURCE_SITE:A7;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8010/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/14/13;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Infiltrating Carcinoma NOS;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:154;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A7-A5ZV.FA5CF5A2-F44A-4303-9200-32250FAEF374.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:940;SITE_OF_TUMOR_TISSUE:Breast;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Equivocal;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;HER2_IHC_SCORE:2;ER_STATUS_BY_IHC:Negative;HER2_FISH_STATUS:Negative;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Sentinel node biopsy alone;CENT17_COPY_NUMBER:2.5;HER2_CENT17_RATIO:1.5;HER2_COPY_NUMBER:3.8;HER2_FISH_METHOD:PathVysion HER-2 DNA Probe Kit;MICROMET_DETECTION_BY_IHC:NO;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"BREAST INVASIVE CARCINOMA BRCA" NA
"BREAST INVASIVE CARCINOMA NOS" NA
"BREAST INVASIVE CARCINOMA, NOS" "CANCER_TYPE_DETAILED:Breast Invasive Carcinoma, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCNOS;TMB_NONSYNONYMOUS:4.666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.5955;SAMPLE_TYPE:Primary;OS_MONTHS:12.09;OS_STATUS:0:LIVING;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.09;TISSUE_SOURCE_SITE:A7;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8010/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/14/13;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Infiltrating Carcinoma NOS;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:154;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A7-A5ZV.FA5CF5A2-F44A-4303-9200-32250FAEF374.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:940;SITE_OF_TUMOR_TISSUE:Breast;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Equivocal;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;HER2_IHC_SCORE:2;ER_STATUS_BY_IHC:Negative;HER2_FISH_STATUS:Negative;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Sentinel node biopsy alone;CENT17_COPY_NUMBER:2.5;HER2_CENT17_RATIO:1.5;HER2_COPY_NUMBER:3.8;HER2_FISH_METHOD:PathVysion HER-2 DNA Probe Kit;MICROMET_DETECTION_BY_IHC:NO;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"BREAST INVASIVE CARCINOSARCOMA, NOS" "CANCER_TYPE_DETAILED:Breast Invasive Carcinosarcoma, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:CSNOS;TMB_NONSYNONYMOUS:5.18818857;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1583;SAMPLE_TYPE:Metastasis;RACE:WHITE;ETHNICITY:Unknown whether Spanish or not;PRIMARY_SITE:Breast;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lung;MSI_SCORE:0.18;MSI_TYPE:Stable;AGE_AT_SEQ_REPORTED_YEARS:57;AGE_CURRENT:61"
"BREAST INVASIVE DUCTAL CARCINOMA" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:1.366666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;FRACTION_GENOME_ALTERED:0.4696;SAMPLE_TYPE:Primary;OS_MONTHS:17.21;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:12.71;TISSUE_SOURCE_SITE:AR;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/28/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIA;HISTOLOGICAL_DIAGNOSIS:Infiltrating Ductal Carcinoma;HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1416;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AR-A1AR.747FB91B-F523-4FA0-91DD-6014EF55643D.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:250;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left Lower Inner Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;ER_STATUS_BY_IHC:Negative;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Axillary lymph node dissection alone;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"BREAST INVASIVE LOBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Breast Invasive Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ILC;TMB_NONSYNONYMOUS:1.033333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:74;FRACTION_GENOME_ALTERED:0.3999;SAMPLE_TYPE:Primary;OS_MONTHS:23.46;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:23.46;TISSUE_SOURCE_SITE:A2;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8520/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/26/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Infiltrating Lobular Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:372;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A2-A1FV.074223E9-5E1C-47E8-BE40-1C4442CAE9F0.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:150;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0 (i+);AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);METASTATIC_TUMOR_INDICATOR:NO;PATH_MARGIN:Negative;HER2_IHC_SCORE:1;ER_STATUS_BY_IHC:Positive;HER2_FISH_STATUS:Negative;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel node biopsy alone;ER_POSITIVITY_SCALE_OTHER:Strong;ER_STATUS_IHC_PERCENT_POSITIVE:90-99%;HER2_CENT17_RATIO:0.92;MICROMET_DETECTION_BY_IHC:YES;PR_POSITIVITY_SCALE_OTHER:Strong;PR_STATUS_IHC_PERCENT_POSITIVE:<10%;SURGICAL_PROCEDURE_FIRST:Simple Mastectomy"
"BREAST INVASIVE MIXED MUCINOUS CARCINOMA" "CANCER_TYPE_DETAILED:Breast Invasive Mixed Mucinous Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IMMC;TMB_NONSYNONYMOUS:0.733333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:38;FRACTION_GENOME_ALTERED:0.2376;SAMPLE_TYPE:Primary;OS_MONTHS:10.41;OS_STATUS:0:LIVING;RACE:ASIAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:10.41;TISSUE_SOURCE_SITE:C8;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8480/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/2/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIA;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:94;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C8-A1HL.ACA6B606-681C-427F-8923-77BAA7390795.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:980;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;PRIMARY_SITE_PATIENT:Left;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Patey's Surgery;IHC_HER2:Equivocal;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);METASTATIC_TUMOR_INDICATOR:NO;PATH_MARGIN:Negative;HER2_IHC_SCORE:2;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Axillary lymph node dissection alone;ER_POSITIVITY_SCALE_OTHER:Allred Score 8;FIRST_SURGICAL_PROCEDURE_OTHER:Patey's Surgery;SURGICAL_PROCEDURE_FIRST:Other"
"BREAST MICROINVASIVE CARCINOMA" "CANCER_TYPE_DETAILED:Breast Microinvasive Carcinoma;CANCER_TYPE:Breast Carcinoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Targeted_Therapy;Immunotherapy;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:826;DIAGNOSIS AGE:62;GDNA(NG):4440;SMOKE STATUS:Unknown;TUMOR_PURTITY:30"
"BREAST MIXED DUCTAL AND LOBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:68;FRACTION_GENOME_ALTERED:0.2619;SAMPLE_TYPE:Primary;OS_MONTHS:91.92;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/6/11;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1999;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4330;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A1EO.A2B755DD-00C4-4349-8E11-C1196EBC91D3.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:100;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1c;HISTOLOGICAL_SUBTYPE:ductal and lobular features;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Excisional Biopsy;PRIMARY_SITE_PATIENT:Right;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);METASTATIC_TUMOR_INDICATOR:NO;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;FIRST_SURGICAL_PROCEDURE_OTHER:right segmental mastectomy witrh axillary node dissection;SURGICAL_PROCEDURE_FIRST:Other"
"BREAST NEOPLASM, NOS" "CANCER_TYPE_DETAILED:Breast Neoplasm, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BNNOS;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Metastasis;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Breast;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:CSF;MSI_SCORE:0.06;MSI_TYPE:Stable;AGE_AT_SEQ_REPORTED_YEARS:67;AGE_CURRENT:66"
"BREAST SARCOMA" "CANCER_TYPE_DETAILED:Benign Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BPT;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:55;ETHNICITY:Chinese;HISTOLOGICAL_DIAGNOSIS:Benign PT;TUMOR_SIZE:180;SURGERY:Excision;MEAN_COVERAGE:50;NUM_SOMATIC_MUTATION:16"
"BREAST_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:18.7333333333;SEX:Female;AGE:43;FRACTION_GENOME_ALTERED:0.7080;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Breast;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:breast;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:223.3824299;GENOME_DOUBLINGS:1;DOUBLING_TIME:74.1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherenet;DISEASE_ONTOLOGY:breast_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI 1640 + 10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:breast;LINEAGE_MOLECULAR_SUBTYPE:HER2_amp;LINEAGE_SUB_SUBTYPE:ERneg_HER2pos;LINEAGE_SUBTYPE:breast_adenocarcinoma;NAME:AU565;PATHOLOGIST_ANNOTATION:Breast:Carcinoma;PROTEOMICS_TMT_LABEL:127c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:breast"
"BREAST_CANCER" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:10.4666666667;SEX:Female;AGE:50;FRACTION_GENOME_ALTERED:0.6557;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Breast;SUBTYPE:Breast Ductal Carcinoma;TUMOR_TYPE:breast;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:96.75975762;GENOME_DOUBLINGS:0;DOUBLING_TIME:103.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent, single cells and loosely attached clusters;DISEASE_ONTOLOGY:breast_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640 + 10% FBS;HIST_SUBTYPE1:ductal_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:breast;LINEAGE_MOLECULAR_SUBTYPE:basal_A;LINEAGE_SUB_SUBTYPE:ERneg_HER2neg;LINEAGE_SUBTYPE:breast_ductal_carcinoma;NAME:HCC38;PATHOLOGIST_ANNOTATION:Breast:Carcinoma;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:breast"
"BREAST_CARCINOMA" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:8.66666666667;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.2617;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Breast;SUBTYPE:Carcinoma;TUMOR_TYPE:breast;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:107.2866384;GENOME_DOUBLINGS:0;DOUBLING_TIME:145.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:suspension, multicell aggregates;DISEASE_ONTOLOGY:breast_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640 + 10% FBS;HIST_SUBTYPE1:ductal_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:breast;LINEAGE_MOLECULAR_SUBTYPE:luminal_HER2_amp;LINEAGE_SUB_SUBTYPE:ERneg_HER2neg;LINEAGE_SUBTYPE:breast_carcinoma;NAME:DU4475;PATHOLOGIST_ANNOTATION:Breast:Carcinoma;SITE_OF_FINDING:breast;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:breast"
"BREAST_DUCTAL_CARCINOMA" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:13.2333333333;SEX:Female;AGE:48;FRACTION_GENOME_ALTERED:0.8813;SAMPLE_TYPE:Primary;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Breast;SUBTYPE:Breast Ductal Carcinoma;TUMOR_TYPE:breast;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:173.1865428;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:ductal_carcinoma;HIST_SUBTYPE1:ductal_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:breast;LINEAGE_MOLECULAR_SUBTYPE:basal_A;LINEAGE_SUB_SUBTYPE:ERneg_HER2neg;LINEAGE_SUBTYPE:breast_ductal_carcinoma;NAME:HCC2157;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:breast"
"BRENNER TUMOR" "CANCER_TYPE_DETAILED:Brenner Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:BTOV;TMB_NONSYNONYMOUS:3.96666666667;SEX:Female;AGE:45;FRACTION_GENOME_ALTERED:0.5798;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Carcinoma, brenner;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:124.2318571;GENOME_DOUBLINGS:1;DOUBLING_TIME:36.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:ADHERENT, EPITHELIAL MONOLAYER;DOUBLING_TIME_FROM_VENDOR:40;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:Brenner_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUBTYPE:brenner_tumor;NAME:SNU-840;PATHOLOGIST_ANNOTATION:Ovary:Germline;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"BRENNER_TUMOR" "CANCER_TYPE_DETAILED:Brenner Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:BTOV;TMB_NONSYNONYMOUS:3.96666666667;SEX:Female;AGE:45;FRACTION_GENOME_ALTERED:0.5798;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Carcinoma, brenner;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:124.2318571;GENOME_DOUBLINGS:1;DOUBLING_TIME:36.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:ADHERENT, EPITHELIAL MONOLAYER;DOUBLING_TIME_FROM_VENDOR:40;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:Brenner_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUBTYPE:brenner_tumor;NAME:SNU-840;PATHOLOGIST_ANNOTATION:Ovary:Germline;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"BRENNER_TUMOUR" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:3.0944516151;SEX:Female;FRACTION_GENOME_ALTERED:0.5796;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Brenner_Tumour;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:KCLB;SAMPLE_ORIGIN:Solid"
"BRONCHIOALVEOLAR_CARCINOMA" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:41.4666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.5624;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:218.724336;GENOME_DOUBLINGS:1;DOUBLING_TIME:73.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherenet;DISEASE_ONTOLOGY:bronchioalveolar_carcinoma; non-small_cell lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:bronchioloalveolar_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenocarcinoma;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H358;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"BRONCHIOLOALVEOLAR_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:2.76290322777;SEX:Male;FRACTION_GENOME_ALTERED:0.2885;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Bronchioloalveolar_Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"BURKITT LYMPHOMA" "CANCER_TYPE_DETAILED:Burkitt Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:BL;TMB_NONSYNONYMOUS:4.0890967771;SEX:Male;FRACTION_GENOME_ALTERED:0.1882;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Burkitt;HISTOLOGICAL_SUBTYPE:Burkitt_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"BURKITTS LYMPHOMA" "CANCER_TYPE_DETAILED:Burkitt Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:BL;TMB_NONSYNONYMOUS:11.4;SEX:Male;AGE:7;FRACTION_GENOME_ALTERED:0.0851;SAMPLE_TYPE:Metastasis;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins, Burkitts;TUMOR_TYPE:lymphoma_Burkitt;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:166.4564059;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Burkitts lymphoma;HIST_SUBTYPE1:Burkitt_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_burkitt;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:P3HR-1;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_Burkitt"
"BURKITT_LYMPHOMA" "CANCER_TYPE_DETAILED:Burkitt Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:BL;TMB_NONSYNONYMOUS:4.0890967771;SEX:Male;FRACTION_GENOME_ALTERED:0.1882;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Burkitt;HISTOLOGICAL_SUBTYPE:Burkitt_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"B_CELL_BURKITT" "CANCER_TYPE_DETAILED:Burkitt Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:BL;TMB_NONSYNONYMOUS:11.4;SEX:Male;AGE:7;FRACTION_GENOME_ALTERED:0.0851;SAMPLE_TYPE:Metastasis;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins, Burkitts;TUMOR_TYPE:lymphoma_Burkitt;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:166.4564059;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Burkitts lymphoma;HIST_SUBTYPE1:Burkitt_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_burkitt;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:P3HR-1;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_Burkitt"
"B_CELL_FOLLICULAR" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:5.66666666667;SUBTYPE:B-cell, Non-Hodgkins, Follicular;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_follicular;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"B_CELL_LYMPHOMA_UNSPECIFIED" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:16.024838721;SEX:Male;FRACTION_GENOME_ALTERED:0.1932;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:B_Cell_Lymphoma_Unspecified;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"B_CELL_MANTLE_CELL" "CANCER_TYPE_DETAILED:Mantle Cell Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:MCL;TMB_NONSYNONYMOUS:5.0;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.1503;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins, Mantle Cell;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:0.99;MUTATION_RATE:73.86512393;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:spheroid cells growing in suspention, singly or in clumps;DISEASE_ONTOLOGY:mantle_cell_lymphoma;DOUBLING_TIME_FROM_VENDOR:~ 49 hrs;GROWTH_MEDIUM:90% Dulbecco's MEM(4.5 g/L glucose) +10% h.i.FBS;HIST_SUBTYPE1:mantle_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_mantle_cell;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:GRANTA-519;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM L-glutamine;TYPE_REFINED:B-cell_lymphoma_other"
"B_CELL_MEDIASTINAL_LARGE" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:9.46666666667;SUBTYPE:B-cell, Non-Hodgkins, Mediastinal Large;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_mediastinal_large;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"B_CELL_NON_HODGKIN_LYMPHOMA" "CANCER_TYPE_DETAILED:Mature B-Cell Neoplasms;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:MBN;TMB_NONSYNONYMOUS:4.1;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.2132;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:124.7637218;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:large round cells growing in suspention;DISEASE_ONTOLOGY:b_cell_non_hodgkin_lymphoma;DOUBLING_TIME_FROM_VENDOR:~  48-72 hrs;GROWTH_MEDIUM:90% RPMI 1640 +10% h.i. FBS;HIST_SUBTYPE1:B_cell_lymphoma_unspecified;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:RI-1;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:B-cell_lymphoma_other"
"B_CELL_PRIMARY_EFFUSION" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:7.33333333333;SUBTYPE:B-cell, Non-Hodgkins, Primary Effusion;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_primary_effusion;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"CAECUM ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:10.7333333333;SEX:Male;AGE:55;FRACTION_GENOME_ALTERED:0.4813;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Large_Intestine;SUBTYPE:Caecum Adenocarcinoma;TUMOR_TYPE:colorectal;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:94.03118402;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:colorectal;LINEAGE_SUBTYPE:caecum_adenocarcinoma;NAME:NCI-H508;PATHOLOGIST_ANNOTATION:Colorectal:Carcinoma;SITE_OF_FINDING:abdominal_wall;SITE_SUBTYPE1:caecum;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:colorectal"
"CAECUM_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:10.7333333333;SEX:Male;AGE:55;FRACTION_GENOME_ALTERED:0.4813;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Large_Intestine;SUBTYPE:Caecum Adenocarcinoma;TUMOR_TYPE:colorectal;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:94.03118402;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:colorectal;LINEAGE_SUBTYPE:caecum_adenocarcinoma;NAME:NCI-H508;PATHOLOGIST_ANNOTATION:Colorectal:Carcinoma;SITE_OF_FINDING:abdominal_wall;SITE_SUBTYPE1:caecum;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:colorectal"
"CANCER IDENTIFICATION IDC" NA
"CANCER IDENTIFICATION ILC" NA
"CANCER IDENTIFICATION MIDLC" NA
"CANCER OF UNKNOWN PRIMARY" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:5.08374193909;SEX:Male;FRACTION_GENOME_ALTERED:0.5864;PRIMARY_SITE:Salivary Gland;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_SUBTYPE:Mucoepidermoid_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CANCER OF UNKNOWN PRIMARY, NOS" "CANCER_TYPE_DETAILED:Cancer of Unknown Primary, NOS;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:CUPNOS;TMB_NONSYNONYMOUS:13.83516952;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.4925;SAMPLE_TYPE:Metastasis;OS_MONTHS:1.282;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Cancer of Unknown Primary;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Liver;TUMOR_PURITY:30;MSI_SCORE:0.44;MSI_TYPE:Stable;SAMPLE_COVERAGE:623;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:75;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:JEWISH;AGE_CURRENT:74;ARCHER:YES;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:YES"
"CARCINOID" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:8.06767742508;SEX:Female;FRACTION_GENOME_ALTERED:0.7674;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_TYPE:Carcinoid-Endocrine Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CARCINOID TUMOR" "CANCER_TYPE_DETAILED:Carcinoid Tumor;CANCER_TYPE:Other;SEX:Female;AGE:17.38809013;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:224"
"CARCINOID-ENDOCRINE TUMOUR" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:8.06767742508;SEX:Female;FRACTION_GENOME_ALTERED:0.7674;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_TYPE:Carcinoid-Endocrine Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CARCINOMA" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"CARCINOMA OF UTERINE CERVIX" "CANCER_TYPE_DETAILED:Endometrial Adenocarcinoma;CANCER_TYPE:Carcinoma of Uterine Cervix;TMB_NONSYNONYMOUS:0.166666666667;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:II;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1206;DIAGNOSIS AGE:55;GDNA(NG):5244;SMOKE STATUS:Unknown;TUMOR_PURTITY:45"
"CARCINOMA SMALL CELL" "CANCER_TYPE_DETAILED:Small Cell Lung Cancer;CANCER_TYPE:Small Cell Lung Cancer;ONCOTREE_CODE:SCLC;TMB_NONSYNONYMOUS:2.53333333333;SOMATIC_STATUS:Matched;SAMPLE_TYPE:Paired Primary Tumor;SAMPLE_CLASS:Tumor;DIAGNOSIS:Carcinoma Small Cell;PRIMARY_TISSUE:Lung;SAMPLE_NAME:HF-18666-(1)"
"CARCINOMA WITH CHONDROID METAPLASIA" "CANCER_TYPE_DETAILED:Carcinoma with Chondroid Metaplasia;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:CCHM;TMB_NONSYNONYMOUS:5.76666666667;SOMATIC_STATUS:Matched;AGE:54;SAMPLE_TYPE:Metastatic;OS_MONTHS:29.8;OS_STATUS:1:DECEASED;MSI_SCORE:1.49;ANALYSIS_COHORT:MISC;TUMOR_CONTENT:63;BIOPSY_SITE:Lymph Node;BIOPSY_COHORT:Lymphatic System;GENDER:Female;HRD_SCORE:64;ICI:Pembrolizumab;ICI_BEST_RESPONSE:Progressive disease;ICI_DURABLE_CLINICAL_BENEFIT:No durable clinical benefit;ICI_MUTATION_CATEGORY:Mut per Mb < 10;T_CELLS_CD4_MEMORY_ACTIVATED:0;T_CELLS_CD4_MEMORY_RESTING:0.158512524;T_CELLS_CD4_NAIVE:0;T_CELLS_CD8:0.186254729;T_CELLS_FOLLICULAR_HELPER:0.147327938;T_CELLS_GAMMA_DELTA:0.025437075;T_CELLS_REGULATORY_TREGS:0.012678043;TREATED_WITH_ICI:Yes;TREATMENT_CATEGORY:PD-1"
"CARCINOMA WITH OSSEOUS METAPLASIA" "CANCER_TYPE_DETAILED:Carcinoma with Osseous Metaplasia;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:COM;TMB_NONSYNONYMOUS:2.73333333333;SOMATIC_STATUS:Matched;AGE:60;SAMPLE_TYPE:Metastatic;OS_MONTHS:27.07;OS_STATUS:1:DECEASED;MSI_SCORE:2.89;ANALYSIS_COHORT:MISC;TUMOR_CONTENT:48;BIOPSY_SITE:Lung;BIOPSY_COHORT:Respiratory System;GENDER:Female;HRD_SCORE:46;TREATED_WITH_ICI:No"
"CARCINOMA WITH SQUAMOUS DIFFERENTIATION" "CANCER_TYPE_DETAILED:Squamous Cell Carcinoma of Gallbladder;CANCER_TYPE:Carcinoma with Squamous Differentiation;TMB_NONSYNONYMOUS:2.93615909284;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2220;SAMPLE_TYPE:Metastasis;OS_MONTHS:20.46817248;OS_STATUS:1:DECEASED;ETHNICITY:White;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT410;METASTATIC_SITE:Liver;TUMOR_PURITY:30;MSI_SCORE:0.51;MSI_TYPE:Stable;SAMPLE_COVERAGE:328;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:59;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:58;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:3;PARTA_CONSENTED_12_245:YES;DATE_ADDED:4/7/15;MONTH_ADDED:2015/04;WEEK_ADDED:2015, Wk. 15;CRDB_CONSENT_DATE_DAYS:21213;CRDB_OFF_STUDY_DAYS:21402;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:21402;CVR_TMB_COHORT_PERCENTILE:37.9;CVR_TMB_TT_COHORT_PERCENTILE:48.8;SAMPLE_NAME:P-0003363-T01-IM5;CBIOPORTAL_SAMPLE_CLASS:Tumor;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:20.46817248;OVERALL_SURVIVAL_MONTHS:20.46817248;TUMOR_STAGE_COLLECTION:4"
"CARCINOMA, BRENNER" "CANCER_TYPE_DETAILED:Brenner Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:BTOV;TMB_NONSYNONYMOUS:3.96666666667;SEX:Female;AGE:45;FRACTION_GENOME_ALTERED:0.5798;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Carcinoma, brenner;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:124.2318571;GENOME_DOUBLINGS:1;DOUBLING_TIME:36.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:ADHERENT, EPITHELIAL MONOLAYER;DOUBLING_TIME_FROM_VENDOR:40;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:Brenner_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUBTYPE:brenner_tumor;NAME:SNU-840;PATHOLOGIST_ANNOTATION:Ovary:Germline;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"CARCINOMA, FOLLICULAR" "CANCER_TYPE_DETAILED:Follicular Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THFO;TMB_NONSYNONYMOUS:7.86666666667;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.4758;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Carcinoma, follicular;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;GENOME_DOUBLINGS:1;DOUBLING_TIME:31.6;GEOGRAPHIC_DISTRIBUTION:chinese;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Adherent large epitheloid cells with long processes growing in monolayers with multilayer foci;DOUBLING_TIME_FROM_VENDOR:20-25hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:RPMI1640+10%FBS;HIST_SUBTYPE1:follicular_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:follicular;LINEAGE_SUBTYPE:thyroid_carcinoma;NAME:CGTH-W-1;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_OF_FINDING:sternum;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"CARCINOMA, GIANT CELL" "CANCER_TYPE_DETAILED:Thyroid;CANCER_TYPE:Thyroid Cancer, NOS;ONCOTREE_CODE:THYROID;TMB_NONSYNONYMOUS:9.5;SUBTYPE:Carcinoma, giant cell;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:giant_cell;LINEAGE_SUBTYPE:thyroid_carcinoma;TYPE_REFINED:thyroid"
"CARCINOMA, GINGIVAL" "CANCER_TYPE_DETAILED:Head and Neck Carcinoma, Other;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OHNCA;TMB_NONSYNONYMOUS:12.8;SUBTYPE:Carcinoma, gingival;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:gingival;LINEAGE_SUBTYPE:upper_aerodigestive_carcinoma;TYPE_REFINED:upper_aerodigestive"
"CARCINOMA, MUCOEPIDERMOID" "CANCER_TYPE_DETAILED:Mucoepidermoid Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:MUCC;TMB_NONSYNONYMOUS:4.56666666667;SUBTYPE:Carcinoma, mucoepidermoid;LINEAGE:upper_aerodigestive;TYPE_REFINED:upper_aerodigestive"
"CARCINOMA, PAPILLARY" "CANCER_TYPE_DETAILED:Anaplastic Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THAP;TMB_NONSYNONYMOUS:7.46666666667;SEX:Female;AGE:63;FRACTION_GENOME_ALTERED:0.4997;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Carcinoma, papillary;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:103.9713223;GENOME_DOUBLINGS:2;DOUBLING_TIME:38.5;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:epithelial- like cells growing in monolayers;DOUBLING_TIME_FROM_VENDOR:~  2-3 days;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:80% Dulbecco's MEM +20% h.i. FBS +0.5% human serum (+0.005 lu/ml TSH +5ug/ml human insulin-cells grow also without these latter supplements);HIST_SUBTYPE1:anaplastic_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:papillary;LINEAGE_SUBTYPE:thyroid_carcinoma;NAME:BHT-101;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.5%human serum(+0.005;TYPE_REFINED:thyroid"
"CARCINOMA, VULVAR" "CANCER_TYPE_DETAILED:Squamous Cell Carcinoma of the Vulva/Vagina;CANCER_TYPE:Vaginal Cancer;ONCOTREE_CODE:VSC;TMB_NONSYNONYMOUS:8.33333333333;SUBTYPE:Squamous Cell Carcinoma, vulvar;LINEAGE:skin;LINEAGE_SUBTYPE:skin_squamous"
"CARCINOSARCOMA-MALIGNANT_MESODERMAL_MIXED_TUMOUR" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:15.6932903337;SEX:Female;FRACTION_GENOME_ALTERED:0.0874;PRIMARY_SITE:Endometrium;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Endometrium;HISTOLOGICAL_SUBTYPE:Carcinosarcoma-Malignant_Mesodermal_Mixed_Tumour;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"CARCINOSARCOMA-MAMMARY GLAND" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:12;SOMATIC_STATUS:Matched;SEX:Female;AGE:74;FRACTION_GENOME_ALTERED:0.2795;SAMPLE_TYPE:Primary;HISTOLOGICAL_SUBTYPE:Carcinosarcoma-mammary gland; breast;DOUBLING_TIME:53.8;P53:MT;CATEGORY_SAMPLE:Primary;EPITHELIAL:Yes"
"CARCINOSARCOMA-MAMMARY GLAND; BREAST" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:12;SOMATIC_STATUS:Matched;SEX:Female;AGE:74;FRACTION_GENOME_ALTERED:0.2795;SAMPLE_TYPE:Primary;HISTOLOGICAL_SUBTYPE:Carcinosarcoma-mammary gland; breast;DOUBLING_TIME:53.8;P53:MT;CATEGORY_SAMPLE:Primary;EPITHELIAL:Yes"
"CASTRATION-RESISTANT PROSTATE CANCER" "CANCER_TYPE_DETAILED:Castration-Resistant Prostate Cancer;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PROSTATE;TMB_NONSYNONYMOUS:0.633333333333;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1890;TUMOR_TISSUE_SITE:Bone;DISEASE_CODE:CRPC-Adeno;CLONET_PURITY:0.43;GENOMIC_BURDEN:0.0003;PATHOLOGY_CLASSIFICATION:A;CONTROL_SITE:Blood"
"CCOV" "CANCER_TYPE_DETAILED:Clear Cell Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:CCOV;TMB_NONSYNONYMOUS:7.26666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.6831;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, clear cell;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:155.1495548;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:epithelial-like;GROWTH_MEDIUM:(DMEM: HamF12=1:1) +10%FBS;HIST_SUBTYPE1:clear_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:clear_cell;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOC-5;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1mM NEAA;TYPE_REFINED:ovary"
"CCRCC" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CCRCC;TMB_NONSYNONYMOUS:2.266666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:75;TUMOR_TISSUE_SITE:Perinephric Metastasis;HISTOLOGICAL_DIAGNOSIS:Clear cell renal cell carcinoma;STAGE:IV;TNMSTAGE:T3N2M1;CANER_TYPE_DETAILED:Renal Clear Cell Carcinoma;FUHRMAN_GRADE:1-4"
"CD30+_ANAPLASTIC_LARGE_CELL_LYMPHOMA" NA
"CELLULAR SCHWANNOMA" "CANCER_TYPE_DETAILED:Cellular Schwannoma;CANCER_TYPE:Nerve Sheath Tumor;ONCOTREE_CODE:CSCHW;SEX:Male;AGE:37.74674988;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:Yes;TERT_ALKYLATING_TX:2nd tertile;TERT_ANTHRACYCLINE_TX:1st tertile;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:2nd tertile;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:1st tertile;TIME_FROM_DX_TO_SEQ:195;TIME_TO_BLOOD_DRAW_FROM_TX:132;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"CENTRAL NEUROCYTOMA" "CANCER_TYPE_DETAILED:Central Neurocytoma;CANCER_TYPE:CNS;SEX:Female;AGE:16.19712448;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:1288"
"CENTROBLASTIC" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:0.933333333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:127.46666670000002;OS_STATUS:0:LIVING;PFS_MONTHS:127.46666670000002;PFS_STATUS:0:Not Progressed;AGE_AT_DIAGNOSIS:63.0;COHORT:Goettingen;MEAN_TARGET_COVERAGE_TUMOR:75.9;PURITY_ABSOLUTE:0.86;SAMPLE_COLLECTION_SOURCE:Frozen;IPI:3.0;NUM_NONSILENT_MUTATION:28;TESTICULAR_INVOLVEMENT:No;DRIVER_MUTATIONS:5;IPI_AGE:1.0;IPI_ECOG:0.0;IPI_LDH:1.0;MORPHOLOGY_SUBTYPE:Centroblastic;NONSILENT_MUTATION_DENSITY:0.860556;NUM_SILENT_MUTATION:11;TOTAL_CNA:58;CLUSTER:2;CNS_INVOLVEMENT:No;DBSNP_MUTATION_DENSITY:0.307;DRIVER_MUTATION_DENSITY:0.154;IPI_EXBM:0.0;IPI_STAGE:1.0;MUTATION_DENSITY:1.198632;NUM_DBSNP_MUTATIONS:10;NUM_DRIVER_SCNA:11;NUM_DRIVER_SV:0;R_CHOP_LIKE_CHEMO:Yes;SILENT_MUTATION_DENSITY:0.338;TOTAL_REARRANGEMENT:0;TUMOR_IN_NORMAL_ESTIMATE:0.005"
"CERVICAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Endocervical Adenocarcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:ECAD;TMB_NONSYNONYMOUS:2.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.1305;SAMPLE_TYPE:Primary;OS_MONTHS:34.99;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:18.23;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/19/11;GRADE:G3;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Endocervical Type of Adenocarcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3120;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A1M9.6D91450A-9499-4B66-90DF-E68B4880E64C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:160;WEIGHT:49;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3b;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:155;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);CLINICAL_STAGE:Stage IB1;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);CT_SCAN_PREOP_RESULTS:Extra-Pelvic Metastatic Disease Present|Paraaortic Nodes Present|Pelvic Nodes Present|Supraclavicular Absent;HISTORY_HORMONAL_CONTRACEPTIVES_USE:Former User;CORPUS_INVOLVEMENT:ABSENT;DAYS_TO_DIAGNOSTIC_COMPUTED_TOMOGRAPHY_PERFORMED:5;DAYS_TO_FDG_OR_CT_PET_PERFORMED:5;FEDPET_OR_CT_RESULTS:Bladder Absent|Extra-Pelvic Metastatic Disease Present|Parametrium Absent|Paraaortic Nodes Present|Pelvic Nodes Present|Supraclavicular Absent;HPV_TYPES_POSITIVE:HPV 16;HYSTERECTOMY_TYPE:Radical Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:margins free of tumor;POS_LYMPH_NODE_LOCATION:Pelvic (external iliac, internal iliac, obturator)|Para-aortic|Supraclavicular;PREGNANT_AT_DIAGNOSIS:NO"
"CERVICAL ADENOCARCINOMA IN SITU" "CANCER_TYPE_DETAILED:Cervical Adenocarcinoma In Situ;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEAIS;TMB_NONSYNONYMOUS:0.966666666667;SOMATIC_STATUS:Matched;AGE:45;SAMPLE_TYPE:Metastatic;OS_MONTHS:12.32;OS_STATUS:0:LIVING;MSI_SCORE:0;ANALYSIS_COHORT:CERV;TUMOR_CONTENT:56;BIOPSY_SITE:Lymph Node;BIOPSY_COHORT:Lymphatic System;GENDER:Female;HRD_SCORE:43;TREATED_WITH_ICI:No"
"CERVICAL ADENOID CYSTIC CARCINOMA" "CANCER_TYPE_DETAILED:Cervical Adenoid Cystic Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CACC;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;AGE:54;SAMPLE_TYPE:Metastatic;OS_MONTHS:61.89;OS_STATUS:1:DECEASED;PRIMARY_SITE:unknown;MSI_SCORE:0;ANALYSIS_COHORT:SECR;TUMOR_CONTENT:42;BIOPSY_SITE:Rectus Muscle;BIOPSY_COHORT:Soft Tissue;GENDER:Female;HRD_SCORE:0;TREATED_WITH_ICI:No"
"CERVICAL ADENOSQUAMOUS CARCINOMA" "CANCER_TYPE_DETAILED:Cervical Adenosquamous Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEAS;TMB_NONSYNONYMOUS:1.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:25;FRACTION_GENOME_ALTERED:0.3921;SAMPLE_TYPE:Primary;OS_MONTHS:1.12;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:1.12;TISSUE_SOURCE_SITE:DG;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/11/13;GRADE:GX;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Adenosquamous;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DG-A2KH.E92814BB-F3A7-45E6-9F18-B775CD53693F.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:120;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b1;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:4;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);CLINICAL_STAGE:Stage IB1;PERFORMANCE_STATUS_TIMING:Pre-Adjuvant Therapy;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);CORPUS_INVOLVEMENT:ABSENT;HYSTERECTOMY_TYPE:Radical Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:ABSENT;PELVIC_EXTENSION_COMMENT:The pelvic nodules show circumscribed area of adipose tissue with local fat necrosis. No evidence of malignancy within this pelvic nodule.;PREGNANT_AT_DIAGNOSIS:NO"
"CERVICAL CANCER" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Unmatched;SEX:Female;OS_MONTHS:5.69;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:39.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:190;AGE_AT_PROCUREMENT:39;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:3;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Allogeneic - Sibling;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];PB_BLAST_PERCENTAGE:80;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:70;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI;CUMULATIVE_TREATMENT_STAGES:Allogeneic - Sibling | Consolidation | Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Fludarabine, TBI;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:p.Arg882His; MAF 41.8%;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PRIOR_CANCER:Cervical Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;SURFACE_ANTIGENS:Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"CERVICAL CANCER, NOS" "CANCER_TYPE_DETAILED:Cervix;CANCER_TYPE:Cervical Cancer, NOS;ONCOTREE_CODE:CERVIX;SOMATIC_STATUS:Matched;SEX:Female;AGE:34;FRACTION_GENOME_ALTERED:0.2769;SAMPLE_TYPE:Metastasis;OS_MONTHS:9.43;OS_STATUS:0:LIVING;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:9.43;TISSUE_SOURCE_SITE:HM;ICD_O_3_SITE:C56.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C56.9;ICD_O_3_HISTOLOGY:8070/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/18/13;GRADE:G3;AJCC_STAGING_EDITION:2009;HISTOLOGICAL_DIAGNOSIS:Adenosquamous;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;RETROSPECTIVE_COLLECTION:NO;SMOKING_PACK_YEARS:8;WEIGHT:89;SITE_OF_TUMOR_TISSUE:Cervical;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M1;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2a;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:160;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);SMOKING_YEAR_STARTED:27;TARGETED_MOLECULAR_THERAPY:YES;CLINICAL_STAGE:Stage IVB;PERFORMANCE_STATUS_TIMING:Preoperative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);CT_SCAN_PREOP_RESULTS:[Not Available]|Paraaortic Nodes Absent|Pelvic Nodes Absent;HISTORY_HORMONAL_CONTRACEPTIVES_USE:Former User;CHEMO_CONCURRENT_COURSE:Once weekly;CHEMO_CONCURRENT_DOSE:70mg;CHEMO_CONCURRENT_FRACTIONS_TOTAL:6;CHEMO_CONCURRENT_TYPE:Cisplatin;DAYS_TO_DIAGNOSTIC_COMPUTED_TOMOGRAPHY_PERFORMED:9;DAYS_TO_FDG_OR_CT_PET_PERFORMED:62;DAYS_TO_PERFORMANCE_STATUS_ASSESSMENT:28;FEDPET_OR_CT_RESULTS:Extra-Pelvic Metastatic Disease Absent|Parametrium Absent|Paraaortic Nodes Absent|Pelvic Nodes Absent|Supraclavicular Absent;HYSTERECTOMY_TYPE:Radical Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;PELVIC_EXTENSION_COMMENT:Metastases to Right Ovary;PREGNANT_AT_DIAGNOSIS:NO;RADIATION_THERAPY_XRT_TYPE:IMRT;RT_TX_TOTAL_DOSE_TO_PELVIS:4500"
"CERVICAL CLEAR CELL CARCINOMA" "CANCER_TYPE_DETAILED:Cervical Clear Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CECC;TMB_NONSYNONYMOUS:5.872318186;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2659;SAMPLE_TYPE:Metastasis;OS_MONTHS:19.56;OS_STATUS:1:DECEASED;PRIMARY_SITE:Cervix;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Abdominal Wall;TUMOR_PURITY:30;SAMPLE_COVERAGE:361;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"CERVICAL ENDOMETRIOID CARCINOMA" "CANCER_TYPE_DETAILED:Cervical Endometrioid Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEEN;TMB_NONSYNONYMOUS:30.1;SOMATIC_STATUS:Matched;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.3128;SAMPLE_TYPE:Primary;OS_MONTHS:137.06;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:137.06;TISSUE_SOURCE_SITE:IR;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8384/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/24/13;GRADE:G3;AJCC_STAGING_EDITION:2009;HISTOLOGICAL_DIAGNOSIS:Endometrioid Adenocarcinoma of Endocervix;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3401;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-IR-A3LA.65E053F4-BCDB-40E2-A76B-1CA62FD61E1B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:170;WEIGHT:101;SITE_OF_TUMOR_TISSUE:Cervical;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b1;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;TARGETED_MOLECULAR_THERAPY:YES;CLINICAL_STAGE:Stage IB1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Dilation & curettage;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);HISTORY_HORMONAL_CONTRACEPTIVES_USE:Never Used;CHEMO_CONCURRENT_COURSE:[Not Available]|[Not Available];CHEMO_CONCURRENT_DOSE:70 mg/m2|750 mg/m2;CHEMO_CONCURRENT_FRACTIONS_TOTAL:4|4;CHEMO_CONCURRENT_TYPE:Cisplatin|Other;CHEMO_CONCURRENT_TYPE_OTHER:[Not Applicable]|Fluorouracil (5-FU);CORPUS_INVOLVEMENT:ABSENT;HYSTERECTOMY_TYPE:Simple Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;PREGNANT_AT_DIAGNOSIS:NO;RADIATION_THERAPY_DOSE_PARAAORTIC_NODES:0;RADIATION_THERAPY_XRT_TYPE:External beam radiation;RT_TX_TOTAL_DOSE_TO_PELVIS:5040"
"CERVICAL NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Cervical Neuroendocrine Tumor;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CENE;TMB_NONSYNONYMOUS:1.76666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:27;FRACTION_GENOME_ALTERED:0.2452;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Cervix;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Cervix;PRIOR_THERAPY:No;INTERVAL_MONTHS:1"
"CERVICAL SQUAMOUS CELL" "CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;TMB_NONSYNONYMOUS:2.13333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.1555;SAMPLE_TYPE:Primary;OS_MONTHS:68.79;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:54.99;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8072/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/12/11;GRADE:G2;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Cervical Squamous Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3839;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A1BE.0A21AE44-27DF-4F41-BAB5-209A25087C0A.pdf;VIAL_NUMBER:B;SAMPLE_INITIAL_WEIGHT:40;WEIGHT:76;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1b;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:3;HEIGHT:149;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Cone Biopsy / LEEP;CLINICAL_STAGE:Stage IB2;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);CORPUS_INVOLVEMENT:PRESENT;HYSTERECTOMY_TYPE:Radical Hysterectomy;KERATINIZATION_SQUAMOUS_CELL:Non-keratinizing squamous cell carcinoma;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:Anterior lower uterine segment;POS_LYMPH_NODE_LOCATION:Pelvic (external iliac, internal iliac, obturator);PREGNANT_AT_DIAGNOSIS:NO"
"CERVICAL SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;TMB_NONSYNONYMOUS:2.13333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.1555;SAMPLE_TYPE:Primary;OS_MONTHS:68.79;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:54.99;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8072/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/12/11;GRADE:G2;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Cervical Squamous Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3839;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A1BE.0A21AE44-27DF-4F41-BAB5-209A25087C0A.pdf;VIAL_NUMBER:B;SAMPLE_INITIAL_WEIGHT:40;WEIGHT:76;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1b;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:3;HEIGHT:149;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Cone Biopsy / LEEP;CLINICAL_STAGE:Stage IB2;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);CORPUS_INVOLVEMENT:PRESENT;HYSTERECTOMY_TYPE:Radical Hysterectomy;KERATINIZATION_SQUAMOUS_CELL:Non-keratinizing squamous cell carcinoma;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:Anterior lower uterine segment;POS_LYMPH_NODE_LOCATION:Pelvic (external iliac, internal iliac, obturator);PREGNANT_AT_DIAGNOSIS:NO"
"CERVICAL_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Cervical Adenocarcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEAD;TMB_NONSYNONYMOUS:11.0;SUBTYPE:Cervical Adenocarcinoma;LINEAGE:cervix;LINEAGE_SUBTYPE:cervical_adenocarcinoma;TYPE_REFINED:cervix"
"CERVICAL_CARCINOMA" "CANCER_TYPE_DETAILED:Cervix;CANCER_TYPE:Cervical Cancer, NOS;ONCOTREE_CODE:CERVIX;TMB_NONSYNONYMOUS:13.1666666667;SUBTYPE:Carcinoma;LINEAGE:cervix;LINEAGE_SUBTYPE:cervical_carcinoma;TYPE_REFINED:cervix"
"CERVICAL_SMALL_CELL" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Cervix;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:SCCE;TMB_NONSYNONYMOUS:8.56666666667;SUBTYPE:Small Cell Carcinoma;LINEAGE:cervix;LINEAGE_SUBTYPE:cervical_small_cell"
"CERVICAL_SQUAMOUS" "CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;TMB_NONSYNONYMOUS:14.0;SUBTYPE:Squamous Cell Carcinoma;LINEAGE:cervix;LINEAGE_SUBTYPE:cervical_squamous;TYPE_REFINED:cervix"
"CESC" "CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;TMB_NONSYNONYMOUS:2.13333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.1555;SAMPLE_TYPE:Primary;OS_MONTHS:68.79;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:54.99;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8072/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/12/11;GRADE:G2;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Cervical Squamous Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3839;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A1BE.0A21AE44-27DF-4F41-BAB5-209A25087C0A.pdf;VIAL_NUMBER:B;SAMPLE_INITIAL_WEIGHT:40;WEIGHT:76;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1b;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:3;HEIGHT:149;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Cone Biopsy / LEEP;CLINICAL_STAGE:Stage IB2;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);CORPUS_INVOLVEMENT:PRESENT;HYSTERECTOMY_TYPE:Radical Hysterectomy;KERATINIZATION_SQUAMOUS_CELL:Non-keratinizing squamous cell carcinoma;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:Anterior lower uterine segment;POS_LYMPH_NODE_LOCATION:Pelvic (external iliac, internal iliac, obturator);PREGNANT_AT_DIAGNOSIS:NO"
"CESC_SQUAMOUSCARCINOMA" "CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;TMB_NONSYNONYMOUS:379.2;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.0479;SAMPLE_TYPE:Primary;OS_MONTHS:17.52309564;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:17.52309564;TISSUE_SOURCE_SITE:University of New Mexico;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8560/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:5/15/14;GRADE:G3;PFS_MONTHS:17.52309564;AJCC_STAGING_EDITION:2009;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Cervical;SUBTYPE:CESC_SquamousCarcinoma;TUMOR_TYPE:Adenosquamous;PATH_T_STAGE:T2A2;RADIATION_THERAPY:Yes;DAYS_LAST_FOLLOWUP:533;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-18886;MSI_SENSOR_SCORE:13.19;CANCER_TYPE_ACRONYM:CESC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.6087;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:2W;DSS_MONTHS:17.52309564;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:42;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:33;RAGNUM_HYPOXIA_SCORE:22;WINTER_HYPOXIA_SCORE:28;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"CHOL" "CANCER_TYPE_DETAILED:Cholangiocarcinoma;CANCER_TYPE:Cholangiocarcinoma;ONCOTREE_CODE:CHOL;TMB_NONSYNONYMOUS:4.533333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.0049;SAMPLE_TYPE:Primary;OS_MONTHS:11.14;OS_STATUS:1:DECEASED;RACE:ASIAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/9/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; intrahepatic;HISTORY_OTHER_MALIGNANCY:Yes;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1113;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAV9.3E7DD345-7A2C-4D7B-B5A2-2207949186CA.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:740;WEIGHT:52;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;ECOG_SCORE:0;HEIGHT:169;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;FAMILY_HISTORY_CANCER_RELATIONSHIP:Brother|Brother;FAMILY_HISTORY_OF_CANCER:YES;ISHAK_FIBROSIS_SCORE:0 - No Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:1.1;CREATININE_NORM_RANGE_LOWER:0.6;CREATININE_NORM_RANGE_UPPER:1.4;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2010;BILIRUBIN_TOTAL:0.2;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.4;CHILD_PUGH_CLASSIFICATION:B;DEFINITIVE_SURGICAL_PROCEDURE:Other (specify);FAMILY_HISTORY_CANCER_NUMBER_RELATIVES:2;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Ulcerative colitis;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:2.7"
"CHOL EXTRA" "CANCER_TYPE_DETAILED:Extrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:EHCH;TMB_NONSYNONYMOUS:2.2183106012;SEX:Female;FRACTION_GENOME_ALTERED:0.0132;SAMPLE_TYPE:Primary;OS_MONTHS:8.18;OS_STATUS:1:DECEASED;RACE:Asian-far east/indian subcont;PRIMARY_SITE:Liver;GENE_PANEL:IMPACT341;TUMOR_PURITY:50;SUBTYPE:Cholangio Extrahepatic;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:224;AGE_AT_SURGERY:68.58;FGA:0.013;AGE_AT_SEQUENCING:69.43;ORGAN_SYSTEM:Developmental GI Tract;AGE_AT_DEATH:70.12;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CHOL extra"
"CHOL INTRA" "CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:4.43662120239;SEX:Female;FRACTION_GENOME_ALTERED:0.1874;SAMPLE_TYPE:Metastasis;OS_MONTHS:11.56;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Liver;GENE_PANEL:IMPACT341;METASTATIC_SITE:Lymph;TUMOR_PURITY:60;SUBTYPE:Cholangio Intrahepatic;MSI_SCORE:0.47;MSI_TYPE:Stable;SAMPLE_COVERAGE:938;AGE_AT_SURGERY:57.88;FGA:0.187;AGE_AT_SEQUENCING:58.09;ORGAN_SYSTEM:Developmental GI Tract;AGE_AT_DEATH:59.06;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CHOL intra"
"CHOLANGIO EXTRAHEPATIC" "CANCER_TYPE_DETAILED:Extrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:EHCH;TMB_NONSYNONYMOUS:2.2183106012;SEX:Female;FRACTION_GENOME_ALTERED:0.0132;SAMPLE_TYPE:Primary;OS_MONTHS:8.18;OS_STATUS:1:DECEASED;RACE:Asian-far east/indian subcont;PRIMARY_SITE:Liver;GENE_PANEL:IMPACT341;TUMOR_PURITY:50;SUBTYPE:Cholangio Extrahepatic;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:224;AGE_AT_SURGERY:68.58;FGA:0.013;AGE_AT_SEQUENCING:69.43;ORGAN_SYSTEM:Developmental GI Tract;AGE_AT_DEATH:70.12;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CHOL extra"
"CHOLANGIO INTRAHEPATIC" "CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:4.43662120239;SEX:Female;FRACTION_GENOME_ALTERED:0.1874;SAMPLE_TYPE:Metastasis;OS_MONTHS:11.56;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Liver;GENE_PANEL:IMPACT341;METASTATIC_SITE:Lymph;TUMOR_PURITY:60;SUBTYPE:Cholangio Intrahepatic;MSI_SCORE:0.47;MSI_TYPE:Stable;SAMPLE_COVERAGE:938;AGE_AT_SURGERY:57.88;FGA:0.187;AGE_AT_SEQUENCING:58.09;ORGAN_SYSTEM:Developmental GI Tract;AGE_AT_DEATH:59.06;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CHOL intra"
"CHOLANGIOCARCINOMA" "CANCER_TYPE_DETAILED:Cholangiocarcinoma;CANCER_TYPE:Cholangiocarcinoma;ONCOTREE_CODE:CHOL;TMB_NONSYNONYMOUS:4.533333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.0049;SAMPLE_TYPE:Primary;OS_MONTHS:11.14;OS_STATUS:1:DECEASED;RACE:ASIAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/9/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; intrahepatic;HISTORY_OTHER_MALIGNANCY:Yes;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1113;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAV9.3E7DD345-7A2C-4D7B-B5A2-2207949186CA.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:740;WEIGHT:52;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;ECOG_SCORE:0;HEIGHT:169;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;FAMILY_HISTORY_CANCER_RELATIONSHIP:Brother|Brother;FAMILY_HISTORY_OF_CANCER:YES;ISHAK_FIBROSIS_SCORE:0 - No Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:1.1;CREATININE_NORM_RANGE_LOWER:0.6;CREATININE_NORM_RANGE_UPPER:1.4;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2010;BILIRUBIN_TOTAL:0.2;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.4;CHILD_PUGH_CLASSIFICATION:B;DEFINITIVE_SURGICAL_PROCEDURE:Other (specify);FAMILY_HISTORY_CANCER_NUMBER_RELATIVES:2;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Ulcerative colitis;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:2.7"
"CHOLANGIOCARCINOMA, INTRAHEPATIC" "CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Cholangiocarcinoma;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:1.433333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.0049;SAMPLE_TYPE:Primary;OS_MONTHS:11.14508334;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.101292041;TISSUE_SOURCE_SITE:Alberta Health Services;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/9/14;GRADE:G2;PFS_MONTHS:7.101292041;AJCC_STAGING_EDITION:7TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Bile Duct;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:CHOL;TUMOR_TYPE:Cholangiocarcinoma, Intrahepatic;PATH_T_STAGE:T1;RADIATION_THERAPY:No;DSS_STATUS:1:DEAD WITH TUMOR;DAYS_TO_BIRTH:-26349;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:CHOL;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3138;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:3X;DSS_MONTHS:11.14508334;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:Yes;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:52;PATH_M_STAGE:M0"
"CHOLANGIOCARCINOMA; DISTAL" "CANCER_TYPE_DETAILED:Extrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:EHCH;TMB_NONSYNONYMOUS:3.2;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.2422;SAMPLE_TYPE:Primary;OS_MONTHS:12.09;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.09;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C24.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C24.0;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/9/14;GRADE:G1;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IVB;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; distal;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:386;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVB.BEA4C577-73ED-48F0-9417-AA8BD143B5C8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:420;WEIGHT:76;TUMOR_SITE:Bile duct;AJCC_METASTASIS_PATHOLOGIC_PM:M1;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;ECOG_SCORE:0;HEIGHT:170;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;FAMILY_HISTORY_OF_CANCER:NO;CREATININE_LEVEL_PRERESECTION:0.9;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;BILIRUBIN_TOTAL:1.7;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.2;CHILD_PUGH_CLASSIFICATION:A;DEFINITIVE_SURGICAL_PROCEDURE:Pancreaticoduodenectomy (Whipple Resection);HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:No History of Primary Risk Factors;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:0.9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:1.1;PROTHROMBIN_TIME_NORM_RANGE_UPPER:1.1;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:4.3"
"CHOLANGIOCARCINOMA; HILAR/PERIHILAR" "CANCER_TYPE_DETAILED:Perihilar Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:PHCH;TMB_NONSYNONYMOUS:4.633333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.5353;SAMPLE_TYPE:Primary;OS_MONTHS:12.19;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.19;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C24.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C24.0;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/11/14;GRADE:G3;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; hilar/perihilar;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:428;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVC.88206A8B-257B-4C0F-B42C-905DEA9483FB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:230;WEIGHT:104;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;ECOG_SCORE:0;HEIGHT:159;PERINEURAL_INVASION:NO;VASCULAR_INVASION:None;ISHAK_FIBROSIS_SCORE:1,2 - Portal Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:0.8;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;BILIRUBIN_TOTAL:0.5;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.2;CHILD_PUGH_CLASSIFICATION:B;DEFINITIVE_SURGICAL_PROCEDURE:Segmentectomy, Multiple;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Other;OTHER_HEPATO_CARCINOMA_RISK_FACTORS:Pancreatitis;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:0.9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:1.1;PROTHROMBIN_TIME_NORM_RANGE_UPPER:1.1;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:2.4"
"CHOLANGIOCARCINOMA; INTRAHEPATIC" "CANCER_TYPE_DETAILED:Cholangiocarcinoma;CANCER_TYPE:Cholangiocarcinoma;ONCOTREE_CODE:CHOL;TMB_NONSYNONYMOUS:4.533333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.0049;SAMPLE_TYPE:Primary;OS_MONTHS:11.14;OS_STATUS:1:DECEASED;RACE:ASIAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/9/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; intrahepatic;HISTORY_OTHER_MALIGNANCY:Yes;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1113;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAV9.3E7DD345-7A2C-4D7B-B5A2-2207949186CA.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:740;WEIGHT:52;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;ECOG_SCORE:0;HEIGHT:169;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;FAMILY_HISTORY_CANCER_RELATIONSHIP:Brother|Brother;FAMILY_HISTORY_OF_CANCER:YES;ISHAK_FIBROSIS_SCORE:0 - No Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:1.1;CREATININE_NORM_RANGE_LOWER:0.6;CREATININE_NORM_RANGE_UPPER:1.4;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2010;BILIRUBIN_TOTAL:0.2;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.4;CHILD_PUGH_CLASSIFICATION:B;DEFINITIVE_SURGICAL_PROCEDURE:Other (specify);FAMILY_HISTORY_CANCER_NUMBER_RELATIVES:2;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Ulcerative colitis;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:2.7"
"CHONDROBLASTIC OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Chondroblastic Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHOS;TMB_NONSYNONYMOUS:8.06666666667;SEX:Male;OS_MONTHS:24;OS_STATUS:1:DECEASED;PRIMARY_SITE:Femur;SAMPLE_CLASS:Tumor;GRADE:High grade; ypT2, ypNX;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:14;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Femur;NGS_TEST:467 cancer gene panel;AGE_TESTING_YEARS:15.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:24;SAMPLE_TESTED_CATEGORY:Primary disease"
"CHONDROBLASTOMA" "CANCER_TYPE_DETAILED:Chondroblastoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHBL;SEX:Female;AGE:54.00136948;RACE:Black;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;EQD_TERTILES:3rd tertile;TIME_FROM_DX_TO_SEQ:3311;XRT_TX:Yes"
"CHONDROSARCOMA" "CANCER_TYPE_DETAILED:Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHS;TMB_NONSYNONYMOUS:4.64167742265;SEX:Male;FRACTION_GENOME_ALTERED:0.6024;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Chondrosarcoma;HISTOLOGICAL_SUBTYPE:Dedifferentiated;HISTOLOGICAL_TYPE:Chondrosarcoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"CHORDOMA" "CANCER_TYPE_DETAILED:Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHS;TMB_NONSYNONYMOUS:3.0;SUBTYPE:Chordoma, sacral;LINEAGE:bone;LINEAGE_SUB_SUBTYPE:chordoma_sacral;LINEAGE_SUBTYPE:chordoma"
"CHORDOMA, SACRAL" "CANCER_TYPE_DETAILED:Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHS;TMB_NONSYNONYMOUS:3.0;SUBTYPE:Chordoma, sacral;LINEAGE:bone;LINEAGE_SUB_SUBTYPE:chordoma_sacral;LINEAGE_SUBTYPE:chordoma"
"CHORDOMA_SACRAL" "CANCER_TYPE_DETAILED:Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHS;TMB_NONSYNONYMOUS:3.0;SUBTYPE:Chordoma, sacral;LINEAGE:bone;LINEAGE_SUB_SUBTYPE:chordoma_sacral;LINEAGE_SUBTYPE:chordoma"
"CHORIOCARCINOMA" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:12.3;SUBTYPE:Choriocarcinoma;LINEAGE:gastric;LINEAGE_SUBTYPE:choriocarcinoma;TYPE_REFINED:stomach"
"CHOROID PLEXUS PAPILLOMA" "CANCER_TYPE_DETAILED:Choroid Plexus Papilloma;CANCER_TYPE:Choroid Plexus Tumor;ONCOTREE_CODE:CPP;TMB_NONSYNONYMOUS:2.6;SEX:Male;OS_MONTHS:131;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade I;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain;NGS_TEST:Tumor-normal  WES;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:122;SAMPLE_TESTED_CATEGORY:Primary disease"
"CHOROID PLEXUS TUMOR" "CANCER_TYPE_DETAILED:Choroid Plexus Papilloma;CANCER_TYPE:Choroid Plexus Tumor;ONCOTREE_CODE:CPP;TMB_NONSYNONYMOUS:2.6;SEX:Male;OS_MONTHS:131;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade I;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain;NGS_TEST:Tumor-normal  WES;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:122;SAMPLE_TESTED_CATEGORY:Primary disease"
"CHROMOPHOBE" "CANCER_TYPE_DETAILED:Chromophobe Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CHRCC;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:38.04;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:29.93;TISSUE_SOURCE_SITE:KL;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8317/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2012-7-24;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Kidney Chromophobe;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-KL-8323.9f3120ac-7238-4b68-8ac0-6175a7a86b4b.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Kidney;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T3b;TREATMENT_OUTCOME_FIRST_COURSE:[Unknown];LYMPH_NODES_EXAMINED:NO;TOBACCO_SMOKING_HISTORY_INDICATOR:1;SPECIMEN_SECOND_LONGEST_DIMENSION:0.5;LATERALITY:Right;LONGEST_DIMENSION:0.7;SHORTEST_DIMENSION:0.4;TARGETED_MOLECULAR_THERAPY:YES;WBC:Elevated;HEMOGLOBIN_LEVEL:Normal;ERYTHROCYTE_SEDIMENTATION_RATE:[Not Evaluated];SERUM_CALCIUM_LEVEL:Low"
"CHROMOPHOBE KIDNEY RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Chromophobe Kidney Renal Cell Carcinoma;CANCER_TYPE:Kidney Renal Cell Carcinoma;TMB_NONSYNONYMOUS:0;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:I;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1250;DIAGNOSIS AGE:24;GDNA(NG):4836;SMOKE STATUS:Unknown;TUMOR_PURTITY:70"
"CHROMOPHOBE RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Chromophobe Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CHRCC;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:38.04;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:29.93;TISSUE_SOURCE_SITE:KL;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8317/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2012-7-24;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Kidney Chromophobe;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-KL-8323.9f3120ac-7238-4b68-8ac0-6175a7a86b4b.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Kidney;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T3b;TREATMENT_OUTCOME_FIRST_COURSE:[Unknown];LYMPH_NODES_EXAMINED:NO;TOBACCO_SMOKING_HISTORY_INDICATOR:1;SPECIMEN_SECOND_LONGEST_DIMENSION:0.5;LATERALITY:Right;LONGEST_DIMENSION:0.7;SHORTEST_DIMENSION:0.4;TARGETED_MOLECULAR_THERAPY:YES;WBC:Elevated;HEMOGLOBIN_LEVEL:Normal;ERYTHROCYTE_SEDIMENTATION_RATE:[Not Evaluated];SERUM_CALCIUM_LEVEL:Low"
"CHROMOPHOBE RENAL CELL CARCINOMA" NA
"CHROMOPHOBE, CLASSIC" "CANCER_TYPE_DETAILED:Renal Non-Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:NCCRCC;TMB_NONSYNONYMOUS:0.7;SOMATIC_STATUS:Matched;SEX:Female;AGE:73;TUMOR_TISSUE_SITE:Kidney;SUBTYPE:chromophobe;HISTOLOGICAL_DIAGNOSIS:chromophobe, classic;PLATFORM:Exome;COHORT:discovery;TUMOR_CONTENT:95"
"CHROMOPHOBE, EOSINOPHILIC" "CANCER_TYPE_DETAILED:Renal Non-Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:NCCRCC;TMB_NONSYNONYMOUS:0.233333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;TUMOR_TISSUE_SITE:Kidney;SUBTYPE:chromophobe;HISTOLOGICAL_DIAGNOSIS:chromophobe, eosinophilic;PLATFORM:Exome;COHORT:discovery;TUMOR_CONTENT:85"
"CHRONIC LYMPHOBLASTIC LEUKEMIA CLL, B-CELL" NA
"CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA" "CANCER_TYPE_DETAILED:Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:CLLSLL;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;PLATFORM:WES,WGS;IGHV_GENE:IGHV1-3;EPIGENETIC:Naive-like CLL;EXOME_CAPTURE:SureSelect Human All Exon;IGHV_MUTATED:UNMUT"
"CHRONIC MYELOGENOUS LEUKEMIA" "CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"CHRONIC MYELOGENOUS LEUKEMIA CML" NA
"CHRONIC MYELOID LEUKEMIA, BCR-ABL1+" "CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"CHRONIC MYELOMONOCYTIC LEUKAEMIA" "CANCER_TYPE_DETAILED:Chronic Myelomonocytic Leukemia;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:CMML;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:10.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:70.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:21;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:70;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M4;HEMOGLOBIN_LEVEL:9.7;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.18;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:9;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:36;CUMULATIVE_TREATMENT_REGIMENS:Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin);LDH_LEVEL:231;MOST_RECENT_TREATMENT_DURATION:4;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:153;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:28.7;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:Yes;MEAN_CORPUSCULAR_VOLUME:99.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.6;PB_ALT_LEVEL:19;PB_AST_LEVEL:22;PB_BASOPHILS_PERCENTAGE:5;PB_EOSINOPHILS_PERCENTAGE:5;PB_LYMPHOCYTES_PERCENTAGE:21;PB_MONOCYTES_PERCENTAGE:38;PB_NEUTROPHILS_PERCENTAGE:22;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myelomonocytic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Chronic myelomonocytic leukaemia;SURFACE_ANTIGENS:CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive;TOTAL_PROTEIN_LEVEL:7.1;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"CHRONIC MYELOMONOCYTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Chronic Myelomonocytic Leukemia;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:CMML;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:10.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:70.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:21;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:70;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M4;HEMOGLOBIN_LEVEL:9.7;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.18;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:9;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:36;CUMULATIVE_TREATMENT_REGIMENS:Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin);LDH_LEVEL:231;MOST_RECENT_TREATMENT_DURATION:4;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:153;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:28.7;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:Yes;MEAN_CORPUSCULAR_VOLUME:99.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.6;PB_ALT_LEVEL:19;PB_AST_LEVEL:22;PB_BASOPHILS_PERCENTAGE:5;PB_EOSINOPHILS_PERCENTAGE:5;PB_LYMPHOCYTES_PERCENTAGE:21;PB_MONOCYTES_PERCENTAGE:38;PB_NEUTROPHILS_PERCENTAGE:22;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myelomonocytic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Chronic myelomonocytic leukaemia;SURFACE_ANTIGENS:CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive;TOTAL_PROTEIN_LEVEL:7.1;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"CHRONIC MYELOMONOCYTIC LEUKEMIA 1" "CANCER_TYPE_DETAILED:Chronic Myelomonocytic Leukemia;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:CMML;TMB_NONSYNONYMOUS:0.466666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:48;TUMOR_TISSUE_SITE:Peripheral blood(CD3-);WHO_CLASS:Chronic Myelomonocytic Leukemia 1;CYTOGENETICS:46,XY;GERMLINE_CONTROL:CD3+ T cell;IPSS_SCORE:ND"
"CHRONIC MYELOMONOCYTIC LEUKEMIA 2" "CANCER_TYPE_DETAILED:Chronic Myelomonocytic Leukemia;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:CMML;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:83;TUMOR_TISSUE_SITE:Bone marrow;WHO_CLASS:Chronic Myelomonocytic Leukemia 2;CYTOGENETICS:47,XY,+14;GERMLINE_CONTROL:CD3+ T cell;IPSS_SCORE:ND"
"CHRONIC_LYMPHOCYTIC_LEUKAEMIA-SMALL_LYMPHOCYTIC_LYMPHOMA" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:1.43670967844;SEX:Female;FRACTION_GENOME_ALTERED:0.0252;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:Chronic_Lymphocytic_Leukaemia-Small_Lymphocytic_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"CHRONIC_MYELOID_LEUKAEMIA" "CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"CILIATED MUCONODULAR PAPILLARY TUMOR OF THE LUNG" "CANCER_TYPE_DETAILED:Ciliated Muconodular Papillary Tumor of the Lung;CANCER_TYPE:Lung Cancer;ONCOTREE_CODE:CMPT;TMB_NONSYNONYMOUS:1.766666667;SEX:Male;AGE:81;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;ICD_10:C34.8;HISTOLOGY:Papillary carcinoma, NOS;PURITY:0.91;PROJECT_CODE:LUAD-US;WGD:no_wgd;SEQUENCING_TYPE:WGS;ORGAN_SYSTEM:LUNG & BRONCHUS;ANCESTRY_PRIMARY:ASN;HISTOLOGY_ABBREVIATION:Lung-AdenoCA;HISTOLOGY_TIER1:ENDODERM;HISTOLOGY_TIER2:Lung;HISTOLOGY_TIER3:Adenocarcinoma;HISTOLOGY_TIER4:Adenocarcinoma, invasive;PURITY_CONFUGURATION:0.002;TUMOR_SAMPLE_HISTOLOGY_CODE:8050/3"
"CLASSICAL HCA" "CANCER_TYPE_DETAILED:Hepatocellular Adenoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:LIAD;TMB_NONSYNONYMOUS:0.566666666667;SEX:Male;AGE:35;BMI:<= 25;ISHAK_FIBROSIS_SCORE:F0-F1;PATHOLOGICAL_DIAGNOSIS:Classical HCA;KNOWN_MOLECULAR_CLASSIFIER:bIHCA;NODULE_NUMBER:1;NODULE_SIZE:60;ORAL_CONTRACEPTION:No"
"CLASSICAL HODGKIN LYMPHOMA" "CANCER_TYPE_DETAILED:Classical Hodgkin Lymphoma;CANCER_TYPE:Hodgkin Lymphoma;ONCOTREE_CODE:CHL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Unmatched;SEX:Male;FRACTION_GENOME_ALTERED:0.0001;SAMPLE_TYPE:Primary;OS_MONTHS:10.98;OS_STATUS:0:LIVING;PRIMARY_SITE:Lymph Node;SAMPLE_CLASS:Tumor;SAMPLE_COVERAGE:969;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Unmatched;DNA_INPUT:250"
"CLEAR CELL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:CLEAR CELL ADENOCARCINOMA;CANCER_TYPE:Carcinoma;SEX:Female;AGE:21.25393486;RACE:Black;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;CHEMO_TX:Yes;EQD_TERTILES:3rd tertile;IO_TX:Yes;TARGETED_TX:Yes;TERT_IO_TX:3rd tertile;TERT_TARGETED_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:419;XRT_TX:Yes"
"CLEAR CELL BORDERLINE OVARIAN TUMOR" "CANCER_TYPE_DETAILED:Clear Cell Borderline Ovarian Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:CCBOV;SEX:Female;AGE:56.96098709;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:Yes;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:Yes;TAXANE_TX:Yes;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:2nd tertile;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CARBOLATIN_TX:3rd tertile;TERT_CISPLATIN_TX:3rd tertile;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:3rd tertile;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:3rd tertile;TERT_TARGETED_TX:3rd tertile;TERT_TAXANE_TX:2nd tertile;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:2410;TIME_TO_BLOOD_DRAW_FROM_TX:2353;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"CLEAR CELL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:2.0998064531;SEX:Female;FRACTION_GENOME_ALTERED:0.1797;PRIMARY_SITE:Kidney;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Kidney;HISTOLOGICAL_SUBTYPE:Clear_Cell_Renal_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CLEAR CELL CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Clear Cell Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:CCLC;TMB_NONSYNONYMOUS:1.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.6108;SAMPLE_TYPE:Metastasis;RACE:Caucasian;BIOPSY_SITE:Tongue;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:161;OTHER_CANCER_HISTORY:Clinoidal Meningioma"
"CLEAR CELL ODONTOGENIC CARCINOMA" "CANCER_TYPE_DETAILED:Clear Cell Odontogenic Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:CCOC;TMB_NONSYNONYMOUS:0.0;SOMATIC_STATUS:Matched;SEX:Female;AGE:61.0;FRACTION_GENOME_ALTERED:0.0036;SAMPLE_TYPE:Primary;OS_MONTHS:44.2;OS_STATUS:0:LIVING;RACE:White;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:13.6;PRIMARY_SITE:Maxilla;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;SAMPLE_COVERAGE:1069;VITAL_STATUS:AWD;SMOKING_HISTORY:Never;PARTC_CONSENTED_12_245:NO;ALCOHOL_HISTORY_DOCUMENTED:Never;SITE_OF_RECURRENCE:Distant and Regional;AGENT:None;DISEASE_EXTENT:Locoregional & Distant;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:Yes;DISTANT_METS:Yes;SMOKING:Smoking Pack:0;TNM:T3N0M0;CLINICAL_TRIAL:None;DETAILED_PRIMARY_SITE:Maxilla;INITIAL_TREATMENT:Surgery + Radiation;SITE_SEQUENCED:Original Primary;PRIOR_TX_TO_IMPACT_SAMPLE:None;VAR_12_245:12-245"
"CLEAR CELL OVARIAN CANCER" "CANCER_TYPE_DETAILED:Clear Cell Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:CCOV;TMB_NONSYNONYMOUS:7.26666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.6831;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, clear cell;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:155.1495548;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:epithelial-like;GROWTH_MEDIUM:(DMEM: HamF12=1:1) +10%FBS;HIST_SUBTYPE1:clear_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:clear_cell;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOC-5;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1mM NEAA;TYPE_REFINED:ovary"
"CLEAR CELL PAPILLARY RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Clear Cell Papillary Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CCPRC;SEX:Male;AGE:49.60438156;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:Yes;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:3rd tertile;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:2nd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:1st tertile;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:142;TIME_TO_BLOOD_DRAW_FROM_TX:114;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"CLEAR CELL RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CCRCC;TMB_NONSYNONYMOUS:2.266666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:75;TUMOR_TISSUE_SITE:Perinephric Metastasis;HISTOLOGICAL_DIAGNOSIS:Clear cell renal cell carcinoma;STAGE:IV;TNMSTAGE:T3N2M1;CANER_TYPE_DETAILED:Renal Clear Cell Carcinoma;FUHRMAN_GRADE:1-4"
"CLEAR CELL SARCOMA" "CANCER_TYPE_DETAILED:Clear Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:CCS;TMB_NONSYNONYMOUS:4.36666666667;SEX:Female;AGE:14;FRACTION_GENOME_ALTERED:0.0898;NOTE:Houghton;SAMPLE_SITE:Mediastinum;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:Clear Cell Sarcoma;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Relapse;REPORTED_ETHNICITY:European;SITE_OF_SPECIMEN:Lymph Node met"
"CLEAR_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:6.52045161753;SEX:Female;FRACTION_GENOME_ALTERED:0.4090;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Clear_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CLEAR_CELL_RENAL_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:2.0998064531;SEX:Female;FRACTION_GENOME_ALTERED:0.1797;PRIMARY_SITE:Kidney;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Kidney;HISTOLOGICAL_SUBTYPE:Clear_Cell_Renal_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CLL" "CANCER_TYPE_DETAILED:Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:CLLSLL;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;PLATFORM:WES,WGS;IGHV_GENE:IGHV1-3;EPIGENETIC:Naive-like CLL;EXOME_CAPTURE:SureSelect Human All Exon;IGHV_MUTATED:UNMUT"
"CML" "CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"CMML" "CANCER_TYPE_DETAILED:Chronic Myelomonocytic Leukemia;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:CMML;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:10.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:70.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:21;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:70;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M4;HEMOGLOBIN_LEVEL:9.7;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.18;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:9;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:36;CUMULATIVE_TREATMENT_REGIMENS:Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin);LDH_LEVEL:231;MOST_RECENT_TREATMENT_DURATION:4;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:153;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:28.7;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:Yes;MEAN_CORPUSCULAR_VOLUME:99.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.6;PB_ALT_LEVEL:19;PB_AST_LEVEL:22;PB_BASOPHILS_PERCENTAGE:5;PB_EOSINOPHILS_PERCENTAGE:5;PB_LYMPHOCYTES_PERCENTAGE:21;PB_MONOCYTES_PERCENTAGE:38;PB_NEUTROPHILS_PERCENTAGE:22;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myelomonocytic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Chronic myelomonocytic leukaemia;SURFACE_ANTIGENS:CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive;TOTAL_PROTEIN_LEVEL:7.1;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"CNS" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;SOMATIC_STATUS:Matched;SEX:Female;AGE:8.0;FRACTION_GENOME_ALTERED:0.1200;OS_MONTHS:114.0;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic or Latino;MOLECULAR_SUBTYPE:ETV6-RUNX1;ANALYSIS_COHORT:DISCOVERY;PROTOCOL:AALL0232;WBC:117.0;OS_DAYS:3464.0;AGE_IN_DAYS:2872.0;DAYS_TO_EVENT:1764.0;FIRST_EVENT:Relapse;CNS_SITE_OF_RELAPSE:No;CNS_STATUS:CNS 1;KARYOTYPE:46,XX,t(1;17)(q42;q25),-2,add(16)(q22),+r[3]/46,XX[27];BONE_MARROW_SITE_OF_RELAPSE:Yes;DNA_INDEX:1;MLL_STATUS:Negative;OTHER_SITE_OF_RELAPSE:No;BCR_ABL1_STATUS:Negative;BM_DAY_29:1.0;BM_DAY_8:1.0;CELL_OF_ORIGIN:B-Precursor;CONGENITAL_ABNORMALITY:No;ETV6_RUNX1_FUSION_STATUS:Positive;MRD_PERCENT_DAY_29:0.03;MRD_PERCENT_DAY_29_SENSITIVITY:0.01;TCF3_PBX1_STATUS:Negative;TESTES_SITE_OF_RELAPSE:No;TRISOMY_4_10:Negative"
"CNS CANCER" "CANCER_TYPE_DETAILED:Ependymomal Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:EPMT;SEX:Male;AGE:1;OS_MONTHS:16;OS_STATUS:0:LIVING;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Progression;TREATMENT:Modified Treatment;CHEMOTHERAPY:Yes;SURGERY:No;TREATMENT_STATUS:Post-treatment;BRAF_STATUS:RELA Wild Type;AGE_AT_INITIAL_DIAGNOSIS:616;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_START:1076;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1104;AGE_AT_SPECIMEN_DIAGNOSIS:797;BRAF_RELA_STATUS:RELA Wild Type;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 WT;EPENDYMOMA_RELA_STATUS:RELA Wild Type;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:CTNNB1 WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ependymoma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS,Seizure disorder;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:No;SAMPLE_ANNOTATION:Post-treatment;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:12 Month Update;TUMOR_LOCATION_CONDENSED:Posterior Fossa;UPDATED_GRADE:III"
"CNS EMBRYONAL NOS" "CANCER_TYPE_DETAILED:Embryonal Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:EMBT;TMB_NONSYNONYMOUS:3.9;SEX:Unknown;FRACTION_GENOME_ALTERED:0.0001;NOTE:Houghton;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:CNS embryonal NOS;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Unknown;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Unknown"
"CNS EMBRYONAL TUMOR, NOS" "CANCER_TYPE_DETAILED:CNS Embryonal tumor, NOS;CANCER_TYPE:CNS;SEX:Female;AGE:13.782341;RACE:White;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"CNS GERMINOMA" "CANCER_TYPE_DETAILED:Germinoma;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:GMN;TMB_NONSYNONYMOUS:0;SEX:Female;FRACTION_GENOME_ALTERED:0.0363;NOTE:Li, XN;SAMPLE_SITE:Cerebrum;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:CNS germinoma;EXPRESSION:NO;INFERRED_ETHNICITY:Mixed_or_Unknown;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Cerebrum"
"COAD" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:4.53116129354;SEX:Male;FRACTION_GENOME_ALTERED:0.4099;PRIMARY_SITE:Large Intestine;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Colorectal;HISTOLOGICAL_SUBTYPE:Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"COAD_GS" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:2.066666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:80;FRACTION_GENOME_ALTERED:0.0607;SAMPLE_TYPE:Primary;OS_MONTHS:22.09290857;OS_STATUS:0:LIVING;RACE:Black or African American;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:Indivumed;ICD_O_3_SITE:C18.2;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C18.2;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:8/31/11;PFS_MONTHS:6.016372423;AJCC_STAGING_EDITION:7TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Colon;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIIC;SUBTYPE:COAD_GS;TUMOR_TYPE:Colon Adenocarcinoma;PATH_T_STAGE:T4A;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:672;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-29426;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:COAD;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.4019;PATH_N_STAGE:N2A;TISSUE_SOURCE_SITE_CODE:A6;DSS_MONTHS:22.09290857;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:70.3;PATH_M_STAGE:MX;BUFFA_HYPOXIA_SCORE:31;RAGNUM_HYPOXIA_SCORE:26;WINTER_HYPOXIA_SCORE:26;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"COLLECTING DUCT RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Collecting Duct Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CDRCC;TMB_NONSYNONYMOUS:2.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.0736;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Kidney;ANALYSIS_COHORT:KDNY;BIOPSY_SITE:Lymph Node;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:8"
"COLON ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:5.3;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Primary;RACE:African American;SAMPLE_CLASS:Tumor;STAGE:Stage IV;MSI_STATUS:MSS;HISTOLOGICAL_TYPE:Adenocarcinoma;SAMPLE_SITE_SOURCE:Colon"
"COLON ADENOCARCINOMA IN SITU" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma In Situ;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:CAIS;SEX:Male;FRACTION_GENOME_ALTERED:0.1791;SAMPLE_TYPE:Primary;PRIMARY_SITE:Rectum;TUMOR_PURITY:50;MSI_SCORE:0.13;MSI_TYPE:Stable;SAMPLE_COVERAGE:464;AGE_AT_DIAGNOSIS:51;STAGE_AT_DIAGNOSIS:Early stage (1-2);CVR_TMB_SCORE:12.3;TUMOR_LOCATION:Distal;WGD:FALSE;GROUP:Indeterminate-Indeterminate;SURVIVAL_STATUS:Alive;DRIVER1_CLONAL_CALL:Indeterminate;DRIVER1_MUTATION:KRAS p.G13D;DRIVER2_CLONAL_CALL:Indeterminate;DRIVER2_MUTATION:KRAS p.G12A;GENOMIC_QC:PASS;HIGHEST_LEVEL_ONCOKB:LEVEL_4;METASTATIC:Yes;METASTATIC_AT_DX:No"
"COLON CANCER" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:0.3;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:83.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:85.9;AGE_AT_PROCUREMENT:83;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;FAB:M5;HEMOGLOBIN_LEVEL:6.2;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:2.48;CURRENT_STAGE:NONE;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:47,XY,+8[6]/46,XY[13];PB_BLAST_PERCENTAGE:90;WHOLE_EXOME_SEQUENCING:No;CURRENT_REGIMEN:NONE;LDH_LEVEL:2037;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:trisomy 8;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Intermediate-II;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:17.6;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-1;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:94.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:1.9;PB_ALT_LEVEL:242;PB_AST_LEVEL:341;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:7;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_CANCER:Colon Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:Immunophenotype:  CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive;TOTAL_PROTEIN_LEVEL:3.6"
"COLON CARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:11.1333333333;SUBTYPE:Colon Carcinoma;LINEAGE:colorectal;LINEAGE_SUBTYPE:colorectal_adenocarcinoma;TYPE_REFINED:colorectal"
"COLON MUCINOUS ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Mucinous Adenocarcinoma of the Colon and Rectum;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:MACR;SOMATIC_STATUS:Matched;SEX:Male;AGE:47;FRACTION_GENOME_ALTERED:0.3042;SAMPLE_TYPE:Primary;OS_MONTHS:0.2;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:0.2;TISSUE_SOURCE_SITE:AY;ICD_O_3_SITE:C18.2;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C18.2;ICD_O_3_HISTOLOGY:8480/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/14/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIC;HISTOLOGICAL_DIAGNOSIS:Colon Mucinous Adenocarcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-AY-6196.e6e1533f-49e4-4e98-ae67-540b48beddfd.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Colon;AJCC_NODES_PATHOLOGIC_PN:N2b;AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;SPECIMEN_SECOND_LONGEST_DIMENSION:1;LONGEST_DIMENSION:1.5;SHORTEST_DIMENSION:0.6;PRIMARY_SITE_PATIENT:Cecum;PERINEURAL_INVASION:NO;KRAS_GENE_ANALYSIS_INDICATOR:NO;LYMPHOVASCULAR_INVASION_INDICATOR:YES;VASCULAR_INVASION_INDICATOR:NO;BRAF_GENE_ANALYSIS_INDICATOR:NO"
"COLONIC TYPE ADENOCARCINOMA OF THE APPENDIX" "CANCER_TYPE_DETAILED:Colonic Type Adenocarcinoma of the Appendix;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:CTAAP;TMB_NONSYNONYMOUS:1.109155301;SEX:Female;FRACTION_GENOME_ALTERED:0.0002;SAMPLE_TYPE:Primary;OS_MONTHS:29;OS_STATUS:1:DECEASED;RACE:White;TUMOR_PURITY:10;STAGE:IV;HISTOLOGY:Colonic Type Adenocarcinoma;MOLECULAR_SUBTYPE:RAS-mut Predominant;FGA:2.00E-04;DIFFERENTIATION:Poorly Differentiated;ECOG:1;AGE_AT_SEQUENCING:71;AGE_AT_METS:71;CRS_NUMBER:0;FIRSTLINE_CHEMO_GROUP:FOLFOX_or_CAPEOX"
"COLON_CANCER" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:10.3;SEX:Male;AGE:70;FRACTION_GENOME_ALTERED:0.4437;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Large_Intestine;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:colorectal;HISTOLOGY:Carcinoma;PURITY:1;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;DISEASE_ONTOLOGY:colon_cancer;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:colorectal;LINEAGE_SUBTYPE:colorectal_adenocarcinoma;NAME:COLO 205;PROTEOMICS_TMT_LABEL:126;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:colon;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:colorectal"
"COLON_CARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:106.5;SEX:Male;FRACTION_GENOME_ALTERED:0.0820;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Large_Intestine;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:colorectal;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:726.558281;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:colon_carcinoma;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:adult;LINEAGE:colorectal;LINEAGE_MOLECULAR_SUBTYPE:MSI;LINEAGE_SUBTYPE:colorectal_adenocarcinoma;NAME:HCT 116;PATHOLOGIST_ANNOTATION:Colorectal:Carcinoma;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:colon;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:colorectal"
"COLORECTAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:4.53116129354;SEX:Male;FRACTION_GENOME_ALTERED:0.4099;PRIMARY_SITE:Large Intestine;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Colorectal;HISTOLOGICAL_SUBTYPE:Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"COLORECTAL CANCER" "CANCER_TYPE_DETAILED:Angiosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:1.36666666667;SEX:FEMALE;FRACTION_GENOME_ALTERED:0.1501;SAMPLE_TIMEPOINT:ASCProject_EAuOu4uD_T1;BX_LOCATION:BREAST;BX_TIME_DAYS:13;BX_TYPE:RESECTION;AGE_AT_DIAGNOSIS_GROUP:36-40;PRD_HISPANIC:NOT REPORTED;PRD_OTHER_CANCER:YES;PRD_TREATED_AT_ENROLLMENT:NOT REPORTED;BX_NUCLEAR_GRADE:LOW;BX_SPINDLE_CELL:NO;BX_VASOFORMATIVE:YES;DX_BIOPSY_LOCATION:BREAST;PRD_DIAGNOSIS_LOC:NOT REPORTED;PRD_EVER_LOCATION:NOT REPORTED;PRD_LOCATION_AT_ENROLLMENT:NOT REPORTED;PRD_OTHER_CANCER_LIST:COLORECTAL CANCER;PRD_OTHER_CANCER_RADIATION:YES;PRD_RACE:NOT REPORTED;PRD_RADIATION:YES;PRD_RADIATION_SURGERY:AFTER;PRD_SURGERY:YES;PRD_SURGERY_CLEAN_MARGINS:YES;MEDR_PRIMARY_SITE:BREAST (PARENCHYMAL)"
"COLORECTAL CARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:75.4;SUBTYPE:Colorectal Carcinoma;LINEAGE:colorectal;LINEAGE_SUBTYPE:colorectal_adenocarcinoma;TYPE_REFINED:colorectal"
"COLORECTAL CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Colorectal Carcinoma Other;CANCER_TYPE:Colorectal Carcinoma;TMB_NONSYNONYMOUS:0.3;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Radiation_Therapy;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:647;DIAGNOSIS AGE:60;GDNA(NG):4692;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"COLORECTAL HYPERMUTATED" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:54.3486097293;SEX:Female;FRACTION_GENOME_ALTERED:0.1389;SAMPLE_TYPE:Primary;OS_MONTHS:31.15;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Cecum;GENE_PANEL:IMPACT341;TUMOR_PURITY:40;SUBTYPE:Colorectal Hypermutated;MSI_SCORE:45.94;MSI_TYPE:Instable;SAMPLE_COVERAGE:453;AGE_AT_SURGERY:74.95;FGA:0.139;AGE_AT_SEQUENCING:75.11;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:77.71;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CRC HM"
"COLORECTAL MSS" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:9.98239770538;SEX:Female;FRACTION_GENOME_ALTERED:0.2312;SAMPLE_TYPE:Metastasis;OS_MONTHS:1.45;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Cecum;GENE_PANEL:IMPACT341;METASTATIC_SITE:Ovary;TUMOR_PURITY:70;SUBTYPE:Colorectal MSS;MSI_SCORE:0.72;MSI_TYPE:Stable;SAMPLE_COVERAGE:610;AGE_AT_SURGERY:68.57;FGA:0.231;AGE_AT_SEQUENCING:69.63;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:69.75;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:Yes;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CRC MSS"
"COLORECTAL NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Colorectal Neuroendocrine Tumor;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;TMB_NONSYNONYMOUS:0.333333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1038;DIAGNOSIS AGE:76;GDNA(NG):4200;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"COLORECTAL_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:12.0333333333;SEX:Male;AGE:73;FRACTION_GENOME_ALTERED:0.6339;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Large_Intestine;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:colorectal;HISTOLOGY:Carcinoma;PURITY:0.97;MUTATION_RATE:94.37319183;GENOME_DOUBLINGS:1;DOUBLING_TIME:123.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:L15+10%FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:colorectal;LINEAGE_SUBTYPE:colorectal_adenocarcinoma;NAME:SW1116;PATHOLOGIST_ANNOTATION:Colorectal:Carcinoma;SITE_SUBTYPE1:colon;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:colorectal"
"COLORECTAL_CANCER" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:77.5;SEX:Male;AGE:56;FRACTION_GENOME_ALTERED:0.2092;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Large_Intestine;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:colorectal;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:453.4224896;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:colorectal_cancer;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:colorectal;LINEAGE_MOLECULAR_SUBTYPE:MSI;LINEAGE_SUBTYPE:colorectal_adenocarcinoma;NAME:LoVo;PATHOLOGIST_ANNOTATION:Colorectal:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:colon;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:colorectal"
"COLUMNAR CELL VARIANT" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:4.83;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:4.83;TISSUE_SOURCE_SITE:BJ;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C73;ICD_O_3_HISTOLOGY:8344/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/12/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:30;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BJ-A191.B78E5312-059F-441C-8C8D-932FA38812D3.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:340;SITE_OF_TUMOR_TISSUE:Thyroid;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b;HISTOLOGICAL_SUBTYPE:columnar cell variant;LYMPH_NODES_EXAMINED:YES;LATERALITY:Left lobe;BRAF_MUTATION:not identified"
"COMBINED SMALL CELL LUNG CARCINOMA" "CANCER_TYPE_DETAILED:Combined Small Cell Lung Carcinoma;CANCER_TYPE:Small Cell Lung Cancer;ONCOTREE_CODE:CSCLC;TMB_NONSYNONYMOUS:8.80847727853;SEX:Male;FRACTION_GENOME_ALTERED:0.7032;SAMPLE_TYPE:Metastasis;OS_MONTHS:15.43;OS_STATUS:1:DECEASED;RACE:Caucasian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:54;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:72;M_STAGE:M1;SMOKING_HISTORY:Former;TISSUE_SITE:Brain, Left Occipital;T_STAGE:T2A;N_STAGE:N0;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:463;YEAR_OF_DIAGNOSIS:2015;PROCEDURE_TYPE:Surgical;PRETREATED:Yes"
"CONGENITAL FIBROSARCOMA" "CANCER_TYPE_DETAILED:Congenital Fibrosarcoma;CANCER_TYPE:Fibrosarcoma;ONCOTREE_CODE:FIBS;TMB_NONSYNONYMOUS:0;SEX:Male;OS_MONTHS:57;OS_STATUS:0:LIVING;PRIMARY_SITE:Forearm;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Metastatic;TISSUE_SEQUENCED:Lung;NGS_TEST:RNA-seq;AGE_TESTING_YEARS:2.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:48;SAMPLE_TESTED_CATEGORY:Primary disease"
"CONVENTIONAL LEIOMYOSARCOMA" "CANCER_TYPE_DETAILED:Leiomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:LMS;TMB_NONSYNONYMOUS:0.466666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.1282;SAMPLE_TYPE:Primary;OS_MONTHS:31.11;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:31.11;TISSUE_SOURCE_SITE:FX;ICD_O_3_SITE:C48.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C48.0;ICD_O_3_HISTOLOGY:8890/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/17/12;HISTOLOGICAL_DIAGNOSIS:Leiomyosarcoma (LMS);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:49;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-FX-A3NJ.BF4B953D-7BE2-47DF-8F1C-EF022291CE52.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:190;SITE_OF_TUMOR_TISSUE:Retroperitoneum/Upper abdominal - Kidney;HISTOLOGICAL_SUBTYPE:Conventional leiomyosarcoma;PATH_MARGIN:Negative;DISEASE_MULTIFOCAL_INDICATOR:NO;LEIOMYO_MAJOR_VESSEL_INVOLVEMENT:No Major Vessel Involvement;TUMOR_TOTAL_DEPTH:Deep;LEIOMYOSARCOMA_UTERINE_INVOLVEMENT:NO;NTE_LESION_PATHOLOGIC_DEPTH:5.5;NTE_LESION_PATHOLOGIC_LENGTH:7;TUMOR_TOTAL_NECROSIS:0% (no necrosis or no mention of necrosis)"
"COPY-NUMBER HIGH SEROUS-LIKE" NA
"COPY-NUMBER LOW ENDOMETRIOD" NA
"CRANIOPHARYNGIOMA" "CANCER_TYPE_DETAILED:Craniopharyngioma, Adamantinomatous Type;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:ACPG;SEX:Female;AGE:3;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;TUMOR_TISSUE_SITE:Suprasellar/Hypothalamic/Pituitary;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:No;SURGERY:Yes;SAMPLE_ORIGIN:Repeat resection;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1344;AGE_CLASS:[0,5);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1344;AGE_AT_SPECIMEN_DIAGNOSIS:1344;CANCER_PREDISPOSITIONS:None documented;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 Mutant;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;H3F3A_CTNNB1_STATUS:CTNNB1 Mutant;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Craniopharyngioma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:No;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:No;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Suprasellar/Hypothalamic/Pituitary;UPDATED_GRADE:I"
"CRANIOPHARYNGIOMA, ADAMANTINOMATOUS TYPE" "CANCER_TYPE_DETAILED:Craniopharyngioma, Adamantinomatous Type;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:ACPG;SEX:Female;AGE:3;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;TUMOR_TISSUE_SITE:Suprasellar/Hypothalamic/Pituitary;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:No;SURGERY:Yes;SAMPLE_ORIGIN:Repeat resection;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1344;AGE_CLASS:[0,5);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1344;AGE_AT_SPECIMEN_DIAGNOSIS:1344;CANCER_PREDISPOSITIONS:None documented;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 Mutant;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;H3F3A_CTNNB1_STATUS:CTNNB1 Mutant;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Craniopharyngioma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:No;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:No;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Suprasellar/Hypothalamic/Pituitary;UPDATED_GRADE:I"
"CRC HM" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:54.3486097293;SEX:Female;FRACTION_GENOME_ALTERED:0.1389;SAMPLE_TYPE:Primary;OS_MONTHS:31.15;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Cecum;GENE_PANEL:IMPACT341;TUMOR_PURITY:40;SUBTYPE:Colorectal Hypermutated;MSI_SCORE:45.94;MSI_TYPE:Instable;SAMPLE_COVERAGE:453;AGE_AT_SURGERY:74.95;FGA:0.139;AGE_AT_SEQUENCING:75.11;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:77.71;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CRC HM"
"CRC MSS" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:9.98239770538;SEX:Female;FRACTION_GENOME_ALTERED:0.2312;SAMPLE_TYPE:Metastasis;OS_MONTHS:1.45;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Cecum;GENE_PANEL:IMPACT341;METASTATIC_SITE:Ovary;TUMOR_PURITY:70;SUBTYPE:Colorectal MSS;MSI_SCORE:0.72;MSI_TYPE:Stable;SAMPLE_COVERAGE:610;AGE_AT_SURGERY:68.57;FGA:0.231;AGE_AT_SEQUENCING:69.63;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:69.75;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:Yes;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CRC MSS"
"CRIBIFORM MORULAR" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:0.133333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:28;FRACTION_GENOME_ALTERED:0.0114;SAMPLE_TYPE:Primary;OS_MONTHS:21.52;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:21.52;TISSUE_SOURCE_SITE:EM;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C73;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/14/13;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:52;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-EM-A4FR.1728DFCA-35E6-4192-9479-79736497884E.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:60;SITE_OF_TUMOR_TISSUE:Thyroid;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:cribiform morular;LYMPH_NODES_EXAMINED:YES;LATERALITY:Right lobe;CLINICAL_STATUS_WITHIN_3_MTHS_SURGERY:No imaging evidence of disease"
"CSCC" "CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:9.43333333333;SUBTYPE:Squamous Cell Carcinoma;LINEAGE:epidermoid_carcinoma;LINEAGE_SUBTYPE:skin_squamous"
"CUTANEOUS MALIGNANCY OF HAIR MATRIX CELLS" "CANCER_TYPE_DETAILED:Pilomatrix carcinoma;CANCER_TYPE:Cutaneous malignancy of hair matrix cells;ONCOTREE_CODE:CUP;TMB_NONSYNONYMOUS:0.933333333333;SEX:Male;OS_MONTHS:13;OS_STATUS:1:DECEASED;PRIMARY_SITE:Scalp;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:14;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Scalp;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:14.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:13;SAMPLE_TESTED_CATEGORY:Primary disease"
"CUTANEOUS MELANOMA" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:2.43135484044;SEX:Male;FRACTION_GENOME_ALTERED:0.7563;PRIMARY_SITE:Skin;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Melanoma;HISTOLOGICAL_TYPE:Malignant Melanoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CUTANEOUS SQUAMOUS CELL" "CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:9.43333333333;SUBTYPE:Squamous Cell Carcinoma;LINEAGE:epidermoid_carcinoma;LINEAGE_SUBTYPE:skin_squamous"
"CUTANEOUS SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:9.43333333333;SUBTYPE:Squamous Cell Carcinoma;LINEAGE:epidermoid_carcinoma;LINEAGE_SUBTYPE:skin_squamous"
"CUTANEOUS T CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Adult T-Cell Leukemia/Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:ATLL;TMB_NONSYNONYMOUS:7.43333333333;SEX:Male;AGE:61;FRACTION_GENOME_ALTERED:0.2069;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:T-cell_ALL;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:79.63113609;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:cutaneous T cell lymphoma;HIST_SUBTYPE1:adult_T_cell_lymphoma-leukaemia;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HH;PATHOLOGIST_ANNOTATION:Leukemia:ALL;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_ALL"
"CYSTADENOCARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:8.03333333333;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.9354;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Cystadenocarcinoma, mucinous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:178.9165928;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:RMUG-S;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"CYSTADENOCARCINOMA, CLEAR CELL" "CANCER_TYPE_DETAILED:Clear Cell Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:CCOV;TMB_NONSYNONYMOUS:84.2;SEX:Female;AGE:39;FRACTION_GENOME_ALTERED:0.2585;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Cystadenocarcinoma, clear cell;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:532.8167513;GENOME_DOUBLINGS:1;DOUBLING_TIME:41.8;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ICLC;CHARACTERISTICS:Epithelial-like grown in monolayer;FREEZING_MEDIUM:5;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:serous_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:clear_cell;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OC 314;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM L-glutamine;TYPE_REFINED:ovary"
"CYSTADENOCARCINOMA, MUCINOUS" "CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:8.03333333333;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.9354;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Cystadenocarcinoma, mucinous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:178.9165928;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:RMUG-S;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"DEDIFFERENTIATED" "CANCER_TYPE_DETAILED:Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHS;TMB_NONSYNONYMOUS:4.64167742265;SEX:Male;FRACTION_GENOME_ALTERED:0.6024;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Chondrosarcoma;HISTOLOGICAL_SUBTYPE:Dedifferentiated;HISTOLOGICAL_TYPE:Chondrosarcoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"DEDIFFERENTIATED CHONDROSARCOMA" "CANCER_TYPE_DETAILED:Dedifferentiated Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:DDCHS;TMB_NONSYNONYMOUS:1.9;SOMATIC_STATUS:Matched;SEX:Male;AGE:59;FRACTION_GENOME_ALTERED:0.3406;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Thigh;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:108"
"DEDIFFERENTIATED LIPOSARCOMA" "CANCER_TYPE_DETAILED:Dedifferentiated Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DDLS;TMB_NONSYNONYMOUS:1.43333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.3390;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Retroperitoneum;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Shoulder;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:124"
"DERMATOFIBROMA" "CANCER_TYPE_DETAILED:Dermatofibroma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:DF;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0007;SAMPLE_TYPE:Primary;OS_MONTHS:23.5;OS_STATUS:0:LIVING;PRIMARY_SITE:Skin;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:697;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"DERMATOFIBROSARCOMA PROTUBERANS" "CANCER_TYPE_DETAILED:Dermatofibrosarcoma Protuberans;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:DFSP;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.1047;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Skin (Neck);ANALYSIS_COHORT:SARC;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:29"
"DESMOID FIBROMATOSIS" "CANCER_TYPE_DETAILED:Desmoid Fibromatosis;CANCER_TYPE:Sarcoma;SEX:Male;AGE:2.269678354;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"DESMOID TUMOR" "CANCER_TYPE_DETAILED:Desmoid/Aggressive Fibromatosis;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DES;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:24;FRACTION_GENOME_ALTERED:0.0126;SAMPLE_TYPE:Primary;OS_MONTHS:4.37;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:4.37;TISSUE_SOURCE_SITE:Z4;ICD_O_3_SITE:C49.3;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C49.3;ICD_O_3_HISTOLOGY:8821/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/13/14;HISTOLOGICAL_DIAGNOSIS:Desmoid Tumor;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:164;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-Z4-A8JB.C3019CCF-9E1F-4C37-94EC-9D3603D79D0E.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SITE_OF_TUMOR_TISSUE:Retroperitoneum/Upper abdominal - Retroperitoneum;PHARMACEUTICAL_TX_ADJUVANT:NO;PATH_MARGIN:Negative;DISEASE_MULTIFOCAL_INDICATOR:NO;TUMOR_TOTAL_DEPTH:Deep;NTE_LESION_PATHOLOGIC_DEPTH:3.8;NTE_LESION_PATHOLOGIC_LENGTH:9"
"DESMOID/AGGRESSIVE FIBROMATOSIS" "CANCER_TYPE_DETAILED:Desmoid/Aggressive Fibromatosis;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DES;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:24;FRACTION_GENOME_ALTERED:0.0126;SAMPLE_TYPE:Primary;OS_MONTHS:4.37;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:4.37;TISSUE_SOURCE_SITE:Z4;ICD_O_3_SITE:C49.3;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C49.3;ICD_O_3_HISTOLOGY:8821/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/13/14;HISTOLOGICAL_DIAGNOSIS:Desmoid Tumor;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:164;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-Z4-A8JB.C3019CCF-9E1F-4C37-94EC-9D3603D79D0E.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SITE_OF_TUMOR_TISSUE:Retroperitoneum/Upper abdominal - Retroperitoneum;PHARMACEUTICAL_TX_ADJUVANT:NO;PATH_MARGIN:Negative;DISEASE_MULTIFOCAL_INDICATOR:NO;TUMOR_TOTAL_DEPTH:Deep;NTE_LESION_PATHOLOGIC_DEPTH:3.8;NTE_LESION_PATHOLOGIC_LENGTH:9"
"DESMOPLASTIC MELANOMA" "CANCER_TYPE_DETAILED:Desmoplastic Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:DESM;TMB_NONSYNONYMOUS:16.9666666667;SOMATIC_STATUS:Matched;AGE:71;GENE_PANEL:Exome, Whole Genome;HISTOLOGICAL_SUBTYPE:Neurotropic;PLATFORM:Agilent 1Mil;COHORT:Discovery;SOURCE:Fresh Frozen;TOTAL_MUTATIONS:797;ANATOMIC_REGION:Shoulder;DETAILED_SAMPLE_HISTOLOGY_CATEGORY:Pure;SECONDARY_PLATFORM:Exome CN Inference"
"DESMOPLASTIC SMALL ROUND CELL TUMOR" "CANCER_TYPE_DETAILED:Desmoplastic Small Round Cell Tumor;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Male;FRACTION_GENOME_ALTERED:0.3721;SAMPLE_TYPE:Metastasis;OS_MONTHS:24.131;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Visceral;GENE_PANEL:IMPACT341;TUMOR_PURITY:50;MSI_SCORE:1.61;MSI_TYPE:Stable;SAMPLE_COVERAGE:829;PURITY:0.765886754;CVR_TMB_SCORE:3.3;AGE_AT_SEQ_REPORT:32;DETAILED_PRIMARY_SITE:Soft Tissue;FACETS:YES;FRACTION_CNA:0.73167915;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.3721"
"DESMOPLASTIC SMALL-ROUND-CELL TUMOR" "CANCER_TYPE_DETAILED:Desmoplastic Small-Round-Cell Tumor;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DSRCT;TMB_NONSYNONYMOUS:1.33333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:28;FRACTION_GENOME_ALTERED:0.1835;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Pancreas;ANALYSIS_COHORT:PAAD;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:41"
"DESMOPLASTIC/NODULAR MEDULLOBLASTOMA" "CANCER_TYPE_DETAILED:Desmoplastic/Nodular Medulloblastoma;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:DMBL;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Unmatched;SEX:Male;AGE:8.0;OS_MONTHS:14.0;OS_STATUS:1:DECEASED;M_STAGE:M3;NOTE:WGS for primary and recurrence 1;OVERALL_PATIENT_HISTOLOGY:Desmoplastic;LOCATION:Local;RNASEQ_DATA:Yes, primary and recurrence;SUBGROUP:Group4;GERMLINE_CONTROL:No"
"DIFFSE LARGE B-CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-cell lymphoma;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:4.333333333;SEX:Male;AGE:84;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;ICD_10:C83.3;STAGE:unknown;HISTOLOGY:ML, large B-cell, diffuse;PURITY:0.82;TOBACCO_SMOKING_HISTORY_INDICATOR:Smoking history not documented;PROJECT_CODE:MALY-DE;WGD:wgd;SEQUENCING_TYPE:WGS;CELLULARITY:85;ALCOHOL:Don't know/Not sure;FIRST_THERAPY:Other Therapy;ORGAN_SYSTEM:LYMPH NODES;ALCOHOL_HISTORY_INTENSITY:Not Documented;ANCESTRY_PRIMARY:EUR;FIRST THERAPY_RESPONSE:Partial Response;HISTOLOGY_ABBREVIATION:Lymph-BNHL;HISTOLOGY_TIER1:MESODERM;HISTOLOGY_TIER2:Lymphoid;HISTOLOGY_TIER3:Mature B-cell lymphoma;HISTOLOGY_TIER4:Diffse large B-cell lymphoma;PURITY_CONFUGURATION:0.015;TUMOR_SAMPLE_HISTOLOGY_CODE:9680/3"
"DIFFUSE ASTROCYTOMA" "CANCER_TYPE_DETAILED:Diffuse Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:DASTR;TMB_NONSYNONYMOUS:1.23333333333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2428;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:37;OS_STATUS:1:DECEASED;GENE_PANEL:WGS;SAMPLE_CLASS:Tumor;GRADE:II;HISTOLOGY:Oligoastrocytoma;TUMOR_LOCATION:Temporal lobe;AGE_AT_DX:37;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-HK-0002-TP-01D-WGS-DRX7N4;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;HYPERMUTATION_STATUS:Yes;INITIAL_GRADE:II;INITIAL_HISTOLOGY:Astrocytoma;POST_RECURRENCE_SURVIVAL_MONTHS:11;RADIOTHERAPY:No;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:26;TISSUE_SOURCE:Chinese University of Hong Kong;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Diffuse Astrocytoma, IDH-mutant;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:Yes"
"DIFFUSE ASTROCYTOMA, IDH-MUTANT" "CANCER_TYPE_DETAILED:Diffuse Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:DASTR;TMB_NONSYNONYMOUS:1.23333333333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2428;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:37;OS_STATUS:1:DECEASED;GENE_PANEL:WGS;SAMPLE_CLASS:Tumor;GRADE:II;HISTOLOGY:Oligoastrocytoma;TUMOR_LOCATION:Temporal lobe;AGE_AT_DX:37;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-HK-0002-TP-01D-WGS-DRX7N4;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;HYPERMUTATION_STATUS:Yes;INITIAL_GRADE:II;INITIAL_HISTOLOGY:Astrocytoma;POST_RECURRENCE_SURVIVAL_MONTHS:11;RADIOTHERAPY:No;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:26;TISSUE_SOURCE:Chinese University of Hong Kong;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Diffuse Astrocytoma, IDH-mutant;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:Yes"
"DIFFUSE GLIOMA" "CANCER_TYPE_DETAILED:Diffuse Glioma;CANCER_TYPE:Glioma;ONCOTREE_CODE:DIFG;TMB_NONSYNONYMOUS:1.53333333333;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.0542;SAMPLE_TYPE:Tumor Primary;GENE_PANEL:WXS;SAMPLE_CLASS:Tumor;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-DK-0001-TP-01D-WXS-CB26AA;CASE_PROJECT:GLSS;HYPERMUTATION_STATUS:No;MGMT_METHYLATION:Unmethylated;MGMT_METHYLATION_METHOD:Array;MNP_CLASSIFICATION:CONTR, INFLAM;SURGERY NUMBER:2;TISSUE_SOURCE:German Cancer Research Center;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:No"
"DIFFUSE INTRINSIC PONTINE GLIOMA" "CANCER_TYPE_DETAILED:Diffuse Intrinsic Pontine Glioma;CANCER_TYPE:Diffuse Glioma;ONCOTREE_CODE:DIPG;TMB_NONSYNONYMOUS:1.8;SEX:Female;OS_MONTHS:11;OS_STATUS:1:DECEASED;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade III;SPECIMEN_PRESERVATION_TYPE:Fresh frozen (RNA); FFPE (DNA);AGE_AT_DIAGNOSIS:8;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain- pontine mass;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:8.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:11;SAMPLE_TESTED_CATEGORY:Primary disease"
"DIFFUSE LARGE B-CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.96251613397;SEX:Female;FRACTION_GENOME_ALTERED:0.2331;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Dlbcl;HISTOLOGICAL_SUBTYPE:Diffuse_Large_B_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Haematopoietic"
"DIFFUSE LARGE B-CELL LYMPHOMA DLBCL" NA
"DIFFUSE LARGE B-CELL LYMPHOMA DLBCL NOS ANY ANATOMIC SITE NODAL OR EXTRANODAL" NA
"DIFFUSE LARGE B-CELL LYMPHOMA, NOS" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.96251613397;SEX:Female;FRACTION_GENOME_ALTERED:0.2331;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Dlbcl;HISTOLOGICAL_SUBTYPE:Diffuse_Large_B_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Haematopoietic"
"DIFFUSE LEPTOMENINGEAL  GLIONEURONAL TUMOR" "CANCER_TYPE_DETAILED:Diffuse Leptomeningeal  Glioneuronal Tumor;CANCER_TYPE:CNS;SEX:Male;AGE:12.27378464;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:1st tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:3rd tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:1823;TIME_TO_BLOOD_DRAW_FROM_TX:1757;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"DIFFUSE MALIGNANT MESOTHELIOMA - NOS" "CANCER_TYPE_DETAILED:Pleural Mesothelioma;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLMESO;TMB_NONSYNONYMOUS:1.03333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:60;FRACTION_GENOME_ALTERED:0.2758;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:LK;ICD_O_3_SITE:C38.4;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C45.0;ICD_O_3_HISTOLOGY:9050/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/6/13;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IV;HISTOLOGICAL_DIAGNOSIS:Diffuse malignant mesothelioma - NOS;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1863;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-LK-A4NW.9FA130FA-B7F3-44C9-824D-4B332B72CB3E.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:530;SITE_OF_TUMOR_TISSUE:Pleura;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T4;LATERALITY:Left;OCCUPATION_PRIMARY:Steel Mill"
"DIFFUSE MIDLINE GLIOMA" "CANCER_TYPE_DETAILED:Diffuse Midline Glioma;CANCER_TYPE:CNS;SEX:Male;AGE:21.88090324;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:1st tertile;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:33;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:Yes"
"DIFFUSE MIDLINE GLIOMA, H3K27M MUTANT" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:23.5666666667;SOMATIC_STATUS:Unmatched;SEX:Male;AGE:54;SAMPLE_TYPE:Primary;OS_MONTHS:10.08;OS_STATUS:1:DECEASED;TUMOR_LOCATION:Left cerebellum;WHO_CLASS:Diffuse midline glioma, H3K27M mutant;MORPHOLOGY:Fibrillary;TREATMENT_DETAIL_BEFORE_PDX:None"
"DIFFUSE SCLEROSING VARIANT" "CANCER_TYPE_DETAILED:Follicular Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THFO;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:22;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:36.4;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:36.4;TISSUE_SOURCE_SITE:DJ;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C73;ICD_O_3_HISTOLOGY:8350/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/21/12;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:541;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DJ-A3VJ.C8FBA360-6E43-4B3C-8D77-C0E57EB7937C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:200;SITE_OF_TUMOR_TISSUE:Thyroid;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1a;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Papillary carcinoma, diffuse sclerosing variant;LYMPH_NODES_EXAMINED:YES;LATERALITY:Bilateral;CLINICAL_STATUS_WITHIN_3_MTHS_SURGERY:No imaging evidence of disease"
"DIFFUSE TYPE STOMACH ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Diffuse Type Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:DSTAD;TMB_NONSYNONYMOUS:15.3666666667;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.5532;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:194.2359967;GENOME_DOUBLINGS:2;DOUBLING_TIME:48.5;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSRRB;CHARACTERISTICS:ADHRENT EPITHELIAL; was clumpy;DOUBLING_TIME_FROM_VENDOR:95 hrs;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM + 10% FBS;HIST_SUBTYPE1:diffuse_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUB_SUBTYPE:diffuse_gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:FU97;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:10mg/L INSULIN;TYPE_REFINED:stomach"
"DIFFUSE_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:5.41529032642;SEX:Female;FRACTION_GENOME_ALTERED:0.5530;PRIMARY_SITE:Stomach;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Stomach;HISTOLOGICAL_SUBTYPE:Diffuse_Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Solid"
"DIFFUSE_GASTRIC" "CANCER_TYPE_DETAILED:Diffuse Type Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:DSTAD;TMB_NONSYNONYMOUS:15.3666666667;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.5532;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:194.2359967;GENOME_DOUBLINGS:2;DOUBLING_TIME:48.5;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSRRB;CHARACTERISTICS:ADHRENT EPITHELIAL; was clumpy;DOUBLING_TIME_FROM_VENDOR:95 hrs;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM + 10% FBS;HIST_SUBTYPE1:diffuse_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUB_SUBTYPE:diffuse_gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:FU97;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:10mg/L INSULIN;TYPE_REFINED:stomach"
"DIFFUSE_HISTIOCYTIC_LYMPHOMA" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.73333333333;SEX:Male;AGE:25;FRACTION_GENOME_ALTERED:0.1371;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Diffuse Large B-cell Lymphoma (DLBCL);TUMOR_TYPE:lymphoma_DLBCL;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:92.25565066;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:round lymphoid cells growing singly or in clumps in suspention;DISEASE_ONTOLOGY:diffuse_histiocytic_lymphoma;DOUBLING_TIME_FROM_VENDOR:~ 30-50 hrs;GROWTH_MEDIUM:80-90% RPMI 1640 +10-20% h.i. FBS;HIST_SUBTYPE1:diffuse_large_B_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:DLBCL;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:SU-DHL-10;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_DLBCL"
"DIFFUSE_LARGE_B_CELL_LYMPHOMA" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.96251613397;SEX:Female;FRACTION_GENOME_ALTERED:0.2331;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Dlbcl;HISTOLOGICAL_SUBTYPE:Diffuse_Large_B_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Haematopoietic"
"DIPG" "CANCER_TYPE_DETAILED:Diffuse Intrinsic Pontine Glioma;CANCER_TYPE:Diffuse Glioma;ONCOTREE_CODE:DIPG;TMB_NONSYNONYMOUS:1.8;SEX:Female;OS_MONTHS:11;OS_STATUS:1:DECEASED;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade III;SPECIMEN_PRESERVATION_TYPE:Fresh frozen (RNA); FFPE (DNA);AGE_AT_DIAGNOSIS:8;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain- pontine mass;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:8.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:11;SAMPLE_TESTED_CATEGORY:Primary disease"
"DISSEMINATED JUVENILE XANTHOGRANULOMA" "CANCER_TYPE_DETAILED:Disseminated Juvenile Xanthogranuloma;CANCER_TYPE:Histiocytosis;ONCOTREE_CODE:JXG;SEX:Male;FRACTION_GENOME_ALTERED:0.2603;RACE:Asain;ETHNICITY:Non-Hispanic;VITAL_STATUS:AWD"
"DLBC" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.96251613397;SEX:Female;FRACTION_GENOME_ALTERED:0.2331;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Dlbcl;HISTOLOGICAL_SUBTYPE:Diffuse_Large_B_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Haematopoietic"
"DLBCL" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.96251613397;SEX:Female;FRACTION_GENOME_ALTERED:0.2331;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Dlbcl;HISTOLOGICAL_SUBTYPE:Diffuse_Large_B_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Haematopoietic"
"DOWN SYNDROME; ACUTE MEGAKARYOBLASTIC LEUKAEMIA" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:16.2;SEX:Male;AGE:0.8333;FRACTION_GENOME_ALTERED:0.5228;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Acute Myelogenous Leukemia (AML), M7 (Megakaryoblastic);TUMOR_TYPE:AML;HISTOLOGY:Haematopoietic_Neoplasm;PURITY:1;MUTATION_RATE:179.7006765;GENOME_DOUBLINGS:0;DOUBLING_TIME:37.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:single, multiformed, large cells growing in suspension, sometimes loosely adherent (<3%); 2-3% giant, multinucleated cells;DISEASE_ONTOLOGY:Down syndrome; acute megakaryoblastic leukaemia;DOUBLING_TIME_FROM_VENDOR:~  40-50 hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:80% RPMI 1640 + 20% h.i. FBS;HIST_SUBTYPE1:acute_myeloid_leukaemia;HIST_SUBTYPE2:M7;HIST_SUBTYPE3:NS;LINEAGE:blood;LINEAGE_SUB_SUBTYPE:M7;LINEAGE_SUBTYPE:AML;NAME:CMK;PATHOLOGIST_ANNOTATION:Leukemia:AML;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:AML"
"DUCTAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:3.53333333333;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.5531;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Pancreas;SUBTYPE:Ductal Adenocarcinoma, exocrine;TUMOR_TYPE:pancreas;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:82.48705026;GENOME_DOUBLINGS:1;DOUBLING_TIME:110;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Adherent epitheloid cells in monolayer;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:DMEM + 10%FBS;HIST_SUBTYPE1:ductal_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:pancreas;LINEAGE_SUB_SUBTYPE:exocrine_adenocarcinoma;LINEAGE_SUBTYPE:exocrine;NAME:PA-TU-8988S;PATHOLOGIST_ANNOTATION:Pancreas:Carcinoma;SITE_OF_FINDING:liver;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM L-Glutamine;TYPE_REFINED:pancreas"
"DUCTAL AND LOBULAR" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:68;FRACTION_GENOME_ALTERED:0.2619;SAMPLE_TYPE:Primary;OS_MONTHS:91.92;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/6/11;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1999;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4330;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A1EO.A2B755DD-00C4-4349-8E11-C1196EBC91D3.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:100;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1c;HISTOLOGICAL_SUBTYPE:ductal and lobular features;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Excisional Biopsy;PRIMARY_SITE_PATIENT:Right;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);METASTATIC_TUMOR_INDICATOR:NO;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;FIRST_SURGICAL_PROCEDURE_OTHER:right segmental mastectomy witrh axillary node dissection;SURGICAL_PROCEDURE_FIRST:Other"
"DUCTAL AND LOBULAR FEATURES" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:68;FRACTION_GENOME_ALTERED:0.2619;SAMPLE_TYPE:Primary;OS_MONTHS:91.92;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/6/11;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1999;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4330;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A1EO.A2B755DD-00C4-4349-8E11-C1196EBC91D3.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:100;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1c;HISTOLOGICAL_SUBTYPE:ductal and lobular features;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Excisional Biopsy;PRIMARY_SITE_PATIENT:Right;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);METASTATIC_TUMOR_INDICATOR:NO;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;FIRST_SURGICAL_PROCEDURE_OTHER:right segmental mastectomy witrh axillary node dissection;SURGICAL_PROCEDURE_FIRST:Other"
"DUCTAL CARCINOMA" "CANCER_TYPE_DETAILED:Infiltrating Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:2.53333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;GRADE:III;SUBTYPE:HER2;STAGE:III;PURITY:0.27;ER_STATUS:Negative;PR_STATUS:Negative;MENOPAUSE_STATUS:Premenopausal;HER2_AMPLIFICATION_STATUS:Yes;SILENT_RATE:0.72;NONSILENT_RATE:2.62"
"DUCTAL CARCINOMA IN SITU DCIS" NA
"DUCTAL CARCINOMA- MAMMARY GLAND" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:15.63333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:31;FRACTION_GENOME_ALTERED:0.1742;HISTOLOGICAL_SUBTYPE:Ductal carcinoma- mammary gland; breast; duct; metastatic site: pleural effusion;;DOUBLING_TIME:25.8;P53:MT;CATEGORY_SAMPLE:Pleural effusion;EPITHELIAL:No;MDR:20"
"DUCTAL/LOBULAR" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Female;AGE:73;FRACTION_GENOME_ALTERED:0.4882;SAMPLE_TYPE:Primary;OS_MONTHS:102.69;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:91.56;TISSUE_SOURCE_SITE:B6;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/2/10;AJCC_STAGING_EDITION:4th;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1994;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:5890;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-B6-A0RP.889D6E80-A656-49FA-9DFA-1674EB3877F6.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:230;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1b;AJCC_TUMOR_PATHOLOGIC_PT:T2;HISTOLOGICAL_SUBTYPE:ductal/lobular;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;PRIMARY_SITE_PATIENT:Left Upper Outer Quadrant|Left;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Biopsy, NOS;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Positive;BRACHYTHERAPY_TOTAL_DOSE_POINT_A:Image Analysis;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Axillary lymph node dissection alone;MARGIN_STATUS_REEXCISION:Negative;MICROMET_DETECTION_BY_IHC:NO;PR_POSITIVITY_DEFINE_METHOD:Image Analysis;SURGERY_FOR_POSITIVE_MARGINS:Modified radical mastectomy;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"DUCTAL/NST" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0;SEX:Female;SAMPLE_TYPE:Primary;OS_MONTHS:140.5;OS_STATUS:0:LIVING;GRADE:3;VITAL_STATUS:Living;HISTOLOGICAL_SUBTYPE:Ductal/NST;AGE_AT_DIAGNOSIS:75.65;COHORT:1;TUMOR_STAGE:2;TUMOR_SIZE:22;LATERALITY:Right;ER_STATUS:Positive;CHEMOTHERAPY:NO;HER2_STATUS:Negative;PR_STATUS:Negative;RFS_STATUS:0:Not Recurred;LYMPH_NODES_EXAMINED_POSITIVE:10;RFS_MONTHS:138.65;BREAST_SURGERY:MASTECTOMY;CLAUDIN_SUBTYPE:claudin-low;ER_IHC:Positve;HER2_SNP6:NEUTRAL;HORMONE_THERAPY:YES;INFERRED_MENOPAUSAL_STATE:Post;INTCLUST:4ER+;NPI:6.044;RADIO_THERAPY:YES;THREEGENE:ER-/HER2-"
"DUCTAL_CARCINOMA" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:3.42600000243;SEX:Female;FRACTION_GENOME_ALTERED:0.9761;PRIMARY_SITE:Pancreas;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Pancreas;HISTOLOGICAL_SUBTYPE:Ductal_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"DUODENAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:African_american;PRIMARY_SITE:Stomach;SUBTYPE:Duodenal Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;GENOME_DOUBLINGS:0;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:duodenal_adenocarcinoma;NAME:AZ-521;SITE_OF_FINDING:NS;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"DUODENAL_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:African_american;PRIMARY_SITE:Stomach;SUBTYPE:Duodenal Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;GENOME_DOUBLINGS:0;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:duodenal_adenocarcinoma;NAME:AZ-521;SITE_OF_FINDING:NS;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR" "CANCER_TYPE_DETAILED:Dysembryoplastic Neuroepithelial Tumor;CANCER_TYPE:CNS;SEX:Male;AGE:10.217659;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:1913"
"DYSGERMINOMA" "CANCER_TYPE_DETAILED:Dysgerminoma;CANCER_TYPE:Germ Cell;SEX:Female;AGE:8.145106316;RACE:Asian;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;CHEMO_TX:Yes;IO_TX:Yes;TERT_IO_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:26"
"EARLY T-CELL PRECURSOR LYMPHOBLASTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Early T-Cell Precursor Lymphoblastic Leukemia;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:ETPLL;TMB_NONSYNONYMOUS:4.53333333333;SEX:Male;AGE:16;FRACTION_GENOME_ALTERED:0.0691;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:ETP-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow"
"EBV-ASSOCIATED" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:4.2;SOMATIC_STATUS:Matched;SEX:Female;AGE_AT_DIAGNOSIS:59.0;COHORT:Goettingen;MEAN_TARGET_COVERAGE_TUMOR:71.9;PURITY_ABSOLUTE:0.18;SAMPLE_COLLECTION_SOURCE:Frozen;IPI:3.0;NUM_NONSILENT_MUTATION:125;TESTICULAR_INVOLVEMENT:No;DRIVER_MUTATIONS:14;IPI_AGE:0.0;IPI_ECOG:1.0;IPI_LDH:1.0;MORPHOLOGY_SUBTYPE:EBV-associated;NONSILENT_MUTATION_DENSITY:3.810966;NUM_SILENT_MUTATION:44;TOTAL_CNA:10;CLUSTER:4;CNS_INVOLVEMENT:No;DBSNP_MUTATION_DENSITY:0.762;DRIVER_MUTATION_DENSITY:0.427;IPI_EXBM:0.0;IPI_STAGE:1.0;MUTATION_DENSITY:5.152426;NUM_DBSNP_MUTATIONS:25;NUM_DRIVER_SCNA:1;NUM_DRIVER_SV:0;R_CHOP_LIKE_CHEMO:No;SILENT_MUTATION_DENSITY:1.34;TOTAL_REARRANGEMENT:3;TUMOR_IN_NORMAL_ESTIMATE:0"
"EMBRYONAL" "CANCER_TYPE_DETAILED:Atypical Teratoid/Rhabdoid Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ATRT;SEX:Male;AGE:2;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6;TUMOR_TISSUE_SITE:Frontal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1038;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_STOP:1163;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1471;AGE_AT_RADIATION_START:1183;AGE_AT_RADIATION_STOP:1225;AGE_AT_SPECIMEN_DIAGNOSIS:1038;CANCER_PREDISPOSITIONS:None documented;CHEMOTHERAPY_AGENTS:Not Reported;CHEMOTHERAPY_TYPE:Treatment follows a protocol and subject is enrolled on a protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:5400 cGy;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;FORMULATION:Not Reported;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Atypical Teratoid Rhabdoid Tumor (ATRT);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:SJYC07;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Supratentorial;UPDATED_GRADE:IV"
"EMBRYONAL CARCINOMA" "CANCER_TYPE_DETAILED:Embryonal Carcinoma;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:EMBCA;TMB_NONSYNONYMOUS:7.8;SUBTYPE:Carcinoma;LINEAGE:embryo;LINEAGE_SUBTYPE:embryo_carcinoma"
"EMBRYONAL CARCINOMA[NOT AVAILABLE]" "CANCER_TYPE_DETAILED:Mixed Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:BMGCT;SEX:Female;FRACTION_GENOME_ALTERED:0.2877;SAMPLE_TYPE:Primary;RACE:Non-Hispanic;ETHNICITY:White;PRIMARY_SITE:Mediastinum;VITAL_STATUS:DOD;NOTE:Germinoma embryonal carcinoma and YST with associated embryonal carcinoma;SURGERY:Right mediastinal mass excision;CENTER:MSKCC;AFP_AT_PROCUREMENT:0.7;CHEMO_CYCLES:4;FIRST_LINE_THERAPY:BEP;LDH:1403;TIME_TO_RECURRENCE_MONTHS:3;BHCG:<3;DX_ORG_INST:Extragonadal Germ Cell Tumor;LOCATION_RECURRED:Pleura, Lymph node;METASTATIC_DX:Lung, Lymph node;PATH_DX_MSK:Mixed Germ Cell Tumor;REC_AFTER_FIRST_LINE:Responded then recurred;RESPONDED_SECOND_LINE:Responded then recurred;SECOND_LINE_TC_OR_SURGERY:TIPx4;THIRD_LINE:TKI"
"EMBRYONAL CARCINOMA[NOT AVAILABLE][NOT AVAILABLE][NOT AVAILABLE]" "CANCER_TYPE_DETAILED:Mixed Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:BMGCT;SEX:Female;FRACTION_GENOME_ALTERED:0.2877;SAMPLE_TYPE:Primary;RACE:Non-Hispanic;ETHNICITY:White;PRIMARY_SITE:Mediastinum;VITAL_STATUS:DOD;NOTE:Germinoma embryonal carcinoma and YST with associated embryonal carcinoma;SURGERY:Right mediastinal mass excision;CENTER:MSKCC;AFP_AT_PROCUREMENT:0.7;CHEMO_CYCLES:4;FIRST_LINE_THERAPY:BEP;LDH:1403;TIME_TO_RECURRENCE_MONTHS:3;BHCG:<3;DX_ORG_INST:Extragonadal Germ Cell Tumor;LOCATION_RECURRED:Pleura, Lymph node;METASTATIC_DX:Lung, Lymph node;PATH_DX_MSK:Mixed Germ Cell Tumor;REC_AFTER_FIRST_LINE:Responded then recurred;RESPONDED_SECOND_LINE:Responded then recurred;SECOND_LINE_TC_OR_SURGERY:TIPx4;THIRD_LINE:TKI"
"EMBRYONAL RHABDOMYOSARCOMA" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:2.65238709866;SEX:Female;FRACTION_GENOME_ALTERED:0.0237;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Rhabdomyosarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"EMBRYONAL TUMOR" "CANCER_TYPE_DETAILED:Atypical Teratoid/Rhabdoid Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ATRT;SEX:Male;AGE:2;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6;TUMOR_TISSUE_SITE:Frontal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1038;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_STOP:1163;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1471;AGE_AT_RADIATION_START:1183;AGE_AT_RADIATION_STOP:1225;AGE_AT_SPECIMEN_DIAGNOSIS:1038;CANCER_PREDISPOSITIONS:None documented;CHEMOTHERAPY_AGENTS:Not Reported;CHEMOTHERAPY_TYPE:Treatment follows a protocol and subject is enrolled on a protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:5400 cGy;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;FORMULATION:Not Reported;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Atypical Teratoid Rhabdoid Tumor (ATRT);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:SJYC07;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Supratentorial;UPDATED_GRADE:IV"
"EMBRYONAL TUMOR WITH ABUNDANT NEUROPIL AND TRUE ROSETTES" "CANCER_TYPE_DETAILED:Embryonal Tumor with Abundant Neuropil and True Rosettes;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ETANTR;TMB_NONSYNONYMOUS:5.36666666667;SEX:Male;AGE:3;FRACTION_GENOME_ALTERED:0.1085;NOTE:Li, XN;SAMPLE_SITE:Brain stem;HISTOPATHOLOGY:sPNET, GFAP+, SYN+,P53+,Ki67+, Myc-, PTEN loss, C19MC amplification by genetics, ETMR by genetics;CANCER_SUBTYPE_CURATED:ETMR;EXPRESSION:NO;INFERRED_ETHNICITY:SouthAsianOrHispanic;PHASE:Diagnosis;REPORTED_ETHNICITY:Hispanic or Latino;SITE_OF_SPECIMEN:Brain stem"
"EMBRYO_CARCINOMA" "CANCER_TYPE_DETAILED:Embryonal Carcinoma;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:EMBCA;TMB_NONSYNONYMOUS:7.8;SUBTYPE:Carcinoma;LINEAGE:embryo;LINEAGE_SUBTYPE:embryo_carcinoma"
"EMBT" "CANCER_TYPE_DETAILED:Embryonal Tumor;CANCER_TYPE:Embryonal Tumor;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:2;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WGS;ONCOTREE_CODE_CANCER_TYPE:EMBT;TUMOR_DETAILS:Embryonal tumor with multilayered rosettes"
"ENCAPSULATED GLIOMA" "CANCER_TYPE_DETAILED:Anaplastic pleomorphic xanthoastrocytoma;CANCER_TYPE:Encapsulated Glioma;ONCOTREE_CODE:APXA;TMB_NONSYNONYMOUS:2.13333333333;SEX:Female;OS_MONTHS:34;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade III;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:10;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Brain- mesial left temporal brain tumor;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:24;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"ENDOCERVICAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Endocervical Adenocarcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:ECAD;TMB_NONSYNONYMOUS:2.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.1305;SAMPLE_TYPE:Primary;OS_MONTHS:34.99;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:18.23;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/19/11;GRADE:G3;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Endocervical Type of Adenocarcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3120;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A1M9.6D91450A-9499-4B66-90DF-E68B4880E64C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:160;WEIGHT:49;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3b;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:155;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);CLINICAL_STAGE:Stage IB1;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);CT_SCAN_PREOP_RESULTS:Extra-Pelvic Metastatic Disease Present|Paraaortic Nodes Present|Pelvic Nodes Present|Supraclavicular Absent;HISTORY_HORMONAL_CONTRACEPTIVES_USE:Former User;CORPUS_INVOLVEMENT:ABSENT;DAYS_TO_DIAGNOSTIC_COMPUTED_TOMOGRAPHY_PERFORMED:5;DAYS_TO_FDG_OR_CT_PET_PERFORMED:5;FEDPET_OR_CT_RESULTS:Bladder Absent|Extra-Pelvic Metastatic Disease Present|Parametrium Absent|Paraaortic Nodes Present|Pelvic Nodes Present|Supraclavicular Absent;HPV_TYPES_POSITIVE:HPV 16;HYSTERECTOMY_TYPE:Radical Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:margins free of tumor;POS_LYMPH_NODE_LOCATION:Pelvic (external iliac, internal iliac, obturator)|Para-aortic|Supraclavicular;PREGNANT_AT_DIAGNOSIS:NO"
"ENDOCERVICAL ADENOCARCINOMA OF THE USUAL TYPE" "CANCER_TYPE_DETAILED:Endocervical Adenocarcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:ECAD;TMB_NONSYNONYMOUS:1.4;SOMATIC_STATUS:Matched;SEX:Female;AGE:37;FRACTION_GENOME_ALTERED:0.0954;SAMPLE_TYPE:Primary;OS_MONTHS:44.19;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:44.19;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8380/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/3/14;GRADE:G1;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Endocervical Adenocarcinoma of the Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2199;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A2LS.0D3F75AE-DFF5-47DB-A875-78D35DE393E0.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SMOKING_PACK_YEARS:11;WEIGHT:92;SITE_OF_TUMOR_TISSUE:Cervical;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b2;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:173;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);SMOKING_YEAR_STARTED:17;TARGETED_MOLECULAR_THERAPY:NO;CLINICAL_STAGE:Stage IB2;HYSTERECTOMY_TYPE:Radical Hysterectomy;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:margins free of tumor;PREGNANT_AT_DIAGNOSIS:NO"
"ENDOCERVICAL TYPE OF ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Endocervical Adenocarcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:ECAD;TMB_NONSYNONYMOUS:2.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.1305;SAMPLE_TYPE:Primary;OS_MONTHS:34.99;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:18.23;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/19/11;GRADE:G3;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Endocervical Type of Adenocarcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3120;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A1M9.6D91450A-9499-4B66-90DF-E68B4880E64C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:160;WEIGHT:49;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3b;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:155;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);CLINICAL_STAGE:Stage IB1;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);CT_SCAN_PREOP_RESULTS:Extra-Pelvic Metastatic Disease Present|Paraaortic Nodes Present|Pelvic Nodes Present|Supraclavicular Absent;HISTORY_HORMONAL_CONTRACEPTIVES_USE:Former User;CORPUS_INVOLVEMENT:ABSENT;DAYS_TO_DIAGNOSTIC_COMPUTED_TOMOGRAPHY_PERFORMED:5;DAYS_TO_FDG_OR_CT_PET_PERFORMED:5;FEDPET_OR_CT_RESULTS:Bladder Absent|Extra-Pelvic Metastatic Disease Present|Parametrium Absent|Paraaortic Nodes Present|Pelvic Nodes Present|Supraclavicular Absent;HPV_TYPES_POSITIVE:HPV 16;HYSTERECTOMY_TYPE:Radical Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:margins free of tumor;POS_LYMPH_NODE_LOCATION:Pelvic (external iliac, internal iliac, obturator)|Para-aortic|Supraclavicular;PREGNANT_AT_DIAGNOSIS:NO"
"ENDOMETRIAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Endometrioid Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEEN;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:38;FRACTION_GENOME_ALTERED:0.3635;SAMPLE_TYPE:Primary;OS_MONTHS:14.89298747;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:14.89298747;TISSUE_SOURCE_SITE:Asterand;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8380/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:4/22/13;GRADE:G3;PFS_MONTHS:14.89298747;AJCC_STAGING_EDITION:2009;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Cervical;TUMOR_TYPE:Endometrioid Endometrial Adenocarcinoma;PATH_T_STAGE:T1B1;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:453;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-13988;MSI_SENSOR_SCORE:0.06;CANCER_TYPE_ACRONYM:CESC;IN_PANCANPATHWAYS_FREEZE:No;MSI_SCORE_MANTIS:0.2958;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:EA;DSS_MONTHS:14.89298747;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:62;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:27;RAGNUM_HYPOXIA_SCORE:14;WINTER_HYPOXIA_SCORE:42;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"ENDOMETRIAL ADENOSQUAMOUS CARCINOMA" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:83.0666666667;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.1162;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Endometrium;SUBTYPE:Endometrial Adenosquamous Carcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:580.6253132;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:mixed_adenosquamous_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_adenosquamous;NAME:RL95-2;PATHOLOGIST_ANNOTATION:Endometrium:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"ENDOMETRIAL CANCER" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.333333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:14.74;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:64.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:4.2;AGE_AT_PROCUREMENT:64;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:6;TREATMENT_TYPE:Supportive/Palliative Care|Other;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Post-Chemotherapy;KARYOTYPE:46,XX[20];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:1;CUMULATIVE_TREATMENT_REGIMENS:Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU;CUMULATIVE_TREATMENT_STAGES:Symptom Control | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Supportive/Palliative Care | Other;CURRENT_REGIMEN:Paclitaxel;MOST_RECENT_TREATMENT_DURATION:274;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_MONOCYTES_PERCENTAGE:0;PRIOR_CANCER:Endometrial cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:Granulocytes are significantly decreased"
"ENDOMETRIAL CARCINOMA" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:27.6290322777;SEX:Female;FRACTION_GENOME_ALTERED:0.2266;PRIMARY_SITE:Endometrium;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Endometrium;HISTOLOGICAL_SUBTYPE:Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"ENDOMETRIAL SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:10.5666666667;SUBTYPE:Endometrial Squamous Cell Carcinoma;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_squamous"
"ENDOMETRIAL STROMAL SARCOMA" "CANCER_TYPE_DETAILED:Endometrial Stromal Sarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:ESS;TMB_NONSYNONYMOUS:36.1666666667;SEX:Female;AGE:76;FRACTION_GENOME_ALTERED:0.0878;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Endometrium;SUBTYPE:Endometrial Stromal Sarcoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:0.9;MUTATION_RATE:369.3726971;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.1;ANNOTATION_SOURCE:CCLE;DOUBLING_TIME_FROM_VENDOR:120hrs??;FREEZING_MEDIUM:5% DMSO;HIST_SUBTYPE1:carcinosarcoma-malignant_mesodermal_mixed_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_stromal_sarcoma;NAME:ESS-1;PATHOLOGIST_ANNOTATION:Endometrium:Others;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"ENDOMETRIAL_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:6.4;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.8110;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Endometrium;SUBTYPE:Endometrial Adenocarcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:96.20381721;GENOME_DOUBLINGS:1;DOUBLING_TIME:70.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_adenocarcinoma;NAME:KLE;PATHOLOGIST_ANNOTATION:Endometrium:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"ENDOMETRIAL_ADENOSQUAMOUS" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:83.0666666667;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.1162;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Endometrium;SUBTYPE:Endometrial Adenosquamous Carcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:580.6253132;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:mixed_adenosquamous_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_adenosquamous;NAME:RL95-2;PATHOLOGIST_ANNOTATION:Endometrium:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"ENDOMETRIAL_SQUAMOUS" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:10.5666666667;SUBTYPE:Endometrial Squamous Cell Carcinoma;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_squamous"
"ENDOMETRIAL_STROMAL_SARCOMA" "CANCER_TYPE_DETAILED:Endometrial Stromal Sarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:ESS;TMB_NONSYNONYMOUS:36.1666666667;SEX:Female;AGE:76;FRACTION_GENOME_ALTERED:0.0878;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Endometrium;SUBTYPE:Endometrial Stromal Sarcoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:0.9;MUTATION_RATE:369.3726971;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.1;ANNOTATION_SOURCE:CCLE;DOUBLING_TIME_FROM_VENDOR:120hrs??;FREEZING_MEDIUM:5% DMSO;HIST_SUBTYPE1:carcinosarcoma-malignant_mesodermal_mixed_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_stromal_sarcoma;NAME:ESS-1;PATHOLOGIST_ANNOTATION:Endometrium:Others;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"ENDOMETRIOID" "CANCER_TYPE_DETAILED:Cervical Endometrioid Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEEN;TMB_NONSYNONYMOUS:30.1;SOMATIC_STATUS:Matched;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.3128;SAMPLE_TYPE:Primary;OS_MONTHS:137.06;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:137.06;TISSUE_SOURCE_SITE:IR;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8384/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/24/13;GRADE:G3;AJCC_STAGING_EDITION:2009;HISTOLOGICAL_DIAGNOSIS:Endometrioid Adenocarcinoma of Endocervix;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3401;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-IR-A3LA.65E053F4-BCDB-40E2-A76B-1CA62FD61E1B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:170;WEIGHT:101;SITE_OF_TUMOR_TISSUE:Cervical;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b1;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;TARGETED_MOLECULAR_THERAPY:YES;CLINICAL_STAGE:Stage IB1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Dilation & curettage;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);HISTORY_HORMONAL_CONTRACEPTIVES_USE:Never Used;CHEMO_CONCURRENT_COURSE:[Not Available]|[Not Available];CHEMO_CONCURRENT_DOSE:70 mg/m2|750 mg/m2;CHEMO_CONCURRENT_FRACTIONS_TOTAL:4|4;CHEMO_CONCURRENT_TYPE:Cisplatin|Other;CHEMO_CONCURRENT_TYPE_OTHER:[Not Applicable]|Fluorouracil (5-FU);CORPUS_INVOLVEMENT:ABSENT;HYSTERECTOMY_TYPE:Simple Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;PREGNANT_AT_DIAGNOSIS:NO;RADIATION_THERAPY_DOSE_PARAAORTIC_NODES:0;RADIATION_THERAPY_XRT_TYPE:External beam radiation;RT_TX_TOTAL_DOSE_TO_PELVIS:5040"
"ENDOMETRIOID ADENOCARCINOMA OF ENDOCERVIX" "CANCER_TYPE_DETAILED:Cervical Endometrioid Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEEN;TMB_NONSYNONYMOUS:30.1;SOMATIC_STATUS:Matched;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.3128;SAMPLE_TYPE:Primary;OS_MONTHS:137.06;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:137.06;TISSUE_SOURCE_SITE:IR;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8384/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/24/13;GRADE:G3;AJCC_STAGING_EDITION:2009;HISTOLOGICAL_DIAGNOSIS:Endometrioid Adenocarcinoma of Endocervix;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3401;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-IR-A3LA.65E053F4-BCDB-40E2-A76B-1CA62FD61E1B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:170;WEIGHT:101;SITE_OF_TUMOR_TISSUE:Cervical;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b1;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;TARGETED_MOLECULAR_THERAPY:YES;CLINICAL_STAGE:Stage IB1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Dilation & curettage;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);HISTORY_HORMONAL_CONTRACEPTIVES_USE:Never Used;CHEMO_CONCURRENT_COURSE:[Not Available]|[Not Available];CHEMO_CONCURRENT_DOSE:70 mg/m2|750 mg/m2;CHEMO_CONCURRENT_FRACTIONS_TOTAL:4|4;CHEMO_CONCURRENT_TYPE:Cisplatin|Other;CHEMO_CONCURRENT_TYPE_OTHER:[Not Applicable]|Fluorouracil (5-FU);CORPUS_INVOLVEMENT:ABSENT;HYSTERECTOMY_TYPE:Simple Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;PREGNANT_AT_DIAGNOSIS:NO;RADIATION_THERAPY_DOSE_PARAAORTIC_NODES:0;RADIATION_THERAPY_XRT_TYPE:External beam radiation;RT_TX_TOTAL_DOSE_TO_PELVIS:5040"
"ENDOMETRIOID CARCINOMA" "CANCER_TYPE_DETAILED:Cervical Endometrioid Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEEN;TMB_NONSYNONYMOUS:30.1;SOMATIC_STATUS:Matched;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.3128;SAMPLE_TYPE:Primary;OS_MONTHS:137.06;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:137.06;TISSUE_SOURCE_SITE:IR;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8384/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/24/13;GRADE:G3;AJCC_STAGING_EDITION:2009;HISTOLOGICAL_DIAGNOSIS:Endometrioid Adenocarcinoma of Endocervix;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3401;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-IR-A3LA.65E053F4-BCDB-40E2-A76B-1CA62FD61E1B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:170;WEIGHT:101;SITE_OF_TUMOR_TISSUE:Cervical;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b1;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;TARGETED_MOLECULAR_THERAPY:YES;CLINICAL_STAGE:Stage IB1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Dilation & curettage;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);HISTORY_HORMONAL_CONTRACEPTIVES_USE:Never Used;CHEMO_CONCURRENT_COURSE:[Not Available]|[Not Available];CHEMO_CONCURRENT_DOSE:70 mg/m2|750 mg/m2;CHEMO_CONCURRENT_FRACTIONS_TOTAL:4|4;CHEMO_CONCURRENT_TYPE:Cisplatin|Other;CHEMO_CONCURRENT_TYPE_OTHER:[Not Applicable]|Fluorouracil (5-FU);CORPUS_INVOLVEMENT:ABSENT;HYSTERECTOMY_TYPE:Simple Hysterectomy;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;PREGNANT_AT_DIAGNOSIS:NO;RADIATION_THERAPY_DOSE_PARAAORTIC_NODES:0;RADIATION_THERAPY_XRT_TYPE:External beam radiation;RT_TX_TOTAL_DOSE_TO_PELVIS:5040"
"ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Endometrioid Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEEN;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:38;FRACTION_GENOME_ALTERED:0.3635;SAMPLE_TYPE:Primary;OS_MONTHS:14.89298747;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:14.89298747;TISSUE_SOURCE_SITE:Asterand;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8380/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:4/22/13;GRADE:G3;PFS_MONTHS:14.89298747;AJCC_STAGING_EDITION:2009;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Cervical;TUMOR_TYPE:Endometrioid Endometrial Adenocarcinoma;PATH_T_STAGE:T1B1;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:453;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-13988;MSI_SENSOR_SCORE:0.06;CANCER_TYPE_ACRONYM:CESC;IN_PANCANPATHWAYS_FREEZE:No;MSI_SCORE_MANTIS:0.2958;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:EA;DSS_MONTHS:14.89298747;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:62;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:27;RAGNUM_HYPOXIA_SCORE:14;WINTER_HYPOXIA_SCORE:42;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"ENDOMETRIOID OVARIAN CANCER" "CANCER_TYPE_DETAILED:Endometrioid Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:EOV;TMB_NONSYNONYMOUS:61.4333333333;SEX:Female;FRACTION_GENOME_ALTERED:0.1109;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, endometrioid;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:0.97;MUTATION_RATE:545.552709;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:Riken;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:MEM+10% FBS;HIST_SUBTYPE1:endometrioid_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:endometrioid;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OVK18;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"ENDOMETRIOID_CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:21.5506451766;FRACTION_GENOME_ALTERED:0.1103;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Endometrioid_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:RIKEN;SAMPLE_ORIGIN:Solid"
"EPENDYMOBLASTOMA" "CANCER_TYPE_DETAILED:Embryonal Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:EMBT;TMB_NONSYNONYMOUS:4.26666666667;SEX:Female;AGE:2.17;FRACTION_GENOME_ALTERED:0.0001;NOTE:Li, XN;SAMPLE_SITE:Cerebrum;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:Ependymoblastoma;EXPRESSION:NO;INFERRED_ETHNICITY:SouthAsianOrHispanic;PHASE:Diagnosis;REPORTED_ETHNICITY:Hispanic or Latino;SITE_OF_SPECIMEN:Cerebrum"
"EPENDYMOMA" "CANCER_TYPE_DETAILED:Ependymomal Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:EPMT;SEX:Male;AGE:1;OS_MONTHS:16;OS_STATUS:0:LIVING;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Progression;TREATMENT:Modified Treatment;CHEMOTHERAPY:Yes;SURGERY:No;TREATMENT_STATUS:Post-treatment;BRAF_STATUS:RELA Wild Type;AGE_AT_INITIAL_DIAGNOSIS:616;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_START:1076;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1104;AGE_AT_SPECIMEN_DIAGNOSIS:797;BRAF_RELA_STATUS:RELA Wild Type;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 WT;EPENDYMOMA_RELA_STATUS:RELA Wild Type;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:CTNNB1 WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ependymoma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS,Seizure disorder;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:No;SAMPLE_ANNOTATION:Post-treatment;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:12 Month Update;TUMOR_LOCATION_CONDENSED:Posterior Fossa;UPDATED_GRADE:III"
"EPENDYMOMAL TUMOR" "CANCER_TYPE_DETAILED:Ependymomal Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:EPMT;SEX:Male;AGE:1;OS_MONTHS:16;OS_STATUS:0:LIVING;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Progression;TREATMENT:Modified Treatment;CHEMOTHERAPY:Yes;SURGERY:No;TREATMENT_STATUS:Post-treatment;BRAF_STATUS:RELA Wild Type;AGE_AT_INITIAL_DIAGNOSIS:616;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_START:1076;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1104;AGE_AT_SPECIMEN_DIAGNOSIS:797;BRAF_RELA_STATUS:RELA Wild Type;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 WT;EPENDYMOMA_RELA_STATUS:RELA Wild Type;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:CTNNB1 WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ependymoma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS,Seizure disorder;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:No;SAMPLE_ANNOTATION:Post-treatment;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:12 Month Update;TUMOR_LOCATION_CONDENSED:Posterior Fossa;UPDATED_GRADE:III"
"EPITHELIAL-MYOEPITHELIAL CARCINOMA" "CANCER_TYPE_DETAILED:Epithelial-Myoepithelial Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:EMYOCA;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2848;SAMPLE_TYPE:Primary;OS_MONTHS:24.29;OS_STATUS:0:LIVING;PRIMARY_SITE:Major Salivary Gland;SAMPLE_CLASS:Tumor;TUMOR_PURITY:50;SAMPLE_COVERAGE:696;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"EPITHELIOID CELL TUMOR" "CANCER_TYPE_DETAILED:Perivascular Epithelioid Cell Tumor;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:PECOMA;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.0043;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:4"
"EPITHELIOID FIBROSARCOMA" "CANCER_TYPE_DETAILED:Epithelioid Fibrosarcoma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:23.29089737;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"EPITHELIOID HEMANGIOENDOTHELIOMA" "CANCER_TYPE_DETAILED:Epithelioid Hemangioendothelioma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1012;DIAGNOSIS AGE:48;GDNA(NG):5736;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"EPITHELIOID MESOTHELIOMA" "CANCER_TYPE_DETAILED:Pleural Mesothelioma, Epithelioid Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLEMESO;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:75;FRACTION_GENOME_ALTERED:0.1033;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:LK;ICD_O_3_SITE:C38.4;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C45.0;ICD_O_3_HISTOLOGY:9052/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/6/13;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Epithelioid mesothelioma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1087;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-LK-A4NZ.ABE9C586-6C72-42F3-8007-22762DA9C7A9.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:400;SITE_OF_TUMOR_TISSUE:Pleura;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;LATERALITY:Right;FAMILY_HISTORY_CANCER_RELATIONSHIP:Sibling|Sibling|Parent;FAMILY_HISTORY_CANCER_TYPE:Other, specify|Other, specify|Other, specify"
"EPITHELIOID SARCOMA" "CANCER_TYPE_DETAILED:Epithelioid Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:EPIS;TMB_NONSYNONYMOUS:4.0;SUBTYPE:Epithelioid;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:epithelioid_sarcoma"
"EPITHELIOID TROPHOBLASTIC TUMOR" "CANCER_TYPE_DETAILED:Epithelioid Trophoblastic Tumor;CANCER_TYPE:Gestational Trophoblastic Disease;ONCOTREE_CODE:ETT;SEX:Female;AGE:45.69472885;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:Yes;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:3rd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:3rd tertile;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:1st tertile;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:3rd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:319;TIME_TO_BLOOD_DRAW_FROM_TX:287;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"EPITHELIOID_SARCOMA" "CANCER_TYPE_DETAILED:Epithelioid Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:EPIS;TMB_NONSYNONYMOUS:4.0;SUBTYPE:Epithelioid;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:epithelioid_sarcoma"
"EPM" "CANCER_TYPE_DETAILED:Ependymomal Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:EPMT;SEX:Male;AGE:1;OS_MONTHS:16;OS_STATUS:0:LIVING;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Progression;TREATMENT:Modified Treatment;CHEMOTHERAPY:Yes;SURGERY:No;TREATMENT_STATUS:Post-treatment;BRAF_STATUS:RELA Wild Type;AGE_AT_INITIAL_DIAGNOSIS:616;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_START:1076;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1104;AGE_AT_SPECIMEN_DIAGNOSIS:797;BRAF_RELA_STATUS:RELA Wild Type;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 WT;EPENDYMOMA_RELA_STATUS:RELA Wild Type;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:CTNNB1 WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ependymoma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS,Seizure disorder;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:No;SAMPLE_ANNOTATION:Post-treatment;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:12 Month Update;TUMOR_LOCATION_CONDENSED:Posterior Fossa;UPDATED_GRADE:III"
"ERDHEIM-CHESTER DISEASE" "CANCER_TYPE_DETAILED:Erdheim-Chester Disease;CANCER_TYPE:Histiocytosis;ONCOTREE_CODE:ECD;TMB_NONSYNONYMOUS:0.864698095;SOMATIC_STATUS:Unmatched;SEX:Female;FRACTION_GENOME_ALTERED:0.0040;SAMPLE_TYPE:Primary;OS_MONTHS:39.616;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Orbit - Right;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:10;MSI_SCORE:14.85;MSI_TYPE:Do not report;SAMPLE_COVERAGE:760;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:83;RELIGION:METHODIST;AGE_CURRENT:87;ARCHER:YES;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:YES;CRDB_CONSENT_DATE_DAYS:30153;CRDB_SURVIVAL_STATUS:Alive"
"ERYTHROLEUKEMIA" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:7.03333333333;SEX:Male;AGE:30;FRACTION_GENOME_ALTERED:0.4684;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Acute Myelogenous Leukemia (AML), M6 (Erythroleukemia);TUMOR_TYPE:AML;HISTOLOGY:Haematopoietic_Neoplasm;PURITY:1;MUTATION_RATE:98.18537713;GENOME_DOUBLINGS:1;DOUBLING_TIME:38.4;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Round cells to occasionally polynucleated, single cells in suspension, few adherent;DOUBLING_TIME_FROM_VENDOR:36 hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:RPMI1640+10%FBS;HIST_SUBTYPE1:acute_myeloid_leukaemia;HIST_SUBTYPE2:M6;HIST_SUBTYPE3:NS;LINEAGE:blood;LINEAGE_SUB_SUBTYPE:M6;LINEAGE_SUBTYPE:AML;NAME:HEL;PATHOLOGIST_ANNOTATION:Leukemia:AML;PROTEOMICS_TMT_LABEL:128c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:AML"
"ES" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ESCA" "CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:4.53116129354;SEX:Female;FRACTION_GENOME_ALTERED:0.7452;PRIMARY_SITE:Oesophagus;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Esophagus;HISTOLOGICAL_SUBTYPE:Squamous_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"ESCA_GS" "CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:2.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.2507;SAMPLE_TYPE:Primary;OS_MONTHS:26.33395798;OS_STATUS:1:DECEASED;RACE:White;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:26.33395798;TISSUE_SOURCE_SITE:University of Michigan;ICD_O_3_SITE:C15.5;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C15.5;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:2/12/13;GRADE:G3;PFS_MONTHS:26.33395798;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Esophagus;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIB;SUBTYPE:ESCA_GS;TUMOR_TYPE:Esophagus Adenocarcinoma (NOS);PATH_T_STAGE:T1;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:112;DAYS_TO_BIRTH:-23194;MSI_SENSOR_SCORE:0.09;CANCER_TYPE_ACRONYM:ESCA;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3264;PATH_N_STAGE:N1;TISSUE_SOURCE_SITE_CODE:L5;DSS_MONTHS:26.33395798;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;WEIGHT:193;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"ESOPHAGEAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:4.53116129354;SEX:Female;FRACTION_GENOME_ALTERED:0.7452;PRIMARY_SITE:Oesophagus;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Esophagus;HISTOLOGICAL_SUBTYPE:Squamous_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"ESOPHAGEAL ADENOCARINOMA" "CANCER_TYPE_DETAILED:Adenocarcinoma of the Gastroesophageal Junction;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:GEJ;TMB_NONSYNONYMOUS:6.65493180359;SEX:Male;FRACTION_GENOME_ALTERED:0.4074;SAMPLE_TYPE:Primary;OS_MONTHS:13.21;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Esophagus;GENE_PANEL:IMPACT341;TUMOR_PURITY:30;SUBTYPE:Esophageal Adenocarinoma;MSI_SCORE:2.22;MSI_TYPE:Stable;SAMPLE_COVERAGE:1176;AGE_AT_SURGERY:78.6;FGA:0.407;AGE_AT_SEQUENCING:79.45;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:80.55;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:Yes;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:Yes;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:Yes;DMETS_DX_PNS:No;DMETS_DX_SKIN:Yes;DMETS_DX_UNSPECIFIED:No;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:ESCA"
"ESOPHAGEAL ADENOSQUAMOUS CARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Adenosquamous Carcinoma;CANCER_TYPE:Esophageal Carcinoma;TMB_NONSYNONYMOUS:0.266666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:II;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1210;DIAGNOSIS AGE:54;GDNA(NG):438;SMOKE STATUS:Unknown;TUMOR_PURTITY:20"
"ESOPHAGEAL CANCER" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:19.9;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:240.43;AGE_AT_PROCUREMENT:80;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Other;HEMOGLOBIN_LEVEL:8.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.28;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Residual Disease|Post-Chemotherapy;KARYOTYPE:45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19];PB_BLAST_PERCENTAGE:70;WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Maintenance;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Other;CURRENT_REGIMEN:AG-120;LDH_LEVEL:1897;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Other;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200];DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:25.6;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-29;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.6;PB_ALT_LEVEL:11;PB_AST_LEVEL:57;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:7;PB_MONOCYTES_PERCENTAGE:3;PB_NEUTROPHILS_PERCENTAGE:9;PRIOR_CANCER:Esophageal Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +).;TOTAL_PROTEIN_LEVEL:4.3;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ESOPHAGEAL CARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophageal Carcinoma;TMB_NONSYNONYMOUS:0.166666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1828;DIAGNOSIS AGE:73;GDNA(NG):732;SMOKE STATUS:Unknown;TUMOR_PURTITY:12"
"ESOPHAGEAL CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Esophageal Carcinoma Other;CANCER_TYPE:Esophageal Carcinoma;TMB_NONSYNONYMOUS:0.266666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:II;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1133;DIAGNOSIS AGE:62;GDNA(NG):13020;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"ESOPHAGEAL NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Esophageal Neuroendocrine Tumor;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;TMB_NONSYNONYMOUS:0.433333333333;SEX:Male;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Chemotherapy;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1014;DIAGNOSIS AGE:56;GDNA(NG):79;SMOKE STATUS:Unknown;TUMOR_PURTITY:20"
"ESOPHAGEAL POORLY DIFFERENTIATED CARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Poorly Differentiated Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:EPDCA;TMB_NONSYNONYMOUS:5.1942580682;SEX:Male;FRACTION_GENOME_ALTERED:0.6785;PRIMARY_SITE:Upper Aerodigestive Tract;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Upper_Aerodigestive;HISTOLOGICAL_SUBTYPE:Squamous_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"ESOPHAGEAL SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:27.4080000195;SEX:Male;FRACTION_GENOME_ALTERED:0.1025;PRIMARY_SITE:Stomach;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Stomach;HISTOLOGICAL_SUBTYPE:Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"ESOPHAGEAL/STOMACH CANCER, NOS" "CANCER_TYPE_DETAILED:Esophagus/Stomach;CANCER_TYPE:Esophageal/Stomach Cancer, NOS;ONCOTREE_CODE:STOMACH;TMB_NONSYNONYMOUS:8.4;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_squamous;LINEAGE_SUBTYPE:NSCLC;TYPE_REFINED:lung_NSC"
"ESOPHAGOGASTRIC ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophagogastric Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:EGC;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Male;AGE:25;OS_STATUS:0:LIVING;GRADE:3;SUBTYPE:D;STAGE:3;PLATFORM:WXS;CLIN_M_STAGE:0.0;CLIN_T_STAGE:4.0;CLIN_N_STAGE:1;TP53_MUTATION:Mut;EBV_STATUS:Negative;LOCATION:Antrum;EBV_PRESENT:1270.0;CDH1_STATUS:CDH1_mut;CLONAL_LABEL:Non-Ultraclonal;DNA_REPAIR_STATUS:NonDef"
"ESOPHAGUS ADENOCARCINOMA, NOS" "CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:5.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:81;FRACTION_GENOME_ALTERED:0.0324;SAMPLE_TYPE:Primary;OS_MONTHS:3.15;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:3.15;TISSUE_SOURCE_SITE:L5;ICD_O_3_SITE:C15.5;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C15.5;ICD_O_3_HISTOLOGY:8480/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/16/13;GRADE:GX;AJCC_STAGING_EDITION:6th;HISTOLOGICAL_DIAGNOSIS:Esophagus Adenocarcinoma, NOS;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1091;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-L5-A43C.86D3E142-C83D-47A7-A5C3-58F74CDCB7DE.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:230;SMOKING_PACK_YEARS:78;WEIGHT:95;SITE_OF_TUMOR_TISSUE:Esophagus;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:4;HEIGHT:155;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;SMOKING_YEAR_STARTED:29;SMOKING_YEAR_STOPPED:2009;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Excisional Biopsy;AJCC_METASTASIS_CLINICAL_CM:MX;AJCC_CLINICAL_TUMOR_STAGE:Stage III;AJCC_NODES_CLINICAL_CN:N1;AJCC_NODES_CLINICAL_CT:T3;ALCOHOL_CONSUMPTION_FREQUENCY:1;ALCOHOL_HISTORY_DOCUMENTED:YES;H_PYLORI_INFECTION:Never;REFLUX_HISTORY:NO;CITY_OF_PROCUREMENT:Ann Arbor;ESOPHAGEAL_TUMOR_LOCATION_CENTERED:Distal;TREATMENT_PRIOR_TO_SURGERY_INDICATOR:No Treatment;CANCER_PROCUREMENT_STATE_PROVINCE:MI;COLUMNAR_METAPLASIA_GOBLET_CELL_INDICATOR:NO;ESOPH_COLUMNAR_METAPLASIA_INDICATOR:NO;ESOPH_NON_CA_DEGREE_OF_DYSPLASIA:Negative/no dysplasia;ESOPHAGEAL_TUMOR_LOCATION_INVOLVED:Distal;FAMILY_HISTORY_ESOPH_GASTIC_CANCER:NO;HISTORY_BARRETTS_ESOPHAGEAL_INDICATOR:No;INITIAL_DIAGNOSIS_ESOPHAGEAL_CA_TYPE:Symptomatic;PATIENT_TO_UNDERGO_SURGERY:Surgery already performed"
"ESOPHAGUS SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:7.233333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.2437;SAMPLE_TYPE:Primary;OS_MONTHS:33.25;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:33.25;TISSUE_SOURCE_SITE:IG;ICD_O_3_SITE:C15.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C15.9;ICD_O_3_HISTOLOGY:8071/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/26/12;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Esophagus Squamous Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:241;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-IG-A3I8.713A7788-1D77-4810-96FD-7E803185A1D9.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:140;WEIGHT:48;SITE_OF_TUMOR_TISSUE:Esophagus;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:1;KARNOFSKY_PERFORMANCE_SCORE:80;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:165;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Surgical resection;ALCOHOL_HISTORY_DOCUMENTED:NO;CITY_OF_PROCUREMENT:Tver;ESOPHAGEAL_TUMOR_LOCATION_CENTERED:Distal;COLUMNAR_METAPLASIA_GOBLET_CELL_INDICATOR:NO;ESOPH_COLUMNAR_METAPLASIA_INDICATOR:NO;ESOPHAGEAL_TUMOR_LOCATION_INVOLVED:Distal;FAMILY_HISTORY_ESOPH_GASTIC_CANCER:NO;HISTORY_BARRETTS_ESOPHAGEAL_INDICATOR:No;INITIAL_DIAGNOSIS_ESOPHAGEAL_CA_TYPE:Symptomatic"
"ESOPHAGUS/STOMACH" "CANCER_TYPE_DETAILED:Esophagus/Stomach;CANCER_TYPE:Esophageal/Stomach Cancer, NOS;ONCOTREE_CODE:STOMACH;TMB_NONSYNONYMOUS:8.4;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_squamous;LINEAGE_SUBTYPE:NSCLC;TYPE_REFINED:lung_NSC"
"ESOPHAGUS_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:7.93333333333;SEX:Female;AGE:73;FRACTION_GENOME_ALTERED:0.4923;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Oesophagus;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:esophagus;HISTOLOGY:Other;PURITY:1;MUTATION_RATE:99.55688748;GENOME_DOUBLINGS:1;DOUBLING_TIME:61.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HPACC;CHARACTERISTICS:EPITHELIAL, ADHERENT;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:metaplasia;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:esophagus;LINEAGE_SUBTYPE:esophagus_adenocarcinoma;NAME:OE33;PATHOLOGIST_ANNOTATION:Oesophagus:Benign;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:lower_third;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM l-GLUTAMINE;TYPE_REFINED:esophagus"
"ESOPHAGUS_SQUAMOUS" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:24.8;SEX:Male;AGE:59;FRACTION_GENOME_ALTERED:0.5306;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Oesophagus;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:esophagus;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:324.7573697;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;DISEASE_ONTOLOGY:well differentiated invasive eosphageal squamous cell carcinoma;DOUBLING_TIME_FROM_VENDOR:~ 30 hrs;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:esophagus;LINEAGE_SUBTYPE:esophagus_squamous;NAME:KYSE-450;PATHOLOGIST_ANNOTATION:Oesophagus:Carcinoma;PROTEOMICS_TMT_LABEL:129c;SITE_SUBTYPE1:middle_third;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:esophagus"
"ESSENTIAL THROMBOCYTHAEMIA" "CANCER_TYPE_DETAILED:Essential Thrombocythemia;CANCER_TYPE:Myeloproliferative Neoplasms;ONCOTREE_CODE:ET;TMB_NONSYNONYMOUS:0.166666667;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:174.51;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:64.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Myeloproliferative Neoplasms;AGE_AT_PROCUREMENT:77;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:7;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Residual Disease|Post-Chemotherapy;KARYOTYPE:47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:15;CUMULATIVE_TREATMENT_REGIMENS:Ruxolitinib|Imatinib|Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Ruxolitinib;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:Yes;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome.;DIAGNOSIS_AT_INCLUSION:Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:4626;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Essential thrombocythaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Essential thrombocythaemia;SURFACE_ANTIGENS:dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ESSENTIAL THROMBOCYTHEMIA" "CANCER_TYPE_DETAILED:Essential Thrombocythemia;CANCER_TYPE:Myeloproliferative Neoplasms;ONCOTREE_CODE:ET;TMB_NONSYNONYMOUS:0.166666667;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:174.51;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:64.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Myeloproliferative Neoplasms;AGE_AT_PROCUREMENT:77;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:7;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Residual Disease|Post-Chemotherapy;KARYOTYPE:47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:15;CUMULATIVE_TREATMENT_REGIMENS:Ruxolitinib|Imatinib|Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Ruxolitinib;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:Yes;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome.;DIAGNOSIS_AT_INCLUSION:Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:4626;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Essential thrombocythaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Essential thrombocythaemia;SURFACE_ANTIGENS:dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ESSENTIAL_THROMBOCYTHAEMIA" "CANCER_TYPE_DETAILED:Acute Undifferentiated Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;TMB_NONSYNONYMOUS:4.53116129354;SEX:Female;FRACTION_GENOME_ALTERED:0.2058;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Leukemia_Other;HISTOLOGICAL_SUBTYPE:Essential_Thrombocythaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"ETMR" "CANCER_TYPE_DETAILED:Embryonal Tumor with Abundant Neuropil and True Rosettes;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ETANTR;TMB_NONSYNONYMOUS:5.36666666667;SEX:Male;AGE:3;FRACTION_GENOME_ALTERED:0.1085;NOTE:Li, XN;SAMPLE_SITE:Brain stem;HISTOPATHOLOGY:sPNET, GFAP+, SYN+,P53+,Ki67+, Myc-, PTEN loss, C19MC amplification by genetics, ETMR by genetics;CANCER_SUBTYPE_CURATED:ETMR;EXPRESSION:NO;INFERRED_ETHNICITY:SouthAsianOrHispanic;PHASE:Diagnosis;REPORTED_ETHNICITY:Hispanic or Latino;SITE_OF_SPECIMEN:Brain stem"
"ETP-ALL" "CANCER_TYPE_DETAILED:Early T-Cell Precursor Lymphoblastic Leukemia;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:ETPLL;TMB_NONSYNONYMOUS:4.53333333333;SEX:Male;AGE:16;FRACTION_GENOME_ALTERED:0.0691;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:ETP-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow"
"EWING FAMILY TUMOR" "CANCER_TYPE_DETAILED:Ewing Sarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:4.53333333333;SEX:Male;AGE:19;FRACTION_GENOME_ALTERED:0.5302;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Bone;SUBTYPE:Ewings Sarcoma;TUMOR_TYPE:Ewings_Sarcoma;HISTOLOGY:Ewings_Sarcoma-Peripheral_Primitive_Neuroectodermal_Tumour;PURITY:1;MUTATION_RATE:75.29215428;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Ewing family tumor;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bone;LINEAGE_MOLECULAR_SUBTYPE:EWS_FLI;LINEAGE_SUBTYPE:Ewing_sarcoma;NAME:RD-ES;PATHOLOGIST_ANNOTATION:Bone:Sarcoma_Ewing;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:Ewings_sarcoma"
"EWING SARCOMA" "CANCER_TYPE_DETAILED:Ewing Sarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:1.76825806577;SEX:Female;FRACTION_GENOME_ALTERED:0.1447;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ewings_Sarcoma;HISTOLOGICAL_TYPE:Ewings Sarcoma-Peripheral Primitive Neuroectodermal Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"EWING'S SARCOMA" "CANCER_TYPE_DETAILED:Ewing's sarcoma;CANCER_TYPE:Bone Cancer;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:13;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:ES;SUBTYPE_DETAILS:No_Fusion;TUMOR_DETAILS:Ewing's sarcoma"
"EWING-LIKE SARCOMA" "CANCER_TYPE_DETAILED:Ewing-like sarcoma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:13.35523605;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:2nd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:2nd tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:43;TIME_TO_BLOOD_DRAW_FROM_TX:20;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"EWINGS SARCOMA" "CANCER_TYPE_DETAILED:Ewing Sarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:1.76825806577;SEX:Female;FRACTION_GENOME_ALTERED:0.1447;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ewings_Sarcoma;HISTOLOGICAL_TYPE:Ewings Sarcoma-Peripheral Primitive Neuroectodermal Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"EWINGS SARCOMA-PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOUR" "CANCER_TYPE_DETAILED:Ewing Sarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:1.76825806577;SEX:Female;FRACTION_GENOME_ALTERED:0.1447;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ewings_Sarcoma;HISTOLOGICAL_TYPE:Ewings Sarcoma-Peripheral Primitive Neuroectodermal Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"EWINGS_SARCOMA" "CANCER_TYPE_DETAILED:Ewing Sarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:1.76825806577;SEX:Female;FRACTION_GENOME_ALTERED:0.1447;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ewings_Sarcoma;HISTOLOGICAL_TYPE:Ewings Sarcoma-Peripheral Primitive Neuroectodermal Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"EWING_SARCOMA" "CANCER_TYPE_DETAILED:Ewing Sarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:11.0;SEX:Male;AGE:22;FRACTION_GENOME_ALTERED:0.3084;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Bone;SUBTYPE:Ewings Sarcoma;TUMOR_TYPE:Ewings_Sarcoma;HISTOLOGY:Ewings_Sarcoma-Peripheral_Primitive_Neuroectodermal_Tumour;PURITY:1;MUTATION_RATE:116.191956;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Ewings_sarcoma;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bone;LINEAGE_SUBTYPE:Ewing_sarcoma;NAME:TC-71;PATHOLOGIST_ANNOTATION:Bone:Sarcoma_Ewing;PROTEOMICS_TMT_LABEL:130c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:Ewings_sarcoma"
"EXTRA GONADAL GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Extra Gonadal Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:EGCT;TMB_NONSYNONYMOUS:9.023819602;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0503;SAMPLE_TYPE:Metastasis;OS_MONTHS:0;OS_STATUS:1:DECEASED;RACE:ASIAN-FAR EAST/INDIAN SUBCONT;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Mediastinum;GENE_PANEL:IMPACT505;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Brain;TUMOR_PURITY:40;MSI_SCORE:1.46;MSI_TYPE:Stable;SAMPLE_COVERAGE:469;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:20;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:NONE;AGE_CURRENT:19;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"EXTRA-ADRENAL PHEOCHROMOCYTOMA" "CANCER_TYPE_DETAILED:Paraganglioma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:PGNG;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.0679;SAMPLE_TYPE:Primary;OS_MONTHS:9.205378571;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;TISSUE_SOURCE_SITE:QR;ICD_O_3_SITE:C49.3;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C49.3;ICD_O_3_HISTOLOGY:8680/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/21/14;HISTOLOGICAL_DIAGNOSIS:Paraganglioma; Extra-adrenal Pheochromocytoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;DAYS_LAST_FOLLOWUP:280;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:155;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-QR-A6H0.25844561-A084-4F60-ACAF-69C5DD2A1525.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:30;TUMOR_SITE:Extra-adrenal Site;PHARMACEUTICAL_TX_ADJUVANT:NO;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;PRIMARY_SITE_OTHER:paraspinal;CT_SCAN_PREOP_RESULTS:YES;DISEASE_DETECTED_ON_SCREENING:YES;HISTORY_PHEO_OR_PARA_ANATOMIC_SITE:Mediastinal PGL;HISTORY_PHEO_OR_PARA_INCLUDE_BENIGN:YES"
"EXTRAGONADAL GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Mixed Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:BMGCT;SEX:Female;FRACTION_GENOME_ALTERED:0.2877;SAMPLE_TYPE:Primary;RACE:Non-Hispanic;ETHNICITY:White;PRIMARY_SITE:Mediastinum;VITAL_STATUS:DOD;NOTE:Germinoma embryonal carcinoma and YST with associated embryonal carcinoma;SURGERY:Right mediastinal mass excision;CENTER:MSKCC;AFP_AT_PROCUREMENT:0.7;CHEMO_CYCLES:4;FIRST_LINE_THERAPY:BEP;LDH:1403;TIME_TO_RECURRENCE_MONTHS:3;BHCG:<3;DX_ORG_INST:Extragonadal Germ Cell Tumor;LOCATION_RECURRED:Pleura, Lymph node;METASTATIC_DX:Lung, Lymph node;PATH_DX_MSK:Mixed Germ Cell Tumor;REC_AFTER_FIRST_LINE:Responded then recurred;RESPONDED_SECOND_LINE:Responded then recurred;SECOND_LINE_TC_OR_SURGERY:TIPx4;THIRD_LINE:TKI"
"EXTRAHEPATIC CHOLANGIOCARCINOMA" "CANCER_TYPE_DETAILED:Extrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:EHCH;TMB_NONSYNONYMOUS:3.2;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.2422;SAMPLE_TYPE:Primary;OS_MONTHS:12.09;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.09;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C24.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C24.0;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/9/14;GRADE:G1;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IVB;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; distal;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:386;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVB.BEA4C577-73ED-48F0-9417-AA8BD143B5C8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:420;WEIGHT:76;TUMOR_SITE:Bile duct;AJCC_METASTASIS_PATHOLOGIC_PM:M1;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;ECOG_SCORE:0;HEIGHT:170;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;FAMILY_HISTORY_OF_CANCER:NO;CREATININE_LEVEL_PRERESECTION:0.9;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;BILIRUBIN_TOTAL:1.7;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.2;CHILD_PUGH_CLASSIFICATION:A;DEFINITIVE_SURGICAL_PROCEDURE:Pancreaticoduodenectomy (Whipple Resection);HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:No History of Primary Risk Factors;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:0.9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:1.1;PROTHROMBIN_TIME_NORM_RANGE_UPPER:1.1;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:4.3"
"EXTRAMAMMARY PAGET DISEASE" "CANCER_TYPE_DETAILED:Extramammary Paget Disease;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:EMPD;TMB_NONSYNONYMOUS:2.7;SOMATIC_STATUS:Matched;SEX:Male;AGE:71;FRACTION_GENOME_ALTERED:0.0397;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Scrotum;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Lymph Node;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:18"
"EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE MALT LYMPHOMA" NA
"EXTRARENAL RHABDOID TUMOR" "CANCER_TYPE_DETAILED:Extrarenal Rhabdoid Tumor;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:I;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1346;DIAGNOSIS AGE:1;GDNA(NG):1308;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"EXTRASKELETAL MYXOID CHONDROSARCOMA" "CANCER_TYPE_DETAILED:Extraskeletal Myxoid Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:EMCHS;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.0677;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Thigh;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:36"
"EXTRASKELETAL OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Extraskeletal Osteosarcoma;CANCER_TYPE:Bone Cancer;SEX:Male;FRACTION_GENOME_ALTERED:0.2798;SAMPLE_TYPE:Metastasis;OS_MONTHS:15.945;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Extremity;GENE_PANEL:IMPACT410;TUMOR_PURITY:70;MSI_SCORE:1;MSI_TYPE:Stable;SAMPLE_COVERAGE:468;PURITY:0.53156452;AGE_AT_SEQ_REPORT:51;DETAILED_PRIMARY_SITE:Leg;FACETS:YES;FRACTION_CNA:0.916722504;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.2798"
"EXTRAVENTRICULAR NEUROCYTOMA" "CANCER_TYPE_DETAILED:Extraventricular Neurocytoma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:EVN;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.6418;SAMPLE_TYPE:Primary;OS_MONTHS:7.59;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:80;SAMPLE_COVERAGE:514;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:DNA;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"FH-DEFICIENT RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:FH-Deficient Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:FHRCC;TMB_NONSYNONYMOUS:2.2183106012;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Metastasis;OS_MONTHS:17;OS_STATUS:0:LIVING;PRIMARY_SITE:Kidney;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lymph Node;TUMOR_PURITY:20;SAMPLE_COVERAGE:532;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORT:52;AGE_GROUP:50-60;DRUG_TYPE:PD-1/PDL-1"
"FIBROBLASTIC MYOFIBROBLASTIC TUMOR" "CANCER_TYPE_DETAILED:Fibroblastic Myofibroblastic Tumor;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:613;DIAGNOSIS AGE:42;GDNA(NG):1740;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"FIBROBLASTIC OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Fibroblastic Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:FIOS;TMB_NONSYNONYMOUS:2.16666666667;SEX:Male;AGE:20;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Bone;SUBTYPE:Bone;TUMOR_TYPE:osteosarcoma;HISTOLOGY:Osteosarcoma;PURITY:0.99;MUTATION_RATE:109.9014919;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_bone;NAME:Hs 888.T;SITE_OF_FINDING:lung;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:fibroblast_like"
"FIBROBLAST_SKIN" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:3.23333333333;SEX:Female;AGE:48;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Skin;SUBTYPE:Skin;TUMOR_TYPE:melanoma;HISTOLOGY:Malignant_Melanoma;PURITY:1;MUTATION_RATE:56.09099205;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_skin;NAME:Hs 895.T;PATHOLOGIST_ANNOTATION:Skin:Melanoma;SITE_OF_FINDING:lung;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:fibroblast_like"
"FIBROLAMELLAR CARCINOMA" "CANCER_TYPE_DETAILED:Fibrolamellar Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:FLC;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Male;AGE:25;FRACTION_GENOME_ALTERED:0.0850;SAMPLE_TYPE:Primary;OS_MONTHS:32.49;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:29.96;TISSUE_SOURCE_SITE:DD;ICD_O_3_SITE:C22.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C22.0;ICD_O_3_HISTOLOGY:8171/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:12/18/12;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Fibrolamellar Carcinoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:464;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DD-A4NB.963CA9F8-DA47-4E2E-892E-14E7AB0EB76E.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:180;WEIGHT:69;SITE_OF_TUMOR_TISSUE:Liver;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;ECOG_SCORE:1;HEIGHT:185;VASCULAR_INVASION:None;AFP_AT_PROCUREMENT:3;FAMILY_HISTORY_OF_CANCER:YES;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:0.8;CREATININE_NORM_RANGE_LOWER:0.8;CREATININE_NORM_RANGE_UPPER:1.3;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2011;AFP_NORM_RANGE_LOWER:0;AFP_NORM_RANGE_UPPER:6;BILIRUBIN_TOTAL:1;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0.1;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1;DEFINITIVE_SURGICAL_PROCEDURE:Segmentectomy, Multiple;FAMILY_HISTORY_CANCER_NUMBER_RELATIVES:2;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:No History of Primary Risk Factors;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:450;PROTHROM_TIME_INR_NORM_RANGE_LOWER:9.5;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:13.9;PROTHROMBIN_TIME_NORM_RANGE_UPPER:13.8;HEPATIC_INFLAMMATION_ADJ_TISSUE:Mild"
"FIBROLAMELLAR HEPATOCELLUAR CARCINOMA" "CANCER_TYPE_DETAILED:Fibrolamellar Hepatocelluar Carcinoma;CANCER_TYPE:Carcinoma;SEX:Female;AGE:20.59685135;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:1363"
"FIBROMATOSIS" "CANCER_TYPE_DETAILED:Desmoid Fibromatosis;CANCER_TYPE:Sarcoma;SEX:Male;AGE:2.269678354;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"FIBROSARCOMA" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:2.21032258221;SEX:Male;FRACTION_GENOME_ALTERED:0.0636;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Fibrosarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"FIBROSARCOMA_CANCER" "CANCER_TYPE_DETAILED:Fibrosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:FIBS;TMB_NONSYNONYMOUS:4.3;SEX:Male;AGE:35;FRACTION_GENOME_ALTERED:0.0645;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Fibrosarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Fibrosarcoma;PURITY:0.98;MUTATION_RATE:79.58792792;GENOME_DOUBLINGS:0;DOUBLING_TIME:42.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Epithelial Adherent;DISEASE_ONTOLOGY:fibrosarcoma_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:EMEM+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:fibrosarcoma;NAME:HT-1080;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Fibro;PROTEOMICS_TMT_LABEL:128c;SITE_OF_FINDING:acetabulum;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"FL" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.433333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:7.8;GENE_PANEL:WXS;PROTOCOL:AALL03B1;CYTOGENETICS:52(26,X,+Y,+14,+21)x2[4]/46,XY[17];SNAPSHOT_MUTATIONS:NRAS,FLT3,PAX5,CDKN2A/B,Histone (6p22);DNA_INDEX:0.54;KNOWN_MOLECULAR_CLASSIFIER:Near haploid"
"FOCAL NEUROENDOCRINE COMPONENT" "CANCER_TYPE_DETAILED:Duodenal Adenocarcinoma;CANCER_TYPE:Small Bowel Cancer;ONCOTREE_CODE:DA;TMB_NONSYNONYMOUS:3.45879238;SOMATIC_STATUS:Matched;SEX:Male;AGE:57;FRACTION_GENOME_ALTERED:0.0054;SAMPLE_TYPE:Primary;OS_MONTHS:47.967;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Small Intestine;GENE_PANEL:IMPACT468;TUMOR_PURITY:20;MSI_SCORE:0.23;MSI_TYPE:Do not report;SAMPLE_COVERAGE:664;INSTITUTE:MSK-IMPACT;AGE_AT_SEQ_REPORTED_YEARS:69;RELIGION:JEWISH;AGE_CURRENT:73;ARCHER:YES;SO_COMMENTS:Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.;PED_IND:No;PARTC_CONSENTED_12_245:YES;STAGE_AT_DIAGNOSIS:3;CVR_TMB_SCORE:1.8;PARTA_CONSENTED_12_245:YES;DATE_ADDED:11/11/16;MONTH_ADDED:2016/11;WEEK_ADDED:2016, Wk. 45;CRDB_CONSENT_DATE_DAYS:25427;CRDB_SURVIVAL_STATUS:Alive;CVR_TMB_COHORT_PERCENTILE:25.2;CVR_TMB_TT_COHORT_PERCENTILE:10.7;DIFFERENTIATION:Poor;PRIMARY_HISTOLOGY:poorly diff;TISSUE_SEQUENCED:Small Bowel;CLASSIFICATION_OF_PRIMARY_SITE:small intestine;DURATION_IBD_AT_DX_10_YEARS:greater;IBD:Crohn's;IBD_STATUS_AT_DIAGNOSIS:Quiescent;LOW_TUMOR_CONTENT:1;MEDIAN_COVERAGE:664;PRESENTATION:Bowel Symptoms;RESECTABLE:No;SPECIAL_HISTOLOGY:focal neuroendocrine component"
"FOLLICULAR CARCINOMA" "CANCER_TYPE_DETAILED:Follicular Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THFO;SOMATIC_STATUS:Matched;SEX:Female;AGE:54;SAMPLE_TYPE:Primary;OS_MONTHS:39.98;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.15;TISSUE_SOURCE_SITE:BJ;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C73;ICD_O_3_HISTOLOGY:8335/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/22/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:118;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BJ-A0ZF.A9CCA0D6-C4EE-475E-8932-C99F5619D6FE.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:270;SITE_OF_TUMOR_TISSUE:Thyroid;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;HISTOLOGICAL_SUBTYPE:Follicular Carcinoma;LATERALITY:Right lobe"
"FOLLICULAR DENDRITIC CELL SARCOMA" "CANCER_TYPE_DETAILED:Follicular Dendritic Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:FDCS;TMB_NONSYNONYMOUS:1.86666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:62;FRACTION_GENOME_ALTERED:0.1872;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Shoulder;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Neck;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:33"
"FOLLICULAR LYMPHOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:0.53;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:61.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:53;AGE_AT_PROCUREMENT:61;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:2;HEMOGLOBIN_LEVEL:8.4;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.84;CURRENT_STAGE:NONE;FUSION:Unknown;GROUP:Initial Acute Leukemia Diagnosis;PB_BLAST_PERCENTAGE:89;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:50;CURRENT_REGIMEN:NONE;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:25.3;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.5;PB_ALT_LEVEL:61;PB_BASOPHILS_PERCENTAGE:1;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:0;PB_MONOCYTES_PERCENTAGE:0;PB_NEUTROPHILS_PERCENTAGE:0;PRIOR_CANCER:Follicular lymphoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-;TOTAL_PROTEIN_LEVEL:4.5"
"FOLLICULAR THYROID CANCER" "CANCER_TYPE_DETAILED:Follicular Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THFO;TMB_NONSYNONYMOUS:7.86666666667;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.4758;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Carcinoma, follicular;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;GENOME_DOUBLINGS:1;DOUBLING_TIME:31.6;GEOGRAPHIC_DISTRIBUTION:chinese;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Adherent large epitheloid cells with long processes growing in monolayers with multilayer foci;DOUBLING_TIME_FROM_VENDOR:20-25hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:RPMI1640+10%FBS;HIST_SUBTYPE1:follicular_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:follicular;LINEAGE_SUBTYPE:thyroid_carcinoma;NAME:CGTH-W-1;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_OF_FINDING:sternum;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"FOLLICULAR THYROID CARCINOMA" "CANCER_TYPE_DETAILED:Follicular Thyroid Carcinoma;CANCER_TYPE:Thyroid Carcinoma;TMB_NONSYNONYMOUS:0;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1679;DIAGNOSIS AGE:69;GDNA(NG):3372;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"FOLLICULAR, PAPILLARY" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:0.0666666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.0025;SAMPLE_TYPE:Primary;OS_MONTHS:75.82;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;METASTATIC_SITE:No;TUMOR_PURITY:0.9;PATH_T_STAGE:T3/T4;PATH_N_STAGE:Nx/N0;SPECIMEN_PRESERVATION_TYPE:FFPE;M_STAGE:M0;CYTOLOGICAL_PHENOTYPE:follicular, papillary;GROWTH_PATTERN:solid;PDTC_DEFINITION:PDTC-Turin"
"FOLLICULAR_CARCINOMA" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:4.0890967771;SEX:Female;FRACTION_GENOME_ALTERED:0.4865;PRIMARY_SITE:Thyroid;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Thyroid;HISTOLOGICAL_SUBTYPE:Follicular_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"FUSION+ RMS" NA
"FUSION- RMS" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:4.4;SEX:Male;AGE:3;FRACTION_GENOME_ALTERED:0.0006;NOTE:Houghton;SAMPLE_SITE:R. Buttock;HISTOPATHOLOGY:Embryonal;CANCER_SUBTYPE_CURATED:Fusion- RMS;EXPRESSION:NO;INFERRED_ETHNICITY:African;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:R. Buttock"
"GALLBLADDER ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Gallbladder Adenocarcinoma, NOS;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBAD;TMB_NONSYNONYMOUS:7.5;FRACTION_GENOME_ALTERED:0.6468;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Biliary_Tract;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:bile_duct;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:115.4161995;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:48 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bile_duct;LINEAGE_SUBTYPE:gallbladder_adenocarcinoma;NAME:SNU-308;PATHOLOGIST_ANNOTATION:Biliary_Tract:Carcinoma;SITE_SUBTYPE1:bile_duct;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:bile_duct"
"GALLBLADDER ADENOCARCINOMA, NOS" "CANCER_TYPE_DETAILED:Gallbladder Adenocarcinoma, NOS;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBAD;TMB_NONSYNONYMOUS:7.5;FRACTION_GENOME_ALTERED:0.6468;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Biliary_Tract;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:bile_duct;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:115.4161995;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:48 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bile_duct;LINEAGE_SUBTYPE:gallbladder_adenocarcinoma;NAME:SNU-308;PATHOLOGIST_ANNOTATION:Biliary_Tract:Carcinoma;SITE_SUBTYPE1:bile_duct;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:bile_duct"
"GALLBLADDER ADENOSQUAMOUS CARCINOMA" "CANCER_TYPE_DETAILED:Gallbladder Adenosquamous Carcinoma;CANCER_TYPE:Gallbladder Carcinoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:III-IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1174;DIAGNOSIS AGE:65;GDNA(NG):5184;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"GALLBLADDER CANCER" "CANCER_TYPE_DETAILED:Gallbladder Cancer;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBC;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:61;OS_STATUS:1:DECEASED;GENE_PANEL:WXS, TDS;GRADE:moderate;TUMOR_TISSUE_SITE:neck;TNMSTAGE:IIIA;PERINEURAL_INVASION:NO;TIME_TO_LAST_FOLLOWUP:10.3;GALLBLADDER_STONES:NO;LYMPH_NODE_METASTASIS:NO;MARGIN_STATUS:R1;ERBB_PATHWAY_MUTATION:NO;JAUNDICE:YES"
"GALLBLADDER CARCINOMA" "CANCER_TYPE_DETAILED:Gallbladder Adenocarcinoma;CANCER_TYPE:Gallbladder Carcinoma;TMB_NONSYNONYMOUS:0.3;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Chemotherapy;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:925;DIAGNOSIS AGE:58;GDNA(NG):5868;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"GALLBLADDER CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Gallbladder Carcinoma Other;CANCER_TYPE:Gallbladder Carcinoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1452;DIAGNOSIS AGE:64;GDNA(NG):636;SMOKE STATUS:Unknown;TUMOR_PURTITY:20"
"GALLBLADDER NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Gallbladder Neuroendocrine Tumor;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;TMB_NONSYNONYMOUS:0.4;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:II;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:611;DIAGNOSIS AGE:43;GDNA(NG):4848;SMOKE STATUS:Unknown;TUMOR_PURTITY:70"
"GALLBLADDER_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Gallbladder Adenocarcinoma, NOS;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBAD;TMB_NONSYNONYMOUS:7.5;FRACTION_GENOME_ALTERED:0.6468;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Biliary_Tract;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:bile_duct;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:115.4161995;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:48 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bile_duct;LINEAGE_SUBTYPE:gallbladder_adenocarcinoma;NAME:SNU-308;PATHOLOGIST_ANNOTATION:Biliary_Tract:Carcinoma;SITE_SUBTYPE1:bile_duct;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:bile_duct"
"GANGLIOGLIOMA" "CANCER_TYPE_DETAILED:Ganglioglioma;CANCER_TYPE:Glioma;ONCOTREE_CODE:GNG;SEX:Female;AGE:3;OS_MONTHS:57;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:57;TUMOR_TISSUE_SITE:Temporal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:No;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1441;AGE_CLASS:[0,5);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:3198;AGE_AT_SPECIMEN_DIAGNOSIS:1441;CANCER_PREDISPOSITIONS:None documented;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;EXTENT_OF_TUMOR_RESECTION:Partial resection;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ganglioglioma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Other medical conditions NOS,Seizure disorder;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:No;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Temporal Lobe;UPDATED_GRADE:I"
"GANGLIONEUROBLASTOMA" "CANCER_TYPE_DETAILED:Neuroblastoma;CANCER_TYPE:Peripheral Nervous System;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:3;FRACTION_GENOME_ALTERED:0.0321;OS_MONTHS:85.0;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;GRADE:Undifferentiated or Poorly Differentiated;ANALYSIS_COHORT:DISCOVERY;DIAGNOSIS:Ganglioneuroblastoma, nodular;PROTOCOL:ANBL00B1;OS_DAYS:2556.0;TUMOR_SAMPLE_HISTOLOGY:Unfavorable;YEAR_OF_DIAGNOSIS:2008;AGE_IN_DAYS:911;RISK_GROUP:High Risk;PERCENTAGE_NECROSIS:10;FIRST_EVENT:Censored;INSS_STAGE:Stage 4;PERCENTAGE_TUMOR_PURITY:80;MKI:Intermediate;MYCN:Not Amplified;EFS_TIME:2556.0;EFSCENS:0.0;ICDO:C48.0;ICDO_SNOMED_DESCRIPTION:Retroperitoneum Periadrenal tissue Perinephric tissue Peripancreatic tissue Perirenal tissue Retrocecal tissue Retroperitoneal tissue;LAST_FOLLOWUP_YEAR:2015.0;PERCENT_TUMOR_VS_STROMA:80/20;SCENS:0.0;SNOMED:999;STIME:1.0"
"GANGLIONEUROBLASTOMA, INTERMIXED" "CANCER_TYPE_DETAILED:Neuroblastoma;CANCER_TYPE:Peripheral Nervous System;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:4;OS_MONTHS:56.0;OS_STATUS:0:LIVING;RACE:Asian;ETHNICITY:Unknown;GRADE:Unknown;ANALYSIS_COHORT:VALIDATION;DIAGNOSIS:Ganglioneuroblastoma, intermixed;PROTOCOL:ANBL00B1, ANBL0532;OS_DAYS:1675.0;TUMOR_SAMPLE_HISTOLOGY:Favorable;YEAR_OF_DIAGNOSIS:2010;AGE_IN_DAYS:1411;RISK_GROUP:High Risk;FIRST_EVENT:Progression;CNS_SITE_OF_RELAPSE:Metastases only;INSS_STAGE:Stage 4;PERCENTAGE_TUMOR_PURITY:90;MKI:Unknown;MYCN:Not Amplified;EFS_TIME:153.0;ICDO:C76.2;ICDO_SNOMED_DESCRIPTION:Abdomen, NOS Abdominal wall, NOS Intra-abdominal site, NOS;LAST_FOLLOWUP_YEAR:2015.0"
"GANGLIONEUROBLASTOMA, NODULAR" "CANCER_TYPE_DETAILED:Neuroblastoma;CANCER_TYPE:Peripheral Nervous System;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:3;FRACTION_GENOME_ALTERED:0.0321;OS_MONTHS:85.0;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;GRADE:Undifferentiated or Poorly Differentiated;ANALYSIS_COHORT:DISCOVERY;DIAGNOSIS:Ganglioneuroblastoma, nodular;PROTOCOL:ANBL00B1;OS_DAYS:2556.0;TUMOR_SAMPLE_HISTOLOGY:Unfavorable;YEAR_OF_DIAGNOSIS:2008;AGE_IN_DAYS:911;RISK_GROUP:High Risk;PERCENTAGE_NECROSIS:10;FIRST_EVENT:Censored;INSS_STAGE:Stage 4;PERCENTAGE_TUMOR_PURITY:80;MKI:Intermediate;MYCN:Not Amplified;EFS_TIME:2556.0;EFSCENS:0.0;ICDO:C48.0;ICDO_SNOMED_DESCRIPTION:Retroperitoneum Periadrenal tissue Perinephric tissue Peripancreatic tissue Perirenal tissue Retrocecal tissue Retroperitoneal tissue;LAST_FOLLOWUP_YEAR:2015.0;PERCENT_TUMOR_VS_STROMA:80/20;SCENS:0.0;SNOMED:999;STIME:1.0"
"GANGLIONEUROMA" "CANCER_TYPE_DETAILED:Neuroblastoma;CANCER_TYPE:Peripheral Nervous System;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:3;OS_MONTHS:66.0;OS_STATUS:0:LIVING;RACE:Not Reported;ETHNICITY:Hispanic or Latino;GRADE:Unknown;ANALYSIS_COHORT:VALIDATION;DIAGNOSIS:Ganglioneuroma, maturing subtype OR Ganglioneuroblastoma, well differentiated;PROTOCOL:ANBL00B1, ANBL0531;OS_DAYS:2002.0;TUMOR_SAMPLE_HISTOLOGY:Favorable;YEAR_OF_DIAGNOSIS:2009;AGE_IN_DAYS:1075;RISK_GROUP:Intermediate Risk;FIRST_EVENT:Censored;INSS_STAGE:Stage 3;PERCENTAGE_TUMOR_PURITY:80;MKI:Unknown;MYCN:Not Amplified;EFS_TIME:2002.0;ICDO:C74.9;ICDO_SNOMED_DESCRIPTION:Adrenal gland, NOS Suprarenal gland Adrenal, NOS;LAST_FOLLOWUP_YEAR:2014.0"
"GASTRIC ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophagogastric Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:EGC;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Male;AGE:25;OS_STATUS:0:LIVING;GRADE:3;SUBTYPE:D;STAGE:3;PLATFORM:WXS;CLIN_M_STAGE:0.0;CLIN_T_STAGE:4.0;CLIN_N_STAGE:1;TP53_MUTATION:Mut;EBV_STATUS:Negative;LOCATION:Antrum;EBV_PRESENT:1270.0;CDH1_STATUS:CDH1_mut;CLONAL_LABEL:Non-Ultraclonal;DNA_REPAIR_STATUS:NonDef"
"GASTRIC CANCER" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:27.4080000195;SEX:Male;FRACTION_GENOME_ALTERED:0.1025;PRIMARY_SITE:Stomach;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Stomach;HISTOLOGICAL_SUBTYPE:Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"GASTRIC CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Gastric Carcinoma Other;CANCER_TYPE:Gastric Cancer;TMB_NONSYNONYMOUS:0.2;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1281;DIAGNOSIS AGE:86;GDNA(NG):1452;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"GASTRIC NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Gastric Neuroendocrine Tumor;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:841;DIAGNOSIS AGE:52;GDNA(NG):4668;SMOKE STATUS:Unknown;TUMOR_PURTITY:40"
"GASTRIC_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:9.23333333333;SEX:Male;AGE:41;FRACTION_GENOME_ALTERED:0.7735;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:113.3381055;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:RERF-GC-1B;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"GASTRIC_CANCER" "CANCER_TYPE_DETAILED:Tubular Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:TSTAD;TMB_NONSYNONYMOUS:17.4333333333;SEX:Male;AGE:37;FRACTION_GENOME_ALTERED:0.4229;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:190.5846245;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:epithelial-like;DISEASE_ONTOLOGY:gastric_cancer;GROWTH_MEDIUM:RPMI 1640 medium with 10% heat inactivated fetal bovine serum;HIST_SUBTYPE1:tubular_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:MKN74;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:liver;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"GASTRIC_SMALL_CELL" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Stomach;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STSC;TMB_NONSYNONYMOUS:13.5;FRACTION_GENOME_ALTERED:0.5144;SAMPLE_TYPE:Metastasis;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Small Cell Carcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:158.8387503;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:other;GROWTH_MEDIUM:RPMI 1640 +10%FBS;HIST_SUBTYPE1:small_cell_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_small_cell;NAME:ECC10;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:liver;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"GASTROINTESTINAL NEUROENDOCRINE" "CANCER_TYPE_DETAILED:Well-Differentiated Neuroendocrine Tumor of the Appendix;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;ONCOTREE_CODE:AWDNET;SEX:Female;AGE:54.41752243;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:733;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"GASTROINTESTINAL NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Well-Differentiated Neuroendocrine Tumor of the Appendix;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;ONCOTREE_CODE:AWDNET;SEX:Female;AGE:54.41752243;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:733;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"GASTROINTESTINAL NEUROENDOCRINE TUMORS" "CANCER_TYPE_DETAILED:Gastrointestinal Neuroendocrine Tumors;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;ONCOTREE_CODE:GINET;TMB_NONSYNONYMOUS:2.796842924;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Metastasis;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Rectum;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;METASTATIC_SITE:Liver;MSI_SCORE:-1;SAMPLE_COVERAGE:1555;INSTITUTE:MSKCC;RELIGION:NONE;AGE_CURRENT:58;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:NO"
"GASTROINTESTINAL STROMAL" "CANCER_TYPE_DETAILED:Gastrointestinal Stromal Tumor;CANCER_TYPE:Gastrointestinal Stromal Tumor;ONCOTREE_CODE:GIST;TMB_NONSYNONYMOUS:0.966666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:67;FRACTION_GENOME_ALTERED:0.3632;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Stomach;ANALYSIS_COHORT:STAD;BIOPSY_SITE:Retroperitoneum;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:127"
"GASTROINTESTINAL STROMAL TUMOR" "CANCER_TYPE_DETAILED:Gastrointestinal Stromal Tumor;CANCER_TYPE:Gastrointestinal Stromal Tumor;ONCOTREE_CODE:GIST;TMB_NONSYNONYMOUS:0.966666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:67;FRACTION_GENOME_ALTERED:0.3632;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Stomach;ANALYSIS_COHORT:STAD;BIOPSY_SITE:Retroperitoneum;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:127"
"GB" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:0.0;FRACTION_GENOME_ALTERED:0.5645;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Astrocytoma;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"GBC" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:61.3333333333;SEX:Female;FRACTION_GENOME_ALTERED:0.1261;SAMPLE_TYPE:Metastasis;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:506.6036089;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:epithelial-like;GROWTH_MEDIUM:DMEM +5%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:TGBC11TKB;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"GBM" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:0.0;FRACTION_GENOME_ALTERED:0.5645;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Astrocytoma;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Ovarian Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:OGCT;TMB_NONSYNONYMOUS:9.56666666667;LINEAGE:ovary;LINEAGE_SUBTYPE:mixed_germ_cell;TYPE_REFINED:ovary"
"GERM CELL TUMOR (EMBRYONAL CARCINOMA)" NA
"GERM CELL TUMOR WITH SOMATIC-TYPE MALIGNANCY" "CANCER_TYPE_DETAILED:Germ Cell Tumor with Somatic-Type Malignancy;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:GCTSTM;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Unknown;OS_MONTHS:12.888;OS_STATUS:0:LIVING;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;MSI_SCORE:-1;SAMPLE_COVERAGE:1299;INSTITUTE:MSKCC;RELIGION:NONE;AGE_CURRENT:29;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"GERM CELL TUMOR, BRAIN" "CANCER_TYPE_DETAILED:Germ Cell Tumor, Brain;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:BGCT;SEX:Female;FRACTION_GENOME_ALTERED:0.1672;SAMPLE_TYPE:Primary;RACE:Black/African American;ETHNICITY:Non-Hispanic;PRIMARY_SITE:Sacrum;VITAL_STATUS:NED;SURGERY:Sacrococcygeal Resection;CENTER:MSKCC;AFP_AT_PROCUREMENT:3953.3;CHEMO_CYCLES:4;FIRST_LINE_THERAPY:BEP;TIME_TO_RECURRENCE_MONTHS:3;DX_ORG_INST:Yolk Sac Tumor;LOCATION_RECURRED:Rectum;METASTATIC_DX:Lung, Left iliac;PATH_DX_MSK:Sacrococcygeal Teratoma;REC_AFTER_FIRST_LINE:Responded then recurred;RESPONDED_SECOND_LINE:Responded to second line;SECOND_LINE_TC_OR_SURGERY:3 cycles Vac/IE and 2 cycles ICE"
"GERMINAL CENTER B-CELL TYPE" "CANCER_TYPE_DETAILED:Germinal Center B-Cell Type;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:GCB;TMB_NONSYNONYMOUS:4.5;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:45.2;OS_STATUS:1:DECEASED;PFS_MONTHS:29.8;PFS_STATUS:1:Progressed;AGE_AT_DIAGNOSIS:66.0;COHORT:Mayo/Iowa;MEAN_TARGET_COVERAGE_TUMOR:100.1;PURITY_ABSOLUTE:0.82;SAMPLE_COLLECTION_SOURCE:Frozen;IPI:2.0;NUM_NONSILENT_MUTATION:134;TESTICULAR_INVOLVEMENT:No;DRIVER_MUTATIONS:4;IPI_AGE:1.0;IPI_ECOG:0.0;IPI_LDH:1.0;NONSILENT_MUTATION_DENSITY:3.961107;NUM_SILENT_MUTATION:50;TOTAL_CNA:85;ANY_COO:GCB;CCC:BCR;CLUSTER:2;CNS_INVOLVEMENT:No;COO_GEP:GCB;DBSNP_MUTATION_DENSITY:1.09;DRIVER_MUTATION_DENSITY:0.118;IPI_EXBM:0.0;IPI_STAGE:0.0;MUTATION_DENSITY:5.439132;NUM_DBSNP_MUTATIONS:37;NUM_DRIVER_SCNA:28;NUM_DRIVER_SV:0;R_CHOP_LIKE_CHEMO:Yes;SILENT_MUTATION_DENSITY:1.48;TOTAL_REARRANGEMENT:0;TUMOR_IN_NORMAL_ESTIMATE:0"
"GERMINAL CENTER B-CELL-LIKE GCB DLBCL" NA
"GIANT CELL 'MFH' / UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH GIANT CELLS" "CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:MFH;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:42;FRACTION_GENOME_ALTERED:0.0001;SAMPLE_TYPE:Primary;OS_MONTHS:1.84;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:1.84;TISSUE_SOURCE_SITE:QQ;ICD_O_3_SITE:C49.5;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C49.5;ICD_O_3_HISTOLOGY:8830/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/27/13;HISTOLOGICAL_DIAGNOSIS:Giant cell 'MFH' / Undifferentiated pleomorphic sarcoma with giant cells;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2006;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2339;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-QQ-A5V2.D012487F-29E2-4425-AB2B-DD8F0D6122A0.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:180;SITE_OF_TUMOR_TISSUE:Lower abdominal/Pelvic - Pelvic;DISEASE_MULTIFOCAL_INDICATOR:NO;TUMOR_TOTAL_DEPTH:Superficial;NTE_LESION_PATHOLOGIC_DEPTH:4.5;NTE_LESION_PATHOLOGIC_LENGTH:11;TUMOR_TOTAL_NECROSIS:0% (no necrosis or no mention of necrosis)"
"GIANT CELL TUMOR OF BONE" "CANCER_TYPE_DETAILED:Giant Cell Tumor of Bone;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:GCTB;TMB_NONSYNONYMOUS:3.13333333333;SEX:Female;AGE:16;FRACTION_GENOME_ALTERED:0.0325;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Bone;SUBTYPE:Bone;TUMOR_TYPE:giant_cell_tumour;HISTOLOGY:Giant_Cell_Tumour;PURITY:0.97;MUTATION_RATE:83.60584105;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_bone;NAME:Hs 706.T;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:giant_cell_tumour"
"GIANT CELL TUMOUR" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:1.65774193666;SEX:Female;FRACTION_GENOME_ALTERED:0.0314;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_TYPE:Giant Cell Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"GIANT_CELL_TUMOUR" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:1.98929032399;SEX:Female;FRACTION_GENOME_ALTERED:0.0223;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_SUBTYPE:Giant_Cell_Tumour;HISTOLOGICAL_TYPE:Other;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"GINET" "CANCER_TYPE_DETAILED:Gastrointestinal Neuroendocrine Tumors;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;ONCOTREE_CODE:GINET;TMB_NONSYNONYMOUS:2.796842924;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Metastasis;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Rectum;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;METASTATIC_SITE:Liver;MSI_SCORE:-1;SAMPLE_COVERAGE:1555;INSTITUTE:MSKCC;RELIGION:NONE;AGE_CURRENT:58;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:NO"
"GIST" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:4.0;SOMATIC_STATUS:Matched;SEX:Female;AGE:84;FRACTION_GENOME_ALTERED:0.0008;SAMPLE_TYPE:Primary;OS_MONTHS:17.61;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:17.35;TISSUE_SOURCE_SITE:DK;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/13/11;GRADE:High Grade;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IV;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:129;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DK-A1AF.587A4629-6ADF-46A3-9F02-A167120286D2.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:200;WEIGHT:65.3;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:152;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Trigone;METASTATIC_SITE_PATIENT:None;ANGIOLYMPHATIC_INVASION:YES;FAMILY_HISTORY_CANCER_RELATIONSHIP:Brother|Brother;FAMILY_HISTORY_CANCER_TYPE:Liver-Primary-NOS|Liver-Primary-NOS;OCCUPATION_PRIMARY:Ophthalmologist;EXTRACAPSULAR_EXTENSION:YES;OCCUPATION_CURRENT:Retired;OCCUPATION_PRIMARY_CHEMICAL_EXPOSURE:None;OCCUPATION_PRIMARY_INDUSTRY:Medicine"
"GLIOBLASTOMA" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:0.0;FRACTION_GENOME_ALTERED:0.5645;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Astrocytoma;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"GLIOBLASTOMA MULTIFORME" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:0.0;FRACTION_GENOME_ALTERED:0.5645;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Astrocytoma;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"GLIOBLASTOMA MULTIFORME GBM" NA
"GLIOBLASTOMA, IDH-MUTANT" "CANCER_TYPE_DETAILED:Glioblastoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:GB;TMB_NONSYNONYMOUS:1.4;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.3091;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:11;OS_STATUS:1:DECEASED;GENE_PANEL:WXS;SAMPLE_CLASS:Tumor;GRADE:IV;HISTOLOGY:Glioblastoma;TUMOR_LOCATION:Frontal lobe;TYPE_OF_SURGERY:Craniotomy;AGE_AT_DX:34;EXTENT_OF_RESECTION:Total;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-19-0279-TP-01D-WXS-GQ9A87;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;CHEMO_OTHER:0;CONCURRENT_TMZ:Yes;HYPERMUTATION_STATUS:Yes;INITIAL_GRADE:IV;INITIAL_HISTOLOGY:Glioblastoma;POST_RECURRENCE_SURVIVAL_MONTHS:2;RADIATION_DOSE:60;RADIATION_OTHER:IMRT;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:30;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:9;TISSUE_SOURCE:Case Western  Reserve University;TMZ_CYCLES:4;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Glioblastoma, IDH-mutant;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:No"
"GLIOBLASTOMA, IDH-WILDTPYE" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:2.43333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;SAMPLE_TYPE:Primary;OS_MONTHS:55.2;OS_STATUS:1:DECEASED;TUMOR_LOCATION:Left frontal;WHO_CLASS:Glioblastoma, IDH-wildtpye;MORPHOLOGY:Fibrillary;TREATMENT_DETAIL_BEFORE_PDX:None"
"GLIOBLASTOMA, IDH-WILDTYPE" "CANCER_TYPE_DETAILED:Glioblastoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:GB;TMB_NONSYNONYMOUS:2.7;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2084;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:35;OS_STATUS:1:DECEASED;GENE_PANEL:WXS;SAMPLE_CLASS:Tumor;GRADE:IV;HISTOLOGY:Glioblastoma;TUMOR_LOCATION:Occipital lobe;TYPE_OF_SURGERY:Craniotomy;AGE_AT_DX:71;EXTENT_OF_RESECTION:Total;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-19-0266-TP-01D-WXS-F78XXN;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;CONCURRENT_TMZ:Yes;HYPERMUTATION_STATUS:No;INITIAL_GRADE:IV;INITIAL_HISTOLOGY:Glioblastoma;MGMT_METHYLATION:Methylated;MGMT_METHYLATION_METHOD:Array;POST_RECURRENCE_SURVIVAL_MONTHS:17;RADIATION_DOSE:60;RADIATION_OTHER:IMRT, Gamma knife;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:30;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:18;TISSUE_SOURCE:Case Western  Reserve University;TMZ_CYCLES:12;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Glioblastoma, IDH-wildtype;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:No"
"GLIOBLASTOMA_MULTIFORME" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:13.8666666667;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.5836;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Glioblastoma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;PURITY:1;MUTATION_RATE:139.4221578;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:astrocytoma_Grade_IV;HIST_SUBTYPE2:glioblastoma_multiforme;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUB_SUBTYPE:glioblastoma;LINEAGE_SUBTYPE:glioma;NAME:LN-229;PATHOLOGIST_ANNOTATION:CNS:Glioma_HighGrade;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:brain;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:glioma"
"GLIOMA" "CANCER_TYPE_DETAILED:Ganglioglioma;CANCER_TYPE:Glioma;ONCOTREE_CODE:GNG;SEX:Female;AGE:3;OS_MONTHS:57;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:57;TUMOR_TISSUE_SITE:Temporal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:No;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1441;AGE_CLASS:[0,5);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:3198;AGE_AT_SPECIMEN_DIAGNOSIS:1441;CANCER_PREDISPOSITIONS:None documented;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;EXTENT_OF_TUMOR_RESECTION:Partial resection;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ganglioglioma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Other medical conditions NOS,Seizure disorder;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:No;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Temporal Lobe;UPDATED_GRADE:I"
"GLIONEURONAL TUMOR" "CANCER_TYPE_DETAILED:Rosette-forming Glioneuronal Tumor of the Fourth Ventricle;CANCER_TYPE:CNS;SEX:Male;AGE:21.81519508;RACE:Black;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:37"
"GLIOSARCOMA" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:5.1942580682;SEX:Male;FRACTION_GENOME_ALTERED:0.4211;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Gliosarcoma;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:RIKEN;SAMPLE_ORIGIN:Solid"
"GLOMANGIOSARCOMA" "CANCER_TYPE_DETAILED:Glomangiosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Male;FRACTION_GENOME_ALTERED:0.1513;SAMPLE_TYPE:Primary;OS_MONTHS:41.688;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT410;TUMOR_PURITY:90;MSI_SCORE:0.56;MSI_TYPE:Stable;SAMPLE_COVERAGE:639;PURITY:0.969139834;AGE_AT_SEQ_REPORT:48;DETAILED_PRIMARY_SITE:Femoral Tendon;FACETS:YES;FRACTION_CNA:0.210271238;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.1513"
"GOBLET CELL ADENOCARCINOMA OF THE APPENDIX" "CANCER_TYPE_DETAILED:Goblet Cell Adenocarcinoma of the Appendix;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:GCCAP;TMB_NONSYNONYMOUS:6.654931804;SEX:Male;FRACTION_GENOME_ALTERED:0.0744;SAMPLE_TYPE:Primary;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Black;TUMOR_PURITY:15;STAGE:IV;HISTOLOGY:Goblet Cell Adenocarcinoma;MOLECULAR_SUBTYPE:TP53-mut Predominant;FGA:0.0744;DIFFERENTIATION:Poorly Differentiated;ECOG:2;AGE_AT_SEQUENCING:44;AGE_AT_METS:45;CRS_NUMBER:0;FIRSTLINE_CHEMO_GROUP:FOLFOX_or_CAPEOX;IPCHEMO_FIRST_CRS:No"
"GOBLET CELL CARCINOID OF THE APPENDIX" "CANCER_TYPE_DETAILED:Goblet Cell Carcinoid of the Appendix;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:GCCAP;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0384;SAMPLE_TYPE:Primary;OS_MONTHS:11.47;OS_STATUS:0:LIVING;PRIMARY_SITE:Appendix;SAMPLE_CLASS:Tumor;TUMOR_PURITY:10;SAMPLE_COVERAGE:546;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"GRANULAR CELL TUMOR" "CANCER_TYPE_DETAILED:Granular Cell Tumor;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:GCT;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Male;AGE:39;FRACTION_GENOME_ALTERED:0.1913;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Testes;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Scapular Mass;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:40"
"GRANULOSA CELL TUMOR" "CANCER_TYPE_DETAILED:Granulosa Cell Tumor;CANCER_TYPE:Sex Cord Stromal Tumor;ONCOTREE_CODE:GRCT;TMB_NONSYNONYMOUS:3.53333333333;SEX:Female;FRACTION_GENOME_ALTERED:0.0240;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, endometrioid;TUMOR_TYPE:ovary;HISTOLOGY:Sex_Cord-Stromal_Tumour;PURITY:1;MUTATION_RATE:88.95089442;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;HIST_SUBTYPE1:granulosa_cell_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:endometrioid;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:COV434;PATHOLOGIST_ANNOTATION:Ovary:Germline;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"GRANULOSA_CELL_TUMOR" "CANCER_TYPE_DETAILED:Granulosa Cell Tumor;CANCER_TYPE:Sex Cord Stromal Tumor;ONCOTREE_CODE:GRCT;TMB_NONSYNONYMOUS:6.96666666667;SUBTYPE:Granulosa Cell Tumor;LINEAGE:ovary;LINEAGE_SUBTYPE:granulosa_cell_tumor;TYPE_REFINED:ovary"
"GRANULOSA_CELL_TUMOUR" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:2.32083871132;SEX:Female;FRACTION_GENOME_ALTERED:0.0234;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Granulosa_Cell_Tumour;HISTOLOGICAL_TYPE:Sex Cord-Stromal Tumour;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"HAEMATOPOIETIC NEOPLASM" "CANCER_TYPE_DETAILED:Acute Undifferentiated Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;TMB_NONSYNONYMOUS:1.98929032399;SEX:Male;FRACTION_GENOME_ALTERED:0.1062;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Leukemia_Other;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"HAIRY CELL LEUKEMIA" "CANCER_TYPE_DETAILED:Hairy Cell Leukemia;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:HCL;TMB_NONSYNONYMOUS:4.93333333333;SUBTYPE:Hairy Cell;LINEAGE:blood;LINEAGE_SUBTYPE:hairy_cell_leukemia"
"HAIRY_CELL_LEUKEMIA" "CANCER_TYPE_DETAILED:Hairy Cell Leukemia;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:HCL;TMB_NONSYNONYMOUS:4.93333333333;SUBTYPE:Hairy Cell;LINEAGE:blood;LINEAGE_SUBTYPE:hairy_cell_leukemia"
"HCC" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:11.0516129111;SEX:Male;FRACTION_GENOME_ALTERED:0.7311;PRIMARY_SITE:Liver;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Liver;HISTOLOGICAL_SUBTYPE:Hepatocellular_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Solid"
"HEAD & NECK SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:5.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.3306;SAMPLE_TYPE:Primary;OS_MONTHS:50.03;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:17.74;TISSUE_SOURCE_SITE:CN;ICD_O_3_SITE:C32.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C32.9;ICD_O_3_HISTOLOGY:8070/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/13/11;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IVA;HISTOLOGICAL_DIAGNOSIS:Head & Neck Squamous Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-CN-6010.9dbd408c-79f3-4417-ad5e-383eb60903b6.pdf;VIAL_NUMBER:A;SMOKING_PACK_YEARS:67.5;SITE_OF_TUMOR_TISSUE:Head and Neck;AJCC_NODES_PATHOLOGIC_PN:N2c;AJCC_TUMOR_PATHOLOGIC_PT:T4a;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:2;SPECIMEN_SECOND_LONGEST_DIMENSION:0.8;LONGEST_DIMENSION:1;SHORTEST_DIMENSION:0.5;PRIMARY_SITE_PATIENT:Larynx;SMOKING_YEAR_STARTED:1964;CLINICAL_STAGE:Stage IVA;CLIN_M_STAGE:M0;CLIN_T_STAGE:T4a;PERINEURAL_INVASION:NO;ANGIOLYMPHATIC_INVASION:YES;CLIN_N_STAGE:N0;PATH_MARGIN:Negative;ALCOHOL_CONSUMPTION_FREQUENCY:7;ALCOHOL_HISTORY_DOCUMENTED:YES;DAILY_ALCOHOL:4;AMPLIFICATION_STATUS:Amplified;EXTRACAPSULAR_SPREAD_PATHOLOGIC:No Extranodal Extension;HPV_STATUS_ISH:Negative;HPV_STATUS_P16:Negative;LYMPH_NODE_DISSECTION_METHOD:Modified Radical Neck Dissection;LYMPH_NODE_NECK_DISSECTION_INDICATOR:YES"
"HEAD & NECK SQUAMOUS CELL CARCINOMA BASALOID TYPE" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:2.13333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.2801;SAMPLE_TYPE:Primary;OS_MONTHS:22.01;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:22.01;TISSUE_SOURCE_SITE:HD;ICD_O_3_SITE:C01.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C01;ICD_O_3_HISTOLOGY:8083/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/9/12;GRADE:G4;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Head & Neck Squamous Cell Carcinoma Basaloid Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-HD-8314.b9c245ac-7857-4cae-9e8b-6a4f189f3604.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Head and Neck;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;SPECIMEN_SECOND_LONGEST_DIMENSION:0.6;LATERALITY:Left;LONGEST_DIMENSION:1;SHORTEST_DIMENSION:0.5;PRIMARY_SITE_PATIENT:Base of tongue;CLINICAL_STAGE:Stage III;CLIN_M_STAGE:M0;CLIN_T_STAGE:T1;PERINEURAL_INVASION:NO;ANGIOLYMPHATIC_INVASION:YES;CLIN_N_STAGE:N1;PATH_MARGIN:Close;ALCOHOL_HISTORY_DOCUMENTED:NO;HPV_STATUS_P16:Positive;LYMPH_NODE_DISSECTION_METHOD:Modified Radical Neck Dissection;LYMPH_NODE_NECK_DISSECTION_INDICATOR:YES"
"HEAD AND NECK CANCER" "CANCER_TYPE_DETAILED:Oral Cavity Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OCSC;TMB_NONSYNONYMOUS:9.1;SEX:Female;FRACTION_GENOME_ALTERED:0.1756;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, oral;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:157.1906164;GENOME_DOUBLINGS:0;DOUBLING_TIME:142.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM + 10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:oral;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:BICR 56;SITE_SUBTYPE1:mouth;SITE_SUBTYPE2:tongue;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM GLUTAMINE+0.4UG/ML HYDROCORTISONE;TYPE_REFINED:upper_aerodigestive"
"HEAD AND NECK CANCER, NOS" "CANCER_TYPE_DETAILED:Head and Neck;CANCER_TYPE:Head and Neck Cancer, NOS;ONCOTREE_CODE:HEAD_NECK;TMB_NONSYNONYMOUS:1.33333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:33;FRACTION_GENOME_ALTERED:0.0042;SAMPLE_TYPE:Metastasis;RACE:Hispanic;PRIMARY_SITE:Mandible;ANALYSIS_COHORT:SECR;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:86"
"HEAD AND NECK CARCINOMA" "CANCER_TYPE_DETAILED:Head and Neck Carcinoma, Other;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OHNCA;TMB_NONSYNONYMOUS:12.8;SUBTYPE:Carcinoma, gingival;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:gingival;LINEAGE_SUBTYPE:upper_aerodigestive_carcinoma;TYPE_REFINED:upper_aerodigestive"
"HEAD AND NECK CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Head and Neck Carcinoma Other;CANCER_TYPE:Head and Neck Carcinoma;TMB_NONSYNONYMOUS:0.0333333333333;SEX:Male;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1043;DIAGNOSIS AGE:19;GDNA(NG):3594;SMOKE STATUS:Nonsmoker;TUMOR_PURTITY:30"
"HEAD AND NECK CARCINOMA, OTHER" "CANCER_TYPE_DETAILED:Head and Neck Carcinoma, Other;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OHNCA;TMB_NONSYNONYMOUS:12.8;SUBTYPE:Carcinoma, gingival;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:gingival;LINEAGE_SUBTYPE:upper_aerodigestive_carcinoma;TYPE_REFINED:upper_aerodigestive"
"HEAD AND NECK MUCOSAL MELANOMA" "CANCER_TYPE_DETAILED:Head and Neck Mucosal Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:HNMUCM;TMB_NONSYNONYMOUS:9.03333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.1861;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Sinus;ANALYSIS_COHORT:SKCM;BIOPSY_SITE:Cheek;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:48"
"HEAD AND NECK NEUROENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Head and Neck Neuroendocrine Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNNE;TMB_NONSYNONYMOUS:2.43333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:66;FRACTION_GENOME_ALTERED:0.6323;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Larynx;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Abdom. Mass;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:15"
"HEAD AND NECK SQUAMOUS" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:338.633333333;SEX:Male;FRACTION_GENOME_ALTERED:0.7090;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:212.3890798;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:BICR 18;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:larynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"HEAD AND NECK SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:338.633333333;SEX:Male;FRACTION_GENOME_ALTERED:0.7090;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:212.3890798;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:BICR 18;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:larynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"HEAD AND NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma of Unknown Primary;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSCUP;TMB_NONSYNONYMOUS:11.7446363714;SOMATIC_STATUS:Matched;SEX:Female;AGE:48.0;FRACTION_GENOME_ALTERED:0.4034;SAMPLE_TYPE:Metastasis;OS_MONTHS:28.0;OS_STATUS:1:DECEASED;RACE:White;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lymph Node;TUMOR_PURITY:30;SAMPLE_COVERAGE:890;VITAL_STATUS:DOD;SMOKING_HISTORY:Current;PARTC_CONSENTED_12_245:NO;HPV_STATUS:Positive;ALCOHOL_HISTORY_DOCUMENTED:Never;SITE_OF_RECURRENCE:Distant, Regional (lymph nodes and neck skin), Distant;AGENT:BKM120 + Carboplatin + Paclitaxel;DISEASE_EXTENT:Locoregional & Distant;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:yes;DISTANT_METS:Yes;SMOKING:Smoking Pack:35;TNM:TxN2cMX;CLINICAL_TRIAL:10-192;DETAILED_METASTATIC_SITE:Lymph Node;DETAILED_PRIMARY_SITE:Unknown Primary;INITIAL_TREATMENT:Chemoradiation;SITE_SEQUENCED:Regional recurrence;PRIOR_TX_TO_IMPACT_SAMPLE:RT, Chemo, & Cetuximab;TOBACCO_TYPE:Cigarettes;VAR_12_245:Clinical"
"HEAD AND NECK SQUAMOUS CELL CARCINOMA" NA
"HEAD_NECK_CANCER" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:7.33333333333;SEX:Male;AGE:25;FRACTION_GENOME_ALTERED:0.4181;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:80.66946436;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:head_neck_cancer;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:SCC-9;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:mouth;SITE_SUBTYPE2:tongue;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"HEMANGIOBLASTOMA" "CANCER_TYPE_DETAILED:cervicomedullary Hemangioblastoma;CANCER_TYPE:Other;SEX:Female;AGE:17.8836422;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:6"
"HEMANGIOMA" "CANCER_TYPE_DETAILED:HEMANGIOMA;CANCER_TYPE:Sarcoma;SEX:Female;AGE:23.71252632;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"HEMANGIOPERICYTOMA OF THE CENTRAL NERVOUS SYSTEM" "CANCER_TYPE_DETAILED:Hemangiopericytoma of the Central Nervous System;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:HPCCNS;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0012;SAMPLE_TYPE:Primary;OS_MONTHS:23.73;OS_STATUS:1:DECEASED;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:756;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:165.6"
"HEPATOBILIARY CANCER" "CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:2.866666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;FRACTION_GENOME_ALTERED:0.2021;SAMPLE_TYPE:Primary;OS_MONTHS:14.62;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:8.71;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/2/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; intrahepatic;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:510;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVA.4C9A220D-03E9-41CF-8FA9-4B7FD05A625A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:480;WEIGHT:92;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T2b;ECOG_SCORE:1;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;AFP_AT_PROCUREMENT:5.4;FAMILY_HISTORY_OF_CANCER:NO;ISHAK_FIBROSIS_SCORE:1,2 - Portal Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:0.5;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;AFP_NORM_RANGE_LOWER:0;AFP_NORM_RANGE_UPPER:10;DEFINITIVE_SURGICAL_PROCEDURE:Segmentectomy, Single;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Diabetes mellitus|Smoking;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400"
"HEPATOBLASTOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:25.0;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.1396;SAMPLE_TYPE:Primary;OS_MONTHS:59.26;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:G2;ICD_O_3_SITE:C67.3;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.3;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/27/11;GRADE:High Grade;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:597;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-G2-A2EO.AB5DCF8B-A35D-4B20-A108-AB443795D3F3.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:350;WEIGHT:89.2;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3a;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:NO;ECOG_SCORE:1;KARNOFSKY_PERFORMANCE_SCORE:90;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:182;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;METASTATIC_SITE_PATIENT:None;FAMILY_HISTORY_CANCER_RELATIONSHIP:Mother|[Not Available];FAMILY_HISTORY_CANCER_TYPE:Liver-Hepatoblastoma|Adrenal Cortical Tumor;OCCUPATION_PRIMARY:Computer Analyst;OCCUPATION_CURRENT:Retired Computer Analyst"
"HEPATOCELLULAR ADENOMA" "CANCER_TYPE_DETAILED:Hepatocellular Adenoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:LIAD;TMB_NONSYNONYMOUS:1.1091553006;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.0002;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;SAMPLE_ORIGIN:Frozen"
"HEPATOCELLULAR CARCINOMA" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:11.0516129111;SEX:Male;FRACTION_GENOME_ALTERED:0.7311;PRIMARY_SITE:Liver;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Liver;HISTOLOGICAL_SUBTYPE:Hepatocellular_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Solid"
"HEPATOCELLULAR_CANCER" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:10.3666666667;SEX:Male;AGE:52;FRACTION_GENOME_ALTERED:0.7226;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Liver;SUBTYPE:Hepatocellular Carcinoma;TUMOR_TYPE:liver;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:153.5990748;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:korea;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:hepatocellular_cancer;HIST_SUBTYPE1:hepatocellular_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:liver;LINEAGE_SUBTYPE:hepatocellular_carcinoma;NAME:SNU-449;PATHOLOGIST_ANNOTATION:Liver:HCC;PROTEOMICS_TMT_LABEL:130c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:liver"
"HEPATOCELLULAR_CARCINOMA" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:11.0516129111;SEX:Male;FRACTION_GENOME_ALTERED:0.7311;PRIMARY_SITE:Liver;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Liver;HISTOLOGICAL_SUBTYPE:Hepatocellular_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Solid"
"HEPATOCHOLANGIOCARCINOMA MIXED" NA
"HEPTOCELLULAR CARCINOMA" NA
"HER2" "CANCER_TYPE_DETAILED:Adenoid Cystic Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ACBC;TMB_NONSYNONYMOUS:0.366666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;SAMPLE_TYPE:Primary;PRIMARY_SITE:Breast;RADIATION_THERAPY:Not performed;VITAL_STATUS:Alive;PLATFORM:WES;TUMOR_STAGE:II;TUMOR_SIZE:40;STUDY:ACbC (MSKCC/Breast 2015);FUSION_STATUS:YES;GENOMIC_ALTERATIONS:15;IHC_HER2:Negative;OVERALL_PATIENT_HISTOLOGY:Cribriform/Tubular;METASTATIC_TUMOR_INDICATOR:No;MYB_MYBL1_FUSION:MYB-NFIB Fusion;ADJUVANT_CHEMO:Not performed;ADJUVANT_TX:Not performed;MYB_NFIB_FISH:Negative;TYPE_OF_SURGERY:Breast Conservation/Mastectomy;ER_STATUS_BY_IHC:Negative;NEOADJUVANT_CHEMO:Not performed;PR_STATUS_BY_IHC:Negative;LOCAL_REGIONAL_RECURRENCE:Positive;MYB_NFIB_REARRANGEMENT:MYB Exon 14-NFIB Exon 9;FOLLOWUP_YEARS:8;MYB_NFIB_CNA:9q13-q34.2 loss"
"HER2-ENRICHED" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:5.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:89.0;FRACTION_GENOME_ALTERED:0.5383;SAMPLE_TYPE:Primary;OS_MONTHS:9.99;OS_STATUS:1:DECEASED;TUMOR_STAGE:T3;ER_STATUS:Positive;HER2_STATUS:Negative;METHYLATION_CLUSTER:4;PR_STATUS:Negative;METASTASIS:M0;RPPA_CLUSTER:X;MIRNA_CLUSTER:1;PAM50_SUBTYPE:HER2-enriched;CN_CLUSTER:1;CONVERTED_STAGE:Stage IIIA;INTEGRATED_CLUSTERS_NO_EXP:5;INTEGRATED_CLUSTERS_UNSUP_EXP:2;INTEGRATED_CLUSTERS_WITH_PAM50:1;METASTASIS_CODED:Negative;NODE_CODED:Positive;NODES:N2;SIGCLUST_INTRINSIC_MRNA:-2;SIGCLUST_UNSUPERVISED_MRNA:-6;SURVIVAL_DATA_FORM:enrollment;TUMOR_T1_CODED:T_Other"
"HGGNOS" "CANCER_TYPE_DETAILED:High-Grade Glioma, NOS;CANCER_TYPE:Glioma;ONCOTREE_CODE:HGGNOS;TMB_NONSYNONYMOUS:9.4;FRACTION_GENOME_ALTERED:0.7080;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Glioma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;MUTATION_RATE:157.8096027;DOUBLING_TIME:63;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:Garraway Lab;CHARACTERISTICS:Mix;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+ 5% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUBTYPE:glioma;NAME:SF268;PATHOLOGIST_ANNOTATION:CNS:Glioma_HighGrade;SITE_SUBTYPE1:brain;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:glioma"
"HGS" "CANCER_TYPE_DETAILED:High-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:HGSOC;TMB_NONSYNONYMOUS:12.1333333333;SEX:Female;AGE:44;FRACTION_GENOME_ALTERED:0.7144;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:160.5655743;GENOME_DOUBLINGS:0;DOUBLING_TIME:127.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM:F12 + 10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOS-4;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1 mM NEAA;TYPE_REFINED:ovary"
"HGSOC" "CANCER_TYPE_DETAILED:High-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:HGSOC;TMB_NONSYNONYMOUS:12.1333333333;SEX:Female;AGE:44;FRACTION_GENOME_ALTERED:0.7144;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:160.5655743;GENOME_DOUBLINGS:0;DOUBLING_TIME:127.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM:F12 + 10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOS-4;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1 mM NEAA;TYPE_REFINED:ovary"
"HIGH-GRADE B-CELL LYMPHOMA, NOS" "CANCER_TYPE_DETAILED:High-Grade B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:HGBCL;TMB_NONSYNONYMOUS:0.233333333333;FRACTION_GENOME_ALTERED:0.0994;SAMPLE_TYPE:Primary;INSTITUTE:BWH;SPECIMEN_PRESERVATION_TYPE:FFPE;MOLECULAR_SUBTYPE:mBL"
"HIGH-GRADE B-CELL LYMPHOMA, WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS" "CANCER_TYPE_DETAILED:High-Grade B-Cell Lymphoma, with MYC and BCL2 and/or BCL6 Rearrangements;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:HGBCLMYCBCL2;TMB_NONSYNONYMOUS:0.466666666667;FRACTION_GENOME_ALTERED:0.1697;SAMPLE_TYPE:Primary;INSTITUTE:BWH;SPECIMEN_PRESERVATION_TYPE:FFPE;MOLECULAR_SUBTYPE:non-mBL"
"HIGH-GRADE GLIOMA, NOS" "CANCER_TYPE_DETAILED:High-Grade Glioma, NOS;CANCER_TYPE:Glioma;ONCOTREE_CODE:HGGNOS;TMB_NONSYNONYMOUS:9.4;FRACTION_GENOME_ALTERED:0.7080;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Glioma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;MUTATION_RATE:157.8096027;DOUBLING_TIME:63;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:Garraway Lab;CHARACTERISTICS:Mix;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+ 5% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUBTYPE:glioma;NAME:SF268;PATHOLOGIST_ANNOTATION:CNS:Glioma_HighGrade;SITE_SUBTYPE1:brain;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:glioma"
"HIGH-GRADE NEUROENDOCRINE CARCINOMA OF THE COLON AND RECTUM" "TMB_NONSYNONYMOUS:0.533333333333;GENE_PANEL:MSK-ACCESS;TUMOR_TYPE:High-Grade Neuroendocrine Carcinoma of the Colon and Rectum;RECIST_RESPONSE:3.057;MONTHS_ON_TREATMENT:0.7;OVERALL_RESPONSE:PD;TIMEPOINT:Baseline;ACCESS:TRUE;ACCESS_TIMEPOINTS:TRUE;ALT_TYPE:Fusion;EXOME_DATA:FALSE;IMPACT_DATA:FALSE;ONCOTREE_PATIENT:HGNEC;ONGOING_STATUS:FALSE;PFS:3;PRIOR_LINES:5;PRIOR_MKI:FALSE;RET_AF:0.213;RET_ALT:TAF3-RET;SOURCE_TYPE:Plasma;WEEKS_ON_TREATMENT:3"
"HIGH-GRADE SEROUS FALLOPIAN TUBE CANCER" NA
"HIGH-GRADE SEROUS OVARIAN CANCER" "CANCER_TYPE_DETAILED:High-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:HGSOC;TMB_NONSYNONYMOUS:12.1333333333;SEX:Female;AGE:44;FRACTION_GENOME_ALTERED:0.7144;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:160.5655743;GENOME_DOUBLINGS:0;DOUBLING_TIME:127.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM:F12 + 10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOS-4;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1 mM NEAA;TYPE_REFINED:ovary"
"HIGH_GRADE_SEROUS" "CANCER_TYPE_DETAILED:High-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:HGSOC;TMB_NONSYNONYMOUS:12.1333333333;SEX:Female;AGE:44;FRACTION_GENOME_ALTERED:0.7144;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:160.5655743;GENOME_DOUBLINGS:0;DOUBLING_TIME:127.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM:F12 + 10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOS-4;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1 mM NEAA;TYPE_REFINED:ovary"
"HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS" "CANCER_TYPE_DETAILED:Histiocytic and Dendritic Cell Neoplasms;CANCER_TYPE:Histiocytosis;ONCOTREE_CODE:HDCN;TMB_NONSYNONYMOUS:0.233333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:63.3;PFS_MONTHS:1.58;PFS_STATUS:1:Progressed;VITAL_STATUS:0;PLATFORM:WXS;PATIENT_DISPLAY_NAME:PATIENT-COBI-1;TOTAL_MUTATIONS:1;RECIST_RESPONSE:NE;IMMUNOSUPPRESSION:1;ECOG_STATUS:3;MAPK_PATHWAY_ALTERATION:ARAF S225V;OFF_STUDY_REASON:Death;DISEASE_AT_DIAGNOSIS:ECD;DOSE_REDUCTION:0;DOT_MONTHS:1.58;EVALUABLE_FOR_PET:0;EVALUABLE_FOR_RECIST:0;INTERFERON_ALPHA:1;KINASE_INHIBITOR:0;NERVOUS_SYSTEM_INVOLVEMENT:0;ON_STUDY:0;ON_TREATMENT:0;PATIENT_ASSAYS:WES, TES;PERCENT_CHANGE_BY_PET:0.0;PET_BEST_RESPONSE:NE;PRIOR_SYSTEMIC_THERAPIES:2"
"HISTIOCYTIC DENDRITIC CELL SARCOMA" "CANCER_TYPE_DETAILED:Histiocytic Dendritic Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:HDCS;TMB_NONSYNONYMOUS:8.808477279;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0010;SAMPLE_TYPE:Primary;OS_MONTHS:16.37;OS_STATUS:0:LIVING;PRIMARY_SITE:Lymph Node;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:824;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:DNA;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"HISTIOCYTIC SARCOMA" "CANCER_TYPE_DETAILED:Histiocytic Sarcoma;CANCER_TYPE:Histiocytosis;TMB_NONSYNONYMOUS:2.93615909284;SOMATIC_STATUS:Unmatched;SEX:Male;SPECIMEN_PRESERVATION_TYPE:FFPE;PLATFORM:IMPACT410;PATIENT_DISPLAY_NAME:P-0003533;SAMPLE_DISPLAY_NAME:P-0003533-T03-IM5"
"HISTIOCYTIC_LYMPHOMA" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:10.2;SEX:Male;AGE:37;FRACTION_GENOME_ALTERED:0.8617;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Acute Myelogenous Leukemia (AML);TUMOR_TYPE:lymphoma_DLBCL;HISTOLOGY:Lymphoid_Neoplasm;PURITY:0.99;MUTATION_RATE:125.2330331;GENOME_DOUBLINGS:1;DOUBLING_TIME:115.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:histiocytic_lymphoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640 + 10% FBS;HIST_SUBTYPE1:diffuse_large_B_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:blood;LINEAGE_SUBTYPE:AML;NAME:U-937;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:AML"
"HNSC" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:338.633333333;SEX:Male;FRACTION_GENOME_ALTERED:0.7090;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:212.3890798;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:BICR 18;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:larynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"HODGKIN LYMPHOMA" "CANCER_TYPE_DETAILED:Angiosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ANGS;TMB_NONSYNONYMOUS:4.8;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.5401;RACE:WHITE;PRIMARY_SITE_PATIENT:BONELIMB;SAMPLE_TIMEPOINT:ASCProject_7bt2t8IJ_T3;TMB:5.519764283;BX_LOCATION:NECK;BX_TIME_DAYS:2394;BX_TYPE:RESECTION;AGE_AT_DIAGNOSIS_GROUP:36-40;PRD_HISPANIC:NO;PRD_OTHER_CANCER:YES;PRD_TREATED_AT_ENROLLMENT:YES;BX_NUCLEAR_GRADE:HIGH;BX_SPINDLE_CELL:YES;BX_VASOFORMATIVE:YES;DX_BIOPSY_LOCATION:BONELIMB;PRD_DIAGNOSIS_LOC:HEADFACENECK;PRD_EVER_LOCATION:HEADFACENECK,LIVER,BONELIMB,CHEST;PRD_LOCATION_AT_ENROLLMENT:HEADFACENECK,LIVER,BONELIMB;PRD_OTHER_CANCER_LIST:HODGKIN LYMPHOMA,SQUAMOUS CELL CARCINOMA OF THE SKIN,BREAST CANCER;PRD_OTHER_CANCER_RADIATION:NO;PRD_RADIATION:NO;PRD_RADIATION_SURGERY:NONE;PRD_SURGERY:YES;PRD_SURGERY_CLEAN_MARGINS:NO;PRIMARY_SITE_NOTES:TRAPEZIUS MUSCLE"
"HODGKINS" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:0.36;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:21.6;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:5;TP53_MUTATION:p.P19H; MAF 8.9%;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q2;PB_BLAST_PERCENTAGE:14;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:60;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Lenalidomide|Decitabine;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:Yes;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_MONOCYTES_PERCENTAGE:7;PRIOR_CANCER:Non-Hodgkins Lymphoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry."
"HODGKIN_LYMPHOMA" "CANCER_TYPE_DETAILED:Hodgkin Lymphoma;CANCER_TYPE:Hodgkin Lymphoma;ONCOTREE_CODE:HL;TMB_NONSYNONYMOUS:4.53116129354;SEX:Male;FRACTION_GENOME_ALTERED:0.2450;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Hodgkin;HISTOLOGICAL_SUBTYPE:Hodgkin_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"HURTHLE" "CANCER_TYPE_DETAILED:Hurthle Cell Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THHC;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.9979;SAMPLE_TYPE:Primary;OS_MONTHS:26.1;OS_STATUS:0:LIVING;PRIMARY_SITE:Thyroid;SAMPLE_CLASS:Tumor;TUMOR_PURITY:80;SAMPLE_COVERAGE:1064;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"HURTHLE CELL THYROID CANCER" "CANCER_TYPE_DETAILED:Hurthle Cell Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THHC;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.9979;SAMPLE_TYPE:Primary;OS_MONTHS:26.1;OS_STATUS:0:LIVING;PRIMARY_SITE:Thyroid;SAMPLE_CLASS:Tumor;TUMOR_PURITY:80;SAMPLE_COVERAGE:1064;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"HYPERMUTATED" "CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:33.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:78;FRACTION_GENOME_ALTERED:0.0515;OS_MONTHS:31;OS_STATUS:0:LIVING;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:32;PRIMARY_SITE:Hepatix Flexure;STAGE:Stage III;TUMOR_SITE:Hepatix Flexure;HISTOLOGY:Mucinous;MSI_STATUS:MSI-H;MUTATION_RATE:39.7667;SEQUENCED:1;MRNA_DATA:1;METHYLATION_STATUS:0;COPY_NUMBER:1;INTEGRATED_PHENOTYPE:Hypermutated;MICRORNA_DATA:1;MUTATION_PHENOTYPE:MSI-H;PATHOLOGY_N_STAGE:N2a;PATHOLOGY_STATUS:Malignant;PATHOLOGY_T_STAGE:T3;PHOSPHOPROTEIN:1;POLYPS_HISTORY:Yes;POLYPS_PRESENT:No;PROTEIN:1;SPECIMEN_PRESERVATION:Frozen Tissue"
"HYPOPHARYNGEAL" "CANCER_TYPE_DETAILED:Hypopharynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HPHSC;TMB_NONSYNONYMOUS:7.73333333333;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, hypopharyngeal;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;MUTATION_RATE:148.1733319;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:hypopharyngeal;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:SNU-1041;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:pharynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"HYPOPHARYNX SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Hypopharynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HPHSC;TMB_NONSYNONYMOUS:7.73333333333;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, hypopharyngeal;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;MUTATION_RATE:148.1733319;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:hypopharyngeal;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:SNU-1041;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:pharynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"IDC" "CANCER_TYPE_DETAILED:Infiltrating Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:2.53333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;GRADE:III;SUBTYPE:HER2;STAGE:III;PURITY:0.27;ER_STATUS:Negative;PR_STATUS:Negative;MENOPAUSE_STATUS:Premenopausal;HER2_AMPLIFICATION_STATUS:Yes;SILENT_RATE:0.72;NONSILENT_RATE:2.62"
"IMMATURE TERATOMA" "CANCER_TYPE_DETAILED:Immature Teratoma;CANCER_TYPE:Ovarian Germ Cell Tumor;ONCOTREE_CODE:OIMT;TMB_NONSYNONYMOUS:2.1;SEX:Female;OS_MONTHS:61;OS_STATUS:0:LIVING;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:9;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Peritoneum;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Germ cell;GMED_OS_MONTHS:52;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"IMMUNOBLASTIC" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:3.93333333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:4.8296;OS_STATUS:1:DECEASED;PFS_MONTHS:4.8296;PFS_STATUS:1:Progressed;AGE_AT_DIAGNOSIS:61.0;COHORT:RICOVER;MEAN_TARGET_COVERAGE_TUMOR:108.7;PURITY_ABSOLUTE:0.4;SAMPLE_COLLECTION_SOURCE:FFPE;IPI:5.0;NUM_NONSILENT_MUTATION:118;TESTICULAR_INVOLVEMENT:No;DRIVER_MUTATIONS:5;IPI_AGE:1.0;IPI_ECOG:1.0;IPI_LDH:1.0;MORPHOLOGY_SUBTYPE:Immunoblastic;NONSILENT_MUTATION_DENSITY:3.758421;NUM_SILENT_MUTATION:28;TOTAL_CNA:54;ANY_COO:Unclassified;CLUSTER:2;CNS_INVOLVEMENT:No;COO_LYMPH2CX:Unclassified;DBSNP_MUTATION_DENSITY:0.35;DRIVER_MUTATION_DENSITY:0.159;IPI_EXBM:1.0;IPI_STAGE:1.0;MUTATION_DENSITY:4.65025;NUM_DBSNP_MUTATIONS:11;NUM_DRIVER_SCNA:20;NUM_DRIVER_SV:1;R_CHOP_LIKE_CHEMO:Yes;SILENT_MUTATION_DENSITY:0.892;TOTAL_REARRANGEMENT:1;TUMOR_IN_NORMAL_ESTIMATE:0.005"
"INFANTILE FIBROSARCOMA" "CANCER_TYPE_DETAILED:Fibrosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:FIBS;TMB_NONSYNONYMOUS:0.2;SEX:Female;AGE:1;FRACTION_GENOME_ALTERED:0.0790;PFS_STATUS:Yes;RADIATION_THERAPY:Unknown/NA;STAGE:Unknown;RFS_STATUS:Yes;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Unknown;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Infantile Fibrosarcoma;DOB_LASTFU_TIME_YRS:3;DOB_PROG_START_TIME_YRS:1;DOB_PROG_TIME_YRS:1;DOB_RECUR_TIME_YRS:1;DOB_REPORT_TIME_YRS:1;DOB_TISSUE_TIME_YRS:1;LINE_OBR_CHEMO:SD;LINE_OBR_CHEMO_G:No-Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:SD;LINE_OBR_NOTRK_G:No-Response;LINE_OBR_NTRK:CR;LINE_OBR_NTRK_G:Response;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:PD;LINE1_BR_NOTRK_G:No-Response;NUM_LINES:5;NUM_LINES_CHEMO:4;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:1;NUM_LINES_TARGETED:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:Archer;PROG_DEATH:No;PROG_DEATH_TIME_YRS:1;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:1"
"INFANTILE MYOFIBROMA" "CANCER_TYPE_DETAILED:Infantile Myofibroma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:0.810403824;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"INFANTILE SARCOMA" "CANCER_TYPE_DETAILED:Infantile Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Female;FRACTION_GENOME_ALTERED:0.0790;SAMPLE_TYPE:Metastasis;OS_MONTHS:6.378;OS_STATUS:0:LIVING;RACE:NO VALUE ENTERED;ETHNICITY:Unknown whether Spanish or not;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT410;TUMOR_PURITY:40;MSI_SCORE:0.22;MSI_TYPE:Do not report;SAMPLE_COVERAGE:794;PURITY:0.436840784;CVR_TMB_SCORE:5.9;AGE_AT_SEQ_REPORT:2;DETAILED_PRIMARY_SITE:Soft Tissue;FACETS:YES;FRACTION_CNA:0.219465272;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.079"
"INFILTRATING CARCINOMA NOS" "CANCER_TYPE_DETAILED:Breast Invasive Carcinoma, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCNOS;TMB_NONSYNONYMOUS:4.666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.5955;SAMPLE_TYPE:Primary;OS_MONTHS:12.09;OS_STATUS:0:LIVING;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.09;TISSUE_SOURCE_SITE:A7;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8010/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/14/13;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Infiltrating Carcinoma NOS;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:154;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A7-A5ZV.FA5CF5A2-F44A-4303-9200-32250FAEF374.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:940;SITE_OF_TUMOR_TISSUE:Breast;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Equivocal;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;HER2_IHC_SCORE:2;ER_STATUS_BY_IHC:Negative;HER2_FISH_STATUS:Negative;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Sentinel node biopsy alone;CENT17_COPY_NUMBER:2.5;HER2_CENT17_RATIO:1.5;HER2_COPY_NUMBER:3.8;HER2_FISH_METHOD:PathVysion HER-2 DNA Probe Kit;MICROMET_DETECTION_BY_IHC:NO;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"INFILTRATING DUCTAL & LOBULAR" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:1.533333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.8633;SAMPLE_TYPE:Primary;OS_MONTHS:37.19;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:37.19;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/4/10;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIC;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2006;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1266;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A0BA.142F03FE-5B60-416D-8DCD-EC34DB5495DB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:360;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N3a;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Infiltrating ductal & lobular;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left Upper Inner Quadrant|Left Upper Outer Quadrant|Left Lower Inner Quadrant|Left Lower Outer Quadrant|Left;IHC_HER2:Negative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);PATH_MARGIN:Negative;HER2_IHC_SCORE:1;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel lymph node biopsy plus axillary dissection;ER_STATUS_IHC_PERCENT_POSITIVE:80-89%;IHC_SCORE:3;MICROMET_DETECTION_BY_IHC:NO;PR_POSITIVITY_IHC_INTENSITY_SCORE:1+;PR_STATUS_IHC_PERCENT_POSITIVE:40-49%;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"INFILTRATING DUCTAL AND LOBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:2.466666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.3875;SAMPLE_TYPE:Primary;OS_MONTHS:36.53;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:36.53;TISSUE_SOURCE_SITE:E9;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/23/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:42;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-E9-A1NA.595BB256-2F3D-493A-AA90-022BE0CC995F.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:110;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;HISTOLOGICAL_SUBTYPE:Infiltrating ductal and lobular carcinoma;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;PRIMARY_SITE_PATIENT:Left Lower Outer Quadrant;IHC_HER2:Positive;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);METASTATIC_TUMOR_INDICATOR:NO;PATH_MARGIN:Negative;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Axillary lymph node dissection alone;MICROMET_DETECTION_BY_IHC:YES"
"INFILTRATING DUCTAL CARCINOMA" "CANCER_TYPE_DETAILED:Infiltrating Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:2.53333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;GRADE:III;SUBTYPE:HER2;STAGE:III;PURITY:0.27;ER_STATUS:Negative;PR_STATUS:Negative;MENOPAUSE_STATUS:Premenopausal;HER2_AMPLIFICATION_STATUS:Yes;SILENT_RATE:0.72;NONSILENT_RATE:2.62"
"INFILTRATING LOBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Infiltrating Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ILC;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Female;AGE:59;SUBTYPE:Luminal A;STAGE:II;PURITY:0.3;ER_STATUS:Positive;HER2_STATUS:Negative;PR_STATUS:Positive;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.2;NONSILENT_RATE:0.65"
"INFILTRATING TUBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Infiltrating Tubular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:0.933333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:54;GRADE:I;SUBTYPE:Luminal A;STAGE:III;PURITY:0.44;ER_STATUS:Positive;HER2_STATUS:Negative;PR_STATUS:Positive;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.51;NONSILENT_RATE:0.95"
"INFLAMMATORY BREAST CANCER" "CANCER_TYPE_DETAILED:Inflammatory Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IBC;TMB_NONSYNONYMOUS:1.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.4268;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Breast;ANALYSIS_COHORT:BRCA;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:79"
"INFLAMMATORY MYOFIBROBLASTIC LUNG TUMOR" "CANCER_TYPE_DETAILED:Inflammatory Myofibroblastic Lung Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:IMTL;TMB_NONSYNONYMOUS:0;SEX:Male;AGE:3;PFS_STATUS:Unknown/NA;RADIATION_THERAPY:No;STAGE:Unknown;RFS_STATUS:No;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:Unknown/NA;ANY_LINE_HORMONE:Unknown/NA;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Unknown/NA;ANY_LINE_TARGETED:Unknown/NA;ANY_SYSTX:No;CANCER_TYPE_HISTOLOGY:Inflammatory Myofibroblastic Tumor;DOB_LASTFU_TIME_YRS:4;DOB_RECUR_START_TIME_YRS:3;DOB_REPORT_TIME_YRS:3;DOB_TISSUE_TIME_YRS:3;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Negative;POS_METHOD:Archer;PROG_DEATH:Unknown/NA;PROG_EVAL_C:No;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:0"
"INFLAMMATORY MYOFIBROBLASTIC TUMOR" "CANCER_TYPE_DETAILED:Inflammatory myofibroblastic tumor;CANCER_TYPE:Soft Tissue Tumor;ONCOTREE_CODE:IMT;TMB_NONSYNONYMOUS:0.733333333333;SEX:Female;OS_MONTHS:86;OS_STATUS:0:LIVING;PRIMARY_SITE:Liver;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:9;SAMPLE_TIMEPOINT:Refractory;TISSUE_SEQUENCED:Hepatic artery;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:12.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:77;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"INITIAL CNS TUMOR" "CANCER_TYPE_DETAILED:Atypical Teratoid/Rhabdoid Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ATRT;SEX:Male;AGE:2;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6;TUMOR_TISSUE_SITE:Frontal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1038;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_STOP:1163;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1471;AGE_AT_RADIATION_START:1183;AGE_AT_RADIATION_STOP:1225;AGE_AT_SPECIMEN_DIAGNOSIS:1038;CANCER_PREDISPOSITIONS:None documented;CHEMOTHERAPY_AGENTS:Not Reported;CHEMOTHERAPY_TYPE:Treatment follows a protocol and subject is enrolled on a protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:5400 cGy;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;FORMULATION:Not Reported;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Atypical Teratoid Rhabdoid Tumor (ATRT);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:SJYC07;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Supratentorial;UPDATED_GRADE:IV"
"INITIAL CNS TUMOR FIRST HGG RECORD" NA
"INITIAL CNS TUMOR LAST INITIAL" NA
"INITIAL CNS TUMOR NEW LOCATION" NA
"INTESTINAL TYPE MUCINOUS CARCINOMA" "CANCER_TYPE_DETAILED:Intestinal Type Mucinous Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:ICEMU;TMB_NONSYNONYMOUS:7.829757581;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0907;SAMPLE_TYPE:Metastasis;OS_MONTHS:13.54;OS_STATUS:0:LIVING;PRIMARY_SITE:Cervix;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Diaphragm;TUMOR_PURITY:30;SAMPLE_COVERAGE:968;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"INTESTINAL TYPE STOMACH ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Intestinal Type Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ISTAD;TMB_NONSYNONYMOUS:61.1666666667;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.1480;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:387.6541767;GENOME_DOUBLINGS:0;DOUBLING_TIME:40.2;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSRRB;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM +10%FBS;HIST_SUBTYPE1:intestinal_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:IM95;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;PROTEOMICS_TMT_LABEL:128n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:10mg/L insulin;TYPE_REFINED:stomach"
"INTESTINAL_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:21.8821935639;SEX:Male;FRACTION_GENOME_ALTERED:0.1475;PRIMARY_SITE:Stomach;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Stomach;HISTOLOGICAL_SUBTYPE:Intestinal_Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Solid"
"INTIMAL SARCOMA" "CANCER_TYPE_DETAILED:Intimal Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Male;FRACTION_GENOME_ALTERED:0.1051;SAMPLE_TYPE:Metastasis;OS_MONTHS:77.983;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT341;TUMOR_PURITY:50;MSI_SCORE:4.42;MSI_TYPE:Indeterminate;SAMPLE_COVERAGE:297;PURITY:0.404247419;CVR_TMB_SCORE:1.1;AGE_AT_SEQ_REPORT:43;DETAILED_PRIMARY_SITE:Blood Vessel;FACETS:YES;FRACTION_CNA:0.672020508;FACETS_REVIEW:YES;FACETS_WGD:TRUE;FGA_REPORTED:0.1051"
"INTRACHOLECYSTIC PAPILLARY NEOPLASM" "CANCER_TYPE_DETAILED:Intracholecystic Papillary Neoplasm;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:ICPN;TMB_NONSYNONYMOUS:2.066666667;SEX:Female;AGE:65;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;ICD_10:C22.1;STAGE:III;HISTOLOGY:Papillary adenocarcinoma, NOS;PURITY:0.477;PROJECT_CODE:BTCA-SG;WGD:no_wgd;SEQUENCING_TYPE:WGS;ORGAN_SYSTEM:GALLBLADDER & EXTRAHEPATIC BILE DUCTS;ANCESTRY_PRIMARY:ASN;HISTOLOGY_ABBREVIATION:Biliary-AdenoCA;HISTOLOGY_TIER1:ENDODERM;HISTOLOGY_TIER2:Biliary;HISTOLOGY_TIER3:Adenocarcinoma;HISTOLOGY_TIER4:Cholangiocarcinoma, papillary;PURITY_CONFUGURATION:0.007;TUMOR_SAMPLE_HISTOLOGY_CODE:8260/3"
"INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM" "CANCER_TYPE_DETAILED:Intraductal Papillary Mucinous Neoplasm;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:IPMN;SEX:Female;AGE:55.55920792;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:3rd tertile;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:Yes;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:3rd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:2nd tertile;TERT_PLATINUM_TX:2nd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:1022;TIME_TO_BLOOD_DRAW_FROM_TX:963;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:Yes"
"INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM WITH AN ASSOCIATED INVASIVE CARCINOMA" "CANCER_TYPE_DETAILED:Intraductal Papillary Mucinous Neoplasm with an associated Invasive Carcinoma;CANCER_TYPE:Pancreatic Cancer;TMB_NONSYNONYMOUS:0.133333333333;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1291;DIAGNOSIS AGE:58;GDNA(NG):3768;SMOKE STATUS:Unknown;TUMOR_PURTITY:25"
"INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM WITH INVASION" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:79;ETHNICITY:White/Caucasian;SAMPLE_CLASS:Cell line;AJCC_PATHOLOGIC_TUMOR_STAGE:IIB;HISTOLOGICAL_SUBTYPE:Intraductal Papillary Mucinous Neoplasm with invasion;SMOKER:Stopped Smoking;TUMOR_GRADE:3 - Poorly differentiated;STATUS:DOD;LOCATION:Head"
"INTRADUCTAL TUBULOPAPILLARY NEOPLASM" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;SOMATIC_STATUS:Matched;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.3951;SAMPLE_TYPE:Primary;OS_MONTHS:32.13;OS_STATUS:0:LIVING;RACE:ASIAN;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:11.37;TISSUE_SOURCE_SITE:HV;ICD_O_3_SITE:C25.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C25.0;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/3/14;GRADE:GX;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Pancreas-Adenocarcinoma-Other Subtype;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:453;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-HV-A7OP.9CF238DA-57D1-4DDF-9ECB-23BC9F887056.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:80;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Intraductal tubulopapillary neoplasm;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;PRIMARY_SITE_PATIENT:Head of Pancreas;TARGETED_MOLECULAR_THERAPY:YES;ALCOHOL_CONSUMPTION_FREQUENCY:3;ALCOHOL_HISTORY_DOCUMENTED:YES;DAILY_ALCOHOL:0.5;FAMILY_HISTORY_OF_CANCER:NO;DIABETES_DIAGNOSIS_INDICATOR:NO;TUMOR_RESECTED_MAX_DIMENSION:6.5;ALCOHOL_EXPOSURE_INTENSITY:Weekly Drinker;GRADE_TIER_SYSTEM:Three Tier;HISTORY_CHRONIC_PANCREATITIS:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"INTRAHEPATIC CHOLANGIOCARCINOMA" "CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:2.866666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;FRACTION_GENOME_ALTERED:0.2021;SAMPLE_TYPE:Primary;OS_MONTHS:14.62;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:8.71;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/2/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; intrahepatic;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:510;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVA.4C9A220D-03E9-41CF-8FA9-4B7FD05A625A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:480;WEIGHT:92;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T2b;ECOG_SCORE:1;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;AFP_AT_PROCUREMENT:5.4;FAMILY_HISTORY_OF_CANCER:NO;ISHAK_FIBROSIS_SCORE:1,2 - Portal Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:0.5;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;AFP_NORM_RANGE_LOWER:0;AFP_NORM_RANGE_UPPER:10;DEFINITIVE_SURGICAL_PROCEDURE:Segmentectomy, Single;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Diabetes mellitus|Smoking;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400"
"INVASIVE BREAST CANCER" "CANCER_TYPE_DETAILED:Invasive Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:3.93333333333;SOMATIC_STATUS:Unmatched;SAMPLE_CLASS:Tumor;SEQUENCING_TYPE:Targeted"
"INVASIVE BREAST CARCINOMA" "CANCER_TYPE_DETAILED:Adenoid Cystic Breast Cancer;CANCER_TYPE:Invasive Breast Carcinoma;ONCOTREE_CODE:ACBC;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:67;SAMPLE_TYPE:Primary;PRIMARY_SITE:Breast;RADIATION_THERAPY:Performed;VITAL_STATUS:Alive;PLATFORM:WES;TUMOR_STAGE:I;TUMOR_SIZE:35;STUDY:ACbC (MSKCC/Breast 2015);FUSION_STATUS:YES;GENOMIC_ALTERATIONS:31;IHC_HER2:Negative;OVERALL_PATIENT_HISTOLOGY:Cribriform/Tubular;METASTATIC_TUMOR_INDICATOR:No;MYB_MYBL1_FUSION:MYB-NFIB Fusion;ADJUVANT_CHEMO:Not performed;ADJUVANT_TX:Chemotherapy/Radiation Therapy;MYB_NFIB_FISH:Positive;TYPE_OF_SURGERY:Mastectomy;ER_STATUS_BY_IHC:Negative;NEOADJUVANT_CHEMO:Adriamycine, Endoxan, Taxotere;PR_STATUS_BY_IHC:Negative;LOCAL_REGIONAL_RECURRENCE:Negative;MYB_NFIB_REARRANGEMENT:MYB Exon 14-NFIB Exon 9;FOLLOWUP_YEARS:8;MYB_NFIB_CNA:17q21-q25.1 gain; 17p13.3-p11.2 loss"
"INVASIVE DUCTAL AND LOBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Female;AGE:56;FRACTION_GENOME_ALTERED:0.2134;SAMPLE_TYPE:Primary;OS_MONTHS:43.4;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:43.4;TISSUE_SOURCE_SITE:A1;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:12/6/10;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1672;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A1-A0SE.CFF567FC-8867-4CA4-85AE-81A7D30095E7.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:90;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0 (i-);AJCC_TUMOR_PATHOLOGIC_PT:T1c;HISTOLOGICAL_SUBTYPE:invasive ductal and lobular carcinoma;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left Upper Outer Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);PATH_MARGIN:Negative;HER2_IHC_SCORE:1;ER_STATUS_BY_IHC:Positive;HER2_FISH_STATUS:Negative;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel lymph node biopsy plus axillary dissection;CENT17_COPY_NUMBER:2;ER_STATUS_IHC_PERCENT_POSITIVE:80-89%;HER2_CENT17_RATIO:1;HER2_COPY_NUMBER:2;IHC_SCORE:3;PR_POSITIVITY_IHC_INTENSITY_SCORE:3+;PR_STATUS_IHC_PERCENT_POSITIVE:90-99%;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"INVASIVE MIXED DUCTAL AND LOBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Breast Invasive Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ILC;SOMATIC_STATUS:Matched;SEX:Female;AGE:71;FRACTION_GENOME_ALTERED:0.1632;SAMPLE_TYPE:Primary;OS_MONTHS:18.46;OS_STATUS:0:LIVING;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:18.46;TISSUE_SOURCE_SITE:S3;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8520/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/12/13;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:102;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-S3-A6ZG.47D02B80-47DA-4135-A288-21077C5947A9.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:980;SITE_OF_TUMOR_TISSUE:Breast;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T2;HISTOLOGICAL_SUBTYPE:Invasive mixed ductal and lobular carcinoma;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Excisional Biopsy;PRIMARY_SITE_PATIENT:Left|Left Upper Outer Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;BRACHYTHERAPY_TOTAL_DOSE_POINT_A:CAP scoring guideline 2010;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel node biopsy alone;ER_POSITIVITY_SCALE_OTHER:Moderate;ER_POSITIVITY_SCALE_USED:3 Point Scale;ER_STATUS_IHC_PERCENT_POSITIVE:90-99%;HER2_IHC_PERCENT_POSITIVE:<10%;HER2_POSITIVITY_METHOD_TEXT:CAP scoring guidelines 2010;MICROMET_DETECTION_BY_IHC:YES;PR_POSITIVITY_DEFINE_METHOD:CAP scoring guideline 2010;PR_POSITIVITY_SCALE_OTHER:Moderate;PR_POSITIVITY_SCALE_USED:3 Point Scale;PR_STATUS_IHC_PERCENT_POSITIVE:80-89%;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"INVASIVE MUCINOUS ADCA" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:2.33333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:59;FRACTION_GENOME_ALTERED:0.5169;OS_MONTHS:1.8;OS_STATUS:1:DECEASED;ETHNICITY:Chinese;SAMPLE_CLASS:Tumor;STAGE:III;COHORT:GSK;PURITY:0.34;SMOKING_STATUS:No;CHEMOTHERAPY:Yes;SEQUENCING_TYPE:WES + RNA-Seq;RNA_SEQ_ANALYSIS:Tumor;ADENOCARCINOMA_SUBTYPE_WHO2015:Invasive mucinous ADCA;EXOME_SEQ:Paired;IMSIG_B_CELLS:0.054882;IMSIG_INTERFERON:0.098017;IMSIG_MACROPHAGES:0.104452;IMSIG_MONOCYTES:0.09733;IMSIG_NEUTROPHILS:0.093404;IMSIG_NK_CELLS:0.026549;IMSIG_PLASMA_CELLS:0.082673;IMSIG_PROLIFERATION:0.066602;IMSIG_T_CELLS:0.077242;IMSIG_TRANSLATION:0.137537;TKI_TREATMENT:No"
"INVASIVE MUCINOUS ADENOCARCINOMA 82533" NA
"INVASIVE-MUCINOUS" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:0.666666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:59;ETHNICITY:Han;SAMPLE_CLASS:Tumor;WEIGHT:50;SMOKING_HISTORY:Lifelong non-smoker: Less than 100 cigarettes smoked in lifetime;HEIGHT:151;SMOKING_STATUS:Non-Smoker;BMI:21.93;EXPERIMENT:3;SECONDHAND_SMOKE:Exposure to secondhand smoke history not available;TMT_CHANNEL:126;ALK_FUSION:1;ARAF_MUTATION_STATUS:0;BRAF_MUTATION_STATUS:0;CIMP_STATUS:CIMP-2;DOMINANT_HISTOLOGICAL_SUBTYPE:invasive-mucinous;EGFR_MUTATION_STATUS:0;ERBB2_MUTATION_STATUS:0;ESTIMATE IMMUNESCORE:4146.195774;ESTIMATE STROMALSCORE:1040.817318;ESTIMATESCORE:5187.013092;KEAP1_MUTATION_STATUS:0;KRAS_MUTATION_STATUS:0;MRNA_EXPRESSION_SUBTYPE_TCGA:Terminal Respiratory Unit;MRNA_STEMNESS_INDEX:0.730123199;MUTATION_SIGNATURE_ACTIVITY_W1_COSMIC5:13.8727398;MUTATION_SIGNATURE_ACTIVITY_W2_COSMIC4:5.624444814;MUTATION_SIGNATURE_ACTIVITY_W3_COSMIC2:0.918460926;NMF_CLUSTER_MEMBERSHIP:0.693;NMF_CONSENSUS:C4;NUMBER_SOMATIC_MUTATIONS:20;PUTATIVE_DRIVER_MUTATION:ALK-Fusion;RB1_MUTATION_STATUS:0;REGION_OF_ORIGIN:Asian;RET_FUSION:0;ROS1_FUSION:0;SMOKING_SCORE_WGS:0.0002813;SMOKING_SIGNATURE_FRACTION_WGS:1.05E-26;STK11_MUTATION_STATUS:0;TP53_MUTATION_STATUS:0;TSNET PURITY:0.711808008;TUMOR_PURITY_BYESTIMATE_RNASEQ:0.67053895"
"INVASIVE_DUCTAL_CARCINOMA" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:11.9666666667;SEX:Female;AGE:56;FRACTION_GENOME_ALTERED:0.4968;SAMPLE_TYPE:Metastasis;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Breast;SUBTYPE:Breast Ductal Carcinoma;TUMOR_TYPE:breast;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:157.8873017;GENOME_DOUBLINGS:0;DOUBLING_TIME:133.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:invasive_ductal_carcinoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:ductal_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:breast;LINEAGE_MOLECULAR_SUBTYPE:HER2_amp;LINEAGE_SUB_SUBTYPE:ERpos_HER2neg;LINEAGE_SUBTYPE:breast_ductal_carcinoma;NAME:MDA-MB-175-VII;PATHOLOGIST_ANNOTATION:Breast:Carcinoma;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:breast"
"ISLET CELL TUMOR" "CANCER_TYPE_DETAILED:Pancreatic Neuroendocrine Tumor;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PANET;TMB_NONSYNONYMOUS:0.733333333333;SOMATIC_STATUS:Matched;SEX:Male;GRADE:3;METASTATIC_SITE:liver;TUMOR_STAGE:IV;HISTOLOGICAL_TYPE:islet cell tumor;TISSUE_SEQUENCED:Liver"
"JUVENILE GRANULOSA CELL TUMOR" "CANCER_TYPE_DETAILED:Juvenile Granulosa Cell Tumor;CANCER_TYPE:Other;SEX:Female;AGE:6.611909866;RACE:White;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;OTHER_CYTOTOXIC_TX:Yes;PLATINUM_TX:Yes;TERT_CISPLATIN_TX:2nd tertile;TERT_CYTOTOXIC_TX:2nd tertile;TERT_OTHER_CYTOTOXIC_TX:1st tertile;TERT_PLATINUM_TX:2nd tertile;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:0;TIME_TO_BLOOD_DRAW_FROM_TX:35;TOPO_II_TX:Yes"
"JUVENILE SECRETORY CARCINOMA OF THE BREAST" "CANCER_TYPE_DETAILED:Juvenile Secretory Carcinoma of the Breast;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:JSCB;TMB_NONSYNONYMOUS:0.864698095;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2936;SAMPLE_TYPE:Metastasis;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Breast;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Chest Wall;MSI_SCORE:0.13;MSI_TYPE:Stable;AGE_AT_SEQ_REPORTED_YEARS:34;AGE_CURRENT:34"
"KERATOACANTHOMA" "CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:29.2;SUBTYPE:Squamous Cell Carcinoma;LINEAGE:skin;LINEAGE_SUB_SUBTYPE:keratoacanthoma;LINEAGE_SUBTYPE:skin_squamous"
"KICH" "CANCER_TYPE_DETAILED:Chromophobe Renal Cell Carcinoma;CANCER_TYPE:Renal Non-Clear Cell Carcinoma;ONCOTREE_CODE:CHRCC;TMB_NONSYNONYMOUS:1;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:38.07081566;OS_STATUS:1:DECEASED;RACE:White;TISSUE_SOURCE_SITE:MSKCC;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8317/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/24/12;PFS_MONTHS:24.92027485;AJCC_STAGING_EDITION:5TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Kidney;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE III;SUBTYPE:KICH;TUMOR_TYPE:Kidney Chromophobe Renal Cell Carcinoma;PATH_T_STAGE:T3B;RADIATION_THERAPY:No;DSS_STATUS:1:DEAD WITH TUMOR;DAYS_TO_BIRTH:-20849;MSI_SENSOR_SCORE:0.52;CANCER_TYPE_ACRONYM:KICH;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3383;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:KL;DSS_MONTHS:38.07081566;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:No"
"KIDNEY CANCER" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CCRCC;TMB_NONSYNONYMOUS:8.2;SEX:Male;FRACTION_GENOME_ALTERED:0.3877;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Kidney;SUBTYPE:Renal Carcinoma, clear cell;TUMOR_TYPE:kidney;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:207.7442122;GENOME_DOUBLINGS:0;DOUBLING_TIME:113.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSRRB;DISEASE_ONTOLOGY:Kidney Cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:DMEM+10% FBS;HIST_SUBTYPE1:clear_cell_renal_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:kidney;LINEAGE_SUB_SUBTYPE:clear_cell;LINEAGE_SUBTYPE:renal_cell_carcinoma;NAME:KMRC-2;PATHOLOGIST_ANNOTATION:Kidney:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:kidney"
"KIDNEY CANCER, NOS" "CANCER_TYPE_DETAILED:Kidney;CANCER_TYPE:Kidney Cancer, NOS;ONCOTREE_CODE:KIDNEY;TMB_NONSYNONYMOUS:1.96666666667;FRACTION_GENOME_ALTERED:0.1107;ETHNICITY:Caucasian;PRIMARY_SITE:Kidney;TUMOR_TYPE:kidney;HISTOLOGY:Other;MUTATION_RATE:69.89031879;ANNOTATION_SOURCE:ACHILLES;HIST_SUBTYPE1:immortalized_epithelial;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:engineered_kidney;NAME:HEK TE;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:kidney"
"KIDNEY CHROMOPHOBE" "CANCER_TYPE_DETAILED:Chromophobe Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CHRCC;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:38.04;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:29.93;TISSUE_SOURCE_SITE:KL;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8317/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2012-7-24;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Kidney Chromophobe;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-KL-8323.9f3120ac-7238-4b68-8ac0-6175a7a86b4b.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Kidney;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T3b;TREATMENT_OUTCOME_FIRST_COURSE:[Unknown];LYMPH_NODES_EXAMINED:NO;TOBACCO_SMOKING_HISTORY_INDICATOR:1;SPECIMEN_SECOND_LONGEST_DIMENSION:0.5;LATERALITY:Right;LONGEST_DIMENSION:0.7;SHORTEST_DIMENSION:0.4;TARGETED_MOLECULAR_THERAPY:YES;WBC:Elevated;HEMOGLOBIN_LEVEL:Normal;ERYTHROCYTE_SEDIMENTATION_RATE:[Not Evaluated];SERUM_CALCIUM_LEVEL:Low"
"KIDNEY CLEAR CELL RENAL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CCRCC;TMB_NONSYNONYMOUS:2.13333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:77;FRACTION_GENOME_ALTERED:0.1021;SAMPLE_TYPE:Primary;OS_MONTHS:119.28;OS_STATUS:0:LIVING;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:119.28;TISSUE_SOURCE_SITE:B0;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8310/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/2/11;GRADE:G3;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Kidney Clear Cell Renal Carcinoma;HISTORY_OTHER_MALIGNANCY:Yes;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-B0-5698.ff834af5-4186-4625-8e6f-349261544fd8.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Kidney;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b;LYMPH_NODES_EXAMINED:NO;SPECIMEN_SECOND_LONGEST_DIMENSION:1.2;LATERALITY:Right;LONGEST_DIMENSION:1.8;SHORTEST_DIMENSION:0.4;WBC:Normal;HEMOGLOBIN_LEVEL:Normal;SERUM_CALCIUM_LEVEL:Low"
"KIDNEY PAPILLARY RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Papillary Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:PRCC;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.2548;SAMPLE_TYPE:Primary;OS_MONTHS:25.33;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:25.33;TISSUE_SOURCE_SITE:BQ;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C64.1;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/11/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;TUMOR_TYPE:Type 2;HISTOLOGICAL_DIAGNOSIS:Kidney Papillary Renal Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-BQ-5887.aad105e0-56cc-4057-89fc-834cff6f1567.pdf;VIAL_NUMBER:A;WEIGHT:78;SITE_OF_TUMOR_TISSUE:Kidney;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3a;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:4;HEIGHT:170;SPECIMEN_SECOND_LONGEST_DIMENSION:1;LATERALITY:Right;LONGEST_DIMENSION:1.3;SHORTEST_DIMENSION:0.3;WBC:Normal;AJCC_METASTASIS_CLINICAL_CM:M0;LYMPH_NODES_EXAMINED_POSITIVE:0;AJCC_CLINICAL_TUMOR_STAGE:Stage III;AJCC_NODES_CLINICAL_CN:N0;AJCC_NODES_CLINICAL_CT:T3a;HEMOGLOBIN_LEVEL:Normal;SERUM_CALCIUM_LEVEL:Normal"
"KIDNEY RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Kidney Renal Cell Carcinoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1417;DIAGNOSIS AGE:72;GDNA(NG):301;SMOKE STATUS:Unknown;TUMOR_PURTITY:15"
"KIDNEY RENAL CELL CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Kidney Renal Cell Carcinoma Other;CANCER_TYPE:Kidney Renal Cell Carcinoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:I;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:974;DIAGNOSIS AGE:55;GDNA(NG):4092;SMOKE STATUS:Unknown;TUMOR_PURTITY:40"
"KIDNEY_CANCER" "CANCER_TYPE_DETAILED:Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:12.9333333333;SEX:Male;AGE:78;FRACTION_GENOME_ALTERED:0.3140;SAMPLE_TYPE:Primary;ETHNICITY:African_american;PRIMARY_SITE:Kidney;SUBTYPE:Renal Cell Carcinoma;TUMOR_TYPE:kidney;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:114.8901438;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;DISEASE_ONTOLOGY:kidney_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:MEM+10% FBS;HIST_SUBTYPE1:renal_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:kidney;LINEAGE_SUBTYPE:renal_cell_carcinoma;NAME:A-704;PATHOLOGIST_ANNOTATION:Kidney:Carcinoma;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:kidney"
"KIRC" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Clear Cell Carcinoma;ONCOTREE_CODE:CCRCC;TMB_NONSYNONYMOUS:2.666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.2240;SAMPLE_TYPE:Primary;OS_MONTHS:12.65739554;OS_STATUS:0:LIVING;RACE:Black or African American;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.65739554;TISSUE_SOURCE_SITE:Mary Bird Perkins Cancer Center - Our Lady of the Lake;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8310/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:11/11/14;GRADE:G2;PFS_MONTHS:12.65739554;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Kidney;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:KIRC;TUMOR_TYPE:Kidney Clear Cell Renal Carcinoma;PATH_T_STAGE:T1A;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:385;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-25205;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:KIRC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3119;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:3Z;DSS_MONTHS:12.65739554;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:5;RAGNUM_HYPOXIA_SCORE:-8;WINTER_HYPOXIA_SCORE:-10;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:No"
"KIRP" "CANCER_TYPE_DETAILED:Papillary Renal Cell Carcinoma;CANCER_TYPE:Renal Non-Clear Cell Carcinoma;ONCOTREE_CODE:PRCC;TMB_NONSYNONYMOUS:1.833333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.0757;SAMPLE_TYPE:Primary;OS_MONTHS:7.035539337;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:7.035539337;TISSUE_SOURCE_SITE:Greenville Health System;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C64.1;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:4/18/14;PFS_MONTHS:7.035539337;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Kidney;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE II;SUBTYPE:KIRP;TUMOR_TYPE:Kidney Papillary Renal Cell Carcinoma;PATH_T_STAGE:T2B;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:214;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-19603;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:KIRP;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3053;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:2K;DSS_MONTHS:7.035539337;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;WEIGHT:97.73;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:5;RAGNUM_HYPOXIA_SCORE:0;WINTER_HYPOXIA_SCORE:-6;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:No"
"LAML" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0.366666667;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.0002;SAMPLE_TYPE:Primary;OS_MONTHS:11.9998685;OS_STATUS:1:DECEASED;TISSUE_SOURCE_SITE:Washington University;TUMOR_TYPE:Acute Myeloid Leukemia;CANCER_TYPE_ACRONYM:LAML;IN_PANCANPATHWAYS_FREEZE:No;TISSUE_SOURCE_SITE_CODE:AB"
"LANGERHANS CELL HISTIOCYTOSIS" "TMB_NONSYNONYMOUS:0;GENE_PANEL:MSK-ACCESS;TUMOR_TYPE:Non Langerhans Cell Histiocytosis;WGD:FALSE;TMB:0.222193954;MONTHS_ON_TREATMENT:10.9;MSI:0.45;OVERALL_RESPONSE:CR;TIMEPOINT:Baseline;ACCESS:TRUE;ACCESS_TIMEPOINTS:FALSE;ALT_TYPE:Fusion;EXOME_DATA:TRUE;IMPACT_DATA:FALSE;ONCOTREE_PATIENT:HDCN;ONGOING_STATUS:TRUE;PFS:47.6;PRIOR_LINES:1;PRIOR_MKI:FALSE;RET_AF:0;RET_ALT:NCOA4-RET;SOURCE_TYPE:Plasma;WEEKS_ON_TREATMENT:47.6"
"LARGE CELL LUNG CARCINOMA" "CANCER_TYPE_DETAILED:Large Cell Lung Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LCLC;TMB_NONSYNONYMOUS:10.9333333333;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.3708;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Large Cell Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:139.7910668;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:JCRB;CHARACTERISTICS:Lymphocyte like with partially attached cells;DISEASE_ONTOLOGY:lung_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI 1640+10%FBS;HIST_SUBTYPE1:non_small_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_large_cell;LINEAGE_SUBTYPE:NSCLC;NAME:LU65;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Large_Cell;PROTEOMICS_TMT_LABEL:128n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LARGE CELL NEUROENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Large Cell Neuroendocrine Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUNE;TMB_NONSYNONYMOUS:7.82975758092;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2667;SAMPLE_TYPE:Primary;OS_MONTHS:11.07;OS_STATUS:1:DECEASED;RACE:Unknown;ETHNICITY:Non-Spanish;Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:706;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;AGE_AT_SEQ_REPORTED_YEARS:67;M_STAGE:M1;SMOKING_HISTORY:Never;ARCHER:NO;SO_COMMENTS:Note: The MYC,RECQL4 and  YES1 copy number gains fall slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated.;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:332;YEAR_OF_DIAGNOSIS:2015;PRETREATED:Yes"
"LARGE CELL NEUROENDOCRINE CARCINOMA OF GALLBLADDER" "CANCER_TYPE_DETAILED:Large Cell Neuroendocrine Carcinoma of Gallbladder;CANCER_TYPE:Poorly Differentiated NEC;TMB_NONSYNONYMOUS:7.78228285485;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1714;SAMPLE_TYPE:Metastasis;OS_MONTHS:2.924024641;OS_STATUS:1:DECEASED;ETHNICITY:White;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT468;METASTATIC_SITE:Liver;TUMOR_PURITY:30;MSI_SCORE:0.46;MSI_TYPE:Stable;SAMPLE_COVERAGE:1141;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:72;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CHRISTIAN ORTHODOX;AGE_CURRENT:71;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:7;PARTA_CONSENTED_12_245:YES;TUMOR_GRADE:Poor;DATE_ADDED:10/3/20;MONTH_ADDED:2020/10;WEEK_ADDED:2020, Wk. 40;CVR_TMB_COHORT_PERCENTILE:75.3;CVR_TMB_TT_COHORT_PERCENTILE:89.3;SAMPLE_NAME:P-0058337-T01-IM6;CBIOPORTAL_SAMPLE_CLASS:Tumor;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:2.924024641;OVERALL_SURVIVAL_MONTHS:2.924024641;TUMOR_STAGE_COLLECTION:4"
"LARGE CELL/ANAPLASTIC MEDULLOBLASTOMA" "CANCER_TYPE_DETAILED:Large Cell/Anaplastic Medulloblastoma;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:AMBL;TMB_NONSYNONYMOUS:1.56666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:2.0;OS_MONTHS:33.0;OS_STATUS:0:LIVING;M_STAGE:M3;NOTE:WGS for germline, primary and recurrence 1;OVERALL_PATIENT_HISTOLOGY:LCA;RNASEQ_DATA:No;SUBGROUP:SHH;GERMLINE_CONTROL:Yes;SOURCE_OF_RECURRENCE_TISSUE:Biopsy"
"LARGE_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:5.85735484287;SEX:Male;FRACTION_GENOME_ALTERED:0.3532;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Large_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"LARGE_CELL_LUNG_CANCER" "CANCER_TYPE_DETAILED:Large Cell Lung Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LCLC;TMB_NONSYNONYMOUS:13.2666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.8784;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Large Cell Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:119.6353574;GENOME_DOUBLINGS:1;DOUBLING_TIME:25.5;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:large_cell_lung_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+10%FBS;HIST_SUBTYPE1:large_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_large_cell;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H460;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Large_Cell;PROTEOMICS_TMT_LABEL:128c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LARYNX SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Larynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:LXSC;TMB_NONSYNONYMOUS:10.3333333333;SEX:Male;AGE:55;FRACTION_GENOME_ALTERED:0.2747;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, laryngeal;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:193.9530872;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:96 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:laryngeal;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:SNU-1214;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:larynx;SITE_SUBTYPE2:glottis;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"LEIOMYOSARCOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Unmatched;SEX:Female;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:39.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:40;CENTER:3;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Residual Disease|Post-Chemotherapy|Post-Transplant;KARYOTYPE:46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim);CUMULATIVE_TREATMENT_STAGES:Allogeneic - Sibling | Salvage | Induction | Re-induction | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Azacitidine;MOST_RECENT_TREATMENT_DURATION:4;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:30;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:Yes;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_CANCER:Leiomyosarcoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:Increased atypical CD34 positive, CD7 positive myeloblasts;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"LEIOMYOSARCOMA LMS" NA
"LENTIGO MALIGNA" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:140.633333333;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:21.93333333;OS_STATUS:0:LIVING;PFS_MONTHS:21.93333333;PFS_STATUS:0:CENSORED;HISTOLOGY:Lentigo maligna Melanoma;M_STAGE:M1b;PURITY:0.67;TOTAL_MUTATIONS:6550;BIOPSY_SITE:skin;LDH_ELEVATED:No;MUTS_CLONAL:3501;MUTS_SUBCLONAL:618;ALKYLATING_CHEMOTHERAPY:32.7697567;BIOPSY_CONTEXT:Pre-PD1;BIOPSY_SITE_CATEG:skin;BR:Partial Response;CNA_PROP:0.110598811;COSMIC_AGING:145.722245;CUT_SUBQ_MET:No;CYCLES_ON_THERAPY:41;HETEROGENEITY:0.150036417;IO_THERAPY:Nivolumab;LIVER_VISC_MET:No;LN_MET:Yes;LUNG_MET:Yes;MET_BONE:No;MET_BRAIN:No;NUM_PRIOR_THERAPIES:0;POAR_COMBINED_CTLA_PD1:No;POST_CTLA4:No;POST_MAPK_TX:No;PRIMARY_TYPE:skin;PRIOR_CTLA4:No;PRIOR_MAPK_TX:No;TIME_TO_BR:72;TOTAL_NEOANTIGEN:10277;TX_START_ECOG:1;TX_START_LDH:217;UV_INDUCED_MUTATIONS:6191.56215"
"LENTIGO MALIGNA MELANOMA" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:140.633333333;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:21.93333333;OS_STATUS:0:LIVING;PFS_MONTHS:21.93333333;PFS_STATUS:0:CENSORED;HISTOLOGY:Lentigo maligna Melanoma;M_STAGE:M1b;PURITY:0.67;TOTAL_MUTATIONS:6550;BIOPSY_SITE:skin;LDH_ELEVATED:No;MUTS_CLONAL:3501;MUTS_SUBCLONAL:618;ALKYLATING_CHEMOTHERAPY:32.7697567;BIOPSY_CONTEXT:Pre-PD1;BIOPSY_SITE_CATEG:skin;BR:Partial Response;CNA_PROP:0.110598811;COSMIC_AGING:145.722245;CUT_SUBQ_MET:No;CYCLES_ON_THERAPY:41;HETEROGENEITY:0.150036417;IO_THERAPY:Nivolumab;LIVER_VISC_MET:No;LN_MET:Yes;LUNG_MET:Yes;MET_BONE:No;MET_BRAIN:No;NUM_PRIOR_THERAPIES:0;POAR_COMBINED_CTLA_PD1:No;POST_CTLA4:No;POST_MAPK_TX:No;PRIMARY_TYPE:skin;PRIOR_CTLA4:No;PRIOR_MAPK_TX:No;TIME_TO_BR:72;TOTAL_NEOANTIGEN:10277;TX_START_ECOG:1;TX_START_LDH:217;UV_INDUCED_MUTATIONS:6191.56215"
"LEPIDIC" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:7.43333333333;SOMATIC_STATUS:Matched;SEX:Female;ETHNICITY:European;PFS_MONTHS:4.1;PLATFORM:WES+WGS;TUMOR_CELLULARITY_PATHOLOGY_REVIEW:Lung adenocarcinoma, lepidic predomint;SAMPLE_COLLECTION_SOURCE:OICR;CENSORED:FALSE"
"LEPIDIC ADENOCARCINOMA 82503" NA
"LEUKAEMIA" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.98;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:73.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:94;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:73;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M1;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.79;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:97;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:94;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:AC220 (Ambit);LDH_LEVEL:441;MOST_RECENT_TREATMENT_DURATION:30;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Intermediate-I;ELN_2017:Favorable or Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:19.3;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:100.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:4.1;PB_ALT_LEVEL:19;PB_AST_LEVEL:28;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:2;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;SURFACE_ANTIGENS:CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative;TOTAL_PROTEIN_LEVEL:7.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"LEUKEMIA" "CANCER_TYPE_DETAILED:B-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:BALL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.17;GENE_PANEL:WGS;COHORT:INF_MLLr_Discovery;MUTATION_RATE:3.97E-08;MLL_STATUS:INF_MLLr;LEUKEMIA_TYPE:Pre-B"
"LEUKEMIA_OTHER" "CANCER_TYPE_DETAILED:Acute Undifferentiated Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;TMB_NONSYNONYMOUS:1.98929032399;SEX:Male;FRACTION_GENOME_ALTERED:0.1062;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Leukemia_Other;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"LGG" "CANCER_TYPE_DETAILED:Pediatric Low Grade Gliomas;CANCER_TYPE:Low-grade glioma/astrocytoma;ONCOTREE_CODE:PLGG;SEX:Male;AGE:5;OS_MONTHS:59;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:16;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Primary;TREATMENT:Modified Treatment;CHEMOTHERAPY:Not Reported;SURGERY:Not Reported;TREATMENT_STATUS:Treatment naive;BRAF_STATUS:BRAF fusion;AGE_AT_INITIAL_DIAGNOSIS:1986;AGE_CLASS:[5-10);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:3812;AGE_AT_SPECIMEN_DIAGNOSIS:1986;BRAF_RELA_STATUS:BRAF fusion;BRAF_STATUS2:BRAF mutant;CANCER_PREDISPOSITIONS:None documented;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Low-grade glioma/astrocytoma (WHO grade I/II);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;LGG_BRAF_STATUS:BRAF fusion;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits);MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:No;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:Not Reported;RADIATION_TYPE:Not Reported;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:18 Month Update;TUMOR_LOCATION_CONDENSED:Cerebellum/Posterior Fossa;UPDATED_GRADE:I"
"LGSOC" "CANCER_TYPE_DETAILED:Low-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:LGSOC;TMB_NONSYNONYMOUS:8.86666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.4479;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, low grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:111.0355795;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Ovarian Cancer;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:low_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:Hey-A8;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:127c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"LIHB" "CANCER_TYPE_DETAILED:Hepatoblastoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:LIHB;TMB_NONSYNONYMOUS:11.8666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.5928;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Liver;SUBTYPE:Hepatoblastoma;TUMOR_TYPE:liver;HISTOLOGY:Other;PURITY:0.99;MUTATION_RATE:174.0189681;GENOME_DOUBLINGS:0;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:epithelial-like;GROWTH_MEDIUM:DMEM + 10%FBS;HIST_SUBTYPE1:hepatoblastoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:pediatric;LINEAGE:liver;LINEAGE_SUBTYPE:hepatoblastoma;NAME:HuH-6;PATHOLOGIST_ANNOTATION:Liver:Hepatoblastoma;PROTEOMICS_TMT_LABEL:128n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:liver"
"LIHC" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:2.866666667;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2041;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;RACE:Asian;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;TISSUE_SOURCE_SITE:University of California San Diego;ICD_O_3_SITE:C22.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C22.0;ICD_O_3_HISTOLOGY:8170/3;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:6/15/15;GRADE:G3;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Liver;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE II;SUBTYPE:LIHC;TUMOR_TYPE:Hepatocellular Carcinoma;PATH_T_STAGE:T2;RADIATION_THERAPY:No;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:LIHC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3003;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:2V;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;WEIGHT:78;PATH_M_STAGE:MX;BUFFA_HYPOXIA_SCORE:-13;RAGNUM_HYPOXIA_SCORE:-10;WINTER_HYPOXIA_SCORE:-16"
"LIPOFIBROMATOSIS-LIKE NEURAL TUMOR" "CANCER_TYPE_DETAILED:Lipofibromatosis-like Neural tumor;CANCER_TYPE:Sarcoma;SEX:Female;AGE:0.881587982;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;CHEMO_TX:Yes;TARGETED_TX:Yes;TERT_TARGETED_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:321"
"LIPOSARCOMA" "CANCER_TYPE_DETAILED:Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:LIPO;TMB_NONSYNONYMOUS:8.6;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:liposarcoma"
"LIVER CANCER, NOS" "CANCER_TYPE_DETAILED:Liver Cancer, NOS;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:LIVER;SOMATIC_STATUS:Matched;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.4431;SAMPLE_TYPE:Recurrence;OS_MONTHS:79.24;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:20.89;TISSUE_SOURCE_SITE:ZS;ICD_O_3_SITE:C22.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.0;ICD_O_3_HISTOLOGY:8170/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/1/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Hepatocellular Carcinoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;RETROSPECTIVE_COLLECTION:YES;SITE_OF_TUMOR_TISSUE:Liver;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T2;ECOG_SCORE:0;VASCULAR_INVASION:Micro;ISHAK_FIBROSIS_SCORE:0 - No Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:89;CREATININE_NORM_RANGE_LOWER:62;CREATININE_NORM_RANGE_UPPER:106;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2008;BILIRUBIN_TOTAL:19;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:17;DEFINITIVE_SURGICAL_PROCEDURE:Lobectomy;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Hemochromatosis;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:10.2;PROTHROMBIN_TIME_NORM_RANGE_UPPER:12;SERUM_ALBUMIN_NORM_RANGE_LOWER:36;SERUM_ALBUMIN_NORM_RANGE_UPPER:50;SERUM_ALBUMIN_PRERESECTION:51;HEPATIC_INFLAMMATION_ADJ_TISSUE:None"
"LIVER HEPATOCELLULAR CARCINOMA" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Liver Hepatocellular Carcinoma;TMB_NONSYNONYMOUS:0.166666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:I;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:935;DIAGNOSIS AGE:53;GDNA(NG):2412;SMOKE STATUS:Unknown;TUMOR_PURTITY:85"
"LIVER TUMOR" "CANCER_TYPE_DETAILED:Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:CHOL;TMB_NONSYNONYMOUS:0.0;SEX:Female;AGE:40.28310152;FRACTION_GENOME_ALTERED:0.0003;OS_MONTHS:72.47837039;OS_STATUS:1:DECEASED;TUMOR_SIZE:5;SMOKING_STATUS:Never smoked;TUMOR_GRADE:Moderately differentiated;BMI:23.1;RFS_STATUS:1:RELAPSED;CIRRHOSIS:0;RFS_MONTHS:24.11564998;ADJUVANT_CHEMO:1;CHRONIC_HEPATITIS_ANY_TYPE:0;NEOADJ_CHEMO:0;PNI:1;TREATMENT_GROUP:Resected;CLIN_PSC:0;DIABETES_STATUS:0;DUCT_TYPE:Small bile duct type;DZ_EXTENT:Solitary liver tumor;ECOG_BIN:0;HAIC:1;HEP_B:0;HEP_C:0;LVI:No;OS_MONTHS_FROM_RX:71.32844157;PD_INF:0;POSITIVE_LYMPH_NODE:0;POSITIVE_MARGIN:0;STEATOSIS:0;SYSTEMIC_CHEMO:1"
"LIVER_CANCER" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:9.03333333333;SEX:Male;AGE:15;FRACTION_GENOME_ALTERED:0.2212;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Liver;SUBTYPE:Hepatocellular Carcinoma;TUMOR_TYPE:liver;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:169.6811465;GENOME_DOUBLINGS:0;DOUBLING_TIME:40.7;GEOGRAPHIC_DISTRIBUTION:argentina;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI/ATCC;CHARACTERISTICS:Epithelial adherent;DISEASE_ONTOLOGY:liver_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:EMEM +10%FBS;HIST_SUBTYPE1:hepatocellular_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:liver;LINEAGE_SUBTYPE:hepatocellular_carcinoma;NAME:Hep G2;PATHOLOGIST_ANNOTATION:Liver:HCC;PROTEOMICS_TMT_LABEL:127n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:liver"
"LNET" "CANCER_TYPE_DETAILED:Lung Neuroendocrine Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LNET;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.4080;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.87;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:33;M_STAGE:M1;SMOKING_HISTORY:Never;TISSUE_SITE:Pleural Effusion, Right;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:176;YEAR_OF_DIAGNOSIS:2016;PROCEDURE_TYPE:Pleural Effusion;PRETREATED:No"
"LOBULAR CARCINOMA" "CANCER_TYPE_DETAILED:Infiltrating Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ILC;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Female;AGE:59;SUBTYPE:Luminal A;STAGE:II;PURITY:0.3;ER_STATUS:Positive;HER2_STATUS:Negative;PR_STATUS:Positive;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.2;NONSILENT_RATE:0.65"
"LOBULAR CARCINOMA WITH DUCTAL FEATURES" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.466666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:43;FRACTION_GENOME_ALTERED:0.0332;SAMPLE_TYPE:Primary;OS_MONTHS:118.5;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:84.13;TISSUE_SOURCE_SITE:AR;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/16/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2213;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AR-A24O.887F0E3A-DC70-4CD4-AAAF-3C613195D895.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:700;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Lobular carcinoma with ductal features;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Incisional Biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Negative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);PATH_MARGIN:Positive;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;MARGIN_STATUS_REEXCISION:Negative;SURGERY_FOR_POSITIVE_MARGINS:Mastectomy NOS;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"LOBULAR/DUCTAL" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;SOMATIC_STATUS:Matched;SEX:Female;AGE:73;FRACTION_GENOME_ALTERED:0.1065;SAMPLE_TYPE:Primary;OS_MONTHS:7.98;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:7.98;TISSUE_SOURCE_SITE:A8;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/27/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:119;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A8-A07S.AC2E3DDC-3AF6-45F0-8269-E9DA68F4367A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2;HISTOLOGICAL_SUBTYPE:lobular/ductal;PRIMARY_SITE_PATIENT:Left Upper Outer Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Positive;ER_STATUS_BY_IHC:Positive;HER2_FISH_STATUS:Negative;PR_STATUS_BY_IHC:Negative;FIRST_SURGICAL_PROCEDURE_OTHER:Surgical Resection;SURGICAL_PROCEDURE_FIRST:Other"
"LOCALLY ADVANCED" "CANCER_TYPE_DETAILED:Oral Cavity Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OCSC;TMB_NONSYNONYMOUS:29.3615909284;SOMATIC_STATUS:Matched;SEX:Female;AGE:99.0;FRACTION_GENOME_ALTERED:0.1232;SAMPLE_TYPE:Primary;OS_MONTHS:40.2;OS_STATUS:0:LIVING;RACE:White;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:40.2;PRIMARY_SITE:Oral Cavity;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;SAMPLE_COVERAGE:318;VITAL_STATUS:NED;SMOKING_HISTORY:Former;PARTC_CONSENTED_12_245:NO;HPV_STATUS:Positive;ALCOHOL_HISTORY_DOCUMENTED:Never;AGENT:None;DISEASE_EXTENT:Locally advanced;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:no;DISTANT_METS:No;SMOKING:Smoking Pack:0.5;TNM:T3N2bM0;CLINICAL_TRIAL:None;DETAILED_PRIMARY_SITE:Oral Tongue;INITIAL_TREATMENT:Cetuximab;SITE_SEQUENCED:Index primary;PRIOR_TX_TO_IMPACT_SAMPLE:None;TOBACCO_TYPE:Cigarettes;VAR_12_245:12-245"
"LOCOREGIONAL RECURRENCE" "CANCER_TYPE_DETAILED:Dedifferentiated Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DDLS;TMB_NONSYNONYMOUS:1.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:67;FRACTION_GENOME_ALTERED:0.3116;OS_MONTHS:19.7;OS_STATUS:1:DECEASED;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.5;TISSUE_SOURCE_SITE:3B;TUMOR_TISSUE_SITE:Retroperitoneum/Upper abdominal - Retroperitoneum;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;DSS_STATUS:0.0;INITIAL_PATHOLOGIC_DX_YEAR:2011;PHARMACEUTICAL_TX_ADJUVANT:YES;TUMOR_SIZE:18;METHYLATION_CLUSTER:M1;RPPA_CLUSTER:C5;LOCAL_RECURRENCE:Locoregional Recurrence;MIRNA_CLUSTER:2;ICLUSTER:2;MRNA_EXPRESSION_CLUSTER:1;CN_CLUSTER:2;DISEASE_MULTIFOCAL_INDICATOR:NO;DISTANT_RECURRENCE:Distant Metastasis;LOCAL_RECURRENCE_MONTHS:7.5;MITOTIC_RATE:7;TUMOR_TOTAL_DEPTH:Unknown;AMP_12Q15_CDK4:3.657;AMP_12Q15_DDIT3:-0.189;AMP_12Q15_FRS2:3.657;AMP_12Q15_HMGA2:3.657;AMP_12Q15_MDM2:3.657;AVG_CN_12Q13_15:25;DAYS_TO_NEW_TUMOR_EVENT:229.0;DISTANT_RECURRENCE_SITE:Lung;FNCLCC_GRADE:2;LEUKOCYTE_FRACTION:0.182637297;MONTHS_TO_DISTANT_RECURRENCE:7.532894737;NEW_TUMOR_EVENT_DX_INDICATOR:YES;PARADIGM_CLUSTER:4;SHORT_HISTOLOGY:DDLPS"
"LOW GRADE FIBROMYXOID SARCOMA" "CANCER_TYPE_DETAILED:Low grade Fibromyxoid Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.0333333333333;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1138;DIAGNOSIS AGE:47;GDNA(NG):870;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"LOW HYPODIPLOID" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:8;GENE_PANEL:WGS;PROTOCOL:99,009,907;CYTOGENETICS:36,X,+Y,+1,+5,+6,+8,+10,+11,+13,+15,+18,+19,+21,+22[cp17]/46,XY[3];BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:95;SNAPSHOT_MUTATIONS:IKZF2,CDKN2A,TP53;DNA_INDEX:0.75;KNOWN_MOLECULAR_CLASSIFIER:Low hypodiploid"
"LOW-GRADE ENDOMETRIAL STROMAL SARCOMA" "CANCER_TYPE_DETAILED:Low-Grade Endometrial Stromal Sarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:LGESS;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0264;SAMPLE_TYPE:Metastasis;OS_MONTHS:209.04;OS_STATUS:1:DECEASED;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;GRADE:Low;METASTATIC_SITE:Abdomen;MSI_SCORE:0.67;WGD:FALSE;CURRENT_STAGE:IVB;CANCER_TYPE_DETAILED_CODE:LGESS;INITIAL_FIGO_STAGE:IA;METASTASIS_SITE_CODE:Abdomen;SMP_OS_MOS:209.04"
"LOW-GRADE FIBROMYXOID SARCOMA" "CANCER_TYPE_DETAILED:Low-Grade Fibromyxoid Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Female;FRACTION_GENOME_ALTERED:0.1372;SAMPLE_TYPE:Metastasis;OS_MONTHS:70.882;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Extremity;GENE_PANEL:IMPACT341;TUMOR_PURITY:60;MSI_SCORE:1.66;MSI_TYPE:Stable;SAMPLE_COVERAGE:565;PURITY:0.710166804;CVR_TMB_SCORE:1.1;AGE_AT_SEQ_REPORT:51;DETAILED_PRIMARY_SITE:Soft Tissue;FACETS:YES;FRACTION_CNA:0.78033473;FACETS_REVIEW:YES;FACETS_WGD:TRUE;FGA_REPORTED:0.1372"
"LOW-GRADE GLIOMA NOS" NA
"LOW-GRADE GLIOMA, NOS" "CANCER_TYPE_DETAILED:Low-Grade Glioma, NOS;CANCER_TYPE:Glioma;ONCOTREE_CODE:LGGNOS;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0369;SAMPLE_TYPE:Primary;OS_MONTHS:23.54;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:717;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:142.8"
"LOW-GRADE NEUROEPITHELIAL TUMOR" "CANCER_TYPE_DETAILED:Low-Grade Neuroepithelial Tumor;CANCER_TYPE:Miscellaneous Brain Tumor;ONCOTREE_CODE:LGNET;TMB_NONSYNONYMOUS:0;SEX:Male;AGE:11;PFS_STATUS:Unknown/NA;RADIATION_THERAPY:Unknown/NA;STAGE:Stage IV;RFS_STATUS:Unknown/NA;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Unknown;ANY_LINE_CHEMO:Unknown/NA;ANY_LINE_HORMONE:Unknown/NA;ANY_LINE_IODINE:Unknown/NA;ANY_LINE_NTRK:Unknown/NA;ANY_LINE_TARGETED:Unknown/NA;ANY_SYSTX:No;CANCER_TYPE_HISTOLOGY:Neuroepithelial;DOB_LASTFU_TIME_YRS:12;DOB_REPORT_TIME_YRS:12;DOB_TISSUE_TIME_YRS:12;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Negative;POS_METHOD:Archer;PROG_DEATH:Unknown/NA;PROG_EVAL_C:No;RECUR_EVAL_C:No;TISSUE_REPORT_TIME_YRS:0"
"LOW-GRADE SEROUS OVARIAN CANCER" "CANCER_TYPE_DETAILED:Low-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:LGSOC;TMB_NONSYNONYMOUS:8.86666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.4479;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, low grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:111.0355795;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Ovarian Cancer;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:low_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:Hey-A8;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:127c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"LOW_GRADE_SEROUS" "CANCER_TYPE_DETAILED:Low-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:LGSOC;TMB_NONSYNONYMOUS:8.86666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.4479;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, low grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:111.0355795;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Ovarian Cancer;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:low_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:Hey-A8;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:127c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"LUAD" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:10.9333333333;SEX:Male;FRACTION_GENOME_ALTERED:0.6542;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:215.9785902;GENOME_DOUBLINGS:1;DOUBLING_TIME:70.1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:adherent epithelial-like;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenocarcinoma;LINEAGE_SUBTYPE:NSCLC;NAME:RERF-LC-Ad2;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LUMA" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;TMB_NONSYNONYMOUS:1.66666666667;SEX:Female;AGE:35;ETHNICITY:White;TUMOR_STAGE:Stage IIB;ESTIMATE_IMMUNE_SCORE:1119.306238;ESTIMATE_STROMAL_SCORE:468.365511;ESTIMATE_TUMORPURITY:0.668922;STEMNESS_SCORE:0.644329816;TMT_CHANNEL:128N;APOBEC_SIGNATURE:N;CANCER TYPE:Breast Cancer;CD3_TILS_STATUS:not performed;CHROMOSOME_INSTABILITY_INDEX_CIN_:1.379587319;CIBERSORT_ABSOLUTE_SCORE:0.720781;ER_UPDATED_CLINICAL_STATUS:Positive;ERBB2_GENE_AMPLIFIED:0;ERBB2_PROTEOGENOMIC_STATUS:Negative;ERBB2_UPDATED_CLINICAL_STATUS:Negative;ISCHEMIA_TIME_IN_MINUTES:1;NMF_CLUSTER:LumA-I;NMF_CLUSTER_MEMBERSHIP_SCORE:0.55;NUMBER_OF_NON_SYNONYMOUS_MUTATIONS:55;ONCOTREE CODE:BRCA;PAM50:LumA;PR_CLINICAL_STATUS:positive;TMT_PLEX:2;TNBC_UPDATED_CLINICAL_STATUS:negative;TOP2A_GENE_AMPLIFIED:0;TOP2A_PROTEOGENOMIC_STATUS:negative;XCELL_IMMUNE_SCORE:0.0638;XCELL_STROMAL_SCORE:0.043"
"LUMB" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:2.63333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.6419;SAMPLE_TYPE:Primary;OS_MONTHS:5.19;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:5.19;TISSUE_SOURCE_SITE:CU;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/24/12;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IV;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:182;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-CU-A3QU.3197D149-9CF0-4644-B192-F7BB6028AF45.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:940;SMOKING_PACK_YEARS:15;WEIGHT:87;SITE_OF_TUMOR_TISSUE:Bladder;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T2b;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:1;TOBACCO_SMOKING_HISTORY_INDICATOR:4;HEIGHT:173;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;ANGIOLYMPHATIC_INVASION:YES;OCCUPATION_PRIMARY:Lumber/Sawmill business owner;EXTRACAPSULAR_EXTENSION:NO;NONINVASIVE_BLADDER_HISTORY:NO;OCCUPATION_CURRENT:Lumber/Sawmill business owner;OCCUPATION_PRIMARY_INDUSTRY:Lumber"
"LUMINAL A" "CANCER_TYPE_DETAILED:Ductal Carcinoma In Situ (DCIS);CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:DCIS;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:69;SUBTYPE:Luminal A;STAGE:II;PURITY:0.7;MENOPAUSE_STATUS:Postmenopausal;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.17;NONSILENT_RATE:0.72"
"LUMINAL B" "CANCER_TYPE_DETAILED:Infiltrating Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:1.96666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:53;GRADE:III;SUBTYPE:Luminal B;STAGE:III;PURITY:0.52;ER_STATUS:Positive;PR_STATUS:Positive;MENOPAUSE_STATUS:Postmenopausal;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.54;NONSILENT_RATE:2.07"
"LUMINALA" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0.433333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:42.86;SAMPLE_TYPE:Primary;RACE:ASIAN;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;COHORT:IBC;CENTER:SMC;TREATMENT_CHEMOTHERAPY:No;MUTATION_BURDEN:1.11394;PAM50_SUBTYPE:LuminalA;IHC_SUBTYPE:ER+;MENOPAUSAL_STATUS_AT_DIAGNOSIS:Pre;CYT_SCORE:18.37942872;HISTOLOGY_SUBTYPE:Ductal Carcinoma;INITIAL_TNM_STAGE:2A;SUBTYPE_CONSENSUS:ER+"
"LUMINALB" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0.666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:58.91;SAMPLE_TYPE:Primary;RACE:ASIAN;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;COHORT:IBC;CENTER:SMC;TREATMENT_CHEMOTHERAPY:No;MUTATION_BURDEN:1.30103;PAM50_SUBTYPE:LuminalB;IHC_SUBTYPE:ER+;MENOPAUSAL_STATUS_AT_DIAGNOSIS:Post;CYT_SCORE:11.65587835;HISTOLOGY_SUBTYPE:Ductal Carcinoma;INITIAL_TNM_STAGE:3A;SUBTYPE_CONSENSUS:ER+"
"LUNG ACINAR ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:1.93333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:69;FRACTION_GENOME_ALTERED:0.4060;SAMPLE_TYPE:Primary;OS_MONTHS:12.2548777;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.1;ICD_O_3_HISTOLOGY:8550/3;HISTOLOGICAL_SUBTYPE:Lung Acinar Adenocarcinoma;TUMOR_STAGE_2009:Stage IA;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:MX;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T1;PRIOR_DIAGNOSIS:NO"
"LUNG ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:10.9333333333;SEX:Male;FRACTION_GENOME_ALTERED:0.6542;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:215.9785902;GENOME_DOUBLINGS:1;DOUBLING_TIME:70.1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:adherent epithelial-like;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenocarcinoma;LINEAGE_SUBTYPE:NSCLC;NAME:RERF-LC-Ad2;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LUNG ADENOCARCINOMA IN SITU" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma In Situ;CANCER_TYPE:Lung Cancer;ONCOTREE_CODE:LAIS;TMB_NONSYNONYMOUS:0.533333333;SEX:Female;AGE:74;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;ICD_10:C34.3;HISTOLOGY:Bronchiolo-alveolar carcinoma, non-mucinous;PURITY:0.272;PROJECT_CODE:LUAD-US;WGD:wgd;SEQUENCING_TYPE:WGS;ORGAN_SYSTEM:LUNG & BRONCHUS;ANCESTRY_PRIMARY:EUR;HISTOLOGY_ABBREVIATION:Lung-AdenoCA;HISTOLOGY_TIER1:ENDODERM;HISTOLOGY_TIER2:Lung;HISTOLOGY_TIER3:Adenocarcinoma;HISTOLOGY_TIER4:Adenocarcinoma, in situ;PURITY_CONFUGURATION:0.033;TUMOR_SAMPLE_HISTOLOGY_CODE:8252/3"
"LUNG ADENOCARCINOMA MIXED SUBTYPE" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:44.0333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:68;FRACTION_GENOME_ALTERED:0.0854;SAMPLE_TYPE:Primary;OS_MONTHS:19.9100694;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.1;ICD_O_3_HISTOLOGY:8255/3;HISTOLOGICAL_SUBTYPE:Lung Adenocarcinoma Mixed Subtype;TOBACCO_SMOKING_HISTORY_INDICATOR:Current reformed smoker for < or = 15 years;TUMOR_STAGE_2009:Stage IB;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:M0;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T2;PRIOR_DIAGNOSIS:YES"
"LUNG ADENOCARCINOMA- NOT OTHERWISE SPECIFIED NOS" NA
"LUNG ADENOSQUAMOUS CARCINOMA" "CANCER_TYPE_DETAILED:Lung Adenosquamous Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAS;TMB_NONSYNONYMOUS:13.7;SEX:Male;AGE:73;FRACTION_GENOME_ALTERED:0.5852;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenosquamous Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:130.0234562;GENOME_DOUBLINGS:1;DOUBLING_TIME:156.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:mixed_adenosquamous_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenosquamous;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H596;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LUNG BRONCHIOLOALVEOLAR CARCINOMA MUCINOUS" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:0.666666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.2923;SAMPLE_TYPE:Primary;OS_MONTHS:0.0657098;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.1;ICD_O_3_HISTOLOGY:8253/3;HISTOLOGICAL_SUBTYPE:Lung Bronchioloalveolar Carcinoma Mucinous;TOBACCO_SMOKING_HISTORY_INDICATOR:Current reformed smoker for < or = 15 years;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T1;PRIOR_DIAGNOSIS:NO"
"LUNG BRONCHIOLOALVEOLAR CARCINOMA NONMUCINOUS" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:4.83333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.2515;SAMPLE_TYPE:Primary;OS_MONTHS:13.7333482;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.1;ICD_O_3_HISTOLOGY:8252/3;HISTOLOGICAL_SUBTYPE:Lung Bronchioloalveolar Carcinoma Nonmucinous;TOBACCO_SMOKING_HISTORY_INDICATOR:Current reformed smoker for < or = 15 years;TUMOR_STAGE_2009:Stage IIIB;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:M0;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T4;PRIOR_DIAGNOSIS:NO"
"LUNG CANCER" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:40.72;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:68.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:47.2;SAMPLE_TIMEPOINT:Relapse;AGE_AT_PROCUREMENT:72;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7.6;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Relapse;KARYOTYPE:47,XY,del(9)(q22),+13[18]/48,idem,+mar[2];WHOLE_EXOME_SEQUENCING:No;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:556;MOST_RECENT_TREATMENT_DURATION:9;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing ABL and ASS signal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:22.7;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:93.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:14.9;PB_MONOCYTES_PERCENTAGE:0.8;PB_NEUTROPHILS_PERCENTAGE:2.5;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_CANCER:Lung Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:Yes;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"LUNG CANCER, NOS" "CANCER_TYPE_DETAILED:Lung;CANCER_TYPE:Lung Cancer, NOS;ONCOTREE_CODE:LUNG;TMB_NONSYNONYMOUS:3.9;SEX:Female;AGE:60;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Lung;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:108.9966548;GENOME_DOUBLINGS:0;DOUBLING_TIME:30;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM +10 %FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_lung;NAME:Hs 618.T;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:4.5 g/L glucose, 1.5 g/L sodium bicarbonate;TYPE_REFINED:fibroblast_like"
"LUNG CARCINOID" "CANCER_TYPE_DETAILED:Lung Carcinoid;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUCA;TMB_NONSYNONYMOUS:19.5666666667;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.7677;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Carcinoid;TUMOR_TYPE:other;HISTOLOGY:Carcinoid-Endocrine_Tumour;PURITY:0.99;MUTATION_RATE:165.1770758;GENOME_DOUBLINGS:1;DOUBLING_TIME:65.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI 1640 +10% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:lung_carcinoid;NAME:NCI-H727;PATHOLOGIST_ANNOTATION:Endocrine;SITE_SUBTYPE1:bronchus;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"LUNG MICROPAPILLARY ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:0.766666666667;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2365;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.3;ICD_O_3_HISTOLOGY:8507/3;HISTOLOGICAL_SUBTYPE:Lung Micropapillary Adenocarcinoma;TOBACCO_SMOKING_HISTORY_INDICATOR:Lifelong Non-smoker;TUMOR_STAGE_2009:Stage IIA;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:M0;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T2;PRIOR_DIAGNOSIS:NO"
"LUNG MUCINOUS ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.1369;SAMPLE_TYPE:Primary;OS_MONTHS:9.9221798;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.3;ICD_O_3_HISTOLOGY:8480/3;HISTOLOGICAL_SUBTYPE:Lung Mucinous Adenocarcinoma;TOBACCO_SMOKING_HISTORY_INDICATOR:Current reformed smoker for > 15 years;TUMOR_STAGE_2009:Stage IIB;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:M0;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T3;PRIOR_DIAGNOSIS:YES"
"LUNG NEUROENDOCRINE" "CANCER_TYPE_DETAILED:Lung Neuroendocrine Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LNET;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.4080;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.87;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:33;M_STAGE:M1;SMOKING_HISTORY:Never;TISSUE_SITE:Pleural Effusion, Right;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:176;YEAR_OF_DIAGNOSIS:2016;PROCEDURE_TYPE:Pleural Effusion;PRETREATED:No"
"LUNG NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Lung Neuroendocrine Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LNET;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.4080;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.87;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:33;M_STAGE:M1;SMOKING_HISTORY:Never;TISSUE_SITE:Pleural Effusion, Right;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:176;YEAR_OF_DIAGNOSIS:2016;PROCEDURE_TYPE:Pleural Effusion;PRETREATED:No"
"LUNG PAPILLARY ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:9.26666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:79;FRACTION_GENOME_ALTERED:0.2725;SAMPLE_TYPE:Primary;OS_MONTHS:43.1713386;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.1;ICD_O_3_HISTOLOGY:8260/3;HISTOLOGICAL_SUBTYPE:Lung Papillary Adenocarcinoma;TOBACCO_SMOKING_HISTORY_INDICATOR:Current reformed smoker for > 15 years;TUMOR_STAGE_2009:Stage IA;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:M0;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T1;PRIOR_DIAGNOSIS:NO"
"LUNG SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Lung Squamous Cell Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUSC;TMB_NONSYNONYMOUS:7.16666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.1999;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:93.36313254;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.8;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;DISEASE_ONTOLOGY:lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_squamous;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H226;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Squamous;PROTEOMICS_TMT_LABEL:127c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LUNG_CANCER" "CANCER_TYPE_DETAILED:Small Cell Lung Cancer;CANCER_TYPE:Small Cell Lung Cancer;ONCOTREE_CODE:SCLC;TMB_NONSYNONYMOUS:23.3333333333;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.7551;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Small Cell Lung Cancer (SCLC);TUMOR_TYPE:lung_small_cell;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:157.2416381;GENOME_DOUBLINGS:1;DOUBLING_TIME:450;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:Waymouth's +10%FBS;HIST_SUBTYPE1:small_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:SCLC;NAME:DMS 53;PATHOLOGIST_ANNOTATION:Lung:SCLC;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_small_cell"
"LUNG_CARCINOID" "CANCER_TYPE_DETAILED:Lung Carcinoid;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUCA;TMB_NONSYNONYMOUS:19.5666666667;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.7677;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Carcinoid;TUMOR_TYPE:other;HISTOLOGY:Carcinoid-Endocrine_Tumour;PURITY:0.99;MUTATION_RATE:165.1770758;GENOME_DOUBLINGS:1;DOUBLING_TIME:65.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI 1640 +10% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:lung_carcinoid;NAME:NCI-H727;PATHOLOGIST_ANNOTATION:Endocrine;SITE_SUBTYPE1:bronchus;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"LUNG_CARCINOMA" "CANCER_TYPE_DETAILED:Pleura;CANCER_TYPE:Pleural Cancer, NOS;ONCOTREE_CODE:PLEURA;TMB_NONSYNONYMOUS:16.8666666667;SUBTYPE:Carcinoma;LINEAGE:lung;LINEAGE_SUBTYPE:lung_carcinoma"
"LUNG_NSC" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"LUNG_SMALL_CELL" "CANCER_TYPE_DETAILED:Small Cell Lung Cancer;CANCER_TYPE:Small Cell Lung Cancer;ONCOTREE_CODE:SCLC;TMB_NONSYNONYMOUS:7.07303226308;SEX:Female;FRACTION_GENOME_ALTERED:0.4481;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Small_Cell;HISTOLOGICAL_SUBTYPE:Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"LUSC" "CANCER_TYPE_DETAILED:Lung Squamous Cell Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUSC;TMB_NONSYNONYMOUS:7.16666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.1999;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:93.36313254;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.8;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;DISEASE_ONTOLOGY:lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_squamous;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H226;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Squamous;PROTEOMICS_TMT_LABEL:127c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LYMPHATIC CANCER, NOS" "CANCER_TYPE_DETAILED:Lymphoid Neoplasm;CANCER_TYPE:Lymphatic Cancer, NOS;ONCOTREE_CODE:LNM;TMB_NONSYNONYMOUS:1.7;FRACTION_GENOME_ALTERED:0.0251;SUBTYPE:Lymphoma;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_lymphocyte"
"LYMPHOBLASTIC LYMPHOMA" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:10.9666666667;SUBTYPE:Lymphoblastic Lymphoma;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:lymphoblastic_lymphoma;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;TYPE_REFINED:B-cell_ALL"
"LYMPHOBLASTIC_LYMPHOMA" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:10.9666666667;SUBTYPE:Lymphoblastic Lymphoma;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:lymphoblastic_lymphoma;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;TYPE_REFINED:B-cell_ALL"
"LYMPHOEPITHELIOMA-LIKE CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Lymphoepithelioma-like Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LECLC;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0006;SAMPLE_TYPE:Metastasis;OS_MONTHS:23.37;OS_STATUS:0:LIVING;PRIMARY_SITE:Lung;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lymph Node;TUMOR_PURITY:20;SAMPLE_COVERAGE:663;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"LYMPHOID CANCER" "CANCER_TYPE_DETAILED:Mature B-Cell Neoplasms;CANCER_TYPE:Lymphoid Cancer;ONCOTREE_CODE:MBN;TMB_NONSYNONYMOUS:4.73333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:75;FRACTION_GENOME_ALTERED:0.0105;SAMPLE_TYPE:Primary;OS_MONTHS:4.34;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:4.34;TISSUE_SOURCE_SITE:FA;ICD_O_3_SITE:C16.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:[Unknown];ICD_10:C83.3;ICD_O_3_HISTOLOGY:9680/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/12/12;AJCC_STAGING_EDITION:7th;HISTOLOGICAL_DIAGNOSIS:Diffuse large B-cell lymphoma (DLBCL) NOS (any anatomic site nodal or extranodal);HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:[Unknown];TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-FA-8693.977683b9-1cad-4033-9825-7dbb84b171e1.pdf;VIAL_NUMBER:A;WEIGHT:82.0;SITE_OF_TUMOR_TISSUE:Stomach;HEIGHT:169.0;SPECIMEN_SECOND_LONGEST_DIMENSION:1.5;LONGEST_DIMENSION:2.8;SHORTEST_DIMENSION:0.5;TARGETED_MOLECULAR_THERAPY:[Unknown];CLINICAL_STAGE:Stage I;EBV_STATUS:[Not Evaluated];FOLLICULAR_COMPONENT_PERCENT:< or = 10%;EXTRANODAL_INVOLVEMENT:1;EXTRANODAL_LYMPHOMATOUS_INVOLVEMENT:YES;HISTORY_IMMUNOLOGICAL_DISEASE:[Unknown];HISTORY_IMMUNOSUPPRESIVE_DX:None;HIV_STATUS:Negative;IGH_GENOTYPE_RESULT:[Not Evaluated];IGK_GENOTYPE_RESULT:[Not Evaluated];IMMUNOPHENOTYPIC_ANALYSIS_METHOD:Immunohistochemistry|Immunohistochemistry|Immunohistochemistry|Immunohistochemistry;IMMUNOPHENOTYPIC_ANALYSIS_RESULTS:Negative|Positive|Negative|Negative;IMMUNOPHENOTYPIC_ANALYSIS_TESTED:CD10 > 30%|CD20|CD5|Cyclin D1;MIB_1_POSITIVE_PERCENT_RANGE:51 - 75%"
"LYMPHOID NEOPLASM" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.96251613397;SEX:Female;FRACTION_GENOME_ALTERED:0.2331;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Dlbcl;HISTOLOGICAL_SUBTYPE:Diffuse_Large_B_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Haematopoietic"
"LYMPHOMA" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:7.5;GENE_PANEL:WXS;PROTOCOL:9900;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:90;SNAPSHOT_MUTATIONS:IKZF1,ETV6;DNA_INDEX:0.52;KNOWN_MOLECULAR_CLASSIFIER:Near haploid"
"LYMPHOMA_BURKITT" "CANCER_TYPE_DETAILED:Burkitt Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:BL;TMB_NONSYNONYMOUS:4.0890967771;SEX:Male;FRACTION_GENOME_ALTERED:0.1882;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Burkitt;HISTOLOGICAL_SUBTYPE:Burkitt_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"LYMPHOMA_DLBCL" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:6.96251613397;SEX:Female;FRACTION_GENOME_ALTERED:0.2331;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Dlbcl;HISTOLOGICAL_SUBTYPE:Diffuse_Large_B_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Haematopoietic"
"LYMPHOMA_HODGKIN" "CANCER_TYPE_DETAILED:Hodgkin Lymphoma;CANCER_TYPE:Hodgkin Lymphoma;ONCOTREE_CODE:HL;TMB_NONSYNONYMOUS:4.53116129354;SEX:Male;FRACTION_GENOME_ALTERED:0.2450;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Hodgkin;HISTOLOGICAL_SUBTYPE:Hodgkin_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"LYMPHOMA_UNSPECIFIED" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:16.024838721;SEX:Male;FRACTION_GENOME_ALTERED:0.1932;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:B_Cell_Lymphoma_Unspecified;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"M0" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"M2" "CANCER_TYPE_DETAILED:AML with Maturation;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AM;SOMATIC_STATUS:Matched;SEX:Male;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:61.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:16.5;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:61;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;FAB:M2;HEMOGLOBIN_LEVEL:8.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.05;CURRENT_STAGE:Induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:66;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:46;CUMULATIVE_TREATMENT_REGIMENS:3+7 (Cytarabine, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:3+7 (Cytarabine, Daunorubicin);LDH_LEVEL:551;MOST_RECENT_TREATMENT_DURATION:7;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.4;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:89.1;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:18;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:24;PB_MONOCYTES_PERCENTAGE:5;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with maturation;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with maturation;SURFACE_ANTIGENS:CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+);TOTAL_PROTEIN_LEVEL:7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"M3" "CANCER_TYPE_DETAILED:APL with PML-RARA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:APLPMLRARA;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:0.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:65.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:9.8;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:65;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;FAB:M3;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.6;CURRENT_STAGE:Induction;FUSION:PML-RARA;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3];PB_BLAST_PERCENTAGE:57;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:72;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:3+7 (Cytarabine, Daunorubicin);LDH_LEVEL:398;MOST_RECENT_TREATMENT_DURATION:3;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Unusual t(15;17), with the fusion signal on the derivative chromosome 15;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Adverse;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:20.7;INDUCTION_RESPONSE:Unknown;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.2;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:2.9;PB_ALT_LEVEL:24;PB_AST_LEVEL:33;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:36;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:8;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SURFACE_ANTIGENS:partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive;TOTAL_PROTEIN_LEVEL:5.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"M4" "CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:ACYC;TMB_NONSYNONYMOUS:1.366666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:50;SAMPLE_TYPE:Primary;PRIMARY_SITE:Head and Neck;TUMOR_TISSUE_SITE:Maxilla;PLATFORM:WGS;TUMOR_SIZE:2;STUDY:ACyC (MDA 2015);HISTOLOGICAL_TYPE:Cribriform/Solid/Tubular;PERINEURAL_INVASION:Yes;FUSION_STATUS:YES;GENOMIC_ALTERATIONS:55;MYB_MYBL1_FUSION:MYB-NFIB;MYB_NFIB_FISH:Positive;FUSION_OTHER:ATRNL1-ACVR1B, EGLN1-KCNH1, NEDD9-VPS54, RBM47-PDE8A, SLC8A1-ALK, ZFP37-UBR4;MYB_MYBL1_FUSION_METHOD:WGS;MYB_NFIB_TRANSLOCATION:t(6;9);NFIB_FUSION_OTHER:Negative"
"M5" "CANCER_TYPE_DETAILED:B-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:BALL;TMB_NONSYNONYMOUS:3.35249282986;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.06;GENE_PANEL:Targeted_Seq;COHORT:INF_MLLr_Validation;MLL_STATUS:INF_MLLr;LEUKEMIA_TYPE:MixedPreB-M5"
"M5A" "CANCER_TYPE_DETAILED:AML with Recurrent Genetic Abnormalities;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLRGA;TMB_NONSYNONYMOUS:0.833333333;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:32.2;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:62.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:14.66;AGE_AT_PROCUREMENT:62;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:3;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;FAB:M5a;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Allogeneic - Matched Unrelated Donor;FUSION:MLLT3-KMT2A;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11];PB_BLAST_PERCENTAGE:58;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:93;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Fludarabine, TBI;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-1;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_CANCER:Prostate Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with t(9;11)(p22;q23); MLLT3-MLL;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with t(9;11)(p22;q23); MLLT3-MLL;SURFACE_ANTIGENS:Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"M6" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;SOMATIC_STATUS:Matched;SEX:Male;AGE:4.0;OS_MONTHS:4.0;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;ANALYSIS_COHORT:DISCOVERY;PROTOCOL:CCG-2961;WBC:13.9;OS_DAYS:112.0;AGE_IN_DAYS:1248.0;RISK_GROUP:Standard;DAYS_TO_EVENT:107.0;FAB:M6;FIRST_EVENT:Relapse;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:14.0;CNS_SITE_OF_RELAPSE:No;BONE_MARROW_SITE_OF_RELAPSE:Yes;CEBPA_MUTATION:No;OTHER_SITE_OF_RELAPSE:No;PERIPHERAL_BLASTS_PERCENTAGE:3.0;CBFT2A3_GLIS:Not Done;CHLOROMA:No;CHLOROMA_RELAPSE_SITE:No;CKIT_EXON_17_MUTATION:Not done;CKIT_EXON_8_MUTATION:Not done;CNS_DISEASE:No;CR_STATUS_AT_END_OF_COURSE_1:CR;CR_STATUS_AT_END_OF_COURSE_2:CR;CYTOGENETIC_COMPLEXITY:2;CYTOGENETIC_RELAPSE_SITE:No;DEL_5Q:No;DEL_7Q:No;DEL_9Q:Yes;FLT3_ITD_POSITIVE:No;FLT3_PM:No;INV_16:No;ISCN:46,XY,del(9)(q22q34)[13]/46,idem,add(18)(p13)[4]/46,XY[3];MINUS_X:No;MINUS_Y:No;MLL:No;MONOSOMY_5:No;MONOSOMY_7:No;MRD_AT_END_OF_COURSE_1:Unknown;MRD_AT_END_OF_COURSE_2:Unknown;NPM_MUTATION:Unknown;NUP98_NSD1:Not Done;OTHER_MLL:No;PRIMARY_CYTOGENETIC_CODE:Other;SCT_IN_FIRST_CR:No;T_10_11_P11_2_Q23:No;T_11_19_Q23_P13_1:No;T_3_5_Q25_Q34:No;T_6_11_Q27_Q23:No;T_6_9:No;T_8_21:No;T_9_11_P22_Q23:No;TRISOMY_21:No;TRISOMY_8:No;WT1_MUTATION:Unknown"
"M7" "CANCER_TYPE_DETAILED:AML with Biallelic Mutations of CEBPA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLCEBPA;TMB_NONSYNONYMOUS:0.666666667;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:8.98;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:42.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:7.9;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:42;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;FAB:M7;HEMOGLOBIN_LEVEL:12;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.81;CURRENT_STAGE:Re-induction;FUSION:Unknown;GROUP:Initial Acute Leukemia Diagnosis;PB_BLAST_PERCENTAGE:9;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:70;CEBPA_MUTATION:p.V119?M120insV; MAF 30%;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone);CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:MEC (Cytarabine, Etoposide, Mitoxantrone);LDH_LEVEL:762;MOST_RECENT_TREATMENT_DURATION:4;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:34.8;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:85.2;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.5;PB_ALT_LEVEL:36;PB_AST_LEVEL:28;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:43;PB_MONOCYTES_PERCENTAGE:6;PB_NEUTROPHILS_PERCENTAGE:38;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated CEBPA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated CEBPA;SURFACE_ANTIGENS:CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive;TOTAL_PROTEIN_LEVEL:6.8;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MALIGNANT AMELANOTIC MELANOMA" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:12.43333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.1862;HISTOLOGICAL_SUBTYPE:Malignant amelanotic melanoma;PRIOR_TREATMENT:None;DOUBLING_TIME:20.5;P53:WT;EPITHELIAL:No;MDR:12"
"MALIGNANT FIBROUS HISTIOCYTOMA" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:9.39387097441;SEX:Male;FRACTION_GENOME_ALTERED:0.4426;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Malignant Fibrous Histiocytoma-Pleomorphic Sarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"MALIGNANT FIBROUS HISTIOCYTOMA-PLEOMORPHIC SARCOMA" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:9.39387097441;SEX:Male;FRACTION_GENOME_ALTERED:0.4426;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Malignant Fibrous Histiocytoma-Pleomorphic Sarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"MALIGNANT LYMPHOMA" "CANCER_TYPE_DETAILED:Diffse large B-cell lymphoma;CANCER_TYPE:Mature B-cell lymphoma;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:2.633333333;SEX:Female;AGE:56;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;ICD_10:C85.1;STAGE:unknown;HISTOLOGY:Follicular lymphoma;PURITY:0.325;TOBACCO_SMOKING_HISTORY_INDICATOR:Smoking history not documented;PROJECT_CODE:MALY-DE;WGD:no_wgd;SEQUENCING_TYPE:WGS;CELLULARITY:60;ALCOHOL:Don't know/Not sure;FIRST_THERAPY:Other Therapy;ORGAN_SYSTEM:LYMPH NODES;ALCOHOL_HISTORY_INTENSITY:Not Documented;ANCESTRY_PRIMARY:EUR;FIRST THERAPY_RESPONSE:Stable Disease;HISTOLOGY_ABBREVIATION:Lymph-BNHL;HISTOLOGY_TIER1:MESODERM;HISTOLOGY_TIER2:Lymphoid;HISTOLOGY_TIER3:Lymphoma, NOS;HISTOLOGY_TIER4:Malignant lymphoma, NOS;PURITY_CONFUGURATION:0.007;TUMOR_SAMPLE_HISTOLOGY_CODE:9590/3"
"MALIGNANT MELANOMA" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:2.43135484044;SEX:Male;FRACTION_GENOME_ALTERED:0.7563;PRIMARY_SITE:Skin;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Melanoma;HISTOLOGICAL_TYPE:Malignant Melanoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"MALIGNANT MELANOTIC MELANOMA" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:7.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:43;FRACTION_GENOME_ALTERED:0.2589;SAMPLE_TYPE:Metastasis;HISTOLOGICAL_SUBTYPE:Malignant melanotic melanoma;PRIOR_TREATMENT:None;DOUBLING_TIME:46.2;P53:WT;CATEGORY_SAMPLE:Metastasis;EPITHELIAL:No;MDR:22"
"MALIGNANT MIXED MULLERIAN TUMOR MMMT" NA
"MALIGNANT PERIPHERAL NERVE SHEATH TUMOR" "CANCER_TYPE_DETAILED:Malignant Peripheral Nerve Sheath Tumor;CANCER_TYPE:Sarcoma;SEX:Male;AGE:15.43600273;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:23;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"MALIGNANT PERIPHERAL NERVE SHEATH TUMORS MPNST" NA
"MALIGNANT PHYLLODES TUMOR OF THE BREAST" "CANCER_TYPE_DETAILED:Malignant Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:MPT;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:53;ETHNICITY:Malay;HISTOLOGICAL_DIAGNOSIS:Malignant PT;TUMOR_SIZE:63;SURGERY:Wide Excision;MEAN_COVERAGE:71;NUM_SOMATIC_MUTATION:25"
"MALIGNANT PT" "CANCER_TYPE_DETAILED:Malignant Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:MPT;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:53;ETHNICITY:Malay;HISTOLOGICAL_DIAGNOSIS:Malignant PT;TUMOR_SIZE:63;SURGERY:Wide Excision;MEAN_COVERAGE:71;NUM_SOMATIC_MUTATION:25"
"MALIGNANT RHABDOID TUMOR" "CANCER_TYPE_DETAILED:Rhabdoid Cancer;CANCER_TYPE:Rhabdoid Cancer;ONCOTREE_CODE:MRT;TMB_NONSYNONYMOUS:7.0;SEX:Female;AGE:1;FRACTION_GENOME_ALTERED:0.0248;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Malignant Rhabdoid Tumor;TUMOR_TYPE:soft_tissue;HISTOLOGY:Rhabdoid_Tumour;PURITY:1;MUTATION_RATE:92.67187107;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:pediatric;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:malignant_rhabdoid_tumor;NAME:A-204;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Rhabdoid;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:striated_muscle;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"MALIGNANT SACROCOCCYGEAL TERATOMA" "CANCER_TYPE_DETAILED:Germ Cell Tumor, Brain;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:BGCT;SEX:Female;FRACTION_GENOME_ALTERED:0.1464;SAMPLE_TYPE:Primary;RACE:White;ETHNICITY:Non-Hispanic;PRIMARY_SITE:Sacrum;VITAL_STATUS:NED;SURGERY:Sacrococcygeal Resection;CENTER:MAI;AFP_AT_PROCUREMENT:125;CHEMO_CYCLES:7;FIRST_LINE_THERAPY:PEB;TIME_TO_RECURRENCE_MONTHS:7;DX_ORG_INST:Malignant Sacrococcygeal Teratoma;PATH_DX_MSK:Sacrococcygeal Teratoma;REC_AFTER_FIRST_LINE:Responded then recurred;RESPONDED_SECOND_LINE:Responded to second line;SECOND_LINE_TC_OR_SURGERY:Paclitaxel, ifosfamide, carboplatin"
"MALIGNANT SMALL CELL TUMOR" "CANCER_TYPE_DETAILED:Malignant Small Cell Tumor;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.1;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1231;DIAGNOSIS AGE:31;GDNA(NG):3300;SMOKE STATUS:Unknown;TUMOR_PURTITY:30"
"MALIGNANT TUMOR" "CANCER_TYPE_DETAILED:Malignant Tumor;CANCER_TYPE:Miscellaneous Brain Tumor;ONCOTREE_CODE:MT;TMB_NONSYNONYMOUS:3.45879237993;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1016;SAMPLE_TYPE:Metastasis;OS_MONTHS:7.47;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;MSI_SCORE:0.11;MSI_TYPE:Stable;SAMPLE_COVERAGE:466;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;AGE_AT_SEQ_REPORTED_YEARS:72;M_STAGE:M1;SMOKING_HISTORY:never;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;ARCHER:NO;T_STAGE:Tx;N_STAGE:Nx;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:224;YEAR_OF_DIAGNOSIS:2017;PRETREATED:yes"
"MALIGNANT_FIBROUS_HISTIOCYTOMA" "CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:MFH;TMB_NONSYNONYMOUS:23.8666666667;SEX:Male;AGE:29;FRACTION_GENOME_ALTERED:0.4429;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Pleomorphic Sarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Malignant_Fibrous_Histiocytoma-Pleomorphic_Sarcoma;PURITY:1;MUTATION_RATE:179.4906831;GENOME_DOUBLINGS:1;DOUBLING_TIME:64.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:pleomorphic_sarcoma;NAME:GCT;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_FibrousHistiocytoma;SITE_OF_FINDING:lung;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"MALIGNANT_MELANOMA" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:12.1333333333;SEX:Male;AGE:28;FRACTION_GENOME_ALTERED:0.4180;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Skin;SUBTYPE:Melanoma;TUMOR_TYPE:melanoma;HISTOLOGY:Malignant_Melanoma;PURITY:1;GENOME_DOUBLINGS:1;DOUBLING_TIME:49.5;GEOGRAPHIC_DISTRIBUTION:europe;ANNOTATION_SOURCE:CCLE;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI1640+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:skin;LINEAGE_SUBTYPE:melanoma;NAME:RVH-421;PATHOLOGIST_ANNOTATION:Skin:Melanoma;PROTEOMICS_TMT_LABEL:129c;SITE_OF_FINDING:brain;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:melanoma"
"MALIGNANT_PAPILLARY_SEROUS_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Mixed Ovarian Carcinoma;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:MXOV;TMB_NONSYNONYMOUS:6.6;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.2507;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:93.71418335;GENOME_DOUBLINGS:0;DOUBLING_TIME:91.2;GEOGRAPHIC_DISTRIBUTION:canada;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;CHARACTERISTICS:Epithelial Adherent;DISEASE_ONTOLOGY:malignant_papillary_serous_adenocarcinoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:MCDB 105 (1:1)Medium 199 +15%FBS;HIST_SUBTYPE1:mixed_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OV-90;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"MALIGNANT_RHABDOID_TUMOR" "CANCER_TYPE_DETAILED:Rhabdoid Cancer;CANCER_TYPE:Rhabdoid Cancer;ONCOTREE_CODE:MRT;TMB_NONSYNONYMOUS:7.0;SEX:Female;AGE:1;FRACTION_GENOME_ALTERED:0.0248;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Malignant Rhabdoid Tumor;TUMOR_TYPE:soft_tissue;HISTOLOGY:Rhabdoid_Tumour;PURITY:1;MUTATION_RATE:92.67187107;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:pediatric;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:malignant_rhabdoid_tumor;NAME:A-204;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Rhabdoid;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:striated_muscle;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"MAMMARY ANALOGUE SECRETORY CARCINOMA OF SALIVARY GLAND ORIGIN" "CANCER_TYPE_DETAILED:Mammary Analogue Secretory Carcinoma of Salivary Gland Origin;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:HNMASC;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Female;AGE:34;FRACTION_GENOME_ALTERED:0.2271;PFS_STATUS:Yes;RADIATION_THERAPY:Yes;STAGE:Stage III;RFS_STATUS:Yes;SURGERY:Yes;DEATH:Yes;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:Yes;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Salivary Carcinoma;DOB_LASTFU_TIME_YRS:44;DOB_PROG_START_TIME_YRS:40;DOB_PROG_TIME_YRS:40;DOB_RECUR_START_TIME_YRS:34;DOB_RECUR_TIME_YRS:39;DOB_REPORT_TIME_YRS:41;DOB_TISSUE_TIME_YRS:41;LINE_OBR_CHEMO:PR;LINE_OBR_CHEMO_G:Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:PR;LINE_OBR_NOTRK_G:Response;LINE_OBR_NTRK:PR;LINE_OBR_NTRK_G:Response;LINE_OBR_TARGETED:PR;LINE_OBR_TARGETED_G:Response;LINE1_BR_NOTRK:PD;LINE1_BR_NOTRK_G:No-Response;NUM_LINES:8;NUM_LINES_CHEMO:3;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:4;NUM_LINES_TARGETED:2;POS_ARCHER:Negative;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:IMPACT Only;PROG_DEATH:Yes;PROG_DEATH_TIME_YRS:4;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:1"
"MANTLE CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Mantle Cell Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:MCL;TMB_NONSYNONYMOUS:5.0;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.1503;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins, Mantle Cell;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:0.99;MUTATION_RATE:73.86512393;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:spheroid cells growing in suspention, singly or in clumps;DISEASE_ONTOLOGY:mantle_cell_lymphoma;DOUBLING_TIME_FROM_VENDOR:~ 49 hrs;GROWTH_MEDIUM:90% Dulbecco's MEM(4.5 g/L glucose) +10% h.i.FBS;HIST_SUBTYPE1:mantle_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_mantle_cell;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:GRANTA-519;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM L-glutamine;TYPE_REFINED:B-cell_lymphoma_other"
"MANTLE_CELL_LYMPHOMA" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:2.54187096955;SEX:Female;FRACTION_GENOME_ALTERED:0.1489;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:Mantle_Cell_Lymphoma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"MARGINAL ZONE LYMPHOMA" "CANCER_TYPE_DETAILED:Marginal Zone Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:MZL;TMB_NONSYNONYMOUS:0.1;FRACTION_GENOME_ALTERED:0.1345;SAMPLE_TYPE:Primary;INSTITUTE:UNMC;SPECIMEN_PRESERVATION_TYPE:Fresh/Frozen;MOLECULAR_SUBTYPE:unknown"
"MASKED LOW HYPODIPLOID" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:16.1;GENE_PANEL:WGS;PROTOCOL:AALL03B1,ASCT0431;CYTOGENETICS:35,X,+1,+5,+6,+8,+10,der(10)t(7;10)(q11.2;q24),+11,+12,+14,+18,+19,+21,+mar[cp4]/61<2n>,X,+X,-Y,+1,+5,+6,+8,+8,+10,+10,der(10)t(7;10)x2,+11,+12,+12,i(13)(q10), +14,+18,+19,+21,+21[cp7]/61<2n>,X,+X,-Y,+1,+5,+6,+8,+8,+10,+10,der(10)t(7;10)x2,+11,+12,+12,i(1;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:90;SNAPSHOT_MUTATIONS:TP53,RB1;DNA_INDEX:0.791 in 58%; 37% hyperdiploid peak;KNOWN_MOLECULAR_CLASSIFIER:Masked low hypodiploid"
"MASTOCYTOSIS" "CANCER_TYPE_DETAILED:Mastocytosis;CANCER_TYPE:Mastocytosis;ONCOTREE_CODE:MCD;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:12.01;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:66.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:11.9;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:67;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:NOS;HEMOGLOBIN_LEVEL:12;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.83;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Residual Disease|Post-Chemotherapy;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:63;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:75;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Quizartinib;LDH_LEVEL:226;MOST_RECENT_TREATMENT_DURATION:57;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:Yes;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Not Enough Information;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:35;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:95.2;MPN_TWO_MONTHS_PRIOR_AML:Yes;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:107;PB_AST_LEVEL:47;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:8;PB_MONOCYTES_PERCENTAGE:0;PB_NEUTROPHILS_PERCENTAGE:23;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mastocytosis;SURFACE_ANTIGENS:CD13, CD33, partial CD34, CD38, CD117 and CD123;TOTAL_PROTEIN_LEVEL:5.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MATURE B-CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Follicular lymphoma;CANCER_TYPE:Mature B-cell lymphoma;ONCOTREE_CODE:FL;TMB_NONSYNONYMOUS:1.6;SEX:Male;AGE:46;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;ICD_10:C82.0;STAGE:unknown;HISTOLOGY:Follicular lymphoma, grade 1;PURITY:0.62;TOBACCO_SMOKING_HISTORY_INDICATOR:Smoking history not documented;PROJECT_CODE:MALY-DE;WGD:no_wgd;SEQUENCING_TYPE:WGS;CELLULARITY:70;ALCOHOL:Don't know/Not sure;FIRST_THERAPY:Other Therapy;ORGAN_SYSTEM:LYMPH NODES;ALCOHOL_HISTORY_INTENSITY:Not Documented;ANCESTRY_PRIMARY:EUR;FIRST THERAPY_RESPONSE:Partial Response;HISTOLOGY_ABBREVIATION:Lymph-BNHL;HISTOLOGY_TIER1:MESODERM;HISTOLOGY_TIER2:Lymphoid;HISTOLOGY_TIER3:Mature B-cell lymphoma;HISTOLOGY_TIER4:Follicular lymphoma;PURITY_CONFUGURATION:0.031;TUMOR_SAMPLE_HISTOLOGY_CODE:9695/3"
"MATURE B-CELL NEOPLASMS" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:63.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Mature B-Cell Neoplasms;WBC:7.14;AGE_AT_PROCUREMENT:63;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.99;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Unknown;KARYOTYPE:44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide);CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:RVD (Bortezomib, Dexamethasone, Lenalidomide);LDH_LEVEL:249;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Abnormal;DIAGNOSIS_AT_INCLUSION:Mature B-Cell Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:16;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:22;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.6;PB_ALT_LEVEL:22;PB_AST_LEVEL:24;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0.9;PB_LYMPHOCYTES_PERCENTAGE:28.7;PB_MONOCYTES_PERCENTAGE:8.3;PB_NEUTROPHILS_PERCENTAGE:60.2;PB_NUCLEATED_RBC_PERCENTAGE:0.6;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Plasma cell myeloma;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Plasma cell myeloma;TOTAL_PROTEIN_LEVEL:4.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MATURE T AND NK NEOPLASMS" "CANCER_TYPE_DETAILED:Mycosis Fungoides;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:MYCF;TMB_NONSYNONYMOUS:5.33333333333;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.4604;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:118.2175686;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:sezary_syndrome;HIST_SUBTYPE1:mycosis_fungoides-Sezary_syndrome;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HuT 78;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:skin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"MATURE TERATOMA" "CANCER_TYPE_DETAILED:Immature Teratoma;CANCER_TYPE:Ovarian Germ Cell Tumor;ONCOTREE_CODE:OIMT;TMB_NONSYNONYMOUS:2.1;SEX:Female;OS_MONTHS:61;OS_STATUS:0:LIVING;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:9;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Peritoneum;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Germ cell;GMED_OS_MONTHS:52;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"MBL" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;SOMATIC_STATUS:Matched;SEX:Male;AGE:66;FRACTION_GENOME_ALTERED:0.2678;SAMPLE_TYPE:Primary;OS_MONTHS:59.33;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:59.33;TISSUE_SOURCE_SITE:ZF;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/15/14;GRADE:High Grade;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2008;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1850;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-ZF-AA4V.52B54951-E580-49D6-BBB5-4F2329A271B0.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:290;SMOKING_PACK_YEARS:28;WEIGHT:85;SITE_OF_TUMOR_TISSUE:Bladder;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3b;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:177;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;SMOKING_YEAR_STARTED:15;CLIN_T_STAGE:T2;ANGIOLYMPHATIC_INVASION:[Not Reported];FAMILY_HISTORY_CANCER_RELATIONSHIP:Father|Child;FAMILY_HISTORY_CANCER_TYPE:Lung/Bronchus|Breast-Fem;OCCUPATION_PRIMARY:radio and tv engineer;OCCUPATION_PRIMARY_YEARS_WORKED:34;EXTRACAPSULAR_EXTENSION:NO;NONINVASIVE_BLADDER_HISTORY:NO;OCCUPATION_CURRENT:retired;OCCUPATION_PRIMARY_CHEMICAL_EXPOSURE:soldering, assembling and repairng electrical goods;OCCUPATION_PRIMARY_INDUSTRY:telecommunications"
"MCRC METASTASIS" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:9.98239770538;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2312;SAMPLE_TYPE:Metastasis;OS_MONTHS:27.37;OS_STATUS:1:DECEASED;PRIMARY_SITE:Cecum;GENE_PANEL:IMPACT341;MSI_SCORE:0.72;VITAL_STATUS:Deceased;AGE_AT_DIAGNOSIS:67;STAGE_AT_DIAGNOSIS:IV;MOLECULAR_SUBTYPE:MSI Status;SPECIMEN_TYPE:Resection;TUMOR_SAMPLE_HISTOLOGY:Conventional;PATIENT_GRADE:Mod_Diff;PRIMARY_TUMOR_LOCATION:Right;FIRST_SITE_OF_METS:Liver, Peritoneum;TIME_TO_METASTASIS_MONTHS:0;CHEMO_EXP_SEQ_SPECIMEN:Yes;MCRC_TYPE:mCRC Metastasis;METASTASECTOMY:0;METASTASES_SITE_FIRST_BONE:0;METASTASES_SITE_FIRST_BRAIN:0;METASTASES_SITE_FIRST_GYN:0;METASTASES_SITE_FIRST_LIVER:1;METASTASES_SITE_FIRST_LN:0;METASTASES_SITE_FIRST_LUNG:0;METASTASES_SITE_FIRST_PELVIS:0;METASTASES_SITE_FIRST_PERITONEUM_OMENTUM_ABDOMEN:1;METASTATIC_BIOPSY_SITE:Ovary;OTHER_SITES_OF_METS:0;TIME_FROM_MET_DX_SEQUENCING:38.93333333"
"MDS" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.98;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:73.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:94;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:73;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M1;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.79;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:97;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:94;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:AC220 (Ambit);LDH_LEVEL:441;MOST_RECENT_TREATMENT_DURATION:30;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Intermediate-I;ELN_2017:Favorable or Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:19.3;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:100.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:4.1;PB_ALT_LEVEL:19;PB_AST_LEVEL:28;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:2;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;SURFACE_ANTIGENS:CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative;TOTAL_PROTEIN_LEVEL:7.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MDS WITH EXCESS BLASTS" "CANCER_TYPE_DETAILED:MDS with Excess Blasts;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSEB;TMB_NONSYNONYMOUS:0.966666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:3.82;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;CHEMOTHERAPY:Yes;DIAGNOSIS:Myelodysplastic Syndromes;CAUSE_OF_DEATH_SOURCE:Dead-Unknown;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Induction;FUSION:None;GROUP:Unknown;KARYOTYPE:46,XY[20];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;MOST_RECENT_TREATMENT_DURATION:60;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200];DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:60;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-3;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Refractory anaemia with excess blasts;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Refractory anaemia with excess blasts;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MDS WITH EXCESS BLASTS-2" "CANCER_TYPE_DETAILED:MDS with excess blasts-2;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSEB2;TMB_NONSYNONYMOUS:4.6626176495;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:MDS with excess blasts-2"
"MDS WITH ISOLATED DEL5Q" NA
"MDS WITH MULTILINEAGE DYSPLASIA" "CANCER_TYPE_DETAILED:MDS with Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSMD;SOMATIC_STATUS:Unmatched;SEX:Female;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:59.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic Syndromes;WBC:2.8;AGE_AT_PROCUREMENT:59;CENTER:5;TREATMENT_TYPE:Unknown;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Unknown;FUSION:None;GROUP:Post-Chemotherapy;KARYOTYPE:46,XX,del(9)(q21q31-33)[10]/46,XX[10];WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:2;CEBPA_MUTATION:p.E10K; MAF 26.7%;CUMULATIVE_TREATMENT_REGIMENS:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);CUMULATIVE_TREATMENT_STAGES:Unknown;CUMULATIVE_TREATMENT_TYPES:Unknown;CURRENT_REGIMEN:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Unknown;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Refractory cytopenia with multilineage dysplasia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Refractory cytopenia with multilineage dysplasia"
"MDS WITH RING SIDEROBLASTS" "CANCER_TYPE_DETAILED:MDS with Ring Sideroblasts and Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSRSMD;TMB_NONSYNONYMOUS:8.3927117691;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:MDS with Ring Sideroblasts and Multilineage Dysplasia"
"MDS WITH RING SIDEROBLASTS AND MULTILINEAGE DYSPLASIA" "CANCER_TYPE_DETAILED:MDS with Ring Sideroblasts and Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSRSMD;TMB_NONSYNONYMOUS:8.3927117691;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:MDS with Ring Sideroblasts and Multilineage Dysplasia"
"MDS WITH RING SIDEROBLASTS AND SINGLE LINEAGE DYSPLASIA" "CANCER_TYPE_DETAILED:MDS with Ring Sideroblasts and Single Lineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSRSSLD;TMB_NONSYNONYMOUS:0.9325235299;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:MDS with Ring Sideroblasts and Single Lineage Dysplasia"
"MDS WITH SINGLE LINEAGE DYSPLASIA" "CANCER_TYPE_DETAILED:MDS with Single Lineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSSLD;TMB_NONSYNONYMOUS:6.5276647093;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:MDS with Single Lineage Dysplasia"
"MDS, UNCLASSIFIABLE" "CANCER_TYPE_DETAILED:MDS, Unclassifiable;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSU;TMB_NONSYNONYMOUS:1.066666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:9.84;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:68.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Myelodysplastic Syndromes;WBC:2.42;AGE_AT_PROCUREMENT:68;CAUSE_OF_DEATH_SOURCE:Dead-Unknown;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.18;CURRENT_STAGE:Induction;FUSION:None;GROUP:Unknown;KARYOTYPE:45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4];PB_BLAST_PERCENTAGE:15;WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine;LDH_LEVEL:1138;MOST_RECENT_TREATMENT_DURATION:6;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:21;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-13;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:88.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3;PB_ALT_LEVEL:27;PB_AST_LEVEL:23;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1.7;PB_LYMPHOCYTES_PERCENTAGE:38.7;PB_MONOCYTES_PERCENTAGE:3.4;PB_NEUTROPHILS_PERCENTAGE:30.3;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myelodysplastic syndrome, unclassifiable;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myelodysplastic syndrome, unclassifiable;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive;TOTAL_PROTEIN_LEVEL:5.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MDS-U" "TMB_NONSYNONYMOUS:23.920895772307865;SEX:Male;AGE:76;OS_MONTHS:29.72054795;OS_STATUS:1:DECEASED;WBC:3.9;CYTOGENETICS:46,xy,del(3)(q26q27)[15]/46,xy[5];FLT3_ITD:FALSE;ANC:1.9;BM_BLAST:1;CHR_TP53_LOCUS:normal;COMPLEX_KARYOTYPE:non-complex;CYTO_IPSSR:Int;HB:8.9;IPSSM:High;IPSSM_SCORE:1.28;IPSSR:Int;IPSSR_SCORE:3.5;LFS_MONTHS:29.72054795;LFS_STATUS:1:Transformed/Deceased;MDS_TYPE:primary;MLL_PTD:FALSE;MONOCYTES:0.1;PB_BLAST:0;PLT:77;WHO_2016:MDS-U"
"MDS/MPN WITH RING SIDEROBLASTS AND THROMBOCYTOSIS" "CANCER_TYPE_DETAILED:MDS/MPN with Ring Sideroblasts and Thrombocytosis;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNRST;TMB_NONSYNONYMOUS:0.033333333;SEX:Male;AGE:77;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;ICD_10:D75.81;HISTOLOGY:Refractory anemia with sideroblasts;PURITY:0.745;PROJECT_CODE:CMDI-UK;WGD:no_wgd;FIRST_THERAPY:Other Therapy;FIRST THERAPY_RESPONSE:Stable Disease;PURITY_CONFUGURATION:0.121"
"MDS/MPN, UNCLASSIFIABLE" "CANCER_TYPE_DETAILED:MDS/MPN, Unclassifiable;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNU;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;ETHNICITY:White;PLATFORM:WES;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;AGE_AT_PROCUREMENT:74;CENTER:7;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:NONE;FUSION:None;GROUP:Unknown;KARYOTYPE:46,XX[20], normal female chromosome complement.;WHOLE_EXOME_SEQUENCING:Yes;CURRENT_REGIMEN:NONE;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:u;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable"
"MDSMPN" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.98;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:73.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:94;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:73;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M1;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.79;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:97;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:94;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:AC220 (Ambit);LDH_LEVEL:441;MOST_RECENT_TREATMENT_DURATION:30;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Intermediate-I;ELN_2017:Favorable or Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:19.3;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:100.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:4.1;PB_ALT_LEVEL:19;PB_AST_LEVEL:28;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:2;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;SURFACE_ANTIGENS:CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative;TOTAL_PROTEIN_LEVEL:7.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MDSMPN DIAGNOSIS AT ACQUISITION" NA
"MEDULLARY" "CANCER_TYPE_DETAILED:Ampullary Carcinoma;CANCER_TYPE:Ampullary Cancer;ONCOTREE_CODE:AMPCA;TMB_NONSYNONYMOUS:40;SOMATIC_STATUS:Matched;OS_MONTHS:67.93;OS_STATUS:0:LIVING;PRIMARY_SITE:DUODENUM;GRADE:Undifferentiated;VITAL_STATUS:NED;TNMSTAGE:III;DAYS_TO_LAST_FOLLOWUP:2065;NOTE:MSI tumor;DATA_SOURCE:Technical University of Dresden;PB_BLAST_PERCENTAGE:0.0;ALLELE_FREQUENCY_CELLULARITY:43;IHC_SUBTYPE:Pancreatobiliary;MORPHOLOGY_SUBTYPE:Intestinal;ASSOCIATED_ADENOMA:Absent;INTESTINAL_PERCENTAGE:100;MORPHOLOGY_OTHER_FEATURES:Medullary"
"MEDULLARY BREAST CARCINOMA" "CANCER_TYPE_DETAILED:Medullary Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:1.56666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:65;SUBTYPE:Basal;STAGE:III;PURITY:0.29;ER_STATUS:Negative;HER2_STATUS:Negative;PR_STATUS:Negative;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.58;NONSILENT_RATE:1.73"
"MEDULLARY CARCINOMA" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:2;SOMATIC_STATUS:Matched;SEX:Female;AGE:78;FRACTION_GENOME_ALTERED:0.4675;SAMPLE_TYPE:Primary;OS_MONTHS:114.06;OS_STATUS:1:DECEASED;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8510/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/8/11;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Medullary Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1998;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4456;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A1FC.7B1B31D2-0CC5-4EE6-8AF3-16DF726BE13F.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:90;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1b;AJCC_TUMOR_PATHOLOGIC_PT:T1c;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Fine needle aspiration biopsy;PRIMARY_SITE_PATIENT:Right Upper Outer Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);ER_STATUS_BY_IHC:Negative;PR_STATUS_BY_IHC:Negative;FIRST_SURGICAL_PROCEDURE_OTHER:localized segmental mastectomy with axillary node dissection;SURGICAL_PROCEDURE_FIRST:Other"
"MEDULLARY CARCINOMA OF THE COLON" "CANCER_TYPE_DETAILED:Medullary Carcinoma of the Colon;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:CMC;TMB_NONSYNONYMOUS:0;SEX:Female;AGE:58;PFS_STATUS:Unknown/NA;RADIATION_THERAPY:No;STAGE:Stage II;RFS_STATUS:No;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:Unknown/NA;ANY_LINE_HORMONE:Unknown/NA;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Unknown/NA;ANY_LINE_TARGETED:Unknown/NA;ANY_SYSTX:No;CANCER_TYPE_HISTOLOGY:Colon Cancer;DOB_LASTFU_TIME_YRS:59;DOB_RECUR_START_TIME_YRS:58;DOB_REPORT_TIME_YRS:58;DOB_TISSUE_TIME_YRS:58;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Negative;POS_METHOD:Archer;PROG_DEATH:Unknown/NA;PROG_EVAL_C:No;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:0"
"MEDULLARY THYROID CANCER" "CANCER_TYPE_DETAILED:Medullary Thyroid Cancer;CANCER_TYPE:Other;SEX:Female;AGE:13.17453766;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:1686;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"MEDULLARY THYROID CARCINOMA" "CANCER_TYPE_DETAILED:Medullary Thyroid Carcinoma;CANCER_TYPE:Thyroid Carcinoma;TMB_NONSYNONYMOUS:0.166666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:563;DIAGNOSIS AGE:66;GDNA(NG):3708;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"MEDULLA_CARCINOMA" "CANCER_TYPE_DETAILED:Thyroid;CANCER_TYPE:Thyroid Cancer, NOS;ONCOTREE_CODE:THYROID;TMB_NONSYNONYMOUS:11.5666666667;SEX:Female;AGE:77;FRACTION_GENOME_ALTERED:0.3209;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:85.58672632;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:medulla_carcinoma;HIST_SUBTYPE1:medullary_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUBTYPE:thyroid_squamous;NAME:TT;PATHOLOGIST_ANNOTATION:Oesophagus:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"MEDULLOBLASTOMA" "CANCER_TYPE_DETAILED:Pediatric High Grade Gliomas;CANCER_TYPE:High-grade glioma/astrocytoma;ONCOTREE_CODE:PHGG;SEX:Female;AGE:15;OS_MONTHS:19;OS_STATUS:1:DECEASED;RACE:Black or African American;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:19;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Second Malignancy;TREATMENT:Modified Treatment;CHEMOTHERAPY:Not Reported;SURGERY:Not Reported;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:5694;AGE_CLASS:[15,20);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:6299;AGE_AT_SPECIMEN_DIAGNOSIS:5694;CANCER_PREDISPOSITIONS:Not Reported;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;H3F3A_CTNNB1_STATUS:H3F3A WT;HGG_H3F3A_STATUS:H3F3A WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Medulloblastoma;INITIAL_DIAGNOSIS_TYPE:Second Malignancy;MEDICAL_CONDITIONS:Endocrinopathy,Other medical conditions NOS;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:Not Reported;RADIATION_TYPE:Not Reported;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:18 Month Update;TUMOR_LOCATION_CONDENSED:Cerebellar;UPDATED_GRADE:IV"
"MED_GROUP_3" "CANCER_TYPE_DETAILED:Medulloblastoma;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:MBL;TMB_NONSYNONYMOUS:7.1;SEX:Male;AGE:6;FRACTION_GENOME_ALTERED:0.1837;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Medulloblastoma;TUMOR_TYPE:medulloblastoma;HISTOLOGY:Primitive_Neuroectodermal_Tumour-Medulloblastoma;PURITY:1;MUTATION_RATE:85.48175072;GENOME_DOUBLINGS:0;DOUBLING_TIME:243.4;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_MOLECULAR_SUBTYPE:MYC_exp;LINEAGE_SUB_SUBTYPE:med_group_3;LINEAGE_SUBTYPE:medulloblastoma;NAME:D283 Med;PATHOLOGIST_ANNOTATION:CNS:Medulloblastoma;SITE_OF_FINDING:peritoneum;SITE_SUBTYPE1:cerebellum;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:medulloblastoma"
"MELANOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:7.86666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:79;FRACTION_GENOME_ALTERED:0.5545;SAMPLE_TYPE:Primary;OS_MONTHS:2.14;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:DK;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/11/11;GRADE:High Grade;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:120;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DK-A1A5.07970DA4-6136-48BA-BCA4-3ACC8C3DC1E9.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:210;SMOKING_PACK_YEARS:20;WEIGHT:60;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2b;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:1;TOBACCO_SMOKING_HISTORY_INDICATOR:3;HEIGHT:165;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Wall Posterior;SMOKING_YEAR_STARTED:38;SMOKING_YEAR_STOPPED:1978;METASTATIC_SITE_PATIENT:None;ANGIOLYMPHATIC_INVASION:YES;FAMILY_HISTORY_CANCER_RELATIONSHIP:Sister;FAMILY_HISTORY_CANCER_TYPE:Melanoma;OCCUPATION_PRIMARY:Economist;OCCUPATION_CURRENT:Investment manager and economist;OCCUPATION_PRIMARY_CHEMICAL_EXPOSURE:None;OCCUPATION_PRIMARY_INDUSTRY:Economics"
"MELANOMA CUTANEOUS" "CANCER_TYPE_DETAILED:Melanoma of Unknown Primary;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MUP;TMB_NONSYNONYMOUS:42.1479014227;SEX:Male;FRACTION_GENOME_ALTERED:0.2306;SAMPLE_TYPE:Metastasis;OS_MONTHS:71.62;OS_STATUS:0:LIVING;RACE:White;PRIMARY_SITE:Cancer of Unknown Primary;GENE_PANEL:IMPACT341;METASTATIC_SITE:Lymph;TUMOR_PURITY:70;SUBTYPE:Melanoma Cutaneous;MSI_SCORE:0.1;MSI_TYPE:Stable;SAMPLE_COVERAGE:612;AGE_AT_SURGERY:70.81;FGA:0.231;AGE_AT_SEQUENCING:70.92;ORGAN_SYSTEM:Skin;AGE_AT_LAST_CONTACT:76.89;DMETS_DX_ADRENAL_GLAND:Yes;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SKCM"
"MELANOMA MUCOSAL" "CANCER_TYPE_DETAILED:Anorectal Mucosal Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:ARMM;TMB_NONSYNONYMOUS:3.45879237993;SEX:Male;FRACTION_GENOME_ALTERED:0.5854;SAMPLE_TYPE:Metastasis;OS_MONTHS:59.73;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Anus;GENE_PANEL:IMPACT468;METASTATIC_SITE:CNS/Brain;TUMOR_PURITY:90;SUBTYPE:Melanoma Mucosal;MSI_SCORE:0.9;MSI_TYPE:Stable;SAMPLE_COVERAGE:587;AGE_AT_SURGERY:74.26;FGA:0.585;AGE_AT_SEQUENCING:74.28;ORGAN_SYSTEM:Skin;AGE_AT_DEATH:74.75;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:Yes;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:No;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:Yes;DMETS_DX_SKIN:Yes;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:MUCM"
"MELANOMA OF UNKNOWN PRIMARY" "CANCER_TYPE_DETAILED:Melanoma of Unknown Primary;TMB_NONSYNONYMOUS:42.1479014227;SEX:Male;FRACTION_GENOME_ALTERED:0.2306;SAMPLE_TYPE:Metastasis;OS_MONTHS:56.01973684;OS_STATUS:0:LIVING;METASTATIC_SITE:Parotid Gland;ECOG:0;AGE_AT_INITIAL_DIAGNOSIS:70.7;LDH:121;AJCC_7:M1c;AJCC_8:M1c;BONE:0;CNS:0;DMT_PRIMARY_SITE:Unknown Primary;DMT_PRIMARY_SITE_CLASSIFIED:Unknown;DRIVER_CLASS:NF1;LDH_ABNL:0;LDH_RATIO:0.484;LIVER_METS:0;LUNG:0;NLR:4.4;NLR_GREATER_THAN_4_DOT_73:0;REC_GREATER_THAN_1_DOT_5:0;RLC_GREATER_THAN_17_DOT_5:0;SIMPLIFIED_METASTATIC_SITE:LR / In-Transit / Regional LN"
"MELANOMA OTHER" "CANCER_TYPE_DETAILED:Melanoma Other;CANCER_TYPE:Melanoma;TMB_NONSYNONYMOUS:0;SEX:Male;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:893;DIAGNOSIS AGE:34;GDNA(NG):34680;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"MELANOMA UVEAL" "CANCER_TYPE_DETAILED:Uveal Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:UM;TMB_NONSYNONYMOUS:3.32746590179;SEX:Male;FRACTION_GENOME_ALTERED:0.3065;SAMPLE_TYPE:Metastasis;OS_MONTHS:50.33;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Eye;GENE_PANEL:IMPACT341;METASTATIC_SITE:Lung;TUMOR_PURITY:80;SUBTYPE:Melanoma Uveal;MSI_SCORE:0.15;MSI_TYPE:Stable;SAMPLE_COVERAGE:331;AGE_AT_SURGERY:73.86;FGA:0.307;AGE_AT_SEQUENCING:74.85;ORGAN_SYSTEM:Skin;AGE_AT_DEATH:79.04;DMETS_DX_ADRENAL_GLAND:Yes;DMETS_DX_BILIARY_TRACT:Yes;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:Yes;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:UM"
"MELANOMA, AMELANOTIC" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:20.0666666667;SEX:Female;AGE:31;FRACTION_GENOME_ALTERED:0.8913;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Skin;SUBTYPE:Melanoma, amelanotic;TUMOR_TYPE:melanoma;HISTOLOGY:Malignant_Melanoma;PURITY:0.99;MUTATION_RATE:237.862854;GENOME_DOUBLINGS:1;DOUBLING_TIME:42;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;DISEASE_ONTOLOGY:melanoma;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:skin;LINEAGE_SUB_SUBTYPE:amelanotic;LINEAGE_SUBTYPE:melanoma;NAME:MDA-MB-435S;PATHOLOGIST_ANNOTATION:Skin:Melanoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:melanoma"
"MELANOTIC MELANOMA" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:12.43333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.1862;HISTOLOGICAL_SUBTYPE:Malignant amelanotic melanoma;PRIOR_TREATMENT:None;DOUBLING_TIME:20.5;P53:WT;EPITHELIAL:No;MDR:12"
"MELANOTIC SCHWANNOMA" "CANCER_TYPE_DETAILED:Melanotic Schwannoma;CANCER_TYPE:Nerve Sheath Tumor;ONCOTREE_CODE:MSCHW;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.7002;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.23;OS_STATUS:1:DECEASED;PRIMARY_SITE:Nerve Sheath;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Eye;TUMOR_PURITY:50;SAMPLE_COVERAGE:315;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"MENINGIOMA" "CANCER_TYPE_DETAILED:Meningioma;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:MNG;SEX:Male;FRACTION_GENOME_ALTERED:0.0898;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Meningioma;TUMOR_TYPE:meningioma;HISTOLOGY:Meningioma;PURITY:0.98;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:ACHILLES;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUBTYPE:meningioma;NAME:F5;SITE_SUBTYPE1:meninges;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:meningioma"
"MENINGOTHELIAL TUMOR" "CANCER_TYPE_DETAILED:Meningothelial Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:MNGT;SEX:Female;AGE:47.39219666;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:No;CHEMO_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:3rd tertile;TERT_ALKYLATING_TX:3rd tertile;TERT_CYTOTOXIC_TX:1st tertile;TIME_FROM_DX_TO_SEQ:5113;TIME_TO_BLOOD_DRAW_FROM_TX:2587;XRT_TX:Yes"
"MERKEL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Merkel Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:MCC;SUBTYPE:Merkel Cell Carcinoma;LINEAGE:skin;LINEAGE_SUBTYPE:merkel_cell_carcinoma"
"MERKEL_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Merkel Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:MCC;SUBTYPE:Merkel Cell Carcinoma;LINEAGE:skin;LINEAGE_SUBTYPE:merkel_cell_carcinoma"
"MESENCHYMAL CHONDROSARCOMA" "CANCER_TYPE_DETAILED:Mesenchymal Chondrosarcoma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:22.06981468;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:2nd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:2nd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:1st tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:47;TIME_TO_BLOOD_DRAW_FROM_TX:23;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"MESENCHYMAL NEOPLASM" "CANCER_TYPE_DETAILED:MESENCHYMAL NEOPLASM;CANCER_TYPE:Sarcoma;SEX:Female;AGE:8.632443428;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:1"
"MESONEPHRIC CARCINOMA" "CANCER_TYPE_DETAILED:Mesonephric Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CEMN;TMB_NONSYNONYMOUS:7.829757581;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.4527;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Cervix;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:754;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"METAPLASTIC BREAST CANCER" "CANCER_TYPE_DETAILED:Metaplastic Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MBC;TMB_NONSYNONYMOUS:2.6;SOMATIC_STATUS:Matched;SEX:Female;AGE:55;FRACTION_GENOME_ALTERED:0.3177;SAMPLE_TYPE:Primary;OS_MONTHS:24.24;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:24.24;TISSUE_SOURCE_SITE:A7;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8575/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/8/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IA;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:Yes;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:173;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A7-A26F.46A75AD3-BAD1-4A16-873E-0099BD10FA8C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:190;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Fine needle aspiration biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Equivocal;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);METASTATIC_TUMOR_INDICATOR:NO;PATH_MARGIN:Close;HER2_IHC_SCORE:2;ER_STATUS_BY_IHC:Negative;HER2_FISH_STATUS:Negative;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Sentinel node biopsy alone;CENT17_COPY_NUMBER:1.8;HER2_CENT17_RATIO:1.1;HER2_COPY_NUMBER:1.9;HER2_FISH_METHOD:PathVysion HER-2 DNA probe kit.;MARGIN_STATUS_REEXCISION:Negative;MICROMET_DETECTION_BY_IHC:NO;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"METAPLASTIC CARCINOMA" "CANCER_TYPE_DETAILED:Metaplastic Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MBC;TMB_NONSYNONYMOUS:2.4;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.4092;SAMPLE_TYPE:Primary;OS_MONTHS:33.02;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:33.02;TISSUE_SOURCE_SITE:AC;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8575/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/18/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Metaplastic Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:108;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AC-A2QH.C2A0E948-2B9E-4E49-90C4-57CE4C4A95B3.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:150;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Right Upper Outer Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);METASTATIC_TUMOR_INDICATOR:NO;PATH_MARGIN:Negative;ER_STATUS_BY_IHC:Negative;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Axillary lymph node dissection alone;MICROMET_DETECTION_BY_IHC:YES;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"METAPLASTIC_BREAST_CARCINOMA" "CANCER_TYPE_DETAILED:Metaplastic Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MBC;TMB_NONSYNONYMOUS:72.9;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.5420;SAMPLE_TYPE:Primary;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Breast;SUBTYPE:Carcinoma;TUMOR_TYPE:breast;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:486.8665091;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CHARACTERISTICS:mixed;DISEASE_ONTOLOGY:metaplastic_breast_carcinoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI1640+10%FBS;HIST_SUBTYPE1:metaplastic_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:breast;LINEAGE_MOLECULAR_SUBTYPE:basal_A;LINEAGE_SUB_SUBTYPE:ERneg_HER2pos;LINEAGE_SUBTYPE:breast_carcinoma;NAME:HCC1569;PATHOLOGIST_ANNOTATION:Breast:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:breast"
"METAPLASTIC_CARCINOMA" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:17.3510322704;SEX:Female;FRACTION_GENOME_ALTERED:0.5634;PRIMARY_SITE:Breast;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Breast;HISTOLOGICAL_SUBTYPE:Metaplastic_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"METASTATIC CARCINOMA" "CANCER_TYPE_DETAILED:Prostate;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PROSTATE;TMB_NONSYNONYMOUS:45.83333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.2989;SAMPLE_TYPE:Metastasis;HISTOLOGICAL_SUBTYPE:prostate; metastatic site: brain; carcinoma (patient with metastatic carcinoma of the prostate and a 3 year history of lymphocytic leukemia.);PRIOR_TREATMENT:Androgen independent and unresposive to hormone therapy;DOUBLING_TIME:32.3;P53:?;CATEGORY_SAMPLE:Metastasis;EPITHELIAL:Yes;MDR:4"
"METASTATIC HORMONE-SENSITIVE" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0023;RACE:White;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:708;INSTITUTE:MSKCC;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;ARCHER:NO;TISSUE_SITE:Lymph Node;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES;PSA:6;DISEASE_EXTENT:Metastatic hormone-sensitive;SURVIVAL_STATUS:Dead;ANDROGEN_DEPRIVATION_THERAPY:No;BIOPSY_GLEASON_SCORE:9-10;AGE_AT_SAMPLE_COLLECTION:55;DENOVO_METASTATSIS:De-novo metastatic;DZ_VOLUME:Low-volume disease;IS_CRPC:Yes;OS_SMP_MONTHS:38.75;SMP_CRPC_MONTHS:20.03"
"METASTATIC, VARIANT HISTOLOGY" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:3.45879238;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.3258;SAMPLE_TYPE:Metastatic;RACE:White;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;VITAL_STATUS:Dead;AGE_AT_DIAGNOSIS:81.2;M_STAGE:M1;PSA:6.2;TUMOR_SAMPLE_HISTOLOGY:Adenocarcinoma / poorly differentiated carcinoma;AGE_AT_PROCUREMENT:81.2;DISEASE_EXTENT:Metastatic, variant histology;SMOKING:Former;TISSUE_TYPE:Prostate;8Q_ARM:Gain"
"METASTATIC_OVARIAN_CANCER" "CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:3.3;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.2085;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;GENOME_DOUBLINGS:0;DOUBLING_TIME:88.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Grow as clusters and single cells in suspension; dt=30-40hrs;DISEASE_ONTOLOGY:metastatic_ovarian_cancer;DOUBLING_TIME_FROM_VENDOR:30-40 hrs;FREEZING_MEDIUM:10% DMSO;GROWTH_MEDIUM:RPMI-1640+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:COLO-704;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"METATYPICAL" "CANCER_TYPE_DETAILED:Skin Cancer, Non-Melanoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:BCC;TMB_NONSYNONYMOUS:25.5042984552;SOMATIC_STATUS:No;GENE_PANEL:CancerPanel;HISTOLOGICAL_SUBTYPE:Metatypical;MULTIPLE_TUMORS:No;AGE_RESECTED:78;GORLIN_SPORADIC:sporadic;POPULATION:non-reduntant sample;SCNA_ANALYSIS:No;TUMOR_NUMBER:T1;VISMO_STATUS:naive"
"MGUS" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:1.0;SOMATIC_STATUS:Matched;SEX:Male;AGE:36;RACE:Caucasian;ETHNICITY:Not Hispanic or Latino;DIAGNOSIS:Multiple Myeloma;PREVIOUS_TREATMENT:No;HEAVY_CHAIN:G;LIGHT_CHAIN:Kappa;PRIOR_MGUS:No"
"MICROPAPILLARY ADENOCARCINOMA 82653" NA
"MINIMALLY INVASIVE ADENOCARCINOMA, NON-MUCINOUS 82502" NA
"MISCELLANEOUS BRAIN TUMOR" "CANCER_TYPE_DETAILED:Malignant Tumor;CANCER_TYPE:Miscellaneous Brain Tumor;ONCOTREE_CODE:MT;TMB_NONSYNONYMOUS:3.45879237993;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1016;SAMPLE_TYPE:Metastasis;OS_MONTHS:7.47;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;MSI_SCORE:0.11;MSI_TYPE:Stable;SAMPLE_COVERAGE:466;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;AGE_AT_SEQ_REPORTED_YEARS:72;M_STAGE:M1;SMOKING_HISTORY:never;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;ARCHER:NO;T_STAGE:Tx;N_STAGE:Nx;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:224;YEAR_OF_DIAGNOSIS:2017;PRETREATED:yes"
"MISCELLANEOUS NEUROEPITHELIAL TUMOR" "CANCER_TYPE_DETAILED:Angiocentric Glioma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:ANGL;TMB_NONSYNONYMOUS:0;SEX:Female;AGE:62.13004684;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:1256"
"MIT FAMILY TRANSLOCATION RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:MiT family translocation renal cell carcinoma;CANCER_TYPE:Kidney Renal Cell Carcinoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1264;DIAGNOSIS AGE:18;GDNA(NG):5184;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"MIXED 80% ALVEOLAR" "CANCER_TYPE_DETAILED:Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:RMS;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:3;HISTOLOGICAL_SUBTYPE:Mixed 80% Alveolar;TUMOR_SAMPLE_HISTOLOGY:Mixed Alveolar/Embryonal;RISK_GROUP:Intermediate;PRIMARY_TUMOR_LOCATION:Extremity;PAX_FUSION:Fusion Negative (RT-PCR)"
"MIXED ACINAR-DUCTAL CARCINOMA" "CANCER_TYPE_DETAILED:Acinar Cell Carcinoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAC;TMB_NONSYNONYMOUS:1.03333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:73;ETHNICITY:White;STAGE:2B;DIAGNOSIS:Mixed Acinar-Ductal Carcinoma;IMMUNOHISTOCHEMISTRY:Trypsin +"
"MIXED ACINAR-NEUROENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Acinar Cell Carcinoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAC;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:19;ETHNICITY:White;STAGE:1B;DIAGNOSIS:Mixed Acinar-Neuroendocrine Carcinoma;IMMUNOHISTOCHEMISTRY:Alpha-1-Antitrypsin +, Lipase +"
"MIXED ADENOCARCINOMA AND NEUROENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Mixed Adenocarcinoma and Neuroendocrine Carcinoma;CANCER_TYPE:Poorly Differentiated NEC;TMB_NONSYNONYMOUS:8.80847727853;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.4137;SAMPLE_TYPE:Primary;ETHNICITY:White;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT410;TUMOR_PURITY:60;MSI_SCORE:0.95;MSI_TYPE:Stable;SAMPLE_COVERAGE:886;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:76;RELIGION:NONE;AGE_CURRENT:76;ARCHER:NO;T_STAGE:1/2;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:8.9;PARTA_CONSENTED_12_245:YES;TUMOR_GRADE:Poor;DATE_ADDED:12/26/15;MONTH_ADDED:2015/12;WEEK_ADDED:2015, Wk. 52;CRDB_CONSENT_DATE_DAYS:27696;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:27759;CVR_TMB_COHORT_PERCENTILE:85;CVR_TMB_TT_COHORT_PERCENTILE:93.7;CBIOPORTAL_SAMPLE_CLASS:Tumor;CHOLELITHIASIS:1;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:3.219712526;OVERALL_SURVIVAL_MONTHS:3.219712526;TUMOR_STAGE_COLLECTION:4"
"MIXED CANCER TYPES" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:5.08374193909;SEX:Male;FRACTION_GENOME_ALTERED:0.5864;PRIMARY_SITE:Salivary Gland;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_SUBTYPE:Mucoepidermoid_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"MIXED CARCINOMA" "CANCER_TYPE_DETAILED:Mixed Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:0.866666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:79;GRADE:I;SUBTYPE:Luminal A;STAGE:II;PURITY:0.58;ER_STATUS:Positive;HER2_STATUS:Negative;PR_STATUS:Positive;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.2;NONSILENT_RATE:0.85"
"MIXED GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Non-seminomatous Mixed Germ Cell Tumor;CANCER_TYPE:Non-Seminomatous Germ Cell Tumor;ONCOTREE_CODE:MGCT;TMB_NONSYNONYMOUS:9.4;SEX:Male;OS_MONTHS:53;OS_STATUS:0:LIVING;PRIMARY_SITE:Testis;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:21;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Testis;NGS_TEST:467 cancer gene panel;AGE_TESTING_YEARS:23.0;DIAGNOSTIC_CATEGORY:Germ Cell;GMED_OS_MONTHS:44;SAMPLE_TESTED_CATEGORY:Primary disease"
"MIXED INFILTRATING LOBULAR AND GRADE 1 DUCTAL CARCINOMA" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.933333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:78;FRACTION_GENOME_ALTERED:0.1221;SAMPLE_TYPE:Primary;OS_MONTHS:34.26;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:34.26;TISSUE_SOURCE_SITE:A7;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/7/10;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:93;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-A7-A0CG.2BE28F5D-2DBB-476F-9AFF-6B2103ECF0CE.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:200;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0 (i-);AJCC_TUMOR_PATHOLOGIC_PT:T2;HISTOLOGICAL_SUBTYPE:Mixed infiltrating lobular and grade 1 ductal carcinoma;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Right Upper Outer Quadrant|Right;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Close;HER2_IHC_SCORE:1;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Sentinel lymph node biopsy plus axillary dissection;ER_STATUS_IHC_PERCENT_POSITIVE:90-99%;MICROMET_DETECTION_BY_IHC:YES;PR_STATUS_IHC_PERCENT_POSITIVE:<10%;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"MIXED INVASIVE DUCTAL AND INVASIVE LOBULAR" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.433333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:38;FRACTION_GENOME_ALTERED:0.1579;SAMPLE_TYPE:Primary;OS_MONTHS:120.24;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:120.24;TISSUE_SOURCE_SITE:AR;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/12/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIA;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2245;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AR-A24M.56DFBCCE-A9D9-4F08-AC7E-33998F3439B2.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:400;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T2;HISTOLOGICAL_SUBTYPE:Mixed invasive ductal and invasive lobular;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left Upper Outer Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);PATH_MARGIN:Negative;HER2_IHC_SCORE:1;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel lymph node biopsy plus axillary dissection;ER_STATUS_IHC_PERCENT_POSITIVE:10-19%;FIRST_SURGICAL_PROCEDURE_OTHER:Wide local excision;PR_STATUS_IHC_PERCENT_POSITIVE:10-19%;SURGICAL_PROCEDURE_FIRST:Other"
"MIXED PHENOTYPE ACUTE LEUKAEMIA, B/MYELOID, NOS" "CANCER_TYPE_DETAILED:Acute Leukemias of Ambiguous Lineage;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;SEX:Female;OS_MONTHS:8.416438356164385;OS_STATUS:1:DECEASED;RACE:White;AGE_AT_DIAGNOSIS:29;COHORT:Waves3+4;SPECIMEN_TYPE:Bone Marrow Aspirate;CAUSE_OF_DEATH:Dead-Other;CURRENT_STAGE:NONE;KARYOTYPE:30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20];CURRENT_REGIMEN:NONE;FLT3_ITD:Negative;MOST_RECENT_TREATMENT_TYPE:None;PRIOR_MDS:No;PRIOR_MPN:No;AGE_AT_SPECIMEN_ACQUISITION:29;ALLELIC_RATIO:0;CUMULATIVE_CHEMO:Yes;DISEASE_STAGE_AT_SPECIMEN_COLLECTION:Initial Diagnosis;DX_AT_INCLUSION:Acute Leukaemias Of Ambiguous Lineage;ELN2017:Adverse;IS_DENOVO:False;IS_RELAPSE:False;IS_TRANSFORMED:False;NON_AML_MDSMPN_SPECIFIC_DX_AT_ACQUISITION:False;NPM1:Negative;OTHER_CYTOGENETICS:Negative for 9;22 and MLL;PRIOR_MALIGNANCY_RADIATION_TX:No;PRIOR_MALIGNANCY_TYPE:Breast Cancer;PRIOR_MDS_MORE_THAN_TWO_MTHS:No;PRIOR_MDS_MPN:No;PRIOR_MDS_MPN_MORE_THAN_TWO_MTHS:No;PRIOR_MPN_MORE_THAN_TWO_MONTHS:No;SPECIFIC_DX_AT_ACQUISITION_MDSMPN:False;SPECIFIC_DX_AT_INCLUSION:Mixed phenotype acute leukaemia, B/myeloid, NOS;SPECIMEN_GROUPS:Initial Acute Leukemia Diagnosis;SURFACE_ANTIGENS_IMMUNOHISTOCHEMICAL_STAINS:positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant);TIME_OF_SAMPLE_COLLECTION_RELATIVE_TO_INCLUSION:0;TP53:TP53 (p.V122Dfs*26; 87.5%);USED_IN_MANUSCRIPT:Yes;VARIANT_SUMMARY:CREBBP|NF1|TP53"
"MIXED PHENOTYPE ACUTE LEUKAEMIA, T/MYELOID, NOS" "CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, T/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALTNOS;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:13.29;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:52.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;WBC:14;AGE_AT_PROCUREMENT:53;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:11.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.68;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Post-Transplant|Post-Chemotherapy|Residual Disease;KARYOTYPE:45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3];PB_BLAST_PERCENTAGE:59;WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Decitabine;LDH_LEVEL:167;MOST_RECENT_TREATMENT_DURATION:80;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Deleted 5q;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:34;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:32;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:29;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Mixed phenotype acute leukaemia, T/myeloid, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mixed phenotype acute leukaemia, T/myeloid, NOS;TOTAL_PROTEIN_LEVEL:6.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MIXED PHENOTYPE ACUTE LEUKEMIA, B/MYELOID, NOS" "CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, B/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALBNOS;TMB_NONSYNONYMOUS:0.9325235299;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:Mixed Phenotype Acute Leukemia, B/Myeloid, NOS"
"MIXED PHENOTYPE ACUTE LEUKEMIA, T/MYELOID, NOS" "CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, T/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALTNOS;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:13.29;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:52.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;WBC:14;AGE_AT_PROCUREMENT:53;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:11.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.68;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Post-Transplant|Post-Chemotherapy|Residual Disease;KARYOTYPE:45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3];PB_BLAST_PERCENTAGE:59;WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Decitabine;LDH_LEVEL:167;MOST_RECENT_TREATMENT_DURATION:80;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Deleted 5q;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:34;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:32;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:29;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Mixed phenotype acute leukaemia, T/myeloid, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mixed phenotype acute leukaemia, T/myeloid, NOS;TOTAL_PROTEIN_LEVEL:6.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MIXED SEROUS AND ENDOMETRIOID" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.3765;SAMPLE_TYPE:Primary;OS_MONTHS:23.03;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:23.03;TISSUE_SOURCE_SITE:AX;ICD_O_3_SITE:C54.1;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C54.1;ICD_O_3_HISTOLOGY:8441/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/12/11;GRADE:G3;AJCC_STAGING_EDITION:1988;HISTOLOGICAL_DIAGNOSIS:Mixed serous and endometrioid;HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:274;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AX-A1CR.7623CA86-87C5-43E8-A0A7-25BD9526D1AA.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:110;WEIGHT:97;SITE_OF_TUMOR_TISSUE:Endometrial;HEIGHT:165;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Dilation and curettage procedure;CLINICAL_STAGE:Stage IIB;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);LYMPH_NODES_AORTIC_POS_TOTAL:0;LYMPH_NODES_PELVIC_POS_TOTAL:0;PERITONEAL_WASHING:negative;SURGICAL_APPROACH_AT_DIAGNOSIS:open;TUMOR_INVASION_PERCENT:50"
"MIXED_ADENOSQUAMOUS_CARCINOMA" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:7.07303226308;SEX:Male;FRACTION_GENOME_ALTERED:0.6655;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Mixed_Adenosquamous_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:KCLB;SAMPLE_ORIGIN:Solid"
"MIXED_CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:3.64703226065;SEX:Female;FRACTION_GENOME_ALTERED:0.2492;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Mixed_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"MIXED_GERM_CELL" "CANCER_TYPE_DETAILED:Ovarian Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:OGCT;TMB_NONSYNONYMOUS:9.56666666667;LINEAGE:ovary;LINEAGE_SUBTYPE:mixed_germ_cell;TYPE_REFINED:ovary"
"MLL TRANSLOCATION, T9;11" NA
"MLL-ALL" "CANCER_TYPE_DETAILED:Acute Leukemias of Ambiguous Lineage;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;TMB_NONSYNONYMOUS:4.4;SEX:Female;AGE:12.92;FRACTION_GENOME_ALTERED:0.0004;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:t(11;19), MLL-MLLT1;CANCER_SUBTYPE_CURATED:MLL-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow;TX_17-DMAG:2;TX_19D12:1;TX_ABRAXANE:0;TX_ABT-199:0;TX_ABT-263:5;TX_ACTINOMYCIN D:0;TX_AZD-2171:1;TX_AZD-6244:2;TX_AZD1480:0;TX_AZD8055:0;TX_BAL101553:0;TX_BI6727 (VOLASERTIB):0;TX_BMN-673:0;TX_BMS-354825:3;TX_BMS-754807:1;TX_BORTEZOMIB:2;TX_CABOZANTINIB (XL-148):0;TX_CBL0137:0;TX_CDX-011 (GLEMBATUMUMAB):0;TX_CGC(PG)-11047:2;TX_CISPLATIN:2;TX_CLORETAZINE:0;TX_CPX351:0;TX_CX-5461 (POL1):0;TX_CYTARABINE:0;TX_E7438/EPZ6438:0;TX_EC1456:0;TX_ERIBULIN:0;TX_GENZ-644282:0;TX_GS-9820:0;TX_GSK690693:1;TX_GSK923295A:0;TX_HGS-ETR1:1;TX_IMC-A12:0;TX_INK128-1110-028:0;TX_JNJ26481585:3;TX_JNJ26854165:4;TX_KPT-330:0;TX_LAPATINIB:1;TX_LY 2606368:0;TX_MK-2206:0;TX_MK-8242:0;TX_MLN4924:3;TX_MLN8237:5;TX_MM-141:0;TX_NSC060043:0;TX_NSC750854:0;TX_PCI-32765:1;TX_PF-03084014:0;TX_PIXANTRONE:0;TX_PR-104:6;TX_RAPAMYCIN:2;TX_RG7112:0;TX_RO4929097:1;TX_RUXOLITINIB:0;TX_SAHA:1;TX_SAR3419:2;TX_SB-715992:4;TX_SCH 727965:0;TX_SGI-1776:1;TX_SGN-CD19A:0;TX_SORAFENIB:1;TX_STA9090 (GANETESPIB):0;TX_STF-118804:0;TX_SU11248:2;TX_SVV-001:0;TX_TAK-701:0;TX_TB-403:0;TX_TL32711:0;TX_TOPOTECAN:5;TX_TRISENOX(ATO):0;TX_VINCRISTINE:6;TX_VS-4718:0;TX_XL147:0;TX_XL765:0"
"MMMT" "CANCER_TYPE_DETAILED:Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCS;TMB_NONSYNONYMOUS:7.3;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.7482;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Endometrium;SUBTYPE:Malignant Mixed Mullerian Tumor (MMMT);TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:133.0971004;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:polypoid; monolayer;DOUBLING_TIME_FROM_VENDOR:20 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:carcinosarcoma-malignant_mesodermal_mixed_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:MMMT;NAME:SNU-685;PATHOLOGIST_ANNOTATION:Endometrium:Others;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:endometrium"
"MONOCLONAL B-CELL LYMPHOCYTOSIS" "CANCER_TYPE_DETAILED:Monoclonal B-Cell Lymphocytosis;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:MCBCL;TMB_NONSYNONYMOUS:0.566666666667;SOMATIC_STATUS:Matched;PLATFORM:WES;EPIGENETIC:Intermediate CLL;EXOME_CAPTURE:SureSelect XT Human All Exon v4+UTRs;IGHV_MUTATED:Undetermined"
"MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:MEITL;SOMATIC_STATUS:Yes;SEX:Male;STAGE:I;AGE_AT_DIAGNOSIS:49;PATIENT_DISPLAY_NAME:MEITL_1;SAMPLE_DISPLAY_NAME:MEITL_1;BIOPSY_SITE:Small bowel;LDH_ELEVATED:No;BONE_MARROW_POS:No;ECOG_GT_2:No;EXTRANODAL_DISEASE:No;FIRST_LINE_TREATMENT:EPOCH;MAINTENANCE_TX:No;MSK_IMPACT_ON_DIAGNOSTIC_BIOPSY:Yes;MSK_IMPACT_PANEL:IMPACT-HEME-400;PFS_EVENT:Yes"
"MORPHEAN" "CANCER_TYPE_DETAILED:Skin Cancer, Non-Melanoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:BCC;TMB_NONSYNONYMOUS:40.2183167948;SOMATIC_STATUS:No;GENE_PANEL:CancerPanel;HISTOLOGICAL_SUBTYPE:Morphean;MULTIPLE_TUMORS:No;AGE_RESECTED:60;GORLIN_SPORADIC:sporadic;POPULATION:non-reduntant sample;SCNA_ANALYSIS:No;TUMOR_NUMBER:T1;VISMO_STATUS:naive"
"MUCINOUS ADENOCARCINOMA OF THE APPENDIX" "CANCER_TYPE_DETAILED:Mucinous Adenocarcinoma of the Appendix;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:MAAP;TMB_NONSYNONYMOUS:0.1;SEX:Male;AGE:73;FRACTION_GENOME_ALTERED:0.1090;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Stage IV;RFS_STATUS:Unknown/NA;SURGERY:Yes;DEATH:Yes;LOCALIZED_VS_METS_AT_DX:Metastatic;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Appendiceal Adenocarcinoma;DOB_LASTFU_TIME_YRS:75;DOB_PROG_START_TIME_YRS:73;DOB_PROG_TIME_YRS:75;DOB_REPORT_TIME_YRS:74;DOB_TISSUE_TIME_YRS:73;LINE_OBR_CHEMO:SD;LINE_OBR_CHEMO_G:No-Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:SD;LINE_OBR_NOTRK_G:No-Response;LINE_OBR_NTRK:SD;LINE_OBR_NTRK_G:No-Response;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:SD;LINE1_BR_NOTRK_G:No-Response;NUM_LINES:5;NUM_LINES_CHEMO:3;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:2;NUM_LINES_TARGETED:0;POS_ARCHER:Negative;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:IMPACT Only;PROG_DEATH:Yes;PROG_DEATH_TIME_YRS:2;PROG_EVAL_C:Yes;RECUR_EVAL_C:No;TISSUE_REPORT_TIME_YRS:1"
"MUCINOUS CARCINOMA" "CANCER_TYPE_DETAILED:Mucinous Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IMMC;TMB_NONSYNONYMOUS:1.03333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:59;SUBTYPE:Luminal B;STAGE:II;PURITY:0.8;HER2_AMPLIFICATION_STATUS:No;SILENT_RATE:0.1;NONSILENT_RATE:1.05"
"MUCINOUS COLLOID ADENOCARCINOMA" NA
"MUCINOUS CYSTADENOCARCINOMA" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:0.766666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:69;SAMPLE_TYPE:Primary;ETHNICITY:White/Caucasian;SAMPLE_CLASS:Tumour;AJCC_PATHOLOGIC_TUMOR_STAGE:IIA;HISTOLOGICAL_SUBTYPE:Mucinous Cystadenocarcinoma;SMOKER:Never Smoked;TUMOR_GRADE:1 - Well differentiated;STATUS:AWD;LOCATION:Tail"
"MUCINOUS CYSTIC NEOPLASM" "CANCER_TYPE_DETAILED:Mucinous Cystic Neoplasm;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:MCN;TMB_NONSYNONYMOUS:0.266666666667;SOMATIC_STATUS:Matched;SEX:Female;SMOKER:Never;LOCATION:Tail;TYPE_OF_SURGERY:Distal pancreatectomy + splenectomy;TUMOR_FOCALITY:Unifocal;CYST_SIZE:16;DYSPLASIA:Low grade;RELEVANT_MEDICAL_HISTORY:Unremarkable"
"MUCINOUS OVARIAN CANCER" "CANCER_TYPE_DETAILED:Mucinous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:MOV;TMB_NONSYNONYMOUS:4.63333333333;SEX:Female;FRACTION_GENOME_ALTERED:0.7673;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, mucinous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:102.7469499;GENOME_DOUBLINGS:1;DOUBLING_TIME:60;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:ADHERENT; EPITHELIAL-LIKE;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM:F12+10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOM-1;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1mM NEAA;TYPE_REFINED:ovary"
"MUCINOUS STOMACH ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Mucinous Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:MSTAD;TMB_NONSYNONYMOUS:18.3666666667;FRACTION_GENOME_ALTERED:0.5378;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma, mucinous;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:207.7215689;GENOME_DOUBLINGS:2;DOUBLING_TIME:66;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI 1640 +10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:SH-10-TC;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"MUCINOUS_CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:22.2137419512;SEX:Female;FRACTION_GENOME_ALTERED:0.1451;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Mucinous_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"MUCM" "CANCER_TYPE_DETAILED:Head and Neck Mucosal Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:HNMUCM;TMB_NONSYNONYMOUS:9.03333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:72;FRACTION_GENOME_ALTERED:0.1861;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Sinus;ANALYSIS_COHORT:SKCM;BIOPSY_SITE:Cheek;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:48"
"MUCOEPIDERMOID CARCINOMA" "CANCER_TYPE_DETAILED:Mucoepidermoid Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:MUCC;TMB_NONSYNONYMOUS:5.93333333333;SEX:Male;AGE:39;FRACTION_GENOME_ALTERED:0.4409;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Salivary_Gland;SUBTYPE:Squamous Cell Carcinoma, tongue;TUMOR_TYPE:other;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:195.9930868;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:19.8 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:mucoepidermoid_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:tongue;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:YD-15;PATHOLOGIST_ANNOTATION:Salivary_Gland:Carcinoma;SITE_SUBTYPE1:tongue;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"MUCOEPIDERMOID CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Mucoepidermoid Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUMEC;TMB_NONSYNONYMOUS:9.26666666667;SEX:Female;AGE:32;FRACTION_GENOME_ALTERED:0.1954;SAMPLE_TYPE:Metastasis;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Mucoepidermoid Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:117.719142;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:mucoepidermoid_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_mucoepidermoid;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H292;PATHOLOGIST_ANNOTATION:Lung:Others;PROTEOMICS_TMT_LABEL:128c;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"MUCOEPIDERMOID_CARCINOMA" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:5.08374193909;SEX:Male;FRACTION_GENOME_ALTERED:0.5864;PRIMARY_SITE:Salivary Gland;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_SUBTYPE:Mucoepidermoid_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"MUCOSAL MELANOMA OF THE ESOPHAGUS" "CANCER_TYPE_DETAILED:Mucosal Melanoma of the Esophagus;CANCER_TYPE:Melanoma;ONCOTREE_CODE:ESMM;TMB_NONSYNONYMOUS:5.593685847;SOMATIC_STATUS:Matched;SEX:Female;SAMPLE_TYPE:Unknown;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Esophagus;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;MSI_SCORE:-1;SAMPLE_COVERAGE:1776;INSTITUTE:MSKCC;RELIGION:JEWISH;AGE_CURRENT:79;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"MUCOSAL MELANOMA OF THE URETHRA" "CANCER_TYPE_DETAILED:Mucosal Melanoma of the Urethra;CANCER_TYPE:Melanoma;ONCOTREE_CODE:URMM;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.6083;SAMPLE_TYPE:Primary;OS_MONTHS:17.46;OS_STATUS:1:DECEASED;PRIMARY_SITE:Urethra;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:859;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"MUCOSAL MELANOMA OF THE VULVA/VAGINA" "CANCER_TYPE_DETAILED:Mucosal Melanoma of the Vulva/Vagina;CANCER_TYPE:Melanoma;ONCOTREE_CODE:VMM;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1276;SAMPLE_TYPE:Primary;OS_MONTHS:11.24;OS_STATUS:1:DECEASED;PRIMARY_SITE:Vagina;SAMPLE_CLASS:Tumor;TUMOR_PURITY:50;SAMPLE_COVERAGE:425;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"MULLERIAN CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCS;TMB_NONSYNONYMOUS:8.3;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.5526;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Endometrium;SUBTYPE:Mullerian Carcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:115.6656794;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:polypoid; monolayer;DOUBLING_TIME_FROM_VENDOR:43 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:carcinosarcoma-malignant_mesodermal_mixed_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:mullerian_carcinoma;NAME:SNU-1077;PATHOLOGIST_ANNOTATION:Endometrium:Others;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:endometrium"
"MULLERIAN_CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCS;TMB_NONSYNONYMOUS:8.3;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.5526;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Endometrium;SUBTYPE:Mullerian Carcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:115.6656794;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:polypoid; monolayer;DOUBLING_TIME_FROM_VENDOR:43 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:carcinosarcoma-malignant_mesodermal_mixed_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:mullerian_carcinoma;NAME:SNU-1077;PATHOLOGIST_ANNOTATION:Endometrium:Others;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:endometrium"
"MULTIPLE MYELOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:6.13333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:74;FRACTION_GENOME_ALTERED:0.2382;SAMPLE_TYPE:Primary;OS_MONTHS:17.71;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:8.21;TISSUE_SOURCE_SITE:DK;ICD_O_3_SITE:C67.4;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.4;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/12/12;GRADE:High Grade;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:230;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DK-A3IQ.11C9802C-072A-4B09-96FB-0CAC21BF43D8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:280;SMOKING_PACK_YEARS:40;WEIGHT:75.4;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Papillary;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:3;HEIGHT:173;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Wall Posterior;METASTATIC_SITE_PATIENT:None;FAMILY_HISTORY_CANCER_RELATIONSHIP:Mother|Father|Brother;FAMILY_HISTORY_CANCER_TYPE:Breast-Fem|Lung/Bronchus|Colon|Kidney-except Pelvis|Multiple Myeloma;OCCUPATION_PRIMARY:Real Estate Developer;OCCUPATION_CURRENT:Retired;OCCUPATION_PRIMARY_INDUSTRY:Real Estate"
"MULTIPLE_MYELOMA" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:6.1889032302;SEX:Female;FRACTION_GENOME_ALTERED:0.5516;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Multiple_Myeloma;HISTOLOGICAL_SUBTYPE:Plasma_Cell_Myeloma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"MUSCLE INVASIVE UROTHELIAL CARCINOMA PT2 OR ABOVE" NA
"MYCOSIS FUNGOIDES" "CANCER_TYPE_DETAILED:Mycosis Fungoides;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:MYCF;TMB_NONSYNONYMOUS:5.33333333333;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.4604;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:118.2175686;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:sezary_syndrome;HIST_SUBTYPE1:mycosis_fungoides-Sezary_syndrome;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HuT 78;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:skin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"MYCOSIS_FUNGOIDES" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:2.32083871132;SEX:Male;FRACTION_GENOME_ALTERED:0.0224;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:Mycosis_Fungoides-Sezary_Syndrome;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"MYCOSIS_FUNGOIDES-SEZARY_SYNDROME" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:2.32083871132;SEX:Male;FRACTION_GENOME_ALTERED:0.0224;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:Mycosis_Fungoides-Sezary_Syndrome;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"MYELODYSPLASTIC SYNDROME ASSOCIATED WITH ISOLATED DEL(5Q)" NA
"MYELODYSPLASTIC SYNDROME ASSOCIATED WITH ISOLATED DEL5Q" NA
"MYELODYSPLASTIC SYNDROME, UNCLASSIFIABLE" "CANCER_TYPE_DETAILED:MDS, Unclassifiable;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSU;TMB_NONSYNONYMOUS:1.066666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:9.84;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:68.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Myelodysplastic Syndromes;WBC:2.42;AGE_AT_PROCUREMENT:68;CAUSE_OF_DEATH_SOURCE:Dead-Unknown;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.18;CURRENT_STAGE:Induction;FUSION:None;GROUP:Unknown;KARYOTYPE:45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4];PB_BLAST_PERCENTAGE:15;WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine;LDH_LEVEL:1138;MOST_RECENT_TREATMENT_DURATION:6;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:21;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-13;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:88.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3;PB_ALT_LEVEL:27;PB_AST_LEVEL:23;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1.7;PB_LYMPHOCYTES_PERCENTAGE:38.7;PB_MONOCYTES_PERCENTAGE:3.4;PB_NEUTROPHILS_PERCENTAGE:30.3;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myelodysplastic syndrome, unclassifiable;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myelodysplastic syndrome, unclassifiable;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive;TOTAL_PROTEIN_LEVEL:5.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYELODYSPLASTIC SYNDROMES" "CANCER_TYPE_DETAILED:MDS with Excess Blasts;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSEB;TMB_NONSYNONYMOUS:0.966666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:3.82;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;CHEMOTHERAPY:Yes;DIAGNOSIS:Myelodysplastic Syndromes;CAUSE_OF_DEATH_SOURCE:Dead-Unknown;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Induction;FUSION:None;GROUP:Unknown;KARYOTYPE:46,XY[20];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;MOST_RECENT_TREATMENT_DURATION:60;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200];DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:60;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-3;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Refractory anaemia with excess blasts;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Refractory anaemia with excess blasts;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE" "CANCER_TYPE_DETAILED:MDS/MPN, Unclassifiable;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNU;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;ETHNICITY:White;PLATFORM:WES;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;AGE_AT_PROCUREMENT:74;CENTER:7;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:NONE;FUSION:None;GROUP:Unknown;KARYOTYPE:46,XX[20], normal female chromosome complement.;WHOLE_EXOME_SEQUENCING:Yes;CURRENT_REGIMEN:NONE;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:u;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable"
"MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS" "CANCER_TYPE_DETAILED:Chronic Myelomonocytic Leukemia;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:CMML;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:10.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:70.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:21;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:70;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M4;HEMOGLOBIN_LEVEL:9.7;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.18;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:9;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:36;CUMULATIVE_TREATMENT_REGIMENS:Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin);LDH_LEVEL:231;MOST_RECENT_TREATMENT_DURATION:4;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:153;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:28.7;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:Yes;MEAN_CORPUSCULAR_VOLUME:99.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.6;PB_ALT_LEVEL:19;PB_AST_LEVEL:22;PB_BASOPHILS_PERCENTAGE:5;PB_EOSINOPHILS_PERCENTAGE:5;PB_LYMPHOCYTES_PERCENTAGE:21;PB_MONOCYTES_PERCENTAGE:38;PB_NEUTROPHILS_PERCENTAGE:22;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myelomonocytic leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Chronic myelomonocytic leukaemia;SURFACE_ANTIGENS:CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive;TOTAL_PROTEIN_LEVEL:7.1;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYELOID ATYPICAL" "CANCER_TYPE_DETAILED:Myeloid Atypical;CANCER_TYPE:Blood Cancer, NOS;ONCOTREE_CODE:MATPL;SEX:Male;FRACTION_GENOME_ALTERED:0.0000;RACE:White;ETHNICITY:Non-Hispanic;VITAL_STATUS:NED;FIRST_LINE_THERAPY:Vinblastine"
"MYELOID LEUKAEMIA ASSOCIATED WITH DOWN SYNDROME" "CANCER_TYPE_DETAILED:Myeloid Leukemia Associated with Down Syndrome;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MLADS;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:5.66;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:8.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:67.53;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:8;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy|Intrathecal;HEMOGLOBIN_LEVEL:9.3;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.72;CURRENT_STAGE:CNS;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:47,XY,+21c[20];WHOLE_EXOME_SEQUENCING:Yes;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine;CUMULATIVE_TREATMENT_STAGES:Induction | CNS;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Intrathecal;CURRENT_REGIMEN:Cytarabine;MOST_RECENT_TREATMENT_DURATION:151;MOST_RECENT_TREATMENT_TYPE:Intrathecal;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:151;ELN_2008:Intermediate-II;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:26.8;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:13;PB_AST_LEVEL:25;PB_BASOPHILS_PERCENTAGE:10.8;PB_EOSINOPHILS_PERCENTAGE:0;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:1.8;PB_LYMPHOCYTES_PERCENTAGE:8.1;PB_MONOCYTES_PERCENTAGE:13.5;PB_NEUTROPHILS_PERCENTAGE:8.1;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myeloid leukaemia associated with Down syndrome;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myeloid leukaemia associated with Down syndrome;TOTAL_PROTEIN_LEVEL:8.2;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYELOID LEUKEMIA ASSOCIATED WITH DOWN SYNDROME" "CANCER_TYPE_DETAILED:Myeloid Leukemia Associated with Down Syndrome;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MLADS;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:5.66;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:8.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:67.53;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:8;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy|Intrathecal;HEMOGLOBIN_LEVEL:9.3;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.72;CURRENT_STAGE:CNS;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:47,XY,+21c[20];WHOLE_EXOME_SEQUENCING:Yes;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine;CUMULATIVE_TREATMENT_STAGES:Induction | CNS;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Intrathecal;CURRENT_REGIMEN:Cytarabine;MOST_RECENT_TREATMENT_DURATION:151;MOST_RECENT_TREATMENT_TYPE:Intrathecal;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:151;ELN_2008:Intermediate-II;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:26.8;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:13;PB_AST_LEVEL:25;PB_BASOPHILS_PERCENTAGE:10.8;PB_EOSINOPHILS_PERCENTAGE:0;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:1.8;PB_LYMPHOCYTES_PERCENTAGE:8.1;PB_MONOCYTES_PERCENTAGE:13.5;PB_NEUTROPHILS_PERCENTAGE:8.1;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myeloid leukaemia associated with Down syndrome;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myeloid leukaemia associated with Down syndrome;TOTAL_PROTEIN_LEVEL:8.2;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYELOID NEOPLASM" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:4.84;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:81.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:37.1;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:81;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Supportive/Palliative Care;FAB:M5;HEMOGLOBIN_LEVEL:8.8;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.08;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12];WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Supportive/Palliative Care;CURRENT_REGIMEN:Azacitidine;LDH_LEVEL:2700;MOST_RECENT_TREATMENT_DURATION:42;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.6;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-112;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:92.4;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:60;PB_AST_LEVEL:64;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:12;PB_MONOCYTES_PERCENTAGE:33;PB_NEUTROPHILS_PERCENTAGE:7;PRIOR_CANCER:Anal carcinoma|Breast Cancer;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:Yes;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;TOTAL_PROTEIN_LEVEL:6.3"
"MYELOID SARCOMA" "CANCER_TYPE_DETAILED:Myeloid Sarcoma;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MS;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:19.61;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:61.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:5.16;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:61;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:DLI|Standard Chemotherapy|Bone Marrow Transplant;HEMOGLOBIN_LEVEL:14;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.94;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease|Post-Transplant;KARYOTYPE:46,XY[23];PB_BLAST_PERCENTAGE:0;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:3;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:DLI | Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Azacitidine;LDH_LEVEL:753;MOST_RECENT_TREATMENT_DURATION:269;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:42.5;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:1;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:Yes;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:Yes;MEAN_CORPUSCULAR_VOLUME:87.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.3;PB_ALT_LEVEL:51;PB_AST_LEVEL:76;PB_BASOPHILS_PERCENTAGE:0.6;PB_EOSINOPHILS_PERCENTAGE:7.2;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0.4;PB_LYMPHOCYTES_PERCENTAGE:31.8;PB_MONOCYTES_PERCENTAGE:13;PB_NEUTROPHILS_PERCENTAGE:47;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myeloid sarcoma;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myeloid sarcoma;SURFACE_ANTIGENS:maturing myeloid population. Myeloid blasts are about 2%. Monocytes are 6/7% and without antigen aberrancy.Lymphocytes are 10-11%. Mostly T cells and these have a 1:1 CD4:CD8 ratio.There are approximately 20% of lymphocytes as B cells and these are polycl;TOTAL_PROTEIN_LEVEL:6.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYELOMA" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:63.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Mature B-Cell Neoplasms;WBC:7.14;AGE_AT_PROCUREMENT:63;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.99;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Unknown;KARYOTYPE:44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide);CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:RVD (Bortezomib, Dexamethasone, Lenalidomide);LDH_LEVEL:249;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Abnormal;DIAGNOSIS_AT_INCLUSION:Mature B-Cell Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:16;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:22;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.6;PB_ALT_LEVEL:22;PB_AST_LEVEL:24;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0.9;PB_LYMPHOCYTES_PERCENTAGE:28.7;PB_MONOCYTES_PERCENTAGE:8.3;PB_NEUTROPHILS_PERCENTAGE:60.2;PB_NUCLEATED_RBC_PERCENTAGE:0.6;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Plasma cell myeloma;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Plasma cell myeloma;TOTAL_PROTEIN_LEVEL:4.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYELOPROLIFERATIVE NEOPLASMS" "CANCER_TYPE_DETAILED:Mastocytosis;CANCER_TYPE:Mastocytosis;ONCOTREE_CODE:MCD;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:12.01;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:66.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:11.9;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:67;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:NOS;HEMOGLOBIN_LEVEL:12;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.83;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Residual Disease|Post-Chemotherapy;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:63;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:75;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Quizartinib;LDH_LEVEL:226;MOST_RECENT_TREATMENT_DURATION:57;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:Yes;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Not Enough Information;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:35;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:95.2;MPN_TWO_MONTHS_PRIOR_AML:Yes;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:107;PB_AST_LEVEL:47;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:8;PB_MONOCYTES_PERCENTAGE:0;PB_NEUTROPHILS_PERCENTAGE:23;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mastocytosis;SURFACE_ANTIGENS:CD13, CD33, partial CD34, CD38, CD117 and CD123;TOTAL_PROTEIN_LEVEL:5.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MYOEPITHELIAL CARCINOMA" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:0.133333333333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.4577;SAMPLE_TYPE:Primary;OS_MONTHS:35.7;OS_STATUS:1:DECEASED;DFS_MONTHS:19.1;VITAL_STATUS:Deceased;M_STAGE:M0;LATERALITY:Left;T_STAGE:T3;N_STAGE:N2b;STAGE_AT_DIAGNOSIS:IIIA;ER_STATUS:Negative;PR_STATUS:Negative;TUMOR_SAMPLE_HISTOLOGY:Breast Invasive Myoepithelial Carcinoma;HER2_IHC_SCORE:0-1+;SAMPLE_SITE:Treatment Naive Primary;LAST_CONTACT_DAYS_TO:10897;MENOPAUSAL_STATUS_AT_DIAGNOSIS:Pre;DFS_EVENT:1;ER_PCT_PRIMARY:0;ER_STATUS_PRIMARY:Negative;HER2_IHC_PRIMARY:Negative;HER2_IHC_STATUS:Negative;HER2_IHC_VALUE_PRIMARY:0+;HER2_STATUS_PRIMARY:Negative;HR_STATUS:Negative;INVASIVE_CARCINOMA_DX_AGE:27;INVASIVE_CARCINOMA_DX_TIME:322.7;METASTATIC_DZ_FUP:Yes;METASTATIC_RECURRENCE_TIME_MONTHS:342.0;NGS_SAMPLE_COLLECTION_TIME:323;OVERALL_HER2_STATUS:Negative;OVERALL_HER2_STATUS_PATIENT:Negative;OVERALL_HR_STATUS_PATIENT:Negative;OVERALL_RECEPTOR_STATUS_PATIENT:Triple Negative;OVERALL_TUMOR_GRADE:III High Grade (Poorly Differentiated);PR_PCT_PRIMARY:0;PR_STATUS_PRIMARY:Negative;PRIMARY_NUCLEAR_GRADE:II (Intermediate);PRIOR_BREAST_PRIMARY:No;PRIOR_LOCAL_RECURRENCE:No;RECEPTOR_STATUS_PRIMARY:Triple Negative;TIME_TO_DEATH_MONTHS:358.0;TUMOR_TISSUE_ORIGIN:Breast"
"MYOFIBROMA" "CANCER_TYPE_DETAILED:Infantile Myofibroma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:0.810403824;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"MYXOFIBROSARCOMA" "CANCER_TYPE_DETAILED:Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SOC;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:71;FRACTION_GENOME_ALTERED:0.9705;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Ovary;ANALYSIS_COHORT:MISC;TUMOR_CONTENT:0.6;BIOPSY_SITE:Omentum;PRIOR_THERAPY:No;APC_CLUSTER:0;IMMUNE_CLUSTER:1;INFILTRATION_NOMINATION:negative;INTERVAL_MONTHS:2;MIMM_SCORE:-152.6;NUM_TCRB_CLONES:3587;NUM_TCRB_TEMPLATE:7697;OTHER_CANCER_HISTORY:Myxofibrosarcoma;STROMA_SCORE:-70.6;T_CELL_CLUSTER:0"
"MYXOID CHONDROSARCOMA" "CANCER_TYPE_DETAILED:Extraskeletal Myxoid Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:EMCHS;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.0677;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Thigh;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:36"
"MYXOID FIBROSARCOMA" "CANCER_TYPE_DETAILED:Myxoid Fibrosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:I;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:705;DIAGNOSIS AGE:77;GDNA(NG):2892;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"MYXOID LIPOSARCOMA" "CANCER_TYPE_DETAILED:Myxoid liposarcoma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:15.50992489;RACE:Black;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:13"
"MYXOINFLAMMATORY FIBROBLASTIC SARCOMA" "CANCER_TYPE_DETAILED:Myxoinflammatory Fibroblastic Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Male;FRACTION_GENOME_ALTERED:0.0001;SAMPLE_TYPE:Primary;OS_MONTHS:57.764;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT341;TUMOR_PURITY:60;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:636;AGE_AT_SEQ_REPORT:38;DETAILED_PRIMARY_SITE:Soft Tissue;FACETS:YES;FACETS_REVIEW:NO;FGA_REPORTED:1.00E-04"
"MYXOMA" "CANCER_TYPE_DETAILED:Myxoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:MYXO;TMB_NONSYNONYMOUS:0.978719698;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0076;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Soft Tissue;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:742;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"MYXOPAPILLARY EPENDYMOMA" "CANCER_TYPE_DETAILED:Myxopapillary Ependymoma;CANCER_TYPE:CNS;SEX:Female;AGE:16.49281311;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;EQD_TERTILES:3rd tertile;TIME_FROM_DX_TO_SEQ:2175;XRT_TX:Yes"
"NASOPHARYNGEAL CARCINOMA" "CANCER_TYPE_DETAILED:Nasopharyngeal Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:NPC;TMB_NONSYNONYMOUS:11.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:61;OS_MONTHS:50.0;OS_STATUS:0:LIVING;SMOKING_HISTORY:NO;CLINICAL_STAGE:III;FOLLOW_UP_TIME_MONTHS:50.0;METASTASIS:0.0;TUMOR_CELLULARITY_PATHOLOGY_REVIEW:85%;PRIMARY_TUMOR_SIZE:3;REGIONAL_LYMPH_NODE:0;TUMOR_CELLULARITY_DOMINANT_CLONE_VAF:84.21%"
"NATURAL KILLER CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA" "CANCER_TYPE_DETAILED:Natural Killer (NK) Cell Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:NKCLL;TMB_NONSYNONYMOUS:18.2;SUBTYPE:Natural Killer Cell Lymphoblastic Leukemia/Lymphoma;LINEAGE:blood;LINEAGE_SUBTYPE:NKC"
"NATURAL KILLER NK CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA" NA
"NBL" "CANCER_TYPE_DETAILED:Peripheral Nervous System;CANCER_TYPE:Neuroblastoma;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:0.0;SEX:Female;FRACTION_GENOME_ALTERED:0.1928;PRIMARY_SITE:Autonomic Ganglia;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Neuroblastoma;HISTOLOGICAL_TYPE:Neuroblastoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"NERVE SHEATH TUMOR" "CANCER_TYPE_DETAILED:Plexiform Schwannoma;CANCER_TYPE:Nerve Sheath Tumor;ONCOTREE_CODE:SCHW;TMB_NONSYNONYMOUS:2.26666666667;SEX:Male;OS_MONTHS:45;OS_STATUS:0:LIVING;PRIMARY_SITE:Penis/scrotum;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Penis/scrotum;NGS_TEST:Tumor-normal  WES;AGE_TESTING_YEARS:1.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:36;SAMPLE_TESTED_CATEGORY:Primary disease"
"NESTED STROMAL EPITHELIAL TUMOR OF THE LIVER" "CANCER_TYPE_DETAILED:Nested stromal epithelial tumor of the liver;CANCER_TYPE:Nested stromal epithelial tumor of the liver;ONCOTREE_CODE:LIVER;TMB_NONSYNONYMOUS:2.3;SEX:Male;OS_MONTHS:97;OS_STATUS:1:DECEASED;PRIMARY_SITE:Liver;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:9;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Diaphragmatic mass;NGS_TEST:Tumor-normal  WES;AGE_TESTING_YEARS:18.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:97;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"NEUROBLASTOMA" "CANCER_TYPE_DETAILED:Peripheral Nervous System;CANCER_TYPE:Neuroblastoma;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:0.0;SEX:Female;FRACTION_GENOME_ALTERED:0.1928;PRIMARY_SITE:Autonomic Ganglia;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Neuroblastoma;HISTOLOGICAL_TYPE:Neuroblastoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"NEUROBLASTOMA" NA
"NEUROENDOCRINE" "CANCER_TYPE_DETAILED:Large Cell Neuroendocrine Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUNE;TMB_NONSYNONYMOUS:7.82975758092;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2667;SAMPLE_TYPE:Primary;OS_MONTHS:11.07;OS_STATUS:1:DECEASED;RACE:Unknown;ETHNICITY:Non-Spanish;Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:706;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;AGE_AT_SEQ_REPORTED_YEARS:67;M_STAGE:M1;SMOKING_HISTORY:Never;ARCHER:NO;SO_COMMENTS:Note: The MYC,RECQL4 and  YES1 copy number gains fall slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated.;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:332;YEAR_OF_DIAGNOSIS:2015;PRETREATED:Yes"
"NEUROENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Large Cell Neuroendocrine Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUNE;TMB_NONSYNONYMOUS:7.82975758092;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2667;SAMPLE_TYPE:Primary;OS_MONTHS:11.07;OS_STATUS:1:DECEASED;RACE:Unknown;ETHNICITY:Non-Spanish;Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:706;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;AGE_AT_SEQ_REPORTED_YEARS:67;M_STAGE:M1;SMOKING_HISTORY:Never;ARCHER:NO;SO_COMMENTS:Note: The MYC,RECQL4 and  YES1 copy number gains fall slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated.;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:332;YEAR_OF_DIAGNOSIS:2015;PRETREATED:Yes"
"NEUROENDOCRINE CARCINOMA NOS" "CANCER_TYPE_DETAILED:Pancreatic Neuroendocrine Tumor;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PANET;SOMATIC_STATUS:Matched;SEX:Female;AGE:39;FRACTION_GENOME_ALTERED:0.6590;SAMPLE_TYPE:Primary;OS_MONTHS:90.05;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:90.05;TISSUE_SOURCE_SITE:3A;ICD_O_3_SITE:C25.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C25.1;ICD_O_3_HISTOLOGY:8246/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/22/14;GRADE:G1;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Pancreas-Adenocarcinoma-Other Subtype;HISTORY_OTHER_MALIGNANCY:Yes, History of Prior Malignancy;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2505;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3A-A9IL.530378DE-962E-4E7F-A75A-42A5BE91712C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_TUMOR_PATHOLOGIC_PT:T1;HISTOLOGICAL_SUBTYPE:NEUROENDOCRINE CARCINOMA NOS;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tissue Biopsy;PRIMARY_SITE_PATIENT:Head of Pancreas;TARGETED_MOLECULAR_THERAPY:NO;ALCOHOL_HISTORY_DOCUMENTED:NO;FAMILY_HISTORY_OF_CANCER:NO;DIABETES_DIAGNOSIS_INDICATOR:NO;TUMOR_RESECTED_MAX_DIMENSION:1.3;GRADE_TIER_SYSTEM:Four Tier;HISTORY_CHRONIC_PANCREATITIS:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"NEUROENDOCRINE CARCINOMA, NOS" "CANCER_TYPE_DETAILED:Neuroendocrine Carcinoma, NOS;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:NECNOS;TMB_NONSYNONYMOUS:4.323490475;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.4458;SAMPLE_TYPE:Unknown;OS_MONTHS:31.003;OS_STATUS:1:DECEASED;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;MSI_SCORE:1.76;MSI_TYPE:Stable;SAMPLE_COVERAGE:715;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:60;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:59;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES;CRDB_CONSENT_DATE_DAYS:20563;CRDB_SURVIVAL_STATUS:Alive"
"NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Lung Neuroendocrine Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LNET;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.4080;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.87;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:33;M_STAGE:M1;SMOKING_HISTORY:Never;TISSUE_SITE:Pleural Effusion, Right;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:176;YEAR_OF_DIAGNOSIS:2016;PROCEDURE_TYPE:Pleural Effusion;PRETREATED:No"
"NEUROENDOCRINE TUMOR, NOS" "CANCER_TYPE_DETAILED:Neuroendocrine Tumor, NOS;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:NETNOS;TMB_NONSYNONYMOUS:5.06666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.5456;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:6"
"NEUROEPITHELIAL TUMOR" "CANCER_TYPE_DETAILED:Primary Neuroepithelial Tumor;CANCER_TYPE:Miscellaneous Brain Tumor;ONCOTREE_CODE:PRNET;TMB_NONSYNONYMOUS:0;SEX:Male;AGE:1;FRACTION_GENOME_ALTERED:0.0851;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Stage IV;RFS_STATUS:Yes;SURGERY:Yes;DEATH:No;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Neuroepithelial;DOB_LASTFU_TIME_YRS:4;DOB_PROG_START_TIME_YRS:1;DOB_PROG_TIME_YRS:3;DOB_RECUR_TIME_YRS:1;DOB_REPORT_TIME_YRS:3;DOB_TISSUE_TIME_YRS:3;LINE_OBR_CHEMO:Unknown;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK:Unknown;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:2;NUM_LINES_CHEMO:1;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:1;NUM_LINES_TARGETED:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:Archer;PROG_DEATH:No;PROG_DEATH_TIME_YRS:3;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:0"
"NEUROEPITHELIOMA" "CANCER_TYPE_DETAILED:Ewing Sarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:3.76666666667;SEX:Female;AGE:14;FRACTION_GENOME_ALTERED:0.2148;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Bone;SUBTYPE:Ewings Sarcoma;TUMOR_TYPE:Ewings_Sarcoma;HISTOLOGY:Ewings_Sarcoma-Peripheral_Primitive_Neuroectodermal_Tumour;PURITY:1;MUTATION_RATE:53.24884517;GENOME_DOUBLINGS:0;DOUBLING_TIME:32.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial.;DISEASE_ONTOLOGY:neuroepithelioma;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:EMEM + 10% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:bone;LINEAGE_MOLECULAR_SUBTYPE:EWS_FLI;LINEAGE_SUBTYPE:Ewing_sarcoma;NAME:SK-N-MC;PATHOLOGIST_ANNOTATION:Bone:Sarcoma_Ewing;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:supra_orbital_area;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:Ewings_sarcoma"
"NEUROFIBROMA" "CANCER_TYPE_DETAILED:Malignant Peripheral Nerve Sheath Tumor;CANCER_TYPE:Nerve Sheath Tumor;ONCOTREE_CODE:MPNST;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Matched;SEX:Male;AGE:29;FRACTION_GENOME_ALTERED:0.5383;SAMPLE_TYPE:Primary;OS_MONTHS:22.8;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:22.44;TISSUE_SOURCE_SITE:SI;ICD_O_3_SITE:C49.2;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C49.2;ICD_O_3_HISTOLOGY:9540/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/20/14;HISTOLOGICAL_DIAGNOSIS:Malignant Peripheral Nerve Sheath Tumors (MPNST);HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:202;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-SI-A71O.69A5812B-1109-4A09-928E-158B2A55E81E.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:500;SITE_OF_TUMOR_TISSUE:Lower Extremity - Other (please specify;PHARMACEUTICAL_TX_ADJUVANT:YES;METASTATIC_SITE_PATIENT:Lung;PRIMARY_SITE_OTHER:Right Hip;PATH_MARGIN:Positive;DISEASE_MULTIFOCAL_INDICATOR:NO;TUMOR_TOTAL_DEPTH:Deep;CONTIGUOUS_ORGAN_INVADED:NO;LOCOREGIONAL_RECURRENCE_INDICATOR:NO;METASTATIC_DISEASE_CONFIRMED:YES;MPNST_NF_INDICATOR:No;MPNST_NF1_GENETIC_TESTING_INDICATOR:No;MPNST_PLEXIFORM_NEUROFIBROMA_SITE:NO;NTE_LESION_PATHOLOGIC_DEPTH:15;NTE_LESION_PATHOLOGIC_LENGTH:22;NTE_LESION_RADIOLOGIC_DEPTH:12.0;NTE_LESION_RADIOLOGIC_LENGTH:14;TUMOR_TOTAL_NECROSIS:0% (no necrosis or no mention of necrosis)"
"NEUROTROPIC" "CANCER_TYPE_DETAILED:Desmoplastic Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:DESM;TMB_NONSYNONYMOUS:16.9666666667;SOMATIC_STATUS:Matched;AGE:71;GENE_PANEL:Exome, Whole Genome;HISTOLOGICAL_SUBTYPE:Neurotropic;PLATFORM:Agilent 1Mil;COHORT:Discovery;SOURCE:Fresh Frozen;TOTAL_MUTATIONS:797;ANATOMIC_REGION:Shoulder;DETAILED_SAMPLE_HISTOLOGY_CATEGORY:Pure;SECONDARY_PLATFORM:Exome CN Inference"
"NHL" "CANCER_TYPE_DETAILED:Non-Hodgkin Lymphoma;CANCER_TYPE:Non-Hodgkin Lymphoma;ONCOTREE_CODE:NHL;TMB_NONSYNONYMOUS:10.9333333333;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous, Sezary Syndrome;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"NKC" "CANCER_TYPE_DETAILED:Natural Killer (NK) Cell Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:NKCLL;TMB_NONSYNONYMOUS:18.2;SUBTYPE:Natural Killer Cell Lymphoblastic Leukemia/Lymphoma;LINEAGE:blood;LINEAGE_SUBTYPE:NKC"
"NODAL MARGINAL ZONE LYMPHOMA" "CANCER_TYPE_DETAILED:Nodal Marginal Zone Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:NMZL;TMB_NONSYNONYMOUS:2.8;SEX:Female;AGE:72;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;ICD_10:C83.0;STAGE:unknown;HISTOLOGY:Marginal zone B-cell lymphoma, NOS;PURITY:0.759;TOBACCO_SMOKING_HISTORY_INDICATOR:Smoking history not documented;PROJECT_CODE:MALY-DE;WGD:no_wgd;SEQUENCING_TYPE:WGS;CELLULARITY:80;ALCOHOL:Don't know/Not sure;FIRST_THERAPY:Other Therapy;ORGAN_SYSTEM:LYMPH NODES;ALCOHOL_HISTORY_INTENSITY:Not Documented;ANCESTRY_PRIMARY:EUR;FIRST THERAPY_RESPONSE:Stable Disease;HISTOLOGY_ABBREVIATION:Lymph-BNHL;HISTOLOGY_TIER1:MESODERM;HISTOLOGY_TIER2:Lymphoid;HISTOLOGY_TIER3:Mature B-cell lymphoma;HISTOLOGY_TIER4:Marginal zone B-cell lymphoma;PURITY_CONFUGURATION:0.016;TUMOR_SAMPLE_HISTOLOGY_CODE:9699/3"
"NODAL PERIPHERAL T-CELL LYMPHOMA WITH TFH PHENOTYPE" "CANCER_TYPE_DETAILED:Nodal Peripheral T-Cell Lymphoma with TFH Phenotype;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:NPTLTFH;SOMATIC_STATUS:Yes;SEX:Male;STAGE:IV;AGE_AT_DIAGNOSIS:75;PATIENT_DISPLAY_NAME:PTCL_TFH_1;SAMPLE_DISPLAY_NAME:PTCL_TFH_1;BIOPSY_SITE:LN;LDH_ELEVATED:Yes;BONE_MARROW_POS:No;ECOG_GT_2:No;EXTRANODAL_DISEASE:Yes;FIRST_LINE_TREATMENT:CHOP;MSK_IMPACT_BEYOND_FIRST_RELAPSE_BIOPSY:Yes;MSK_IMPACT_ON_DIAGNOSTIC_BIOPSY:No;MSK_IMPACT_ON_FIRST_RELAPSE_BIOPSY:No;MSK_IMPACT_PANEL:IMPACT-HEME-400;PFS_EVENT:Yes"
"NODULAR" "CANCER_TYPE_DETAILED:Skin Cancer, Non-Melanoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:BCC;TMB_NONSYNONYMOUS:35.3136440149;SOMATIC_STATUS:No;GENE_PANEL:CancerPanel;HISTOLOGICAL_SUBTYPE:Nodular;MULTIPLE_TUMORS:No;AGE_RESECTED:48;GORLIN_SPORADIC:sporadic;POPULATION:non-reduntant sample;SCNA_ANALYSIS:No;TUMOR_NUMBER:T1;VISMO_STATUS:naive"
"NON AML MDSMPN DIAGNOSIS AT ACQUISITION" NA
"NON SMALL CELL LUNG CANCER" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non Small Cell Lung Cancer;TMB_NONSYNONYMOUS:0.433333333333;SEX:Male;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:I;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Targeted_Therapy;Chemotherapy;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1440.082599;DIAGNOSIS AGE:48;GDNA(NG):558;SMOKE STATUS:Nonsmoker;TUMOR_PURTITY:50"
"NON SMALL CELL LUNG CANCER OTHER" "CANCER_TYPE_DETAILED:Non Small Cell Lung Cancer Other;CANCER_TYPE:Non Small Cell Lung Cancer;TMB_NONSYNONYMOUS:0.166666666667;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Targeted_Therapy;Chemotherapy;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1909;DIAGNOSIS AGE:56;GDNA(NG):792;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"NON-GERMINOMATOUS GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Pineal Germ Cell Tumor;CANCER_TYPE:Non-Germinomatous Germ Cell Tumor;ONCOTREE_CODE:BGCT;TMB_NONSYNONYMOUS:7.4;SEX:Male;OS_MONTHS:30;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:15;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain;NGS_TEST:467 cancer gene panel;AGE_TESTING_YEARS:15.0;DIAGNOSTIC_CATEGORY:Germ Cell;GMED_OS_MONTHS:21;SAMPLE_TESTED_CATEGORY:Primary disease"
"NON-HODGKIN LYMPHOMA" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:16.7333333333;SEX:Male;AGE:43;FRACTION_GENOME_ALTERED:0.2067;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Diffuse Large B-cell Lymphoma (DLBCL);TUMOR_TYPE:lymphoma_DLBCL;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:128.1284701;GENOME_DOUBLINGS:0;DOUBLING_TIME:48;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:SUSPENSION;DISEASE_ONTOLOGY:B-cell non-Hodgkin lymphoma;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+ 20% FBS;HIST_SUBTYPE1:diffuse_large_B_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:DLBCL;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:SU-DHL-6;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:peritoneum;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_DLBCL"
"NON-HODGKINS LYMPHOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:0.36;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:21.6;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:5;TP53_MUTATION:p.P19H; MAF 8.9%;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q2;PB_BLAST_PERCENTAGE:14;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:60;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Lenalidomide|Decitabine;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:Yes;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_MONOCYTES_PERCENTAGE:7;PRIOR_CANCER:Non-Hodgkins Lymphoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry."
"NON-SEMINOMA" "CANCER_TYPE_DETAILED:Non-Seminomatous Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1543;SPECIMEN_PRESERVATION_TYPE:Fresh;PLATFORM:WES;PATIENT_DISPLAY_NAME:P-0003533;SAMPLE_DISPLAY_NAME:s_AML_GCT_2T1"
"NON-SEMINOMATOUS GERM CELL TUMO" "CANCER_TYPE_DETAILED:Non-Seminomatous Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1543;SPECIMEN_PRESERVATION_TYPE:Fresh;PLATFORM:WES;PATIENT_DISPLAY_NAME:P-0003533;SAMPLE_DISPLAY_NAME:s_AML_GCT_2T1"
"NON-SEMINOMATOUS GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Non-Seminomatous Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1543;SPECIMEN_PRESERVATION_TYPE:Fresh;PLATFORM:WES;PATIENT_DISPLAY_NAME:P-0003533;SAMPLE_DISPLAY_NAME:s_AML_GCT_2T1"
"NON-SMALL CELL LUNG" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"NON-SMALL CELL LUNG CANCER" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"NON-SMALL CELL LUNG CANCER NSCLC, SQUAMOUS CELL CARCINOMA" NA
"NON-SMALL CELL LUNG CANCER NSCLC, UNSPECIFIED" NA
"NON-SMALL_CELL LUNG_CANCER" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:41.4666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.5624;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:218.724336;GENOME_DOUBLINGS:1;DOUBLING_TIME:73.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherenet;DISEASE_ONTOLOGY:bronchioalveolar_carcinoma; non-small_cell lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:bronchioloalveolar_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenocarcinoma;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H358;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"NON_HODGKIN_LYMPHOMA" "CANCER_TYPE_DETAILED:Burkitt Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:BL;TMB_NONSYNONYMOUS:11.4;SEX:Male;AGE:7;FRACTION_GENOME_ALTERED:0.0851;SAMPLE_TYPE:Metastasis;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:B-cell, Non-Hodgkins, Burkitts;TUMOR_TYPE:lymphoma_Burkitt;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:166.4564059;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Burkitts lymphoma;HIST_SUBTYPE1:Burkitt_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_burkitt;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:P3HR-1;PATHOLOGIST_ANNOTATION:Lymphoma:NH_B_cell;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lymphoma_Burkitt"
"NON_SMALL_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"NON_SMALL_CELL_LUNG_CANCER" "CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:37.1;SEX:Male;AGE:51;FRACTION_GENOME_ALTERED:0.7685;SAMPLE_TYPE:Primary;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:261.733481;GENOME_DOUBLINGS:1;DOUBLING_TIME:58.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;DISEASE_ONTOLOGY:non_small_cell_lung_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI 1640 + 10% FBS;HIST_SUBTYPE1:non_small_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenocarcinoma;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H23;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;PROTEOMICS_TMT_LABEL:129c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"NORMAL-LIKE" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;TMB_NONSYNONYMOUS:3.5;SEX:Female;AGE:51;ETHNICITY:Hispanic or Latino;ESTIMATE_IMMUNE_SCORE:1442.230636;ESTIMATE_STROMAL_SCORE:1521.072943;ESTIMATE_TUMORPURITY:0.50625;STEMNESS_SCORE:0.45327286;TMT_CHANNEL:126;CANCER TYPE:Breast Cancer;CD3_TILS_STATUS:not performed;CHROMOSOME_INSTABILITY_INDEX_CIN_:0.158407665;CIBERSORT_ABSOLUTE_SCORE:0.882338;ER_UPDATED_CLINICAL_STATUS:Negative;ERBB2_GENE_AMPLIFIED:1;ERBB2_PROTEOGENOMIC_STATUS:Positive;ERBB2_UPDATED_CLINICAL_STATUS:equivocal;ISCHEMIA_TIME_IN_MINUTES:14;NMF_CLUSTER:LumA-I;NMF_CLUSTER_MEMBERSHIP_SCORE:0.824;NUMBER_OF_NON_SYNONYMOUS_MUTATIONS:109;ONCOTREE CODE:BRCA;PAM50:Normal-like;PR_CLINICAL_STATUS:negative;TMT_PLEX:2;TNBC_UPDATED_CLINICAL_STATUS:Negative;TOP2A_GENE_AMPLIFIED:0;TOP2A_PROTEOGENOMIC_STATUS:Negative;XCELL_IMMUNE_SCORE:0.0071;XCELL_STROMAL_SCORE:0.3597"
"NO_FUSION" "CANCER_TYPE_DETAILED:Ewing's sarcoma;CANCER_TYPE:Bone Cancer;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:13;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:ES;SUBTYPE_DETAILS:No_Fusion;TUMOR_DETAILS:Ewing's sarcoma"
"NSCLC" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"NSCLC_SQUAMOUS" "CANCER_TYPE_DETAILED:Lung Squamous Cell Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUSC;TMB_NONSYNONYMOUS:7.16666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.1999;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:93.36313254;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.8;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;DISEASE_ONTOLOGY:lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_squamous;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H226;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Squamous;PROTEOMICS_TMT_LABEL:127c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"OCULAR MELANOMA" "CANCER_TYPE_DETAILED:Ocular Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:OM;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Unknown;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Spanish  NOS; Hispanic NOS, Latino NOS;PRIMARY_SITE:Eye;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;MSI_SCORE:-1;SAMPLE_COVERAGE:1836;INSTITUTE:MSKCC;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:33;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:YES"
"ODONTOGENIC CARCINOMA" "CANCER_TYPE_DETAILED:Clear Cell Odontogenic Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:CCOC;TMB_NONSYNONYMOUS:0.0;SOMATIC_STATUS:Matched;SEX:Female;AGE:61.0;FRACTION_GENOME_ALTERED:0.0036;SAMPLE_TYPE:Primary;OS_MONTHS:44.2;OS_STATUS:0:LIVING;RACE:White;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:13.6;PRIMARY_SITE:Maxilla;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;SAMPLE_COVERAGE:1069;VITAL_STATUS:AWD;SMOKING_HISTORY:Never;PARTC_CONSENTED_12_245:NO;ALCOHOL_HISTORY_DOCUMENTED:Never;SITE_OF_RECURRENCE:Distant and Regional;AGENT:None;DISEASE_EXTENT:Locoregional & Distant;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:Yes;DISTANT_METS:Yes;SMOKING:Smoking Pack:0;TNM:T3N0M0;CLINICAL_TRIAL:None;DETAILED_PRIMARY_SITE:Maxilla;INITIAL_TREATMENT:Surgery + Radiation;SITE_SEQUENCED:Original Primary;PRIOR_TX_TO_IMPACT_SAMPLE:None;VAR_12_245:12-245"
"OESOPHAGEAL SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:8.93333333333;SEX:Male;AGE:74;FRACTION_GENOME_ALTERED:0.6199;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Oesophagus;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:esophagus;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:108.4608605;GENOME_DOUBLINGS:1;DOUBLING_TIME:59;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HPACC;CHARACTERISTICS:ADHERENT EPITHELIAL;;DISEASE_ONTOLOGY:oesophageal squamous cell carcinoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:esophagus;LINEAGE_SUBTYPE:esophagus_squamous;NAME:OE21;PATHOLOGIST_ANNOTATION:Oesophagus:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM L-GLUTAMINE;TYPE_REFINED:esophagus"
"OLFACTORY NEUROBLASTOMA" "CANCER_TYPE_DETAILED:Olfactory Neuroblastoma;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ONBL;TMB_NONSYNONYMOUS:0.0;SOMATIC_STATUS:Matched;SEX:Male;AGE:60.0;FRACTION_GENOME_ALTERED:0.5943;SAMPLE_TYPE:Primary;OS_MONTHS:202.3;OS_STATUS:0:LIVING;RACE:White;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:15.6;PRIMARY_SITE:Maxilla;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:707;VITAL_STATUS:AWD;SMOKING_HISTORY:Former;PARTC_CONSENTED_12_245:NO;ALCOHOL_CONSUMPTION_FREQUENCY:Occasional;ALCOHOL_HISTORY_DOCUMENTED:Current;DISEASE_EXTENT:Locoregional;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:No;DISTANT_METS:No;SMOKING:Smoking Pack:10;TNM:Unknown;DETAILED_METASTATIC_SITE:Lymph Node;DETAILED_PRIMARY_SITE:Nasal Cavity;INITIAL_TREATMENT:Surgery + Radiation;SITE_SEQUENCED:Regional recurrence;PRIOR_TX_TO_IMPACT_SAMPLE:RT;TOBACCO_TYPE:Cigarettes"
"OLIGOASTROCYTOMA" "CANCER_TYPE_DETAILED:Diffuse Astrocytoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:DASTR;TMB_NONSYNONYMOUS:1.23333333333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2428;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:37;OS_STATUS:1:DECEASED;GENE_PANEL:WGS;SAMPLE_CLASS:Tumor;GRADE:II;HISTOLOGY:Oligoastrocytoma;TUMOR_LOCATION:Temporal lobe;AGE_AT_DX:37;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-HK-0002-TP-01D-WGS-DRX7N4;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;HYPERMUTATION_STATUS:Yes;INITIAL_GRADE:II;INITIAL_HISTOLOGY:Astrocytoma;POST_RECURRENCE_SURVIVAL_MONTHS:11;RADIOTHERAPY:No;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:26;TISSUE_SOURCE:Chinese University of Hong Kong;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Diffuse Astrocytoma, IDH-mutant;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:Yes"
"OLIGODENDROGLIOMA" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;TMB_NONSYNONYMOUS:6.07838710109;SEX:Male;FRACTION_GENOME_ALTERED:0.5608;PRIMARY_SITE:Central Nervous System;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Glioma;HISTOLOGICAL_SUBTYPE:Oligodendroglioma;HISTOLOGICAL_TYPE:Glioma;DATA_SOURCE:KCLB;SAMPLE_ORIGIN:Solid"
"OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED" "CANCER_TYPE_DETAILED:Oligodendroglioma;CANCER_TYPE:Glioma;ONCOTREE_CODE:ODG;TMB_NONSYNONYMOUS:2.3;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2867;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:257;OS_STATUS:1:DECEASED;GENE_PANEL:WGS;SAMPLE_CLASS:Tumor;GRADE:II;HISTOLOGY:Oligodendroglioma;TUMOR_LOCATION:Temporal lobe;TYPE_OF_SURGERY:Craniotomy;COMMENTS:frist surgery 3 days prior;AGE_AT_DX:45;EXTENT_OF_RESECTION:Total;TUMOR_LATERALITY:Right;1P19Q_STATUS:codel;ALIQUOT_BARCODE:GLSS-MD-0001-TP-01D-WGS-GETLNC;CASE_PROJECT:GLSS;CHEMO_OTHER:Yes;HYPERMUTATION_STATUS:No;INITIAL_GRADE:II;INITIAL_HISTOLOGY:Oligodendroglioma;POST_RECURRENCE_SURVIVAL_MONTHS:18;RADIATION_DOSE:54;RADIATION_OTHER:Other;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:30;SURGERY NUMBER:1;SURGERY_INDICATION:Adjuvant;TIME_TO_FIRST_RECURRENCE:239;TISSUE_SOURCE:MD Anderson Cancer Center;WHO_CLASSIFICATION:Oligodendroglioma, IDH-mutant and 1p/19q-codeleted;WHOLE_EXOME_SEQUENCED:No;WHOLE_GENOME_SEQUENCED:Yes"
"ONCOCYTIC" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.93333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:99.8;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:99.80;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/17/13;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical Carcinoma- Oncocytic Type;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;DAYS_LAST_FOLLOWUP:2782;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2571;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5JD.AA05D1FB-38B5-4D96-B9EE-07523C95C481.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;LATERALITY:Left;CLIN_M_STAGE:M0;MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:None;MITOSES_PER_50_HPF:4;NECROSIS:Necrosis Absent;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Present;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ONCOCYTIC ADENOMA OF THE THYROID" "CANCER_TYPE_DETAILED:Oncocytic Adenoma of the Thyroid;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:OAT;TMB_NONSYNONYMOUS:0.2;SEX:Female;AGE:70.97878265;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:No;ANTHRACYCLINE_TX:Yes;CHEMO_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:3rd tertile;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:Yes;RADIOTHERAPY_TX:Yes;TARGETED_TX:Yes;TERT_TARGETED_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:7620;TIME_TO_BLOOD_DRAW_FROM_TX:7771;TOPO_II_TX:Yes;XRT_TX:Yes"
"ONCOCYTOMA" "CANCER_TYPE_DETAILED:Renal Non-Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:NCCRCC;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;TUMOR_TISSUE_SITE:Kidney;SUBTYPE:oncocytoma;HISTOLOGICAL_DIAGNOSIS:oncocytoma;PLATFORM:Exome;COHORT:discovery;TUMOR_CONTENT:80"
"OPTIC NERVE GLIOMA" "CANCER_TYPE_DETAILED:Optic nerve glioma;CANCER_TYPE:Brain Cancer;ONCOTREE_CODE:GNOS;TMB_NONSYNONYMOUS:9.16666666667;SEX:Male;OS_MONTHS:23;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade I;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:3;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain- soft tissue mass-orbital excision;NGS_TEST:467 cancer gene panel;AGE_TESTING_YEARS:3.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:14;SAMPLE_TESTED_CATEGORY:Primary disease"
"OPTIC PATHWAY GLIOMA" "CANCER_TYPE_DETAILED:Optic Pathway Glioma;CANCER_TYPE:CNS;SEX:Male;AGE:14.70225906;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:3rd tertile;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:2nd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:3rd tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:3rd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:4373;TIME_TO_BLOOD_DRAW_FROM_TX:4366;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"ORAL CAVITY SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Oral Cavity Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OCSC;TMB_NONSYNONYMOUS:9.1;SEX:Female;FRACTION_GENOME_ALTERED:0.1756;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, oral;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:157.1906164;GENOME_DOUBLINGS:0;DOUBLING_TIME:142.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM + 10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:oral;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:BICR 56;SITE_SUBTYPE1:mouth;SITE_SUBTYPE2:tongue;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM GLUTAMINE+0.4UG/ML HYDROCORTISONE;TYPE_REFINED:upper_aerodigestive"
"OROPHARYNX SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Oropharynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OPHSC;TMB_NONSYNONYMOUS:6.8;SEX:Female;FRACTION_GENOME_ALTERED:0.6029;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, pharynx;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:92.96836238;GENOME_DOUBLINGS:1;DOUBLING_TIME:60.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;FREEZING_MEDIUM:5%DMSO;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:adult;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:pharynx;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:Detroit 562;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:pharynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"OS" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"OSSIFYING FIBROMYXOID TUMOR" "CANCER_TYPE_DETAILED:Ossifying Fibromyxoid Tumor;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:OFMT;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.3140;SAMPLE_TYPE:Metastasis;OS_STATUS:1:DECEASED;PRIMARY_SITE:Thyroid;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Larynx;TUMOR_PURITY:90;SAMPLE_COVERAGE:336;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"OSTEOBLASTIC OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Osteoblastic Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:OSOS;TMB_NONSYNONYMOUS:4.33333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:57;FRACTION_GENOME_ALTERED:0.7120;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Arm;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Chest Wall;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:54"
"OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:OS;TMB_NONSYNONYMOUS:0.0;SEX:Female;FRACTION_GENOME_ALTERED:0.5005;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Osteosarcoma;HISTOLOGICAL_TYPE:Osteosarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"OTHER UTERINE TUMOR" "CANCER_TYPE_DETAILED:Other Uterine Tumor;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:OUTT;SEX:Female;AGE:61.34428406;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;CARBOPLATIN_TX:Yes;CHEMO_TX:Yes;CYTOTOXIC_TX:Yes;PLATINUM_TX:Yes;TAXANE_TX:Yes;TERT_CARBOLATIN_TX:2nd tertile;TERT_CYTOTOXIC_TX:1st tertile;TERT_PLATINUM_TX:2nd tertile;TERT_TAXANE_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:6313;TIME_TO_BLOOD_DRAW_FROM_TX:91"
"OV" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"OVARIAN ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Adenocarcinoma;CANCER_TYPE:Ovarian Carcinoma;TMB_NONSYNONYMOUS:0.3;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Chemotherapy;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:801;DIAGNOSIS AGE:35;GDNA(NG):5412;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"OVARIAN CANCER" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:4.54;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:57.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:19.5;AGE_AT_PROCUREMENT:57;CAUSE_OF_DEATH_SOURCE:Dead-Unknown;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy|Supportive/Palliative Care;HEMOGLOBIN_LEVEL:9.6;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Supportive/Palliative Care;FUSION:Complex;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1];PB_BLAST_PERCENTAGE:79;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:76;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Re-induction | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Supportive/Palliative Care;CURRENT_REGIMEN:Decitabine, Hydroxyurea;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200];DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:28.6;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:45;PB_AST_LEVEL:41;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:5;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_CANCER:Ovarian cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+);TOTAL_PROTEIN_LEVEL:6.3;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"OVARIAN CANCER, OTHER" "CANCER_TYPE_DETAILED:Ovarian Cancer, Other;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OOVC;TMB_NONSYNONYMOUS:5.545776503;SOMATIC_STATUS:Unmatched;SEX:Female;FRACTION_GENOME_ALTERED:0.0652;SAMPLE_TYPE:Metastasis;OS_MONTHS:8.55;OS_STATUS:1:DECEASED;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Omentum;TUMOR_PURITY:50;SAMPLE_COVERAGE:844;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Unmatched;DNA_INPUT:250"
"OVARIAN CARCINOMA" "CANCER_TYPE_DETAILED:Mixed Ovarian Carcinoma;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:MXOV;TMB_NONSYNONYMOUS:6.6;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.2507;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:93.71418335;GENOME_DOUBLINGS:0;DOUBLING_TIME:91.2;GEOGRAPHIC_DISTRIBUTION:canada;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;CHARACTERISTICS:Epithelial Adherent;DISEASE_ONTOLOGY:malignant_papillary_serous_adenocarcinoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:MCDB 105 (1:1)Medium 199 +15%FBS;HIST_SUBTYPE1:mixed_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OV-90;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"OVARIAN CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Ovarian Carcinoma Other;CANCER_TYPE:Ovarian Carcinoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Chemotherapy;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1533;DIAGNOSIS AGE:46;GDNA(NG):4620;SMOKE STATUS:Unknown;TUMOR_PURTITY:80"
"OVARIAN CARCINOSARCOMA/MALIGNANT MIXED MESODERMAL TUMOR" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:2.76290322777;SEX:Female;FRACTION_GENOME_ALTERED:0.6142;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"OVARIAN CLEAR CELL" "CANCER_TYPE_DETAILED:Clear Cell Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:CCOV;TMB_NONSYNONYMOUS:3.32746590179;SEX:Female;FRACTION_GENOME_ALTERED:0.3375;SAMPLE_TYPE:Primary;OS_MONTHS:32.43;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Ovary;GENE_PANEL:IMPACT341;TUMOR_PURITY:60;SUBTYPE:Ovarian Clear Cell;MSI_SCORE:0.63;MSI_TYPE:Stable;SAMPLE_COVERAGE:687;AGE_AT_SURGERY:64.74;FGA:0.337;AGE_AT_SEQUENCING:66.99;ORGAN_SYSTEM:Gynecologic;AGE_AT_DEATH:69.69;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:Yes;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CCOV"
"OVARIAN EPITHELIAL CARCINOMA OVCA" NA
"OVARIAN EPITHELIAL TUMOR" "CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:8.03333333333;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.9354;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Cystadenocarcinoma, mucinous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:178.9165928;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:RMUG-S;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"OVARIAN GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Ovarian Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:OGCT;TMB_NONSYNONYMOUS:9.56666666667;LINEAGE:ovary;LINEAGE_SUBTYPE:mixed_germ_cell;TYPE_REFINED:ovary"
"OVARIAN GRANULOSA CELL TUMOR" "CANCER_TYPE_DETAILED:Ovarian Granulosa Cell Tumor;CANCER_TYPE:Ovarian Carcinoma;TMB_NONSYNONYMOUS:0.166666666667;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Radiation_Therapy;Chemotherapy;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1112;DIAGNOSIS AGE:47;GDNA(NG):600;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"OVARIAN HIGH-GRADE SEROUS" "CANCER_TYPE_DETAILED:High-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:HGSOC;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.7238;SAMPLE_TYPE:Metastasis;OS_MONTHS:24.48;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Ovary;GENE_PANEL:IMPACT410;METASTATIC_SITE:Unspecified;TUMOR_PURITY:80;SUBTYPE:Ovarian High-Grade Serous;MSI_SCORE:4.09;MSI_TYPE:Indeterminate;SAMPLE_COVERAGE:952;AGE_AT_SURGERY:58.53;FGA:0.724;AGE_AT_SEQUENCING:58.98;ORGAN_SYSTEM:Gynecologic;AGE_AT_DEATH:59;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:Yes;DMETS_DX_BLADDER_UT:Yes;DMETS_DX_BONE:No;DMETS_DX_BOWEL:Yes;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:Yes;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:Yes;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:HGSOC"
"OVARIAN LOW-GRADE SEROUS" "CANCER_TYPE_DETAILED:Low-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:LGSOC;TMB_NONSYNONYMOUS:4.43662120239;SEX:Female;FRACTION_GENOME_ALTERED:0.0874;SAMPLE_TYPE:Metastasis;OS_MONTHS:58.12;OS_STATUS:0:LIVING;RACE:Asian-far east/indian subcont;PRIMARY_SITE:Ovary;GENE_PANEL:IMPACT341;METASTATIC_SITE:Lymph;TUMOR_PURITY:70;SUBTYPE:Ovarian Low-Grade Serous;MSI_SCORE:0.11;MSI_TYPE:Stable;SAMPLE_COVERAGE:378;AGE_AT_SURGERY:57.03;FGA:0.087;AGE_AT_SEQUENCING:60.47;ORGAN_SYSTEM:Gynecologic;AGE_AT_LAST_CONTACT:65.31;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:Yes;DMETS_DX_BLADDER_UT:Yes;DMETS_DX_BONE:Yes;DMETS_DX_BOWEL:Yes;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:Yes;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:Yes;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:LGSOC"
"OVARIAN SEROMUCINOUS CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Seromucinous Carcinoma;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OSMCA;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0591;SAMPLE_TYPE:Primary;OS_MONTHS:16.93;OS_STATUS:1:DECEASED;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;SAMPLE_COVERAGE:329;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"OVARIAN SEROUS CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Serous Carcinoma;CANCER_TYPE:Ovarian Carcinoma;TMB_NONSYNONYMOUS:0.0333333333333;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:605.193762;DIAGNOSIS AGE:52;GDNA(NG):310;SMOKE STATUS:Unknown;TUMOR_PURTITY:20"
"OVARIAN_CANCER" "CANCER_TYPE_DETAILED:High-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:HGSOC;TMB_NONSYNONYMOUS:12.2333333333;SEX:Female;AGE:42;FRACTION_GENOME_ALTERED:0.7743;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:151.2441609;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:ovarian_cancer;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OVCAR-4;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"OVARIAN_CARCINOMA" "CANCER_TYPE_DETAILED:High-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:HGSOC;TMB_NONSYNONYMOUS:7.5;SEX:Female;FRACTION_GENOME_ALTERED:0.6144;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, high grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:110.6123314;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;DISEASE_ONTOLOGY:ovarian_carcinoma;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:high_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:59M;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"OVARY_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SOC;TMB_NONSYNONYMOUS:5.86666666667;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.2443;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:85.71718592;GENOME_DOUBLINGS:0;DOUBLING_TIME:148.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM:HAM's F12  1:1  +5% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OV56;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:128n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.5 ug/ml hydrocortisone + 10ug/ml insulin;TYPE_REFINED:ovary"
"OVARY_CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:7.56666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.5670;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Carcinoma;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:189.4438445;GENOME_DOUBLINGS:1;DOUBLING_TIME:50;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:Epithelial Adherent;DISEASE_ONTOLOGY:ovarian_cancer;GROWTH_MEDIUM:DMEM+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUBTYPE:ovary_carcinoma;NAME:OAW42;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM L-Glutamine, 20 IU/L Bovine Insuline;TYPE_REFINED:ovary"
"PAAD" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:3.42600000243;SEX:Female;FRACTION_GENOME_ALTERED:0.9761;PRIMARY_SITE:Pancreas;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Pancreas;HISTOLOGICAL_SUBTYPE:Ductal_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"PAGET DISEASE OF THE NIPPLE" "CANCER_TYPE_DETAILED:Paget Disease of the Nipple;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:PD;TMB_NONSYNONYMOUS:1.133333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:53;FRACTION_GENOME_ALTERED:0.4715;SAMPLE_TYPE:Primary;OS_MONTHS:31.5;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8541/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/7/11;AJCC_STAGING_EDITION:5th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIB;HISTOLOGICAL_DIAGNOSIS:Infiltrating Ductal Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:1999;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4147;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A1F2.FA781D93-C180-4453-BF95-B2D01B6CDB5C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:230;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1b;AJCC_TUMOR_PATHOLOGIC_PT:T4b;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Positive;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"PANCREAS-ADENOCARCINOMA DUCTAL TYPE" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;SOMATIC_STATUS:Matched;SEX:Female;AGE:59;FRACTION_GENOME_ALTERED:0.0378;SAMPLE_TYPE:Primary;OS_MONTHS:24.34;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:1.81;TISSUE_SOURCE_SITE:FZ;ICD_O_3_SITE:C25.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C25.0;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/12/13;GRADE:G3;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Pancreas-Adenocarcinoma Ductal Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-FZ-5919.80d1ef4c-4bff-4733-a636-b0d9ae2e05e7.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;TREATMENT_OUTCOME_FIRST_COURSE:Progressive Disease;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;SPECIMEN_SECOND_LONGEST_DIMENSION:0.7;LONGEST_DIMENSION:2;SHORTEST_DIMENSION:0.3;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Cytology (e.g. Peritoneal or pleural fluid);PRIMARY_SITE_PATIENT:Head of Pancreas;TARGETED_MOLECULAR_THERAPY:YES;PATIENT_DEATH_REASON:Pancreatic Cancer;CAUSE_OF_DEATH_SOURCE:Medical Record;FAMILY_HISTORY_CANCER_TYPE:Pancreas;ALCOHOL_HISTORY_DOCUMENTED:NO;FAMILY_HISTORY_OF_CANCER:YES;DIABETES_DIAGNOSIS_INDICATOR:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"PANCREAS-ADENOCARCINOMA-OTHER SUBTYPE" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:1.16666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:57;FRACTION_GENOME_ALTERED:0.2146;SAMPLE_TYPE:Primary;OS_MONTHS:10.97;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6.01;TISSUE_SOURCE_SITE:F2;ICD_O_3_SITE:C25.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C25.0;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/11/12;GRADE:G2;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Pancreas-Adenocarcinoma-Other Subtype;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-F2-6879.2759d3d4-aabe-49c8-b0cc-0365268dc686.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Adenocarcinoma, NOS;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:4;SPECIMEN_SECOND_LONGEST_DIMENSION:0.5;LONGEST_DIMENSION:1;SHORTEST_DIMENSION:0.2;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;PRIMARY_SITE_PATIENT:Head of Pancreas;SMOKING_YEAR_STOPPED:2000;TARGETED_MOLECULAR_THERAPY:NO;FAMILY_HISTORY_CANCER_TYPE:Pancreas;ALCOHOL_HISTORY_DOCUMENTED:YES;DAILY_ALCOHOL:1;FAMILY_HISTORY_OF_CANCER:YES;DIABETES_DIAGNOSIS_INDICATOR:NO;TUMOR_RESECTED_MAX_DIMENSION:4.5;ALCOHOL_EXPOSURE_INTENSITY:Daily Drinker;GRADE_TIER_SYSTEM:Four Tier;HISTORY_CHRONIC_PANCREATITIS:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"PANCREAS-COLLOID MUCINOUS NON-CYSTIC CARCINOMA" NA
"PANCREAS-UNDIFFERENTIATED CARCINOMA" "CANCER_TYPE_DETAILED:Undifferentiated Carcinoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:UCP;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.4243;SAMPLE_TYPE:Primary;OS_MONTHS:15.21;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:15.21;TISSUE_SOURCE_SITE:2J;ICD_O_3_SITE:C25.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C25.0;ICD_O_3_HISTOLOGY:8020/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/16/14;GRADE:G4;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Pancreas-Undifferentiated Carcinoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:237;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-2J-AABP.1AB545A6-DC90-47E9-8112-DD094F6BCD02.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:90;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;PRIMARY_SITE_PATIENT:Tail of Pancreas;TARGETED_MOLECULAR_THERAPY:YES;FAMILY_HISTORY_CANCER_TYPE:Other;ALCOHOL_CONSUMPTION_FREQUENCY:3;ALCOHOL_HISTORY_DOCUMENTED:YES;DAILY_ALCOHOL:1;FAMILY_HISTORY_OF_CANCER:YES;DIABETES_DIAGNOSIS_INDICATOR:NO;TUMOR_RESECTED_MAX_DIMENSION:7.2;ALCOHOL_EXPOSURE_INTENSITY:Weekly Drinker;GRADE_TIER_SYSTEM:Four Tier;HISTORY_CHRONIC_PANCREATITIS:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"PANCREATIC ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.266666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:5.2;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:65.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:161.89;AGE_AT_PROCUREMENT:65;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy|Other;HEMOGLOBIN_LEVEL:6.7;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.65;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis|Post-Chemotherapy;KARYOTYPE:46,XY,i(17)(q10)[20];PB_BLAST_PERCENTAGE:12;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:18;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Other;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:3923;MOST_RECENT_TREATMENT_DURATION:9;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metapha;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Intermediate-II;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:20.1;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:81;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:p.G12D; MAF 46%;PB_ALBUMIN_LEVEL:2.9;PB_ALT_LEVEL:44;PB_AST_LEVEL:165;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0.9;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:32;PB_LYMPHOCYTES_PERCENTAGE:7.4;PB_MONOCYTES_PERCENTAGE:35.2;PB_NEUTROPHILS_PERCENTAGE:18.5;PB_NUCLEATED_RBC_PERCENTAGE:4.8;PRIOR_CANCER:Pancreatic adenocarcinoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD13, CD33, CD34, CD117, and HLA-DR positive;TOTAL_PROTEIN_LEVEL:5.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"PANCREATIC CANCER" "CANCER_TYPE_DETAILED:Ampullary Carcinoma;CANCER_TYPE:Ampullary Cancer;ONCOTREE_CODE:AMPCA;TMB_NONSYNONYMOUS:2.3;SOMATIC_STATUS:Matched;OS_MONTHS:72.07;OS_STATUS:0:LIVING;PRIMARY_SITE:INTRA-AMP;GRADE:Poor Diff;VITAL_STATUS:NED;TNMSTAGE:III;DAYS_TO_LAST_FOLLOWUP:2191;TUMOR_CELLULARITY_PATHOLOGY_REVIEW:50;DATA_SOURCE:Australian Pancreatic Cancer Genome Initiative;PB_BLAST_PERCENTAGE:0.0;ALLELE_FREQUENCY_CELLULARITY:37;IHC_SUBTYPE:Intestinal;MORPHOLOGY_SUBTYPE:Intestinal;ASSOCIATED_ADENOMA:Absent;INTESTINAL_PERCENTAGE:100"
"PANCREATIC CANCER OTHER" "CANCER_TYPE_DETAILED:Pancreatic Cancer Other;CANCER_TYPE:Pancreatic Cancer;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1258.93681;DIAGNOSIS AGE:50;GDNA(NG):3948;SMOKE STATUS:Unknown;TUMOR_PURTITY:70"
"PANCREATIC CANCER, NOS" "CANCER_TYPE_DETAILED:Pancreas;CANCER_TYPE:Pancreatic Cancer, NOS;ONCOTREE_CODE:PANCREAS;SOMATIC_STATUS:Matched;SEX:Male;AGE:70;FRACTION_GENOME_ALTERED:0.4523;SAMPLE_TYPE:Metastasis;OS_MONTHS:19.81;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:18.23;TISSUE_SOURCE_SITE:HZ;ICD_O_3_SITE:C25.2;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C25.2;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/1/15;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IV;HISTOLOGICAL_DIAGNOSIS:Pancreas-Adenocarcinoma-Other Subtype;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;RETROSPECTIVE_COLLECTION:NO;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:M1;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Adenocarcinoma, NOS;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;PRIMARY_SITE_PATIENT:Tail of Pancreas;TARGETED_MOLECULAR_THERAPY:YES;ALCOHOL_HISTORY_DOCUMENTED:NO;TUMOR_RESECTED_MAX_DIMENSION:8;GRADE_TIER_SYSTEM:Four Tier;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"PANCREATIC DUCTAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;SOMATIC_STATUS:Matched;SEX:Male;AGE:65;SAMPLE_CLASS:Cell line;AJCC_PATHOLOGIC_TUMOR_STAGE:Unknown;HISTOLOGICAL_SUBTYPE:Pancreatic Ductal Adenocarcinoma;STATUS:Unknown"
"PANCREATIC NEUROENDOCRINE" "CANCER_TYPE_DETAILED:Pancreatic Neuroendocrine Tumor;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PANET;TMB_NONSYNONYMOUS:1.96666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.8528;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Pancreas;ANALYSIS_COHORT:PAAD;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:33"
"PANCREATIC NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Pancreatic Neuroendocrine Tumor;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PANET;TMB_NONSYNONYMOUS:1.96666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.8528;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Pancreas;ANALYSIS_COHORT:PAAD;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:33"
"PANCREATIC_CANCER" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:7.66666666667;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.9761;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Pancreas;SUBTYPE:Ductal Adenocarcinoma, exocrine;TUMOR_TYPE:pancreas;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:88.07978724;GENOME_DOUBLINGS:1;DOUBLING_TIME:171.5;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:pancreatic_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640 10% FBS +1 mM Sodium pyruvate;HIST_SUBTYPE1:ductal_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:pancreas;LINEAGE_SUB_SUBTYPE:exocrine_adenocarcinoma;LINEAGE_SUBTYPE:exocrine;NAME:AsPC-1;PATHOLOGIST_ANNOTATION:Pancreas:Carcinoma;PROTEOMICS_TMT_LABEL:126;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:pancreas"
"PANCREATOBILIARY" "CANCER_TYPE_DETAILED:Ampullary Carcinoma;CANCER_TYPE:Ampullary Cancer;ONCOTREE_CODE:AMPCA;TMB_NONSYNONYMOUS:0.233333333;SOMATIC_STATUS:Matched;OS_MONTHS:92.04;OS_STATUS:0:LIVING;PRIMARY_SITE:AMP;GRADE:Mod Diff;VITAL_STATUS:NED;TNMSTAGE:IB;DAYS_TO_LAST_FOLLOWUP:2798;NOTE:Low cellularity;TUMOR_CELLULARITY_PATHOLOGY_REVIEW:<1;DATA_SOURCE:Baylor College of Medicine Elkins Pancreatic Center;PB_BLAST_PERCENTAGE:100.0;ALLELE_FREQUENCY_CELLULARITY:5;IHC_SUBTYPE:Pancreatobiliary;MORPHOLOGY_SUBTYPE:Pancreatobiliary;ASSOCIATED_ADENOMA:Absent;INTESTINAL_PERCENTAGE:0"
"PANCREATOBILIARY AMPULLARY CARCINOMA" "CANCER_TYPE_DETAILED:Pancreatobiliary Ampullary Carcinoma;CANCER_TYPE:Ampullary Cancer;ONCOTREE_CODE:PAMPCA;TMB_NONSYNONYMOUS:6.96666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.0223;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Ampulla of Vater;ANALYSIS_COHORT:CHOL;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:44"
"PANCREATOBLASTOMA" "CANCER_TYPE_DETAILED:Pancreatoblastoma;CANCER_TYPE:Other;SEX:Female;AGE:5.023956299;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:3rd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:2nd tertile;TERT_CYTOTOXIC_TX:2nd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:2nd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:62;TIME_TO_BLOOD_DRAW_FROM_TX:43;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"PANET" "CANCER_TYPE_DETAILED:Pancreatic Neuroendocrine Tumor;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PANET;TMB_NONSYNONYMOUS:1.96666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.8528;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Pancreas;ANALYSIS_COHORT:PAAD;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:33"
"PAPILLARY ADENOCARCINOMA 82603" NA
"PAPILLARY CARCINOMA" "CANCER_TYPE_DETAILED:Solid Papillary Carcinoma of the Breast;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:SPC;TMB_NONSYNONYMOUS:0.633333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.0443;SAMPLE_TYPE:Primary;OS_MONTHS:24.77;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:AC;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8050/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/3/12;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:114;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AC-A3YJ.0F890724-8554-4B2B-B4EC-6B9B24C757D8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N0 (i-);AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Right;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel node biopsy alone;MICROMET_DETECTION_BY_IHC:YES;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"PAPILLARY CARCINOMA, DIFFUSE SCLEROSING VARIANT" "CANCER_TYPE_DETAILED:Follicular Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THFO;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:22;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:36.4;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:36.4;TISSUE_SOURCE_SITE:DJ;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C73;ICD_O_3_HISTOLOGY:8350/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/21/12;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:541;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DJ-A3VJ.C8FBA360-6E43-4B3C-8D77-C0E57EB7937C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:200;SITE_OF_TUMOR_TISSUE:Thyroid;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1a;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Papillary carcinoma, diffuse sclerosing variant;LYMPH_NODES_EXAMINED:YES;LATERALITY:Bilateral;CLINICAL_STATUS_WITHIN_3_MTHS_SURGERY:No imaging evidence of disease"
"PAPILLARY CARCINOMA: MIXED PAPILLARY AND FOLLICULAR VARIANT" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:37;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:92.48;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:92.48;TISSUE_SOURCE_SITE:E3;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C73;ICD_O_3_HISTOLOGY:8340/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/12/12;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1682;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-E3-A3DY.C455F124-6CC8-4B9E-9CA6-68DF0A518639.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SITE_OF_TUMOR_TISSUE:Thyroid;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1a;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Papillary carcinoma: mixed papillary and follicular variant;LYMPH_NODES_EXAMINED:YES;LATERALITY:Bilateral"
"PAPILLARY INFILTRATING DUCTAL CARCINOMA-MAMMARY GLAND" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:5.833333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.3550;SAMPLE_TYPE:Metastasis;HISTOLOGICAL_SUBTYPE:Papillary infiltrating ductal carcinoma-mammary gland; breast;DOUBLING_TIME:53.9;P53:?;CATEGORY_SAMPLE:Metastasis;EPITHELIAL:Yes;MDR:-45"
"PAPILLARY INFILTRATING DUCTAL CARCINOMA-MAMMARY GLAND; BREAST" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:5.833333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.3550;SAMPLE_TYPE:Metastasis;HISTOLOGICAL_SUBTYPE:Papillary infiltrating ductal carcinoma-mammary gland; breast;DOUBLING_TIME:53.9;P53:?;CATEGORY_SAMPLE:Metastasis;EPITHELIAL:Yes;MDR:-45"
"PAPILLARY KIDNEY RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Papillary Kidney Renal Cell Carcinoma;CANCER_TYPE:Kidney Renal Cell Carcinoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:618;DIAGNOSIS AGE:65;GDNA(NG):3744;SMOKE STATUS:Unknown;TUMOR_PURTITY:80"
"PAPILLARY RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Papillary Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:PRCC;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.2548;SAMPLE_TYPE:Primary;OS_MONTHS:25.33;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:25.33;TISSUE_SOURCE_SITE:BQ;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C64.1;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/11/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;TUMOR_TYPE:Type 2;HISTOLOGICAL_DIAGNOSIS:Kidney Papillary Renal Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-BQ-5887.aad105e0-56cc-4057-89fc-834cff6f1567.pdf;VIAL_NUMBER:A;WEIGHT:78;SITE_OF_TUMOR_TISSUE:Kidney;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3a;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:4;HEIGHT:170;SPECIMEN_SECOND_LONGEST_DIMENSION:1;LATERALITY:Right;LONGEST_DIMENSION:1.3;SHORTEST_DIMENSION:0.3;WBC:Normal;AJCC_METASTASIS_CLINICAL_CM:M0;LYMPH_NODES_EXAMINED_POSITIVE:0;AJCC_CLINICAL_TUMOR_STAGE:Stage III;AJCC_NODES_CLINICAL_CN:N0;AJCC_NODES_CLINICAL_CT:T3a;HEMOGLOBIN_LEVEL:Normal;SERUM_CALCIUM_LEVEL:Normal"
"PAPILLARY STOMACH ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Papillary Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:PSTAD;TMB_NONSYNONYMOUS:2.566666667;SEX:Male;AGE:74;SAMPLE_TYPE:Primary;OS_MONTHS:0;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;ICD_10:C16.0;HISTOLOGY:Papillary carcinoma, NOS;PURITY:0.792;PROJECT_CODE:STAD-US;WGD:wgd;SEQUENCING_TYPE:WGS;ORGAN_SYSTEM:STOMACH;ANCESTRY_PRIMARY:ASN;HISTOLOGY_ABBREVIATION:Stomach-AdenoCA;HISTOLOGY_TIER1:ENDODERM;HISTOLOGY_TIER2:Stomach;HISTOLOGY_TIER3:Adenocarcinoma;HISTOLOGY_TIER4:Adenocarcinoma, papillary;PURITY_CONFUGURATION:0.011;TUMOR_SAMPLE_HISTOLOGY_CODE:8050/3"
"PAPILLARY THROID CARCINOMA" "CANCER_TYPE_DETAILED:Papillary Throid Carcinoma;CANCER_TYPE:Thyroid Carcinoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1227;DIAGNOSIS AGE:46;GDNA(NG):4368;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"PAPILLARY THYROID CANCER" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:8.46666666667;SEX:Female;AGE:76;FRACTION_GENOME_ALTERED:0.3951;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Carcinoma, papillary;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:112.5260944;GENOME_DOUBLINGS:1;DOUBLING_TIME:36.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Spindle- or round-shaped cells growing adherently as monolayer;DOUBLING_TIME_FROM_VENDOR:~  30 hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:90% RPMI 1640 + 10% h.i.FBS;HIST_SUBTYPE1:papillary_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:papillary;LINEAGE_SUBTYPE:thyroid_carcinoma;NAME:B-CPAP;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"PAPILLARY, FOLLICULAR" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Unmatched;SEX:Male;AGE:71;FRACTION_GENOME_ALTERED:0.0571;SAMPLE_TYPE:Primary;OS_MONTHS:56.88;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;METASTATIC_SITE:lungs,bone;TUMOR_PURITY:0.64;PATH_T_STAGE:T3/T4;PATH_N_STAGE:Nx/N0;SPECIMEN_PRESERVATION_TYPE:FFPE;M_STAGE:M1;CYTOLOGICAL_PHENOTYPE:papillary, follicular;GROWTH_PATTERN:solid;PDTC_DEFINITION:PDTC-Turin"
"PAPILLARY, TALL CELL VARIANT" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Matched;SEX:Female;AGE:36;FRACTION_GENOME_ALTERED:0.0105;SAMPLE_TYPE:Primary;OS_MONTHS:70.92;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;METASTATIC_SITE:No;TUMOR_PURITY:0.53;PATH_T_STAGE:T3/T4;PATH_N_STAGE:N1a/N1b;SPECIMEN_PRESERVATION_TYPE:FFPE;M_STAGE:M0;CYTOLOGICAL_PHENOTYPE:papillary, tall cell variant;GROWTH_PATTERN:papillary;PDTC_DEFINITION:PDTC-MSK"
"PAPILLARY_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Small Cell Lung Cancer;CANCER_TYPE:Small Cell Lung Cancer;ONCOTREE_CODE:SCLC;TMB_NONSYNONYMOUS:12.2;SEX:Male;AGE:55;FRACTION_GENOME_ALTERED:0.9443;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Small Cell Lung Cancer (SCLC);TUMOR_TYPE:lung_small_cell;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:101.4376589;GENOME_DOUBLINGS:0;DOUBLING_TIME:98.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:floating aggregates;DISEASE_ONTOLOGY:papillary_adenocarcinoma;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI 1640 + 10% FBS;HIST_SUBTYPE1:small_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:SCLC;NAME:NCI-H69;PATHOLOGIST_ANNOTATION:Lung:SCLC;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_small_cell"
"PAPILLARY_CARCINOMA" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:4.19961290621;SEX:Female;FRACTION_GENOME_ALTERED:0.3948;PRIMARY_SITE:Thyroid;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Thyroid;HISTOLOGICAL_SUBTYPE:Papillary_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"PAPILLARY_TRANSITIONAL_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:5.86666666667;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.4023;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Urinary_Tract;SUBTYPE:Transitional Cell Carcinoma;TUMOR_TYPE:urinary_tract;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:89.00340325;GENOME_DOUBLINGS:1;DOUBLING_TIME:103.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:McCoy's 5A +10%;HIST_SUBTYPE1:transitional_cell_carcinoma;HIST_SUBTYPE2:papillary_transitional_cell_carcinoma;HIST_SUBTYPE3:NS;LINEAGE:urinary_tract;LINEAGE_SUB_SUBTYPE:bladder_transitional_cell;LINEAGE_SUBTYPE:bladder_carcinoma;NAME:RT4;PATHOLOGIST_ANNOTATION:Bladder:Carcinoma;PROTEOMICS_TMT_LABEL:129c;SITE_SUBTYPE1:bladder;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:urinary_tract"
"PAPILLOMA" "CANCER_TYPE_DETAILED:Esophageal Poorly Differentiated Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:EPDCA;TMB_NONSYNONYMOUS:2.21032258221;SEX:Male;FRACTION_GENOME_ALTERED:0.0233;PRIMARY_SITE:Upper Aerodigestive Tract;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Upper_Aerodigestive;HISTOLOGICAL_SUBTYPE:Papilloma;HISTOLOGICAL_TYPE:Other;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"PARAGANGLIOMA" "CANCER_TYPE_DETAILED:Paraganglioma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:PGNG;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:65;FRACTION_GENOME_ALTERED:0.2355;SAMPLE_TYPE:Primary;OS_MONTHS:17.7532301;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;TISSUE_SOURCE_SITE:P8;ICD_O_3_SITE:C48.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C48.0;ICD_O_3_HISTOLOGY:8693/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/26/14;HISTOLOGICAL_DIAGNOSIS:Paraganglioma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;PROSPECTIVE_COLLECTION:YES;DAYS_LAST_FOLLOWUP:29;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:49;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-P8-A6RX.6225EA0C-D8BE-472D-BF48-CBD8876D3A48.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:250;TUMOR_SITE:Extra-adrenal Site;PHARMACEUTICAL_TX_ADJUVANT:NO;LATERALITY:Bilateral;PRIMARY_SITE_OTHER:retrocaval mass;HISTORY_PHEO_OR_PARA_INCLUDE_BENIGN:NO"
"PARAGANGLIOMA; EXTRA-ADRENAL PHEOCHROMOCYTOMA" "CANCER_TYPE_DETAILED:Paraganglioma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:PGNG;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.0679;SAMPLE_TYPE:Primary;OS_MONTHS:9.205378571;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;TISSUE_SOURCE_SITE:QR;ICD_O_3_SITE:C49.3;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C49.3;ICD_O_3_HISTOLOGY:8680/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/21/14;HISTOLOGICAL_DIAGNOSIS:Paraganglioma; Extra-adrenal Pheochromocytoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;DAYS_LAST_FOLLOWUP:280;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:155;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-QR-A6H0.25844561-A084-4F60-ACAF-69C5DD2A1525.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:30;TUMOR_SITE:Extra-adrenal Site;PHARMACEUTICAL_TX_ADJUVANT:NO;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;PRIMARY_SITE_OTHER:paraspinal;CT_SCAN_PREOP_RESULTS:YES;DISEASE_DETECTED_ON_SCREENING:YES;HISTORY_PHEO_OR_PARA_ANATOMIC_SITE:Mediastinal PGL;HISTORY_PHEO_OR_PARA_INCLUDE_BENIGN:YES"
"PARAOSTEAL OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Paraosteal Osteosarcoma;CANCER_TYPE:Bone Cancer;SEX:Female;FRACTION_GENOME_ALTERED:0.0044;SAMPLE_TYPE:Primary;OS_MONTHS:14.499;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Retro-Intraabdominal;GENE_PANEL:IMPACT468;TUMOR_PURITY:30;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:457;PURITY:0.252706225;AGE_AT_SEQ_REPORT:36;DETAILED_PRIMARY_SITE:Bone;FACETS:YES;FRACTION_CNA:0.046887942;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.0044"
"PAST" "CANCER_TYPE_DETAILED:Ependymomal Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:EPMT;SEX:Male;AGE:1;OS_MONTHS:16;OS_STATUS:0:LIVING;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Progression;TREATMENT:Modified Treatment;CHEMOTHERAPY:Yes;SURGERY:No;TREATMENT_STATUS:Post-treatment;BRAF_STATUS:RELA Wild Type;AGE_AT_INITIAL_DIAGNOSIS:616;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_START:1076;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1104;AGE_AT_SPECIMEN_DIAGNOSIS:797;BRAF_RELA_STATUS:RELA Wild Type;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 WT;EPENDYMOMA_RELA_STATUS:RELA Wild Type;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:CTNNB1 WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ependymoma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS,Seizure disorder;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:No;SAMPLE_ANNOTATION:Post-treatment;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:12 Month Update;TUMOR_LOCATION_CONDENSED:Posterior Fossa;UPDATED_GRADE:III"
"PDA -  SIGNET RING" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:1.1;SOMATIC_STATUS:Matched;SEX:Female;AGE:68;SAMPLE_TYPE:Primary;ETHNICITY:White/Caucasian;SAMPLE_CLASS:Tumour;AJCC_PATHOLOGIC_TUMOR_STAGE:IIA;HISTOLOGICAL_SUBTYPE:PDA -  signet ring;SMOKER:Never Smoked;TUMOR_GRADE:2 - Moderately differentiated;DAYS_TO_LAST_FOLLOWUP:912;STATUS:NED;LOCATION:Head"
"PDA - MIXED DUCTAL ENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:0.666666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:87;SAMPLE_TYPE:Primary;ETHNICITY:White/Caucasian;SAMPLE_CLASS:Tumour;AJCC_PATHOLOGIC_TUMOR_STAGE:IIA;HISTOLOGICAL_SUBTYPE:PDA - Mixed ductal endocrine carcinoma;TUMOR_GRADE:3 - Poorly differentiated;STATUS:NED;LOCATION:Head"
"PDA - MUCINOUS NON-CYSTIC CARCINOMA" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:0.0333333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;SAMPLE_TYPE:Primary;ETHNICITY:Black/African;SAMPLE_CLASS:Tumour;AJCC_PATHOLOGIC_TUMOR_STAGE:IIB;HISTOLOGICAL_SUBTYPE:PDA - Mucinous Non-cystic carcinoma;SMOKER:Never Smoked;TUMOR_GRADE:3 - Poorly differentiated;STATUS:DOD;LOCATION:Head"
"PDA - UNDIFFERENTIATED ANAPLASTIC CARCINOMA" NA
"PDA - UNDIFFERENTIATED CARCINOMA SOME MULTINUCLEATED BUT NOT OSTEOCLAST" NA
"PDA - UNDIFFERENTIATED CARCINOMA WITH OSTEOCLAST LIKE GIANT CELLS" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:0.933333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:34;SAMPLE_TYPE:Primary;ETHNICITY:White/Caucasian;SAMPLE_CLASS:Tumour;AJCC_PATHOLOGIC_TUMOR_STAGE:IIA;HISTOLOGICAL_SUBTYPE:PDA - Undifferentiated carcinoma with osteoclast like giant cells;SMOKER:Never Smoked;TUMOR_GRADE:4 - Undifferentiated;DAYS_TO_LAST_FOLLOWUP:404;STATUS:DOD;LOCATION:Head"
"PENILE CANCER" "CANCER_TYPE_DETAILED:Penile Squamous Cell Carcinoma;CANCER_TYPE:Penile Cancer;ONCOTREE_CODE:PSCC;TMB_NONSYNONYMOUS:8.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.2564;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Penis;ANALYSIS_COHORT:HNSC;BIOPSY_SITE:Bone;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:6"
"PENILE SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Penile Squamous Cell Carcinoma;CANCER_TYPE:Penile Cancer;ONCOTREE_CODE:PSCC;TMB_NONSYNONYMOUS:8.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.2564;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Penis;ANALYSIS_COHORT:HNSC;BIOPSY_SITE:Bone;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:6"
"PERIHILAR CHOLANGIOCARCINOMA" "CANCER_TYPE_DETAILED:Perihilar Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:PHCH;TMB_NONSYNONYMOUS:4.633333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.5353;SAMPLE_TYPE:Primary;OS_MONTHS:12.19;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.19;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C24.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C24.0;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/11/14;GRADE:G3;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; hilar/perihilar;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:428;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVC.88206A8B-257B-4C0F-B42C-905DEA9483FB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:230;WEIGHT:104;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;ECOG_SCORE:0;HEIGHT:159;PERINEURAL_INVASION:NO;VASCULAR_INVASION:None;ISHAK_FIBROSIS_SCORE:1,2 - Portal Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:0.8;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;BILIRUBIN_TOTAL:0.5;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.2;CHILD_PUGH_CLASSIFICATION:B;DEFINITIVE_SURGICAL_PROCEDURE:Segmentectomy, Multiple;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Other;OTHER_HEPATO_CARCINOMA_RISK_FACTORS:Pancreatitis;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:0.9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:1.1;PROTHROMBIN_TIME_NORM_RANGE_UPPER:1.1;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:2.4"
"PERIOSTEAL OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Periosteal Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:PEOS;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.4572;SAMPLE_TYPE:Primary;OS_MONTHS:31.726;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Humerus;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;MSI_SCORE:0.75;MSI_TYPE:Stable;SAMPLE_COVERAGE:754;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:26;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CHRISTIAN;AGE_CURRENT:28;ARCHER:NO;PED_IND:Yes;PARTC_CONSENTED_12_245:YES;CVR_TMB_SCORE:0;PARTA_CONSENTED_12_245:YES;CVR_TMB_COHORT_PERCENTILE:0;CVR_TMB_TT_COHORT_PERCENTILE:0"
"PERIPHERAL MEDULLOEPITHELIOMA" "CANCER_TYPE_DETAILED:Peripheral Medulloepithelioma;CANCER_TYPE:CNS;SEX:Male;AGE:6.872005463;RACE:White;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:0"
"PERIPHERAL NEUROECTODERMAL TUMOR" "CANCER_TYPE_DETAILED:PERIPHERAL NEUROECTODERMAL TUMOR;CANCER_TYPE:CNS;SEX:Female;AGE:18.10814476;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:112"
"PERIPHERAL T-CELL LYMPHOMA, NOS" "CANCER_TYPE_DETAILED:Peripheral T-Cell lymphoma, NOS;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:PTCL;TMB_NONSYNONYMOUS:3.26666666667;SEX:Male;AGE:74;FRACTION_GENOME_ALTERED:0.3445;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Acute Lymphoblastic Leukemia (ALL), T-cell;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:76.68730425;GENOME_DOUBLINGS:0;DOUBLING_TIME:78.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:suspension;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI + 10 % FBS;HIST_SUBTYPE1:peripheral_T_cell_lymphoma_unspecified;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:blood;LINEAGE_SUB_SUBTYPE:t_cell;LINEAGE_SUBTYPE:ALL;NAME:SUP-T11;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"PERIPHERAL_T_CELL_LYMPHOMA_UNSPECIFIED" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:2.76290322777;SEX:Male;FRACTION_GENOME_ALTERED:0.3442;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:Peripheral_T_Cell_Lymphoma_Unspecified;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"PERITONEAL CANCER, NOS" NA
"PERITONEAL MESOTHELIOMA" "CANCER_TYPE_DETAILED:Peritoneal Mesothelioma;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PEMESO;SEX:Male;AGE:61.31964493;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:No;ANTIMETABOLITE_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;PLATINUM_TX:Yes;TERT_ALKYLATING_TX:1st tertile;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CISPLATIN_TX:3rd tertile;TERT_CYTOTOXIC_TX:2nd tertile;TERT_PLATINUM_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:245;TIME_TO_BLOOD_DRAW_FROM_TX:166"
"PERITONEAL SEROUS CARCINOMA" NA
"PERIVASCULAR EPITHELIOID CELL TUMOR" "CANCER_TYPE_DETAILED:Perivascular Epithelioid Cell Tumor;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:PECOMA;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.0043;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:4"
"PFA" "CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:4.8;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:PFA;TUMOR_DETAILS:Ependymoma infratentorial"
"PFB" "CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.266666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:17;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:PFB;TUMOR_DETAILS:Ependymoma infratentorial"
"PH+-ALL" NA
"PH-LIKEALL" "CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLLBCRABL1L;TMB_NONSYNONYMOUS:3.43333333333;SEX:Male;AGE:4;FRACTION_GENOME_ALTERED:0.0017;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:Ph-likeALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow"
"PHEOCHROMOCYTOMA" "CANCER_TYPE_DETAILED:Pheochromocytoma;CANCER_TYPE:Pheochromocytoma;ONCOTREE_CODE:PHC;SEX:Male;AGE:27.69062233;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:38;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"PHYLLODES" "CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:67;TUMOR_SIZE:2.8;HISTOLOGICAL_TYPE:Phyllodes;ER_STATUS:Negative;IHC_HER2:Negative;PR_STATUS:Negative;EST_TUMOR_CELLULARITY:High;PAM50_SUBTYPE:Other;IHC_BASAL:EGFR+ve and/or CK5/6+ve;IHC_CK5_6:Negative;IHC_EGFR:Positive"
"PILOCYTIC ASTROCYTOMA" "CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.066666667;SOMATIC_STATUS:Unmatched;SEX:Female;OS_MONTHS:48.13;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:27.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:58.8;AGE_AT_PROCUREMENT:27;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:6.3;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.69;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];WHOLE_EXOME_SEQUENCING:Yes;CEBPA_MUTATION:No Mutation info: RAF: 10-20%;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Sorafenib;LDH_LEVEL:426;MOST_RECENT_TREATMENT_DURATION:105;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:2;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;HEMATOCRIT_LEVEL:17.7;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:3;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:101.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:2.3;PB_ALT_LEVEL:8;PB_AST_LEVEL:15;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:7;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:2;PRIOR_CANCER:Juvenile pilocytic astrocytoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;TOTAL_PROTEIN_LEVEL:5.4;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"PILOMATRIX CARCINOMA" "CANCER_TYPE_DETAILED:Pilomatrix carcinoma;CANCER_TYPE:Cutaneous malignancy of hair matrix cells;ONCOTREE_CODE:CUP;TMB_NONSYNONYMOUS:0.933333333333;SEX:Male;OS_MONTHS:13;OS_STATUS:1:DECEASED;PRIMARY_SITE:Scalp;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:14;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Scalp;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:14.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:13;SAMPLE_TESTED_CATEGORY:Primary disease"
"PILOMYXOID ASTROCYTOMA" "CANCER_TYPE_DETAILED:Pilomyxoid astrocytoma;CANCER_TYPE:Encapsulated Glioma;ONCOTREE_CODE:PMA;TMB_NONSYNONYMOUS:1.56666666667;SEX:Male;OS_MONTHS:71;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade II;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain- suprasellar/ 3rdventricle region;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:5.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:61;SAMPLE_TESTED_CATEGORY:Primary disease"
"PINEAL GERM CELL TUMOR" "CANCER_TYPE_DETAILED:Pineal Germ Cell Tumor;CANCER_TYPE:Non-Germinomatous Germ Cell Tumor;ONCOTREE_CODE:BGCT;TMB_NONSYNONYMOUS:7.4;SEX:Male;OS_MONTHS:30;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:15;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain;NGS_TEST:467 cancer gene panel;AGE_TESTING_YEARS:15.0;DIAGNOSTIC_CATEGORY:Germ Cell;GMED_OS_MONTHS:21;SAMPLE_TESTED_CATEGORY:Primary disease"
"PINEAL PARENCHYMAL TUMOR OF INTERMEDIATE DIFFERENTIATION" "CANCER_TYPE_DETAILED:Pineal Parenchymal Tumor of Intermediate Differentiation;CANCER_TYPE:Pineal Tumor;ONCOTREE_CODE:PPTID;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1019;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:611;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"PINEAL TUMOR" "CANCER_TYPE_DETAILED:Pineoblastoma;CANCER_TYPE:Pineal Tumor;ONCOTREE_CODE:PBL;TMB_NONSYNONYMOUS:2.03333333333;SEX:Female;OS_MONTHS:47;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade IV;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:11;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain- region of the pineal gland;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:13.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:38;SAMPLE_TESTED_CATEGORY:Primary disease"
"PINEOBLASTOMA" "CANCER_TYPE_DETAILED:Pineoblastoma;CANCER_TYPE:Pineal Tumor;ONCOTREE_CODE:PBL;TMB_NONSYNONYMOUS:2.03333333333;SEX:Female;OS_MONTHS:47;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade IV;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:11;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain- region of the pineal gland;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:13.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:38;SAMPLE_TESTED_CATEGORY:Primary disease"
"PITUICYTOMA" "CANCER_TYPE_DETAILED:Pituicytoma;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:PTCY;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2716;SAMPLE_TYPE:Primary;OS_MONTHS:3.42;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:563;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"PITUITARY ADENOMA" "CANCER_TYPE_DETAILED:Pituitary Adenoma;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:PTAD;TMB_NONSYNONYMOUS:1.957439395;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.6172;SAMPLE_TYPE:Primary;OS_MONTHS:2.83;OS_STATUS:0:LIVING;PRIMARY_SITE:Pituitary Gland;SAMPLE_CLASS:Tumor;TUMOR_PURITY:80;SAMPLE_COVERAGE:735;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"PLASMA CELL MYELOMA" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:63.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Mature B-Cell Neoplasms;WBC:7.14;AGE_AT_PROCUREMENT:63;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.99;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Unknown;KARYOTYPE:44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide);CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:RVD (Bortezomib, Dexamethasone, Lenalidomide);LDH_LEVEL:249;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Abnormal;DIAGNOSIS_AT_INCLUSION:Mature B-Cell Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:16;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:22;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.6;PB_ALT_LEVEL:22;PB_AST_LEVEL:24;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0.9;PB_LYMPHOCYTES_PERCENTAGE:28.7;PB_MONOCYTES_PERCENTAGE:8.3;PB_NEUTROPHILS_PERCENTAGE:60.2;PB_NUCLEATED_RBC_PERCENTAGE:0.6;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Plasma cell myeloma;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Plasma cell myeloma;TOTAL_PROTEIN_LEVEL:4.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"PLASMACYTOMA" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:11.8;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.2833;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Multiple Myeloma, plasmacytoma;TUMOR_TYPE:multiple_myeloma;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:125.3581906;GENOME_DOUBLINGS:0;DOUBLING_TIME:198.1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Suspension Lymphoblast;DISEASE_ONTOLOGY:myeloma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI1640+15%FBS;HIST_SUBTYPE1:plasma_cell_myeloma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:plasma_cell;LINEAGE_SUB_SUBTYPE:plasmacytoma;LINEAGE_SUBTYPE:multiple_myeloma;NAME:U266B1;PATHOLOGIST_ANNOTATION:Lymphoma:Multiple_Myeloma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:multiple_myeloma"
"PLASMA_CELL_LEUKEMIA" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:10.0;SEX:Female;AGE:36;FRACTION_GENOME_ALTERED:0.3657;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:Multiple Myeloma;TUMOR_TYPE:multiple_myeloma;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:92.88219793;GENOME_DOUBLINGS:0;DOUBLING_TIME:60.54;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:SUSPENSION;DISEASE_ONTOLOGY:plasma_cell_leukemia;GROWTH_MEDIUM:RPMI-1640+ 15% FBS;HIST_SUBTYPE1:plasma_cell_myeloma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:plasma_cell;LINEAGE_SUBTYPE:multiple_myeloma;NAME:L-363;PATHOLOGIST_ANNOTATION:Lymphoma:Multiple_Myeloma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:multiple_myeloma"
"PLASMA_CELL_MYELOMA" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:6.1889032302;SEX:Female;FRACTION_GENOME_ALTERED:0.5516;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Multiple_Myeloma;HISTOLOGICAL_SUBTYPE:Plasma_Cell_Myeloma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"PLEOMORPHIC 'MFH' / UNDIFFERENTIATED PLEOMORPHIC SARCOMA" "CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:MFH;TMB_NONSYNONYMOUS:1.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:68;FRACTION_GENOME_ALTERED:0.4650;SAMPLE_TYPE:Primary;OS_MONTHS:20.93;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:20.93;TISSUE_SOURCE_SITE:QC;ICD_O_3_SITE:C49.6;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C49.6;ICD_O_3_HISTOLOGY:8805/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/17/14;HISTOLOGICAL_DIAGNOSIS:Pleomorphic 'MFH' / Undifferentiated pleomorphic sarcoma;HISTORY_OTHER_MALIGNANCY:Yes;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:121;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-QC-A6FX.7139C84F-6B44-4912-AB90-6F4B2877C41B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:110;SITE_OF_TUMOR_TISSUE:Superficial Trunk - Back;PHARMACEUTICAL_TX_ADJUVANT:NO;PATH_MARGIN:Negative;PERCENTAGE_NECROSIS:10;DISEASE_MULTIFOCAL_INDICATOR:NO;TUMOR_TOTAL_DEPTH:Deep;CONTIGUOUS_ORGAN_INVADED:NO;LOCOREGIONAL_RECURRENCE_INDICATOR:NO;METASTATIC_DISEASE_CONFIRMED:NO;NTE_LESION_PATHOLOGIC_DEPTH:1.5;NTE_LESION_PATHOLOGIC_LENGTH:5;NTE_LESION_RADIOLOGIC_LENGTH:3.1;TUMOR_BURDEN_PATHOLOGIC:5;TUMOR_BURDEN_RADIOLOGIC:3.1;TUMOR_TOTAL_NECROSIS:Moderate Necrosis (>=10, <50%)"
"PLEOMORPHIC CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Pleomorphic Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUPC;TMB_NONSYNONYMOUS:10.3763771398;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0011;SAMPLE_TYPE:Primary;OS_MONTHS:26.87;OS_STATUS:0:LIVING;RACE:Caucasian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;MSI_SCORE:0.07;MSI_TYPE:Do not report;SAMPLE_COVERAGE:839;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:15;AGE_AT_SEQ_REPORTED_YEARS:62;M_STAGE:M0;SMOKING_HISTORY:Former;ARCHER:NO;T_STAGE:T2A;N_STAGE:N0;STAGE_AT_DIAGNOSIS:IB;OS_DAYS:806;YEAR_OF_DIAGNOSIS:2016;PRETREATED:Yes"
"PLEOMORPHIC HEPATOCELLULAR CARCINOMA" "CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:10.7333333333;SEX:Male;AGE:40;FRACTION_GENOME_ALTERED:0.4969;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Liver;SUBTYPE:Hepatocellular Carcinoma;TUMOR_TYPE:liver;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:141.3075379;GENOME_DOUBLINGS:2;GEOGRAPHIC_DISTRIBUTION:korea;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:pleomorphic hepatocellular carcinoma;HIST_SUBTYPE1:hepatocellular_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:liver;LINEAGE_SUBTYPE:hepatocellular_carcinoma;NAME:SNU-423;PATHOLOGIST_ANNOTATION:Liver:HCC;PROTEOMICS_TMT_LABEL:130n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:liver"
"PLEOMORPHIC LIPOSARCOMA" "CANCER_TYPE_DETAILED:Pleomorphic Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.1;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1095;DIAGNOSIS AGE:43;GDNA(NG):6480;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"PLEOMORPHIC RHABDOMYOSARCOMA" "CANCER_TYPE_DETAILED:Pleomorphic Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Female;SAMPLE_TYPE:Recurrent;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Targeted_Therapy;Chemotherapy;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1299;DIAGNOSIS AGE:61;GDNA(NG):6960;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"PLEOMORPHIC SARCOMA" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:9.39387097441;SEX:Male;FRACTION_GENOME_ALTERED:0.4426;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Malignant Fibrous Histiocytoma-Pleomorphic Sarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"PLEOMORPHIC XANTHOASTROCYTOMA" "CANCER_TYPE_DETAILED:Anaplastic pleomorphic xanthoastrocytoma;CANCER_TYPE:Encapsulated Glioma;ONCOTREE_CODE:APXA;TMB_NONSYNONYMOUS:2.13333333333;SEX:Female;OS_MONTHS:34;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:WHO Grade III;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:10;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Brain- mesial left temporal brain tumor;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:24;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"PLEOMORPHIC_SARCOMA" "CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:MFH;TMB_NONSYNONYMOUS:23.8666666667;SEX:Male;AGE:29;FRACTION_GENOME_ALTERED:0.4429;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Pleomorphic Sarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Malignant_Fibrous_Histiocytoma-Pleomorphic_Sarcoma;PURITY:1;MUTATION_RATE:179.4906831;GENOME_DOUBLINGS:1;DOUBLING_TIME:64.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:pleomorphic_sarcoma;NAME:GCT;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_FibrousHistiocytoma;SITE_OF_FINDING:lung;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"PLEURAL CANCER, NOS" "CANCER_TYPE_DETAILED:Pleura;CANCER_TYPE:Pleural Cancer, NOS;ONCOTREE_CODE:PLEURA;TMB_NONSYNONYMOUS:16.8666666667;SUBTYPE:Carcinoma;LINEAGE:lung;LINEAGE_SUBTYPE:lung_carcinoma"
"PLEURAL MESOTHELIOMA" "CANCER_TYPE_DETAILED:Pleural Mesothelioma, Epithelioid Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLEMESO;TMB_NONSYNONYMOUS:2.87341935688;FRACTION_GENOME_ALTERED:0.3969;PRIMARY_SITE:Pleura;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Mesothelioma;HISTOLOGICAL_TYPE:Mesothelioma;DATA_SOURCE:RIKEN;SAMPLE_ORIGIN:Solid"
"PLEURAL MESOTHELIOMA, BIPHASIC TYPE" "CANCER_TYPE_DETAILED:Pleural Mesothelioma, Biphasic Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLBMESO;TMB_NONSYNONYMOUS:4.89359848807;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0293;SAMPLE_TYPE:Primary;OS_MONTHS:16.48;OS_STATUS:1:DECEASED;RACE:Caucasian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Pleura;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;TUMOR_PURITY:20;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:653;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:192;AGE_AT_SEQ_REPORTED_YEARS:79;M_STAGE:M0;SMOKING_HISTORY:Former;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;ARCHER:NO;T_STAGE:T3;N_STAGE:N0;STAGE_AT_DIAGNOSIS:III;YEAR_OF_DIAGNOSIS:2016;PRETREATED:no"
"PLEURAL MESOTHELIOMA, EPITHELIOID TYPE" "CANCER_TYPE_DETAILED:Pleural Mesothelioma, Epithelioid Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLEMESO;TMB_NONSYNONYMOUS:2.87341935688;FRACTION_GENOME_ALTERED:0.3969;PRIMARY_SITE:Pleura;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Mesothelioma;HISTOLOGICAL_TYPE:Mesothelioma;DATA_SOURCE:RIKEN;SAMPLE_ORIGIN:Solid"
"PLEURAL MESOTHELIOMA, SARCOMATOID TYPE" "CANCER_TYPE_DETAILED:Pleural Mesothelioma, Sarcomatoid Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLSMESO;TMB_NONSYNONYMOUS:1.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:81;FRACTION_GENOME_ALTERED:0.1177;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:LK;ICD_O_3_SITE:C38.4;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C45.0;ICD_O_3_HISTOLOGY:9050/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/6/13;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IA;HISTOLOGICAL_DIAGNOSIS:Sarcomatoid mesothelioma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1024;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-LK-A4O0.2BDA3DE7-2BBC-4D52-B5C7-AAD0043881AF.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:380;SITE_OF_TUMOR_TISSUE:Pleura;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1a;LATERALITY:Left;FAMILY_HISTORY_CANCER_RELATIONSHIP:Parent|Sibling;FAMILY_HISTORY_CANCER_TYPE:Other, specify|Other, specify"
"PLEUROPULMONARY BLASTOMA" "CANCER_TYPE_DETAILED:Pleuropulmonary blastoma;CANCER_TYPE:Lung Cancer;ONCOTREE_CODE:PPB;TMB_NONSYNONYMOUS:1.83333333333;SEX:Male;OS_MONTHS:101;OS_STATUS:0:LIVING;PRIMARY_SITE:Lung;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:2;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Lung;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:8.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:92;SAMPLE_TESTED_CATEGORY:Primary disease"
"PLEUROPULMONARY BLASTOMA PPB" NA
"PLEUROPULMORY BLASTOMA PPB" NA
"PLEXIFORM FIBROHISTIOCYTIC TUMOR" "CANCER_TYPE_DETAILED:Plexiform fibrohistiocytic tumor;CANCER_TYPE:Soft Tissue Tumor;ONCOTREE_CODE:MFH;TMB_NONSYNONYMOUS:1.76666666667;SEX:Female;OS_MONTHS:57;OS_STATUS:0:LIVING;PRIMARY_SITE:Chest wall;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:3;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Anterior chest wall;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:5.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:48;SAMPLE_TESTED_CATEGORY:Primary disease"
"PLEXIFORM NEUROFIBROMA" "CANCER_TYPE_DETAILED:Plexiform Neurofibroma;CANCER_TYPE:Nerve Sheath Tumor;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Matched;SEX:Female;SAMPLE_TYPE:Primary;SAMPLE_CLASS:Tumor;NF1_GENOTYPE:-/-;NF2_GENOTYPE:+/+"
"PLEXIFORM SCHWANNOMA" "CANCER_TYPE_DETAILED:Plexiform Schwannoma;CANCER_TYPE:Nerve Sheath Tumor;ONCOTREE_CODE:SCHW;TMB_NONSYNONYMOUS:2.26666666667;SEX:Male;OS_MONTHS:45;OS_STATUS:0:LIVING;PRIMARY_SITE:Penis/scrotum;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Penis/scrotum;NGS_TEST:Tumor-normal  WES;AGE_TESTING_YEARS:1.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:36;SAMPLE_TESTED_CATEGORY:Primary disease"
"PLMESO" "CANCER_TYPE_DETAILED:Pleural Mesothelioma;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLMESO;TMB_NONSYNONYMOUS:9.93333333333;SEX:Male;AGE:48;FRACTION_GENOME_ALTERED:0.5526;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:African_american;PRIMARY_SITE:Pleura;SUBTYPE:Mesothelioma;TUMOR_TYPE:mesothelioma;HISTOLOGY:Mesothelioma;PURITY:1;MUTATION_RATE:144.0712209;GENOME_DOUBLINGS:1;DOUBLING_TIME:81.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;FREEZING_MEDIUM:10% DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:mesothelioma;NAME:NCI-H28;PATHOLOGIST_ANNOTATION:Lung:Mesothelioma;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:mesothelioma"
"PNET" "CANCER_TYPE_DETAILED:Neuroblastoma;CANCER_TYPE:Peripheral Nervous System;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:7.43333333333;SEX:Female;AGE:0.75;FRACTION_GENOME_ALTERED:0.0846;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Autonomic_Ganglia;TUMOR_TYPE:neuroblastoma;HISTOLOGY:Neuroblastoma;PURITY:1;MUTATION_RATE:115.6076715;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:fibroblast-like;DISEASE_ONTOLOGY:neuroblastoma;GROWTH_MEDIUM:alpha-MEM with 10% fetal calf serum;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:peripheral_nervous_system;LINEAGE_MOLECULAR_SUBTYPE:MYCN_amp;LINEAGE_SUBTYPE:neuroblastoma;NAME:NH-6;PATHOLOGIST_ANNOTATION:PNET:Neuroblastoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:neuroblastoma"
"POLE ULTRA-MUTATED" NA
"POLYCYTHEMIA VERA" "CANCER_TYPE_DETAILED:Myeloid Neoplasm;CANCER_TYPE:Blood Cancer, NOS;ONCOTREE_CODE:MNM;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:5.9;OS_STATUS:1:DECEASED;GENE_PANEL:RMG;AGE_AT_DIAGNOSIS:83.0;PRIOR_TREATMENT:Hydrea for polycythemia vera;SOURCE:WashU_off_protocol;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:86;DISEASE:Relapsed_AML;PERFORMANCE_STATUS:unknown;PERIPHERAL_BLASTS_PERCENTAGE:20.0;AML_FAB:AML with maturation (M2);CLINICAL_ONSET_AML:MDS/MPD related;CYTOGENETIC_RISK:Int;KYRYOTYPE:normal;MORPHOLOGIC_RESPONSE:SD;PERIPHERAL_BLOOD_WBC:9.1;TRANSPLANT:No"
"POORLY DIFFERENTIATED ONCOCYTIC CARCINOMA" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;SOMATIC_STATUS:Matched;SEX:Female;AGE:62;SAMPLE_TYPE:Primary;OS_MONTHS:41.16;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:41.16;TISSUE_SOURCE_SITE:EM;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C73;ICD_O_3_HISTOLOGY:8010/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:12/29/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:176;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-EM-A2CM.26C8884E-4AFB-468D-A974-BE406BD2845F.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:100;SITE_OF_TUMOR_TISSUE:Thyroid;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Poorly Differentiated Oncocytic Carcinoma;LYMPH_NODES_EXAMINED:YES;LATERALITY:Left lobe"
"POORLY DIFFERENTIATED OR PLEOMORPHIC OR EPITHELIOID LEIOMYOSARCOMA" "CANCER_TYPE_DETAILED:Leiomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:LMS;TMB_NONSYNONYMOUS:0.966666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.7129;SAMPLE_TYPE:Primary;OS_MONTHS:34.86;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:22.44;TISSUE_SOURCE_SITE:HB;ICD_O_3_SITE:C55.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C55;ICD_O_3_HISTOLOGY:8890/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/23/12;HISTOLOGICAL_DIAGNOSIS:Leiomyosarcoma (LMS);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:735;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-HB-A3L4.5394ACFD-3583-4E61-9BEC-DB0BB1C1B656.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:190;SITE_OF_TUMOR_TISSUE:Gynecological - Uterus|Gynecological - Cervix;HISTOLOGICAL_SUBTYPE:Poorly differentiated or pleomorphic or epithelioid leiomyosarcoma;METASTATIC_SITE_PATIENT:Lung;PATH_MARGIN:Negative;DISEASE_MULTIFOCAL_INDICATOR:NO;LEIOMYO_MAJOR_VESSEL_INVOLVEMENT:No Major Vessel Involvement;TUMOR_TOTAL_DEPTH:Deep;LEIOMYOSARCOMA_UTERINE_INVOLVEMENT:YES;METASTATIC_DISEASE_CONFIRMED:YES;NTE_LESION_PATHOLOGIC_DEPTH:8;NTE_LESION_PATHOLOGIC_LENGTH:18;NTE_LESION_RADIOLOGIC_DEPTH:9.6;NTE_LESION_RADIOLOGIC_LENGTH:14;TUMOR_BURDEN_PATHOLOGIC:18;TUMOR_BURDEN_RADIOLOGIC:14"
"POORLY DIFFERENTIATED THYROID CANCER" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:4.42064516443;SEX:Female;FRACTION_GENOME_ALTERED:0.5518;PRIMARY_SITE:Thyroid;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Thyroid;HISTOLOGICAL_SUBTYPE:Anaplastic_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"POORLY DIFFERENTIATED THYROID CARCINOMA" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:0.166666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:71;FRACTION_GENOME_ALTERED:0.2766;SAMPLE_TYPE:Primary;OS_MONTHS:3.22;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;METASTATIC_SITE:lungs;PATH_T_STAGE:T3/T4;PATH_N_STAGE:Nx/N0;SPECIMEN_PRESERVATION_TYPE:Frozen;M_STAGE:M1;CYTOLOGICAL_PHENOTYPE:Hurthle;GROWTH_PATTERN:solid;PDTC_DEFINITION:PDTC-Turin"
"POORLY_COHESIVE" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:39.4333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:51.19;FRACTION_GENOME_ALTERED:0.0876;SAMPLE_TYPE:Primary;OS_MONTHS:5.62;OS_STATUS:0:LIVING;RACE:WHITE;PATH_T_STAGE:T4a;PATH_N_STAGE:N0;PATH_M_STAGE:M0;MSI_STATUS:MSI-H;TNMSTAGE:Stage_IIB;MOLECULAR_SUBTYPE:MSI;KRAS_MUTATION:0;METHYLATION_CLUSTER:C3;MUTATION_RATE:47.073;WHO_CLASS:Poorly_Cohesive;TP53_MUTATION:0;LAUREN_CLASS:Diffuse;MLH1_SILENCING:TRUE;ABSOLUTE_EXTRACT_PURITY:0.31;GENE_EXPRESSION_CLUSTER:C2;PIK3CA_MUTATION:1;ANATOMIC_REGION:FUNDUS_BODY;ARHGAP26_ARHGAP6_CLDN18_REARRANGEMENT:1;CDKN2A_SILENCING:FALSE;CIMP_CATEGORY:OTHER;COPY_NUMBER_CLUSTER:Low;EBV_PRESENT:0;ESTIMATED_LEUKOCYTE_PERCENTAGE:0.357;HYPERMUTATED:1;MET_SKIPPED_EXON_2:0;MET_SKIPPED_EXONS_18_AND_19:0;PERCENT_LYMPHOCYTE_INFILTRATION:0;PERCENT_TUMOR_CELLS:55;PERCENT_TUMOR_NUCLEI:70;RHOA_MUTATION:0;SIGNET_RING:0;MICRORNA_EXPRESSION_CLUSTER:C1"
"POROCARCINOMA/SPIROADENOCARCINOMA" "CANCER_TYPE_DETAILED:Porocarcinoma/Spiroadenocarcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:POCA;TMB_NONSYNONYMOUS:0.966666666667;SOMATIC_STATUS:Matched;AGE:67;SAMPLE_TYPE:Metastatic;OS_MONTHS:27.83;OS_STATUS:1:DECEASED;MSI_SCORE:0.08;ANALYSIS_COHORT:MISC;TUMOR_CONTENT:66;BIOPSY_SITE:Lymph Node;BIOPSY_COHORT:Lymphatic System;GENDER:Male;HRD_SCORE:14;TREATED_WITH_ICI:No"
"PRAD" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:28.5131613106;SEX:Male;FRACTION_GENOME_ALTERED:0.1976;PRIMARY_SITE:Prostate;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Prostate;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"PRE-T" "CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Unmatched;SEX:Female;SAMPLE_CLASS:Tumor;TREATMENT_BEST_RESPONSE:Stable Disease;OFF_STUDY_REASON:Toxicity;SAMPLE_COLLECTION_TIMEPOINT:pre-treatment;ALPELISIB_DOSE:300;ALPELISIB_SCHEDULING:Continious;BREAST_CANCER_SUBTYPE:HR+/HER2-;CLINICAL_BENEFIT:No;ENDOCRINE_THERAPY:Exemestane;MEASURABLE_DISEASE:No;PIK3CA_MUT_PRE_TREATMENT_TUMOR:WT;PIK3CA_PRE_TREATMENT_TUMOR:WT;SEQUENCING_PLATFORM:Sequenom;TREATMENT_ARM:B;WEEKS_ON_STUDY:4"
"PRIMARY CNS MELANOMA" "CANCER_TYPE_DETAILED:Primary CNS Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:PCNSM;TMB_NONSYNONYMOUS:4.43662120239;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Primary;OS_MONTHS:7;OS_STATUS:1:DECEASED;PRIMARY_SITE:Skin;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:617;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORT:65;AGE_GROUP:61-70;DRUG_TYPE:CTLA4"
"PRIMARY CUTANEOUS CD30 POSITIVE T-CELL LYMPHOPROLIFERATIVE DISORDERS" "CANCER_TYPE_DETAILED:Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorders;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:PCLPD;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;TUMOR_SUBTYPE:CD30+ LPD (Type D Lymphomatoid papulosis)"
"PRIMARY CUTANEOUS CD8 POSITIVE AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T-CELL LYMPHOMA" "CANCER_TYPE_DETAILED:Primary Cutaneous CD8 Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:PCAECTCL;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched"
"PRIMARY DLBCL OF THE CNS" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma;CANCER_TYPE:Non-Hodgkin Lymphoma;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:5.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.4525;SAMPLE_TYPE:Primary;OS_MONTHS:25.89;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:25.89;TISSUE_SOURCE_SITE:RQ;ICD_O_3_SITE:C71.7;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C71.7;ICD_O_3_HISTOLOGY:9680/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:12/12/13;AJCC_STAGING_EDITION:7th;HISTOLOGICAL_DIAGNOSIS:Primary DLBCL of the CNS;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:461;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-RQ-A68N.B40907C0-DA7B-436F-993A-53DA4C9A56A9.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:150;WEIGHT:58.0;SITE_OF_TUMOR_TISSUE:Brain;TREATMENT_OUTCOME_FIRST_COURSE:Partial Remission/Response;HEIGHT:162.0;TARGETED_MOLECULAR_THERAPY:YES;FOLLICULAR_COMPONENT_PERCENT:< or = 10%;BONE_MARROW_BIOPSY_PERFORMED:YES;BONE_MARROW_INVOLVEMENT:NO;EXTRANODAL_INVOLVEMENT:3;IMMUNOPHENOTYPIC_ANALYSIS_METHOD:Immunohistochemistry|Immunohistochemistry|Immunohistochemistry;IMMUNOPHENOTYPIC_ANALYSIS_RESULTS:Negative|Positive|Positive;IMMUNOPHENOTYPIC_ANALYSIS_TESTED:CD10 > 30%|BCL2|CD20;LYMPH_NODE_INVOLVEMENT_SITE:other"
"PRIMARY EFFUSION LYMPHOMA" "CANCER_TYPE_DETAILED:Primary Effusion Lymphoma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PEL;TMB_NONSYNONYMOUS:8.8;SUBTYPE:B-cell, Non-Hodgkins, Primary Effusion;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_primary_effusion;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"PRIMARY MEDIASTINAL THYMIC DLBCL" NA
"PRIMARY MEDIASTINAL THYMIC LARGE B-CELL LYMPHOMA" NA
"PRIMARY MYELOFIBROSIS" "CANCER_TYPE_DETAILED:Primary Myelofibrosis;CANCER_TYPE:Myeloproliferative Neoplasms;ONCOTREE_CODE:PMF;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:2.37;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:59.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:4.54;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:59;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:8.6;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Post-Transplant|Initial Acute Leukemia Diagnosis|Post-Chemotherapy;KARYOTYPE:45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7];PB_BLAST_PERCENTAGE:25;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:30;CUMULATIVE_TREATMENT_REGIMENS:Fludarabine, Melphalan|Azacitidine|Sorafenib;CUMULATIVE_TREATMENT_STAGES:Induction | Allogeneic - Mismatched Unrelated Donor | Experimental | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Sorafenib;MOST_RECENT_TREATMENT_DURATION:56;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q,;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:153;ELN_2008:Not Enough Information;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:27.3;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:Yes;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:97.2;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.7;PB_ALT_LEVEL:39;PB_AST_LEVEL:22;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0.9;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:23.2;PB_MONOCYTES_PERCENTAGE:11.6;PB_NEUTROPHILS_PERCENTAGE:36.6;PB_NUCLEATED_RBC_PERCENTAGE:0;PRIOR_CANCER:Bladder Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Primary myelofibrosis;SURFACE_ANTIGENS:CD13, dim CD33, CD43, CD117;TOTAL_PROTEIN_LEVEL:6.8;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"PRIMARY MYELOFIBROSIS,OVERT FIBROTIC STAGE" "CANCER_TYPE_DETAILED:Primary Myelofibrosis,Overt Fibrotic Stage;CANCER_TYPE:Myeloproliferative Neoplasms;ONCOTREE_CODE:PMFOFS;TMB_NONSYNONYMOUS:1.8650470598;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:Primary Myelofibrosis,Overt Fibrotic Stage"
"PRIMARY NEUROEPITHELIAL TUMOR" "CANCER_TYPE_DETAILED:Primary Neuroepithelial Tumor;CANCER_TYPE:Miscellaneous Brain Tumor;ONCOTREE_CODE:PRNET;TMB_NONSYNONYMOUS:0;SEX:Male;AGE:1;FRACTION_GENOME_ALTERED:0.0851;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Stage IV;RFS_STATUS:Yes;SURGERY:Yes;DEATH:No;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Neuroepithelial;DOB_LASTFU_TIME_YRS:4;DOB_PROG_START_TIME_YRS:1;DOB_PROG_TIME_YRS:3;DOB_RECUR_TIME_YRS:1;DOB_REPORT_TIME_YRS:3;DOB_TISSUE_TIME_YRS:3;LINE_OBR_CHEMO:Unknown;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK:Unknown;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:2;NUM_LINES_CHEMO:1;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:1;NUM_LINES_TARGETED:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:Archer;PROG_DEATH:No;PROG_DEATH_TIME_YRS:3;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:0"
"PRIMARY RESIDUAL" NA
"PRIMARY TUMOUR" "TMB_NONSYNONYMOUS:45.8;SEX:Male;SAMPLE_TYPE:Primary Tumour;PSA:nan;LST:No;P53:No;MSI:Yes;RNA:1;AREA:primary tumor 1;CGA:nan;ERG:0;ERG_FUS:No;GLEASON_PR:5;GLEASON_SE:5;GLEASON_SU:10;HIST:Usual prostate adenocarcinoma with NE differentiation;ISUP:5;PTEN_CYT:Negative;PTEN_NUC:Negative;SYP:nan;TIME_POINT:1;WES:1"
"PRIMITIVE NEUROECTODERMAL TUMOR" "CANCER_TYPE_DETAILED:Primitive Neuroectodermal Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:PNET;TMB_NONSYNONYMOUS:3.9;SUBTYPE:Primitive Neuroectodermal Tumor (PNET);LINEAGE:central_nervous_system;LINEAGE_SUBTYPE:PNET;TYPE_REFINED:medulloblastoma"
"PRIMITIVE NEUROECTODERMAL TUMOR PNET" NA
"PRO MYELOCYTIC LEUKEMIA" "CANCER_TYPE_DETAILED:Myeloid Neoplasm;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:MNM;TMB_NONSYNONYMOUS:4.733333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:36;FRACTION_GENOME_ALTERED:0.2614;HISTOLOGICAL_SUBTYPE:Pro myelocytic leukemia;PRIOR_TREATMENT:None;DOUBLING_TIME:28.6;P53:MT;CATEGORY_SAMPLE:PBL;EPITHELIAL:No;MDR:-11"
"PROSTATE ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:28.5131613106;SEX:Male;FRACTION_GENOME_ALTERED:0.1976;PRIMARY_SITE:Prostate;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Prostate;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"PROSTATE ADENOCARCINOMA ACINAR TYPE" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.46666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:66;FRACTION_GENOME_ALTERED:0.0836;SAMPLE_TYPE:Primary;OS_MONTHS:15.05;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:15.05;TISSUE_SOURCE_SITE:CH;ICD_O_3_SITE:C61.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C61;ICD_O_3_HISTOLOGY:8550/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/16/12;PATH_T_STAGE:T2c;HISTOLOGICAL_DIAGNOSIS:Prostate Adenocarcinoma Acinar Type;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-CH-5767.237374e0-5b18-407c-ae42-898a95c14fa2.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SITE_OF_TUMOR_TISSUE:Prostate;LYMPH_NODES_EXAMINED:YES;SPECIMEN_SECOND_LONGEST_DIMENSION:0.4;LATERALITY:Bilateral;LONGEST_DIMENSION:1.3;SHORTEST_DIMENSION:0.2;PRIMARY_SITE_PATIENT:Peripheral Zone;CLIN_M_STAGE:M0;GLEASON_SCORE:7;BIOCHEMICAL_RECURRENCE_INDICATOR:NO;CT_SCAN_AB_PELVIS_INDICATOR:NO;DAYS_TO_PSA:377;DIAGNOSTIC_MRI_RESULT:NO;GLEASON_PATTERN_PRIMARY:4;GLEASON_PATTERN_SECONDARY:3;INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD:Core needle biopsy;PSA_MOST_RECENT_RESULTS:0.04"
"PROSTATE ADENOCARCINOMA, NOT OTHERWISED SPECIFIED, WITH DUCTAL FEATUES" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.33333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:71;SAMPLE_TYPE:Primary;OS_MONTHS:6.96;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:6.96;TISSUE_SOURCE_SITE:J9;ICD_O_3_SITE:C61.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C61;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/9/14;PATH_T_STAGE:T3a;HISTOLOGICAL_DIAGNOSIS:Prostate Adenocarcinoma, Other Subtype;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:278;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-J9-A52D.D2AF0639-286D-460B-8F66-E6401F3EE1F7.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Prostate;HISTOLOGICAL_SUBTYPE:Prostate Adenocarcinoma, Not Otherwised Specified, with ductal featues;LYMPH_NODES_EXAMINED:NO;LATERALITY:Bilateral;PRIMARY_SITE_PATIENT:Transition Zone;TARGETED_MOLECULAR_THERAPY:NO;CLIN_M_STAGE:M0;CLIN_T_STAGE:T2b;GLEASON_SCORE:9;BONE_SCAN_RESULT:Normal (no evidence of prostate cancer) [cM0];BIOCHEMICAL_RECURRENCE_INDICATOR:NO;CT_SCAN_AB_PELVIS_INDICATOR:YES;CT_SCAN_AB_PELVIS_RESULTS:No Evidence of Extraprostatic Extension;DAYS_TO_BONE_SCAN_PERFORMED:-6;DAYS_TO_CT_SCAN_AB_PELVIS:21;DAYS_TO_PSA:146;DIAGNOSTIC_MRI_RESULT:NO;GLEASON_PATTERN_PRIMARY:4;GLEASON_PATTERN_SECONDARY:5;GLEASON_PATTERN_TERTIARY:3;INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD:Core needle biopsy;PSA_MOST_RECENT_RESULTS:0.059;TUMOR_LEVEL:Apex|Middle"
"PROSTATE ADENOCARCINOMA, OTHER SUBTYPE" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Male;AGE:71;FRACTION_GENOME_ALTERED:0.2006;SAMPLE_TYPE:Primary;OS_MONTHS:21.94;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:21.94;TISSUE_SOURCE_SITE:EJ;ICD_O_3_SITE:C61.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C61;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/24/13;PATH_T_STAGE:T3a;HISTOLOGICAL_DIAGNOSIS:Prostate Adenocarcinoma, Other Subtype;HISTORY_OTHER_MALIGNANCY:Yes, History of Prior Malignancy;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:219;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-EJ-A46G.ACBA1CE1-E248-47D3-B03D-BE0C1B4A6F21.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:430;SITE_OF_TUMOR_TISSUE:Prostate;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Adenocarcinoma prostate with prominent ductal differentiation identified;LYMPH_NODES_EXAMINED:YES;LATERALITY:Bilateral;TARGETED_MOLECULAR_THERAPY:NO;CLIN_M_STAGE:M0;CLIN_T_STAGE:T3a;GLEASON_SCORE:8;BONE_SCAN_RESULT:Normal (no evidence of prostate cancer) [cM0];BIOCHEMICAL_RECURRENCE_INDICATOR:NO;DAYS_TO_BONE_SCAN_PERFORMED:28;DAYS_TO_PSA:93;GLEASON_PATTERN_PRIMARY:4;GLEASON_PATTERN_SECONDARY:4;GLEASON_PATTERN_TERTIARY:5;INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD:Core needle biopsy;PSA_MOST_RECENT_RESULTS:0.1"
"PROSTATE CANCER" "CANCER_TYPE_DETAILED:AML, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNOS;TMB_NONSYNONYMOUS:1.1;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:5.13;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:7.5;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Unknown;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:8.5;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY;PB_BLAST_PERCENTAGE:58;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:76;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine;MOST_RECENT_TREATMENT_DURATION:55;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200];DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Intermediate-I;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:25;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.1;PB_ALT_LEVEL:27;PB_AST_LEVEL:25;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:2;PB_LYMPHOCYTES_PERCENTAGE:38;PB_MONOCYTES_PERCENTAGE:6;PB_NEUTROPHILS_PERCENTAGE:14;PRIOR_CANCER:Prostate Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myeloid leukaemia, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute myeloid leukaemia, NOS;SURFACE_ANTIGENS:CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial ;TOTAL_PROTEIN_LEVEL:5.8"
"PROSTATE CANCER, NOS" "CANCER_TYPE_DETAILED:Prostate;CANCER_TYPE:Prostate Cancer, NOS;ONCOTREE_CODE:PROSTATE;TMB_NONSYNONYMOUS:3.13333333333;FRACTION_GENOME_ALTERED:0.0603;ETHNICITY:Caucasian;PRIMARY_SITE:Prostate;TUMOR_TYPE:prostate;HISTOLOGY:Other;MUTATION_RATE:64.44913312;ANNOTATION_SOURCE:ACHILLES;HIST_SUBTYPE1:immortalized_epithelial;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:engineered_prostate;NAME:PrEC LH;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:prostate"
"PROSTATE NEUROENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Prostate Neuroendocrine Carcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRNE;TMB_NONSYNONYMOUS:1.2;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.7115;TUMOR_TISSUE_SITE:Pelvic mass;DISEASE_CODE:CRPC-NE;CLONET_PURITY:0.99;GENOMIC_BURDEN:0.4463;PATHOLOGY_CLASSIFICATION:D;CONTROL_SITE:Blood"
"PROSTATE SMALL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Prostate Small Cell Carcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRSCC;TMB_NONSYNONYMOUS:9.63333333333;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.6847;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Prostate;SUBTYPE:Small Cell Carcinoma;TUMOR_TYPE:prostate;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:86.31007528;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;DISEASE_ONTOLOGY:small_cell_carcinoma;HIST_SUBTYPE1:small_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:prostate;LINEAGE_SUBTYPE:prostate_small_cell;NAME:NCI-H660;PATHOLOGIST_ANNOTATION:Prostate:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:prostate"
"PROSTATE SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Prostate Squamous Cell Carcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRSC;TMB_NONSYNONYMOUS:4.323490475;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.0558;SAMPLE_TYPE:Primary;RACE:White;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;VITAL_STATUS:Alive;AGE_AT_DIAGNOSIS:69.5;M_STAGE:M0;GLEASON_SCORE:<7;PSA:5.3;TUMOR_SAMPLE_HISTOLOGY:Other (Text box);AGE_AT_PROCUREMENT:70.8;DISEASE_EXTENT:Localized;SMOKING:Never;TISSUE_TYPE:Prostate;8Q_ARM:Neutral"
"PROSTATE_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:5.53333333333;SEX:Male;AGE:59;FRACTION_GENOME_ALTERED:0.5120;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Prostate;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:prostate;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:84.97649095;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:prostate_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM + 10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:prostate;LINEAGE_SUBTYPE:prostate_adenocarcinoma;NAME:VCaP;PATHOLOGIST_ANNOTATION:Prostate:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:vertebra;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:prostate"
"PROSTATE_CANCER" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:5.53333333333;SEX:Male;AGE:59;FRACTION_GENOME_ALTERED:0.5120;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Prostate;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:prostate;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:84.97649095;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:prostate_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM + 10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:prostate;LINEAGE_SUBTYPE:prostate_adenocarcinoma;NAME:VCaP;PATHOLOGIST_ANNOTATION:Prostate:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:vertebra;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:prostate"
"PROSTATE_SMALL_CELL" "CANCER_TYPE_DETAILED:Prostate Small Cell Carcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRSCC;TMB_NONSYNONYMOUS:9.63333333333;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.6847;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Prostate;SUBTYPE:Small Cell Carcinoma;TUMOR_TYPE:prostate;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:86.31007528;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;DISEASE_ONTOLOGY:small_cell_carcinoma;HIST_SUBTYPE1:small_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:prostate;LINEAGE_SUBTYPE:prostate_small_cell;NAME:NCI-H660;PATHOLOGIST_ANNOTATION:Prostate:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:prostate"
"PROXIMAL-TYPE EPITHELIOID SARCOMA" "CANCER_TYPE_DETAILED:PROXIMAL-TYPE EPITHELIOID SARCOMA (PTES);CANCER_TYPE:Sarcoma;SEX:Male;AGE:15.36208057;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:1st tertile;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:1st tertile;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:1st tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:1st tertile;TIME_FROM_DX_TO_SEQ:519;TIME_TO_BLOOD_DRAW_FROM_TX:1;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:Yes"
"PROXIMAL-TYPE EPITHELIOID SARCOMA PTES" NA
"PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA" "CANCER_TYPE_DETAILED:Pseudomyogenic Hemangioendothelioma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Male;FRACTION_GENOME_ALTERED:0.0010;SAMPLE_TYPE:Primary;OS_MONTHS:0.921;OS_STATUS:0:LIVING;RACE:PT REFUSED TO ANSWER;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT410;TUMOR_PURITY:50;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:345;AGE_AT_SEQ_REPORT:31;DETAILED_PRIMARY_SITE:Soft Tissue;FACETS:YES;FACETS_REVIEW:NO;FGA_REPORTED:0.001"
"PURE ERYTHROID LEUKEMIA" "CANCER_TYPE_DETAILED:Pure Erythroid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:PERL;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:24.77;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:67.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:67;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:3;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Hypomethylating/Low Dose Cytarabine;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:20;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC;CUMULATIVE_TREATMENT_STAGES:Hypomethylating/Low Dose Cytarabine | Consolidation | Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute erythroid leukaemia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute erythroid leukaemia;SURFACE_ANTIGENS:Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45.;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"RA" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"RAEB" "CANCER_TYPE_DETAILED:MDS with Excess Blasts;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSEB;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;STUDY:BeatAML;SEQUENCING_TYPE:Whole-exome;DETAILED_CANCER_TYPE:RAEB"
"RARS" "CANCER_TYPE_DETAILED:MDS/MPN with Ring Sideroblasts and Thrombocytosis;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNRST;TMB_NONSYNONYMOUS:5.95514584152;SOMATIC_STATUS:Unmatched;STUDY:Papaemmanuil_MDS_2013;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:RARS"
"RARS-T" "CANCER_TYPE_DETAILED:MDS/MPN with Ring Sideroblasts and Thrombocytosis;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNRST;TMB_NONSYNONYMOUS:5.95514584152;SOMATIC_STATUS:Unmatched;STUDY:Papaemmanuil_MDS_2013;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:RARS-T"
"RBL" "CANCER_TYPE_DETAILED:Retinoblastoma;CANCER_TYPE:Retinoblastoma;ONCOTREE_CODE:RBL;TMB_NONSYNONYMOUS:5.63333333333;SUBTYPE:Retinoblastoma;LINEAGE:eye;LINEAGE_SUBTYPE:retinoblastoma"
"RCMD" "CANCER_TYPE_DETAILED:MDS with Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSMD;TMB_NONSYNONYMOUS:5.95514584152;SOMATIC_STATUS:Unmatched;STUDY:Papaemmanuil_MDS_2013;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:RCMD"
"RCMD-RS" "CANCER_TYPE_DETAILED:MDS with Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSMD;TMB_NONSYNONYMOUS:8.93271876228;SOMATIC_STATUS:Unmatched;STUDY:Papaemmanuil_MDS_2013;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:RCMD-RS"
"READ" "CANCER_TYPE_DETAILED:AML with Recurrent Genetic Abnormalities;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLRGA;TMB_NONSYNONYMOUS:0.166666667;SOMATIC_STATUS:Unmatched;SEX:Female;ETHNICITY:Black;PLATFORM:WES;AGE_AT_DIAGNOSIS:30.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:5.3;AGE_AT_PROCUREMENT:31;CENTER:6;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:8.5;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.01;CURRENT_STAGE:Consolidation;FUSION:MLLT3-KMT2A;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1];PB_BLAST_PERCENTAGE:43;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:27;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:HiDAC;MOST_RECENT_TREATMENT_DURATION:93;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:27;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.1;INDUCTION_RESPONSE:Complete Response i;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:4.6;PB_ALT_LEVEL:35;PB_AST_LEVEL:62;PB_LYMPHOCYTES_PERCENTAGE:12;PB_MONOCYTES_PERCENTAGE:40;PB_NEUTROPHILS_PERCENTAGE:5;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with t(9;11)(p22;q23); MLLT3-MLL;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with t(9;11)(p22;q23); MLLT3-MLL;SURFACE_ANTIGENS:There are increased abnormal cells in the monocyte gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression.;TOTAL_PROTEIN_LEVEL:7.3;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"READ_GS" "CANCER_TYPE_DETAILED:Rectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:READ;TMB_NONSYNONYMOUS:3.233333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:0.986290561;OS_STATUS:0:LIVING;TISSUE_SOURCE_SITE:Christiana Healthcare;ICD_O_3_SITE:C20.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C20;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:5/18/10;PFS_MONTHS:0.986290561;AJCC_STAGING_EDITION:6TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Rectum;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:READ_GS;TUMOR_TYPE:Rectal Adenocarcinoma;PATH_T_STAGE:T2;DAYS_LAST_FOLLOWUP:30;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-23527;MSI_SENSOR_SCORE:0.06;CANCER_TYPE_ACRONYM:READ;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.2791;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:AG;DSS_MONTHS:0.986290561;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"RECTAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:4.53116129354;SEX:Male;FRACTION_GENOME_ALTERED:0.4099;PRIMARY_SITE:Large Intestine;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Colorectal;HISTOLOGICAL_SUBTYPE:Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"RECTAL MUCINOUS ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Rectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:READ;TMB_NONSYNONYMOUS:1.56666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:67;FRACTION_GENOME_ALTERED:0.0817;SAMPLE_TYPE:Primary;OS_MONTHS:25;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:25;TISSUE_SOURCE_SITE:AG;ICD_O_3_SITE:C19.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C19;ICD_O_3_HISTOLOGY:8480/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/18/10;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIB;HISTOLOGICAL_DIAGNOSIS:Rectal Mucinous Adenocarcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2007;RETROSPECTIVE_COLLECTION:YES;SITE_OF_TUMOR_TISSUE:Rectum;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;PRIMARY_SITE_PATIENT:Rectum;KRAS_GENE_ANALYSIS_INDICATOR:NO;LYMPHOVASCULAR_INVASION_INDICATOR:YES;VASCULAR_INVASION_INDICATOR:NO;BRAF_GENE_ANALYSIS_INDICATOR:NO"
"RECURRENCE FIRST HGG RECORD" NA
"RECURRENT_ENDOMETRIAL_CARCINOMA" "CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;TMB_NONSYNONYMOUS:6.66666666667;SEX:Female;AGE:77;FRACTION_GENOME_ALTERED:0.7914;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Endometrium;SUBTYPE:Endometrial Adenocarcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:86.69118242;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:recurrent_endometrial_carcinoma;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:endometrial_adenocarcinoma;NAME:MFE-280;PATHOLOGIST_ANNOTATION:Endometrium:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"REFRACTORY ANAEMIA WITH EXCESS BLASTS" "CANCER_TYPE_DETAILED:MDS with Excess Blasts;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSEB;TMB_NONSYNONYMOUS:0.966666667;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:3.82;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;CHEMOTHERAPY:Yes;DIAGNOSIS:Myelodysplastic Syndromes;CAUSE_OF_DEATH_SOURCE:Dead-Unknown;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Induction;FUSION:None;GROUP:Unknown;KARYOTYPE:46,XY[20];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;MOST_RECENT_TREATMENT_DURATION:60;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200];DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:60;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-3;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Refractory anaemia with excess blasts;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Refractory anaemia with excess blasts;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"REFRACTORY ANEMIA" "CANCER_TYPE_DETAILED:Myelodysplastic Syndromes;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDS;TMB_NONSYNONYMOUS:0.166666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:45;TUMOR_TISSUE_SITE:Bone marrow;WHO_CLASS:Refractory Anemia;CYTOGENETICS:47,XY,+1,der(1;7)(q10;p10),+8;GERMLINE_CONTROL:CD3+ T cell;IPSS_SCORE:0"
"REFRACTORY ANEMIA WITH EXCESS BLASTS-2" "CANCER_TYPE_DETAILED:Myelodysplastic Syndromes;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDS;TMB_NONSYNONYMOUS:0.366666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:75;TUMOR_TISSUE_SITE:Bone marrow;WHO_CLASS:Refractory Anemia With Excess Blasts-2;CYTOGENETICS:46,XX;GERMLINE_CONTROL:CD3+ T cell;IPSS_SCORE:2"
"REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA" "CANCER_TYPE_DETAILED:MDS with Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSMD;SOMATIC_STATUS:Unmatched;SEX:Female;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:59.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic Syndromes;WBC:2.8;AGE_AT_PROCUREMENT:59;CENTER:5;TREATMENT_TYPE:Unknown;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Unknown;FUSION:None;GROUP:Post-Chemotherapy;KARYOTYPE:46,XX,del(9)(q21q31-33)[10]/46,XX[10];WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:2;CEBPA_MUTATION:p.E10K; MAF 26.7%;CUMULATIVE_TREATMENT_REGIMENS:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);CUMULATIVE_TREATMENT_STAGES:Unknown;CUMULATIVE_TREATMENT_TYPES:Unknown;CURRENT_REGIMEN:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Unknown;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Refractory cytopenia with multilineage dysplasia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Refractory cytopenia with multilineage dysplasia"
"REGIONAL LYMPH NODE METASTASIS" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:9.76666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:65;OS_MONTHS:24;PRIMARY_SITE:Trunk;TUMOR_PURITY:0.29;TUMOR_STAGE:I, NOS;SPECIMEN_TYPE:Regional lymph node metastasis;BRAF_STATUS:V600E;BRESLOW_DEPTH:0.75 mm;NRAS_STATUS:wild type;PATHOLOGIC_PRIMARY_TUMOR_STAGE:T1, NOS;SURVIVAL_AFTER_BIOPSY_MONTHS:15;TREATMENT_PRIOR_TO_RESECTION:None"
"REGIONAL NODES" "CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.957439395;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.0407;SAMPLE_TYPE:Primary;RACE:White;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;VITAL_STATUS:Dead;AGE_AT_DIAGNOSIS:48.3;M_STAGE:M0;GLEASON_SCORE:9-10;PSA:32.6;TUMOR_SAMPLE_HISTOLOGY:Adenocarcinoma / poorly differentiated carcinoma;AGE_AT_PROCUREMENT:48.3;DISEASE_EXTENT:Regional nodes;SMOKING:Former;TISSUE_TYPE:Prostate;8Q_ARM:Neutral"
"REL CELL CARCINOMA" NA
"REL ONCOCYTIC NEOPLASM, FAVOR CHROMOPHOBE, EOSINOPHILIC" "CANCER_TYPE_DETAILED:Renal Non-Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:NCCRCC;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:62;TUMOR_TISSUE_SITE:Kidney;SUBTYPE:chromophobe;HISTOLOGICAL_DIAGNOSIS:Rel oncocytic neoplasm, favor chromophobe, eosinophilic;PLATFORM:Exome;COHORT:discovery;TUMOR_CONTENT:90"
"REL ONCOCYTIC NEOPLASM, FAVOR ONCOCYTOMA" "CANCER_TYPE_DETAILED:Renal Non-Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:NCCRCC;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:67;TUMOR_TISSUE_SITE:Kidney;SUBTYPE:oncocytoma;HISTOLOGICAL_DIAGNOSIS:Rel oncocytic neoplasm, favor oncocytoma;PLATFORM:Exome;COHORT:discovery;TUMOR_CONTENT:95"
"RELA-FUSION" "CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:13.13;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WGS;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:Rela-Fusion;TUMOR_DETAILS:Ependymoma supratentorial"
"RELAPSED_AML" "CANCER_TYPE_DETAILED:Myeloid Neoplasm;CANCER_TYPE:Blood Cancer, NOS;ONCOTREE_CODE:MNM;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:15.1;OS_STATUS:1:DECEASED;GENE_PANEL:Enhanced exome;AGE_AT_DIAGNOSIS:57.1;PRIOR_TREATMENT:7+3, HiDAC, desatinib maintenance;SOURCE:WashU_on_study;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:56;DISEASE:Relapsed_AML;PERFORMANCE_STATUS:1;PERIPHERAL_BLASTS_PERCENTAGE:0.0;AML_FAB:AML without maturation (M1);CLINICAL_ONSET_AML:De novo;CYCLES_COMPLETED:6.0;CYTOGENETIC_RISK:Good;KYRYOTYPE:CBFB 40%;MORPHOLOGIC_RESPONSE:PR;PERIPHERAL_BLOOD_WBC:1.9;TRANSPLANT:No"
"RENAL ANGIOMYOLIPOMA" "CANCER_TYPE_DETAILED:Renal Angiomyolipoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RAML;TMB_NONSYNONYMOUS:0.978719698;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0794;SAMPLE_TYPE:Metastasis;OS_MONTHS:25.64;OS_STATUS:0:LIVING;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lung;TUMOR_PURITY:80;SAMPLE_COVERAGE:525;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"RENAL CANCER" "CANCER_TYPE_DETAILED:Wilms Tumor;CANCER_TYPE:Renal cancer;ONCOTREE_CODE:WT;TMB_NONSYNONYMOUS:1.9;SEX:Male;OS_MONTHS:217;OS_STATUS:0:LIVING;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:5;SAMPLE_TIMEPOINT:Metastatic;TISSUE_SEQUENCED:Lung;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:21.0;DIAGNOSTIC_CATEGORY:Renal;GMED_OS_MONTHS:207;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"RENAL CARCINOMA, CLEAR CELL" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CCRCC;TMB_NONSYNONYMOUS:6.46666666667;SEX:Male;AGE:49;FRACTION_GENOME_ALTERED:0.5861;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Kidney;SUBTYPE:Renal Carcinoma, clear cell;TUMOR_TYPE:kidney;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:116.8955149;GENOME_DOUBLINGS:1;DOUBLING_TIME:88.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial.;DISEASE_ONTOLOGY:clear_cell_carcinoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:McCoy's 5A +10%FBS;HIST_SUBTYPE1:clear_cell_renal_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:kidney;LINEAGE_SUB_SUBTYPE:clear_cell;LINEAGE_SUBTYPE:renal_cell_carcinoma;NAME:Caki-1;PATHOLOGIST_ANNOTATION:Kidney:Carcinoma;PROTEOMICS_TMT_LABEL:126;SITE_OF_FINDING:skin;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:kidney"
"RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:2.0998064531;SEX:Female;FRACTION_GENOME_ALTERED:0.1797;PRIMARY_SITE:Kidney;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Kidney;HISTOLOGICAL_SUBTYPE:Clear_Cell_Renal_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"RENAL CLEAR CELL" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:2.0998064531;SEX:Female;FRACTION_GENOME_ALTERED:0.1797;PRIMARY_SITE:Kidney;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Kidney;HISTOLOGICAL_SUBTYPE:Clear_Cell_Renal_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"RENAL CLEAR CELL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:2.0998064531;SEX:Female;FRACTION_GENOME_ALTERED:0.1797;PRIMARY_SITE:Kidney;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Kidney;HISTOLOGICAL_SUBTYPE:Clear_Cell_Renal_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"RENAL MEDULLARY CARCINOMA" "CANCER_TYPE_DETAILED:Renal Medullary Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:MRC;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0332;SAMPLE_TYPE:Metastasis;OS_MONTHS:6.575;OS_STATUS:1:DECEASED;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Kidney;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Neck;TUMOR_PURITY:30;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:609;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:44;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:BAPTIST;AGE_CURRENT:43;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"RENAL MUCINOUS TUBULAR SPINDLE CELL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Mucinous Tubular Spindle Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:MTSCC;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1177;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:774;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"RENAL NON-CLEAR CELL CARCINOMA" "CANCER_TYPE_DETAILED:Chromophobe Renal Cell Carcinoma;CANCER_TYPE:Renal Non-Clear Cell Carcinoma;ONCOTREE_CODE:CHRCC;TMB_NONSYNONYMOUS:1;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:38.07081566;OS_STATUS:1:DECEASED;RACE:White;TISSUE_SOURCE_SITE:MSKCC;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8317/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/24/12;PFS_MONTHS:24.92027485;AJCC_STAGING_EDITION:5TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Kidney;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE III;SUBTYPE:KICH;TUMOR_TYPE:Kidney Chromophobe Renal Cell Carcinoma;PATH_T_STAGE:T3B;RADIATION_THERAPY:No;DSS_STATUS:1:DEAD WITH TUMOR;DAYS_TO_BIRTH:-20849;MSI_SENSOR_SCORE:0.52;CANCER_TYPE_ACRONYM:KICH;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3383;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:KL;DSS_MONTHS:38.07081566;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:No"
"RENAL ONCOCYTOMA" "CANCER_TYPE_DETAILED:Renal Oncocytoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:ROCY;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0226;SAMPLE_TYPE:Primary;OS_MONTHS:1.58;OS_STATUS:0:LIVING;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;SAMPLE_COVERAGE:752;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:DNA;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"RENAL SPINDLE CELL CARCINOMA" "CANCER_TYPE_DETAILED:Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:8.8;SOMATIC_STATUS:Matched;SEX:Male;AGE:43;FRACTION_GENOME_ALTERED:0.3015;HISTOLOGICAL_SUBTYPE:Renal Spindle cell carcinoma;PRIOR_TREATMENT:None;DOUBLING_TIME:51.3;P53:MT;EPITHELIAL:Yes;MDR:-4"
"RENAL_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:2.0998064531;SEX:Female;FRACTION_GENOME_ALTERED:0.1797;PRIMARY_SITE:Kidney;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Kidney;HISTOLOGICAL_SUBTYPE:Clear_Cell_Renal_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"RETINOBLASTOMA" "CANCER_TYPE_DETAILED:Retinoblastoma;CANCER_TYPE:Retinoblastoma;ONCOTREE_CODE:RBL;TMB_NONSYNONYMOUS:5.63333333333;SUBTYPE:Retinoblastoma;LINEAGE:eye;LINEAGE_SUBTYPE:retinoblastoma"
"RHABDOID CANCER" "CANCER_TYPE_DETAILED:Rhabdoid Cancer;CANCER_TYPE:Rhabdoid Cancer;ONCOTREE_CODE:MRT;TMB_NONSYNONYMOUS:7.0;SEX:Female;AGE:1;FRACTION_GENOME_ALTERED:0.0248;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Malignant Rhabdoid Tumor;TUMOR_TYPE:soft_tissue;HISTOLOGY:Rhabdoid_Tumour;PURITY:1;MUTATION_RATE:92.67187107;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:pediatric;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:malignant_rhabdoid_tumor;NAME:A-204;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Rhabdoid;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:striated_muscle;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"RHABDOID TUMOR" "CANCER_TYPE_DETAILED:Atypical Teratoid/Rhabdoid Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ATRT;SEX:Male;AGE:2;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6;TUMOR_TISSUE_SITE:Frontal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1038;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_STOP:1163;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1471;AGE_AT_RADIATION_START:1183;AGE_AT_RADIATION_STOP:1225;AGE_AT_SPECIMEN_DIAGNOSIS:1038;CANCER_PREDISPOSITIONS:None documented;CHEMOTHERAPY_AGENTS:Not Reported;CHEMOTHERAPY_TYPE:Treatment follows a protocol and subject is enrolled on a protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:5400 cGy;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;FORMULATION:Not Reported;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Atypical Teratoid Rhabdoid Tumor (ATRT);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:SJYC07;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Supratentorial;UPDATED_GRADE:IV"
"RHABDOID TUMOUR" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:2.43135484044;SEX:Male;FRACTION_GENOME_ALTERED:0.0236;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Rhabdoid Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"RHABDOID_TUMOUR" "CANCER_TYPE_DETAILED:Rhabdoid Cancer;CANCER_TYPE:Rhabdoid Cancer;ONCOTREE_CODE:MRT;TMB_NONSYNONYMOUS:7.0;SEX:Female;AGE:1;FRACTION_GENOME_ALTERED:0.0248;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Malignant Rhabdoid Tumor;TUMOR_TYPE:soft_tissue;HISTOLOGY:Rhabdoid_Tumour;PURITY:1;MUTATION_RATE:92.67187107;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:pediatric;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:malignant_rhabdoid_tumor;NAME:A-204;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Rhabdoid;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:striated_muscle;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"RHABDOMYOSARCOMA" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:2.65238709866;SEX:Female;FRACTION_GENOME_ALTERED:0.0237;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Rhabdomyosarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"RHABDOMYOSARCOMA, ALVEOLAR" "CANCER_TYPE_DETAILED:Alveolar Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ARMS;TMB_NONSYNONYMOUS:14.8333333333;SEX:Male;AGE:17;FRACTION_GENOME_ALTERED:0.4922;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Rhabdomyosarcoma, alveolar;TUMOR_TYPE:soft_tissue;HISTOLOGY:Rhabdomyosarcoma;PURITY:0.98;MUTATION_RATE:195.104647;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:adherent epithelial-like cells growing as monolayer;DOUBLING_TIME_FROM_VENDOR:~  35 hrs;GROWTH_MEDIUM:90-95% RPMI 1640 +5-10 h.i. FBS;HIST_SUBTYPE1:alveolar;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUB_SUBTYPE:alveolar;LINEAGE_SUBTYPE:rhabdomyosarcoma;NAME:RH-30;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Rhabdoid;PROTEOMICS_TMT_LABEL:128c;SITE_OF_FINDING:bone_marrow;SITE_SUBTYPE1:striated_muscle;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"RHABDOMYOSARCOMA, ALVEOLAR SUBTYPE" "CANCER_TYPE_DETAILED:Rhabdomyosarcoma, Alveolar subtype;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ARMS;TMB_NONSYNONYMOUS:0.933333333333;SEX:Male;OS_MONTHS:36;OS_STATUS:0:LIVING;PRIMARY_SITE:Thigh;SAMPLE_CLASS:Tumor;GRADE:Stage 4, group 4;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Anterior thigh;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:2.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:27;SAMPLE_TESTED_CATEGORY:Primary disease"
"RHABDOMYOSARCOMA, EMBRYONAL" "CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:9.33333333333;SEX:Female;AGE:7;FRACTION_GENOME_ALTERED:0.4084;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Rhabdomyosarcoma, embryonal;TUMOR_TYPE:soft_tissue;HISTOLOGY:Rhabdomyosarcoma;PURITY:0.99;MUTATION_RATE:90.01144255;GENOME_DOUBLINGS:1;DOUBLING_TIME:49.4;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent Spindle cells and large multinucleated cells;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM +10%FBS;HIST_SUBTYPE1:embryonal;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUB_SUBTYPE:embryonal;LINEAGE_SUBTYPE:rhabdomyosarcoma;NAME:RD;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Rhabdoid;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:striated_muscle;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"RMS" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;SOMATIC_STATUS:Matched;SEX:Male;AGE:71;FRACTION_GENOME_ALTERED:0.3807;SAMPLE_TYPE:Primary;OS_MONTHS:13.63;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:13.63;TISSUE_SOURCE_SITE:DK;ICD_O_3_SITE:C67.2;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C67.2;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/7/14;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:Yes;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:337;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DK-AA71.5C8A75F5-A08D-4CA9-A3D3-67F77C4A65EB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:820;WEIGHT:68;SITE_OF_TUMOR_TISSUE:Bladder;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2b;TREATMENT_OUTCOME_FIRST_COURSE:Stable Disease;HISTOLOGICAL_SUBTYPE:Papillary;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:172;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;METASTATIC_SITE_PATIENT:None;ANGIOLYMPHATIC_INVASION:YES;FAMILY_HISTORY_CANCER_RELATIONSHIP:Mother|Sister;FAMILY_HISTORY_CANCER_TYPE:Breast-Fem|Breast-Fem;OCCUPATION_PRIMARY:Telemarketing and graphic arms;NONINVASIVE_BLADDER_HISTORY:YES;OCCUPATION_CURRENT:Telemarking and graphic arts;OCCUPATION_PRIMARY_CHEMICAL_EXPOSURE:none;OCCUPATION_PRIMARY_INDUSTRY:Media"
"ROSAI-DORFMAN DISEASE" "CANCER_TYPE_DETAILED:Rosai-Dorfman Disease;CANCER_TYPE:Histiocytosis;ONCOTREE_CODE:RDD;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Unknown;OS_MONTHS:69.699;OS_STATUS:0:LIVING;RACE:WHITE;PRIMARY_SITE:Brain;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;MSI_SCORE:-1;SAMPLE_COVERAGE:1242;INSTITUTE:MSKCC;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:36;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:YES;CRDB_CONSENT_DATE_DAYS:11029;CRDB_SURVIVAL_STATUS:Alive"
"ROSETTE-FORMING GLIONEURONAL TUMOR OF THE FOURTH VENTRICLE" "CANCER_TYPE_DETAILED:Rosette-forming Glioneuronal Tumor of the Fourth Ventricle;CANCER_TYPE:CNS;SEX:Male;AGE:21.81519508;RACE:Black;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:37"
"ROUND CELL SARCOMA, NOS" "CANCER_TYPE_DETAILED:ROUND CELL SARCOMA, NOS;CANCER_TYPE:Sarcoma;SEX:Male;AGE:18.206707;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:2nd tertile;TERT_ANTHRACYCLINE_TX:1st tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:1st tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:1st tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:1st tertile;TIME_FROM_DX_TO_SEQ:26;TIME_TO_BLOOD_DRAW_FROM_TX:0;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"ROUND CELL SARCOMA, OTHER" "CANCER_TYPE_DETAILED:Round Cell Sarcoma, Other;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Female;FRACTION_GENOME_ALTERED:0.3691;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;RACE:NO VALUE ENTERED;ETHNICITY:Unknown whether Spanish or not;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT341;TUMOR_PURITY:30;MSI_SCORE:2.04;MSI_TYPE:Stable;SAMPLE_COVERAGE:159;PURITY:0.629866189;CVR_TMB_SCORE:1.1;AGE_AT_SEQ_REPORT:8;DETAILED_PRIMARY_SITE:Bone;FACETS:YES;FRACTION_CNA:0.859147128;FACETS_REVIEW:YES;FACETS_WGD:TRUE;FGA_REPORTED:0.3691"
"RT" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"SALIVARY ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Salivary Adenocarcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:SAAD;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.0108;PFS_STATUS:No;RADIATION_THERAPY:Yes;STAGE:Stage III;RFS_STATUS:Yes;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:No;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:No;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Salivary Carcinoma;DOB_LASTFU_TIME_YRS:57;DOB_PROG_START_TIME_YRS:56;DOB_RECUR_START_TIME_YRS:54;DOB_RECUR_TIME_YRS:55;DOB_REPORT_TIME_YRS:56;DOB_TISSUE_TIME_YRS:55;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK:SD;LINE_OBR_NTRK_G:No-Response;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:1;NUM_LINES_CHEMO:0;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:1;NUM_LINES_TARGETED:0;POS_ARCHER:Negative;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:IMPACT Only;PROG_DEATH:No;PROG_DEATH_TIME_YRS:2;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:1"
"SALIVARY ADENOCARCINOMA NOS" "CANCER_TYPE_DETAILED:Salivary Adenocarcinoma NOS;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:SAAD;TMB_NONSYNONYMOUS:1.95743939523;SOMATIC_STATUS:Matched;SEX:Female;AGE:73.0;FRACTION_GENOME_ALTERED:0.4459;SAMPLE_TYPE:Metastasis;OS_MONTHS:54.8;OS_STATUS:0:LIVING;RACE:White;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.8;PRIMARY_SITE:Minor Salivary Gland;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Liver;TUMOR_PURITY:30;SAMPLE_COVERAGE:735;VITAL_STATUS:AWD;SMOKING_HISTORY:Former;PARTC_CONSENTED_12_245:NO;ALCOHOL_CONSUMPTION_FREQUENCY:Weekly;ALCOHOL_HISTORY_DOCUMENTED:Current;DISEASE_EXTENT:Distant;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:Yes;DISTANT_METS:Yes;SMOKING:Smoking Pack:10;DETAILED_METASTATIC_SITE:Liver;DETAILED_PRIMARY_SITE:Hard Palate;INITIAL_TREATMENT:Surgery + Chemoradiation;SITE_SEQUENCED:Distant metastasis;PRIOR_TX_TO_IMPACT_SAMPLE:RT & Chemo;TOBACCO_TYPE:Cigarettes"
"SALIVARY CANCER" "CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma;CANCER_TYPE:Salivary Cancer;ONCOTREE_CODE:ACYC;TMB_NONSYNONYMOUS:0.933333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:50.0;SAMPLE_TYPE:Primary;STUDY:ACyC (Sanger unpubl.);DATA_SOURCE:Sanger/MDACC"
"SALIVARY CARCINOMA" "CANCER_TYPE_DETAILED:Salivary Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:SACA;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:48;FRACTION_GENOME_ALTERED:0.0878;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Salivary Gland;ANALYSIS_COHORT:SECR;BIOPSY_SITE:Lymph Node;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:10"
"SALIVARY CARCINOMA, OTHER" "CANCER_TYPE_DETAILED:Salivary Carcinoma, Other;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:OSACA;TMB_NONSYNONYMOUS:4.33333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.2773;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Parotid;ANALYSIS_COHORT:SECR;BIOPSY_SITE:Lymph Node;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:30"
"SALIVARY DUCT CARCINOMA" "CANCER_TYPE_DETAILED:Salivary Duct Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:SDCA;TMB_NONSYNONYMOUS:3.56666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:73;FRACTION_GENOME_ALTERED:0.3351;SAMPLE_TYPE:Metastasis;RACE:African American;PRIMARY_SITE:Parotid Gland;ANALYSIS_COHORT:SECR;BIOPSY_SITE:Subq Nodule;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:4"
"SALIVARY GLAND CANCER" "CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:ACYC;SOMATIC_STATUS:Matched;SEX:Male;AGE:39;SAMPLE_TYPE:Primary;PRIMARY_SITE:Salivary gland;TUMOR_TISSUE_SITE:Salivary gland;PLATFORM:Targeted Sequencing;TUMOR_STAGE:III;STUDY:ACyC (FMI 2014);FUSION_STATUS:NO;GENOMIC_ALTERATIONS:0;METASTATIC_TUMOR_INDICATOR:No;PATIENT_GRADE:Intermediate;ACTIONABLE_ALTERATIONS:0"
"SARC" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:1.133333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:5.3;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:5.6;AGE_AT_PROCUREMENT:78;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:4;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;BRAF_MUTATION:Negative;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];PB_BLAST_PERCENTAGE:77;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:78;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine, MLN4924;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine, MLN4924;MOST_RECENT_TREATMENT_DURATION:111;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:111;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_MONOCYTES_PERCENTAGE:1;PRIOR_CANCER:Uterine Sarcoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"SARC LMS" "CANCER_TYPE_DETAILED:Uterine Leiomyosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:ULMS;TMB_NONSYNONYMOUS:5.54577650299;SEX:Female;FRACTION_GENOME_ALTERED:0.3446;SAMPLE_TYPE:Primary;OS_MONTHS:3.35;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;SUBTYPE:Sarcoma Leiomyo;MSI_SCORE:0.55;MSI_TYPE:Stable;SAMPLE_COVERAGE:1065;AGE_AT_SURGERY:60.08;FGA:0.345;AGE_AT_SEQUENCING:60.49;ORGAN_SYSTEM:Soft Tissue;AGE_AT_DEATH:60.77;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:No;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SARC LMS"
"SARC LS" "CANCER_TYPE_DETAILED:Dedifferentiated Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DDLS;TMB_NONSYNONYMOUS:0.0;SEX:Male;FRACTION_GENOME_ALTERED:0.0316;SAMPLE_TYPE:Metastasis;OS_MONTHS:18.14;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Retroperitoneum;GENE_PANEL:IMPACT341;METASTATIC_SITE:Bowel;TUMOR_PURITY:90;SUBTYPE:Sarcoma Lipo;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:557;AGE_AT_SURGERY:56.43;FGA:0.032;AGE_AT_SEQUENCING:57.44;ORGAN_SYSTEM:Soft Tissue;AGE_AT_DEATH:58.95;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:Yes;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:Yes;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SARC LS"
"SARCOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:1.133333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:5.3;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:5.6;AGE_AT_PROCUREMENT:78;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:4;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;BRAF_MUTATION:Negative;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];PB_BLAST_PERCENTAGE:77;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:78;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine, MLN4924;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine, MLN4924;MOST_RECENT_TREATMENT_DURATION:111;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:111;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_MONOCYTES_PERCENTAGE:1;PRIOR_CANCER:Uterine Sarcoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"SARCOMA LEIOMYO" "CANCER_TYPE_DETAILED:Uterine Leiomyosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:ULMS;TMB_NONSYNONYMOUS:5.54577650299;SEX:Female;FRACTION_GENOME_ALTERED:0.3446;SAMPLE_TYPE:Primary;OS_MONTHS:3.35;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;SUBTYPE:Sarcoma Leiomyo;MSI_SCORE:0.55;MSI_TYPE:Stable;SAMPLE_COVERAGE:1065;AGE_AT_SURGERY:60.08;FGA:0.345;AGE_AT_SEQUENCING:60.49;ORGAN_SYSTEM:Soft Tissue;AGE_AT_DEATH:60.77;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:No;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SARC LMS"
"SARCOMA LIPO" "CANCER_TYPE_DETAILED:Dedifferentiated Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DDLS;TMB_NONSYNONYMOUS:0.0;SEX:Male;FRACTION_GENOME_ALTERED:0.0316;SAMPLE_TYPE:Metastasis;OS_MONTHS:18.14;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Retroperitoneum;GENE_PANEL:IMPACT341;METASTATIC_SITE:Bowel;TUMOR_PURITY:90;SUBTYPE:Sarcoma Lipo;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:557;AGE_AT_SURGERY:56.43;FGA:0.032;AGE_AT_SEQUENCING:57.44;ORGAN_SYSTEM:Soft Tissue;AGE_AT_DEATH:58.95;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:Yes;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:Yes;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SARC LS"
"SARCOMA, NOS" "CANCER_TYPE_DETAILED:Breast Invasive Carcinosarcoma, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:CSNOS;TMB_NONSYNONYMOUS:5.18818857;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1583;SAMPLE_TYPE:Metastasis;RACE:WHITE;ETHNICITY:Unknown whether Spanish or not;PRIMARY_SITE:Breast;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lung;MSI_SCORE:0.18;MSI_TYPE:Stable;AGE_AT_SEQ_REPORTED_YEARS:57;AGE_CURRENT:61"
"SARCOMATOID" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma with Sarcomatoid Features;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:SCCRCC;TMB_NONSYNONYMOUS:1.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;GENE_PANEL:WXS;GRADE:3;METASTATIC_SITE:Lung;VITAL_STATUS:LIVING;COHORT:DISCOVERY;STAGE_AT_DIAGNOSIS:pT1bN0M0;FOLLOW_UP_TIME_MONTHS:111;GENE_EXPRESSION_CLUSTER:ccB;VHL_MUTATION_AA:p.F76fs;VHL_MUTATION_CODON:c.224_225delTC"
"SARCOMATOID CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Sarcomatoid Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:SARCL;TMB_NONSYNONYMOUS:4.89359848807;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0030;SAMPLE_TYPE:Primary;OS_MONTHS:4.9;OS_STATUS:1:DECEASED;RACE:Caucasian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;TUMOR_PURITY:20;SAMPLE_COVERAGE:940;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:45;AGE_AT_SEQ_REPORTED_YEARS:86;M_STAGE:M1;SMOKING_HISTORY:Former;ARCHER:NO;T_STAGE:TX;N_STAGE:NX;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:147;YEAR_OF_DIAGNOSIS:2016;PRETREATED:Yes"
"SARCOMATOID MESOTHELIOMA" "CANCER_TYPE_DETAILED:Pleural Mesothelioma, Sarcomatoid Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLSMESO;TMB_NONSYNONYMOUS:1.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:81;FRACTION_GENOME_ALTERED:0.1177;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:LK;ICD_O_3_SITE:C38.4;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C45.0;ICD_O_3_HISTOLOGY:9050/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/6/13;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IA;HISTOLOGICAL_DIAGNOSIS:Sarcomatoid mesothelioma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:1024;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-LK-A4O0.2BDA3DE7-2BBC-4D52-B5C7-AAD0043881AF.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:380;SITE_OF_TUMOR_TISSUE:Pleura;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1a;LATERALITY:Left;FAMILY_HISTORY_CANCER_RELATIONSHIP:Parent|Sibling;FAMILY_HISTORY_CANCER_TYPE:Other, specify|Other, specify"
"SARCOMATOID RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Sarcomatoid Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:SRCC;TMB_NONSYNONYMOUS:0.864698095;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2458;SAMPLE_TYPE:Metastasis;OS_MONTHS:27.518;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Kidney;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Brain;MSI_SCORE:0.29;MSI_TYPE:Stable;SAMPLE_COVERAGE:567;AGE_AT_SEQ_REPORTED_YEARS:3;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:18;ARCHER:NO;PED_IND:Yes;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"SARC_DDLPS" "CANCER_TYPE_DETAILED:Dedifferentiated Liposarcoma;CANCER_TYPE:Sarcoma;ONCOTREE_CODE:DDLS;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Male;AGE:68;FRACTION_GENOME_ALTERED:0.0042;SAMPLE_TYPE:Primary;OS_MONTHS:36.29549265;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:Moffitt Cancer Center;ICD_O_3_SITE:C49.5;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C49.5;ICD_O_3_HISTOLOGY:8858/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:12/5/14;PFS_MONTHS:36.29549265;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Groin;SUBTYPE:SARC_DDLPS;TUMOR_TYPE:Dedifferentiated Liposarcoma;RADIATION_THERAPY:Yes;DAYS_LAST_FOLLOWUP:1104;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-24962;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:SARC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.321;TISSUE_SOURCE_SITE_CODE:3B;DSS_MONTHS:36.29549265;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:Yes;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes"
"SARC_LMS" "CANCER_TYPE_DETAILED:Leiomyosarcoma;CANCER_TYPE:Sarcoma;ONCOTREE_CODE:LMS;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.1762;SAMPLE_TYPE:Primary;OS_MONTHS:53.48982477;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:Moffitt Cancer Center;ICD_O_3_SITE:C48.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C48.0;ICD_O_3_HISTOLOGY:8890/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:12/5/14;PFS_MONTHS:16.99707401;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Retroperitoneum;SUBTYPE:SARC_LMS;TUMOR_TYPE:Leiomyosarcoma (LMS);RADIATION_THERAPY:Yes;DSS_STATUS:1:DEAD WITH TUMOR;DAYS_TO_BIRTH:-21094;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:SARC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.36;TISSUE_SOURCE_SITE_CODE:3B;DSS_MONTHS:53.48982477;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes"
"SARC_OTHER" "CANCER_TYPE_DETAILED:Synovial Sarcoma;CANCER_TYPE:Sarcoma;ONCOTREE_CODE:SYNS;TMB_NONSYNONYMOUS:0.533333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:20;FRACTION_GENOME_ALTERED:0.0899;SAMPLE_TYPE:Primary;OS_MONTHS:152.1188809;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:152.1188809;TISSUE_SOURCE_SITE:Memorial Sloan Kettering;ICD_O_3_SITE:C49.6;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C49.6;ICD_O_3_HISTOLOGY:9043/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:1/10/14;PFS_MONTHS:152.1188809;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Flank;SUBTYPE:SARC_Other;TUMOR_TYPE:Synovial Sarcoma, Biphasic Type;RADIATION_THERAPY:Yes;DAYS_LAST_FOLLOWUP:4121;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-7604;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:SARC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.33;TISSUE_SOURCE_SITE_CODE:DX;DSS_MONTHS:152.1188809;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes"
"SBS" "CANCER_TYPE_DETAILED:Small Bowel Cancer;CANCER_TYPE:Small Bowel Cancer;ONCOTREE_CODE:SBC;TMB_NONSYNONYMOUS:13.3098636072;SEX:Male;FRACTION_GENOME_ALTERED:0.5859;SAMPLE_TYPE:Primary;OS_MONTHS:12.45;OS_STATUS:1:DECEASED;RACE:Other;PRIMARY_SITE:Duodenum-Jejunum;GENE_PANEL:IMPACT341;TUMOR_PURITY:20;SUBTYPE:Small Bowel cancer;MSI_SCORE:3.44;MSI_TYPE:Indeterminate;SAMPLE_COVERAGE:569;AGE_AT_SURGERY:56.7;FGA:0.586;AGE_AT_SEQUENCING:57.6;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:58.63;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:Yes;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SBS"
"SCC HEAD AND NECK" "CANCER_TYPE_DETAILED:SCC head and neck;CANCER_TYPE:Other;SEX:Female;AGE:16.33401871;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:594"
"SCCOHT" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Ovary;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SCCO;TMB_NONSYNONYMOUS:4.9;SUBTYPE:Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT);LINEAGE:ovary;LINEAGE_SUBTYPE:SCCOHT"
"SCHMINKE TUMOR/LYMPHOEPITHELIAL CARCINOMA" "CANCER_TYPE_DETAILED:SCHMINKE TUMOR/LYMPHOEPITHELIAL CARCINOMA;CANCER_TYPE:Carcinoma;SEX:Male;AGE:15.86036968;RACE:Asian;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:78"
"SCHWANNOMA" "CANCER_TYPE_DETAILED:Plexiform Schwannoma;CANCER_TYPE:Nerve Sheath Tumor;ONCOTREE_CODE:SCHW;TMB_NONSYNONYMOUS:2.26666666667;SEX:Male;OS_MONTHS:45;OS_STATUS:0:LIVING;PRIMARY_SITE:Penis/scrotum;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Penis/scrotum;NGS_TEST:Tumor-normal  WES;AGE_TESTING_YEARS:1.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:36;SAMPLE_TESTED_CATEGORY:Primary disease"
"SCLC" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"SCLEROSING EPITHELIOID FIBROSARCOMA" "CANCER_TYPE_DETAILED:Sclerosing Epithelioid Fibrosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Female;FRACTION_GENOME_ALTERED:0.2552;SAMPLE_TYPE:Primary;OS_MONTHS:75.386;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT341;TUMOR_PURITY:40;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:280;PURITY:0.535286026;AGE_AT_SEQ_REPORT:30;DETAILED_PRIMARY_SITE:Soft Tissue;FACETS:YES;FRACTION_CNA:0.63313467;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.2552"
"SCLEROSING RHABDOMYOSARCOMA" "CANCER_TYPE_DETAILED:Spindle Cell/Sclerosing Rhabdomyosarcoma;CANCER_TYPE:Sarcoma;SEX:Male;AGE:8.336755753;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:2nd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:2nd tertile;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:1st tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:2nd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:1st tertile;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:69;TIME_TO_BLOOD_DRAW_FROM_TX:54;TOPO_I_TX:Yes;TOPO_II_TX:Yes;XRT_TX:No"
"SEBACEOUS CARCINOMA" "CANCER_TYPE_DETAILED:Sebaceous Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:SEBA;TMB_NONSYNONYMOUS:1.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.3457;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Orbit of Eye;ANALYSIS_COHORT:SECR;BIOPSY_SITE:Subq Nodule;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:48"
"SECOND MALIGNANCY" "CANCER_TYPE_DETAILED:Pediatric High Grade Gliomas;CANCER_TYPE:High-grade glioma/astrocytoma;ONCOTREE_CODE:PHGG;SEX:Female;AGE:21;OS_MONTHS:13;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:13;TUMOR_TISSUE_SITE:Temporal Lobe;TUMOR_TYPE:Second Malignancy;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Second malignancy;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:7884;AGE_CLASS:20+;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:8282;AGE_AT_RADIATION_START:7911;AGE_AT_RADIATION_STOP:7955;AGE_AT_SPECIMEN_DIAGNOSIS:7884;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:6000 cGy;EXTENT_OF_TUMOR_RESECTION:Partial resection;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:H3F3A WT;HGG_H3F3A_STATUS:H3F3A WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:High-grade glioma/astrocytoma;INITIAL_DIAGNOSIS_TYPE:Second Malignancy (first HGG record);MEDICAL_CONDITIONS:Unavailable;MULTIPLE_MEDICAL_CONDITIONS:No;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Cortical;UPDATED_GRADE:IV"
"SECONDARY OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Secondary Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:SECOS;TMB_NONSYNONYMOUS:0.978719698;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.5529;SAMPLE_TYPE:Primary;OS_MONTHS:10.39;OS_STATUS:1:DECEASED;PRIMARY_SITE:Epidural;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:958;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:DNA;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SELLAR TUMOR" "CANCER_TYPE_DETAILED:Craniopharyngioma, Adamantinomatous Type;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:ACPG;SEX:Female;AGE:3;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:0:DiseaseFree;TUMOR_TISSUE_SITE:Suprasellar/Hypothalamic/Pituitary;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:No;SURGERY:Yes;SAMPLE_ORIGIN:Repeat resection;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1344;AGE_CLASS:[0,5);AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1344;AGE_AT_SPECIMEN_DIAGNOSIS:1344;CANCER_PREDISPOSITIONS:None documented;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 Mutant;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;H3F3A_CTNNB1_STATUS:CTNNB1 Mutant;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Craniopharyngioma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:No;MULTIPLE_TUMOR_LOCATIONS:No;RADIATION:No;SAMPLE_ANNOTATION:Treatment naive;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Suprasellar/Hypothalamic/Pituitary;UPDATED_GRADE:I"
"SEMINAL VESICLE CARCINOMA" "CANCER_TYPE_DETAILED:Seminal Vesicle Carcinoma;CANCER_TYPE:Other;ONCOTREE_CODE:CUP;TMB_NONSYNONYMOUS:8.43333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:61;FRACTION_GENOME_ALTERED:0.6348;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Seminal Vesicle;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Abdom. Mass;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:5"
"SEMINOMA" "CANCER_TYPE_DETAILED:Non-Seminomatous Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1543;SPECIMEN_PRESERVATION_TYPE:Fresh;PLATFORM:WES;PATIENT_DISPLAY_NAME:P-0003533;SAMPLE_DISPLAY_NAME:s_AML_GCT_2T1"
"SEMINOMA; NOS" "CANCER_TYPE_DETAILED:Non-Seminomatous Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:NSGCT;TMB_NONSYNONYMOUS:1.4;SOMATIC_STATUS:Matched;SEX:MALE;AGE:31;FRACTION_GENOME_ALTERED:0.2004;SAMPLE_TYPE:Primary;OS_MONTHS:20.3;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:4.7;TISSUE_SOURCE_SITE:2G;ICD_O_3_SITE:C62.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C62.9;ICD_O_3_HISTOLOGY:9061/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/8/14;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:IS;HISTOLOGICAL_DIAGNOSIS:Seminoma; NOS;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:829;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-2G-AAEW.02452377-4D36-4145-8492-B12046B855FC.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:290;SITE_OF_TUMOR_TISSUE:Testes;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;LATERALITY:Right;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Orchiectomy;PATIENT_DEATH_REASON:Testicular Germ Cell Tumor (TGCT);AJCC_METASTASIS_CLINICAL_CM:M0;CAUSE_OF_DEATH_SOURCE:Medical Record;AJCC_CLINICAL_TUMOR_STAGE:Stage IS;AJCC_NODES_CLINICAL_CN:N0;AJCC_NODES_CLINICAL_CT:T1;DAYS_TO_POST_ORCHI_SERUM_TEST:129;DAYS_TO_PRE_ORCHI_SERUM_TEST:-2;FAMILY_HISTORY_OTHER_CANCER:NO;FAMILY_HISTORY_TESTICULAR_CANCER:NO;FIRST_TREATMENT_SUCCESS:Normalization of Tumor Markers, but Residual Tumor Mass;HISTOLOGIC_DIAGNOSIS_PERCENT:100;HISTORY_FERTILITY:Did not attempt to reproduce;HISTORY_HYPOSPADIAS:NO;HISTORY_OF_UNDESCENDED_TESTIS:Yes; bilateral;INTRATUBULAR_GERM_CELL_NEOPLASM:Present;LEVEL_OF_NON_DESCENT:Inguinal;LYMPHOVASCULAR_INVASION_PRESENT:YES;MOLECULAR_TEST_RESULT:Lactate Dehydrogenase (LDH) - Normal|Human Chorionic Gonadotropin (HCG) - Normal|Alpha Fetaprotein (AFP) - Normal;POST_ORCHI_AFP:5;POST_ORCHI_HCG:53.5;POST_ORCHI_LDH:176;POST_ORCHI_LYMPH_NODE_DISSECTION:No;POSTOPERATIVE_TX:None;PRE_ORCHI_AFP:1.1;PRE_ORCHI_HCG:3;PRE_ORCHI_LDH:218;SERUM_MARKERS:S1;TESTIS_TUMOR_MACROEXTENT:Involves testis only;TESTIS_TUMOR_MICROEXTENT:Rete Testis;UNDESCENDED_TESTIS_CORRECTED:NO"
"SEROUS BORDERLINE OVARIAN TUMOR" "CANCER_TYPE_DETAILED:Serous Borderline Ovarian Tumor, Micropapillary;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SBMOV;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.4721;SAMPLE_TYPE:Primary;OS_MONTHS:24.16;OS_STATUS:0:LIVING;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;SAMPLE_COVERAGE:209;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SEROUS BORDERLINE OVARIAN TUMOR, MICROPAPILLARY" "CANCER_TYPE_DETAILED:Serous Borderline Ovarian Tumor, Micropapillary;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SBMOV;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.4721;SAMPLE_TYPE:Primary;OS_MONTHS:24.16;OS_STATUS:0:LIVING;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;SAMPLE_COVERAGE:209;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SEROUS CYSTADENOCARCINOMA" "CANCER_TYPE_DETAILED:Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SOC;TMB_NONSYNONYMOUS:1.13333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:63;FRACTION_GENOME_ALTERED:0.4703;SAMPLE_TYPE:Primary;OS_MONTHS:25.89;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:9.43;PRIMARY_SITE:Bilateral;TISSUE_SOURCE_SITE:10;ICD_O_3_SITE:C56.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C56.9;ICD_O_3_HISTOLOGY:8441/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/6/09;GRADE:G3;TUMOR_TISSUE_SITE:Ovary;HISTOLOGICAL_DIAGNOSIS:Serous Cystadenocarcinoma;TUMOR_STATUS:WITH TUMOR;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-10-0926.b940b1b3-8278-400e-b43a-e7897e0361b7.pdf;VIAL_NUMBER:A;KARNOFSKY_PERFORMANCE_SCORE:80;SPECIMEN_SECOND_LONGEST_DIMENSION:0.8;LONGEST_DIMENSION:1;SHORTEST_DIMENSION:0.6;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;CLINICAL_STAGE:Stage IIIC;PERFORMANCE_STATUS_TIMING:Preoperative;LYMPHOVASCULAR_INVASION_INDICATOR:NO;VASCULAR_INVASION_INDICATOR:NO"
"SEROUS CYSTADENOMA OF THE PANCREAS" "CANCER_TYPE_DETAILED:Serous Cystadenoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PSC;TMB_NONSYNONYMOUS:0.233333333333;SOMATIC_STATUS:Matched;SEX:Female;SMOKER:Never;LOCATION:Head-uncinate process;TYPE_OF_SURGERY:Pylorus preserving pancreatoduodenectomy;TUMOR_FOCALITY:Unifocal;CYST_SIZE:5.5;RELEVANT_MEDICAL_HISTORY:Unremarkable;SCA_TYPE:Microcystic"
"SEROUS ENDOMETRIAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:USC;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;AGE:76;FRACTION_GENOME_ALTERED:0.5010;SAMPLE_TYPE:Primary;OS_MONTHS:46.75;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:29.73;TISSUE_SOURCE_SITE:AP;ICD_O_3_SITE:C54.1;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C54.1;ICD_O_3_HISTOLOGY:8380/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/9/11;GRADE:High Grade;AJCC_STAGING_EDITION:2009;HISTOLOGICAL_DIAGNOSIS:Serous endometrial adenocarcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2008;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1074;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AP-A1DQ.F5983E58-F466-42CF-8905-B942D2BDF702.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:100;WEIGHT:60;SITE_OF_TUMOR_TISSUE:Endometrial;HEIGHT:163;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Office Endometrial Biopsy;CLINICAL_STAGE:Stage IIIC1;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);LYMPH_NODES_AORTIC_POS_BY_HE:0;LYMPH_NODES_AORTIC_POS_BY_IHC:0;LYMPH_NODES_AORTIC_POS_TOTAL:0;LYMPH_NODES_PELVIC_POS_BY_HE:6;LYMPH_NODES_PELVIC_POS_BY_IHC:0;LYMPH_NODES_PELVIC_POS_TOTAL:6;PERITONEAL_WASHING:negative;SURGICAL_APPROACH_AT_DIAGNOSIS:open;TUMOR_INVASION_PERCENT:82"
"SEROUS OVARIAN CANCER" "CANCER_TYPE_DETAILED:Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SOC;TMB_NONSYNONYMOUS:5.86666666667;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.2443;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:85.71718592;GENOME_DOUBLINGS:0;DOUBLING_TIME:148.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM:HAM's F12  1:1  +5% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:OV56;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:128n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.5 ug/ml hydrocortisone + 10ug/ml insulin;TYPE_REFINED:ovary"
"SEROUS_CARCINOMA" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:3.20496774421;SEX:Female;FRACTION_GENOME_ALTERED:0.6815;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Serous_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"SERTOLI-LEYDIG CELL TUMOR" "CANCER_TYPE_DETAILED:Sertoli-Leydig Cell Tumor;CANCER_TYPE:Germ Cell;SEX:Female;AGE:22.09171867;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:1st tertile;TERT_CYTOTOXIC_TX:1st tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:1st tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:1st tertile;TIME_FROM_DX_TO_SEQ:2511;TIME_TO_BLOOD_DRAW_FROM_TX:2479;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"SEX CORD STROMAL TUMOR" "CANCER_TYPE_DETAILED:Granulosa Cell Tumor;CANCER_TYPE:Sex Cord Stromal Tumor;ONCOTREE_CODE:GRCT;TMB_NONSYNONYMOUS:3.53333333333;SEX:Female;FRACTION_GENOME_ALTERED:0.0240;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, endometrioid;TUMOR_TYPE:ovary;HISTOLOGY:Sex_Cord-Stromal_Tumour;PURITY:1;MUTATION_RATE:88.95089442;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;HIST_SUBTYPE1:granulosa_cell_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:endometrioid;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:COV434;PATHOLOGIST_ANNOTATION:Ovary:Germline;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"SEX CORD-STROMAL TUMOUR" "CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:2.32083871132;SEX:Female;FRACTION_GENOME_ALTERED:0.0234;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Granulosa_Cell_Tumour;HISTOLOGICAL_TYPE:Sex Cord-Stromal Tumour;DATA_SOURCE:ECACC;SAMPLE_ORIGIN:Solid"
"SEZARY SYNDROME" "CANCER_TYPE_DETAILED:Non-Hodgkin Lymphoma;CANCER_TYPE:Non-Hodgkin Lymphoma;ONCOTREE_CODE:NHL;TMB_NONSYNONYMOUS:10.9333333333;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous, Sezary Syndrome;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"SEZARY_SYNDROME" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:2.32083871132;SEX:Male;FRACTION_GENOME_ALTERED:0.0224;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:Mycosis_Fungoides-Sezary_Syndrome;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"SIGNET RING CELL CARCINOMA OF THE STOMACH" "CANCER_TYPE_DETAILED:Signet Ring Cell Carcinoma of the Stomach;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:SSRCC;TMB_NONSYNONYMOUS:13.7333333333;SEX:Female;AGE:35;FRACTION_GENOME_ALTERED:0.8515;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:175.0163689;GENOME_DOUBLINGS:0;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;HIST_SUBTYPE1:signet_ring_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUB_SUBTYPE:diffuse_gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:NUGC-4;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"SIGNET RING CELL TYPE OF THE APPENDIX" "CANCER_TYPE_DETAILED:Signet Ring Cell Type of the Appendix;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:SRAP;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0032;SAMPLE_TYPE:Metastasis;OS_MONTHS:23.6;OS_STATUS:0:LIVING;PRIMARY_SITE:Appendix;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Peritoneum;TUMOR_PURITY:20;SAMPLE_COVERAGE:784;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SINONASAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Sinonasal Adenocarcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:SNA;TMB_NONSYNONYMOUS:3.91487879;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0137;SAMPLE_TYPE:Primary;OS_MONTHS:10.39;OS_STATUS:0:LIVING;PRIMARY_SITE:Sinus;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;SAMPLE_COVERAGE:989;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SINONASAL SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Sinonasal Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:SNSC;TMB_NONSYNONYMOUS:12.5;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0067;OS_MONTHS:12.43;OS_STATUS:0:LIVING;PFS_MONTHS:12.43;PFS_STATUS:1:Progressed;SUBTYPE:moderately differentiated;TUMOR_TYPE:HNSCC;SMOKING_PACK_YEARS:11.0;HISTOLOGY:nasopharynx;SMOKER:yes;RECIST_RESPONSE:stable disease;CENSORED:LIVING;DRUG_TYPE:anti-PD-1/anti-PD-L1;RECIST:SD;OTHER_CONCURRENT_THERAPY:no;P16_ISH:positive;ROH_RESPONSE:clinical benefit;VA_RESPONSE:clinical benefit"
"SINONASAL UNDIFFERENTIATED CARCINOMA" "CANCER_TYPE_DETAILED:Sinonasal Undifferentiated Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:SNUC;TMB_NONSYNONYMOUS:6.851037883;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.5608;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Sinonasal;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:908;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:DNA;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SKCM" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:2.43135484044;SEX:Male;FRACTION_GENOME_ALTERED:0.7563;PRIMARY_SITE:Skin;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Melanoma;HISTOLOGICAL_TYPE:Malignant Melanoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"SKIN CANCER" "CANCER_TYPE_DETAILED:Skin Cancer, Non-Melanoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:BCC;TMB_NONSYNONYMOUS:35.3136440149;SOMATIC_STATUS:No;GENE_PANEL:CancerPanel;HISTOLOGICAL_SUBTYPE:Nodular;MULTIPLE_TUMORS:No;AGE_RESECTED:48;GORLIN_SPORADIC:sporadic;POPULATION:non-reduntant sample;SCNA_ANALYSIS:No;TUMOR_NUMBER:T1;VISMO_STATUS:naive"
"SKIN CANCER, NON-MELANOMA" "CANCER_TYPE_DETAILED:Skin Cancer, Non-Melanoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:BCC;TMB_NONSYNONYMOUS:35.3136440149;SOMATIC_STATUS:No;GENE_PANEL:CancerPanel;HISTOLOGICAL_SUBTYPE:Nodular;MULTIPLE_TUMORS:No;AGE_RESECTED:48;GORLIN_SPORADIC:sporadic;POPULATION:non-reduntant sample;SCNA_ANALYSIS:No;TUMOR_NUMBER:T1;VISMO_STATUS:naive"
"SKIN_CANCER" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:10.6666666667;SEX:Male;AGE:51;FRACTION_GENOME_ALTERED:0.6184;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Skin;SUBTYPE:Melanoma;TUMOR_TYPE:melanoma;HISTOLOGY:Malignant_Melanoma;PURITY:1;MUTATION_RATE:124.5888771;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:skin_cancer;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:skin;LINEAGE_SUBTYPE:melanoma;NAME:SK-MEL-28;PATHOLOGIST_ANNOTATION:Skin:Melanoma;PROTEOMICS_TMT_LABEL:129c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:melanoma"
"SKIN_SQUAMOUS" "CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:9.43333333333;SUBTYPE:Squamous Cell Carcinoma;LINEAGE:epidermoid_carcinoma;LINEAGE_SUBTYPE:skin_squamous"
"SMALL BOWEL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Small Bowel Adenocarcinoma;CANCER_TYPE:Small Bowel Carcinoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:III-IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1730;DIAGNOSIS AGE:57;GDNA(NG):133;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"SMALL BOWEL CANCER" "CANCER_TYPE_DETAILED:Small Intestinal Carcinoma;CANCER_TYPE:Small Bowel Cancer;ONCOTREE_CODE:SIC;TMB_NONSYNONYMOUS:7.96666666667;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.0304;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:African_american;PRIMARY_SITE:Small_Intestine;SUBTYPE:Duodenal Adenocarcinoma;TUMOR_TYPE:other;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:129.2237006;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:duodenal_adenocarcinoma;NAME:HuTu 80;SITE_SUBTYPE1:duodenum;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"SMALL BOWEL CARCINOMA" "CANCER_TYPE_DETAILED:Small Bowel Adenocarcinoma;CANCER_TYPE:Small Bowel Carcinoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:III-IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1730;DIAGNOSIS AGE:57;GDNA(NG):133;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"SMALL BOWEL NEUROENDOCRINE TUMOR" "CANCER_TYPE_DETAILED:Small Bowel Neuroendocrine Tumor;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;TMB_NONSYNONYMOUS:0.266666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1148;DIAGNOSIS AGE:76;GDNA(NG):1392;SMOKE STATUS:Unknown;TUMOR_PURTITY:70"
"SMALL CELL BLADDER CANCER" "CANCER_TYPE_DETAILED:Small Cell Bladder Cancer;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:SCBC;TMB_NONSYNONYMOUS:3.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.6405;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Bladder;ANALYSIS_COHORT:BLCA;BIOPSY_SITE:Abdom. Wall;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:3"
"SMALL CELL BRONCHIOALVEOLAR CARCINOMA" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:13.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:52;FRACTION_GENOME_ALTERED:0.4146;HISTOLOGICAL_SUBTYPE:Small cell Bronchioalveolar Carcinoma;PRIOR_TREATMENT:None;DOUBLING_TIME:35.3;P53:MT;EPITHELIAL:Yes;MDR:-10"
"SMALL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Stomach;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STSC;TMB_NONSYNONYMOUS:13.5;FRACTION_GENOME_ALTERED:0.5144;SAMPLE_TYPE:Metastasis;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Small Cell Carcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:158.8387503;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:other;GROWTH_MEDIUM:RPMI 1640 +10%FBS;HIST_SUBTYPE1:small_cell_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_small_cell;NAME:ECC10;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:liver;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"SMALL CELL CARCINOMA OF  GALLBLADDER" "CANCER_TYPE_DETAILED:Small Cell Neuroendocrine Carcinoma of Gallbladder;CANCER_TYPE:Small Cell Carcinoma of  Gallbladder;TMB_NONSYNONYMOUS:3.32746590179;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.8326;SAMPLE_TYPE:Metastasis;OS_MONTHS:18.98973306;OS_STATUS:1:DECEASED;ETHNICITY:Black/AA;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT341;METASTATIC_SITE:Liver;TUMOR_PURITY:40;MSI_SCORE:3.46;MSI_TYPE:Stable;SAMPLE_COVERAGE:428;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:54;RELIGION:CHRISTIAN;AGE_CURRENT:54;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:3.3;PARTA_CONSENTED_12_245:YES;TUMOR_GRADE:Poor;DATE_ADDED:4/7/15;MONTH_ADDED:2015/04;WEEK_ADDED:2015, Wk. 15;CRDB_CONSENT_DATE_DAYS:19514;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:19756;CVR_TMB_COHORT_PERCENTILE:44.1;CVR_TMB_TT_COHORT_PERCENTILE:59.4;SAMPLE_NAME:P-0001783-T01-IM3;CBIOPORTAL_SAMPLE_CLASS:Tumor;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:18.98973306;OVERALL_SURVIVAL_MONTHS:18.98973306;TUMOR_STAGE_COLLECTION:4"
"SMALL CELL CARCINOMA OF THE CERVIX" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Cervix;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:SCCE;TMB_NONSYNONYMOUS:8.56666666667;SUBTYPE:Small Cell Carcinoma;LINEAGE:cervix;LINEAGE_SUBTYPE:cervical_small_cell"
"SMALL CELL CARCINOMA OF THE OVARY" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Ovary;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SCCO;TMB_NONSYNONYMOUS:4.9;SUBTYPE:Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT);LINEAGE:ovary;LINEAGE_SUBTYPE:SCCOHT"
"SMALL CELL CARCINOMA OF THE OVARY HYPERCALCEMIC TYPE SCCOHT" NA
"SMALL CELL CARCINOMA OF THE STOMACH" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Stomach;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STSC;TMB_NONSYNONYMOUS:13.5;FRACTION_GENOME_ALTERED:0.5144;SAMPLE_TYPE:Metastasis;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Small Cell Carcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:158.8387503;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:other;GROWTH_MEDIUM:RPMI 1640 +10%FBS;HIST_SUBTYPE1:small_cell_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_small_cell;NAME:ECC10;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:liver;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"SMALL CELL CARCINOMA OF UNKNOWN PRIMARY" "CANCER_TYPE_DETAILED:Small Cell Carcinoma of Unknown Primary;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:SCUP;TMB_NONSYNONYMOUS:2.16666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:50;FRACTION_GENOME_ALTERED:0.6758;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:10"
"SMALL CELL LUNG CANCER" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"SMALL CELL LUNG CANCER SCLC" NA
"SMALL CELL NEUROENDOCRINE CARCINOMA OF GALLBLADDER" "CANCER_TYPE_DETAILED:Small Cell Neuroendocrine Carcinoma of Gallbladder;CANCER_TYPE:Small Cell Carcinoma of  Gallbladder;TMB_NONSYNONYMOUS:3.32746590179;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.8326;SAMPLE_TYPE:Metastasis;OS_MONTHS:18.98973306;OS_STATUS:1:DECEASED;ETHNICITY:Black/AA;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT341;METASTATIC_SITE:Liver;TUMOR_PURITY:40;MSI_SCORE:3.46;MSI_TYPE:Stable;SAMPLE_COVERAGE:428;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:54;RELIGION:CHRISTIAN;AGE_CURRENT:54;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:3.3;PARTA_CONSENTED_12_245:YES;TUMOR_GRADE:Poor;DATE_ADDED:4/7/15;MONTH_ADDED:2015/04;WEEK_ADDED:2015, Wk. 15;CRDB_CONSENT_DATE_DAYS:19514;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:19756;CVR_TMB_COHORT_PERCENTILE:44.1;CVR_TMB_TT_COHORT_PERCENTILE:59.4;SAMPLE_NAME:P-0001783-T01-IM3;CBIOPORTAL_SAMPLE_CLASS:Tumor;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:18.98973306;OVERALL_SURVIVAL_MONTHS:18.98973306;TUMOR_STAGE_COLLECTION:4"
"SMALL CELL OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Small Cell Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:SCOS;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0056;SAMPLE_TYPE:Primary;OS_MONTHS:27.15;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:650;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SMALL INTESTINAL CARCINOMA" "CANCER_TYPE_DETAILED:Small Intestinal Carcinoma;CANCER_TYPE:Small Bowel Cancer;ONCOTREE_CODE:SIC;TMB_NONSYNONYMOUS:7.96666666667;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.0304;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:African_american;PRIMARY_SITE:Small_Intestine;SUBTYPE:Duodenal Adenocarcinoma;TUMOR_TYPE:other;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:129.2237006;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:duodenal_adenocarcinoma;NAME:HuTu 80;SITE_SUBTYPE1:duodenum;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"SMALL ROUND BLUE CELL TUMOR" "CANCER_TYPE_DETAILED:Small round blue cell tumor/ Ewing Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ES;TMB_NONSYNONYMOUS:1.5;SEX:Male;OS_MONTHS:26;OS_STATUS:0:LIVING;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;GRADE:Intermediate grade;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:8;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Brain- Broca's area;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:8.0;DIAGNOSTIC_CATEGORY:Brain;GMED_OS_MONTHS:17;SAMPLE_TESTED_CATEGORY:Primary disease"
"SMALL_CELL_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:5.96787097198;FRACTION_GENOME_ALTERED:0.5141;PRIMARY_SITE:Stomach;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Stomach;HISTOLOGICAL_SUBTYPE:Small_Cell_Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:RIKEN;SAMPLE_ORIGIN:Solid"
"SMALL_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"SMOLDERING MYELOMA" "CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:0.333333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:50;RACE:Caucasian;ETHNICITY:Not Hispanic or Latino;DIAGNOSIS:Smoldering Myeloma;PREVIOUS_TREATMENT:No;PRIOR_MGUS:No"
"SOFT TISSUE CANCER, NOS" "CANCER_TYPE_DETAILED:Soft Tissue;CANCER_TYPE:Soft Tissue Cancer, NOS;ONCOTREE_CODE:SOFT_TISSUE;FRACTION_GENOME_ALTERED:0.0220;SUBTYPE:Soft tissue;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_soft_tissue"
"SOFT TISSUE MYOEPITHELIAL CARCINOMA" "CANCER_TYPE_DETAILED:Soft Tissue Myoepithelial Carcinoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:STMYEC;TMB_NONSYNONYMOUS:1.56666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:65;FRACTION_GENOME_ALTERED:0.7221;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Foot;ANALYSIS_COHORT:SECR;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:46"
"SOFT TISSUE SARCOMA" "CANCER_TYPE_DETAILED:Angiosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ANGS;TMB_NONSYNONYMOUS:3.0;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1245;RACE:NOT REPORTED;PRIMARY_SITE_PATIENT:BREAST;SAMPLE_TIMEPOINT:ASCProject_EAuOu4uD_T1;TMB:2.850485825;BX_LOCATION:BREAST;BX_TIME_DAYS:13;BX_TYPE:RESECTION;AGE_AT_DIAGNOSIS_GROUP:36-40;PRD_HISPANIC:NOT REPORTED;PRD_OTHER_CANCER:YES;PRD_TREATED_AT_ENROLLMENT:NOT REPORTED;BX_NUCLEAR_GRADE:LOW;BX_SPINDLE_CELL:NO;BX_VASOFORMATIVE:YES;DX_BIOPSY_LOCATION:BREAST;PRD_DIAGNOSIS_LOC:NOT REPORTED;PRD_EVER_LOCATION:NOT REPORTED;PRD_LOCATION_AT_ENROLLMENT:NOT REPORTED;PRD_OTHER_CANCER_LIST:COLORECTAL;PRD_OTHER_CANCER_RADIATION:YES;PRD_RADIATION:YES;PRD_RADIATION_SURGERY:AFTER;PRD_SURGERY:YES;PRD_SURGERY_CLEAN_MARGINS:YES"
"SOFT TISSUE SARCOMA OTHER" "CANCER_TYPE_DETAILED:Soft Tissue Sarcoma Other;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III-IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Radiation_Therapy;Chemotherapy;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:693.167028;DIAGNOSIS AGE:35;GDNA(NG):3672;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"SOFT TISSUE TUMOR" "CANCER_TYPE_DETAILED:Inflammatory myofibroblastic tumor;CANCER_TYPE:Soft Tissue Tumor;ONCOTREE_CODE:IMT;TMB_NONSYNONYMOUS:0.733333333333;SEX:Female;OS_MONTHS:86;OS_STATUS:0:LIVING;PRIMARY_SITE:Liver;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:9;SAMPLE_TIMEPOINT:Refractory;TISSUE_SEQUENCED:Hepatic artery;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:12.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:77;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"SOLID ADENOCARCINOMA 82303" NA
"SOLID PAPILLARY CARCINOMA OF THE BREAST" "CANCER_TYPE_DETAILED:Solid Papillary Carcinoma of the Breast;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:SPC;TMB_NONSYNONYMOUS:0.633333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.0443;SAMPLE_TYPE:Primary;OS_MONTHS:24.77;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:AC;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8050/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:10/3/12;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIA;HISTOLOGICAL_DIAGNOSIS:Other, specify;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:114;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AC-A3YJ.0F890724-8554-4B2B-B4EC-6B9B24C757D8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N0 (i-);AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Right;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel node biopsy alone;MICROMET_DETECTION_BY_IHC:YES;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"SOLID PSEUDOPAPILLARY NEOPLASM OF THE PANCREAS" "CANCER_TYPE_DETAILED:Solid Pseudopapillary Neoplasm of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:SPN;TMB_NONSYNONYMOUS:1.13333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.1918;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Pancreas;ANALYSIS_COHORT:PAAD;BIOPSY_SITE:Periaortic Mass;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:3"
"SOLITARY FIBROUS TUMOR" "CANCER_TYPE_DETAILED:Solitary Fibrous Tumor/Hemangiopericytoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SFT;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:44;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:108"
"SOLITARY FIBROUS TUMOR OF THE CENTRAL NERVOUS SYSTEM" "CANCER_TYPE_DETAILED:Solitary Fibrous Tumor of the Central Nervous System;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:SFTCNS;TMB_NONSYNONYMOUS:1.957439395;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.6425;SAMPLE_TYPE:Primary;OS_MONTHS:18.77;OS_STATUS:1:DECEASED;PRIMARY_SITE:Bone;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:670;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA" "CANCER_TYPE_DETAILED:Solitary Fibrous Tumor/Hemangiopericytoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SFT;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:44;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:108"
"SOMATOSTATINOMA" "CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:12.2333333333;SEX:Male;AGE:61;FRACTION_GENOME_ALTERED:0.6785;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Pancreas;SUBTYPE:Somatostatinoma;TUMOR_TYPE:pancreas;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:136.6267225;GENOME_DOUBLINGS:2;DOUBLING_TIME:92.1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSRRB;CHARACTERISTICS:adherent epithelial;DISEASE_ONTOLOGY:Pancreatic Cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640 + 10% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:pancreas;LINEAGE_SUB_SUBTYPE:somatostatinoma;LINEAGE_SUBTYPE:endocrine;NAME:QGP-1;PATHOLOGIST_ANNOTATION:Pancreas:Carcinoma;PROTEOMICS_TMT_LABEL:127n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:pancreas"
"SPECIFIC DX AT ACQUISITION MDSMPN" NA
"SPECIFIC_DX_AT_ACQUISITION_MDSMPN" "CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;SEX:Female;OS_MONTHS:48.0986301369863;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:NON-HISPANIC;AGE_AT_DIAGNOSIS:27;COHORT:Waves1+2;SPECIMEN_TYPE:Bone Marrow Aspirate;CAUSE_OF_DEATH:Dead-Disease;CURRENT_STAGE:Experimental;KARYOTYPE:46,XX[20];CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine;CUMULATIVE_TREATMENT_STAGES:Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Sorafenib;FLT3_ITD:Positive;MOST_RECENT_TREATMENT_DURATION:99;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;AGE_AT_SPECIMEN_ACQUISITION:27;ALLELIC_RATIO:0.96078431372549;CUMULATIVE_CHEMO:Yes;DISEASE_STAGE_AT_SPECIMEN_COLLECTION:Initial Diagnosis;DX_AT_INCLUSION:Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms;ELN2017:Intermediate;FAB_BLAST_MORPHOLOGY:M1;IS_DENOVO:False;IS_RELAPSE:False;IS_TRANSFORMED:False;NON_AML_MDSMPN_SPECIFIC_DX_AT_ACQUISITION:False;NPM1:Positive;OTHER_CYTOGENETICS:Normal;PRIOR_MALIGNANCY_RADIATION_TX:No;PRIOR_MALIGNANCY_TYPE:Juvenile pilocytic astrocytoma;PRIOR_MDS_MORE_THAN_TWO_MTHS:No;PRIOR_MDS_MPN:No;PRIOR_MDS_MPN_MORE_THAN_TWO_MTHS:No;PRIOR_MPN_MORE_THAN_TWO_MONTHS:No;RESPONSE_DURATION_TO_INDUCTION_TX:2;RESPONSE_TO_INDUCTION_TX:Complete Response;SPECIFIC_DX_AT_ACQUISITION_MDSMPN:False;SPECIFIC_DX_AT_INCLUSION:AML with mutated NPM1;SPECIMEN_GROUPS:Initial Acute Leukemia Diagnosis;SURFACE_ANTIGENS_IMMUNOHISTOCHEMICAL_STAINS:CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR and MPO positive;TIME_OF_SAMPLE_COLLECTION_RELATIVE_TO_INCLUSION:0;TYPE_INDUCTION_TX:Standard Chemotherapy;USED_IN_MANUSCRIPT:Yes;VARIANT_SUMMARY:CEBPA|FLT3-ITD|NPM1"
"SPINDLE CELL" "CANCER_TYPE_DETAILED:Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:8.8;SOMATIC_STATUS:Matched;SEX:Male;AGE:43;FRACTION_GENOME_ALTERED:0.3015;HISTOLOGICAL_SUBTYPE:Renal Spindle cell carcinoma;PRIOR_TREATMENT:None;DOUBLING_TIME:51.3;P53:MT;EPITHELIAL:Yes;MDR:-4"
"SPINDLE CELL CARCINOMA OF THE LUNG" "CANCER_TYPE_DETAILED:Spindle Cell Carcinoma of the Lung;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:SPCC;TMB_NONSYNONYMOUS:6.91758475987;SEX:Female;FRACTION_GENOME_ALTERED:0.6394;SAMPLE_TYPE:metastasis;OS_MONTHS:7.47;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT468;SAMPLE_CLASS:PDX;GRADE:high;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:71;M_STAGE:M1;SMOKING_HISTORY:never;TISSUE_SITE:liver;T_STAGE:Tx;N_STAGE:Nx;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:224;YEAR_OF_DIAGNOSIS:2017;PROCEDURE_TYPE:Biopsy;PDX_SAMPLE_DAYS_FROM_DIAGNOSIS:104;PRETREATED:yes"
"SPINDLE CELL RHABDOMYOSARCOMA" "CANCER_TYPE_DETAILED:Spindle Cell Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SCRMS;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0945;SAMPLE_TYPE:Primary;OS_MONTHS:16.37;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:478;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SPINDLE CELL SARCOMA" "CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:MFH;TMB_NONSYNONYMOUS:23.8666666667;SEX:Male;AGE:29;FRACTION_GENOME_ALTERED:0.4429;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Pleomorphic Sarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Malignant_Fibrous_Histiocytoma-Pleomorphic_Sarcoma;PURITY:1;MUTATION_RATE:179.4906831;GENOME_DOUBLINGS:1;DOUBLING_TIME:64.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:pleomorphic_sarcoma;NAME:GCT;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_FibrousHistiocytoma;SITE_OF_FINDING:lung;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA" "CANCER_TYPE_DETAILED:Spindle Cell/Sclerosing Rhabdomyosarcoma;CANCER_TYPE:Sarcoma;SEX:Male;AGE:8.336755753;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:2nd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:2nd tertile;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:1st tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:2nd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:1st tertile;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:69;TIME_TO_BLOOD_DRAW_FROM_TX:54;TOPO_I_TX:Yes;TOPO_II_TX:Yes;XRT_TX:No"
"SPITZOID MELANOMA" "CANCER_TYPE_DETAILED:Spitzoid Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SPZM;TMB_NONSYNONYMOUS:0;SEX:Female;AGE:35;PFS_STATUS:Unknown/NA;RADIATION_THERAPY:Unknown/NA;STAGE:Unknown;RFS_STATUS:Unknown/NA;SURGERY:Unknown/NA;DEATH:No;LOCALIZED_VS_METS_AT_DX:Unknown;ANY_LINE_CHEMO:Unknown/NA;ANY_LINE_HORMONE:Unknown/NA;ANY_LINE_IODINE:Unknown/NA;ANY_LINE_NTRK:Unknown/NA;ANY_LINE_TARGETED:Unknown/NA;ANY_SYSTX:No;CANCER_TYPE_HISTOLOGY:Melanoma;DOB_LASTFU_TIME_YRS:35;DOB_REPORT_TIME_YRS:35;DOB_TISSUE_TIME_YRS:35;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Negative;POS_METHOD:Archer;PROG_DEATH:Unknown/NA;PROG_EVAL_C:No;RECUR_EVAL_C:No;TISSUE_REPORT_TIME_YRS:0"
"SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:0.633333333;SOMATIC_STATUS:Matched;SEX:Male;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:69.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:70;CENTER:5;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Other;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Post-Chemotherapy;KARYOTYPE:46,XY[18];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab;CUMULATIVE_TREATMENT_STAGES:Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Other;CURRENT_REGIMEN:Rituximab;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Other;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Not Enough Information;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-54;MDS_TWO_MONTHS_PRIOR_AML:Yes;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_CANCER:Squamous cell carcinoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:Yes;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"SQUAMOUS CELL CARCINOMA OF GALLBLADDER" "CANCER_TYPE_DETAILED:Squamous Cell Carcinoma of Gallbladder;CANCER_TYPE:Carcinoma with Squamous Differentiation;TMB_NONSYNONYMOUS:2.93615909284;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2220;SAMPLE_TYPE:Metastasis;OS_MONTHS:20.46817248;OS_STATUS:1:DECEASED;ETHNICITY:White;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT410;METASTATIC_SITE:Liver;TUMOR_PURITY:30;MSI_SCORE:0.51;MSI_TYPE:Stable;SAMPLE_COVERAGE:328;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:59;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:58;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:3;PARTA_CONSENTED_12_245:YES;DATE_ADDED:4/7/15;MONTH_ADDED:2015/04;WEEK_ADDED:2015, Wk. 15;CRDB_CONSENT_DATE_DAYS:21213;CRDB_OFF_STUDY_DAYS:21402;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:21402;CVR_TMB_COHORT_PERCENTILE:37.9;CVR_TMB_TT_COHORT_PERCENTILE:48.8;SAMPLE_NAME:P-0003363-T01-IM5;CBIOPORTAL_SAMPLE_CLASS:Tumor;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:20.46817248;OVERALL_SURVIVAL_MONTHS:20.46817248;TUMOR_STAGE_COLLECTION:4"
"SQUAMOUS CELL CARCINOMA OF THE VULVA/VAGINA" "CANCER_TYPE_DETAILED:Squamous Cell Carcinoma of the Vulva/Vagina;CANCER_TYPE:Vaginal Cancer;ONCOTREE_CODE:VSC;TMB_NONSYNONYMOUS:8.33333333333;SUBTYPE:Squamous Cell Carcinoma, vulvar;LINEAGE:skin;LINEAGE_SUBTYPE:skin_squamous"
"SQUAMOUS CELL CARCINOMA, BUCCAL MUCOSA" "CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;SUBTYPE:Squamous Cell Carcinoma, buccal mucosa;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:buccal_mucosa;LINEAGE_SUBTYPE:upper_aerodigestive_squamous"
"SQUAMOUS CELL CARCINOMA, HYPOPHARYNGEAL" "CANCER_TYPE_DETAILED:Hypopharynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HPHSC;TMB_NONSYNONYMOUS:7.73333333333;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, hypopharyngeal;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;MUTATION_RATE:148.1733319;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:hypopharyngeal;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:SNU-1041;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:pharynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"SQUAMOUS CELL CARCINOMA, LARYNGEAL" "CANCER_TYPE_DETAILED:Larynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:LXSC;TMB_NONSYNONYMOUS:10.3333333333;SEX:Male;AGE:55;FRACTION_GENOME_ALTERED:0.2747;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, laryngeal;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:193.9530872;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:96 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:laryngeal;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:SNU-1214;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:larynx;SITE_SUBTYPE2:glottis;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"SQUAMOUS CELL CARCINOMA, NOS" "CANCER_TYPE_DETAILED:Squamous Cell Carcinoma, NOS;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:SCCNOS;TMB_NONSYNONYMOUS:5.18818857;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.3516;SAMPLE_TYPE:Metastasis;OS_MONTHS:4.866;OS_STATUS:1:DECEASED;RACE:BLACK OR AFRICAN AMERICAN;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lymph Node;TUMOR_PURITY:60;MSI_SCORE:2.74;MSI_TYPE:Stable;SAMPLE_COVERAGE:841;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:69;MSI_COMMENT:MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.;RELIGION:NONE;AGE_CURRENT:68;ARCHER:NO;PED_IND:No"
"SQUAMOUS CELL CARCINOMA, ORAL" "CANCER_TYPE_DETAILED:Oral Cavity Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OCSC;TMB_NONSYNONYMOUS:9.1;SEX:Female;FRACTION_GENOME_ALTERED:0.1756;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, oral;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:157.1906164;GENOME_DOUBLINGS:0;DOUBLING_TIME:142.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;CHARACTERISTICS:adherent epithelial;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:DMEM + 10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:oral;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:BICR 56;SITE_SUBTYPE1:mouth;SITE_SUBTYPE2:tongue;SITE_SUBTYPE3:NS;SUPPLEMENTS:2mM GLUTAMINE+0.4UG/ML HYDROCORTISONE;TYPE_REFINED:upper_aerodigestive"
"SQUAMOUS CELL CARCINOMA, PHARYNX" "CANCER_TYPE_DETAILED:Oropharynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OPHSC;TMB_NONSYNONYMOUS:6.8;SEX:Female;FRACTION_GENOME_ALTERED:0.6029;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, pharynx;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:0.99;MUTATION_RATE:92.96836238;GENOME_DOUBLINGS:1;DOUBLING_TIME:60.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;FREEZING_MEDIUM:5%DMSO;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:adult;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:pharynx;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:Detroit 562;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:pharynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"SQUAMOUS CELL CARCINOMA, SALIVARY GLAND" "CANCER_TYPE_DETAILED:Mucoepidermoid Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:MUCC;TMB_NONSYNONYMOUS:15.5333333333;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.5868;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Salivary_Gland;SUBTYPE:Squamous Cell Carcinoma, salivary gland;TUMOR_TYPE:other;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:150.1577888;GENOME_DOUBLINGS:1;DOUBLING_TIME:47.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:McCoy's 5A + 10% FBS;HIST_SUBTYPE1:mucoepidermoid_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:salivary_gland;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:A-253;PATHOLOGIST_ANNOTATION:Salivary_Gland:Carcinoma;SITE_SUBTYPE1:submaxillary;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"SQUAMOUS CELL CARCINOMA, TONGUE" "CANCER_TYPE_DETAILED:Mucoepidermoid Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:MUCC;TMB_NONSYNONYMOUS:5.93333333333;SEX:Male;AGE:39;FRACTION_GENOME_ALTERED:0.4409;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Salivary_Gland;SUBTYPE:Squamous Cell Carcinoma, tongue;TUMOR_TYPE:other;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:195.9930868;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;DOUBLING_TIME_FROM_VENDOR:19.8 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:mucoepidermoid_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:tongue;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:YD-15;PATHOLOGIST_ANNOTATION:Salivary_Gland:Carcinoma;SITE_SUBTYPE1:tongue;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"SQUAMOUS CELL CARCINOMA, VULVAR" "CANCER_TYPE_DETAILED:Squamous Cell Carcinoma of the Vulva/Vagina;CANCER_TYPE:Vaginal Cancer;ONCOTREE_CODE:VSC;TMB_NONSYNONYMOUS:8.33333333333;SUBTYPE:Squamous Cell Carcinoma, vulvar;LINEAGE:skin;LINEAGE_SUBTYPE:skin_squamous"
"SQUAMOUS_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Poorly Differentiated Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:EPDCA;TMB_NONSYNONYMOUS:5.1942580682;SEX:Male;FRACTION_GENOME_ALTERED:0.6785;PRIMARY_SITE:Upper Aerodigestive Tract;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Upper_Aerodigestive;HISTOLOGICAL_SUBTYPE:Squamous_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"ST-RELPOS" "CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:8;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:St-Relpos;TUMOR_DETAILS:Ependymoma supratentorial"
"ST-YAP" "CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.5;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:St-Yap;TUMOR_DETAILS:Ependymoma supratentorial"
"STAD" "CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:8.03333333333;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.9354;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Cystadenocarcinoma, mucinous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:178.9165928;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:RMUG-S;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"STAD_GS" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:3.566666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:51;FRACTION_GENOME_ALTERED:0.1752;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:University of Kansas Medical Center;ICD_O_3_SITE:C16.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C16.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/16/14;GRADE:G3;PFS_MONTHS:12.98615906;AJCC_STAGING_EDITION:6TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Stomach;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIIB;SUBTYPE:STAD_GS;TUMOR_TYPE:Stomach Adenocarcinoma (NOS);PATH_T_STAGE:T3;RADIATION_THERAPY:Yes;DSS_STATUS:1:DEAD WITH TUMOR;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:STAD;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3131;PATH_N_STAGE:N2;TISSUE_SOURCE_SITE_CODE:3M;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:MX;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"STEROID CELL TUMOR, NOS" "CANCER_TYPE_DETAILED:Steroid Cell Tumor, NOS;CANCER_TYPE:Sex Cord Stromal Tumor;ONCOTREE_CODE:SCT;TMB_NONSYNONYMOUS:0.978719698;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0325;SAMPLE_TYPE:Metastasis;OS_MONTHS:12.89;OS_STATUS:1:DECEASED;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Abdomen;TUMOR_PURITY:40;SAMPLE_COVERAGE:308;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"STOMACH ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:9.23333333333;SEX:Male;AGE:41;FRACTION_GENOME_ALTERED:0.7735;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:113.3381055;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:RERF-GC-1B;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"STOMACH ADENOCARCINOMA, SIGNET RING TYPE" "CANCER_TYPE_DETAILED:Signet Ring Cell Carcinoma of the Stomach;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:SSRCC;TMB_NONSYNONYMOUS:26.0333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:71;FRACTION_GENOME_ALTERED:0.0798;SAMPLE_TYPE:Primary;OS_MONTHS:26.45;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:26.12;TISSUE_SOURCE_SITE:HJ;ICD_O_3_SITE:C16.2;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C16.2;ICD_O_3_HISTOLOGY:8490/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/31/12;GRADE:G3;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IB;HISTOLOGICAL_DIAGNOSIS:Stomach Adenocarcinoma, Signet Ring Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;PATHOLOGY_REPORT_FILE_NAME:TCGA-HJ-7597.caf9a0a4-2045-4a72-9a3e-39a09a85a0d9.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Stomach;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T2b;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;SPECIMEN_SECOND_LONGEST_DIMENSION:1;LONGEST_DIMENSION:1.1;SHORTEST_DIMENSION:0.6;PRIMARY_SITE_PATIENT:Fundus/Body;TARGETED_MOLECULAR_THERAPY:NO;TREATMENT:YES;PATIENT_DEATH_REASON:Stomach Cancer;TREATMENT_TYPE:Proton Pump Inhibitors|Antacids;H_PYLORI_INFECTION:No;BARRETTS_ESOPHAGUS:Yes;REFLUX_HISTORY:YES;CITY_OF_PROCUREMENT:Buffalo;FAMILY_HISTORY_OF_STOMACH_CANCER:NO;NUMBER_OF_RELATIVES_WITH_STOMACH_CANCER:0"
"STOMACH ADENOCARINOMA" "CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:0.0;SEX:Female;FRACTION_GENOME_ALTERED:0.0014;SAMPLE_TYPE:Metastasis;OS_MONTHS:4.63;OS_STATUS:1:DECEASED;RACE:Pt refused to answer;PRIMARY_SITE:Stomach;GENE_PANEL:IMPACT341;METASTATIC_SITE:Intra-Abdominal;TUMOR_PURITY:20;SUBTYPE:Stomach Adenocarinoma;MSI_SCORE:0.07;MSI_TYPE:Stable;SAMPLE_COVERAGE:971;AGE_AT_SURGERY:62.12;FGA:0.001;AGE_AT_SEQUENCING:62.44;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:62.83;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:No;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:STAD"
"STOMACH CANCER" "CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:0.8;SEX:Male;AGE:63;SAMPLE_TYPE:Primary;RACE:Asian;PRIMARY_SITE:Skin;TUMOR_TYPE:melanoma;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:collaborator;DISEASE_ONTOLOGY:stomach cancer;LINEAGE:fibroblast;NAME:SF8657;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:melanoma"
"STOMACH, ADENOCARCINOMA, DIFFUSE TYPE" "CANCER_TYPE_DETAILED:Diffuse Type Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:DSTAD;TMB_NONSYNONYMOUS:2.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:75;FRACTION_GENOME_ALTERED:0.1758;SAMPLE_TYPE:Primary;OS_MONTHS:19.12;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:19.12;TISSUE_SOURCE_SITE:D7;ICD_O_3_SITE:C16.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C16.0;ICD_O_3_HISTOLOGY:8145/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/23/11;GRADE:G3;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIA;HISTOLOGICAL_DIAGNOSIS:Stomach, Adenocarcinoma, Diffuse Type;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-D7-6518.b78ceab7-f101-43b5-867f-66a3a0b6d5cc.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Stomach;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N3;AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;SPECIMEN_SECOND_LONGEST_DIMENSION:0.7;LONGEST_DIMENSION:1;SHORTEST_DIMENSION:0.5;PRIMARY_SITE_PATIENT:Cardia/Proximal;TREATMENT:NO;REFLUX_HISTORY:NO;CITY_OF_PROCUREMENT:Poznan;FAMILY_HISTORY_OF_STOMACH_CANCER:NO"
"STOMACH, ADENOCARCINOMA, NOT OTHERWISE SPECIFIED NOS" NA
"STOMACH, INTESTINAL ADENOCARCINOMA, MUCINOUS TYPE" "CANCER_TYPE_DETAILED:Mucinous Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:MSTAD;TMB_NONSYNONYMOUS:7.33333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.5793;SAMPLE_TYPE:Primary;OS_MONTHS:19.51;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:19.51;TISSUE_SOURCE_SITE:FP;ICD_O_3_SITE:C16.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C16.0;ICD_O_3_HISTOLOGY:8480/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/9/12;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Stomach, Intestinal Adenocarcinoma, Mucinous Type;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-FP-7829.7ade7a91-922a-4abb-a80c-aa2b70e438d2.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Stomach;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;SPECIMEN_SECOND_LONGEST_DIMENSION:0.3;LONGEST_DIMENSION:0.4;SHORTEST_DIMENSION:0.3;PRIMARY_SITE_PATIENT:Gastroesophageal Junction;CITY_OF_PROCUREMENT:Minneapolis"
"STOMACH, INTESTINAL ADENOCARCINOMA, NOT OTHERWISE SPECIFIED NOS" NA
"STOMACH, INTESTINAL ADENOCARCINOMA, PAPILLARY TYPE" "CANCER_TYPE_DETAILED:Papillary Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:PSTAD;TMB_NONSYNONYMOUS:6.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:62;FRACTION_GENOME_ALTERED:0.3358;SAMPLE_TYPE:Primary;OS_MONTHS:10.25;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:2.46;TISSUE_SOURCE_SITE:D7;ICD_O_3_SITE:C16.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C16.0;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/16/11;GRADE:G2;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Stomach, Intestinal Adenocarcinoma, Papillary Type;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-D7-6527.c2311fda-d860-4c91-a3d7-0fb1402353d9.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Stomach;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T2;LYMPH_NODES_EXAMINED:YES;SPECIMEN_SECOND_LONGEST_DIMENSION:0.3;LONGEST_DIMENSION:0.7;SHORTEST_DIMENSION:0.3;PRIMARY_SITE_PATIENT:Cardia/Proximal;TREATMENT:NO;BARRETTS_ESOPHAGUS:No;REFLUX_HISTORY:NO;CITY_OF_PROCUREMENT:Poznan;FAMILY_HISTORY_OF_STOMACH_CANCER:NO"
"STOMACH, INTESTINAL ADENOCARCINOMA, TUBULAR TYPE" "CANCER_TYPE_DETAILED:Tubular Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:TSTAD;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.3462;SAMPLE_TYPE:Primary;OS_MONTHS:18.82;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:1.51;TISSUE_SOURCE_SITE:D7;ICD_O_3_SITE:C16.3;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C16.3;ICD_O_3_HISTOLOGY:8211/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/13/11;GRADE:G3;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIA;HISTOLOGICAL_DIAGNOSIS:Stomach, Intestinal Adenocarcinoma, Tubular Type;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-D7-6520.9d50e818-91ed-45db-a51d-f70a944017ad.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Stomach;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T2b;LYMPH_NODES_EXAMINED:YES;SPECIMEN_SECOND_LONGEST_DIMENSION:0.5;LONGEST_DIMENSION:1.1;SHORTEST_DIMENSION:0.5;PRIMARY_SITE_PATIENT:Antrum/Distal;TREATMENT:NO;BARRETTS_ESOPHAGUS:No;REFLUX_HISTORY:NO;CITY_OF_PROCUREMENT:Poznan;FAMILY_HISTORY_OF_STOMACH_CANCER:NO"
"SUPERFICIAL SPREADING" "CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:7.36666666667;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:43.86666667;OS_STATUS:0:LIVING;PFS_MONTHS:43.86666667;PFS_STATUS:0:CENSORED;HISTOLOGY:Superficial spreading;M_STAGE:M1c;PURITY:0.6;TOTAL_MUTATIONS:315;BIOPSY_SITE:soft tissue;LDH_ELEVATED:No;MUTS_CLONAL:180;MUTS_SUBCLONAL:25;ALKYLATING_CHEMOTHERAPY:11.0774311;BIOPSY_CONTEXT:Pre-PD1;BIOPSY_SITE_CATEG:soft tissue;BR:Partial Response;CNA_PROP:0.072497872;COSMIC_AGING:52.3271629;CUT_SUBQ_MET:Yes;CYCLES_ON_THERAPY:33;HETEROGENEITY:0.12195122;IO_THERAPY:MK3475;LIVER_VISC_MET:Yes;LN_MET:Yes;LUNG_MET:Yes;MET_BONE:No;MET_BRAIN:No;NUM_PRIOR_THERAPIES:2;POAR_COMBINED_CTLA_PD1:No;POST_CTLA4:No;POST_MAPK_TX:No;PRIMARY_TYPE:skin;PRIOR_CTLA4:Yes;PRIOR_MAPK_TX:No;TIME_TO_BR:83;TOTAL_NEOANTIGEN:729;TX_START_ECOG:1;TX_START_LDH:161;UV_INDUCED_MUTATIONS:231.593849"
"SUPERFICIAL SPREADING MELANOMA" "CANCER_TYPE_DETAILED:SUPERFICIAL SPREADING MELANOMA;CANCER_TYPE:Other;SEX:Female;AGE:22.57631683;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;EQD_TERTILES:No radiation;TIME_FROM_DX_TO_SEQ:2076;XRT_TX:No"
"SWEAT GLAND ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Sweat Gland Adenocarcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:SGAD;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0990;SAMPLE_TYPE:Metastasis;OS_MONTHS:12.46;OS_STATUS:0:LIVING;PRIMARY_SITE:Sweat Gland;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Kidney;SAMPLE_COVERAGE:946;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SWEAT GLAND CARCINOMA/APOCRINE ECCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Sweat Gland Carcinoma/Apocrine Eccrine Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:AECA;TMB_NONSYNONYMOUS:4.436621202;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0175;SAMPLE_TYPE:Metastasis;OS_STATUS:0:LIVING;PRIMARY_SITE:Skin;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lymph Node;TUMOR_PURITY:60;SAMPLE_COVERAGE:1665;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SYNOVIAL" "CANCER_TYPE_DETAILED:Synovial Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SYNS;TMB_NONSYNONYMOUS:18.4666666667;SUBTYPE:Synovial;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:synovial_sarcoma"
"SYNOVIAL SARCOMA" "CANCER_TYPE_DETAILED:Synovial Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SYNS;TMB_NONSYNONYMOUS:18.4666666667;SUBTYPE:Synovial;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:synovial_sarcoma"
"SYNOVIAL SARCOMA - BIPHASIC" "CANCER_TYPE_DETAILED:Synovial Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SYNS;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:20;FRACTION_GENOME_ALTERED:0.0899;SAMPLE_TYPE:Primary;OS_MONTHS:152.0;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:152;TISSUE_SOURCE_SITE:DX;ICD_O_3_SITE:C49.6;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C49.6;ICD_O_3_HISTOLOGY:9043/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/10/14;HISTOLOGICAL_DIAGNOSIS:Synovial Sarcoma - Biphasic;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4095;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DX-A7EO.9D1732CC-080D-4C90-AB74-02EC31824176.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:380;SITE_OF_TUMOR_TISSUE:Superficial Trunk - Flank;PHARMACEUTICAL_TX_ADJUVANT:NO;PATH_MARGIN:Negative;DISEASE_MULTIFOCAL_INDICATOR:NO;SYNOVIAL_SS18SSX_FUSION_STATUS:Positive - SS18-SSX2;TUMOR_TOTAL_DEPTH:Deep;LOCOREGIONAL_RECURRENCE_INDICATOR:NO;METASTATIC_DISEASE_CONFIRMED:NO;NTE_LESION_PATHOLOGIC_DEPTH:4.8;NTE_LESION_PATHOLOGIC_LENGTH:7.1;SYNOVIAL_SS18SSX_TESTING_METHOD:RT-PCR;TUMOR_TOTAL_NECROSIS:0% (no necrosis or no mention of necrosis)"
"SYNOVIAL SARCOMA - MONOPHASIC" "CANCER_TYPE_DETAILED:Synovial Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SYNS;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:28;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:22.37;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:22.37;TISSUE_SOURCE_SITE:MJ;ICD_O_3_SITE:C49.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C71.0;ICD_O_3_HISTOLOGY:9041/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/14/14;HISTOLOGICAL_DIAGNOSIS:Synovial Sarcoma - Monophasic;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:226;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-MJ-A850.16C71B81-171B-499A-83E8-27CB6BB6A23C.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:30;SITE_OF_TUMOR_TISSUE:Head and Neck - Neck|Head and Neck - Other (please specify;PHARMACEUTICAL_TX_ADJUVANT:NO;PRIMARY_SITE_OTHER:Pharynx;PERCENTAGE_NECROSIS:10;DISEASE_MULTIFOCAL_INDICATOR:NO;TUMOR_TOTAL_DEPTH:Deep;CONTIGUOUS_ORGAN_INVADED:NO;METASTATIC_DISEASE_CONFIRMED:NO;NTE_LESION_PATHOLOGIC_DEPTH:2.6;NTE_LESION_PATHOLOGIC_LENGTH:5;NTE_LESION_RADIOLOGIC_DEPTH:2.6;NTE_LESION_RADIOLOGIC_LENGTH:4.6;TUMOR_TOTAL_NECROSIS:<10% (focal necrosis)"
"SYNOVIAL_SARCOMA" "CANCER_TYPE_DETAILED:Synovial Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:SYNS;TMB_NONSYNONYMOUS:18.4666666667;SUBTYPE:Synovial;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:synovial_sarcoma"
"SYSTEMIC MASTOCYTOSIS" "CANCER_TYPE_DETAILED:Mastocytosis;CANCER_TYPE:Mastocytosis;ONCOTREE_CODE:MCD;TMB_NONSYNONYMOUS:0.366666667;SEX:Male;AGE:78;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;ICD_10:C92.00;HISTOLOGY:Malignant mastocytosis;PURITY:0.957;PROJECT_CODE:CMDI-UK;WGD:no_wgd;SEQUENCING_TYPE:WGS;FIRST_THERAPY:Other Therapy;ORGAN_SYSTEM:BLOOD, BONE MARROW, & HEMATOPOIETIC SYS;ANCESTRY_PRIMARY:EUR;FIRST THERAPY_RESPONSE:Stable Disease;HISTOLOGY_ABBREVIATION:Myeloid-MPN;HISTOLOGY_TIER1:MESODERM;HISTOLOGY_TIER2:Myeloid;HISTOLOGY_TIER3:Myeloproliferative neoplasm;HISTOLOGY_TIER4:Systemic mastocytosis;PURITY_CONFUGURATION:0.015;TUMOR_SAMPLE_HISTOLOGY_CODE:9741/3"
"S_T_MDS" "TMB_NONSYNONYMOUS:21.74626888391624;SEX:Male;AGE:64;OS_MONTHS:13.38082192;OS_STATUS:1:DECEASED;WBC:2.8;CYTOGENETICS:46,xy,del(20)(q12)[2]/46,xy[18];FLT3_ITD:FALSE;ANC:0.2;BM_BLAST:14;CHR_TP53_LOCUS:normal;COMPLEX_KARYOTYPE:non-complex;CYTO_IPSSR:Good;HB:7.6;IPSSM:Very-High;IPSSM_SCORE:3.48;IPSSR:High;IPSSR_SCORE:6;LFS_MONTHS:1.117808219;LFS_STATUS:1:Transformed/Deceased;MDS_TYPE:s_t_MDS;MLL_PTD:FALSE;MONOCYTES:0.7;PB_BLAST:0;PLT:119;WHO_2016:MDS-EB2"
"T-ALL" "CANCER_TYPE_DETAILED:T-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AUL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:1;GENE_PANEL:WGS;COHORT:INF_MLLr_Discovery;MUTATION_RATE:7.35E-08;MLL_STATUS:INF_MLLr;LEUKEMIA_TYPE:T-ALL"
"T-CELL ACUTE LYMPHOID LEUKEMIA" "CANCER_TYPE_DETAILED:T-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AUL;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;AGE:1;GENE_PANEL:WGS;COHORT:INF_MLLr_Discovery;MUTATION_RATE:7.35E-08;MLL_STATUS:INF_MLLr;LEUKEMIA_TYPE:T-ALL"
"T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA" "CANCER_TYPE_DETAILED:T-Cell Large Granular Lymphocytic Leukemia;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:TLGL;TMB_NONSYNONYMOUS:0.866666666667;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.1246;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:0.99;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:SINGLE OR CLUSTERED OVOID TO ROUND; SOMETIMES IRREGULAR SHPAED CELLS GROWING IN SUSPENSION;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+20% FBS;HIST_SUBTYPE1:T_cell_large_granular_lymphocytic_leukaemia;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell;LINEAGE_SUBTYPE:lymphoma_unspecified;NAME:MOTN-1;PATHOLOGIST_ANNOTATION:Leukemia:ALL;SITE_SUBTYPE1:lymph_node;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"T-CELL, NON-HODGKINS, ANAPLASTIC LARGE CELL ALCL" NA
"T-CELL, NON-HODGKINS, CUTANEOUS" "CANCER_TYPE_DETAILED:Mycosis Fungoides;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:MYCF;TMB_NONSYNONYMOUS:5.33333333333;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.4604;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:118.2175686;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:sezary_syndrome;HIST_SUBTYPE1:mycosis_fungoides-Sezary_syndrome;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HuT 78;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:skin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"T-CELL, NON-HODGKINS, CUTANEOUS, SEZARY SYNDROME" "CANCER_TYPE_DETAILED:Non-Hodgkin Lymphoma;CANCER_TYPE:Non-Hodgkin Lymphoma;ONCOTREE_CODE:NHL;TMB_NONSYNONYMOUS:10.9333333333;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous, Sezary Syndrome;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"T-CELL_ALL" "CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:24.8661290499;SEX:Male;FRACTION_GENOME_ALTERED:0.1179;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:T-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_T_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"T-CELL_LYMPHOMA_OTHER" "CANCER_TYPE_DETAILED:Mycosis Fungoides;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:MYCF;TMB_NONSYNONYMOUS:5.33333333333;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.4604;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:118.2175686;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:sezary_syndrome;HIST_SUBTYPE1:mycosis_fungoides-Sezary_syndrome;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HuT 78;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:skin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA" "CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:24.8661290499;SEX:Male;FRACTION_GENOME_ALTERED:0.1179;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:T-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_T_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"TALL" "CANCER_TYPE_DETAILED:T-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TALL;TMB_NONSYNONYMOUS:1.67624641493;SOMATIC_STATUS:Matched;SEX:Male;AGE:0.925;GENE_PANEL:Targeted_Seq;COHORT:INF_NON_MLLr_Validation;MLL_STATUS:INF_NON_MLLr;LEUKEMIA_TYPE:T-ALL"
"TALL CELL" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:0.633333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:42.48;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:42.48;TISSUE_SOURCE_SITE:DJ;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:Yes;ICD_10:C73;ICD_O_3_HISTOLOGY:8344/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/25/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:146;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DJ-A1QH.387740C3-B978-4F9B-A971-56A6E8F170E6.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:510;SITE_OF_TUMOR_TISSUE:Thyroid;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1a;AJCC_TUMOR_PATHOLOGIC_PT:T3;LYMPH_NODES_EXAMINED:YES;LATERALITY:Bilateral"
"TALL CELL VARIANT" "CANCER_TYPE_DETAILED:Anaplastic Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THAP;TMB_NONSYNONYMOUS:0.166666666667;SOMATIC_STATUS:Matched;AGE:77;FRACTION_GENOME_ALTERED:0.1114;SAMPLE_TYPE:Primary;OS_MONTHS:4.64;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;TUMOR_PURITY:0.33;PATH_T_STAGE:T3/T4;PATH_N_STAGE:N1a/N1b;SPECIMEN_PRESERVATION_TYPE:Frozen;M_STAGE:Mx;CYTOLOGICAL_PHENOTYPE:tall cell variant"
"TALL CELL VARIANT  PHENOTYPE CHANGED AFTER CONSENSUS UPSTAGED T" NA
"TC:NEC" "CANCER_TYPE_DETAILED:Thymic Epithelial Tumor;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:TET;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:23;TISSUE_SOURCE_SITE:FFPE;GENE_PANEL:WXS;TUMOR_STAGE:IVB;DIAGNOSIS:Thymic Carcinoma;WHO_CLASS:TC:NEC;ACGH_DATA:CGH;GTF2I_MUTATION_STATUS:WT"
"TC:SCC" "CANCER_TYPE_DETAILED:Thymic Epithelial Tumor;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:TET;TMB_NONSYNONYMOUS:1.133333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:76;TISSUE_SOURCE_SITE:Frozen;GENE_PANEL:WXS, RNASeq;TUMOR_STAGE:III;DIAGNOSIS:Thymic Carcinoma;WHO_CLASS:TC:SCC;ACGH_DATA:CGH;GTF2I_MUTATION_STATUS:WT"
"TELANGIECTATIC OSTEOSARCOMA" "CANCER_TYPE_DETAILED:Telangiectatic Osteosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:TEOS;TMB_NONSYNONYMOUS:0.7;SEX:Male;OS_MONTHS:16;OS_STATUS:1:DECEASED;PRIMARY_SITE:Tibia;SAMPLE_CLASS:Tumor;GRADE:High grade;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:17;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Bone- tibia;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:18.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:16;SAMPLE_TESTED_CATEGORY:Primary disease"
"TERATOMA" "CANCER_TYPE_DETAILED:Immature Teratoma;CANCER_TYPE:Ovarian Germ Cell Tumor;ONCOTREE_CODE:OIMT;TMB_NONSYNONYMOUS:2.1;SEX:Female;OS_MONTHS:61;OS_STATUS:0:LIVING;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:9;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Peritoneum;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:10.0;DIAGNOSTIC_CATEGORY:Germ cell;GMED_OS_MONTHS:52;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"TERATOMA IMMATURE" NA
"TERATOMA MATURE" NA
"TERATOMA WITH MALIGNANT TRANSFORMATION" "CANCER_TYPE_DETAILED:Teratoma with Malignant Transformation;CANCER_TYPE:Teratoma with Malignant Transformation;ONCOTREE_CODE:TMT;TMB_NONSYNONYMOUS:0.933333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:42;FRACTION_GENOME_ALTERED:0.6593;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Testicle;ANALYSIS_COHORT:TGCT;BIOPSY_SITE:Lymph Node;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:6"
"TESTICULAR NON-SEMINOMA" "CANCER_TYPE_DETAILED:Mixed Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:BMGCT;TMB_NONSYNONYMOUS:0.0;SEX:Male;FRACTION_GENOME_ALTERED:0.0722;SAMPLE_TYPE:Metastasis;OS_MONTHS:32.3;OS_STATUS:0:LIVING;RACE:White;PRIMARY_SITE:Testis;GENE_PANEL:IMPACT341;METASTATIC_SITE:Unspecified;TUMOR_PURITY:50;SUBTYPE:Testicular Non-Seminoma;MSI_SCORE:0.19;MSI_TYPE:Stable;SAMPLE_COVERAGE:678;AGE_AT_SURGERY:30.06;FGA:0.072;AGE_AT_SEQUENCING:30.91;ORGAN_SYSTEM:Genitourinary;AGE_AT_LAST_CONTACT:33.6;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:Yes;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:Yes;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:TGCT non-SEM"
"TESTICULAR SEMINOMA" "CANCER_TYPE_DETAILED:Seminoma;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:SEM;TMB_NONSYNONYMOUS:3.32746590179;SEX:Male;FRACTION_GENOME_ALTERED:0.4731;SAMPLE_TYPE:Primary;OS_MONTHS:76.09;OS_STATUS:0:LIVING;RACE:White;PRIMARY_SITE:Testis;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;SUBTYPE:Testicular Seminoma;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:772;AGE_AT_SURGERY:28.83;FGA:0.473;AGE_AT_SEQUENCING:28.97;ORGAN_SYSTEM:Genitourinary;AGE_AT_LAST_CONTACT:35.31;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:Yes;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:Yes;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:TGCT SEM"
"TGCT" "CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma with Sarcomatoid Features;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:SCCRCC;TMB_NONSYNONYMOUS:1.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:41;GENE_PANEL:WXS;GRADE:2;VITAL_STATUS:LIVING;COHORT:DISCOVERY;STAGE_AT_DIAGNOSIS:pT1bN0M0;FOLLOW_UP_TIME_MONTHS:62;GENE_EXPRESSION_CLUSTER:ccA;VHL_MUTATION_AA:p.R58fs;VHL_MUTATION_CODON:c.173_192 delGCGGCCGCGGCCCGTGCTGC"
"TGCT NON-SEM" "CANCER_TYPE_DETAILED:Mixed Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:BMGCT;TMB_NONSYNONYMOUS:0.0;SEX:Male;FRACTION_GENOME_ALTERED:0.0722;SAMPLE_TYPE:Metastasis;OS_MONTHS:32.3;OS_STATUS:0:LIVING;RACE:White;PRIMARY_SITE:Testis;GENE_PANEL:IMPACT341;METASTATIC_SITE:Unspecified;TUMOR_PURITY:50;SUBTYPE:Testicular Non-Seminoma;MSI_SCORE:0.19;MSI_TYPE:Stable;SAMPLE_COVERAGE:678;AGE_AT_SURGERY:30.06;FGA:0.072;AGE_AT_SEQUENCING:30.91;ORGAN_SYSTEM:Genitourinary;AGE_AT_LAST_CONTACT:33.6;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:Yes;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:Yes;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:TGCT non-SEM"
"TGCT SEM" "CANCER_TYPE_DETAILED:Seminoma;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:SEM;TMB_NONSYNONYMOUS:3.32746590179;SEX:Male;FRACTION_GENOME_ALTERED:0.4731;SAMPLE_TYPE:Primary;OS_MONTHS:76.09;OS_STATUS:0:LIVING;RACE:White;PRIMARY_SITE:Testis;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;SUBTYPE:Testicular Seminoma;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:772;AGE_AT_SURGERY:28.83;FGA:0.473;AGE_AT_SEQUENCING:28.97;ORGAN_SYSTEM:Genitourinary;AGE_AT_LAST_CONTACT:35.31;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:Yes;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:Yes;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:TGCT SEM"
"TGCT_NON-SEMINOMA" "CANCER_TYPE_DETAILED:Mixed Germ Cell Tumor;CANCER_TYPE:Non-Seminomatous Germ Cell Tumor;ONCOTREE_CODE:MGCT;TMB_NONSYNONYMOUS:0.266666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:41;FRACTION_GENOME_ALTERED:0.3978;SAMPLE_TYPE:Primary;OS_MONTHS:22.19153763;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:22.19153763;TISSUE_SOURCE_SITE:Erasmus MC;ICD_O_3_SITE:C62.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C62.90;ICD_O_3_HISTOLOGY:9070/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:6/3/14;PFS_MONTHS:22.19153763;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Testes;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IB;SUBTYPE:TGCT_non-seminoma;TUMOR_TYPE:Non-Seminoma, Embryonal Carcinoma|Non-Seminoma, Yolk Sac Tumor;PATH_T_STAGE:T2;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:675;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-14976;MSI_SENSOR_SCORE:0.54;CANCER_TYPE_ACRONYM:TGCT;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3121;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:2G;DSS_MONTHS:22.19153763;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0"
"TGCT_SEMINOMA" "CANCER_TYPE_DETAILED:Seminoma;CANCER_TYPE:Seminoma;ONCOTREE_CODE:SEM;TMB_NONSYNONYMOUS:0.466666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:31;FRACTION_GENOME_ALTERED:0.2004;SAMPLE_TYPE:Primary;OS_MONTHS:20.31758556;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:Erasmus MC;ICD_O_3_SITE:C62.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C62.9;ICD_O_3_HISTOLOGY:9061/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:4/8/14;PFS_MONTHS:4.701318342;AJCC_STAGING_EDITION:7TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Testes;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IS;SUBTYPE:TGCT_seminoma;TUMOR_TYPE:Seminoma (NOS);PATH_T_STAGE:T1;RADIATION_THERAPY:No;DSS_STATUS:1:DEAD WITH TUMOR;DAYS_TO_BIRTH:-11325;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:TGCT;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3141;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:2G;DSS_MONTHS:20.31758556;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0"
"THCA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:9.86666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:76;FRACTION_GENOME_ALTERED:0.3163;SAMPLE_TYPE:Primary;OS_MONTHS:31.04;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:31.04;TISSUE_SOURCE_SITE:FJ;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:Yes;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/27/12;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IV;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:Yes;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:539;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-FJ-A3Z7.67B47EFA-A6C9-40B6-AF17-8A4E1FF6656B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:120;WEIGHT:84;SITE_OF_TUMOR_TISSUE:Bladder;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T4a;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:175;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;PRIMARY_SITE_PATIENT:Dome|Wall Anterior|Wall Lateral|Wall Posterior;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Radical Cystectomy w/Nodal Dissection;METASTATIC_SITE_PATIENT:Lymph node only;ANGIOLYMPHATIC_INVASION:YES;OCCUPATION_PRIMARY:Carpenter;EXTRACAPSULAR_EXTENSION:NO;NONINVASIVE_BLADDER_CA_TX_TYPE:Bacillus Calmette-Guerin (BCG);NONINVASIVE_BLADDER_HISTORY:YES;OCCUPATION_CURRENT:Retired;OCCUPATION_PRIMARY_INDUSTRY:Healthcare;TIME_TO_COMPLETE_RESPONSE:26;TX_90DAYS_POST_RESECTION:NO;TX_COMPLETE_RESPONSE:YES;TX_INDUCTION_COURSES_INDICATOR:YES;TX_MAINTENANCE_COURSES_INDICATOR:YES"
"THERAPY-RELATED MYELODYSPLASTIC SYNDROME" "CANCER_TYPE_DETAILED:Therapy-Related Myelodysplastic Syndrome;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMDS;TMB_NONSYNONYMOUS:2.7975705897;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:Therapy-Related Myelodysplastic Syndrome"
"THERAPY-RELATED MYELOID NEOPLASMS" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:4.84;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:81.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:37.1;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:81;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Supportive/Palliative Care;FAB:M5;HEMOGLOBIN_LEVEL:8.8;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.08;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12];WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Supportive/Palliative Care;CURRENT_REGIMEN:Azacitidine;LDH_LEVEL:2700;MOST_RECENT_TREATMENT_DURATION:42;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.6;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-112;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:92.4;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:60;PB_AST_LEVEL:64;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:12;PB_MONOCYTES_PERCENTAGE:33;PB_NEUTROPHILS_PERCENTAGE:7;PRIOR_CANCER:Anal carcinoma|Breast Cancer;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:Yes;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;TOTAL_PROTEIN_LEVEL:6.3"
"THPA" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:8.46666666667;SEX:Female;AGE:76;FRACTION_GENOME_ALTERED:0.3951;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Carcinoma, papillary;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:112.5260944;GENOME_DOUBLINGS:1;DOUBLING_TIME:36.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Spindle- or round-shaped cells growing adherently as monolayer;DOUBLING_TIME_FROM_VENDOR:~  30 hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:90% RPMI 1640 + 10% h.i.FBS;HIST_SUBTYPE1:papillary_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:papillary;LINEAGE_SUBTYPE:thyroid_carcinoma;NAME:B-CPAP;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"THPD" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:4.42064516443;SEX:Female;FRACTION_GENOME_ALTERED:0.5518;PRIMARY_SITE:Thyroid;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Thyroid;HISTOLOGICAL_SUBTYPE:Anaplastic_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"THRBCL" "CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:1.5;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:109.93333329999999;OS_STATUS:1:DECEASED;PFS_MONTHS:31.0;PFS_STATUS:1:Progressed;AGE_AT_DIAGNOSIS:30.0;COHORT:Goettingen;MEAN_TARGET_COVERAGE_TUMOR:75.2;PURITY_ABSOLUTE:0.19;SAMPLE_COLLECTION_SOURCE:Frozen;IPI:3.0;NUM_NONSILENT_MUTATION:45;TESTICULAR_INVOLVEMENT:No;DRIVER_MUTATIONS:1;IPI_AGE:0.0;IPI_ECOG:0.0;IPI_LDH:1.0;MORPHOLOGY_SUBTYPE:THRBCL;NONSILENT_MUTATION_DENSITY:1.383713;NUM_SILENT_MUTATION:19;TOTAL_CNA:14;CLUSTER:0;CNS_INVOLVEMENT:No;DBSNP_MUTATION_DENSITY:0.154;DRIVER_MUTATION_DENSITY:0.0307;IPI_EXBM:1.0;IPI_STAGE:1.0;MUTATION_DENSITY:1.967947;NUM_DBSNP_MUTATIONS:5;NUM_DRIVER_SCNA:0;NUM_DRIVER_SV:0;R_CHOP_LIKE_CHEMO:Yes;SILENT_MUTATION_DENSITY:0.584;TOTAL_REARRANGEMENT:0;TUMOR_IN_NORMAL_ESTIMATE:0.025"
"THYM" "CANCER_TYPE_DETAILED:AML with Recurrent Genetic Abnormalities;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLRGA;TMB_NONSYNONYMOUS:1.1;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:40.33;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:35.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:35;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:2;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Allogeneic - Matched Unrelated Donor;FUSION:MLLT3-KMT2A;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1];WHOLE_EXOME_SEQUENCING:Yes;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Busulfan, Cyclophosphamide, Thymoglobulin;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198];DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;INDUCTION_RESPONSE:Complete Response;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with t(9;11)(p22;q23); MLLT3-MLL;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with t(9;11)(p22;q23); MLLT3-MLL;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"THYMIC CARCINOMA" "CANCER_TYPE_DETAILED:Thymic Carcinoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYC;TMB_NONSYNONYMOUS:0.066666667;SEX:Male;AGE:74.66392517;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:47"
"THYMIC EPITHELIAL TUMOR" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Epithelial Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:47;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:68.58007036;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:MD Anderson Cancer Center;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C37;ICD_O_3_HISTOLOGY:8583/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;PFS_MONTHS:68.58007036;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Thymus;SUBTYPE:THYM;TUMOR_TYPE:Thymoma, Type B1;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:2086;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-17528;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:THYM;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3115;TISSUE_SOURCE_SITE_CODE:3G;DSS_MONTHS:68.58007036;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;WEIGHT:99"
"THYMIC TUMOR" "CANCER_TYPE_DETAILED:Thymic Neuroendocrine Tumor;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:TNET;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Male;AGE:66;FRACTION_GENOME_ALTERED:0.0214;SAMPLE_TYPE:Metastasis;RACE:East Asian;PRIMARY_SITE:Thymus;ANALYSIS_COHORT:THYM;BIOPSY_SITE:Lymph Node;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:26"
"THYMOMA" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:39;FRACTION_GENOME_ALTERED:0.0556;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Thymus;ANALYSIS_COHORT:THYM;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:61"
"THYMOMA; TYPE A" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:66;FRACTION_GENOME_ALTERED:0.0198;SAMPLE_TYPE:Primary;OS_MONTHS:59.1;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:59.1;TISSUE_SOURCE_SITE:3G;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:Yes;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C37;ICD_O_3_HISTOLOGY:8581/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type A;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1681;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3G-AB0Q.76FF0EA8-C540-4F12-B44E-8F2DD900C34B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:50;WEIGHT:67;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:175;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Fine needle aspiration biopsy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"THYMOMA; TYPE AB" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.0070;SAMPLE_TYPE:Primary;OS_MONTHS:62.68;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:62.68;TISSUE_SOURCE_SITE:4V;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C37;ICD_O_3_HISTOLOGY:8582/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type AB;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1502;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-4V-A9QL.2126DC95-17BF-4B43-A168-6930FC2ACD52.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:180;WEIGHT:52;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:150;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Median Sternectomy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"THYMOMA; TYPE B1" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.133333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:47;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:68.53;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:68.53;TISSUE_SOURCE_SITE:3G;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C37;ICD_O_3_HISTOLOGY:8583/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type B1;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1779;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3G-AB0O.6FAA90E1-454A-4862-B6B1-30A3892DECFB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:240;WEIGHT:99;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:172;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"THYMOMA; TYPE B2" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.366666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:51;FRACTION_GENOME_ALTERED:0.1027;SAMPLE_TYPE:Primary;OS_MONTHS:25.46;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:3G;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C37;ICD_O_3_HISTOLOGY:8584/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type B2;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:611;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3G-AB14.0B31AEFF-6AA2-4C90-B827-0EA47BE38B86.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:110;WEIGHT:50;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:169;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Fine needle aspiration biopsy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"THYMOMA; TYPE B3" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.0058;SAMPLE_TYPE:Primary;OS_MONTHS:93.59;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:26.05;TISSUE_SOURCE_SITE:4V;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C37;ICD_O_3_HISTOLOGY:8585/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type B3;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2512;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-4V-A9QJ.537BEDFA-F6F2-48AC-94BB-6279B07DF89D.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:20;WEIGHT:80;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:180;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Median Sternectomy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"THYMOMA; TYPE C" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.5624;SAMPLE_TYPE:Primary;OS_MONTHS:21.12;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.36;TISSUE_SOURCE_SITE:3S;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C37;ICD_O_3_HISTOLOGY:8586/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type C;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:112;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3S-A8YW.F59BF4F4-ED39-45DD-AD20-FC3BDD08F73A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;WEIGHT:91;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:172;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Surgical Resection;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"THYROID CANCER" "CANCER_TYPE_DETAILED:Angiosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ANGS;TMB_NONSYNONYMOUS:3.13333333333;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0226;RACE:NOT REPORTED;PRIMARY_SITE_PATIENT:BLADDER;SAMPLE_TIMEPOINT:ASCProject_03IpIBIR_T1;TMB:2.973428035;BX_LOCATION:BLADDER WALL;BX_TIME_DAYS:181;BX_TYPE:RESECTION;AGE_AT_DIAGNOSIS_GROUP:41-45;PRD_HISPANIC:NOT REPORTED;PRD_OTHER_CANCER:YES;PRD_TREATED_AT_ENROLLMENT:NOT REPORTED;BX_NUCLEAR_GRADE:HIGH;BX_SPINDLE_CELL:YES;BX_VASOFORMATIVE:YES;DX_BIOPSY_LOCATION:BLADDER;PRD_DIAGNOSIS_LOC:NOT REPORTED;PRD_EVER_LOCATION:NOT REPORTED;PRD_LOCATION_AT_ENROLLMENT:NOT REPORTED;PRD_OTHER_CANCER_LIST:THYROID CANCER;PRD_OTHER_CANCER_RADIATION:YES;PRD_RADIATION:NO;PRD_RADIATION_SURGERY:NONE;PRD_SURGERY:YES;PRD_SURGERY_CLEAN_MARGINS:YES"
"THYROID CANCER, NOS" "CANCER_TYPE_DETAILED:Thyroid;CANCER_TYPE:Thyroid Cancer, NOS;ONCOTREE_CODE:THYROID;TMB_NONSYNONYMOUS:11.5666666667;SEX:Female;AGE:77;FRACTION_GENOME_ALTERED:0.3209;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:85.58672632;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:medulla_carcinoma;HIST_SUBTYPE1:medullary_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUBTYPE:thyroid_squamous;NAME:TT;PATHOLOGIST_ANNOTATION:Oesophagus:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"THYROID CARCINOMA" "CANCER_TYPE_DETAILED:Papillary Throid Carcinoma;CANCER_TYPE:Thyroid Carcinoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1227;DIAGNOSIS AGE:46;GDNA(NG):4368;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"THYROID CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Thyroid Carcinoma Other;CANCER_TYPE:Thyroid Carcinoma;TMB_NONSYNONYMOUS:0.2;SEX:Female;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1034;DIAGNOSIS AGE:69;GDNA(NG):110;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"THYROID PAPILLARY" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:33;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:16.33;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:16.33;TISSUE_SOURCE_SITE:BJ;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C73;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/2/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Thyroid Papillary Carcinoma - Classical/usual;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:162;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BJ-A0Z3.EDF3F3EB-AC62-403D-9180-147C2CFD2AA5.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:390;SITE_OF_TUMOR_TISSUE:Thyroid;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;LYMPH_NODES_EXAMINED:YES;LATERALITY:Left lobe;BRAF_MUTATION:V600E identified"
"THYROID PAPILLARY CARCINOMA - CLASSICAL/USUAL" "CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:33;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:16.33;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:16.33;TISSUE_SOURCE_SITE:BJ;ICD_O_3_SITE:C73.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C73;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/2/11;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Thyroid Papillary Carcinoma - Classical/usual;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:162;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BJ-A0Z3.EDF3F3EB-AC62-403D-9180-147C2CFD2AA5.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:390;SITE_OF_TUMOR_TISSUE:Thyroid;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1;LYMPH_NODES_EXAMINED:YES;LATERALITY:Left lobe;BRAF_MUTATION:V600E identified"
"THYROID PAPILLARY CARCINOMA - FOLLICULAR >= 99% FOLLICULAR PATTERNED" NA
"THYROID PAPILLARY CARCINOMA - TALL CELL >= 50% TALL CELL FEATURES" NA
"THYROID POORLY DIFFERENTIATED" "CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:1.1091553006;SEX:Female;FRACTION_GENOME_ALTERED:0.1972;SAMPLE_TYPE:Primary;OS_MONTHS:24.9;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Thyroid;GENE_PANEL:IMPACT341;SUBTYPE:Thyroid Poorly Differentiated;MSI_SCORE:0.33;MSI_TYPE:Stable;SAMPLE_COVERAGE:801;AGE_AT_SURGERY:63.38;FGA:0.197;AGE_AT_SEQUENCING:70.81;ORGAN_SYSTEM:Endocrine;AGE_AT_DEATH:72.88;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:No;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:Yes;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:THPD"
"THYROID SARCOMA" "CANCER_TYPE_DETAILED:Thyroid;CANCER_TYPE:Thyroid Cancer, NOS;ONCOTREE_CODE:THYROID;SEX:Female;AGE:47;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Thyroid Sarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Sarcoma;PURITY:0.97;MUTATION_RATE:70.22262185;GENOME_DOUBLINGS:2;DOUBLING_TIME:107.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Epithelial monolayer;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:thyroid_sarcoma;NAME:S-117;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Others;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:thyroid;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"THYROID_CARCINOMA" "CANCER_TYPE_DETAILED:Follicular Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THFO;TMB_NONSYNONYMOUS:7.86666666667;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.4758;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Carcinoma, follicular;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;GENOME_DOUBLINGS:1;DOUBLING_TIME:31.6;GEOGRAPHIC_DISTRIBUTION:chinese;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Adherent large epitheloid cells with long processes growing in monolayers with multilayer foci;DOUBLING_TIME_FROM_VENDOR:20-25hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:RPMI1640+10%FBS;HIST_SUBTYPE1:follicular_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:follicular;LINEAGE_SUBTYPE:thyroid_carcinoma;NAME:CGTH-W-1;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_OF_FINDING:sternum;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"THYROID_SARCOMA" "CANCER_TYPE_DETAILED:Thyroid;CANCER_TYPE:Thyroid Cancer, NOS;ONCOTREE_CODE:THYROID;SEX:Female;AGE:47;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Thyroid Sarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Sarcoma;PURITY:0.97;MUTATION_RATE:70.22262185;GENOME_DOUBLINGS:2;DOUBLING_TIME:107.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Epithelial monolayer;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:thyroid_sarcoma;NAME:S-117;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Others;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:thyroid;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"TLL" "CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:24.8661290499;SEX:Male;FRACTION_GENOME_ALTERED:0.1179;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:T-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_T_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"TRANSITIONAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:11.5;SEX:Male;FRACTION_GENOME_ALTERED:0.4444;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Urinary_Tract;SUBTYPE:Transitional Cell Carcinoma;TUMOR_TYPE:urinary_tract;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:124.7079624;GENOME_DOUBLINGS:2;DOUBLING_TIME:386.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent epithelial;DISEASE_ONTOLOGY:bladder_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:EMEM +10%FBS;HIST_SUBTYPE1:transitional_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:urinary_tract;LINEAGE_SUB_SUBTYPE:bladder_transitional_cell;LINEAGE_SUBTYPE:bladder_carcinoma;NAME:UM-UC-3;PATHOLOGIST_ANNOTATION:Bladder:Carcinoma;PROTEOMICS_TMT_LABEL:130c;SITE_SUBTYPE1:bladder;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:urinary_tract"
"TRANSITIONAL_CELL_CARCINOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:28.7341935688;SEX:Male;FRACTION_GENOME_ALTERED:0.5143;PRIMARY_SITE:Urinary Tract;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Urinary_Tract;HISTOLOGICAL_SUBTYPE:Transitional_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"TRANSLOCATION-ASSOCIATED RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Translocation-Associated Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:TRCC;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0015;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:424;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"TREATED PRIMARY GBM" "CANCER_TYPE_DETAILED:Glioblastoma Multiforme;CANCER_TYPE:Glioma;ONCOTREE_CODE:GBM;SOMATIC_STATUS:Matched;SEX:Female;AGE:40;FRACTION_GENOME_ALTERED:0.1930;SAMPLE_TYPE:Primary;OS_MONTHS:23.16;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:17.02;TISSUE_SOURCE_SITE:2;ICD_O_3_SITE:C71.9;HISTORY_NEOADJUVANT_TRTYN:Yes;ICD_10:C71.9;ICD_O_3_HISTOLOGY:9440/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:12/16/08;HISTOLOGICAL_DIAGNOSIS:Treated primary GBM;TUMOR_STATUS:WITH TUMOR;INITIAL_PATHOLOGIC_DX_YEAR:2002;IS_FFPE:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-02-0007.915ED9E0-E0FC-459B-97BE-7BBE91B6D100.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Brain;KARNOFSKY_PERFORMANCE_SCORE:80;SPECIMEN_SECOND_LONGEST_DIMENSION:0.8;LONGEST_DIMENSION:1.5;SHORTEST_DIMENSION:0.1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;HISTORY_LGG_DX_OF_BRAIN_TISSUE:NO"
"TRILATERAL" "CANCER_TYPE_DETAILED:Retinoblastoma;CANCER_TYPE:Retinoblastoma;TMB_NONSYNONYMOUS:0.066666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:1.06;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:RBL;SUBTYPE_DETAILS:Trilateral;TUMOR_DETAILS:Retinoblastoma"
"TUBULAR STOMACH ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Tubular Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:TSTAD;TMB_NONSYNONYMOUS:17.4333333333;SEX:Male;AGE:37;FRACTION_GENOME_ALTERED:0.4229;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:190.5846245;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:epithelial-like;DISEASE_ONTOLOGY:gastric_cancer;GROWTH_MEDIUM:RPMI 1640 medium with 10% heat inactivated fetal bovine serum;HIST_SUBTYPE1:tubular_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:MKN74;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:liver;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"TUBULAR_ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Esophageal Squamous Cell Carcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCC;TMB_NONSYNONYMOUS:7.29406452131;SEX:Male;FRACTION_GENOME_ALTERED:0.4218;PRIMARY_SITE:Stomach;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Stomach;HISTOLOGICAL_SUBTYPE:Tubular_Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:HSRRB;SAMPLE_ORIGIN:Solid"
"TUMOR PRIMARY" "CANCER_TYPE_DETAILED:Glioblastoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:GB;TMB_NONSYNONYMOUS:2.7;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2084;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:35;OS_STATUS:1:DECEASED;GENE_PANEL:WXS;SAMPLE_CLASS:Tumor;GRADE:IV;HISTOLOGY:Glioblastoma;TUMOR_LOCATION:Occipital lobe;TYPE_OF_SURGERY:Craniotomy;AGE_AT_DX:71;EXTENT_OF_RESECTION:Total;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-19-0266-TP-01D-WXS-F78XXN;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;CONCURRENT_TMZ:Yes;HYPERMUTATION_STATUS:No;INITIAL_GRADE:IV;INITIAL_HISTOLOGY:Glioblastoma;MGMT_METHYLATION:Methylated;MGMT_METHYLATION_METHOD:Array;POST_RECURRENCE_SURVIVAL_MONTHS:17;RADIATION_DOSE:60;RADIATION_OTHER:IMRT, Gamma knife;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:30;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:18;TISSUE_SOURCE:Case Western  Reserve University;TMZ_CYCLES:12;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Glioblastoma, IDH-wildtype;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:No"
"TYPE A" "CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, T/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALTNOS;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:13.29;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:52.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;WBC:14;AGE_AT_PROCUREMENT:53;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:11.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.68;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Post-Transplant|Post-Chemotherapy|Residual Disease;KARYOTYPE:45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3];PB_BLAST_PERCENTAGE:59;WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Decitabine;LDH_LEVEL:167;MOST_RECENT_TREATMENT_DURATION:80;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Deleted 5q;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:34;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:32;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:29;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Mixed phenotype acute leukaemia, T/myeloid, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mixed phenotype acute leukaemia, T/myeloid, NOS;TOTAL_PROTEIN_LEVEL:6.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"TYPE AB" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.0070;SAMPLE_TYPE:Primary;OS_MONTHS:62.68;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:62.68;TISSUE_SOURCE_SITE:4V;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C37;ICD_O_3_HISTOLOGY:8582/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type AB;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1502;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-4V-A9QL.2126DC95-17BF-4B43-A168-6930FC2ACD52.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:180;WEIGHT:52;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:150;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Median Sternectomy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"TYPE ATHYMOMA" NA
"TYPE B1" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.133333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:47;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:68.53;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:68.53;TISSUE_SOURCE_SITE:3G;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C37;ICD_O_3_HISTOLOGY:8583/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type B1;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1779;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3G-AB0O.6FAA90E1-454A-4862-B6B1-30A3892DECFB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:240;WEIGHT:99;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:172;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"TYPE B1THYMOMA" NA
"TYPE B2" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.366666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:51;FRACTION_GENOME_ALTERED:0.1027;SAMPLE_TYPE:Primary;OS_MONTHS:25.46;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;TISSUE_SOURCE_SITE:3G;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C37;ICD_O_3_HISTOLOGY:8584/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type B2;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:611;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3G-AB14.0B31AEFF-6AA2-4C90-B827-0EA47BE38B86.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:110;WEIGHT:50;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:169;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Fine needle aspiration biopsy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"TYPE B2THYMOMA" NA
"TYPE B3" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.0058;SAMPLE_TYPE:Primary;OS_MONTHS:93.59;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:26.05;TISSUE_SOURCE_SITE:4V;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C37;ICD_O_3_HISTOLOGY:8585/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type B3;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2512;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-4V-A9QJ.537BEDFA-F6F2-48AC-94BB-6279B07DF89D.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:20;WEIGHT:80;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:180;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Median Sternectomy;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"TYPE C" "CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.5624;SAMPLE_TYPE:Primary;OS_MONTHS:21.12;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.36;TISSUE_SOURCE_SITE:3S;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C37;ICD_O_3_HISTOLOGY:8586/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type C;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:112;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3S-A8YW.F59BF4F4-ED39-45DD-AD20-FC3BDD08F73A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;WEIGHT:91;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:172;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Surgical Resection;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"T_CELL_ALCL" "CANCER_TYPE_DETAILED:Anaplastic Large Cell Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:ALCL;TMB_NONSYNONYMOUS:20.3;SEX:Male;AGE:15;FRACTION_GENOME_ALTERED:0.4817;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Anaplastic Large Cell (ALCL);TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:208.2736925;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:lymphoblast-like;GROWTH_MEDIUM:RPMI 1640 medium with 10% fetal calf serum.;HIST_SUBTYPE1:anaplastic_large_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_ALCL;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:Ki-JK;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"T_CELL_CUTANEOUS" "CANCER_TYPE_DETAILED:Mycosis Fungoides;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:MYCF;TMB_NONSYNONYMOUS:5.33333333333;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.4604;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:118.2175686;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:sezary_syndrome;HIST_SUBTYPE1:mycosis_fungoides-Sezary_syndrome;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HuT 78;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:skin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"T_CELL_LARGE_GRANULAR_LYMPHOCYTIC_LEUKAEMIA" "CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:4.0890967771;SEX:Female;FRACTION_GENOME_ALTERED:0.1243;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lymphoma_Other;HISTOLOGICAL_SUBTYPE:T_Cell_Large_Granular_Lymphocytic_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"UCEC ENDO" "CANCER_TYPE_DETAILED:Uterine Endometrioid Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UEC;TMB_NONSYNONYMOUS:6.65493180359;SEX:Female;FRACTION_GENOME_ALTERED:0.3878;SAMPLE_TYPE:Metastasis;OS_MONTHS:35.06;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT341;METASTATIC_SITE:Lung;TUMOR_PURITY:40;SUBTYPE:Uterine Endometrioid;MSI_SCORE:0.72;MSI_TYPE:Stable;SAMPLE_COVERAGE:1016;AGE_AT_SURGERY:61;FGA:0.388;AGE_AT_SEQUENCING:61.33;ORGAN_SYSTEM:Gynecologic;AGE_AT_DEATH:64.25;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:Yes;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:UCEC ENDO"
"UCEC SEROUS" "CANCER_TYPE_DETAILED:Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:USC;TMB_NONSYNONYMOUS:1.95743939523;SEX:Female;FRACTION_GENOME_ALTERED:0.1020;SAMPLE_TYPE:Metastasis;OS_MONTHS:46;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT410;METASTATIC_SITE:Intra-Abdominal;TUMOR_PURITY:30;SUBTYPE:Uterine Serous;MSI_SCORE:0.15;MSI_TYPE:Stable;SAMPLE_COVERAGE:1147;AGE_AT_SURGERY:74.64;FGA:0.102;AGE_AT_SEQUENCING:74.81;ORGAN_SYSTEM:Gynecologic;AGE_AT_DEATH:76.53;DMETS_DX_ADRENAL_GLAND:Yes;DMETS_DX_BILIARY_TRACT:Yes;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:Yes;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:Yes;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:Yes;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:UCEC SEROUS"
"UCS" "CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Cholangiocarcinoma;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:1.233333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.2993;SAMPLE_TYPE:Primary;OS_MONTHS:26.56409245;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Hispanic Or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:18.04911727;TISSUE_SOURCE_SITE:UCSF;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:8/16/14;GRADE:G2;PFS_MONTHS:18.04911727;AJCC_STAGING_EDITION:7TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Bile Duct;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:CHOL;TUMOR_TYPE:Cholangiocarcinoma, Intrahepatic;PATH_T_STAGE:T1;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:549;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-16951;MSI_SENSOR_SCORE:0.24;CANCER_TYPE_ACRONYM:CHOL;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3208;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:W6;DSS_MONTHS:26.56409245;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:61;PATH_M_STAGE:MX"
"UM" "CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"UNCLASSIFIED KIDNEY RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Unclassified Kidney Renal Cell Carcinoma;CANCER_TYPE:Kidney Renal Cell Carcinoma;TMB_NONSYNONYMOUS:0.2;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1073;DIAGNOSIS AGE:73;GDNA(NG):4500;SMOKE STATUS:Unknown;TUMOR_PURTITY:70"
"UNCLASSIFIED RENAL CELL CARCINOMA" "CANCER_TYPE_DETAILED:Unclassified Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:URCC;TMB_NONSYNONYMOUS:0.266666666667;FRACTION_GENOME_ALTERED:0.2557"
"UNCLASSIFIED SARCOMA" "CANCER_TYPE_DETAILED:Unclassified Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.133333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:583;DIAGNOSIS AGE:56;GDNA(NG):3888;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"UNDIFFERENTIATED CARCINOMA" "CANCER_TYPE_DETAILED:Breast;CANCER_TYPE:Breast Cancer, NOS;ONCOTREE_CODE:BREAST;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.3382;SAMPLE_TYPE:Metastasis;OS_MONTHS:26.5;OS_STATUS:1:DECEASED;DFS_MONTHS:1.0;VITAL_STATUS:Deceased;M_STAGE:M1;LATERALITY:Right;T_STAGE:TX;N_STAGE:NX;STAGE_AT_DIAGNOSIS:IV;ER_STATUS:Negative;PR_STATUS:Negative;TUMOR_SAMPLE_HISTOLOGY:Breast Undifferentiated Carcinoma;HER2_IHC_SCORE:0+;SAMPLE_SITE:Lymph Node;HER2_FISH_STATUS:Unk/ND;LAST_CONTACT_DAYS_TO:26543;MENOPAUSAL_STATUS_AT_DIAGNOSIS:Post;DFS_EVENT:1;ER_STATUS_PRIMARY:Unk/ND;HER2_IHC_PRIMARY:Unk/ND;HER2_IHC_STATUS:Negative;HER2_STATUS_PRIMARY:Unk/ND;HR_STATUS:Negative;INVASIVE_CARCINOMA_DX_AGE:70;INVASIVE_CARCINOMA_DX_TIME:846.55;METASTATIC_DZ_FUP:Yes;METASTATIC_RECURRENCE_TIME_MONTHS:848.0;NGS_SAMPLE_COLLECTION_TIME:850;OVERALL_HER2_STATUS:Negative;OVERALL_HER2_STATUS_PATIENT:Negative;OVERALL_HR_STATUS_PATIENT:Negative;OVERALL_RECEPTOR_STATUS_PATIENT:Triple Negative;OVERALL_TUMOR_GRADE:III High Grade (Poorly Differentiated);PR_STATUS_PRIMARY:Unk/ND;PRIMARY_NUCLEAR_GRADE:Unknown;PRIOR_BREAST_PRIMARY:No;PRIOR_LOCAL_RECURRENCE:No;RECEPTOR_STATUS_PRIMARY:Unk/ND;TIME_TO_DEATH_MONTHS:873.0;TUMOR_TISSUE_ORIGIN:Breast"
"UNDIFFERENTIATED CARCINOMA OF THE PANCREAS" "CANCER_TYPE_DETAILED:Undifferentiated Carcinoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:UCP;SOMATIC_STATUS:Matched;SEX:Female;AGE:58;FRACTION_GENOME_ALTERED:0.4243;SAMPLE_TYPE:Primary;OS_MONTHS:15.21;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:15.21;TISSUE_SOURCE_SITE:2J;ICD_O_3_SITE:C25.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C25.0;ICD_O_3_HISTOLOGY:8020/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/16/14;GRADE:G4;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIB;HISTOLOGICAL_DIAGNOSIS:Pancreas-Undifferentiated Carcinoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:237;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-2J-AABP.1AB545A6-DC90-47E9-8112-DD094F6BCD02.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:90;SITE_OF_TUMOR_TISSUE:Pancreas;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Tumor resection;PRIMARY_SITE_PATIENT:Tail of Pancreas;TARGETED_MOLECULAR_THERAPY:YES;FAMILY_HISTORY_CANCER_TYPE:Other;ALCOHOL_CONSUMPTION_FREQUENCY:3;ALCOHOL_HISTORY_DOCUMENTED:YES;DAILY_ALCOHOL:1;FAMILY_HISTORY_OF_CANCER:YES;DIABETES_DIAGNOSIS_INDICATOR:NO;TUMOR_RESECTED_MAX_DIMENSION:7.2;ALCOHOL_EXPOSURE_INTENSITY:Weekly Drinker;GRADE_TIER_SYSTEM:Four Tier;HISTORY_CHRONIC_PANCREATITIS:NO;INVASIVE_ADENOCARCINOMA_INDICATOR:YES"
"UNDIFFERENTIATED MALIGNANT NEOPLASM" "CANCER_TYPE_DETAILED:Undifferentiated Malignant Neoplasm;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:UDMN;TMB_NONSYNONYMOUS:0.466666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:63;FRACTION_GENOME_ALTERED:0.2250;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:11"
"UNDIFFERENTIATED PLEOMORPHIC SARCOMA MALIGNANT FIBROUS HISTIOCYTOMA" "CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma Malignant Fibrous Histiocytoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0.0333333333333;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:915;DIAGNOSIS AGE:51;GDNA(NG):2820;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"UNDIFFERENTIATED PLEOMORPHIC SARCOMA UPS" NA
"UNDIFFERENTIATED PLEOMORPHIC SARCOMA/MALIGANT FIBROUS HISTIOCYTOMA/HIGH-GRADE SPINDLE CELL SARCOMA" "CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma/Maligant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Female;FRACTION_GENOME_ALTERED:0.6899;SAMPLE_TYPE:Primary;OS_MONTHS:1.578;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Retro-Intraabdominal;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;MSI_SCORE:2.53;MSI_TYPE:Stable;SAMPLE_COVERAGE:1106;CVR_TMB_SCORE:1.1;AGE_AT_SEQ_REPORT:66;DETAILED_PRIMARY_SITE:Pelvis;FACETS:YES;FACETS_REVIEW:NO;FGA_REPORTED:0.6899"
"UNDIFFERENTIATED SARCOMA" "CANCER_TYPE_DETAILED:Undifferentiated Sarcoma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:14.68856907;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:2nd tertile;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:3rd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:854;TIME_TO_BLOOD_DRAW_FROM_TX:814;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:Yes"
"UNDIFFERENTIATED STOMACH ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Undifferentiated Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:USTAD;TMB_NONSYNONYMOUS:23.1;FRACTION_GENOME_ALTERED:0.5217;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:247.1007226;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:GNF;HIST_SUBTYPE1:undifferentiated_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:HGC-27;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;PROTEOMICS_TMT_LABEL:128n;SITE_OF_FINDING:lymph_node;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:stomach"
"UNDIFFERENTIATED UTERINE SARCOMA" "CANCER_TYPE_DETAILED:Undifferentiated Uterine Sarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:UUS;TMB_NONSYNONYMOUS:0;SEX:Female;AGE:43;PFS_STATUS:Unknown/NA;RADIATION_THERAPY:No;STAGE:Stage II;RFS_STATUS:Unknown/NA;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:Unknown/NA;ANY_LINE_HORMONE:Unknown/NA;ANY_LINE_IODINE:Unknown/NA;ANY_LINE_NTRK:Unknown/NA;ANY_LINE_TARGETED:Unknown/NA;ANY_SYSTX:No;CANCER_TYPE_HISTOLOGY:Sarcoma NOS;DOB_LASTFU_TIME_YRS:44;DOB_REPORT_TIME_YRS:43;DOB_TISSUE_TIME_YRS:43;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:Archer;PROG_DEATH:Unknown/NA;PROG_EVAL_C:No;RECUR_EVAL_C:No;TISSUE_REPORT_TIME_YRS:0"
"UNDIFFERENTIATED_CARCINOMA" "CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.42600000243;SEX:Female;FRACTION_GENOME_ALTERED:0.6458;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Undifferentiated_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"UNKNOWN TUMOR" "CANCER_TYPE_DETAILED:Biliary Tract;CANCER_TYPE:Biliary Tract Cancer;ONCOTREE_CODE:BILIARY_TRACT;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Female;SAMPLE_TYPE:Unknown Tumor;OS_MONTHS:1.64;OS_STATUS:Uknown;RACE:Uknown;ETHNICITY:Uknown;PRIMARY_SITE:Biliary Tract;GENE_PANEL:MSK-ACCESS_v1;SAMPLE_CLASS:cfDNA;INSTITUTE:MSKCC;RELIGION:Uknown;AGE_CURRENT:Uknown;PED_IND:No;BEST_OVERALL_RESPONSE_BOR:NE"
"URACHAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Urachal Adenocarcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:UA;TMB_NONSYNONYMOUS:6.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.4041;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Urachus;ANALYSIS_COHORT:BLCA;BIOPSY_SITE:Subcut. Periumbilical;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:64"
"URACHAL CARCINOMA" "CANCER_TYPE_DETAILED:Urachal Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:URCA;PFS_MONTHS:0.2;COHORT:Other;AMPLIFICATION_STATUS:no;BUBBLE_GROUP:S310 Hotspot;CENTRAL:NONE;CRITERIA:NE;DATA:NONE;DOMAIN:Furin-like _ECD;DURATION_OF_THERAPY_DAYS:2;GENE:ERBB2;LOCAL_TEST:NGS-GUARDANT HEALTH;ONCOPRINT:NO;ONGOING_TREATMENT:NO;QUALIFYING_MUT:S310F;WATERFALL_GROUP:S310 Hotspot"
"URETHRAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Urethral Adenocarcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:UAD;TMB_NONSYNONYMOUS:2.93615909284;SEX:Female;FRACTION_GENOME_ALTERED:0.0595;SAMPLE_TYPE:Primary;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;TISSUE_SITE:Urethra"
"URETHRAL CANCER" "CANCER_TYPE_DETAILED:Urethral Cancer;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:UCA;TMB_NONSYNONYMOUS:12.10577333;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2582;SAMPLE_TYPE:Primary;OS_MONTHS:40.8;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Urethra;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;MSI_SCORE:0.61;MSI_TYPE:Stable;SAMPLE_COVERAGE:934;AGE_AT_SEQ_REPORTED_YEARS:62;RELIGION:CATHOLIC/ROMAN;SMOKER:Former;PED_IND:No;MET_LOCATION:Distant;TX_BET_PRI_MET_SAMPLE_COLLECTION:Both"
"URETHRAL SQUAMOUS CELL CARCINOMA" "CANCER_TYPE_DETAILED:Urethral Squamous Cell Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:USCC;TMB_NONSYNONYMOUS:8.873242405;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2446;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Urethra;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;SAMPLE_COVERAGE:1249;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"URETHRAL UROTHELIAL CARCINOMA" "CANCER_TYPE_DETAILED:Urethral Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:UCU;TMB_NONSYNONYMOUS:5.53333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.2643;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Urethra;ANALYSIS_COHORT:BLCA;BIOPSY_SITE:Lymph Node;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:24"
"UROTHELIAL CARCINOMA" "CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:3.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.0033;SAMPLE_TYPE:Primary;OS_MONTHS:7.33;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:BL;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/28/11;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:127;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BL-A13I.976FBDBF-55C5-4957-986B-D2DE85FF7540.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:410;SMOKING_PACK_YEARS:15;WEIGHT:51;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Non-Papillary;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;SMOKING_YEAR_STARTED:27;PROJECT_CODE:TCGA;DISEASE_CODE:FPPP;OCCUPATION_CURRENT:Dental Assistant"
"UROTHELIAL CARCINOMA OTHER" "CANCER_TYPE_DETAILED:Urothelial Carcinoma Other;CANCER_TYPE:Urothelial Carcinoma;TMB_NONSYNONYMOUS:0.333333333333;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:I;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1316;DIAGNOSIS AGE:68;GDNA(NG):1752;SMOKE STATUS:Unknown;TUMOR_PURTITY:60"
"UROTHELIAL PAPILLOMA" "CANCER_TYPE_DETAILED:Urothelial Papilloma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:UPA;TMB_NONSYNONYMOUS:0.864698095;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0462;SAMPLE_TYPE:Primary;OS_MONTHS:28.701;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Spanish  NOS; Hispanic NOS, Latino NOS;PRIMARY_SITE:Bladder;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;MSI_SCORE:0.07;MSI_TYPE:Stable;SAMPLE_COVERAGE:667;AGE_AT_SEQ_REPORTED_YEARS:72;RELIGION:CATHOLIC/ROMAN;SMOKER:Former;PED_IND:No;AGE_AT_DX:70;SYSTEMIC_TREATMENT:0;INTRAVESICAL_TREATMENT:0;SPECIMEN_STAGE:1"
"UTERINE ADENOSARCOMA" "CANCER_TYPE_DETAILED:Uterine Adenosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:UAS;TMB_NONSYNONYMOUS:0.978719698;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1453;SAMPLE_TYPE:Metastasis;OS_MONTHS:7.44;OS_STATUS:1:DECEASED;GENE_PANEL:IMPACT410;SAMPLE_CLASS:Tumor;GRADE:High;METASTATIC_SITE:Omentum;MSI_SCORE:0.34;WGD:FALSE;CURRENT_STAGE:IVB;CANCER_TYPE_DETAILED_CODE:HGNonLMS;INITIAL_FIGO_STAGE:IVB;METASTASIS_SITE_CODE:Omentum;SMP_OS_MOS:7.44"
"UTERINE CARCINOSARCOMA" "CANCER_TYPE_DETAILED:Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCS;TMB_NONSYNONYMOUS:8.3;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.5526;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Endometrium;SUBTYPE:Mullerian Carcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:115.6656794;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:polypoid; monolayer;DOUBLING_TIME_FROM_VENDOR:43 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:carcinosarcoma-malignant_mesodermal_mixed_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:mullerian_carcinoma;NAME:SNU-1077;PATHOLOGIST_ANNOTATION:Endometrium:Others;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:endometrium"
"UTERINE CLEAR CELL CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Clear Cell Carcinoma;CANCER_TYPE:Uterine Corpus Endometrial Carcinoma;TMB_NONSYNONYMOUS:0.2;SEX:Female;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1417;DIAGNOSIS AGE:64;GDNA(NG):3360;SMOKE STATUS:Unknown;TUMOR_PURTITY:50"
"UTERINE DEDIFFERENTIATED CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Dedifferentiated Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UDDC;TMB_NONSYNONYMOUS:11.091553006;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0025;GRADE:3;MSI_STATUS:MSS;MMRD_IHC:N;PFS_MONTHS_FIRST_LINE_TX:9.23;POLE_IMPACT:N;PROGRESSION_STATUS:1"
"UTERINE ENDOMETRIOID" "CANCER_TYPE_DETAILED:Uterine Endometrioid Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UEC;TMB_NONSYNONYMOUS:9.26666666667;SEX:Female;AGE:74;FRACTION_GENOME_ALTERED:0.5399;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Endometrium;SUBTYPE:Clear Cell Carcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:147.1543657;GENOME_DOUBLINGS:1;DOUBLING_TIME:178.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;DISEASE_ONTOLOGY:Endometrial Cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:MEM + 10% FBS;HIST_SUBTYPE1:clear_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:clear_cell_carcinoma;NAME:TEN;PATHOLOGIST_ANNOTATION:Endometrium:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"UTERINE ENDOMETRIOID CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Endometrioid Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UEC;TMB_NONSYNONYMOUS:9.26666666667;SEX:Female;AGE:74;FRACTION_GENOME_ALTERED:0.5399;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Endometrium;SUBTYPE:Clear Cell Carcinoma;TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:147.1543657;GENOME_DOUBLINGS:1;DOUBLING_TIME:178.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;DISEASE_ONTOLOGY:Endometrial Cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:MEM + 10% FBS;HIST_SUBTYPE1:clear_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:clear_cell_carcinoma;NAME:TEN;PATHOLOGIST_ANNOTATION:Endometrium:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:endometrium"
"UTERINE EPITHELIOID LEIOMYOSARCOMA" "CANCER_TYPE_DETAILED:Uterine Epithelioid Leiomyosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:UELMS;TMB_NONSYNONYMOUS:73.20424984;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1493;SAMPLE_TYPE:Metastasis;OS_MONTHS:39.72;OS_STATUS:0:LIVING;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;GRADE:High;METASTATIC_SITE:Lung;MSI_SCORE:25.08;WGD:FALSE;CURRENT_STAGE:IVB;CANCER_TYPE_DETAILED_CODE:LMS;INITIAL_FIGO_STAGE:IB;METASTASIS_SITE_CODE:Lung;SMP_OS_MOS:39.72"
"UTERINE LEIOMYOSARCOMA" "CANCER_TYPE_DETAILED:Uterine Leiomyosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:ULMS;TMB_NONSYNONYMOUS:4.26666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:66;FRACTION_GENOME_ALTERED:0.6489;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Uterus;ANALYSIS_COHORT:SARC;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:104"
"UTERINE MYXOID LEIOMYOSARCOMA" "CANCER_TYPE_DETAILED:Uterine Myxoid Leiomyosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:UMLMS;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1235;SAMPLE_TYPE:Primary;OS_MONTHS:40.44;OS_STATUS:1:DECEASED;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;GRADE:High;MSI_SCORE:0;WGD:FALSE;CURRENT_STAGE:IVB;CANCER_TYPE_DETAILED_CODE:LMS;INITIAL_FIGO_STAGE:IVB;SMP_OS_MOS:40.44"
"UTERINE NEUROENDOCRINE CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Neuroendocrine Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UNEC;TMB_NONSYNONYMOUS:3.32746590179;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.6881;GRADE:3;MSI_STATUS:MSS;SCNA_CLUSTER:A;MMRD_IHC:not done;PFS_MONTHS_FIRST_LINE_TX:4.43;POLE_IMPACT:N;PROGRESSION_STATUS:1"
"UTERINE PERIVASCULAR EPITHELIOID CELL TUMOR" "CANCER_TYPE_DETAILED:Uterine Perivascular Epithelioid Cell Tumor;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:UPECOMA;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2905;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Uterus;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;SAMPLE_COVERAGE:841;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"UTERINE SARCOMA" "CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;TMB_NONSYNONYMOUS:1.133333333;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:5.3;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:5.6;AGE_AT_PROCUREMENT:78;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:4;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;BRAF_MUTATION:Negative;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XX[20];PB_BLAST_PERCENTAGE:77;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:78;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine, MLN4924;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Azacitidine, MLN4924;MOST_RECENT_TREATMENT_DURATION:111;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:111;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_MONOCYTES_PERCENTAGE:1;PRIOR_CANCER:Uterine Sarcoma;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;SURFACE_ANTIGENS:CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"UTERINE SARCOMA, OTHER" "CANCER_TYPE_DETAILED:Uterine Sarcoma, Other;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:OUSARC;TMB_NONSYNONYMOUS:0;SEX:Female;AGE:68;PFS_STATUS:Yes;RADIATION_THERAPY:Yes;STAGE:Stage I;RFS_STATUS:Yes;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:Yes;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:No;ANY_LINE_TARGETED:Yes;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Uterine Sarcoma;DOB_LASTFU_TIME_YRS:71;DOB_PROG_START_TIME_YRS:69;DOB_PROG_TIME_YRS:70;DOB_RECUR_START_TIME_YRS:68;DOB_RECUR_TIME_YRS:69;DOB_REPORT_TIME_YRS:71;DOB_TISSUE_TIME_YRS:68;LINE_OBR_CHEMO:Unknown;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED:Unknown;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:4;NUM_LINES_CHEMO:2;NUM_LINES_HORMONE:1;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:0;NUM_LINES_TARGETED:1;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Negative;POS_METHOD:Archer;PROG_DEATH:No;PROG_DEATH_TIME_YRS:2;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:3"
"UTERINE SEROUS" "CANCER_TYPE_DETAILED:Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:USC;TMB_NONSYNONYMOUS:5.18818857;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2151;SAMPLE_TYPE:Primary;OS_MONTHS:30.674;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;MSI_SCORE:0.48;MSI_TYPE:Stable;SAMPLE_COVERAGE:682;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:67;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:68;ARCHER:YES;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"UTERINE SEROUS CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:USC;TMB_NONSYNONYMOUS:5.18818857;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2151;SAMPLE_TYPE:Primary;OS_MONTHS:30.674;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;MSI_SCORE:0.48;MSI_TYPE:Stable;SAMPLE_COVERAGE:682;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:67;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:68;ARCHER:YES;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"UTERINE SEROUS CARCINOMA/UTERINE PAPILLARY SEROUS CARCINOMA" "CANCER_TYPE_DETAILED:Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:USC;TMB_NONSYNONYMOUS:5.18818857;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2151;SAMPLE_TYPE:Primary;OS_MONTHS:30.674;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;MSI_SCORE:0.48;MSI_TYPE:Stable;SAMPLE_COVERAGE:682;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:67;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:68;ARCHER:YES;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES"
"UTERINE SMOOTH MUSCLE TUMOR OF UNCERTAIN MALIGNANT POTENTIAL" "CANCER_TYPE_DETAILED:Uterine Smooth Muscle Tumor of Uncertain Malignant Potential;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:USTUMP;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.3576;SAMPLE_TYPE:Primary;OS_MONTHS:32.04;OS_STATUS:0:LIVING;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;GRADE:Low;MSI_SCORE:1.27;WGD:FALSE;CURRENT_STAGE:IVB;CANCER_TYPE_DETAILED_CODE:USTUMP;INITIAL_FIGO_STAGE:IB;SMP_OS_MOS:32.04"
"UTERINE_SARCOMA" "CANCER_TYPE_DETAILED:Uterine Sarcoma/Mesenchymal;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:USARC;TMB_NONSYNONYMOUS:11.6333333333;SEX:Female;AGE:56;FRACTION_GENOME_ALTERED:0.1154;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Uterine Sarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Sarcoma;PURITY:0.99;MUTATION_RATE:121.3182747;GENOME_DOUBLINGS:0;DOUBLING_TIME:35.3;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Fibroblast  adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:McCoy's 5A + 10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:uterine_sarcoma;NAME:MES-SA;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_Others;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:uterus;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"UVEAL MELANOMA" "CANCER_TYPE_DETAILED:Uveal Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:UM;SUBTYPE:Uveal Melanoma;LINEAGE:eye;LINEAGE_SUBTYPE:uveal_melanoma"
"UVEAL_MELANOMA" "CANCER_TYPE_DETAILED:Uveal Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:UM;SUBTYPE:Uveal Melanoma;LINEAGE:eye;LINEAGE_SUBTYPE:uveal_melanoma"
"UVM" "TMB_NONSYNONYMOUS:8.80847727853;SEX:Male;FRACTION_GENOME_ALTERED:0.0035;SMOKING_PACK_YEARS:30;CLINICAL_STAGE:Stage I;SMOKING_STATUS:Ever Smoker;WGD:FALSE;FGA_FACETS:0.008106495;LN_STATUS:pN-Negative;AGE_AT_RESECTION:70;BIOPSY_CONTAINS_MIP:FALSE;CLIN_N_STAGE_CODE:cN0;TUMOR_MORPHOLOGIC_APPEARANCE_ON_CT:Nonsolid;TUMOR_SIZE_ON_CT:1.5;TUMOR_SUVMAX:0"
"VAGINAL ADENOCARCINOMA" "CANCER_TYPE_DETAILED:Vaginal Adenocarcinoma;CANCER_TYPE:Vaginal Cancer;ONCOTREE_CODE:VA;TMB_NONSYNONYMOUS:0.033333333;SEX:Female;AGE:64.96372223;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;ANTIMETABOLITE_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:1st tertile;PLATINUM_TX:Yes;TIME_FROM_DX_TO_SEQ:3700;TIME_TO_BLOOD_DRAW_FROM_TX:3618;XRT_TX:Yes"
"VAGINAL CANCER" "CANCER_TYPE_DETAILED:Squamous Cell Carcinoma of the Vulva/Vagina;CANCER_TYPE:Vaginal Cancer;ONCOTREE_CODE:VSC;TMB_NONSYNONYMOUS:8.33333333333;SUBTYPE:Squamous Cell Carcinoma, vulvar;LINEAGE:skin;LINEAGE_SUBTYPE:skin_squamous"
"WALDENSTROM MACROGLOBULINEMIA" "CANCER_TYPE_DETAILED:Waldenstrom Macroglobulinemia;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:WM;TMB_NONSYNONYMOUS:3.91487879;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0600;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Lymph Node;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;SAMPLE_COVERAGE:537;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"WELL DIFFERENTIATED LIPOSARCOMA" "CANCER_TYPE_DETAILED:Well Differentiated Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;TMB_NONSYNONYMOUS:0;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1381;DIAGNOSIS AGE:51;GDNA(NG):654;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"WELL-DIFFERENTIATED LEIOMYOSARCOMA RESEMBLING LEIOMYOMA" NA
"WELL-DIFFERENTIATED LIPOSARCOMA" "CANCER_TYPE_DETAILED:Well-Differentiated Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:WDLS;SUBTYPE:WDLPS;LINEAGE:soft_tissue;LINEAGE_SUB_SUBTYPE:WDLPS;LINEAGE_SUBTYPE:liposarcoma"
"WELL-DIFFERENTIATED NEUROENDOCRINE TUMOR OF THE APPENDIX" "CANCER_TYPE_DETAILED:Well-Differentiated Neuroendocrine Tumor of the Appendix;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;ONCOTREE_CODE:AWDNET;SEX:Female;AGE:54.41752243;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:733;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS OF THE STOMACH" "CANCER_TYPE_DETAILED:Well-Differentiated Neuroendocrine Tumors of the Stomach;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;ONCOTREE_CODE:SWDNET;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Metastasis;OS_MONTHS:29.49;OS_STATUS:0:LIVING;PRIMARY_SITE:Stomach;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Liver;TUMOR_PURITY:70;SAMPLE_COVERAGE:480;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"WELL-DIFFERENTIATED THYROID CANCER" "CANCER_TYPE_DETAILED:Well-Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:WDTC;SOMATIC_STATUS:Matched;SAMPLE_TYPE:Primary"
"WILMS" "CANCER_TYPE_DETAILED:Wilms Tumor;CANCER_TYPE:Renal cancer;ONCOTREE_CODE:WT;TMB_NONSYNONYMOUS:1.9;SEX:Male;OS_MONTHS:217;OS_STATUS:0:LIVING;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:5;SAMPLE_TIMEPOINT:Metastatic;TISSUE_SEQUENCED:Lung;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:21.0;DIAGNOSTIC_CATEGORY:Renal;GMED_OS_MONTHS:207;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"WILMS TUMOR" "CANCER_TYPE_DETAILED:Wilms Tumor;CANCER_TYPE:Renal cancer;ONCOTREE_CODE:WT;TMB_NONSYNONYMOUS:1.9;SEX:Male;OS_MONTHS:217;OS_STATUS:0:LIVING;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:5;SAMPLE_TIMEPOINT:Metastatic;TISSUE_SEQUENCED:Lung;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:21.0;DIAGNOSTIC_CATEGORY:Renal;GMED_OS_MONTHS:207;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"WILMS' TUMOR" "CANCER_TYPE_DETAILED:Wilms' Tumor;CANCER_TYPE:Wilms Tumor;ONCOTREE_CODE:WT;SEX:Male;AGE:8.251882553;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:Yes;OXALIPLATIN_TX:No;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:2nd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:1st tertile;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:3rd tertile;TERT_OTHER_CYTOTOXIC_TX:3rd tertile;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:1st tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:94;TIME_TO_BLOOD_DRAW_FROM_TX:94;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"WILMS' TUMORS" "CANCER_TYPE_DETAILED:Wilms' tumors;CANCER_TYPE:Wilms Tumor;TMB_NONSYNONYMOUS:0.166666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:9.25;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:WT;SUBTYPE_DETAILS:Unilateral;TUMOR_DETAILS:Wilms' tumors"
"WITH DUCTAL AND LOBULAR PHENOTYPES" "CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:0.366666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:47;FRACTION_GENOME_ALTERED:0.1667;SAMPLE_TYPE:Primary;OS_MONTHS:88.99;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:87.84;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/11/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage I;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2006;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1335;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A0C3.3A54CF6E-AFDB-4609-A827-77D75BB376A7.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:160;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1c;HISTOLOGICAL_SUBTYPE:with ductal and lobular phenotypes;LYMPH_NODES_EXAMINED:YES;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left;IHC_HER2:Negative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);METASTATIC_TUMOR_INDICATOR:NO;PATH_MARGIN:Negative;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Negative;FIRST_SURGICAL_PROCEDURE_OTHER:Segmental mastectomy with sentinel node biopsy;SURGICAL_PROCEDURE_FIRST:Other"
"WT" "CANCER_TYPE_DETAILED:AML without Maturation;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AWM;TMB_NONSYNONYMOUS:0.166666667;SOMATIC_STATUS:Unmatched;SEX:Female;OS_MONTHS:18.26;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:50.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:1.5;AGE_AT_PROCUREMENT:51;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:6;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Unknown;FUSION:None;GROUP:Residual Disease|Post-Chemotherapy;KARYOTYPE:46,XX[20];WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:12;CUMULATIVE_TREATMENT_REGIMENS:Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib;CUMULATIVE_TREATMENT_STAGES:Unknown | Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant;CURRENT_REGIMEN:Busulfan, Fludarabine;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Bone Marrow Transplant;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_MONOCYTES_PERCENTAGE:17;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML without maturation;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML without maturation;SURFACE_ANTIGENS:FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO.;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"YOLK SAC TUMOR" "CANCER_TYPE_DETAILED:Yolk Sac Tumor;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:TYST;TMB_NONSYNONYMOUS:2.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:38;FRACTION_GENOME_ALTERED:0.5778;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Testes;ANALYSIS_COHORT:TGCT;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:108"
